

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
WO 01/55367 A1

(51) International Patent Classification <sup>7</sup> :	C12N 15/11,	60/226,279	18 August 2000 (18.08.2000)	US
	15/12	60/226,868	22 August 2000 (22.08.2000)	US
(21) International Application Number:	PCT/US01/01338	60/227,182	22 August 2000 (22.08.2000)	US
(22) International Filing Date:	17 January 2001 (17.01.2001)	60/226,681	22 August 2000 (22.08.2000)	US
(25) Filing Language:	English	60/227,009	23 August 2000 (23.08.2000)	US
(26) Publication Language:	English	60/228,924	30 August 2000 (30.08.2000)	US
(30) Priority Data:		60/229,344	1 September 2000 (01.09.2000)	US
		60/229,343	1 September 2000 (01.09.2000)	US
		60/229,287	1 September 2000 (01.09.2000)	US
		60/229,345	1 September 2000 (01.09.2000)	US
		60/229,513	5 September 2000 (05.09.2000)	US
		60/229,509	5 September 2000 (05.09.2000)	US
		60/230,438	6 September 2000 (06.09.2000)	US
		60/230,437	6 September 2000 (06.09.2000)	US
		60/231,413	8 September 2000 (08.09.2000)	US
		60/232,080	8 September 2000 (08.09.2000)	US
		60/231,414	8 September 2000 (08.09.2000)	US
		60/231,244	8 September 2000 (08.09.2000)	US
		60/232,081	8 September 2000 (08.09.2000)	US
		60/231,242	8 September 2000 (08.09.2000)	US
		60/231,243	8 September 2000 (08.09.2000)	US
		60/231,968	12 September 2000 (12.09.2000)	US
		60/232,401	14 September 2000 (14.09.2000)	US
		60/232,399	14 September 2000 (14.09.2000)	US
		60/232,400	14 September 2000 (14.09.2000)	US
		60/232,397	14 September 2000 (14.09.2000)	US
		60/233,063	14 September 2000 (14.09.2000)	US
		60/233,064	14 September 2000 (14.09.2000)	US
		60/233,065	14 September 2000 (14.09.2000)	US
		60/232,398	14 September 2000 (14.09.2000)	US
		60/234,223	21 September 2000 (21.09.2000)	US
		60/234,274	21 September 2000 (21.09.2000)	US
		60/234,997	25 September 2000 (25.09.2000)	US
		60/234,998	25 September 2000 (25.09.2000)	US
		60/235,484	26 September 2000 (26.09.2000)	US
		60/235,834	27 September 2000 (27.09.2000)	US
		60/235,836	27 September 2000 (27.09.2000)	US
		60/236,369	29 September 2000 (29.09.2000)	US
		60/236,327	29 September 2000 (29.09.2000)	US
		60/236,370	29 September 2000 (29.09.2000)	US
		60/236,368	29 September 2000 (29.09.2000)	US

[Continued on next page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens", and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

WO 01/55367 A1



60/236,367	29 September 2000 (29.09.2000)	US	60/250,160	1 December 2000 (01.12.2000)	US
60/237,039	2 October 2000 (02.10.2000)	US	60/256,719	5 December 2000 (05.12.2000)	US
60/237,038	2 October 2000 (02.10.2000)	US	60/251,030	5 December 2000 (05.12.2000)	US
60/237,040	2 October 2000 (02.10.2000)	US	60/251,988	5 December 2000 (05.12.2000)	US
60/237,037	2 October 2000 (02.10.2000)	US	60/251,479	6 December 2000 (06.12.2000)	US
60/236,802	2 October 2000 (02.10.2000)	US	60/251,869	8 December 2000 (08.12.2000)	US
60/239,937	13 October 2000 (13.10.2000)	US	60/251,856	8 December 2000 (08.12.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US	60/251,868	8 December 2000 (08.12.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US	60/251,990	8 December 2000 (08.12.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US	60/251,989	8 December 2000 (08.12.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US	60/254,097	11 December 2000 (11.12.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US	60/259,678	5 January 2001 (05.01.2001)	US
60/241,808	20 October 2000 (20.10.2000)	US			
60/241,221	20 October 2000 (20.10.2000)	US			
60/241,786	20 October 2000 (20.10.2000)	US			
60/241,826	20 October 2000 (20.10.2000)	US			
60/244,617	1 November 2000 (01.11.2000)	US			
60/246,474	8 November 2000 (08.11.2000)	US			
60/246,532	8 November 2000 (08.11.2000)	US			
60/246,476	8 November 2000 (08.11.2000)	US			
60/246,526	8 November 2000 (08.11.2000)	US			
60/246,475	8 November 2000 (08.11.2000)	US			
60/246,525	8 November 2000 (08.11.2000)	US			
60/246,528	8 November 2000 (08.11.2000)	US			
60/246,527	8 November 2000 (08.11.2000)	US			
60/246,477	8 November 2000 (08.11.2000)	US			
60/246,611	8 November 2000 (08.11.2000)	US			
60/246,610	8 November 2000 (08.11.2000)	US			
60/246,613	8 November 2000 (08.11.2000)	US			
60/246,609	8 November 2000 (08.11.2000)	US			
60/246,478	8 November 2000 (08.11.2000)	US			
60/246,524	8 November 2000 (08.11.2000)	US			
60/246,523	8 November 2000 (08.11.2000)	US			
60/249,299	17 November 2000 (17.11.2000)	US			
60/249,210	17 November 2000 (17.11.2000)	US			
60/249,216	17 November 2000 (17.11.2000)	US			
60/249,217	17 November 2000 (17.11.2000)	US			
60/249,211	17 November 2000 (17.11.2000)	US			
60/249,215	17 November 2000 (17.11.2000)	US			
60/249,218	17 November 2000 (17.11.2000)	US			
60/249,208	17 November 2000 (17.11.2000)	US			
60/249,213	17 November 2000 (17.11.2000)	US			
60/249,212	17 November 2000 (17.11.2000)	US			
60/249,207	17 November 2000 (17.11.2000)	US			
60/249,245	17 November 2000 (17.11.2000)	US			
60/249,244	17 November 2000 (17.11.2000)	US			
60/249,297	17 November 2000 (17.11.2000)	US			
60/249,214	17 November 2000 (17.11.2000)	US			
60/249,264	17 November 2000 (17.11.2000)	US			
60/249,209	17 November 2000 (17.11.2000)	US			
60/249,300	17 November 2000 (17.11.2000)	US			
60/249,265	17 November 2000 (17.11.2000)	US			
60/250,391	1 December 2000 (01.12.2000)	US			

(71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). **BARASH, Steven, C.** [US/US]; 111 Watkins Pond Blvd. #301, Rockville, MD 20850 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).

(74) Agents: **HOOVER, Kenley, K.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## **Nucleic Acids, Proteins, and Antibodies**

[001] This application refers to a "Sequence Listing" that is provided only on electronic media in computer readable form pursuant to Administrative Instructions Section 801(a)(i). The Sequence Listing forms a part of this description pursuant to Rule 5.2 and Administrative Instructions Sections 801 to 806, and is hereby incorporated in its entirety.

[002] The Sequence Listing is provided as an electronic file (PC005PCT\_seqList.txt, 7,563,935 bytes in size, created on January 12, 2001) on four identical compact discs (CD-R), labeled "COPY 1," "COPY 2," "COPY 3," and "CRF." The Sequence Listing complies with Annex C of the Administrative Instructions, and may be viewed, for example, on an IBM-PC machine running the MS-Windows operating system by using the V viewer software, version 2000 (see World Wide Web URL: <http://www.fileviewer.com>).

### ***Field of the Invention***

[003] The present invention relates to novel musculoskeletal system related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "musculoskeletal system antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such musculoskeletal system polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the musculoskeletal system, including, but not limited

musculoskeletal system polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including musculoskeletal system cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

### ***Background of the Invention***

[004] The Human Musculoskeletal System is comprised of skeleton (e.g., bone), muscle, tendon, ligament, and other components of joints, which constitute the basic structural framework of the body. Together, the components of this system provide the strength, stability, frame, and elasticity necessary for movement. Additionally, the musculoskeletal system protects the internal organs, stores minerals, and produces blood.

[005] The primary component of the musculoskeletal system is the skeleton itself. The skeleton is a highly organized connection of bones responsible for many functions, including supporting the body against gravity, providing sites for muscle attachment, producing blood cells, protecting the organs and other soft body tissues, and permitting flexible movement.

[006] Anatomically, two types of bones can be distinguished in the skeleton: flat bones (e.g., skull bones, scapula, manible, and ileum) and long bones (e.g., tibia, femur, and humerus). The long bone is composed of two wider extremities (e.g., the epiphyses), a cylindrical tube in the middle (e.g., the midshaft or diaphysis), and a developmental zone (e.g., the metaphysis) between them. In a growing long bone, the epiphysis and the metaphysis are separated by a layer of cartilage (e.g., epiphyseal cartilage or growth plate), responsible for the longitudinal growth of the bones. The

external part of the bones is formed by a layer of calcified tissue (e.g., the cortex or compact bone). In the diaphysis, the cortex encloses the medullary cavity, the location of the hematopoietic bone marrow. Toward the metaphysis and epiphysis, the cortex becomes progressively thinner, containing a network of thin, calcified trabeculae (e.g., trabecular bone or spongy bone) and hematopoietic bone marrow. At the center of most bones is yellow marrow, which is used to store fats. Therefore, the cortical bone fulfills mainly a mechanical and protective function, and the trabecular bone fulfills a metabolic function.

[007] Bone is a balanced, dynamic system, constantly degrading and regenerating. Bone is degraded by cells called osteoclasts that remove from the center of the bone, forming the central cavity of the long bones. Osteoblasts are cells found in the osteoid tissue (e.g., bone matrix prior to calcification) and are responsible for the production of the matrix constituents of bone (e.g., collagen and ground substance). As bone matrix is produced, osteoblasts become progressively embedded and differentiate into osteocytes, or bone cells. As calcification occurs, these osteocytes then differentiate into cortical bone or trabecular bone within the calcified collagen fiber matrix. Blood vessels penetrate the newly calcified bone, bringing the blood supply that will form the hematopoietic bone marrow.

[008] Joints are formed when two bones come together and allow for bending and movement. Tough bands of connective tissue, called ligaments, surround the joints, join the two bones together, and keep the bones properly aligned. The joint capsule is lined by a synovial membrane, which produces synovial fluid for lubricating the joint. Joints may also contain fluid-filled sacs (e.g., bursa) that reduce friction in areas where skin, muscles, tendons, and ligaments rub over bones. Most joints are freely moving synovial joints; however, some joints (e.g., vertebrae) are partly movable and allow some degree of flexibility with cartilage, or menisci, between the bones, while other joints (e.g., skull sutures) do not allow movement at all.

[009] Composed of striated bundles of myosin and actin fibers, skeletal muscles have very long fiber-like cells that contract quickly, but only when stimulated by nerve cells. Muscle is attached to the bone by tough connective tissue, called tendons, and arranged in opposing, balancing groups around joints that facilitate balanced movement.

[010] Although the musculoskeletal system was designed for strength and endurance, the components of this system can become worn, injured, or inflamed. These disorders can range from mild to severe and from acute to chronic. Generally, the treatment depends on the type and severity of the disorder.

#### *Diseases and Disorders of the Bone*

[011] Several types of bone disorders occur from an imbalance of the growth and breakdown cycles of bone. The most common, osteoporosis, is a progressive decrease in the density of bones, causing them to weaken. Osteoporosis occurs in several different types and is seen more often in older women. Postmenopausal osteoporosis is generally found in women between the ages 51 and 75 and is caused by the lack of estrogen. Senile osteoporosis results not only from the imbalance between growth and breakdown but also from the calcium deficiency associated with age. Secondary osteoporosis is caused by secondary effects of another medical condition (e.g., chronic renal failure, hormonal disorders) or by drugs (e.g., barbiturates, anticonvulsants). Idiopathic juvenile osteoporosis is a rare form that occurs in children and young adults who, for no obvious reason, have weak bones. Treatment for all forms of osteoporosis is aimed at increasing bone density (e.g., estrogen intake, bisphosphonates, fluoride supplements).

[012] Paget's Disease also results from an imbalance of the growth and breakdown of bone. The turnover rate in areas affected by Paget's Disease increases tremendously; resulting in abnormal, enlarged bone that is soft and weak. Although no specific genetic pattern has been determined, Paget's Disease tends to appear in family lineages. There is no direct treatment for Paget's Disease, rather treatment is given only to alleviate pain and discomfort.

[013] Bone disorders can also result from infection. Bone can be infected through three routes: bloodstream, direct invasion, and adjacent soft tissue infections. Osteomyelitis is a bone infection usually caused by bacteria (e.g., *Staphylococcus aureus*) which results in swelling of the soft bone marrow tissue, compression of the blood vessels, and possibly death of parts of bone. Pott's disease is an infection of the vertebrae by the bacteria that cause tuberculosis (e.g., *Mycobacterium tuberculosis*, *M. bovis*, or *M. africanum*.) For acute infections, antibiotics are generally the most

effective treatment for this disease. However, if the infection is severe or chronic, surgery may also be required to remove the infected tissue and replaced with healthy bone, muscle, or skin.

[014] Most bone carcinomas are benign. The most common type of benign bone tumor, usually occurring in people aged 10 to 20, is osteochondroma. Osteochondromas are growths on the surface of a bone that protrude as hard lumps. Benign chondromas, usually occurring in people aged 10 to 30, develop in the central part of the bone. Chondroblastomas, usually occurring in people aged 10 to 20, are rare, painful tumors that grow in the ends of bones. Osteoid osteomas are very small tumors that commonly develop in the arms or legs but can occur in any bone. Giant cell tumors, usually occurring in people aged 20-40, most commonly originate in the ends of the bones and may extend into adjacent tissue. Treatment of these tumors generally involves pain management and, possibly, surgery to remove the tumor.

[015] Although rare, malignant bone tumors may be primary or metastatic. In children, most malignant bone tumors are primary; in adults, most are metastatic. The most common type of malignant primary tumor, multiple myeloma, originates in the red bone marrow cells and most commonly occurs in older people. Osteosarcoma, usually occurring in people aged 10-20, commonly occurs in or around the knee and cause pain and swelling. These tumors tend to spread to the lungs. Chondrosarcomas are slow-growing tumors composed of cancerous cartilage cells. Ewing's sarcoma, occurring most commonly in males aged 10 to 20, develop most often in arms and legs. These tumors can become large and can affect the entire length of a bone. Metastatic bone tumors most often originate from breast, lung, prostate, kidney and thyroid cancers.

[016] Treatment for bone tumors depends on the type of cancer. Most treatments are complex and involve a combination of chemotherapy, radiotherapy, and surgery. Prompt treatment is especially important for malignant bone tumors.

#### *Diseases and Disorders of Joints, Ligaments, and Tendons*

[017] The most commonly diseased tissue in the musculoskeletal system is the joint. Disorders affecting the joints and their associated components are considered connective tissue disorders because of the presence of large amounts of connective

tissue in these structures. Most of the disorders of joints involve inflammation and may be the result of an immune or autoimmune reaction.

[018] Treatment of joint disorders varies according to type and severity. Drug treatment is generally aimed at reducing inflammation. For mild inflammation and pain, drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin and ibuprofen) are commonly used. Alternative drug treatments, used in more severe cases, are corticosteroids (e.g., prednisone) and immunosuppressive drugs (e.g., methotrexate, azathioprine, and cyclophosphamide). Other treatment plans, used in conjunction with drugs, include exercise, physical therapy, and sometimes surgery.

[019] Arthritis, or inflammation of the joint, occurs in several forms. The most common form of arthritis, characterized by the degeneration of joint cartilage and adjacent bone, is osteoarthritis, or degenerative arthritis. Osteoarthritis causes the formation of rough, pitted cartilage in the joint resulting in limited joint movement, stiffness, and pain.

[020] Another form of arthritis, rheumatoid arthritis, an autoimmune disorder, is caused when the immune system attacks the tissue (e.g., ligaments, synovial membrane, bursas) that surrounds the joints. The joints, including those in the extremities, become symmetrically inflamed, resulting in swelling, pain, and eventually, destruction of the interior of the joint. Psoriatic Arthritis, occurring in people who have psoriasis, resembles rheumatoid arthritis; however, it doesn't produce the antibodies characteristic of arthritis.

[021] Other autoimmune diseases may also affect the joints and tendons. For example, systemic lupus erythematosus may result in episodes of inflammation in the joints and tendons in addition to other connective tissues and organs. Joint inflammation is common with systemic lupus erythematosus and can lead to deformity and permanent damage to the joint and its surrounding tissue; however, the bone does not erode as it does in rheumatoid arthritis.

[022] Joint disease may also result from infection. Reiter's syndrome, or reactive arthritis, is an inflammation of the joints and tendon attachments resulting from a bacterial infection originating in an area of the body other than the joints. There are two forms of Reiter's syndrome that occur more commonly in men aged 20 to 40. One occurs with sexually transmitted infections (e.g., chlamydial infection); the other

usually follows an intestinal infection (e.g., salmonellosis). Once a person is exposed to these infections, there appears to be a genetic predisposition to this type of disease.

[023] Infectious arthritis develops from an infection of the synovial fluid and tissue of a joint. Different bacteria can infect a joint, depending on the person's age. Infants and young children are most commonly infected by gram-negative bacilli, Staphylococci, and *Hemophilus influenzae*. Older children and adults are most commonly infected by gonococci, staphylococci, and streptococci. Viruses (e.g., HIV, parvoviruses, and the viruses that cause rubella, mumps, and hepatitis B) can infect joints in people of any age. The joints most commonly infected are the knee, shoulder, wrist, hip, finger, and elbow and become red, warm to the touch, swollen, and painful.

[024] Crystal deposits in the joints can cause arthritis and pain. Gout, characterized by sudden, recurring attacks of painful arthritis, is caused by the deposition of monosodium urate crystals in the joints. This accumulation generally accompanies hyperuricemia. In addition to managing the pain associated with this disorder, treatment also involves the administering of drugs to reduce the levels of uric acid in the blood by increasing the excretion of uric acid in the urine. Pseudogout, characterized by intermittent attacks of painful arthritis, is caused by the deposition of calcium pyrophosphate crystals. This disorder usually occurs in older people and causes the degeneration of the affected joints. Unfortunately, there is no effective long-term treatment available for the removals of the calcium pyrophosphate crystals. The only treatment available for pseudogout is pain management.

#### *Diseases and Disorders of Muscles*

[025] Damage to muscles can cause pain, limit control over movement, and reduce the normal range of motion. Diseases of the muscles can develop from injury, inflammation, spasms, or inheritance.

[026] Several muscle disorders are inherited. Muscular dystrophies are a group of inherited muscle disorders leading to muscle weakness. Duchenne's and Becker's muscular dystrophies are caused by different gene defects on the same gene resulting in weakness of the muscles closest to the torso. The gene for both diseases is recessive and carried on the X chromosome. Duchenne's muscular dystrophy is characterized by an almost total lack of dystrophin protein, resulting in progressive muscle loss,

including the heart muscle, and ultimately resulting in death by the age of 20. Becker's muscular dystrophy is a less severe illness characterized by production of an oversized dystrophin protein that does not function properly. Landouzy-Dejerine muscular dystrophy is transmitted by an autosomal dominant gene and results in the muscles of the face, shoulder, and legs weakening. Neither Becker's nor Landouzy-Dejerine muscular dystrophy is fatal. Currently, there is no cure for muscular dystrophies. Treatment regimens involve physical therapy and exercise to prevent the muscles from contracting permanently around the joints, and sometimes surgery to release tight, painful muscles.

[027] Myotonic myopathies are a group of inherited muscle disorders in which the muscles are not capable of fully relaxing after contraction, leading to weakness, muscle spasms, and contractures. For example, Steinert's disease is an autosomal dominant disorder producing both weakness and tight, contracted muscles, especially in the hands. Symptoms can range from mild to severe. In the most severe cases, extreme muscle weakness and many other symptoms (e.g., cataracts, irregular heartbeat, diabetes, and mental retardation) can occur, resulting in death by the age of 50.

[028] Pompe's disease is a severe, autosomal recessive, glycogen storage disease in infants where glycogen accumulates in the liver, muscles, nerves, and heart, preventing them from functioning properly. This disease is fatal by age 2; however, there are less severe forms of Pompe's disease that can affect older children and adults, causing weakness of the extremities and diminished ability to breathe deeply. Current treatments for the less severe forms of Pompe's disease and other glycogen storage diseases involve limiting exercise and diuretics to reduce the level of myoglobin released into the blood due to the muscle damage.

[029] Periodic Paralysis is another rare autosomal dominant disorder that causes sudden attacks of weakness and paralysis where the muscles do not respond to normal nerve impulses or artificial stimulation. In some families, periodic paralysis has been linked to the level of potassium in the blood with some families influenced by high levels (hyperkalemia) and some families by low levels (hypokalemia). Diet (e.g., avoidance of carbohydrate-rich food) and treatment with acetazolamide are the most common treatment to control periodic paralysis episodes.

[030] Muscle disorders may result from inflammation. For example, Polymyositis is a chronic connective tissue disease characterized by painful inflammation and disabling muscle weakness and deterioration. Although the direct cause is unknown, cancer, viruses, or autoimmune reactions may play a role. Current treatment regimens include restricting activities during periods of intense inflammation and treatment with corticosteroids or immunosuppressive drugs to improve the strength and relieve the pain and swelling associated with the disease.

[031] Although the majority of muscle disorders involve deterioration and weakening of the muscle, some disorder result in only stiffness and pain. For example, Polymyalgia rheumatica causes severe pain and stiffness in the neck, shoulders, and hips, especially in the morning and after periods of inactivity. No damage to the muscle is detected; however, erythrocyte sedimentation rate and C-reactive protein levels in the blood are high. Drug treatment involving corticosteroids are generally used to treat this disease.

[032] The discovery of new human musculoskeletal system associated polynucleotides, the polypeptides encoded by them, and the antibodies that immunospecifically bind these polypeptides, satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, prevention and/or prognosis of disorders of musculoskeletal system, particularly disorders of the musculoskeletal system, including, but not limited to, bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and scoliosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders (e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis, polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or as described under "Musculoskeletal System Disorders" below.

### *Summary of the Invention*

[033] The present invention relates to novel musculoskeletal system related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively

referred to as “musculoskeletal system antigens,” and antibodies that immunospecifically bind these polypeptides, and the use of such musculoskeletal system polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the musculoskeletal system, including, but not limited to, the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system nucleic acid molecules are provided encoding novel musculoskeletal system polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

### *Detailed Description*

#### **Tables**

[034] Table 1A summarizes some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:)) and contig nucleotide sequence identifier (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column provides a unique clone identifier, “Clone ID NO:Z”, for a cDNA plasmid related to each musculoskeletal system associated contig sequence disclosed in Table 1A. The second column provides a unique contig identifier, “Contig ID:” for each of the contig sequences disclosed in Table 1A. The third column provides the sequence identifier, “SEQ ID NO:X”, for each of the contig polynucleotide sequences disclosed in Table 1A. The fourth column, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineate

the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1A as SEQ ID NO:Y (column 5). Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4:181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1A as "Predicted Epitopes." In particular embodiments, musculoskeletal system associated polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1A. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 7, "Tissue Distribution" shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first number in column 7 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. For those identifier codes in which the first two letters are not "AR", the second number in column 7 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of <sup>33</sup>P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal,

emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. Column 8, "Cytologic Band," provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, an OMIM identification number is provided in Table 1A, column 9 labeled "OMIM Disease Reference(s)". A key to the OMIM reference identification numbers is provided in Table 5.

[035] Table 1B summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, "SEQ ID NO:X", for each contig sequence. The third column provides a unique contig identifier, "Contig

ID:" for each contig sequence. The fourth column, provides a BAC identifier "BAC ID NO:A" for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, "Exon From-To", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

[036] Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, "Clone ID NO:Z", corresponding to a cDNA disclosed in Table 1A. The second column provides the unique contig identifier, "Contig ID:" corresponding to contigs in Table 1A and allowing for correlation with the information in Table 1A. The third column provides the sequence identifier, "SEQ ID NO:X", for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the row was determined. Comparisons were made between polypeptides encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as "NR"), or a database of protein families (herein referred to as "PFAM") as further described below. The fifth column provides a description of PFAM/NR hits having significant matches to a polypeptide of the invention. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, "Score/Percent Identity", provides a quality score or the percent identity, of the hit disclosed in column five. Columns 8 and 9, "NT From" and "NT To" respectively, delineate the polynucleotides in "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth column. In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by the polynucleotides in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.

[037] Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone

identifier, "Clone ID NO:Z", for a cDNA clone related to musculoskeletal system associated contig sequences disclosed in Table 1A. The second column provides the sequence identifier, "SEQ ID NO:X", for contig polynucleotide sequences disclosed in Table 1A. The third column provides the unique contig identifier, "Contig ID", for contigs disclosed in Table 1A. The fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, represented as "Range of a", and the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, represented as "Range of b", where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the polynucleotides of the invention (including polynucleotide fragments and variants as described herein and diagnostic and/or therapeutic uses based on these polynucleotides) are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

[038] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1A, column 7. Column 1 provides the key to the tissue/cell source identifier code disclosed in Table 1A, Column 7. Columns 2-5 provide a description of the tissue or cell source. Codes corresponding to diseased tissues are indicated in column 6 with the word "disease". The use of the word "disease" in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the "disease" designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a

further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

[039] Table 5 provides a key to the OMIM™ reference identification numbers disclosed in Table 1A, column 9. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 1A, column 8, as determined from the Morbid Map database.

[040] Table 6 summarizes ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application.

[041] Table 7 shows the cDNA libraries sequenced, tissue source description, vector information and ATCC designation numbers relating to these cDNA libraries.

[042] Table 8 provides a physical characterization of clones encompassed by the invention. The first column provides the unique clone identifier, "Clone ID NO:Z", for certain cDNA clones of the invention, as described in Table 1A. The second column provides the size of the cDNA insert contained in the corresponding cDNA clone.

### **Definitions**

[043] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

[044] In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by

electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide sequences of the present invention.

[045] As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof, a nucleic acid sequence contained in SEQ ID NO:X (as described in column 3 of Table 1A) or the complement thereof, a cDNA sequence contained in Clone ID NO:Z (as described in column 1 of Table 1A and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereof. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

[046] As used herein, a "musculoskeletal system antigen" refers collectively to any polynucleotide disclosed herein (e.g., a nucleic acid sequence contained in SEQ ID NO:X or the complement thereof, or cDNA sequence contained in Clone ID NO:Z, or a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B, or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereof and fragments or variants thereof as described herein) or any polypeptide disclosed herein (e.g., an amino acid sequence contained in SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, or the complement thereof, an amino acid sequence encoded by the cDNA sequence contained in Clone ID NO:Z, an amino acid sequence encoded by SEQ ID NO:B, or the complement thereof, and fragments or variants thereof as described herein). These musculoskeletal system antigens have been

determined to be predominantly expressed in musculoskeletal system tissues, including normal or diseased tissues (as shown in Table 1A column 7 and Table 4).

[047] In the present invention, "SEQ ID NO:X" was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown, for example, in column 1 of Table 1A, each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID NO:Z). Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library. Furthermore, certain clones disclosed in this application have been deposited with the ATCC on October 5, 2000, having the ATCC designation numbers PTA 2574 and PTA 2575; and on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2. In addition to the individual cDNA clone deposits, most of the cDNA libraries from which the clones were derived were deposited at the American Type Culture Collection (hereinafter "ATCC"). Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, "HTWE." The name of a cDNA clone (Clone ID NO:Z) isolated from that library begins with the same four characters, for example "HTWEP07". As mentioned below, Table 1A correlates the Clone ID NO:Z names with SEQ ID NO:X. Thus, starting with an SEQ ID NO:X, one can use Tables 1A, 6 and 7 to determine the corresponding Clone ID NO:Z, which library it came from and which ATCC deposit the library is contained in. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

[048] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as

disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[049] A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID NO:Z (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein) and/or the polynucleotide sequence delineated in column 6 of Table 1B or the complement thereof. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

[050] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency), salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

[051] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

[052] Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[053] The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

[054] The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well

known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992).)

[055] "SEQ ID NO:X" refers to a polynucleotide sequence described, for example, in Tables 1A or 2, while "SEQ ID NO:Y" refers to a polypeptide sequence described in column 5 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 3 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. "Clone ID NO:Z" refers to a cDNA clone described in column 1 of Table 1A.

[056] "A polypeptide having biological activity" refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the

present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

[057] Table 1A summarizes some of the musculoskeletal system associated polynucleotides encompassed by the invention (including contig sequences (SEQ ID NO:X) and clones (Clone ID NO:Z) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby.

#### **Polynucleotides and Polypeptides**

#### **TABLE 1A**

Clone ID NO: Z	Contig ID:	SEQ ID NO: X	ORF (From-To)	AA SEQ ID NO: Y	Predicted Epitopes	Tissue Distribution Library code: count (see Table IV for Library Codes)	Cytologic Band	OMIM Disease Reference(s):
HANGA63	927404	11	168 - 254	1034		S0318: 1 and S0316: 1.		
HANGA69	718174	12	86 - 268	1035	Ser-21 to His-27, Ser-33 to Ser-39.	S0318: 1 and S0316: 1.		
HANGA85	746265	13	192 - 317	1036		S0318: 1 and S0316: 1.		
HANGA92	791182	14	24 - 146	1037	Glu-8 to Phe-14, Ser-20 to Gly-27.	S0318: 1 and S0316: 1.		
HANGC05	674059	15	2 - 157	1038	Met-2 to His-18, Phe-21 to Thr-27, Lys-43 to Lys-49.	S0318: 1 and S0316: 1.		
HANGC07	952586	16	95 - 226	1039	Ser-28 to Thr-44.	S0318: 1 and S0316: 1.		
HANGC14	952581	17	5 - 151	1040		S0318: 1 and S0316: 1.		
HANGC30	966430	18	16 - 192	1041	Arg-10 to Ser-17, Tyr-37 to His-43.	S0318: 1 and S0316: 1.		
HANGC33	702072	19	49 - 144	1042	Glu-27 to Pro-32.	S0318: 1 and S0316: 1.		
HANGC59	653577	20	72 - 179	1043	Ser-9 to Lys-36.	S0318: 1 and S0316: 1.		
HANGC84	715991	21	106 - 279	1044	Asp-20 to Asn-26.	S0318: 1 and S0316: 1.		
HANGF36	952583	22	126 - 206	1045	Thr-1 to Lys-8.	S0318: 2 and S0316: 1.		
HANGF49	722635	23	34 - 126	1046		S0318: 1 and S0316: 1.		
HANGG22	848727	24	17 - 247	1047	Pro-71 to Thr-77.	S0316: 2		
HANGH48	718759	25	89 - 232	1048	Thr-4 to Leu-11, Gln-27 to Leu-34, Gln-41 to Arg-47.	S0318: 1 and S0316: 1.		
HANGH53	727914	26	75 - 269	1049	Asn-19 to Glu-25, Val-45 to Asn-54.	S0318: 1 and S0316: 1.		

HANGH58	811987	27	34 - 228	1050		S0318: 1 and S0316: 1.		
HANGH66	661513	28	2 - 220	1051	Tyr-1 to Lys-6, Thr-30 to His-36.	S0318: 1 and S0316: 1.		
HANKD09	625167	29	188 - 298	1052		S0318: 1 and S0316: 1.		
HANKD47	719963	30	227 - 370	1053	Ala-2 to Ser-9.	S0318: 1 and S0316: 1.		
HANKD83	963964	31	130 - 312	1054	Arg-21 to Ile-30, Lys-42 to Lys-48.	S0318: 1 and S0316: 1.		
HANKG78	710760	32	3 - 176	1055		S0318: 1, S0316: 1 and L0777: 1.		
HANKG90	746282	33	133 - 366	1056		S0318: 1 and S0316: 1.		
HANKH48	721340	34	159 - 356	1057	Ser-32 to Asn-41, Ser-44 to Ser-51.	S0318: 2 and S0316: 1.		
HANKH56	733063	35	202 - 318	1058	His-13 to Pro-18.	S0318: 1 and S0316: 1.		
HAOAA57	955693	36	139 - 2	1059		S0312: 2 and S0314: 1.		
HAOAA78	756979	37	384 - 539	1060		S0312: 3 and S0314: 2.		
HAOAA90	919249	38	82 - 279	1061	Leu-14 to Thr-20, Glu-40 to Asp-52.	S0314: 2		
HAOAC05	932017	39	118 - 312	1062	Arg-34 to Thr-43, Glu-53 to Arg-58.	S0314: 2 and S0312: 1.		
HAOAD47	864899	40	235 - 384	1063	Met-1 to Thr-12.	S0314: 2		
HAOAE53	964029	41	112 - 381	1064	Arg-1 to Leu-6, Gly-29 to Met-36.	S0312: 1 and S0314: 1.		
HAOAE56	767915	42	1 - 234	1065		S0312: 1 and S0314: 1.		
HAOAE60	657909	43	2 - 238	1066	Thr-8 to Gln-16, Pro-58 to Pro-68.	S0312: 1 and S0314: 1.		
HAOAF68	752788	44	336 - 581	1067		L0731: 2, S0312: 1 and S0314: 1.		
HAOAH38	705946	45	239 - 337	1068		S0312: 1 and S0314: 1.		

HAOMA13	915881	46	94 - 288	1069	Arg-19 to Ser-26, Val-36 to Asn-44, Gly-52 to Thr-59.	S0312: 2		
HAOMB64	960293	47	138 - 386	1070		S0003: 2 and S0312: 1.		
HAOMC21	670518	48	52 - 237	1071	Ala-11 to Glu-22, Arg-38 to Ser-47.	S0312: 2		
HAOMD90	788658	49	87 - 242	1072	Pro-11 to Ser-24, Ser-35 to Pro-41.	S0312: 2		
HAOME45	705947	50	56 - 280	1073	Gln-1 to Gln-11, Arg-24 to Ile-46, Arg-50 to Cys-61.	S0312: 2		
HBCGA72	756953	51	1 - 150	1074	Pro-5 to Pro-20.	S0334: 2		
HBCKB24	676825	52	239 - 412	1075		S0336: 2		
HBCKB82	779562	53	232 - 516	1076		S0336: 2	12q21	217300, 600808
HBCKE22	674041	54	16 - 159	1077		S0336: 2, L0794: 2, L0523: 1, L0607: 1 and L0559: 1.		
HBCKE78	746109	55	321 - 659	1078		S0336: 1, S0250: 1, L0766: 1 and L0362: 1.		
HBFCMC73	764150	56	200 - 334	1079		S0362: 1 and H0529: 1.		
HBSAK76	506666	57	51 - 176	1080	Tyr-6 to Lys-16.	H0381: 2		
HBSAL69	573004	58	67 - 402	1081	Gly-3 to Tyr-8, Gln-11 to Thr-17.	H0381: 1 and H0419: 1.		
HBSAL80	506580	59	1 - 378	1082	Pro-3 to Phe-10, His-29 to Leu-34, Gln-46 to Val-54, Val-70 to Gln-76.	H0381: 1 and H0419: 1.		
HBSAM46	526732	60	202 - 345	1083		H0381: 2		

HBSAM48	727635	61	26 - 298	1084			H0381: 1 and S0028: 1.		
HBSAP02	920648	62	141 - 338	1085			H0381: 1 and H0041: 1.		
HBSAP73	764589	63	3 - 227	1086		Thr-22 to Arg-27, His-64 to Thr-73.	S0028: 2 and H0381: 1.		
HBSAQ64	530344	64	192 - 308	1087			H0381: 1 and S0003: 1.		
HBSDB50	571365	65	2 - 367	1088		Arg-56 to Glu-76.	AR061: 2, AR089: 0 H0419: 2		
HBSDB63	745211	66	146 - 343	1089		Pro-18 to Pro-45, Leu-49 to Arg-66.	H0419: 2		
HBSDD91	775313	67	42 - 149	1090			H0419: 2		
HCDAA94	661278	68	3 - 167	1091			H0251: 5		
HCDAB17	530726	69	187 - 321	1092			H0251: 2, L0586: 1 and L0589: 1.		
HCDAE77	533925	70	60 - 251	1093		Lys-34 to Glu-43, Val-59 to Leu-64.	H0251: 4		
HCDAF27	592244	71	48 - 200	1094		Ser-3 to Pro-11.	H0251: 5		
HCDAF29	533812	72	80 - 235	1095			H0251: 3		
HCDAF54	530529	73	156 - 434	1096			H0251: 2		
HCDAG92	724693	74	66 - 194	1097			H0251: 7		
HCDAG95	533871	75	102 - 296	1098		Cys-32 to Ile-44.	H0251: 5		
HCDAH34	533870	76	45 - 248	1099		Glu-1 to Gln-10.	H0251: 4		
HCDAJ67	925362	77	18 - 185	1100			H0251: 3		
HCDAK93	523648	78	77 - 199	1101			H0251: 2		
HCDAK96	960047	79	3 - 362	1102		Asp-4 to Ser-9.	H0251: 12		
HCDAM34	523607	80	1 - 231	1103		Phe-30 to Arg-37, Glu-45 to His-50.	H0251: 3		
HCDAO32	530006	81	192 - 314	1104			H0251: 2		

HCDAT56	533881	82	388 - 558	1105			H0251: 3, L0766: 1 and L0756: 1.		
HCDBO13	709590	83	41 - 238	1106			H0251: 10		
HCDBR37	968501	84	80 - 331	1107			H0251: 4	12q14	123829, 147570, 181430, 252940, 264700, 600808, 601284, 601769, 601769, 602116
HCDBR39	921893	85	2 - 361	1108		Ala-1 to Arg-9, Arg-15 to Lys-29, Ala-47 to Ser-59, Gly-81 to Thr-92.	H0251: 10 and S0001: 1.		
HCDBU77	661272	86	53 - 172	1109			H0251: 3		
HCDBW51	556469	87	48 - 293	1110			H0251: 5		
HCDBW61	960044	88	32 - 115	1111			H0251: 2 and L0756: 1.		
HCDBX78	847580	89	63 - 257	1112			H0251: 3		
HCDCB84	670159	90	3 - 125	1113		Lys-1 to Asp-6.	H0251: 3		
HCDCCE48	529893	91	89 - 205	1114		Asn-1 to His-9, Thr-11 to Lys-19.	H0251: 2		
HCDCCE62	523582	92	21 - 161	1115			H0251: 3		
HCDCFI1	967768	93	159 - 248	1116			H0251: 2		
HCDCCK07	865908	94	2 - 148	1117		Leu-22 to Glu-27.	H0251: 2	7q22.1	120160, 120160, 120160, 120160, 126650, 126650
HCDCCK91	592465	95	18 - 176	1118		Arg-13 to Ser-21, Ser-40 to Lys-46.	H0251: 3		
HCDCR26	960048	96	191 - 319	1119			H0251: 3		

HCDCX68	529778	97	30 - 104	1120			H0251: 2		
HCDCY13	921702	98	2 - 73	1121			H0251: 2		
HCDDDB52	847581	99	100 - 267	1122			H0251: 3		
HCDDDB62	529890	100	43 - 177	1123			H0251: 2		
HCDDI61	529937	101	3 - 83	1124			H0251: 2		
HCDDU07	954177	102	3 - 173	1125			H0251: 2		
HCDDV90	847575	103	20 - 157	1126	Pro-36 to Lys-46.		H0251: 3		
HCDDY57	556465	104	244 - 363	1127	Arg-12 to Cys-22.		H0251: 4		
HCDDZ09	523605	105	160 - 396	1128			H0251: 2		
HCDDZ44	863388	106	3 - 458	1129			H0251: 4		
HCDEB49	847572	107	1 - 144	1130	Tyr-1 to Gln-16, Asn-21 to Ala-27.		H0251: 2		
HCDEB78	921710	108	21 - 119	1131			H0251: 2		
HCDEG67	531239	109	257 - 355	1132			H0251: 2		
HCDEG95	533879	110	123 - 287	1133			H0251: 5		
HCDER16	667338	111	85 - 270	1134	Asn-36 to Cys-41.		H0251: 1 and S0028: 1.		
HCDER29	523506	112	2 - 211	1135			H0251: 3		
HCDET89	524045	113	157 - 342	1136			H0251: 3		
HFIAB89	848927	114	1 - 48	1137			S0192: 2		
HFIAB93	713799	115	317 - 463	1138			S0192: 2		
HFIAE82	779898	116	2 - 124	1139	Pro-1 to Leu-9.		S0192: 1 and S0194: 1.		
HFIAB10	964652	117	93 - 236	1140	Asn-22 to Thr-28.		S0192: 2		
HFIAB107	952884	118	21 - 188	1141			S0192: 2 and L0748: 1.		
HFIAB31	697775	119	3 - 203	1142	Ser-22 to Ala-28, Arg-52 to Arg-66.		S0192: 4		
HFIAP89	587844	120	145 - 348	1143			S0192: 3		
HFIAP91	925831	121	486 - 214	1144			S0192: 2		
HFIAB83	780358	122	146 - 36	1145	Lys-24 to Leu-32.		S0192: 2		

HFIAZ63	966761	123	137 - 355	1146	Thr-17 to Ser-22.	S0192: 16 and L0809: 1.		
HFIBI48	587871	124	1 - 210	1147	Arg-1 to Ser-6, Leu-34 to Asp-42.	S0192: 5		
HFICA06	934675	125	2 - 244	1148		S0192: 2		
HFICE40	587918	126	143 - 310	1149		S0192: 5		
HFICF01	916103	127	111 - 212	1150		S0192: 2		
HFICI52	522239	128	2 - 568	1151	Arg-1 to Arg-8.	S0028: 1 and S0192: 1. 1q31-q32	114208, 114208, 119300, 120620, 120620, 120920, 134370, 134370, 134370, 134580, 145001, 145260, 150292, 150310, 150310, 179820, 191045, 208250, 226450, 600105, 600759, 600995, 601494, 601652, 601975	
HFICM95	587875	129	148 - 261	1152	Pro-18 to Asn-23.	S0192: 2		
HFICZ77	934192	130	1 - 141	1153	Pro-1 to Arg-11.	S0192: 2		
HFIDB12	968922	131	288 - 509	1154	Ala-2 to Lys-7, Pro-23 to His-29.	S0192: 2		
HFIDL94	964316	132	122 - 325	1155	Asn-1 to Ser-11.	S0192: 4		
HFIDM69	926894	133	336 - 485	1156		S0192: 4		
HFIDN81	959050	134	454 - 302	1157		S0192: 3		
HFIEC13	883185	135	1 - 525	1158	Glu-1 to Arg-13.	AR061: 168, AR089:		

									145 S0192: 2			
HFIHF04	926824	136	2 - 112	1159		Pro-16 to Val-26.			S0192: 3			
HFIHF79	855196	137	449 - 640	1160					S0192: 55			
HFIHB16	661971	138	1 - 132	1161		Leu-21 to Gly-26, Leu-29 to Glu-35.			S0192: 3 and S0194: 1.			
HFIHD91	702324	139	582 - 734	1162		Asp-10 to Lys-18, Arg-37 to Cys-42, Gln-46 to Asn-51.			S0194: 2 and L0740: 1.			
HFIHE47	857988	140	385 - 1659	1163		Pro-1 to Gly-6, Phe-31 to Thr-36, Gln-66 to Leu-75, Leu-83 to Pro-91.			AR089: 17, AR061: 17 S0250: 1, L0439: 1 and S0194: 1.			
HFIHF63	944246	141	2 - 610	1164					AR061: 1, AR089: 1 L0747: 3, S0250: 1, L0777: 1, L0731: 1, L0758: 1 and S0194: 1.			
	973023	1010	895 - 530	2033		Pro-6 to Cys-13, Pro-15 to Leu-20, Pro-47 to Gly-59, Asn-82 to Ser-88.						
HFIHJ60	740280	142	34 - 177	1165		Lys-39 to Tyr-45.			S0194: 2			
HFIHJ85	707899	143	212 - 385	1166		Met-1 to Thr-7, Gly-10 to Cys-21, Ile-25 to Trp-30, Pro-41 to Glu-49.			S0276: 4 and S0194: 1.			
HFIHL29	690546	144	46 - 156	1167					S0022: 1 and S0194: 1.			
HFIHS76	769952	145	246 - 404	1168		Asn-16 to Arg-21.			S0194: 2			

HFIHZ33	588058	146	279 - 455	1169	Arg-7 to Cys-14, Glu-26 to Ser-32.	L2245: 1, L0731: 1, L0604: 1, S0194: 1 and S0276: 1.		
HFIHZ51	725587	147	1 - 201	1170	Glu-47 to Lys-53.	S0194: 2		
HFIUB73	669594	148	262 - 441	1171		S0194: 1 and S0276: 1.		
HFIUS21	670765	149	141 - 332	1172		S0206: 1 and S0194: 1.		
HFIUF34	703972	150	1 - 144	1173	Glu-1 to Gln-16, Ser-42 to Gly-48.	S0194: 1 and S0276: 1.		
HFIUX48	934328	151	239 - 466	1174	Thr-1 to Asp-8.	S0196: 3 and S0242: 2.		
HFIUZ24	677144	152	28 - 426	1175		S0196: 2		
HFIUE17	855119	153	182 - 307	1176		S0242: 7, S0196: 2 and L0792: 1.		
HFIUH54	929787	154	246 - 443	1177		S0196: 16 and S0242: 13.		
HFIUI66	746397	155	2 - 103	1178	Thr-7 to Asn-12, Ser-21 to Trp-28.	S0242: 1 and S0196: 1.		
HFIUI95	735969	156	48 - 167	1179		S0196: 2		
HFIUM59	724249	157	122 - 244	1180		S0196: 2		
HFIUO63	691921	158	161 - 334	1181	Trp-10 to Pro-15.	L0754: 1, S0242: 1 and S0196: 1.		
HFIUP04	582296	159	2 - 88	1182		S0196: 2	1p22	170995, 191540, 274270, 274270, 600309, 601414, 602094
HFIVB03	924021	160	55 - 195	1183	Ser-5 to Lys-13, Arg-39 to Tyr-47.	S0196: 3 and S0242: 1.		
HFIVB25	678022	161	20 - 130	1184		S0196: 2		
HFIVB62	741665	162	91 - 255	1185	Gln-38 to Arg-48.	S0242: 1 and S0196: 1.		

HFIVQ02	919802	163	214 - 453	1186	Glu-46 to Arg-53.	S0242: 1 and S0196: 1.		
HFIXA30	692637	164	142 - 243	1187		L0759: 2, S0242: 2, L0766: 1 and L0663: 1.		
HFIXC30	692635	165	37 - 282	1188		S0242: 2		
HFIXC44	839536	166	369 - 554	1189	His-1 to Asp-9.	L0439: 6, S0242: 2 and L0438: 1.		
HFIXC49	722886	167	2 - 172	1190	Glu-6 to Leu-17, Ser-36 to Gly-41.	S0242: 2		
HFIXK83	767156	168	170 - 364	1191		S0242: 2		
HFIXK94	943717	169	58 - 417	1192		AR089: 2, AR061: 1 S0242: 1 and S0196: 1.		
HFIXM11	966714	170	3 - 95	1193	Phe-5 to Glu-13.	S0242: 2		
HFIXO03	923735	171	269 - 373	1194		S0242: 2		
HFIXV93	597031	172	115 - 297	1195		S0242: 1 and S0196: 1.		
HFIXY13	656812	173	148 - 258	1196		S0242: 2		
HFIXY57	734580	174	143 - 280	1197		S0242: 2		
HFIXY80	965077	175	1 - 174	1198	Asn-45 to Gly-57.	S0242: 2		
HFIYA86	757155	176	192 - 356	1199		S0242: 1 and S0196: 1.		
HFIYB24	952847	177	107 - 304	1200	Asn-14 to Asn-19.	S0242: 2		
HFIYB40	964251	178	101 - 283	1201	Pro-6 to Arg-13, Gly-46 to Arg-52.	S0242: 4 and S0196: 1.		
HFIYK01	916125	179	1 - 123	1202	Gly-1 to Gln-6.	S0242: 2		
HFIYL01	919416	180	2 - 277	1203	Arg-17 to Pro-23, Asp-52 to Lys-74.	S0242: 1 and S0276: 1.		
HFIYO14	657598	181	2 - 145	1204		S0242: 2 and L0779: 1.		
HFIYP02	919501	182	1 - 162	1205	Pro-8 to Arg-16, Pro-34 to Leu-46.	S0242: 3		
HFIYV01	916064	183	264 - 425	1206	Gly-1 to Gly-12.	S0011: 1 and S0242: 1.		

HFIYV03	923755	184	173 - 298	1207	Lys-31 to Asn-38.	S0242: 2		
HFIYV59	861487	185	25 - 255	1208		S0242: 2		
HFIYW08	958978	186	7 - 198	1209	Gln-47 to Lys-52.	S0242: 2		
HFIYZ13	656795	187	1 - 321	1210	Gln-32 to Arg-40, Ser-49 to Ser-59, Asp-71 to Asn-88.	S0242: 2		
HFIZF95	795734	188	52 - 204	1211		S0242: 2 and L0754: 1.		
HFIZG93	928170	189	239 - 406	1212		S0242: 4		
HFIZH29	953895	190	252 - 392	1213	Lys-1 to Thr-9, Thr-15 to Gly-23.	H0124: 1 and S0242: 1.		
HFIZM92	791267	191	403 - 573	1214		L0754: 2, S0242: 1 and S0194: 1.		
HFOXA79	774901	192	74 - 250	1215	Gly-25 to Trp-30, Gly-36 to Pro-47.	S0276: 2		
HFOXB85	752957	193	195 - 374	1216		S0276: 2		
HFOXC25	677995	194	64 - 186	1217	Thr-7 to Gly-14, His-30 to Pro-35.	S0276: 3		
HFOXC35	638311	195	2 - 358	1218	Pro-1 to Glu-12.	S0276: 2		
HFOXEX83	587955	196	185 - 283	1219	Lys-13 to Gly-29.	S0276: 3		
HFOXLO3	923772	197	160 - 321	1220		S0276: 2		
HFOXMS4	587974	198	53 - 211	1221		S0276: 2		
HFOXN89	587984	199	76 - 2	1222		S0276: 2		
HFOXO24	733377	200	247 - 414	1223	Gly-1 to Tyr-8.	S0214: 1 and S0276: 1.		
HFOXRX28	587994	201	166 - 324	1224	Phe-4 to Ser-10.	S0276: 2		
HFOXRX67	806488	202	3 - 257	1225	Pro-21 to Asn-30.	S0276: 3		
HFOXSR1	588052	203	144 - 383	1226	Ala-5 to Phe-14, His-45 to Lys-58.	S0276: 2		
HFOXU83	887781	204	1 - 267	1227		AR051: 17, AR054: 8.		

									AR050: 5 S0276: 3			
HFOXU92	588057	205	77 - 3	1228				Ile-2 to Ala-16.	S0276: 2			
HFOXV15	964296	206	159 - 335	1229					S0276: 2			
HFOXV80	771290	207	1 - 426	1230				Leu-3 to His-14, Pro-19 to Thr-49, Ala-54 to Gly-59, Leu-77 to Gly-82, Gln-87 to Ala-100.	S0340: 1 and S0276: 1.			
HFOYI36	935532	208	2 - 178	1231				Val-3 to Leu-10, Asn-18 to Lys-37, Pro-45 to Val-51.	S0192: 1 and S0276: 1.			
HFOYL77	494844	209	9 - 185	1232					S0276: 2			
HMUBM26	908912	210	2 - 565	1233				Ser-1 to Ser-9, His-28 to Glu-35, Phe-71 to Asn-76, Val-83 to Gly-96, Phe-99 to Asn-104, Lys-109 to Ser-116, Cys-120 to Cys-129, His-140 to Glu-150, Pro-161 to Trp-170.	AR089: 20, AR061: 8 H0529: 1 and S0032: 1.			
HMUBX25	678004	211	1 - 261	1234				Ser-1 to Ala-8, Pro-65 to Leu-70.	H0529: 2			
HMUBY88	740311	212	1 - 372	1235				Tyr-44 to Pro-55, Thr-72 to Arg-77, Phe-92 to Lys-110.	H0529: 2			
HOAAB15	575254	213	1 - 114	1236				Ser-1 to Gly-7,	H0252: 2			

						Gly-18 to Ala-23, Lys-25 to Val-36.			
HOAAB42	530605	214	3 - 209	1237				H0252: 2	12p11
HOAAB56	507839	215	2 - 190	1238		Phe-38 to Gly-50.		H0252: 3	
HOAAC31	693597	216	3 - 95	1239		Thr-3 to Gly-10.		L0766: 3 and H0252: 2.	
HOAAD05	932756	217	560 - 126	1240				H0252: 2, L0753: 2, L0455: 1, L0770: 1, L0779: 1 and L0731: 1.	
HOAAD52	859628	218	140 - 331	1241		Met-1 to Leu-11, Ser-22 to Lys-29.		H0252: 3	
HOAAE10	968532	219	89 - 208	1242				H0252: 2	
HOAAE45	530602	220	106 - 330	1243		Gly-34 to Asn-51.		H0252: 2	
HOAAE49	859630	221	78 - 302	1244		His-6 to Lys-11, Glu-27 to Lys-38.		H0041: 1 and H0252: 1.	
HOAAE73	960631	222	3 - 161	1245		Arg-13 to Cys-30, Val-37 to Phe-47.		H0252: 3	
HOAAF18	530600	223	156 - 347	1246		Thr-1 to Ala-10.		H0252: 2	
HOAAH10	968368	224	200 - 454	1247		Gly-53 to Asp-64, Pro-72 to Arg-85.		H0252: 2, L0748: 2, L0518: 1 and L0759: 1.	
HOAAI05	932537	225	87 - 251	1248		Asp-32 to Ser-45.		H0252: 2	
HOAAJ23	531389	226	28 - 135	1249		Lys-1 to Asp-8, Lys-12 to Lys-28.		H0252: 2	
HOAAK90	527490	227	2 - 178	1250				H0252: 2	
HOAAM08	960060	228	25 - 201	1251		Ala-14 to Thr-36.		H0252: 2	
HOAAR14	526530	229	2 - 202	1252		Arg-17 to Lys-22, Thr-39 to Lys-54.		H0252: 2	
HOAAV23	527489	230	1 - 306	1253				H0252: 2	

HOAAW21	527487	231	193 - 309	1254	Val-22 to Gly-28, Gly-31 to Gly-36.	H0252: 2		
HOAAZ61	531065	232	31 - 333	1255	Gln-4 to Cys-12.	H0252: 2		
HOABA20	932539	233	23 - 118	1256		H0252: 2		
HOABA93	792929	234	78 - 146	1257		H0252: 2		
HOABD58	738359	235	3 - 110	1258		H0252: 2		
HOABP66	507175	236	86 - 253	1259	Lys-39 to Gly-44.	H0252: 2		
HOABP69	531049	237	2 - 76	1260		H0252: 2		
HOABR40	531051	238	245 - 358	1261	Gly-1 to Asp-8.	H0252: 2		
HOEAK21	954961	239	2 - 280	1262		S0126: 4		
HOEAY14	659258	240	25 - 132	1263		S0126: 3, L0520: 1 and L0749: 1.		
HOEBL44	715851	241	69 - 272	1264		S0126: 2		
HOEBO31	693689	242	2 - 103	1265		S0126: 2		
HOEBP01	916957	243	3 - 470	1266	Lys-11 to Asp-17, Tyr-24 to Asp-29, Leu-50 to Ser-64, Ala-76 to Phe-81, Arg-132 to Ser-137.	L0439: 3 and S0126: 2.		
HOECN79	723113	244	88 - 237	1267		S0126: 9, H0658: 1 and L0602: 1.		
HOECY54	506692	245	31 - 342	1268	Lys-28 to Glu-33, Lys-38 to Thr-54, Pro-61 to Ser-70.	S0126: 2		
HOEDD40	572900	246	86 - 346	1269	Pro-8 to Glu-20, Arg-32 to Gly-41, Ser-49 to Arg-61.	S0126: 2		
HOEDD83	578934	247	34 - 267	1270		S0126: 2		

HOEDK10	915054	248	1 - 276	1271	Gly-10 to Asp-15, Gly-31 to Gly-38, Arg-41 to Asp-55.	S0126: 9	
HOEDT31	826009	249	148 - 474	1272		S0126: 3	
HOEDU54	506576	250	391 - 513	1273	Asn-9 to Pro-15.	S0126: 5 and L0661: 1.	
HOEDU68	713695	251	32 - 169	1274	Arg-28 to Tyr-36, Pro-40 to Ser-46.	S0126: 2	
HOEEB63	745039	252	2 - 310	1275	Gly-6 to Gly-12, Ala-14 to Pro-19.	S0126: 2	
HOEEC02	919822	253	143 - 235	1276	Arg-1 to Gly-14.	S0126: 4	
HOEE045	717754	254	62 - 238	1277		S0126: 2	
HOEEQ17	663719	255	173 - 298	1278	Asp-20 to Ala-25.	S0126: 5	
HOEFG22	744340	256	97 - 285	1279	Ser-13 to Ala-18.	S0126: 1 and S3012: 1.	
HOEFL91	790134	257	1 - 135	1280		S0126: 5, L0022: 1, L0752: 1 and L0581: 1.	
HOEFN92	698444	258	170 - 325	1281	Lys-26 to Gly-31, Pro-35 to Asn-45.	S0126: 2	
HOEFS83	615154	259	2 - 220	1282		S0126: 2	
HOEJE18	666349	260	90 - 278	1283		S0126: 2	
HOEJG04	859251	261	3 - 482	1284	Asp-76 to Ile-84, Thr-122 to Trp-139.	AR089: 1, AR061: 0 S0126: 2, S0028: 1 and 1.	
HOEIW84	859225	262	195 - 425	1285		S0126: 2 and L0748: 2.	
HOEKH88	924112	263	2 - 172	1286	Pro-17 to Lys-23, Leu-31 to Ser-36.	S0126: 3 and S0028: 1.	
HOEKP01	918873	264	3 - 329	1287	Gln-1 to Arg-13, Pro-27 to Pro-41.	S0126: 3	
HOEKP79	963337	265	309 - 467	1288		S0126: 5	

HOEME76	974069	266	6 - 488	1289	Lys-8 to Ser-16, Tyr-81 to Ile-94, Ser-97 to Asp-111.	S0126: 2		
HOEMK02	918364	267	3 - 89	1290		S0126: 2		
HOEMQ65	922789	268	132 - 323	1291		S0126: 2		
HOEOE25	907806	269	2 - 625	1292	Lys-95 to Asp-103, Pro-108 to Leu-115, Lys-150 to Leu-158, Leu-162 to Trp-167, Leu-177 to Lys-186, Glu-201 to Gln-208.	L0766: 4, L0517: 2, S0126: 2, L0794: 1 and L0366: 1.		
HOHAA14	468867	270	185 - 385	1293		S0250: 2		
HOHAB04	665381	271	183 - 284	1294		S0250: 2		
HOHAB21	670814	272	3 - 158	1295	Ser-10 to Phe-16, Asn-22 to Asn-27.	S0250: 2		
HOHAE68	781448	273	20 - 286	1296		S0250: 2		
HOHAM36	782043	274	1 - 138	1297	Gly-27 to Asp-35.	S0250: 2, L0598: 1, L0766: 1 and L0745: 1.		
HOHBE48	588317	275	77 - 364	1298	Lys-1 to Ser-6, Thr-9 to Lys-22, Ser-65 to Lys-73.	S0250: 2		
HOHBF30	859046	276	153 - 518	1299	Leu-43 to Pro-49, Asp-108 to Asp-120.	S0250: 2		
HOHBL11	966720	277	23 - 280	1300	Gln-4 to Gly-13, Arg-21 to Glu-29.	S0250: 2		
HOHBL32	588329	278	273 - 461	1301	Asn-43 to His-52.	S0250: 2		
HOHBO79	588271	279	245 - 442	1302	Pro-1 to Gly-17, Gln-23 to Gly-34.	S0250: 2		

HOHBW86	784723	280	111 - 278	1303	Trp-8 to Gly-17, Glu-25 to Gly-30.	S0250: 1 and S0028: 1.		
HOHBX75	669536	281	3 - 497	1304	Gln-13 to Gly-24, Asn-63 to Ala-70.	S0250: 2		
HOHBY75	840109	282	191 - 304	1305		S0250: 2 and L0465: 1.		
HOHCH04	859047	283	3 - 581	1306	Cys-1 to Pro-8.	S0250: 2		
HOHC105	935123	284	54 - 155	1307		S0250: 2		
HOHCM38	709295	285	114 - 227	1308	Tyr-31 to Phe-38.	S0250: 2		
HOHCM90	703734	286	3 - 152	1309		S0250: 2		
HOHCO85	751299	287	93 - 260	1310	Pro-49 to Lys-56.	S0250: 2	6q12-q13	203310
HOHCP35	656516	288	155 - 295	1311	Tyr-8 to Glu-15, Thr-26 to Lys-34.	S0250: 2		
HOHCQ76	825236	289	157 - 330	1312		S0250: 2		
HOHCQ77	661480	290	2 - 115	1313		S0250: 2		
HOHCV83	735685	291	8 - 241	1314		S0250: 2		
HOHCW02	919142	292	159 - 284	1315		S0250: 2		
HOHDB11	966413	293	3 - 440	1316		S0250: 2, L0740: 2 and L0777: 1.		
HOHDB32	698781	294	1 - 162	1317	Pro-21 to Asn-32, Gln-37 to Thr-54.	S0250: 3		
HOHDD23	675616	295	266 - 412	1318		S0250: 2		
HOHDF40	710748	296	2 - 337	1319	Phe-3 to Trp-10, Asn-27 to Asn-40, Ser-43 to Lys-48, Thr-52 to Ser-61, Met-72 to Asp-77, Leu-82 to Thr-89.	S0250: 2 and L0777: 1.		
HOHDF53	727620	297	219 - 344	1320		S0250: 2		

HOHD148	966379	298	3 - 131	1321	Ser-11 to Lys-20.	S0250: 2		
HOHDY85	764155	299	189 - 347	1322	Gln-1 to Gln-17.	S0250: 2		
HOHDZ61	741382	300	41 - 175	1323		S0250: 2		
HOHEA19	668208	301	112 - 273	1324		S0250: 6		
HOHEC41	712037	302	27 - 470	1325	Asp-1 to Asp-11, Glu-24 to Lys-29.	S0250: 2, L0807: 1 and L0591: 1.		
HOHEN50	662365	303	2 - 163	1326		S0250: 2		
HOSAB04	531565	304	82 - 324	1327	Gln-34 to Lys-42, Ser-73 to Arg-81.	S0003: 2		
HOSAR25	509226	305	2 - 208	1328		S0003: 2		
HOSBR08	925430	306	3 - 107	1329		S0003: 2		
HOSBU17	667195	307	365 - 505	1330	Leu-25 to Arg-30, Lys-34 to Gln-39.	S0003: 2 and L0589: 1.		
HOSBU81	508735	308	43 - 168	1331	Asp-28 to Thr-34.	S0003: 2		
HOSBV22	780092	309	1 - 204	1332	Trp-1 to Asp-7, Glu-14 to Trp-28.	S0003: 2, L0775: 2, L0770: 1, L0804: 1 and L0659: 1.		
HOSBW16	933016	310	6 - 155	1333		S0003: 2		
HOSCG51	967584	311	129 - 422	1334		S0003: 1 and S0122: 1.		
HOSCM15	921336	312	126 - 353	1335	Ser-2 to Gln-7, Tyr-40 to Thr-47.	S0003: 2		
HOSCZ35	707379	313	23 - 256	1336		S0003: 2 and S0126: 1. 5q22	175100, 175100, 175100, 175100, 175100, 175100	
HOSDE63	580959	314	3 - 122	1337		S0003: 1, S0027: 1 and S0032: 1.		
HOSDG51	523872	315	23 - 148	1338		S0003: 2		
HOSDN27	530459	316	2 - 154	1339	Ile-1 to Thr-12.	S0003: 2		

HOSEB61	741812	317	359 - 601	1340	Gly-8 to Ser-17, Ala-50 to Asp-62.	S0003: 1, S0214: 1 and L0756: 1.		
HOSEM84	831049	318	160 - 327	1341	Pro-31 to Gly-38, Leu-49 to Arg-56.	S0214: 2	2	
HOSFO57	736034	319	85 - 234	1342		S0214: 2		
HOSFV63	873010	320	14 - 112	1343		S0214: 2	10	
HOSFY79	774052	321	214 - 336	1344	Gly-1 to Gln-10, Asn-20 to Gly-25, Glu-28 to Arg-35.	S0214: 2		
HOSFZ39	705351	322	180 - 344	1345		S0003: 1 and S0214: 1.		
HOSGH28	686649	323	3 - 374	1346	Asn-101 to Lys-108.	S0214: 2, L0758: 2, L0596: 2, L0760: 1, L0055: 1, L0803: 1, L0526: 1 and L0779: 1.		
HOSGJ17	508870	324	108 - 284	1347	Ile-12 to Gln-19.	S0003: 2 and S0214: 1.		
HOSMD84	959483	325	529 - 762	1348		S0003: 2, L0748: 1, L0756: 1 and S0196: 1.		
HOSNO86	858938	326	150 - 341	1349	Gln-43 to Glu-54.	S0003: 2 and L0752: 1.		
HOSOE05	930946	327	13 - 192	1350	Gly-32 to Ala-38.	S0214: 2 and S0003: 1.		
HRDAB18	509019	328	85 - 276	1351	Arg-1 to Ser-18.	H0124: 2		
HRDAB60	509428	329	134 - 337	1352	Gln-40 to Asn-47, Val-49 to Lys-56.	H0124: 2 and L0530: 2.		
HRDAF07	954331	330	36 - 329	1353	Ser-47 to Gly-63.	H0124: 2		
HRDAF69	956269	331	1 - 225	1354		H0124: 2		
HRDAF90	531026	332	90 - 233	1355	His-31 to Thr-40.	H0124: 2		
HRDAH91	525525	333	79 - 240	1356	Gln-1 to Asn-20.	H0124: 2		
HRDBA76	534304	334	153 - 293	1357		H0124: 5		
HRDBC02	921144	335	117 - 284	1358		H0124: 2		

HRDBC30	530858	336	3 - 152	1359	Pro-28 to Arg-33.	H0124: 2		
HRDBC52	867169	337	72 - 278	1360	Asn-32 to Asn-43, Pro-56 to Cys-63.	H0124: 2		
HRDBD35	525526	338	1 - 189	1361		H0124: 2		
HRDBE07	954289	339	214 - 369	1362		H0124: 2		
HRDBE18	956267	340	145 - 264	1363	Ser-31 to Asn-40.	H0124: 2, L0776: 1, L0748: 1 and L0777: 1.		
HRDBE19	534495	341	161 - 394	1364	Thr-3 to Asp-10, Ser-21 to Asp-26.	H0124: 4		
HRDBE41	530856	342	3 - 158	1365	Glu-1 to Pro-10, Thr-14 to Trp-21, Gln-33 to Gln-42.	H0124: 2		
HRDBG59	507381	343	58 - 234	1366		H0124: 2		
HRDBI81	932761	344	116 - 316	1367		H0124: 2		
HRDBJ28	925457	345	234 - 350	1368		H0124: 2		
HRDBK03	925460	346	226 - 351	1369		H0124: 2		
HRDBL61	575229	347	152 - 334	1370	Gly-1 to Ser-12.	H0124: 2		
HRDBL75	524423	348	3 - 161	1371		H0124: 2		
HRDBM42	530849	349	1 - 375	1372	Asn-1 to Arg-9, Tyr-21 to Cys-27.	H0124: 2		
HRDBQ18	954274	350	1 - 183	1373	Asn-1 to Tyr-15.	H0124: 10		
HRDBQ38	533939	351	1 - 165	1374		H0124: 4, L0521: 1 and L0766: 1.		
HRDBQ64	879705	352	1 - 216	1375	Phe-1 to Gly-6, Ser-17 to Ser-23.	H0124: 34		
HRDBQ82	533947	353	244 - 393	1376	Ser-14 to Cys-24.	H0124: 10		
HRDBR04	927900	354	220 - 354	1377		H0124: 4		
HRDBR35	867167	355	29 - 175	1378	Ile-6 to Thr-21,	H0124: 5		

HRDBT72	507847	356	226 - 354	1379	Glu-35 to Ile-40.	AR089: 49, AR061: 16 H0124: 3		
HRDBU70	971700	357	2 - 88	1380	Ser-17 to Gly-24.	H0124: 3		
HRDCA61	921128	358	280 - 456	1381		H0124: 12		
HRDCB18	968554	359	2 - 232	1382	Pro-11 to Gln-17, Glu-51 to Ser-59.	H0124: 6		
HRDCD12	921796	360	247 - 432	1383		H0124: 12		
HRDDF49	867159	361	3 - 80	1384		H0124: 27		
HRDDF95	967837	362	244 - 435	1385		H0124: 15		
HRDDH84	867156	363	18 - 260	1386	Ser-7 to Ser-19, Arg-58 to Cys-70.	H0124: 2		
HRDDN54	932764	364	61 - 183	1387		H0124: 2		
HRDDN90	531117	365	118 - 324	1388		H0124: 2		
HRDDY26	526783	366	13 - 165	1389	Arg-13 to Ser-18.	H0124: 2		
HRDDY73	574336	367	96 - 374	1390		H0124: 2		
HRDDZ76	574324	368	3 - 92	1391	Leu-1 to Pro-10, Glu-12 to Ile-20.	H0124: 2		
HRDEB78	526861	369	12 - 152	1392		H0124: 3		
HRDEC91	747169	370	287 - 460	1393		H0124: 2		
	790096	1011	2 - 97	2034	Arg-11 to Glu-20.			
HRDED92	936045	371	15 - 218	1394	Cys-19 to Val-25.	H0124: 2		
HRDEG76	574326	372	168 - 254	1395	His-22 to Asn-29.	H0124: 2		
HRDEJ76	574335	373	17 - 109	1396	Glu-20 to Glu-27.	H0124: 2		
HRDEK44	574380	374	31 - 222	1397		H0124: 2		
HRDEL91	790374	375	2 - 217	1398	Thr-2 to Thr-8, Thr-23 to Ile-28.	H0124: 2		
HRDEO12	867140	376	3 - 194	1399	Asn-15 to Lys-21,	H0124: 2		

HRDEO76	952894	377	137 - 256	1400	Asp-49 to Ser-54. Pro-7 to Thr-12.	H0251: 1, H0124: 1 and S0242: 1.		
HRDEP31	766222	378	51 - 143	1401	Asp-1 to Leu-12, Leu-25 to Ser-31.	H0124: 2		
HRDEP75	574431	379	204 - 380	1402	Asp-5 to Lys-12.	H0124: 3		
HRDEQ30	506774	380	1 - 144	1403		H0124: 5 and L0749: 1.		
HRDEQ96	507543	381	189 - 428	1404		H0124: 4 and L0599: 1.		
HRDES52	867115	382	94 - 255	1405	Asn-1 to Glu-6, Ile-36 to Ala-42.	H0124: 2		
HRDES65	526823	383	212 - 385	1406	Pro-22 to Glu-27, Pro-49 to Thr-54.	H0124: 3		
HRDET67	825182	384	89 - 346	1407		H0124: 4		
HRDET91	827084	385	68 - 298	1408		H0124: 3		
HRDEU33	572905	386	78 - 320	1409	Pro-24 to Glu-32, Pro-49 to Arg-65.	H0124: 2		
HRDEU42	881296	387	56 - 325	1410	Arg-3 to Gly-9, Arg-53 to Thr-61.	H0124: 7		
HRDEU43	765813	388	40 - 159	1411		H0124: 3		
HRDEU61	575566	389	349 - 239	1412	Gly-1 to Tyr-7.	H0124: 7		
HRDEU78	573031	390	32 - 205	1413	Leu-8 to Gln-14, Glu-17 to Tyr-32.	H0124: 2		
HRDEU93	844316	391	3 - 461	1414	Arg-2 to Asp-10, Leu-28 to Phe-34, Asn-58 to Val-65, Pro-79 to Ser-84.	H0124: 3		

HRDEV13	574442	392	1 - 120	1415	Arg-106 to Pro-111.			
HRDEW02	848793	393	1 - 333	1416	Asp-18 to Thr-24.	H0124: 2		
					Ser-50 to Trp-56,	H0124: 2		
					Pro-95 to His-100.			
HRDEW30	526812	394	83 - 238	1417		H0124: 4		
HRDEW90	574288	395	110 - 271	1418		H0124: 2		
HRDEY14	574438	396	2 - 196	1419	Thr-32 to Ser-38,	H0124: 3		
					Ser-55 to Trp-64.			
HRDEZ06	936072	397	187 - 282	1420		H0124: 2		
HRDEZ54	867127	398	2 - 307	1421		H0124: 2		
HRDEZ60	919386	399	2 - 220	1422	Gly-24 to Arg-29.	H0124: 2		
HRDEZ64	536668	400	2 - 79	1423	Trp-1 to Cys-7.	H0124: 2		
HRDEZ84	575553	401	230 - 382	1424	Asn-28 to Cys-33.	H0124: 7		
HRDFB47	508001	402	2 - 163	1425	Gln-1 to Trp-7,	H0124: 3		
					Ala-29 to Tyr-35.			
HRDFB78	589478	403	37 - 381	1426	Ala-1 to Trp-9,	H0124: 3		
					Pro-11 to Ser-20.			
HRDFC68	574205	404	2 - 172	1427		H0124: 4		
HRDFE73	574142	405	139 - 276	1428	Gly-10 to Phe-20.	H0124: 3		
HRDFE74	765750	406	152 - 268	1429		H0124: 3		
HRDFF42	953913	407	92 - 3	1430	Lys-1 to Pro-6,	H0124: 2		
					Ser-17 to Thr-26.			
HRDFF62	574436	408	237 - 452	1431		H0124: 2 and L0748:		
						1.		
HRDFG25	574433	409	1 - 183	1432	Arg-2 to Asn-23.	H0124: 2		
HRDFG37	792517	410	3 - 197	1433	Gln-1 to Gln-7.	H0124: 2		
HRDFG46	574439	411	15 - 299	1434		H0124: 2		
HRDFH14	575578	412	24 - 140	1435	Lys-1 to Gln-17.	H0124: 4		

HRDFH24	575245	413	161 - 388	1436	Thr-1 to Arg-10, Ser-26 to Ile-31, Tyr-39 to Ile-46.	H0124: 2		
HRDFH25	953882	414	3 - 191	1437		H0124: 3		
HRDFH39	574558	415	62 - 268	1438	Thr-1 to Trp-11.	H0124: 2		
HRDFH77	953673	416	208 - 387	1439	Ser-17 to Gly-26, Glu-29 to Arg-37.	H0124: 5		
HRDFH13	574561	417	1 - 177	1440	Gly-1 to Ala-6.	H0124: 2		
HRDFJ71	574553	418	173 - 337	1441	Glu-10 to Ala-19.	H0124: 2		
HRDFK03	924925	419	3 - 305	1442	His-1 to Met-14.	H0124: 3		
HRDFK41	867106	420	185 - 328	1443		H0124: 2		
HRDFM18	574435	421	46 - 120	1444	Gly-7 to Glu-12.	H0124: 2		
HRDFN95	574565	422	130 - 38	1445	Arg-1 to Arg-7.	H0124: 2		
HRDFQ64	733847	423	56 - 268	1446	Val-1 to Gly-6, Gly-23 to His-32.	H0124: 2		
HRDFQ75	525524	424	3 - 149	1447	Glu-7 to Phe-15, Asn-32 to Lys-41.	H0124: 2		
HRDFT06	867109	425	57 - 245	1448	Pro-31 to Ser-36, Asn-47 to Glu-59.	H0124: 3		
HRDFT15	574549	426	3 - 134	1449		H0124: 4		
HRDFT45	506584	427	123 - 527	1450		AR061: 1, AR089: 0 H0124: 3		
HRDFT84	584823	428	3 - 458	1451	Pro-19 to Lys-25, Asp-30 to Pro-42, Pro-72 to Asp-83.	H0124: 3	6q16	136550, 602772
HRDFU48	573030	429	3 - 134	1452		H0124: 2		
HSAX53	518795	430	1 - 213	1453		S0037: 3		
HSBVB66	523348	431	155 - 316	1454		S0037: 3		

HSBVB67	529483	432	188 - 301	1455			S0037: 2			
HSBFC34	529313	433	89 - 226	1456			S0037: 2			
HSKCS36	529163	434	2 - 187	1457			S0027: 2			
HSKCT33	866514	435	1 - 264	1458		Gly-1 to Gly-6, Arg-11 to Cys-22, Phe-65 to Lys-73.	S0027: 3			
HSKDA70	757183	436	98 - 613	1459			L0757: 4, L0806: 3, L0761: 2, L0800: 2, S0027: 2, L0770: 1, L0646: 1, L0764: 1, L0662: 1, L0653: 1, L0659: 1, L0787: 1, S0126: 1, S0390: 1, S0037: 1 and L0751: 1.			
HSKDJ16	661928	437	2 - 151	1460		Gly-1 to Arg-6.	S0027: 2			
HSKEF43	866410	438	1 - 270	1461		Pro-1 to Thr-11, Ser-23 to Thr-31, Pro-49 to Ile-57, Thr-75 to Ala-80.	S3014: 1 and S0027: 1.			
HSKEK63	744336	439	138 - 284	1462			H0135: 2 and S0027: 1.			
HSKEM02	969071	440	3 - 401	1463		Gln-31 to Gln-36, Thr-38 to Lys-44, Arg-58 to Arg-64, Tyr-72 to Val-78, Val-96 to Phe-101, Ala-105 to Gly-119.	S3014: 1 and S0027: 1.			
HSKET11	967000	441	2 - 427	1464		Gly-20 to Ser-27, Glu-88 to Lys-95.	S0027: 2			

HSKHJ11	965002	442	299 - 421	1465			S0027: 2 and S3014: 1.		
HSKHS71	911592	443	1 - 381	1466	Ala-94 to Cys-100.		AR089: 6, AR061: 4 S3014: 2		
HSKIT38	855173	444	199 - 381	1467			S3014: 1 and S0194: 1.		
HSKJS05	930979	445	1 - 57	1468			L0766: 1, S3014: 1 and S0206: 1.		
HSKKD70	916984	446	236 - 469	1469	Gly-43 to Trp-48, Met-50 to Asn-60.		S3014: 1 and S0028: 1.		
HSKKL06	934040	447	107 - 409	1470	Pro-13 to Ser-18, Gly-46 to Thr-52.		S0390: 1 and S3014: 1.		
HSKNO53	728210	448	384 - 533	1471			S3012: 1 and S0206: 1.		
HSKWA56	916496	449	272 - 436	1472			S0206: 2		
HSKWA78	731756	450	257 - 406	1473	Glu-10 to Asn-34.		S0206: 2		
HSKWA79	733394	451	148 - 312	1474	Ser-1 to Trp-16.		S0206: 2 and L0749: 1.		
HSKXG06	935455	452	221 - 90	1475			S0206: 2		
HSKXJ15	866373	453	121 - 450	1476			S3012: 1 and S0206: 1.		
HSKXN20	668928	454	116 - 223	1477	Pro-2 to Ile-16, Gln-18 to Lys-23.		S0206: 2		
HSKXP58	955073	455	3 - 134	1478	Pro-33 to Trp-38.		S0206: 2		
HSKXQ58	736045	456	24 - 170	1479			S0206: 2		
HSKYG66	698007	457	88 - 345	1480	Arg-7 to His-12, Pro-22 to Gln-28, Arg-70 to Pro-77.		S0206: 3 and L0758: 1.		
HSKYH52	466574	458	189 - 383	1481	Ser-21 to Lys-32.		S0206: 2		
HSKYJ96	921032	459	101 - 268	1482			H0251: 1 and S0206: 1.		
HSKZE12	970639	460	117 - 61	1483			S0027: 1 and S0206: 1.		
HSKZE32	959400	461	129 - 1	1484	Lys-2 to Cys-15.		S0027: 2, L0748: 2, L0751: 2 and S0192: 1.		

HSLAB77	772652	462	122 - 313	1485	Ala-21 to Gly-26.	S0028: 2		
HSLBO30	574086	463	1 - 210	1486	Ala-14 to Arg-21.	S0028: 2		
HSLBW19	671738	464	104 - 226	1487	Val-25 to Lys-32.	S0028: 2		
HSLBX08	959911	465	2 - 271	1488		S0028: 2		
HSLBX20	574004	466	139 - 435	1489	Leu-17 to Asp-22, Pro-30 to Glu-36, Asn-40 to Asn-46, Pro-61 to Ser-66, Arg-76 to Ile-88.	S0028: 2		
HSLBZ91	573987	467	3 - 284	1490	Val-17 to Glu-22.	AR089: 8, AR061: 5 S0028: 3		
HSLCB15	693455	468	170 - 631	1491	Thr-1 to Trp-7, Thr-9 to Gly-18, Gly-26 to Pro-40, Gln-53 to Asp-66, Ala-70 to Met-107, Glu-110 to Arg-136.	S0028: 2 and L0744: 1.		
HSLCJ46	529622	469	3 - 278	1492	Ser-87 to Asn-92.	S0028: 2		
HSLCJ47	908627	470	6 - 302	1493	Ser-8 to His-20, Glu-28 to Thr-34, Leu-64 to Gly-76.	S3014: 1 and S0028: 1.		
HSLCL38	951028	471	2 - 202	1494	Asp-24 to Cys-30.	S0028: 2		
HSLCP75	529631	472	75 - 353	1495	Pro-7 to Gln-14.	S0028: 2		
HSLCV95	793080	473	164 - 289	1496		S0028: 2		
HSLDA25	679301	474	1 - 297	1497	Ser-1 to His-9, Gln-32 to Asn-37, Tyr-58 to Leu-78.	S0028: 2		
HSLDB29	866340	475	7 - 402	1498		S0028: 2		

HSLDC06	936010	476	3 - 227	1499			S0028: 2		
HSLDG13	913664	477	17 - 232	1500	Arg-1 to Arg-18, Glu-28 to Asn-39.		S0028: 2		
HSLDI16	574014	478	104 - 184	1501	Ile-1 to Thr-6.		S0028: 2		
HSLDJ24	574050	479	1 - 264	1502	Gln-37 to Ile-43, Pro-50 to Leu-58, Glu-64 to Leu-69.		S0028: 2		
HSLDJ94	753657	480	40 - 243	1503	Val-17 to Pro-22, Thr-39 to Trp-45, Gln-63 to Cys-68.		H0251: 1 and S0028: 1.		
HSLDK43	675440	481	132 - 353	1504			S0390: 2 and S0028: 1.		
HSLDM32	699486	482	2 - 163	1505	Pro-8 to Arg-18, Phe-28 to Arg-35.		S0028: 2		
HSLDM79	526740	483	130 - 348	1506			S0028: 3		
HSLDP16	573210	484	2 - 277	1507			AR061: 0, AR089: 0 S0028: 2		
HSLDW65	689722	485	238 - 429	1508			S0028: 2		
HSLEB25	669654	486	125 - 343	1509	Gly-13 to Glu-24.		S0028: 2		
HSLEC25	572859	487	2 - 298	1510	His-35 to Ser-42, Asp-57 to Pro-62, Gly-70 to Gly-77.		S0028: 2		
HSLEC36	936003	488	1 - 282	1511	Ser-7 to Ala-13, Pro-54 to Cys-59.		S0028: 2		
HSLED38	709381	489	102 - 491	1512			AR061: 3, AR089: 2 S0126: 2 and S0028: 1.		
HSLED42	572860	490	38 - 388	1513	Arg-1 to Pro-8.		S0028: 2		
HSLEE46	572878	491	1 - 297	1514	Asp-1 to Asp-6.		S0028: 2		
HSLEF89	572883	492	45 - 257	1515			S0028: 3		

HSLG74	825500	493	3 - 221	1516	Ser-12 to Trp-29.	S0037: 1 and S0028: 1.		
HSLH57	584090	494	2 - 142	1517	Pro-1 to Trp-10, Ala-13 to Glu-18, Thr-31 to Trp-38, Glu-40 to Cys-47.	S0028: 2		
HSLH22	572863	495	59 - 247	1518	Gly-1 to Gly-10, Arg-35 to Gly-44.	S0028: 2		
HSLH46	573212	496	1 - 288	1519		S0028: 2		
HSLH070	841952	497	22 - 207	1520	Asn-20 to Glu-28, Gly-55 to Lys-62.	S0028: 2		
HSLH34	706986	498	3 - 263	1521	Ala-8 to Gly-16, Ser-23 to His-49, Phe-73 to Ser-79.	S0028: 2		
HSLH91	572885	499	10 - 339	1522	Pro-63 to Lys-71.	S0028: 3, L0800: 1, L0803: 1, L0777: 1 and L0731: 1.		
HSLH86	785489	500	2 - 304	1523	Arg-13 to Gly-22.	S0028: 2		
HSLH42	948740	501	25 - 300	1524	Pro-1 to His-7, His-12 to Arg-24, Thr-32 to Gln-45, Arg-80 to Leu-85.	S0028: 2		
HSLH45	717782	502	2 - 136	1525	Arg-1 to Ile-8.	S0028: 2		
HSLH76	725788	503	106 - 396	1526		S0028: 2		
HSLH89	786061	504	73 - 390	1527		S0028: 2		
HSLH01	916448	505	83 - 412	1528		S0028: 2		
HSLH23	675872	506	35 - 448	1529	Phe-1 to Gly-6, Pro-46 to Gln-56.	S0028: 2		
HSLH26	681705	507	160 - 312	1530	Ile-17 to Gln-23,	S0028: 2		

HSLGK79	774049	508	3 - 389	1531	Arg-44 to Tyr-51. Pro-13 to Gly-22, Asp-57 to Ala-63, Ser-78 to Ala-88.	S0028: 2			
HSLGV91	780005	509	50 - 289	1532	Tyr-1 to His-6.	S0028: 2			
HSLGX20	669648	510	115 - 255	1533	His-8 to Ile-15, Tyr-32 to Thr-37.	S0028: 2			
HSLHA55	866273	511	99 - 404	1534		S0028: 3			
HSLHC22	673918	512	312 - 452	1535		S0028: 2 and L0754: 1.			
HSLHP20	669210	513	52 - 432	1536	Gly-29 to Phe-34.	S0028: 2			
HSLIA21	668116	514	3 - 125	1537	Pro-20 to Tyr-28, Pro-30 to Lys-35.	S0028: 2			
HSLIG54	713982	515	67 - 396	1538	Arg-1 to Gly-18, Ser-31 to Ser-37, Arg-39 to Gly-44.	S0028: 2			
HSLII61	918071	516	295 - 426	1539	His-35 to Ser-44.	S0250: 1, S0028: 1, L0748: 1 and L0750: 1.			
HSLIJ57	659533	517	3 - 389	1540	Arg-39 to Gln-44.	AR089: 1, AR061: 0 S0028: 2			
HSLJB11	966227	518	1 - 144	1541	Ala-1 to Trp-6.	S0390: 1 and S0028: 1.			
HSLJJ21	670330	519	14 - 343	1542	Ser-1 to Asp-12, Ala-22 to Asn-28.	S0390: 1 and S0028: 1.			
HSLJJ83	727874	520	47 - 307	1543	Gly-19 to Asn-35.	S0390: 1 and S0028: 1.			
HSLJK88	923108	521	79 - 216	1544		S0390: 2			
HSLJN31	750394	522	3 - 251	1545		S0390: 1 and S0028: 1.			
HSLJN49	920062	523	83 - 394	1546	Pro-35 to Ser-41.	S0390: 2 and S0028: 1.			
HSLJN61	966267	524	160 - 498	1547	Glu-1 to Phe-6, Lys-12 to Pro-31,	S0390: 2 and S0028: 1.			

							Arg-41 to Ile-47, Glu-50 to Arg-55.				
HSLJN71	759941	525	16 - 213	1548			Pro-16 to Arg-22, Lys-29 to His-35.	S0390: 1 and S0028: 1.			
HSLJQ31	961447	526	151 - 399	1549				S0390: 2			
HSLJW53	866261	527	2 - 94	1550				S0390: 2			
HSLKC70	866256	528	102 - 422	1551				S0390: 1 and S0028: 1.			
HSRAX95	747078	529	61 - 324	1552			His-14 to Leu-21, Glu-34 to Leu-46, Glu-62 to Asn-67.	S0011: 2			
HSRBE02	921205	530	60 - 269	1553			Gln-19 to Arg-26, Gln-41 to Leu-47, Arg-53 to Phe-69.	S0011: 2			
HSRDE58	519542	531	32 - 181	1554			Glu-10 to Cys-15, Ser-21 to Cys-39.	S0022: 2			
HSRDI39	921749	532	144 - 386	1555			Ser-40 to Lys-47.	S0022: 4 and S0011: 1.			
HSRDJ68	530333	533	111 - 227	1556				S0022: 1 and S0011: 1.			
HSRDK92	838033	534	1 - 222	1557				S0022: 1 and S0011: 1.			
HSRDL32	530294	535	110 - 232	1558			Pro-1 to His-7, Glu-17 to Lys-30.	S0022: 2			
HSRDM42	523843	536	1 - 150	1559				S0022: 2 and S0011: 1.			
HSRDN23	530334	537	90 - 212	1560			Arg-16 to Glu-21, Leu-23 to Gly-32.	S0022: 2			
HSRDQ89	780221	538	6 - 137	1561				S0022: 1 and S0011: 1.			
HSRDS77	530289	539	148 - 243	1562				S0022: 1 and S0011: 1.			
HSREB43	524678	540	3 - 125	1563			Pro-7 to Cys-27, Tyr-32 to Lys-41.	S0011: 2			
HSREC27	753810	541	62 - 310	1564			Pro-15 to Ile-23,	S0011: 2			

						Ser-31 to Tyr-36, Ala-43 to His-48, Pro-54 to Arg-60.				
HSRED45	530233	542	3 - 146	1565				S0011: 2		
HSREG25	523815	543	156 - 323	1566		Val-22 to Phe-36.		S0011: 2 and S0022: 1.		
HSREG40	712779	544	1 - 513	1567		Val-22 to Pro-31, Pro-43 to Ser-51, Ala-55 to Ala-86, Ala-102 to Ile-120, Pro-122 to Val-148.		S0011: 1, S0242: 1 and S0194: 1.	109270, 109270, 109270, 120150, 120150, 120150, 139250, 148065, 148080, 150200, 154275, 156490, 171190, 176960, 185800, 221820, 249000, 253250, 600119, 600119, 600525, 600852, 601844	
HSREG49	723267	545	1 - 165	1568				S0338: 1 and S0011: 1.		
HSRFC96	558385	546	62 - 178	1569		Met-11 to Asp-16, Ser-23 to Lys-29.		S0022: 2		
HSRFD34	575288	547	29 - 151	1570				S0022: 2		
HSRFD47	973782	548	163 - 357	1571				S0022: 6		
HSRFE58	556519	549	10 - 156	1572				S0022: 2		
HSRFF03	925369	550	33 - 143	1573				S0022: 2		
HSRFG30	920265	551	1 - 273	1574				S0022: 2		
HSRFR21	529767	552	109 - 243	1575		Ser-7 to Ser-12, Gln-21 to Trp-27.		S0022: 2		

HSRZF71	557976	553	62 - 289	1576			S0022: 2		
HSRGA32	529726	554	134 - 268	1577			S0022: 2		
HSRGB23	974538	555	296 - 400	1578		Gly-2 to Gly-14.	S0022: 4		
HSRGE47	974539	556	2 - 214	1579		Lys-24 to Gln-34, His-41 to Arg-46.	S0022: 3		
HSRGG66	556518	557	2 - 112	1580			S0022: 2		
HSRGGK48	535012	558	2 - 124	1581			S0022: 3		
HSRGQ30	534479	559	3 - 248	1582			S0022: 4, L0662: 1 and S0011: 1.		
HSRGS08	960211	560	7 - 195	1583			S0022: 3		
HSRGV79	921005	561	124 - 315	1584		Arg-53 to Thr-58.	S0022: 9		
HSRGW30	529624	562	170 - 310	1585			S0022: 2		
HSRGZ32	699561	563	1 - 240	1586			S0022: 5		
HSRHA45	974551	564	19 - 168	1587			S0022: 7		
HSSAE47	720685	565	193 - 318	1588		Ile-1 to Pro-10.	H0135: 2		
HSSAF46	508117	566	121 - 330	1589			H0135: 2		
HSSAN96	936108	567	57 - 251	1590			H0135: 2		
HSSAP44	508831	568	46 - 234	1591		Gln-7 to Arg-18.	H0135: 2		
HSSAV18	508832	569	90 - 200	1592		Ala-1 to Leu-7, Arg-27 to Gly-33.	H0135: 2		
HSSAV88	508829	570	62 - 241	1593		Asn-1 to Ser-17.	H0135: 2		
HSSBO48	871217	571	2 - 370	1594			H0135: 2		
HSSBO59	707683	572	259 - 402	1595		Ile-4 to Glu-18.	H0135: 2		
HSSCC04	928001	573	46 - 132	1596		Gly-1 to Asn-9.	H0135: 2		
HSSDI02	871226	574	2 - 229	1597			H0135: 2		
HSSDL20	667599	575	2 - 172	1598		Ala-1 to Pro-8, Thr-19 to Pro-27.	H0124: 2 and H0135: 1.		
HSSDL94	526758	576	16 - 297	1599		His-10 to Arg-25.	H0135: 2		

HSSDR63	537329	577	1 - 225	1600	Ala-28 to Glu-34.	H0135: 2		
HSSDX20	783128	578	17 - 127	1601		H0135: 3		
HSSSED56	625572	579	182 - 370	1602	Cys-30 to Arg-35.	H0135: 1 and S0027: 1.		
HSSSEF29	689837	580	152 - 403	1603	Pro-41 to Met-46.	H0135: 2		
HSSEK75	766507	581	57 - 176	1604	Arg-10 to Cys-16.	H0135: 2		
HSSEU91	766573	582	86 - 175	1605	Ser-1 to Lys-8.	H0135: 1 and S0028: 1.		
HSSEU93	911261	583	116 - 370	1606	Asn-1 to Gly-17, Gln-23 to His-55, Glu-68 to Cys-77.	H0135: 2		
HSSEV89	572851	584	62 - 310	1607	Pro-21 to Asp-27, Val-50 to Cys-62.	H0135: 2	16	
HSSFF80	753589	585	3 - 299	1608	Gly-8 to Gly-14.	H0135: 2		
HSSFQ43	715318	586	209 - 328	1609	Asp-12 to Asn-21.	H0135: 2		
HSSFR41	707006	587	75 - 359	1610	Pro-13 to Pro-18, Ala-41 to Cys-50.	H0135: 2		
HSSFX54	708845	588	3 - 248	1611	Pro-42 to Trp-47, Trp-62 to Pro-68.	H0135: 2 and L0581: 1.		
HSSGC65	955064	589	2 - 403	1612	Ala-18 to Ala-24, Pro-26 to Asp-37.	H0135: 3 and L0761: 1.		
HSSGC66	319740	590	101 - 3	1613		H0135: 2		
HSSGC72	760648	591	2 - 91	1614		H0135: 2		
HSSGD37	739505	592	2 - 160	1615	Ser-47 to Ser-52.	H0135: 2		
HSSGH47	720367	593	66 - 353	1616	Gln-1 to Lys-8.	H0135: 2		
HSSGI20	668919	594	114 - 341	1617	Tyr-26 to Glu-31.	H0135: 2		
HSSGI75	767325	595	255 - 16	1618		H0135: 2		
HSSGI91	789411	596	3 - 305	1619	Tyr-18 to Pro-27, Gln-32 to Leu-41, Pro-90 to Gly-99.	H0135: 2		

HSSGK96	960636	597	72 - 287	1620	Gly-12 to His-19.	H0135: 2		
HSSGL55	766115	598	177 - 545	1621		H0135: 4 and L0747: 1.	7q32	180105, 190900, 222800, 246900
HSSGL78	788924	599	211 - 390	1622		H0135: 2		
HSSGM62	707685	600	2 - 409	1623	Ser-1 to Tyr-6, Met-87 to Tyr-93, Ala-108 to Ala-113.	H0135: 2		
HSSGN47	707003	601	3 - 338	1624	His-1 to Gly-28, Ser-54 to Gly-79, Pro-81 to Lys-102.	H0135: 2, L0794: 2, L0636: 1 and L0749: 1.	19q13.1	164731, 172400, 172400, 180901, 180901, 221770, 248600, 600918, 602716
HSSHA92	792714	602	169 - 309	1625	Leu-26 to Asn-38.	H0135: 2		
HSSJN44	716573	603	340 - 438	1626		H0124: 1 and H0135: 1.		
HSSJN49	708841	604	93 - 305	1627	Trp-1 to Asn-6, Gln-37 to Cys-52, Pro-64 to Lys-70.	H0135: 2		
HSSJU66	653212	605	1 - 204	1628	Gly-1 to Ser-6.	H0135: 2		
HSSJV60	970749	606	155 - 373	1629	Arg-1 to Ser-7.	H0135: 2 and L0779: 1.		
HSSKB40	711130	607	68 - 325	1630	Gly-1 to Pro-12, Phe-25 to Asn-34, Arg-40 to Ala-46, Pro-73 to Trp-78, Gln-80 to Pro-86.	H0135: 1, S0037: 1 and L0754: 1.	22	
HSSMT78	712468	608	123 - 380	1631	Gly-6 to Arg-12.	H0135: 2		
HYBAE74	925074	609	36 - 239	1632		H0041: 2		

HYBAG11	967880	610	1 - 207	1633			H0041: 2		
HYBAU83	732419	611	106 - 234	1634			H0041: 2		
HYBAX25	456251	612	97 - 354	1635	Leu-29 to Lys-34, Gly-63 to Cys-69.		H0041: 2		
HYBAY40	531202	613	2 - 298	1636			H0041: 2		
HYBBB24	584989	614	19 - 150	1637			H0041: 2, L0764: 1, L0766: 1 and L0759: 1.		
HYBBI18	584991	615	174 - 350	1638	Lys-27 to His-39.		H0041: 2		
HYBBJ30	693345	616	3 - 215	1639			H0041: 1 and S0011: 1.		
HYBBL17	691328	617	2 - 166	1640	Arg-20 to Ala-27.		H0041: 2		
HYBBK83	505138	618	489 - 127	1641			H0041: 1		
	510490	1012	164 - 544	2035	Ala-40 to Gln-45, Gln-55 to Thr-65, Pro-93 to Ser-101.				
HYBBG93	531201	619	2 - 70	1642			H0041: 1		
HYBAY92	792923	620	193 - 438	1643			L0748: 2 and H0041: 1.		
HYBAW03	925068	621	110 - 295	1644			H0041: 1 and L0758: 1.		
HYBAH65	518736	622	337 - 606	1645	Lys-1 to Gly-7, Arg-12 to Pro-18, Val-22 to Trp-29, Pro-41 to Leu-49, Glu-51 to Asp-64.		L0748: 7, H0041: 1 and L0747: 1.		
HYBAG53	669602	623	296 - 475	1646			L0748: 2, H0041: 1 and L0744: 1.		
HYBAF63	745585	624	308 - 508	1647			H0041: 1 and L0756: 1.		

HSSMZ93	530752	625	7 - 246	1648	Arg-1 to Asn-12, Gln-31 to Gly-37, Pro-48 to Gly-55.	H0135: 1		
HSSMZ01	921800	626	72 - 278	1649	Thr-18 to Val-23, Leu-39 to Gln-45.	H0135: 1		
HSSMW90	975081	627	3 - 191	1650		H0135: 1 and L0755: 1.		
HSSMT76	928421	628	2 - 193	1651	Trp-36 to Pro-45.	H0135: 1		
HSSMT70	530758	629	59 - 214	1652	Pro-22 to Ile-28.	H0135: 1		
HSSMP20	854092	630	144 - 299	1653	Asp-2 to Ala-12, Leu-21 to Ser-45.	H0135: 1 and L0754: 1.		
HSSKD17	726525	631	92 - 511	1654	Gln-1 to Gly-10, Arg-15 to Arg-22, Leu-49 to Asp-58, Arg-72 to Trp-78.	H0135: 1 and L0747: 1.		
HSSJQ60	975185	632	1 - 147	1655	Lys-30 to Phe-37.	H0135: 1		
HSSJP81	911334	633	153 - 440	1656	Arg-11 to Leu-26, Pro-29 to Gly-38, Leu-78 to Ser-84.	H0135: 1, L0766: 1 and L0438: 1.		
HSSJL22	871170	634	141 - 569	1657	Ser-37 to Lys-49.	H0135: 1		
	894004	1013	528 - 358	2036	Val-34 to Pro-39.			
HSSJK65	747891	635	37 - 288	1658		L0748: 2, H0135: 1 and L0749: 1.		
HSSJH78	773558	636	84 - 218	1659	Ile-13 to Cys-19, Ser-23 to Glu-28.	H0135: 1, L0439: 1 and L0747: 1.		
HSSJA08	959336	637	387 - 536	1660		L0764: 2, H0135: 1 and L0804: 1.		
HSSGK12	970714	638	236 - 370	1661	Phe-10 to Lys-17.	AR051: 144, AR050:		

								132, AR054: 132 H0135: 1			
HSSGJ84	781975	639	335 - 505	1662		Lys-9 to Lys-14, Ser-33 to Arg-40.		H0135: 1 and L0748: 1.			
HSSGD96	796410	640	1 - 111	1663		Gly-1 to Ser-16.		H0135: 1			
HSSGD82	779899	641	168 - 524	1664		Met-55 to Gly-66.		H0135: 1 and L0741: 1.			
HSSGD56	608144	642	209 - 379	1665		Arg-1 to Asp-10, Gln-16 to Lys-21.		H0135: 1			
	975065	1014	34 - 204	2037		Arg-1 to Asp-10, Gln-16 to Lys-21.					
HSSFW84	781973	643	36 - 371	1666		Gly-19 to Gly-28, Gly-43 to Gln-67, Ser-86 to Glu-93, Leu-95 to Val-101.		H0135: 1 and L0439: 1.			
HSSFU84	888462	644	1 - 402	1667		Pro-6 to Thr-15, Ala-20 to Arg-36, Pro-38 to Gln-85.		AR051: 21, AR054: 16, AR050: 10 H0135: 1			
HSSFN08	959735	645	243 - 500	1668				H0135: 1 and L0365: 1.	Xq28	300031, 300044, 300048, 300049, 300049, 300055, 300100, 300100, 300104, 300126, 301201, 301590, 302060, 302060, 302060, 302060, 302960, 303700, 303800, 303900.	

									304800, 305900, 305900, 305900, 306700, 306995, 308310, 308840, 308840, 308840, 309200, 309548, 309620, 309900, 310300, 310400, 310460, 310460, 311300, 311510, 314300, 314400
HSSFK90	788687	646	423 - 151	1669				H0135: 1	
HSSFB73	955200	647	334 - 137	1670				H0135: 1 and L0748: 1.	
HSSEU40	891055	648	101 - 238	1671	His-6 to Ala-17, Thr-37 to Trp-44.	AR054: 8, AR051: 3, AR050: 1 H0135: 1 and L0749: 1.			
HSSEP69	871211	649	30 - 287	1672		H0135: 1			
HSSEI90	789157	650	2 - 370	1673	Phe-7 to Arg-13.	H0135: 1 and L0748: 1.			
HSSEG25	679351	651	150 - 338	1674	Pro-10 to Asp-15, Leu-38 to Gly-54.	L0766: 2, L0747: 2, H0135: 1, L0796: 1, L0789: 1 and L0752: 1.			
HSSEF33	702701	652	274 - 522	1675		H0135: 1 and L0748: 1.			
HSSEC79	775312	653	1 - 267	1676	Thr-24 to Asp-43, Pro-53 to Asp-58, 1.	H0135: 1 and L0592: 1.			

HSSDQ07	880720	654	81 - 419	1677	Cys-62 to Gly-67.				
HSSDI03	924975	655	107 - 283	1678	Gly-6 to Thr-12.	H0135: 1			
					Val-1 to Cys-13.	H0135: 1, L0538: 1 and L0747: 1.			
HSSDH37	575460	656	18 - 251	1679	Pro-2 to Ser-11.	H0135: 1			
HSSDC50	724696	657	1 - 219	1680	Arg-1 to Ser-7, Gln-20 to Gly-28.	H0135: 1 and L0439: 1.			
HSSCC14	600216	658	647 - 399	1681		H0135: 1			
HSSAZ04	933015	659	15 - 170	1682		L0766: 2 and H0135: 1.			
HSSAY34	703345	660	104 - 412	1683		H0135: 1 and L0439: 1.			
HSSAP68	564334	661	704 - 417	1684		H0135: 1			
HSSAJ89	875882	662	89 - 316	1685	Val-16 to Gln-26, Ala-32 to Ser-40.	H0135: 1 and L0747: 1.			
HSSAE52	871244	663	10 - 180	1686		H0135: 1 and L0606: 1.			
HSSAA15	965347	664	42 - 491	1687	Ser-13 to Ser-19, Asp-42 to Arg-49, Ser-95 to Lys-104, Gln-145 to Thr-150.	AR050: 62, AR054: 51, AR051: 51 H0135: 1			
HSRAY10	961237	665	28 - 240	1688	Ser-19 to Met-36, Ser-39 to Thr-49.	L0666: 1 and S0011: 1.			
HSRAS82	780222	666	46 - 237	1689	Thr-5 to Asn-13, Pro-40 to His-46, Phe-54 to Phe-59.	L0748: 1 and S0011: 1.			
HSRAF70	524680	667	194 - 379	1690	Lys-1 to Gln-8.	S0011: 1			
HSRAF11	967886	668	176 - 271	1691		S0011: 1			

HSRAD72	539530	669	3 - 221	1692			S0011: 1			
HSRAD65	871268	670	1 - 135	1693	Asn-1 to Arg-12.		S0011: 1		8p21-p12	152760, 173370, 180100, 185430, 270800, 277700, 602629
HSRAD53	525490	671	60 - 335	1694	Ala-1 to Cys-14, Val-72 to Trp-77.		S0011: 1			
HSRAD49	722134	672	211 - 390	1695			L0761: 1, L0749: 1, L0758: 1 and S0011: 1.			
HSRAD31	524845	673	136 - 249	1696	Cys-2 to Pro-11.		S0011: 1			
HSRAD10	968614	674	236 - 445	1697	Lys-10 to Gly-19, Ala-23 to Cys-29.		L0803: 1 and S0011: 1.			
HSRAD03	925505	675	120 - 305	1698	Pro-10 to Met-18, Pro-48 to Glu-62.		S0011: 1			
HSRAB87	823174	676	3 - 122	1699	Thr-10 to Gly-18.		S0011: 1			
HSRAB82	522945	677	49 - 246	1700	Leu-44 to Arg-50.		S0011: 1			
HSRAB76	508105	678	48 - 299	1701			S0011: 1			
HSRAB36	522946	679	2 - 163	1702			S0011: 1			
HSRAB34	706996	680	3 - 146	1703	Phe-1 to Asn-12.		S0011: 1			
HSRAB08	960411	681	2 - 145	1704	Ile-1 to Lys-6.		S0011: 1			
HSRAA86	527194	682	74 - 202	1705			S0011: 1			
HSRAA80	937640	683	2 - 325	1706	Ile-1 to Cys-10, Arg-95 to Phe-106.		AR061: 150, AR089: 93 S0011: 1			
HSRAA64	955314	684	220 - 327	1707			S0011: 1			
HSRAA51	522834	685	3 - 326	1708	Ser-16 to Gly-27, Asp-48 to Ala-53, Thr-70 to Ser-77.		S0011: 1			

HSRAA39	719712	686	1 - 174	1709	Pro-17 to Trp-22.	S0011: 1		
HSRAA37	522837	687	29 - 127	1710	Thr-7 to His-13.	S0011: 1		
HSRAA24	795855	688	3 - 446	1711	Phe-1 to Leu-8, Pro-72 to Trp-86.	S0011: 1		
HSRAA23	524795	689	3 - 251	1712	Pro-8 to His-27, Thr-56 to Ser-61, Leu-77 to Phe-83.	S0011: 1		
HSLKB62	905738	690	212 - 937	1713	Glu-84 to Trp-92, Asn-106 to Gly-115, Lys-184 to Arg-191.	AR050: 220, AR051: 151, AR054: 146, AR061: 7, AR089: 2 S0390: 1		
HSLKB37	929743	691	171 - 374	1714		L0776: 2, L0748: 2, L0598: 1, L0529: 1, S0390: 1 and L0758: 1.		
HSLKA06	934638	692	1 - 222	1715	Gln-8 to Arg-14, Met-21 to Thr-27.	L0659: 1, L0809: 1 and S0390: 1.		
HSLIJ62	742895	693	173 - 436	1716	His-22 to Tyr-32.	L0748: 3 and S0390: 1.		
HSLJF33	938811	694	3 - 521	1717	Glu-70 to Gly-76.	AR089: 1, AR061: 1 S0390: 1		
HSLJD02	965826	695	47 - 907	1718	Leu-53 to Gln-58, Phe-162 to Gly-167, Gln-282 to Ala-287.	AR054: 7, AR051: 1, AR089: 1, AR061: 1, AR050: 0 S0390: 1		
HSLIJ48	721248	696	64 - 570	1719		S0028: 1 and L0748: 1.		
HSLIG07	952493	697	269 - 454	1720	Ser-19 to Asp-24.	L0766: 2, L0740: 2, L0803: 1, S0028: 1, L0745: 1 and L0759: 1.		
HSLIE03	923393	698	163 - 321	1721	Asn-27 to His-34.	S0028: 1 and L0592: 1.		

HSLIC21	670359	699	189 - 512	1722	Pro-3 to Ser-10.	L0742: 2, S0028: 1 and L0366: 1.		
HSLHZ82	779067	700	320 - 526	1723		S0028: 1 and L0748: 1.		
HSLHZ10	963808	701	59 - 307	1724	Val-24 to Asn-29, Arg-56 to Gly-64.	S0028: 1 and L0361: 1.		
HSLHV27	964075	702	983 - 21	1725	His-8 to Gly-18.	AR050: 5, AR061: 2, AR054: 1, AR089: 1 S0028: 1		
HSLHG49	722570	703	162 - 290	1726		L0438: 1, S0028: 1 and L0439: 1.		
HSLHC40	710681	704	230 - 400	1727		L0755: 2 and S0028: 1.		
HSLGY08	959371	705	215 - 397	1728	Tyr-4 to Ser-12, His-23 to Leu-29.	S0028: 1 and L0742: 1.		
HSLGQ48	720956	706	141 - 413	1729	Glu-2 to Thr-9.	L0438: 1, S0028: 1 and L0439: 1.		
HSLGP07	953305	707	224 - 442	1730	Asp-7 to Arg-15.	S0028: 1 and L0753: 1.		
HSLGO19	668634	708	115 - 543	1731		L0665: 1, S0028: 1, L0748: 1 and L0750: 1.		
HSLGN78	773565	709	1 - 156	1732		S0028: 1 and L0591: 1.		
HSLGN52	466026	710	3 - 266	1733	Thr-26 to Gln-40, Glu-47 to Arg-53.	S0028: 1 and L0740: 1. 12		
HSLGK46	719031	711	2 - 226	1734	Gln-8 to Asn-15, His-23 to Gln-28.	S0028: 1 and L0601: 1.		
HSLGK26	929286	712	422 - 607	1735		S0028: 1 and L0748: 1. Iq12-Iq21.2	104770, 107670, 110700, 145001, 146760, 146790, 159001, 191315, 600897, 601412,	

									601652, 601863, 602491
HSLGK23	675266	713	176 - 343	1736				L0747: 2, L0766: 1 and S0028: 1.	
HSLGJ37	708824	714	120 - 452	1737	Thr-80 to Cys-87.			S0028: 1 and L0439: 1.	
HSLGI76	770035	715	379 - 558	1738				S0028: 1 and L0748: 1.	
HSLGI67	465989	716	47 - 253	1739				L0439: 6 and S0028: 1.	
HSLGH70	871888	717	57 - 227	1740	Pro-23 to Leu-30.			S0028: 1 and L0745: 1.	
HSLGG86	784703	718	38 - 202	1741				S0028: 1 and L0439: 1.	
HSLGG79	775146	719	1 - 126	1742	Asp-1 to Thr-16.			S0028: 1 and L0740: 1.	
HSLGA79	774051	720	2 - 151	1743				S0028: 1 and L0599: 1.	
HSLGA45	717776	721	210 - 13	1744	Pro-9 to His-17, Gly-19 to Gly-24, Gly-30 to Ile-38, Leu-42 to Lys-51, Pro-54 to Asn-66.			S0028: 1 and L0777: 1.	
HSLGA24	955333	722	805 - 284	1745	Pro-45 to Arg-50, Glu-56 to Ser-62, Ser-70 to Glu-76, Asp-141 to Arg-149.			AR089: 14, AR061: 3 S0028: 1	
HSLFU18	666405	723	576 - 842	1746	Asp-7 to Lys-13, Asn-63 to Tyr-75.			L0770: 3, L0777: 3, L0731: 3, L0780: 2, L0040: 1, L0764: 1, L0766: 1, L0804: 1, L0809: 1, L0790: 1, L0438: 1, S0028: 1, L0439: 1, L0751: 1, L0745: 1 and L0749: 1.	

HSLFT29	680451	724	1 - 462	1747	Glu-1 to Phe-8, Met-55 to Leu-64, Gly-93 to His-99, Ala-135 to Cys-141.	AR089: 2, AR061: 2 S0028: 1		
HSLFN96	796375	725	3 - 167	1748	Gln-23 to Arg-39.	S0028: 1		
HSLFI01	876881	726	115 - 342	1749	Asp-12 to Thr-18.	S0028: 1 and L0754: 1.		
HSLED70	757319	727	327 - 515	1750	Ser-40 to Ser-47, Pro-52 to Gly-60.	S0028: 1, L0777: 1 and L0759: 1.		
HSLEB84	783130	728	122 - 280	1751		S0028: 1 and L0754: 1.		
HSLDW24	779689	729	33 - 209	1752	Tyr-38 to His-45.	L0756: 2 and S0028: 1.		
HSLDT25	949079	730	1544 - 867	1753		AR051: 22, AR050: 20, AR054: 19, AR089: 17, AR061: 9 S0028: 1		
HSLDR18	578926	731	148 - 270	1754	Glu-1 to Gly-10, Glu-21 to Asn-32.	S0028: 1		
HSLDR05	932128	732	83 - 232	1755	Arg-1 to Asp-7.	S0028: 1		
HSLDP66	866331	733	189 - 401	1756		S0028: 1		
HSLDO01	916969	734	33 - 113	1757		S0028: 1		
HSOLDM82	780055	735	3 - 428	1758	Tyr-18 to Leu-23, Tyr-64 to Ser-70, Glu-77 to Arg-82.	L0361: 2 and S0028: 1. 1p36.3	120550, 120570, 120575, 153454, 236250, 256700	
HSLDF25	430328	736	363 - 1	1759	Gln-38 to Cys-43, Val-55 to Cys-62, Pro-64 to Pro-69, Lys-76 to Phe-83, Ser-85 to Arg-91, Lys-113 to Arg-121.	S0028: 1		

	677994	1015	251 - 123	2038	Pro-1 to Thr-13, Leu-31 to Leu-37.			
HSLCY75	766533	737	326 - 550	1760	Leu-22 to Arg-27.	S0028: 1 and L0749: 1.		
HSLCX61	742031	738	343 - 507	1761	Gly-4 to Tyr-18, Gly-48 to Gly-55.	AR089: 3, AR061: 1 L0439: 2 and S0028: 1.		
HSLCF96	637670	739	355 - 1248	1762	Val-2 to Trp-7, Lys-9 to Trp-18, Gln-20 to Gly-25, Gln-79 to His-85, Pro-134 to Asp-139, Asp-164 to Thr-171, Pro-223 to Arg-228.	AR054: 38, AR050: 26, AR051: 25, AR061: 2, AR089: 1 S0028: 1		
	954777	1016	1332 - 430	2039	Thr-1 to Cys-6, Ser-52 to Gly-57, Gln-111 to His-117.			
HSLBW39	705630	740	1 - 432	1763	Asp-2 to Trp-28, Pro-33 to Asn-39, Pro-88 to Gln-104.	S0028: 1 and L0591: 1.		
HSKZE91	790166	741	75 - 335	1764	Val-1 to Leu-7, Pro-11 to Glu-20.	S0027: 1 and L0605: 1.		
HSKYG48	721631	742	3 - 296	1765	Arg-6 to Lys-17.	S0206: 1		
HSKXA69	754258	743	2 - 169	1766		L0748: 2, S0206: 1 and L0599: 1.		
HSKKE11	965857	744	90 - 245	1767	Arg-1 to Gln-10, Thr-41 to Gln-48.	S3014: 1 and L0750: 1.		
HSKJR15	866396	745	59 - 406	1768	Gln-11 to Gly-18, Asn-25 to Ser-30.	AR089: 1, AR061: 0 L0666: 1, S3014: 1 and L0756: 1.		

HSKJC88	866402	746	154 - 357	1769	Arg-52 to Gln-58.	L0809: 1 and S3014: 1.		
HSKJI90	788894	747	482 - 613	1770		L0599: 2 and S3014: 1.		
HSKHZ47	720286	748	400 - 534	1771	Tyr-1 to Tyr-6.	L0745: 3 and S3014: 1.		
HSKHT93	957866	749	245 - 415	1772		L0766: 1 and S3014: 1. 5q11	253200, 600887	
HSKHP10	964568	750	136 - 240	1773		S3014: 1 and L0779: 1.		
HSKGS69	755046	751	3 - 335	1774	Asn-23 to Pro-31.	S3014: 1, L0748: 1 and L0749: 1.		
HSKEH21	941976	752	2 - 703	1775	Leu-26 to Gly-38, Leu-101 to Thr-116, Glu-144 to Val-151, Pro-177 to Pro-183, Thr-188 to Thr-195, Phe-203 to Asn-234.	AR061: 11, AR089: 4 S0027: 1		
HSKDC06	935452	753	174 - 332	1776		S0027: 1 and L0599: 1.		
HSKCR54	922730	754	86 - 547	1777	Gly-45 to Arg-50.	AR061: 8, AR089: 7 S0027: 1 and L0749: 1.		
HSKCD43	714389	755	3 - 188	1778		L0759: 2, S0027: 1 and 6q21 L0748: 1.	120110, 121014, 601666, 602772	
HSKBW86	785783	756	1 - 180	1779	Tyr-12 to Ile-24, Glu-43 to Lys-49.	AR089: 6, AR061: 3 S0027: 1		
HSKBW62	521937	757	23 - 175	1780		S0027: 1		
HSKBW21	671383	758	46 - 141	1781		S0027: 1 and L0779: 1.		
HSKBV67	561585	759	90 - 257	1782	Leu-15 to Ser-21.	S0027: 1		
HSKAE10	968508	760	640 - 464	1783	Thr-17 to Arg-22.	L0752: 2, L0803: 1 and S0027: 1.		
HSKAC29	535402	761	184 - 375	1784		S0027: 1		
HSJCA03	925252	762	213 - 362	1785		S0032: 1 and L0758: 1.		
HSJAY64	866540	763	123 - 284	1786	Pro-4 to Gln-11,	S0032: 1 and L0361: 1.		

HSJAB49	723261	764	209 - 337	1787	Cys-16 to Gly-21.	S0032: 1 and L0748: 1.		
HSHCL04	840406	765	640 - 1053	1788	Gly-1 to Ser-10. Arg-34 to Asn-39.	AR051: 23, AR050: 17, AR054: 12, AR061: 5, AR089: 4 S0037: 1		
	957191	1017	331 - 2	2040	Arg-22 to Asn-27.			
	957192	1018	3 - 173	2041				
	957193	1019	344 - 192	2042				
HSHCK86	785392	766	1 - 291	1789		S0037: 1		
	792112	1020	574 - 353	2043	Gly-22 to Gln-34, Tyr-48 to Glu-56.			
HSHCJ63	468536	767	73 - 336	1790	Val-19 to Tyr-25, Gln-82 to Ser-87.	S0037: 1		
	470736	1021	478 - 359	2044				
HSHBU07	866636	768	227 - 457	1791	Lys-3 to Lys-15.	S0037: 1		
HSHAH05	932689	769	209 - 96	1792	Gly-31 to Gln-37.	S0037: 1 and L0754: 1.		
HSCAF60	537444	770	59 - 199	1793	Arg-1 to Thr-8, Lys-16 to Asn-21.	S0118: 1		
HRDFU03	924698	771	187 - 357	1794	Lys-1 to Trp-18, Thr-36 to Ser-44.	H0124: 1 and L0748: 1.		
HRDFH46	590391	772	261 - 464	1795	His-1 to Asp-22, Pro-51 to Lys-58.	H0124: 1, L0387: 1, L0747: 1 and L0588: 1.		
HRDFG13	925350	773	1 - 249	1796		H0124: 1 and L0759: 1.		
HRDFF47	740594	774	1 - 114	1797		H0124: 1, L0598: 1, L0655: 1 and L0745: 1.		
HRDFD56	733556	775	47 - 178	1798		H0124: 1, L0439: 1,		

HRDFA03	867122	776	405 - 602	1799			L0745: 1 and L0756: 1. AR054: 74, AR051: 68, AR050: 63 H0124: 1		
HRDEZ73	774414	777	21 - 254	1800	Gln-52 to Cys-57.		L0777: 2, H0124: 1, L0774: 1, L0743: 1, L0744: 1, L0757: 1 and L0758: 1.		
HRDEX24	867123	778	112 - 258	1801	Met-1 to Lys-6, Pro-13 to Asp-19.		L0731: 2, H0124: 1, L0800: 1, L0803: 1 and L0804: 1.		
HRDER90	789140	779	3 - 428	1802			L0748: 2, H0124: 1 and L0592: 1.		
HRDER35	707569	780	66 - 266	1803			H0124: 1 and L0748: 1.		
HRDEP20	690456	781	2 - 274	1804			H0124: 1, L0755: 1 and L0604: 1.		
HRDEK53	867137	782	2 - 181	1805			H0124: 1 and L0749: 1.		
HRDEJ33	487523	783	123 - 31	1806			H0124: 1		
	867143	1022	260 - 556	2045					
	974260	1023	3 - 245	2046	Ala-3 to Ala-10, Ser-49 to Thr-74, Pro-76 to Lys-81.				
HRDDX67	460145	784	1 - 189	1807			H0124: 1		
	462510	1024	243 - 115	2047					
HRDDX01	921501	785	388 - 200	1808	Thr-27 to Trp-42.		H0124: 1, L0659: 1, L0783: 1 and L0779: 1.		

HRDDU41	712572	786	27 - 281	1809	Asn-46 to Ser-55.	H0124: 1		
HRDDR39	867151	787	1 - 222	1810		H0124: 1 and L0777: 1.		
HRDDQ55	490884	788	278 - 126	1811	His-3 to Asp-11, Leu-13 to Glu-26, Pro-46 to Gly-51.	H0124: 1		
	514848	1025	188 - 397	2048	Lys-8 to His-14.			
HRDCD44	715769	789	3 - 197	1812		H0124: 1 and L0740: 1.		
HRDBH52	728715	790	48 - 251	1813	Lys-4 to Lys-10, Pro-39 to Glu-46.	H0124: 1, L0748: 1 and L0747: 1.		
HRDAB42	800333	791	55 - 429	1814	Pro-11 to Arg-16, Pro-27 to Ser-32, Gln-53 to Thr-63.	H0124: 1 and L0748: 1.		
HOSOW01	914804	792	19 - 153	1815	Leu-10 to Pro-16, Leu-39 to Ser-45.	L0748: 2 and S0003: 1.		
HOSNO25	974291	793	417 - 566	1816		S0003: 1		
HOSMP95	948496	794	3 - 278	1817	Ser-2 to Leu-24, Pro-33 to Lys-45.	L0748: 5 and S0003: 1.		
HOSGN29	830653	795	1 - 432	1818	Ser-12 to Thr-27, Pro-32 to Glu-39, Gly-48 to Ile-55, Ile-59 to Leu-80, Gln-108 to Leu-113, Pro-121 to Tyr-131.	S0214: 1 and L0777: 1.		
HOSFV77	856933	796	468 - 659	1819	Leu-27 to Met-32.	S0214: 1, L0439: 1, L0749: 1 and L0595: 1.		
HOSFU59	739262	797	94 - 255	1820	Lys-1 to Leu-11.	S0214: 1 and L0731: 1.		

HOSFL57	734709	798	231 - 365	1821			S0214: 1 and L0754: 1.		
HOSFL07	953183	799	464 - 583	1822			L0766: 2, L0471: 1, S0214: 1, L0748: 1, L0749: 1 and L0756: 1.	1p35	118210, 120550, 120570, 120575, 121800, 130500, 133200, 138140, 138971, 171760, 171760, 172411, 185470, 230350, 255800, 602771
HOSFK40	711140	800	117 - 332	1823		Glu-5 to Ser-16, Gly-49 to Pro-57, Arg-62 to Met-72.	L0803: 2, S0214: 1, L0806: 1, L0788: 1, L0779: 1, L0596: 1 and L0599: 1.		
HOSFI46	719021	801	112 - 300	1824			S0214: 1 and L0756: 1.		
HOSFC66	750560	802	311 - 574	1825			S0214: 1 and L0602: 1.		
HOSFB04	615200	803	238 - 426	1826		Thr-20 to Phe-29, Tyr-40 to Gly-46.	L0439: 3 and S0214: 1.		
HOSDR12	971169	804	259 - 459	1827		Glu-22 to Glu-31.	S0003: 1		
HOSDQ78	858983	805	123 - 290	1828		Ser-1 to His-11, Val-22 to Trp-27.	S0003: 1		
HOSDP27	682113	806	157 - 456	1829		Pro-36 to Thr-43.	S0003: 1 and L0740: 1.		
HOSDG79	781787	807	3 - 590	1830		Leu-4 to Lys-17.	L0748: 2, S0003: 1 and L0749: 1.		
HOSDA04	951842	808	520 - 362	1831			S0003: 1 and L0731: 1.		
HOSCV06	960555	809	59 - 304	1832		Glu-5 to Gly-15, Pro-36 to Arg-42, Pro-58 to Asp-70.	AR089: 8, AR061: 7 S0003: 1, L0498: 1 and L0599: 1.		
HOSCT25	783692	810	155 - 325	1833		Ser-1 to Asn-9,	S0003: 1 and L0748: 1.		

HOSCP67	753874	811	158 - 370	1834	Ala-16 to Lys-22. Lys-15 to Tyr-20, Ser-61 to Thr-71.	L0591: 2 and S0003: 1.		
HOSCO73	764756	812	2 - 163	1835		S0003: 1 and L0599: 1.		
HOSBY89	787182	813	254 - 364	1836	Thr-12 to Ser-26.	L0748: 2 and S0003: 1.		
HOSBX46	719414	814	270 - 365	1837	Phe-6 to Trp-11.	L0756: 2 and S0003: 1. 14		
HOSBX34	706769	815	389 - 547	1838		L0439: 2, S0003: 1 and L0438: 1.		
HOSBR53	728525	816	11 - 208	1839	Ser-8 to Ser-19, Lys-26 to Glu-31, Gln-55 to Cys-64.	S0003: 1 and L0439: 1.		
HOSBO34	706770	817	1 - 99	1840	Thr-1 to Arg-14.	S0003: 1, L0779: 1 and L0589: 1.		
HOSBM55	732550	818	269 - 541	1841	Lys-40 to Thr-45.	L0748: 3 and S0003: 1.		
HOSAY52	728759	819	2 - 154	1842	Leu-29 to Thr-34.	L0756: 2 and S0003: 1. 14		
HOSAX03	960942	820	48 - 812	1843		L0758: 3 and S0003: 1.		
HOSAL10	968710	821	3 - 206	1844	Ala-17 to Asn-22, Pro-24 to Gln-30.	S0003: 1 and L0362: 1.		
HOSAI41	712708	822	859 - 1077	1845	Cys-1 to Gly-6, Gln-26 to Leu-45.	L0748: 3, L0749: 2 and S0003: 1.		
HOSAH30	693406	823	312 - 491	1846		S0003: 1 and L0439: 1.		
HOSAF19	672078	824	124 - 267	1847	Ser-14 to Lys-21, Tyr-33 to Ile-39.	S0003: 1 and L0596: 1.		
HOHEN28	686034	825	2 - 232	1848		L0794: 6, L0768: 2, L0740: 2, L0777: 2, S0250: 1, L0764: 1, L0766: 1, L0655: 1 and L0758: 1.		

HOHEG71	760051	826	262 - 420	1849	Ser-11 to Ser-31, Thr-46 to His-53.	L0777: 2 and S0250: 1.		
HOHDF94	793970	827	456 - 671	1850		S0250: 1 and L0594: 1.		
HOHCV57	734413	828	66 - 380	1851	Phe-2 to Lys-7, Ser-38 to Arg-44, Gly-71 to Asn-94.	S0250: 1 and L0748: 1.		
HOHCL29	634778	829	257 - 6	1852	Asp-7 to Gly-12.	AR054: 9, AR051: 3, AR050: 2 S0250: 1		
HOHCH52	588375	830	2 - 181	1853	Lys-1 to Tyr-8, Lys-10 to Lys-16.	S0250: 1 and L0754: 1.		
HOHCG79	859029	831	1 - 156	1854	Asn-47 to Trp-52.	S0250: 1 and L0763: 1.		
HOHCD58	973105	832	101 - 373	1855	Glu-8 to Pro-14.	S0250: 1		
HOHBZ27	588364	833	203 - 376	1856		S0250: 1, L0435: 1 and L0439: 1.		
HOHBY26	588358	834	3 - 476	1857	Asp-32 to Asn-38, His-116 to Asn-122, Phe-125 to Met-130.	S0250: 1 and L0591: 1.		
HOHBV67	718562	835	3 - 179	1858	Pro-19 to Asn-27, Tyr-46 to His-51.	S0250: 1, L0731: 1, L0597: 1 and L0589: 1.		
HOHBS10	964324	836	157 - 408	1859		S0250: 1 and L0758: 1.		
HOHBP36	708158	837	416 - 141	1860	Ser-12 to Cys-17, Lys-74 to Gly-83.	L0748: 4 and S0250: 1.		
HOHBN56	859041	838	2 - 208	1861	Asn-46 to Leu-51.	L0766: 4 and S0250: 1.		
HOHBL35	973238	839	62 - 256	1862	Ile-23 to Phe-32, Leu-40 to Ala-47.	S0250: 1		
HOHBI84	782908	840	62 - 376	1863	Gly-1 to His-6, Pro-19 to Pro-36,	S0250: 1 and L0742: 1.9q		

HOHBB90	588308	841	300 - 434	1864	Ser-38 to Ser-46.	S0250: 1 and L0754: 1. 17q25	114290, 138033, 162100, 170500, 170500, 170500, 180860, 264470
HOHAV60	489007	842	96 - 668	1865		S0250: 1, L0748: 1 and L0740: 1.	
HOHAT59	867949	843	2 - 214	1866	Ala-58 to Tyr-66.	S0250: 1 and L0370: 1.	
HOHAT11	966727	844	114 - 473	1867	Lys-37 to Tyr-47.	L0180: 1 and S0250: 1.	
HOHAQ65	859057	845	15 - 209	1868		S0250: 1 and L0748: 1.	
HOHAM66	859058	846	1 - 522	1869	Gln-94 to Met-101, Thr-109 to Gly-124, Gln-149 to Gly-155.	L0754: 2 and S0250: 1. 17q12	144200, 148066, 148066, 148067, 148067, 148069, 154275, 180240, 182138, 600119, 600119, 600881, 601363, 601687, 601954
HOHA111	947140	847	1510 - 2127	1870	Phe-22 to Lys-30, Glu-122 to Ser-127, Arg-183 to Lys-190.	S0250: 1	
	965035	1026	338 - 117	2049			
	966030	1027	332 - 490	2050			
HOHAE76	494001	848	94 - 309	1871		S0250: 1	
	859064	1028	156 - 344	2051			
HOEOA28	859156	849	521 - 739	1872	Gly-46 to Gly-51.	L0731: 2, L0763: 1, L0766: 1 and S0126: 1.	
HOENH06	934095	850	1 - 201	1873	Asp-24 to Ala-32.	L0438: 3, L0439: 3,	

							S0126: 1, L0743: 1, L0747: 1, L0749: 1, L0750: 1 and L0758: 1.			
HOELI08	958181	851	413 - 138	1874			L0766: 2, L0769: 1, L0800: 1, L0803: 1, L0804: 1 and S0126: 1.			
HOEX37	708728	852	553 - 717	1875			L0744: 2, S0126: 1 and L0747: 1.			
HOEU57	932562	853	1 - 738	1876		Gly-1 to Arg-15.	AR089: 30, AR061: 7 L0774: 1, S0126: 1 and L0780: 1.			
HOER75	767265	854	278 - 463	1877			L0756: 2 and S0126: 1.			
HOECJ59	739426	855	1 - 462	1878		Cys-1 to Ala-7, Glu-16 to Gly-21, Arg-24 to Gln-30, Ser-41 to Met-52, Trp-75 to His-82.	L0750: 2 and S0126: 1.			
HOECF70	573426	856	39 - 161	1879			S0126: 1			
HOEBT89	921065	857	215 - 364	1880			S0126: 1 and L0754: 1.			
HOACG06	954572	858	88 - 252	1881			L0747: 2, H0252: 1 and L0439: 1.			
HOABY40	711510	859	248 - 466	1882			H0252: 1 and L0756: 1.			
HOABX26	753954	860	93 - 275	1883			H0252: 1, L0769: 1, L0375: 1, L0748: 1 and L0749: 1.			
HOABX21	531390	861	3 - 89	1884		Thr-2 to Lys-18.	H0252: 1			
HOABW12	968797	862	11 - 244	1885		Pro-2 to Ala-7.	H0252: 1 and L0749:			

HOABG91	811156	863	1 - 234	1886	Asp-22 to Ser-27, Asn-29 to Glu-40, His-56 to Gly-73.	1. H0252: 1	11p11.2- p12	133701, 168500, 171650, 176930, 176930, 600623, 600811, 600958
HOABF65	888203	864	149 - 298	1887		AR050: 12, AR051: 10, AR054: 7 H0252: 1		
HOABD07	954060	865	156 - 344	1888	Ser-15 to Gly-20, Ala-26 to Tyr-33.	H0252: 1 and L0777: 1.		
HOABA95	796063	866	101 - 316	1889	Lys-8 to Gln-14, Ile-27 to Thr-52.	H0252: 1 and L0754: 1.		
HOAAW37	708718	867	108 - 242	1890		H0252: 1 and L0748: 1.		
HOAAW11	967660	868	207 - 395	1891	Leu-1 to Trp-6.	H0252: 1 and L0527: 1.		
HOAAW02	920869	869	108 - 329	1892	Thr-1 to Asn-12, Gly-18 to Phe-24, Cys-40 to Trp-45, Thr-50 to His-58.	H0252: 1 and L0766: 1.		
HOAAV77	772512	870	154 - 378	1893	Cys-30 to Arg-38.	L0740: 2 and H0252: 1.		
HOAAO86	859626	871	198 - 443	1894	Pro-18 to Arg-42, Asn-55 to Ala-60.	H0252: 1		
HOAAM67	751947	872	108 - 290	1895	Asp-24 to Pro-31.	H0252: 1 and L0748: 1.		
HOAAK71	761445	873	156 - 389	1896	Thr-18 to Lys-25.	H0252: 1 and L0748: 1.		

HOAAK11	859624	874	1 - 396	1897	Gly-30 to Glu-44, Ser-51 to Glu-56, Arg-91 to Asn-99, Pro-101 to Gly-108, Pro-117 to Leu-122.	H0252: 1		
HOAAI58	859643	875	104 - 238	1898		H0023: 4, L0759: 2, H0252: 1, L0740: 1 and L0596: 1.		
HOAAH77	772514	876	2 - 211	1899	Arg-16 to Ser-23.	H0252: 1 and L0747: 1.		
HOAAH41	712601	877	106 - 246	1900	Ser-9 to Arg-17, Phe-24 to Leu-33.	H0252: 1, L0748: 1 and L0749: 1.		
HMUBZ11	966856	878	161 - 316	1901	Gln-45 to Pro-52.	H0023: 1, H0529: 1 and L0748: 1.		
HMUBY48	721586	879	50 - 154	1902	Ser-8 to Glu-13, Lys-20 to Lys-31.	H0529: 1		
HMUBY20	669581	880	197 - 361	1903	Pro-23 to Asn-29.	H0529: 1		
HMUBV40	837969	881	3 - 434	1904	Tyr-70 to Ser-81, Arg-87 to Arg-97.	H0529: 1		
HMUBR94	793261	882	265 - 450	1905	Leu-10 to Phe-15.	H0529: 1		
HMUBR78	955060	883	75 - 518	1906	Pro-9 to Pro-17, Asp-24 to Glu-30, Asn-65 to Ser-75.	H0529: 1 and L0745: 1.		
HMUBQ01	918052	884	29 - 214	1907	Cys-6 to Val-13, Cys-57 to Asn-62.	H0529: 1		
HMUBP74	765502	885	380 - 553	1908	Ala-1 to His-6.	H0529: 1		
HMUBP38	716800	886	30 - 206	1909		H0529: 1		
HMUBN15	659543	887	258 - 40	1910	Pro-14 to Lys-23.	H0529: 1		

HMUBN05	932057	888	248 - 439	1911			H0529: 1		
HMUBM89	786082	889	458 - 309	1912			H0529: 1		
HMUBM85	784295	890	86 - 229	1913			H0529: 1		
HMUBM23	675296	891	2 - 319	1914		Pro-41 to Ala-47, Arg-50 to Gly-58.	L0439: 3, H0529: 1 and L0438: 1.		
HMUBM21	861218	892	316 - 525	1915			H0529: 1		
HMUBM01	916291	893	1 - 429	1916		Pro-11 to Gly-16, Ser-35 to Gly-55, Gln-63 to Leu-68, Asp-118 to Ser-123, Arg-136 to Ala-141.	H0529: 1 and L0601: 1.		
HMUBL79	774904	894	110 - 229	1917		Gly-15 to Lys-20, Ile-25 to Leu-30.	H0529: 1		
HMUBL25	678011	895	109 - 291	1918		Glu-19 to Arg-25.	H0529: 1 and L0748: 1.		
HMUBI26	424764	896	3 - 209	1919		Lys-6 to Asp-14, Lys-22 to Cys-27.	L0439: 2 and H0529: 1.		
HMUBH84	782971	897	33 - 251	1920		Thr-19 to Thr-28, Ser-43 to Gly-54, Asp-67 to Gly-73.	H0529: 1 and L0749: 1.		
HMUBC76	769968	898	260 - 415	1921		Gly-15 to Ile-21, Ser-24 to Ser-32.	H0529: 1 and L0748: 1.		
HMUBA75	767192	899	214 - 375	1922		Asn-12 to Asn-25.	H0529: 1		
HMUBA61	741710	900	56 - 172	1923			H0529: 1		
HMUA71	772958	901	1 - 264	1924		Ser-15 to Asp-22, Arg-28 to Arg-35.	H0529: 1 and L0601: 1.	6	
HMUA85	783543	902	41 - 259	1925			H0529: 1 and L0731: 1.		

HFOZC29	923288	903	500 - 195	1926	Cys-2 to Asp-8, Ser-59 to Gly-65.	L0384: 1, L0809: 1, L0731: 1 and S0276: 1.		
HFOZA47	909372	904	110 - 262	1927	Ser-26 to Cys-31.	L0748: 1 and S0276: 1.		
HFOYW76	769894	905	129 - 401	1928	Gln-19 to Cys-28.	L0439: 1 and S0276: 1.		
HFOYV08	959038	906	73 - 255	1929	Leu-2 to Arg-8, Lys-42 to Ile-47.	L0021: 1, L0769: 1, L0794: 1, L0803: 1, L0527: 1, L0731: 1, L0758: 1 and S0276: 1.		
HFOYS58	735816	907	134 - 280	1930	Val-10 to Pro-20.	L0589: 1 and S0276: 1.		
HFOYN65	747740	908	3 - 167	1931	Gln-1 to Thr-12.	L0439: 3 and S0276: 1.		
HFOYN01	854780	909	242 - 406	1932		L0591: 1 and S0276: 1.		
HFOYM48	721455	910	64 - 279	1933		L0598: 2, L0766: 1, L0805: 1, L0777: 1 and S0276: 1.		
HFOYL33	702209	911	95 - 508	1934	Ser-1 to Ser-6, Asp-24 to Ala-36, Arg-130 to Leu-135.	L0640: 1, L0748: 1 and S0276: 1.		
HFOYK21	670653	912	28 - 180	1935	Glu-21 to Glu-29, Asn-33 to Tyr-39.	L0758: 2, L0779: 1 and S0276: 1.		
HFOYK02	919458	913	3 - 140	1936		L0750: 2 and S0276: 1.		
HFOYJ30	932485	914	42 - 299	1937		L0747: 1 and S0276: 1.		
HFOYH01	916055	915	259 - 432	1938	Thr-4 to Lys-17, Ser-35 to Gly-40, Thr-44 to Cys-52.	L0761: 1, L0803: 1, L0774: 1, L0775: 1, L0599: 1 and S0276: 1.		
HFOYG88	494875	916	463 - 765	1939		L0747: 3 and S0276: 1.		
HFOYG86	949496	917	220 - 62	1940	Pro-19 to Lys-25, Phe-37 to Asn-44.	AR050: 13, AR054: 7, AR089: 3, AR051: 2, AR061: 1		

	955554	1029	245 - 760	2052	Arg-27 to Gly-35, Tyr-72 to Lys-78, Phe-108 to Lys-114.	L0777: 2, L0731: 2, L0659: 1 and S0276: 1.		
HFOYC08	958975	918	209 - 364	1941	Pro-28 to Thr-33.	L0770: 1 and S0276: 1.		
HFOYA17	662642	919	94 - 348	1942	Arg-32 to Pro-41, Pro-43 to Gly-50.	L0740: 1 and S0276: 1.		
HFOXW67	494854	920	264 - 485	1943	Gln-29 to Asn-37, Lys-55 to Gln-64.	L0439: 1 and S0276: 1.		
HFOXV94	794175	921	2 - 322	1944	Pro-3 to Arg-10, Pro-12 to Arg-18.	L0592: 1 and S0276: 1.		
HFOXT74	875383	922	281 - 535	1945	Ala-31 to Gly-38.	L0749: 1 and S0276: 1.		
HFOXT35	707088	923	143 - 325	1946		S0276: 1		
HFOXSA2	713514	924	352 - 110	1947	Ser-45 to Lys-55.	S0276: 1		
HFOXO57	928171	925	1 - 507	1948	Pro-5 to Gln-14, Lys-26 to Cys-32, Tyr-58 to Gln-69, Gly-78 to Gly-84, Lys-93 to Leu-117.	L0439: 1, L0756: 1 and S0276: 1.		
HFOXO33	702212	926	311 - 493	1949	Asp-32 to Asn-41.	L0623: 1, L0646: 1, L0748: 1 and S0276: 1.		
HFOXM53	587972	927	333 - 560	1950		L0748: 1 and S0276: 1.		
HFOXL88	909839	928	90 - 425	1951	Lys-5 to Ser-12, Thr-17 to Ser-24.	L0562: 1 and S0276: 1.	7q22- q31.1	126650, 126650, 150240, 154276, 173360, 173360, 180105, 222800, 246900, 602136,

									602136, 602136, 602447
HFOXK96	732057	929	83 - 256	1952	Ser-21 to Ile-35, Gln-48 to His-58.			L0750: 1 and S0276: 1.	
HFOXK42	587960	930	3 - 179	1953				L0745: 2, L0415: 1, L0769: 1 and S0276: 1.	
HFOXF91	790103	931	149 - 376	1954				L0439: 3, L0602: 2, L0756: 2 and S0276: 1.	
HFOXF42	854797	932	124 - 378	1955	Ser-6 to Leu-14.			L0485: 1 and S0276: 1.	
HFOXDX78	856499	933	136 - 306	1956				L0438: 1, L0740: 1 and S0276: 1.	
HFOXBX33	701719	934	220 - 432	1957	Leu-53 to Lys-67.			L0590: 1 and S0276: 1.	
HFOXBX26	681593	935	273 - 467	1958	Gln-1 to Val-11.			L0601: 1 and S0276: 1.	
HFOXAX62	743466	936	266 - 430	1959				L0748: 1 and S0276: 1.	
HFIYP86	785341	937	121 - 237	1960	Glu-1 to Asn-6.			L0777: 1 and S0242: 1.	
HFIYB62	743122	938	167 - 304	1961				L0596: 1 and S0242: 1.	
HFIYX08	958977	939	3 - 158	1962				L0749: 2, L0369: 1 and S0242: 1.	
HFIYW79	858618	940	1 - 249	1963	Phe-2 to Arg-11.			L0766: 1, L0744: 1, L0439: 1 and S0242: 1.	
HFIYS11	966702	941	93 - 401	1964	Ser-1 to Ser-6, Gly-58 to Pro-65, Gly-75 to Leu-81.			L0748: 1 and S0242: 1.	
HFIYN50	724175	942	266 - 379	1965				L0777: 2, L0770: 1, L0769: 1, L0780: 1, L0752: 1, L0731: 1, L0759: 1 and S0242: 1.	
HFIYJ92	791305	943	184 - 306	1966				L0439: 5, L0740: 4,	

								L0756: 1, L0752: 1, L0731: 1 and S0242: 1.			
HF1YA08	962212	944	191 - 421	1967			Thr-6 to Lys-13, Phe-37 to His-45, Ala-58 to Ser-72.	L0589: 1 and S0242: 1.			
HF1XZ95	915703	945	2 - 208	1968			Val-2 to Ser-14.	L0608: 1 and S0242: 1.			
HF1XZ19	683033	946	613 - 410	1969				L0758: 1 and S0242: 1.			
HF1XR93	894013	947	242 - 460	1970				L0740: 2 and S0242: 1.			
HF1XR68	752858	948	220 - 342	1971				L0748: 1 and S0242: 1.			
HF1XP31	697759	949	3 - 317	1972			Leu-9 to Asn-16, Thr-92 to Pro-100.	AR089: 4, AR061: 1 L0777: 3, L0809: 1 and S0242: 1.			
HF1XP04	839910	950	185 - 400	1973			Ser-31 to Glu-36, Lys-44 to Cys-51.	L0779: 1 and S0242: 1.			
HF1XJ53	489122	951	94 - 348	1974				L0748: 1 and S0242: 1.			
HF1XB77	772116	952	137 - 352	1975				L0754: 1 and S0242: 1.			
HF1VS81	387591	953	2 - 157	1976				L0439: 1 and S0196: 1.			
HF1VS21	855131	954	1 - 279	1977				L0545: 1 and S0196: 1.			
HF1VS08	959272	955	115 - 255	1978			Pro-1 to Ser-6.	L0021: 1 and S0196: 1.			
HF1UZ63	745033	956	74 - 283	1979			Ser-12 to Gly-17.	L0748: 1 and S0196: 1.			
HF1UY49	855133	957	65 - 382	1980			Leu-10 to Lys-22, Ser-46 to Ala-54, Pro-85 to Phe-91.	S0196: 1			
HF1UV58	735350	958	2 - 205	1981				L0740: 2, L0747: 2 and S0196: 1.			
HF1UV18	787095	959	3 - 248	1982				L0746: 1 and S0196: 1.			
HF1UM33	702319	960	214 - 372	1983				S0196: 1			
HF1UH65	747836	961	34 - 183	1984			Leu-7 to Cys-14,	L0752: 2, L0740: 1,			

							Pro-16 to Ser-24, Gln-43 to His-50.	L0745: 1 and S0196: 1.		
HFIUD47	720254	962	129 - 380	1985				L0750: 2, L0747: 1, L0731: 1, L0591: 1 and S0196: 1.		
HFITH46	718078	963	295 - 672	1986				L0745: 1, L0746: 1 and S0196: 1.		
HFUG36	707883	964	1 - 183	1987			Ser-1 to Asp-9.	L0749: 1 and S0194: 1.		
HFUG20	669580	965	307 - 435	1988				L0748: 1 and S0194: 1.		
HFJF58	735927	966	214 - 492	1989			Lys-1 to Lys-15, Arg-22 to Arg-31, Thr-68 to Pro-73, Pro-79 to Ser-86.	L0777: 2 and S0194: 1.		
HFIZ92	494044	967	170 - 3	1990			Asp-1 to Cys-6, Lys-15 to Phe-23, Asn-46 to Arg-56.	S0194: 1		
	533295	1030	1 - 843	2053			Gly-1 to Val-7, Gln-28 to Thr-34, Ala-100 to Thr-108, Ser-115 to Arg-122, Ser-156 to Glu-162, Ser-174 to Tyr-186, Glu-188 to Phe-193.			
HFIU85	793332	968	242 - 526	1991				L0598: 1 and S0194: 1.		
HFIR63	744994	969	312 - 467	1992			Ala-6 to Ile-12.	L0439: 3 and S0194: 1.		
HFIL37	561375	970	3 - 350	1993			Ser-1 to Gly-18, Gly-27 to Leu-39, Ser-76 to Thr-89.	AR050: 241, AR051: 230, AR054: 157 S0194: 1		

HFIHK75	767222	971	541 - 810	1994	Trp-1 to Val-6, His-20 to Ser-28, Arg-47 to Pro-53, Thr-65 to Pro-71, Ser-78 to Gly-90.	L0439: 2, L0777: 2 and S0194: 1.		
HFIHK32	424259	972	133 - 321	1995	His-5 to Thr-10.	L0754: 1 and S0194: 1.		
HFIHK07	953034	973	84 - 317	1996		L0663: 1 and S0194: 1.		
HFIHJ14	839523	974	429 - 707	1997	Val-17 to His-33, Arg-51 to Leu-60, Leu-85 to Pro-93.	AR054: 62, AR050: 59, AR051: 58 S0194: 1		
HFIHW91	907618	975	3 - 527	1998	Trp-5 to Pro-11.	AR089: 13, AR061: 6 L0779: 1, L0780: 1, L0759: 1 and S0194: 1.		
HFIHW16	858594	976	3 - 272	1999	Gln-22 to Trp-27.	L0744: 1 and S0194: 1.		
HFIHW11	947856	977	22 - 201	2000		L0527: 2 and S0194: 1.		
HFIHV56	470954	978	70 - 378	2001	Ser-1 to Arg-7.	L0592: 1 and S0194: 1.		
HFIHU76	769948	979	133 - 246	2002		L0748: 1 and S0194: 1.		
HFIHS86	785419	980	146 - 325	2003		L0598: 1 and S0194: 1.		
HFIHR78	773512	981	249 - 407	2004		L0745: 1 and S0194: 1.		
HFIHN35	707075	982	327 - 560	2005		L0748: 3, L0749: 1 and S0194: 1.		
HFIHK29	855174	983	97 - 450	2006	Val-3 to Arg-11, Pro-34 to His-47, Ser-58 to Leu-68, Pro-72 to Trp-77.	L0731: 2 and S0194: 1.		
HFIHF53	728259	984	369 - 500	2007	Ile-7 to Ile-13.	L0754: 1 and S0194: 1.		
HFIHD20	669731	985	3 - 338	2008	Arg-6 to Thr-11, Gly-27 to Leu-33.	L0605: 1 and S0194: 1.		

							Lys-52 to Phe-61, Gln-86 to Lys-92, Asn-102 to Arg-112.				
HFIDL68	928475	986	2 - 529	2009			Glu-40 to Lys-46, Phe-120 to Ser-132.			AR089: 7, AR061: 4, AR050: 2, AR054: 2, AR051: 1 S0192: 1	
HFIDL06	837524	987	50 - 487	2010			Val-1 to Gly-8, Gln-48 to Asp-53, Glu-61 to Asp-68, Val-88 to Lys-96, Asp-102 to Lys-108.			L0602: 1 and S0192: 1.	
HFIBK83	939556	988	2 - 502	2011			Val-48 to Pro-56, Asp-58 to Gln-69.			L0439: 1 and S0192: 1.	
HFIA X78	773445	989	80 - 217	2012						S0192: 1	
HFIA S49	722728	990	357 - 611	2013			Leu-5 to Lys-11.			L0740: 1 and S0192: 1.	
HFIA L66	587837	991	339 - 515	2014						L0740: 1 and S0192: 1.	
HCOKA10	907080	992	605 - 171	2015			Phe-13 to Thr-22.			AR054: 7, AR061: 2, AR089: 1, AR051: 1 H0636: 1	
	918918	1031	1663 - 1220	2054							
	919869	1032	1 - 396	2055			Pro-1 to Ser-9, Asp-127 to Asn-132.				
HCDEL02	920831	993	167 - 292	2016						H0251: 1 and L0776: 1.	
HCDDZ69	522220	994	198 - 341	2017						H0251: 1	
HCDDY54	529265	995	23 - 148	2018			Gln-12 to Asp-26.			H0251: 1	

HCDDO80	778563	996	85 - 402	2019	Tyr-8 to Thr-15.	H0251: 1 and L0596: 1.		
HCDCD64	863415	997	23 - 301	2020	Asp-35 to Cys-43.	H0251: 1 and L0740: 1.		
HCDBW41	712648	998	2 - 217	2021	Pro-2 to Lys-7.	L0439: 3 and H0251: 1.		
HCDBO86	784617	999	279 - 509	2022	Thr-62 to Asn-69, Cys-71 to Glu-77.	H0251: 1, L0747: 1, L0756: 1 and L0777: 1.		
HCDAO39	704504	1000	3 - 260	2023		H0251: 1 and L0588: 1.		
HCDA68	753814	1001	412 - 576	2024	Ala-3 to Thr-9, Arg-16 to Pro-23.	H0251: 1 and L0748: 1.		
HBSAP57	531874	1002	298 - 474	2025	Ser-1 to Gly-11, Pro-42 to Lys-54.	AR051: 87, AR054: 84, AR050: 83 H0381: 1		
	533619	1033	392 - 216	2056	Ser-1 to Gly-11, Pro-42 to Lys-54.			
HBCKF23	675613	1003	168 - 425	2026	Gly-9 to His-18.	L0758: 3, S0336: 1 and L0779: 1.		
HBCGD25	677689	1004	97 - 240	2027	Leu-39 to Lys-46.	L0748: 3 and S0334: 1.		
HAOAE95	795674	1005	95 - 217	2028	Gly-12 to Pro-20.	L0605: 2 and S0314: 1.		
HAOAD27	848729	1006	90 - 335	2029		S0314: 1 and L0747: 1.		
HANKG10	963926	1007	34 - 237	2030	Cys-1 to Phe-6, Leu-30 to Gly-38.	S0318: 1, L0766: 1 and L0803: 1.		
HANKB13	827062	1008	2 - 436	2031	Lys-4 to Gln-16, Lys-32 to Lys-39, Met-43 to Asn-48, Gln-70 to Leu-76.	S0318: 1, L0766: 1 and L0666: 1.		

HAMAC79	872774	1009	337 - 867	2032	AR089: 20, AR061: 13 H0122: 1		
---------	--------	------	-----------	------	----------------------------------	--	--

[058] The first column in Table 1A provides a unique "Clone ID NO:Z" for a cDNA clone related to each contig sequence disclosed in Table 1A. This clone ID references the cDNA clone which contains at least the 5' most sequence of the assembled contig, and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone. The reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods known in the art and/or as described elsewhere herein.

[059] The second column in Table 1A provides a unique "Contig ID" identification for each contig sequence. The third column provides the "SEQ ID NO:X" identifier for each of the musculoskeletal system associated contig polynucleotide sequences disclosed in Table 1A. The fourth column, "ORF (From-To)", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1A, column 5, as SEQ ID NO:Y. Where the nucleotide position number "To" is lower than the nucleotide position number "From", the preferred ORF is the reverse complement of the referenced polynucleotide sequence.

[060] The fifth column in Table 1A provides the corresponding SEQ ID NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 4. In one embodiment, the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by "ORF (From-To)". Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto.

[061] Column 6 in Table 1A lists residues comprising epitopes contained in the polypeptides encoded by the preferred ORF (SEQ ID NO:Y), as predicted using the algorithm of Jameson and Wolf, (1988) *Comp. Appl. Biosci.* 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, at least one, two, three, four, five or more of the predicted epitopes as described in Table 1A. It will be appreciated that depending on

the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

[062] Column 7 in Table 1A provides an expression profile and library code: count for each of the contig sequences (SEQ ID NO:X) disclosed in Table 1A, which can routinely be combined with the information provided in Table 4 and used to determine the normal or diseased tissues, cells, and/or cell line libraries which predominantly express the polynucleotides of the invention. The first number in column 7 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4. For those identifier codes in which the first two letters are not "AR", the second number in column 7 (following the colon) represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of  $^{33}\text{P}$  dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. The sequences disclosed herein have been determined to be predominantly expressed in

musculoskeletal system tissues, including normal and diseased musculoskeletal system tissues (See Table 1A, column 7 and Table 4).

[063] Column 8 in Table 1A provides a chromosomal map location for certain polynucleotides of the invention. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Each sequence in the UniGene database is assigned to a "cluster"; all of the ESTs, cDNAs, and STSs in a cluster are believed to be derived from a single gene. Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[064] A modified version of the computer program BLASTN (Altschul et al., J. Mol. Biol. 215:403-410 (1990), and Gish et al., Nat. Genet. 3:266-272 (1993)) was used to search the UniGene database for EST or cDNA sequences that contain exact or near-exact matches to a polynucleotide sequence of the invention (the 'Query'). A sequence from the UniGene database (the 'Subject') was said to be an exact match if it contained a segment of 50 nucleotides in length such that 48 of those nucleotides were in the same order as found in the Query sequence. If all of the matches that met this criteria were in the same UniGene cluster, and mapping data was available for this cluster, it is indicated in Table 1A under the heading "Cytologic Band". Where a cluster had been further localized to a distinct cytologic band, that band is disclosed; where no banding information was available, but the gene had been localized to a single chromosome, the chromosome is disclosed.

[065] Once a presumptive chromosomal location was determined for a polynucleotide of the invention, an associated disease locus was identified by comparison with a database of diseases which have been experimentally associated with genetic loci. The database used was the Morbid Map, derived from OMIM™ (*supra*). If the putative chromosomal location of a polynucleotide of the invention (Query sequence) was associated with a disease in the Morbid Map database, an OMIM reference identification number was noted in column 9, Table 1A, labeled

“OMIM Disease Reference(s)”. Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.

**TABLE 1B**

Clone ID NO:Z	SEQ ID NO:X	CONTIG ID:	BAC ID: A	SEQ ID NO:B	EXON From-To
HANGA63	11	927404	AL133312	2057	1-333
HANGA63	11	927404	AL135752	2058	1-333
HANGA63	11	927404	AL133312	2059	1-467
HANGA63	11	927404	AL135752	2060	1-467
HANGA69	12	718174	AL353590	2061	1-446
HANGA85	13	746265	AC007705	2062	1-330
HANGA92	14	791182	AL359257	2063	1-167
HANGA92	14	791182	AL359257	2064	1-825 1179-1523 1777-2115
HANGC05	15	674059	AC024377	2065	1-119
HANGC05	15	674059	AC018496	2066	1-119
HANGC05	15	674059	AC024377	2067	1-202
HANGC05	15	674059	AC018496	2068	1-187
HANGC30	18	966430	AC022618	2069	1-408
HANGC33	19	702072	AC069127	2070	1-272
HANGC84	21	715991	AL137178	2071	1-1034 1132-1714
HANGC84	21	715991	AC016847	2072	1-1034 1132-1714
HANGF36	22	952583	AC013496	2073	1-255
HANGF36	22	952583	AC013496	2074	1-616
HANGF49	23	722635	AC013465	2075	1-469
HANGF49	23	722635	AC026298	2076	1-123
HANGF49	23	722635	AC016911	2077	1-469
HANGF49	23	722635	AC016749	2078	1-123
HANGF49	23	722635	AC010080	2079	1-469
HANGF49	23	722635	AC006386	2080	1-469
HANGF49	23	722635	AC026298	2081	1-399
HANGF49	23	722635	AC016749	2082	1-399
HANGG22	24	848727	AL355112	2083	1-374
HANGG22	24	848727	AL355112	2084	1-147
HANGH48	25	718759	AC069530	2085	1-378
HANGH48	25	718759	AC069530	2086	1-509
HANGH53	26	727914	AC073319	2087	1-440
HANGH66	28	661513	AC036194	2088	1-457
HANGH66	28	661513	AC026013	2089	1-457
HANGH66	28	661513	AC025534	2090	1-457

HANKD09	29	625167	AC012521	2091	1-409
HANKD09	29	625167	AC027666	2092	1-409
HANKD47	30	719963	AL355592	2093	1-464
HANKD83	31	963964	AC068969	2094	1-316
HANKD83	31	963964	AC067805	2095	1-316
HANKG78	32	710760	AC006514	2096	1-385 594-1524 1793-2194 4246-4590 4888-5238
HANKG78	32	710760	AC006510	2097	1-931 1200-1601
HANKG78	32	710760	AC006510	2098	1-379
HANKG90	33	746282	AP001644	2099	1-437
HANKG90	33	746282	AC021506	2100	1-437
HANKH48	34	721340	AP001203	2101	1-382
HANKH56	35	733063	AC074293	2102	1-417
HANKH56	35	733063	AC068194	2103	1-417
HAOAA78	37	756979	AC008945	2104	1-549
HAOAA78	37	756979	AC008945	2105	1-481
HAOAA90	38	919249	AC044917	2106	1-348
HAOAA90	38	919249	AP001839	2107	1-332
HAOAA90	38	919249	AC023090	2108	1-348
HAOAA90	38	919249	AC018445	2109	1-348
HAOAA90	38	919249	AC044917	2110	1-887
HAOAA90	38	919249	AP001839	2111	1-146 303-921
HAOAA90	38	919249	AC023090	2112	1-887
HAOAC05	39	932017	AC008279	2113	1-516
HAOAC05	39	932017	AC008279	2114	1-478
HAOAH38	45	705946	AC005036	2115	1-345
HAOMA13	46	915881	AC068969	2116	1-368
HAOMA13	46	915881	AC067805	2117	1-368
HAOMA13	46	915881	AC067805	2118	1-536
HAOMB64	47	960293	AC019144	2119	1-1138
HAOMB64	47	960293	AC019144	2120	1-319
HAOMB64	47	960293	AC019144	2121	1-455
HAOMC21	48	670518	AL354920	2122	1-788
HAOMC21	48	670518	AL354920	2123	1-317
HAOMC21	48	670518	AL354920	2124	1-1979 3907-4540 5067-5184 6386-6845
HAOME45	50	705947	AP001011	2125	1-1739
HAOME45	50	705947	AP000937	2126	1-1738
HAOME45	50	705947	AP000898	2127	1-1738

					1771-4394
HAOME45	50	705947	AC015958	2128	1-1739 1772-4400
HAOME45	50	705947	AP000937	2129	1-415 436-874
HAOME45	50	705947	AP001011	2130	1-415 436-874
HAOME45	50	705947	AP000898	2131	1-415 436-874
HAOME45	50	705947	AP000937	2132	1-665
HAOME45	50	705947	AC015958	2133	1-414 435-873
HBCKE22	54	674041	AC016659	2134	1-562 827-886 4639-5057 6461-6525 6654-7045 7193-7882 8357-8477 11540-11583 11943-12257 13444-13934 14354-14528 15155-15287
HBCKE22	54	674041	AC012481	2135	1-691
HBCKE22	54	674041	AC016659	2136	1-258
HBCKE22	54	674041	AC012481	2137	1-121 3184-3224 3587-3901 5088-5578 5998-6172 6799-6931
HBCKE22	54	674041	AC012481	2138	1-392
HBSAK76	57	506666	AC027632	2139	1-349
HBSAK76	57	506666	AC027632	2140	1-425
HBSAL69	58	573004	AC020791	2141	1-433
HBSAL80	59	506580	AC018712	2142	1-380
HBSAL80	59	506580	AC074334	2143	1-125
HBSAL80	59	506580	AC026718	2144	1-420
HBSAP02	62	920648	AC022496	2145	1-490
HBSAP02	62	920648	AC025456	2146	1-130 236-725 796-1013 2665-2751 3801-4267 5755-6475 7371-7547

					9209-9496 9611-10511 11152-11890 11984-12319 12651-12745 16691-17158 17236-17382 22177-22609
HBSAP02	62	920648	AC026437	2147	1-122 228-717 788-1005 2655-2741 3791-4257 5740-6460 7356-7532 9194-9481 9596-10496 11137-11875 11969-12304 12636-12730 16676-17143 17221-17367 22161-22574 29380-29520 36637-36948 37077-37558 38020-38322 39908-40220 41806-41890 42060-43287 43415-44248 44300-44584 44929-45056 45424-45902 46737-46932 47156-49997
HBSAP02	62	920648	AC022496	2148	1-218
HBSAP02	62	920648	AC026437	2149	1-751
HBSAP02	62	920648	AC026437	2150	1-934
HBSAQ64	64	530344	AC027573	2151	1-341
HBSAQ64	64	530344	AC073413	2152	1-341
HBSAQ64	64	530344	AC073413	2153	1-92
HBSDD91	67	775313	AC027644	2154	1-286 361-599 687-919 1726-2633
HBSDD91	67	775313	AC027644	2155	1-234

HCDAA94	68	661278	AC026053	2156	1-259
HCDAA94	68	661278	AC022262	2157	1-274
HCDAA94	68	661278	AL020995	2158	1-259
HCDAA94	68	661278	AC022262	2159	1-526
HCDAA94	68	661278	AL020995	2160	1-526
HCDAG92	74	724693	AP001105	2161	1-496
HCDAG92	74	724693	AP001900	2162	1-496
HCDAG92	74	724693	AP001145	2163	1-496
HCDAG95	75	533871	AC018891	2164	1-441
HCDAG95	75	533871	AC018891	2165	1-327
HCDAH34	76	533870	AC010469	2166	1-483
HCDAH34	76	533870	AC026718	2167	1-483
HCDAH34	76	533870	AC010469	2168	1-122
HCDAH34	76	533870	AC010469	2169	1-272
HCDAJ67	77	925362	AL049875	2170	1-317
HCDAJ67	77	925362	AL049875	2171	1-141
HCDAK93	78	523648	AC027474	2172	1-527
HCDAK93	78	523648	AC010332	2173	1-526
HCDAK93	78	523648	AC021112	2174	1-527
HCDAK93	78	523648	AC027474	2175	1-684
HCDAK93	78	523648	AC010332	2176	1-684
HCDAK93	78	523648	AC021112	2177	1-684
HCDAM34	80	523607	AC005969	2178	1-98 1380-1550
HCDAM34	80	523607	AC005969	2179	1-227
HCDAO32	81	530006	AC068780	2180	1-285
HCDAO32	81	530006	AC073907	2181	1-285
HCDAO32	81	530006	AC068780	2182	1-136
HCDAO32	81	530006	AC073907	2183	1-297
HCDAT56	82	533881	AL109657	2184	1-664 792-1138 1613-2026 6132-6234 6599-7035 7168-7446 8133-8262 8374-8670 8831-9478 9704-9762 9777-10137 10260-11201 11900-12541
HCDAT56	82	533881	AL109657	2185	1-489
HCDAT56	82	533881	AL109657	2186	1-369
HCDBO13	83	709590	AC007411	2187	1-323
HCDBR39	85	921893	AC008594	2188	1-409

HCDBR39	85	921893	AC040160	2189	1-410
HCDBR39	85	921893	AC008594	2190	1-761
HCDBR39	85	921893	AC008594	2191	1-1026
HCDBR39	85	921893	AC040160	2192	1-1026
HCDBR39	85	921893	AC040160	2193	1-761
HCDBU77	86	661272	AL121747	2194	1-400 540-929 957-1393 1904-2140 3206-3745 4498-4693 4849-5203 6468-6828 7645-8255 8418-8525 9502-10126
HCDBU77	86	661272	AL121747	2195	1-756
HCDBW51	87	556469	AL358472	2196	1-288
HCDBW51	87	556469	AL358472	2197	1-309
HCDBX78	89	847580	AC026340	2198	1-252
HCDBX78	89	847580	AC026340	2199	1-111
HCDCB84	90	670159	AL035634	2200	1-241
HCDCB84	90	670159	AL139330	2201	1-77 563-1013 1219-1674 2670-2885 4767-5013 5856-5969 6030-6407 6602-8576
HCDCB84	90	670159	AL035634	2202	1-451 657-1112
HCDCB84	90	670159	AL139330	2203	1-384
HCDC62	92	523582	AL137065	2204	1-305
HCDC62	92	523582	AL031177	2205	1-305
HCDCF11	93	967768	AC021163	2206	1-278
HCDCF11	93	967768	AC006942	2207	1-278
HCDCF11	93	967768	AC021163	2208	1-148 244-287 843-967
HCDCF11	93	967768	AC006942	2209	1-148 244-287 843-967
HCDCF11	93	967768	AC006942	2210	1-476 718-997
HCDC91	95	592465	AC024885	2211	1-3448

HCDCR26	96	960048	AP000087	2212	1-429 732-1074 1121-1255 3513-3762
HCDCR26	96	960048	AP000139	2213	1-429 732-1074 1121-1255 3513-3762
HCDCR26	96	960048	AP000226	2214	1-429 732-1074 1121-1255 3513-3762
HCDCR26	96	960048	AP000226	2215	1-2571
HCDCR26	96	960048	AP000087	2216	1-2571
HCDCR26	96	960048	AP000139	2217	1-2571
HCDCX68	97	529778	AC003692	2218	1-44 153-684 695-1033 2881-3167 3597-8068 8150-9192
HCDCX68	97	529778	AC003692	2219	1-342
HCDCX68	97	529778	AC003692	2220	1-467
HCDDDB62	100	529890	AC015589	2221	1-570
HCDDDB62	100	529890	AC010328	2222	1-570
HCDDDB62	100	529890	AC015589	2223	1-340
HCDDDB62	100	529890	AC010328	2224	1-82 355-795 871-998 1300-1582 1629-2248 2727-2918 4474-4729 4876-6190 6240-9439
HCDDDB62	100	529890	AC010328	2225	1-340
HCDDI61	101	529937	AC005876	2226	1-428
HCDDI61	101	529937	AL358234	2227	1-428
HCDDI61	101	529937	AL161936	2228	1-428
HCDDI61	101	529937	AC005876	2229	1-247
HCDDI61	101	529937	AL358234	2230	1-247
HCDDI61	101	529937	AL161936	2231	1-247
HCDDU07	102	954177	AC005498	2232	1-1881
HCDDU07	102	954177	AC005498	2233	1-380
HCDDV90	103	847575	AC021553	2234	1-251
HCDDV90	103	847575	AC067837	2235	1-251

HCDDV90	103	847575	AC067837	2236	1-1510
HCDDV90	103	847575	AC067837	2237	1-450
HCDDY57	104	556465	AL354936	2238	1-273
HCDDY57	104	556465	AC021410	2239	1-273
HCDDY57	104	556465	AL354936	2240	1-186
HCDDY57	104	556465	AC021410	2241	1-153
HCDDZ09	105	523605	AC008866	2242	1-156
HCDDZ09	105	523605	AC016641	2243	1-156
HCDEB49	107	847572	AC024998	2244	1-242
HCDEB49	107	847572	AL390122	2245	1-242
HCDEB49	107	847572	AF198096	2246	1-242
HCDEB49	107	847572	AL390122	2247	1-430
HCDEB49	107	847572	AL390122	2248	1-419
HCDEB49	107	847572	AF198096	2249	1-430
HCDEB49	107	847572	AF198096	2250	1-500
HCDEB78	108	921710	AL359513	2251	1-300
HCDER16	111	667338	AC008064	2252	1-315
HCDER16	111	667338	AC008064	2253	1-415
HCDER16	111	667338	AC008064	2254	1-259
HCDER29	112	523506	AC022835	2255	1-203
HCDER29	112	523506	AC012476	2256	1-234 244-446 460-664 814-913 3082-3278 3691-4090
HCDER29	112	523506	AC022835	2257	1-155
HCDER29	112	523506	AC012476	2258	1-412
HCDET89	113	524045	AC009719	2259	1-323
HCDET89	113	524045	AC022939	2260	1-323
HCDET89	113	524045	AC009719	2261	1-138
HCDET89	113	524045	AC009719	2262	1-308
HCDET89	113	524045	AC022939	2263	1-138
HCDET89	113	524045	AC022939	2264	1-308
HFIAE82	116	779898	AC020669	2265	1-443
HFIAI07	118	952884	AC005722	2266	1-365 1763-1914 2765-3000 3766-3854 4573-5237 6312-7007 7152-7793 8026-8551 8938-9098 9770-10050 11976-12661

					12934-13016 13421-13727 14047-14140 14549-14721 15329-15864 16167-16198 21769-21933 22605-22741 22939-23176 24138-24261 24368-24492 26100-26500 26685-28818
HFIAP07	118	952884	AC005722	2267	1-491
HFIAP31	119	697775	AL360269	2268	1-291
HFIAP31	119	697775	AL356323	2269	1-374
HFIAP31	119	697775	AC004916	2270	1-374
HFIAP31	119	697775	AC004916	2271	1-480
HFIAP89	120	587844	AC013526	2272	1-343
HFIAP89	120	587844	AC011769	2273	1-342
HFIAP89	120	587844	AC011766	2274	1-342
HFIAP91	121	925831	AC002094	2275	1-282 780-1066 1693-1777 2672-3234 3779-3876 4254-4331 4547-4658 5768-5907 6777-6804 6988-7438 7930-8074 8084-8109 8407-8492 9334-13211 15125-15331 16116-16166 16244-16336 17085-17261 17834-18163 18315-19249 19368-20067 20077-20493 21715-21833
HFIAP91	121	925831	AC002094	2276	1-1458 1484-1825 2941-3033

					3149-3619 4464-4687
HFAP91	121	925831	AC002094	2277	1-139 960-1288 3094-3333 3487-3622 4951-5037 5249-5369 5403-8947 9834-9970
HFIBI48	124	587871	AL162590	2278	1-574
HFIBI48	124	587871	AL161445	2279	1-574
HFIBI48	124	587871	AL162590	2280	1-697
HFIBI48	124	587871	AL162590	2281	1-326
HFIBI48	124	587871	AL161445	2282	1-326
HFIBI48	124	587871	AL161445	2283	1-697
HFICF01	127	916103	AC017083	2284	1-428
HFIDN81	134	959050	AC013705	2285	1-944
HFIDN81	134	959050	AC011644	2286	1-946
HFIDN81	134	959050	AC013705	2287	1-349
HFIDN81	134	959050	AC013705	2288	1-757
HFIDN81	134	959050	AC011644	2289	1-349
HFIHB16	138	661971	AC025919	2290	1-472
HFIHD91	139	702324	AP001901	2291	1-2143
HFIHD91	139	702324	AC016229	2292	1-2144
HFIHD91	139	702324	AP001901	2293	1-608
HFIHD91	139	702324	AC016229	2294	1-44 1477-1919 2015-4862
HFIHE47	140	857988	AC021097	2295	1-1803 2560-3406 3921-4106 4155-6674 6911-7014 7135-7264 7522-8788
HFIHJ60	142	740280	AL132709	2296	1-763 922-2545
HFIHJ60	142	740280	AL132709	2297	1-383
HFIHL29	144	690546	AC067837	2298	1-384
HFIHL29	144	690546	AC021553	2299	1-384
HFIHL29	144	690546	AC067837	2300	1-450
HFIHZ33	146	588058	AC011822	2301	1-993 1199-1868
HFIHZ33	146	588058	AF025422	2302	1-991
HFIHZ33	146	588058	AC011822	2303	1-534

					541-1582
HFIHZ33	146	588058	AF025422	2304	1-534
					541-1582
HFIHZ33	146	588058	AF025422	2305	1-670
HFIHZ51	147	725587	AC015480	2306	1-386
HFIIB73	148	669594	AL109757	2307	1-452
HFIIB73	148	669594	AL031296	2308	1-670
					1590-2584
					3609-3751
					4204-4803
					4847-5271
					9874-10146
					11847-12328
					12493-13051
					13395-13635
					15455-15917
					17288-17739
					18945-19908
					21414-22006
					27737-27823
					35955-36575
					36643-37204
					37341-37504
					39154-39312
					41736-42263
					47221-47669
					47712-48167
					50898-51095
					51163-51655
					51716-52580
					52706-58181
HFIIB73	148	669594	AL109757	2309	1-964
HFIIB73	148	669594	AL031296	2310	1-274
HFIIS21	149	670765	AL359372	2311	1-420
					908-1805
					1962-3333
					3335-4572
					5795-5879
					7151-7262
					7320-7927
HFIIS21	149	670765	AL359372	2312	1-709
HFIJF34	150	703972	AC020726	2313	1-462
HFIUE17	153	855119	AL121809	2314	1-576
HFIUE17	153	855119	AL133501	2315	1-577
HFIUE17	153	855119	AL121809	2316	1-374
HFIUE17	153	855119	AL121809	2317	1-67
					286-666

					3060-3146 3462-3689 4441-4741 8067-8220 9047-9139 9816-10074 11133-11965 14462-14721 15045-15361 15605-16026 17424-17605 17899-18267 18702-18860
HFIUE17	153	855119	AL133501	2318	1-374
HFIUH54	154	929787	AC004774	2319	1-403
HFIUH54	154	929787	AC004774	2320	1-519
HFIUI66	155	746397	AC012385	2321	1-326
HFIUI66	155	746397	AC026491	2322	1-439 1239-1395 1783-2779 2956-3540 3650-3772 3781-4106 6023-6283 6363-7024 7557-7711 10937-11233 12728-12870 13214-13362 13714-15432 16010-16106
HFIUI66	155	746397	AC026491	2323	1-299
HFIUJ95	156	735969	AC009280	2324	1-437
HFIUJ95	156	735969	AC009280	2325	1-296
HFIUO63	158	691921	AC012681	2326	1-969
HFIUO63	158	691921	AC012681	2327	1-614
HFIVB03	160	924021	AC017003	2328	1-335
HFIXC30	165	692635	AP002406	2329	1-418
HFIXC30	165	692635	AC010776	2330	1-418
HFIXC44	166	839536	AC036163	2331	1-588 625-1391
HFIXC44	166	839536	AC036163	2332	1-2530
HFIXK83	168	767156	AC007991	2333	1-400 1386-1821 3975-4075 4188-4312 4711-4794

					4915-5054
HFIXK83	168	767156	AC007991	2334	1-114
HFIXK94	169	943717	AC073231	2335	1-430
HFIXK94	169	943717	AF045448	2336	1-430
HFIXK94	169	943717	AF064860	2337	1-430
HFIXK94	169	943717	AF121897	2338	1-430
HFIXK94	169	943717	AC073231	2339	1-527
HFIXK94	169	943717	AF045448	2340	1-49 3630-4025
HFIXK94	169	943717	AF045448	2341	1-528
HFIXK94	169	943717	AF064860	2342	1-528
HFIXK94	169	943717	AF064860	2343	1-49 3630-4025
HFIXK94	169	943717	AF121897	2344	1-528
HFIXK94	169	943717	AF121897	2345	1-49 3630-4025
HFIXM11	170	966714	AL354946	2346	1-677 1412-3002 3013-3365 3460-4359
HFIXM11	170	966714	AL136324	2347	1-677 1412-3003 3014-3366 3461-4360
HFIXM11	170	966714	AL136324	2348	1-418
HFIXM11	170	966714	AL354946	2349	1-418
HFIXV93	172	597031	AC010810	2350	1-452
HFIXV93	172	597031	AC016252	2351	1-3092 3746-3853 6998-7134 7278-7767 8926-9044 9829-9973
HFIXV93	172	597031	AC010810	2352	1-960
HFIXV93	172	597031	AC016252	2353	1-308
HFIXV93	172	597031	AC016252	2354	1-479
HFIXY13	173	656812	AC020602	2355	1-350
HFIXY13	173	656812	AC020602	2356	1-372
HFIXY13	173	656812	AC020602	2357	1-1346
HFIYA86	176	757155	AF015722	2358	1-356
HFIYA86	176	757155	AF015720	2359	1-352
HFIYA86	176	757155	AF015722	2360	1-649 1041-1647
HFIYA86	176	757155	AF015720	2361	1-649 1048-1655
HFIYB24	177	952847	AL022724	2362	1-372

HFIYB24	177	952847	AL022724	2363	1-317
HFIYB40	178	964251	AC011940	2364	1-467
HFIYB40	178	964251	AC012207	2365	1-467
HFIYB40	178	964251	AC011940	2366	1-432
HFIYB40	178	964251	AC011940	2367	1-360
HFIYB40	178	964251	AC012207	2368	1-360
HFIYB40	178	964251	AC012207	2369	1-432
HFIYK01	179	916125	AC023112	2370	1-1779 1794-2622
HFIYK01	179	916125	AC023112	2371	1-742
HFIYO14	181	657598	AL359915	2372	1-540
HFIYO14	181	657598	AL359915	2373	1-328
HFIYO14	181	657598	AL359915	2374	1-141
HFIYP02	182	919501	AC025118	2375	1-367
HFIYP02	182	919501	AL137818	2376	1-179 1123-1340 1965-2331 2735-2862 5533-5858 6030-6163
HFIYP02	182	919501	AL137818	2377	1-167
HFIYV59	185	861487	AL031730	2378	1-134 1650-1936
HFIZH29	190	953895	AC024472	2379	1-410
HFIZH29	190	953895	AC026552	2380	1-410
HFIZH29	190	953895	AC010257	2381	1-410
HFIZM92	191	791267	AL049844	2382	1-3525 3602-4349 4471-5141 5317-7513
HFIZM92	191	791267	AL049844	2383	1-440
HFOXA79	192	774901	AC023855	2384	1-90 326-1081 1429-1924 2176-2273 2445-2800 3200-3301 3374-4826 4855-5109 5264-5930
HFOXA79	192	774901	AC004150	2385	1-448 545-657 996-1130 1337-1559 1863-2108 4233-4445

					5134-5423 5604-6004 6095-6263 7089-7233 7673-7809 8154-8277 8976-9025 9178-9286 9464-9847 10011-10070 10156-10247 10481-11236 11584-12079 12331-12431 12600-12955 13356-13457 13530-14982 15011-15265 15420-16086
HFOXA79	192	774901	AC023855	2386	1-421
HFOXA79	192	774901	AC004150	2387	1-263 353-526 634-747
HFOXA79	192	774901	AC004150	2388	1-666 892-1059 1257-1378 1574-1668 2078-2186 2497-3209 4530-4716 5099-5612 5629-5808
HFOXB85	193	752957	AL133500	2389	1-945 1307-1680 1837-2397
HFOXB85	193	752957	AL135749	2390	1-682 859-1679 1836-2396
HFOXC25	194	677995	AC020749	2391	1-351
HFOXC25	194	677995	AC020749	2392	1-1056
HFOXC35	195	638311	AL138760	2393	1-228 255-361 370-683
HFOXC35	195	638311	AL138760	2394	1-442
HFOXL03	197	923772	AC024062	2395	1-468
HFOXL03	197	923772	AC019130	2396	1-468
HFOXL03	197	923772	AC024062	2397	1-423

HFOXL03	197	923772	AC019130	2398	1-423
HFOXM54	198	587974	AC046129	2399	1-435
HFOXM54	198	587974	AC016101	2400	1-435
HFOXM54	198	587974	AC064838	2401	1-435
HFOXM54	198	587974	AC046129	2402	1-750
HFOXM54	198	587974	AC016101	2403	1-750
HFOXM54	198	587974	AC064838	2404	1-750
HFOXN89	199	587984	AC034102	2405	1-128
HFOXN89	199	587984	AC025162	2406	1-109
HFOXN89	199	587984	AC034102	2407	1-128
HFOXN89	199	587984	AC025162	2408	1-128
HFOXN89	199	587984	AC034102	2409	1-2775 2895-3382 3790-4134 4616-4957
HFOXR28	201	587994	AC013592	2410	1-325
HFOXR28	201	587994	AC016934	2411	1-325
HFOXU83	204	887781	AL359927	2412	1-649
HFOXU83	204	887781	AC018373	2413	1-649
HFOXU83	204	887781	AL359927	2414	1-604
HFOXU83	204	887781	AC018373	2415	1-604
HFOXU92	205	588057	AC013692	2416	1-380
HFOXU92	205	588057	AC021342	2417	1-380
HFOXU92	205	588057	AC021342	2418	1-370
HFOXV15	206	964296	AC007342	2419	1-143 238-638 1310-2178 2722-2877 2931-3044 3725-3818 4666-4871 5915-6211 7936-8000 8089-8189 8657-8746 8826-8896 9017-9124 10331-10569 10740-13141 13431-14033 14501-14965 15153-16043 18258-18823 19372-19907 20059-21591 22493-22695

					23271-23379 24039-24110 24582-24699
HFOYI36	208	935532	AL357565	2420	1-489
HFOYI36	208	935532	AL357565	2421	1-693
HFOYL77	209	494844	AC068103	2422	1-353
HFOYL77	209	494844	AC016487	2423	1-353
HFOYL77	209	494844	AC020669	2424	1-353
HMUBM26	210	908912	AC008555	2425	1-124 788-1221 1332-2004 2074-4006
HMUBM26	210	908912	AC008555	2426	1-194
HOAAB15	213	575254	AC073970	2427	1-348
HOAAB15	213	575254	AC015909	2428	1-516 865-1153 1381-1669 4707-4818 5309-5534 5726-6148 6454-6533 8810-8836 9053-9813 10575-10603 10889-11099 11988-12127 12668-12869 13224-13274
HOAAB15	213	575254	AC073970	2429	1-289
HOAAB15	213	575254	AC015909	2430	1-106
HOAAB42	214	530605	AC008013	2431	1-106 220-357 575-1050 1060-1459 3153-3870 3965-4359 4392-4496 4756-4977 5025-5078 5198-5418 5593-5895 6301-6763 6941-8173 8913-9547 9927-10355 10651-11058 11461-11749

HOAAB42	214	530605	AC009533	2432	1-221 367-759 1212-1606 3182-3992 4509-4666 4820-4982 5711-5948 7122-7382 7953-8576 8722-9484 9977-10227 10746-10834 11133-11288 11304-11966 12156-12572 14044-14140 14735-15547 15575-16138 16472-16862 17405-17560 18541-18589 18938-19448 20178-20525 21420-21971 22037-22073 22331-22434 22548-22685 22842-23316 23334-23726 25414-26133 26228-26338 26375-26622 26657-26756 27017-27239 27287-27340 27456-27676 27850-28149 28593-28639 28670-29013 29189-29345 29359-30420
HOAAB42	214	530605	AC008013	2433	1-751 869-1288 1741-2134 3713-4192 4219-4525 5032-5188

					6221-6459 7627-7887 8458-9081 9227-9966 10464-10713 11232-11320 11620-11777 11791-12453 12643-13059 14536-14632 15693-16508 16536-17099 17433-17823 18365-18520 19494-19542 19895-20386 20452-21075 21128-21475 22370-22928 22994-23030
HOAAB42	214	530605	AC008013	2434	1-418
HOAAB42	214	530605	AC009533	2435	1-636
HOAAB56	215	507839	AC026519	2436	1-363
HOAAB56	215	507839	AP001026	2437	1-363
HOAAB56	215	507839	AP001026	2438	1-89
HOAAB56	215	507839	AP001026	2439	1-419
HOAAC31	216	693597	AC069475	2440	1-557 813-1462
HOAAC31	216	693597	AL137060	2441	1-557 813-1462
HOAAC31	216	693597	AC069475	2442	1-398
HOAAD52	218	859628	AC044917	2443	1-319
HOAAD52	218	859628	AC023090	2444	1-319
HOAAD52	218	859628	AP001908	2445	1-319
HOAAD52	218	859628	AC023090	2446	1-448
HOAAD52	218	859628	AP001908	2447	1-443
HOAAD52	218	859628	AC044917	2448	1-450
HOAAE10	219	968532	AC016802	2449	1-324
HOAAE10	219	968532	AC016802	2450	1-462
HOAAE49	221	859630	AL138963	2451	1-304
HOAAE49	221	859630	AL138963	2452	1-383
HOAAE73	222	960631	AC022400	2453	1-939 945-1386 2105-2440 2574-2794 2935-3532 3940-4305

					4483-6016 6421-6829 7089-9122
HOAAE73	222	960631	AC021320	2454	1-462 464-587 1007-1360 1538-2418 2450-3078 3474-3779 3854-4068 4130-6114
HOAAE73	222	960631	AC012044	2455	1-956 1025-1096 1451-1600 1640-2005 3280-3518 3840-4065 4611-4921 5754-6678 7938-8584 8639-8910 10151-10355 11341-11941 12710-13025 15001-15745 15751-16194 16911-17246 17380-17600 17741-18337 18768-19114 19292-20172 20207-20833 21241-21551 21626-21839 21901-23934
HOAAE73	222	960631	AC025039	2456	1-311
HOAAE73	222	960631	AC018510	2457	1-727 747-1177 1908-2243 2377-2597 2739-3200 3202-3325 3745-4098 4276-5156 5188-5816 6212-6517 6592-6806

					6868-8900
HOAAE73	222	960631	AC021320	2458	1-221
HOAAE73	222	960631	AC022400	2459	1-413
HOAAE73	222	960631	AC012044	2460	1-1577 1604-2003 2074-2569 3689-4774 4791-5120 5331-5822 5884-10583 10603-10867 11401-12562
HOAAE73	222	960631	AC025039	2461	1-209
HOAAE73	222	960631	AC018510	2462	1-474
HOAAF18	223	530600	AC008130	2463	1-357
HOAAF18	223	530600	AC022529	2464	1-355
HOAAF18	223	530600	AC005289	2465	1-357
HOAAF18	223	530600	AC008130	2466	1-327
HOAAF18	223	530600	AC022529	2467	1-327
HOAAF18	223	530600	AC005289	2468	1-327
HOAAH10	224	968368	AC009560	2469	1-606
HOAAH10	224	968368	AC012344	2470	1-606
HOAAH10	224	968368	AC009560	2471	1-361
HOAAH10	224	968368	AC012344	2472	1-361
HOAAI05	225	932537	AC008923	2473	1-304
HOAAI05	225	932537	AC008799	2474	1-304
HOAAI05	225	932537	AC008923	2475	1-306 609-1254
HOAAI05	225	932537	AC008799	2476	1-306 608-1253
HOAAJ23	226	531389	AC025698	2477	1-299
HOAAJ23	226	531389	AC013720	2478	1-299
HOAAJ23	226	531389	AC025698	2479	1-183
HOAAJ23	226	531389	AC013720	2480	1-105
HOAAK90	227	527490	AL359841	2481	1-285
HOAAK90	227	527490	AL390314	2482	1-285
HOAAK90	227	527490	AC025122	2483	1-285
HOAAK90	227	527490	AL390314	2484	1-185
HOAAK90	227	527490	AL359841	2485	1-129
HOAAK90	227	527490	AL390314	2486	1-129
HOAAK90	227	527490	AC025122	2487	1-129
HOAAK90	227	527490	AC025122	2488	1-185
HOAAR14	229	526530	AC073119	2489	1-270
HOAAR14	229	526530	AC027262	2490	1-270
HOAAR14	229	526530	AC073119	2491	1-540
HOAAR14	229	526530	AC027262	2492	1-273

HOAAR14	229	526530	AC073119	2493	1-273
HOAAR14	229	526530	AC027262	2494	1-540
HOAAV23	230	527489	AC034291	2495	1-301
HOAAV23	230	527489	AC034291	2496	1-422
HOAAW21	231	527487	AL357873	2497	1-362
HOABA93	234	792929	AC013335	2498	1-203
HOABA93	234	792929	AC013774	2499	1-203
HOABR40	238	531051	AC018603	2500	1-364
HOABR40	238	531051	AC018603	2501	1-504
HOABR40	238	531051	AC018603	2502	1-166
HOEAK21	239	954961	AC073936	2503	1-411
HOEAY14	240	659258	AC011597	2504	1-352
HOEAY14	240	659258	AC067726	2505	1-352
HOEAY14	240	659258	AC074266	2506	1-352
HOEAY14	240	659258	AC011597	2507	1-251
HOEAY14	240	659258	AC067726	2508	1-180
HOEAY14	240	659258	AC074266	2509	1-252
HOEBO31	242	693689	AL158165	2510	1-1964 2375-2812 3098-3532 3563-3705
HOEBO31	242	693689	AL158165	2511	1-432
HOEBO31	242	693689	AL158165	2512	1-324
HOECN79	244	723113	AC015671	2513	1-719
HOECN79	244	723113	AL157936	2514	1-719
HOECN79	244	723113	AC015671	2515	1-315
HOECN79	244	723113	AL157936	2516	1-635
HOEDD83	247	578934	AC013746	2517	1-484
HOEDK10	248	915054	AC012531	2518	1-90 532-796
HOEDK10	248	915054	AC015947	2519	1-75 547-793 1103-1159 1234-1498 1641-2181 2468-2930
HOEDK10	248	915054	AC012531	2520	1-610 2290-3222
HOEEB63	252	745039	AC010319	2521	1-135 225-514 639-710 1067-1542 2023-2119 2159-2299
HOEEB63	252	745039	AC010319	2522	1-323 1105-1205

					1282-1400
HOEEB63	252	745039	AC010319	2523	1-104
HOEEQ17	255	663719	AC074333	2524	1-458
HOEFL91	257	790134	AL049830	2525	1-123 262-720
HOEFL91	257	790134	AL049830	2526	1-1002 1026-1232 4208-4825 4861-5260 5409-5634 5942-6155 8211-8327 8673-8926 9876-10034 10125-10164 11131-11196 11675-11807 12890-13048 15640-16084
HOEFL91	257	790134	AL049830	2527	1-110
HOEFS83	259	615154	AC007643	2528	1-471
HOEFS83	259	615154	AL353719	2529	1-2879 3337-3596 4213-4851 5160-5630 5674-5732 6291-6472 6504-6660
HOEFS83	259	615154	AL133353	2530	1-200 456-609 5860-5998 6526-6629 8425-8724 9151-9625 12117-12252 15026-15571 15654-16121 16221-16852 19264-19592 21596-21794 22707-22795 23248-23407 23487-23890 25183-26429 26561-27890 28380-28908 28953-29430

					29490-32385 32577-35455 36789-37427 37736-38206 38250-38308 38867-39048 39075-39236 39491-39811 39971-40302 40401-40871 41105-41186 41719-41801 43440-43567 43732-44141 44689-44855 46395-46619 47357-47643 47700-47887 48174-48294 48469-48728 50284-50469 52382-52845
HOEFS83	259	615154	AC007643	2531	1-639
HOEFS83	259	615154	AL353719	2532	1-321
HOEFS83	259	615154	AC007643	2533	1-182
HOEFS83	259	615154	AL353719	2534	1-2069
HOEFS83	259	615154	AL133353	2535	1-303
HOEFS83	259	615154	AL133353	2536	1-222 225-361 2796-2928 4044-4119 5719-5962 7512-7571 10952-11165 11840-11870 15055-15191 17157-17497 18170-18193 19594-20180 20819-21289 21499-22434 22520-23934
HOEJE18	260	666349	AC025788	2537	1-325
HOEJE18	260	666349	AC026250	2538	1-325
HOEKH88	263	924112	AL355924	2539	1-200 253-1224 1241-1709

HOEKP79	265	963337	AC007643	2540	1-471
HOEKP79	265	963337	AL133353	2541	1-464 2377-2562 4118-4377 4552-4672 4959-5146 5203-5489 6227-6451 7991-8157 8705-9114 9279-9406 11045-11127 11660-11741 11975-12445 12544-12875 13035-13355 13610-13771 13798-13979 14538-14596 14640-15110 15419-16057 17391-20269 20461-23356 23416-23893 23938-24466 24956-26285 26417-27663 28956-29359 29439-29598 30051-30139 31052-31250 33254-33582 35994-36625 36725-37192 37275-37820 40594-40729 43221-43695 44122-44421 46217-46320 46848-46986 52237-52390 52646-52845
HOEKP79	265	963337	AC007643	2542	1-332
HOEKP79	265	963337	AL133353	2543	1-303
HOEKP79	265	963337	AL133353	2544	1-1415 1501-2436 2646-3116

					3755-4341 5742-5765 6438-6778 8744-8880 12065-12095 12770-12983 16364-16423 17973-18216 19816-19891 21007-21139 23574-23710 23713-23934
HOEMK02	267	918364	AC044789	2545	1-720
HOEMQ65	268	922789	AC019142	2546	1-435
HOEMQ65	268	922789	AC019142	2547	1-461
HOEMQ65	268	922789	AC019142	2548	1-422
HOEOE25	269	907806	AC018850	2549	1-599
HOEOE25	269	907806	AC012342	2550	1-599
HOEOE25	269	907806	AC018850	2551	1-197
HOEOE25	269	907806	AC012342	2552	1-198
HOHAE68	273	781448	AC023504	2553	1-1578
HOHBE48	275	588317	AC023449	2554	1-385
HOHBE48	275	588317	AC023449	2555	1-219
HOHBE48	275	588317	AC023449	2556	1-322
HOHBL11	277	966720	AC020708	2557	1-477
HOHBO79	279	588271	AC022677	2558	1-439
HOHBO79	279	588271	AL136126	2559	1-439
HOHBO79	279	588271	AC022677	2560	1-131
HOHBO79	279	588271	AC022677	2561	1-359
HOHBO79	279	588271	AL136126	2562	1-131
HOHBO79	279	588271	AL136126	2563	1-351
HOHBY75	282	840109	AC009708	2564	1-616
HOHBY75	282	840109	AC021004	2565	1-1236
HOHBY75	282	840109	AC021004	2566	1-47 2450-2628 4538-5196
HOHCH04	283	859047	AC024677	2567	1-27 1762-1878 2480-3110 3124-3541 3681-3783
HOHCH04	283	859047	AC027166	2568	1-631
HOHCH04	283	859047	AL355492	2569	1-27 1762-1878 2480-3110 3124-3541

					3681-3783
HOHCH04	283	859047	AC024677	2570	1-327
HOHCH04	283	859047	AC027166	2571	1-418
HOHCH04	283	859047	AL355492	2572	1-83 1649-1839 5074-5151
HOHCI05	284	935123	AL356427	2573	1-393
HOHCI05	284	935123	AL121931	2574	1-393
HOHCO85	287	751299	AL354664	2575	1-149 867-1007 3589-3733 3850-4492 4600-4734 4976-5005
HOHCO85	287	751299	AL353703	2576	1-149 867-1007 3588-3732 3849-4491 4599-4733 4976-5005
HOHCO85	287	751299	AL096771	2577	1-149 867-1007 3589-3733 3850-4492 4600-4734 4976-5005
HOHCO85	287	751299	AL354664	2578	1-588
HOHCO85	287	751299	AL353703	2579	1-588
HOHCO85	287	751299	AL096771	2580	1-588
HOHCQ76	289	825236	AL161454	2581	1-698
HOHCQ76	289	825236	AL161454	2582	1-499 1477-1593 2237-2547
HOHCQ77	290	661480	AP000274	2583	1-381
HOHCQ77	290	661480	AP000104	2584	1-381
HOHCQ77	290	661480	AP000180	2585	1-381
HOHCQ77	290	661480	AP000274	2586	1-888
HOHCQ77	290	661480	AP000104	2587	1-888
HOHCQ77	290	661480	AP000180	2588	1-888
HOHCV83	291	735685	AC010321	2589	1-425
HOHCV83	291	735685	AC010321	2590	1-114
HOHCW02	292	919142	AC036174	2591	1-299
HOHCW02	292	919142	AC036174	2592	1-210
HOHCW02	292	919142	AC036174	2593	1-88
HOHDB32	294	698781	AC016724	2594	1-308
HOHDF40	296	710748	AL139021	2595	1-162

					4326-4476 6562-6730 6974-7075 9334-9459 12688-12802 13427-13516 13743-13821
HOHDF40	296	710748	AL135752	2596	1-162 766-1091 4330-4480 6567-6735 6972-7127 7762-7921 9338-9463 12686-12800 13414-13546 13741-13819
HOHDF53	297	727620	AL355052	2597	1-479
HOHDI48	298	966379	AF233070	2598	1-264
HOHDI48	298	966379	AF233070	2599	1-952
HOHEN50	303	662365	AL161784	2600	1-165
HOHEN50	303	662365	AC011969	2601	1-165
HOHEN50	303	662365	AC006558	2602	1-165
HOHEN50	303	662365	AL161784	2603	1-311
HOHEN50	303	662365	AC011969	2604	1-311
HOHEN50	303	662365	AC011969	2605	1-44 1982-2321 2357-3841 3894-4365 4783-5157
HOHEN50	303	662365	AC006558	2606	1-312
HOHEN50	303	662365	AC006558	2607	1-44 2087-2223 2263-2345 2381-2834 3157-3876 3929-4400 4822-5199
HOSBV22	309	780092	AL354751	2608	1-772
HOSBV22	309	780092	AL354751	2609	1-363
HOSBV22	309	780092	AL354751	2610	1-104
HOSCM15	312	921336	AC023283	2611	1-1174
HOSCM15	312	921336	AC023283	2612	1-248 328-619
HOSCM15	312	921336	AC023283	2613	1-679
HOSDE63	314	580959	AC073611	2614	1-214 411-670

HOSDE63	314	580959	AC021103	2615	1-477 3144-3537
HOSDE63	314	580959	AC073611	2616	1-358 742-1100 1213-2219 2906-2963 3180-3361
HOSDE63	314	580959	AC021103	2617	1-311
HOSDN27	316	530459	AL121894	2618	1-718
HOSDN27	316	530459	AL121894	2619	1-1248
HOSEB61	317	741812	AL049781	2620	1-1283
HOSEB61	317	741812	AL049781	2621	1-309
HOSEM84	318	831049	AC021980	2622	1-509 614-987 1027-2228 2279-3074 3162-3379
HOSEM84	318	831049	AC007383	2623	1-1268 3461-3535 3629-3768 4716-4911 7009-7195 7458-7577 9862-10536 13314-13528 13695-13799 13862-14171 15401-15594 17534-17648 18187-18300 18863-18991 19607-19754 20941-21056 21814-21953 23800-24012 24451-24585 24674-24759 25941-26016 26734-26846 27836-28282 28454-28791 28794-28910 29003-29585 30139-30525 30540-30606 30873-31831 32925-33206

					35019-35447 35904-36391 36475-36983 37087-37460 37500-38466 38662-38692 38752-39547 39635-39852
HOSEM84	318	831049	AC021980	2624	1-444
HOSEM84	318	831049	AC021980	2625	1-443
HOSEM84	318	831049	AC007383	2626	1-2585
HOSFO57	319	736034	AC073334	2627	1-325
HOSFO57	319	736034	AC073334	2628	1-562
HOSFO57	319	736034	AC073334	2629	1-95 232-346
HOSFY79	321	774052	AC018977	2630	1-401
HOSFY79	321	774052	AC018977	2631	1-2343
HOSFZ39	322	705351	AC055117	2632	1-411
HOSFZ39	322	705351	AC055117	2633	1-245
HOSGH28	323	686649	AC068531	2634	1-2365 2457-2668 2911-3285 3553-3980 4160-4543
HOSGH28	323	686649	AC008630	2635	1-139 1963-1988 2524-4898 4990-5210 5444-5815 6084-6515
HOSGH28	323	686649	AC068531	2636	1-141
HOSGH28	323	686649	AC008630	2637	1-423
HOSGJ17	324	508870	AC068234	2638	1-1143 2745-3406
HOSGJ17	324	508870	AC068234	2639	1-333
HOSNO86	326	858938	AC009644	2640	1-176 2355-3224
HOSNO86	326	858938	AP000904	2641	1-176 2354-3223
HOSNO86	326	858938	AP002811	2642	1-176 2354-3223
HOSOE05	327	930946	AC024400	2643	1-482
HOSOE05	327	930946	AC022059	2644	1-479
HOSOE05	327	930946	AC006512	2645	1-247 2812-2918 3488-3953

					3964-4527 4683-5151 5330-9121 9884-10335 10748-10781 10960-11055 11323-12111 12127-12791 12911-13262 13266-13791 14696-14866 15107-15207 16551-16955 17174-17614 18504-18749 19392-19660 19720-20075 20785-21233 21290-21733 23618-23649 23982-24188 24481-24573 24741-25003 26591-26705 26738-27249 28479-28858 29065-31669 31926-32887 33667-34293 35229-35682 38114-38771
HOSOE05	327	930946	AC022059	2646	1-338 1107-1723
HOSOE05	327	930946	AC006512	2647	1-818 963-1440 1469-1958 2220-3076 3455-3663 3931-4285 4549-4632 4696-5069 5245-5337 5461-5775
HOSOE05	327	930946	AC006512	2648	1-738
HRDAB60	329	509428	AC073285	2649	1-460
HRDAB60	329	509428	AC008082	2650	1-460
HRDAF69	331	956269	AL022320	2651	1-175

					2123-2610 2802-2918 5337-5521 5927-6085 7196-7332 8400-8509 8805-8995 11185-11337
HRDAF69	331	956269	AL022320	2652	1-227
HRDAF69	331	956269	AL022320	2653	1-157
HRDAF90	332	531026	AL353141	2654	1-311
HRDAF90	332	531026	AL353141	2655	1-314
HRDBA76	334	534304	AL160281	2656	1-654
HRDBA76	334	534304	Z98304	2657	1-654
HRDBA76	334	534304	AL160281	2658	1-323
HRDBA76	334	534304	AL160281	2659	1-339
HRDBA76	334	534304	Z98304	2660	1-323
HRDBA76	334	534304	Z98304	2661	1-339
HRDBC02	335	921144	AL137780	2662	1-120 179-1066 1899-2055 2150-2610 4802-5459 5700-5854 5982-6112
HRDBC02	335	921144	AL354820	2663	1-120 179-1066 1899-2055 2150-2610 4802-5459 5700-5854 5982-6112
HRDBC30	336	530858	AL136173	2664	1-315 396-1061
HRDBC30	336	530858	AL136173	2665	1-75 1756-2079 2376-2736 3583-4171
HRDBC30	336	530858	AL136173	2666	1-117
HRDBC52	337	867169	AC068528	2667	1-301
HRDBE07	339	954289	AC024583	2668	1-276 456-663 1014-1459 1945-2257 2609-2739 5806-6010 7308-7659

					8014-8242 9821-9982 10722-10844 10921-11553 12075-12213 12336-12424 13519-14781
HRDBE07	339	954289	AC023629	2669	1-369
HRDBE07	339	954289	AC022107	2670	1-276 456-663 1014-1460 1961-2263 2561-2691 3029-3584 3903-4218 5757-5961 7262-7613 7968-8207
HRDBE07	339	954289	AC023629	2671	1-294
HRDBE07	339	954289	AC024583	2672	1-105
HRDBE07	339	954289	AC022107	2673	1-105
HRDBE07	339	954289	AC023629	2674	1-276 457-665
HRDBE19	341	534495	AC016581	2675	1-472
HRDBE19	341	534495	AC008935	2676	1-472
HRDBE41	342	530856	AC006138	2677	1-2049 2103-2296 2446-2562 2812-2888 3066-3445 3609-3858 3955-4116 4190-4339 4598-5041 5181-5479 5520-5869 6069-6244 6382-6463 7442-7493 7906-8006 8104-8360 8381-8519 8678-9386 9440-9543
HRDBE41	342	530856	AB023049	2678	1-2642 2696-2889 3039-3155

					3405-3481 3659-4038 4202-4451 4548-4709 4783-4932 5191-5634 5773-6073 6113-6462 6662-6837 6975-7056 8035-8086 8500-8600 8698-8954 8975-9113 9272-9980 10034-10137 13874-14412 15839-16314 16629-17195 18035-18278 18755-18802 19686-19796 19902-20001 20116-20184 20235-20526 20771-20927 21443-21561 23024-23093 24623-25138 25146-25453 25695-26591
HRDBE41	342	530856	AC006138	2679	1-388
HRDBE41	342	530856	AB023049	2680	1-149 617-675 791-885 1009-1078 1188-1302 1484-1797 2714-2955 3680-3955 4502-4651 4802-5433 6327-6574 6847-6963 7884-8446 9168-9385 9477-9730

					9987-10023 11007-11124 11660-12154 12622-12937 13533-13581 13608-13983 14317-14874 14882-15823 16071-17843 18385-18504 19059-19134 19207-20247
HRDBE41	342	530856	AB023049	2681	1-103
HRDBG59	343	507381	AL138803	2682	1-313
HRDBG59	343	507381	AL121905	2683	1-313
HRDBG59	343	507381	AL138803	2684	1-123
HRDBG59	343	507381	AL138803	2685	1-193
HRDBG59	343	507381	AL121905	2686	1-104
HRDBJ28	345	925457	AC073334	2687	1-347
HRDBJ28	345	925457	AC073334	2688	1-131
HRDBL61	347	575229	AL359977	2689	1-937
HRDBL61	347	575229	AL359977	2690	1-306 2924-3292 3699-4656
HRDBL75	348	524423	AC020557	2691	1-83 1023-1263
HRDBL75	348	524423	AP001620	2692	1-83 1023-1263
HRDBL75	348	524423	AC020557	2693	1-285
HRDBL75	348	524423	AP001620	2694	1-285
HRDBQ18	350	954274	U53331	2695	1-86 1346-1623 1706-2191 4151-4593 4667-4762 5022-5343 5875-6206 9831-10269 10732-10901 11640-11747 12310-12703 14008-14301 14840-15086 16199-16673 17070-17190 17916-17996
HRDBQ18	350	954274	U53331	2696	1-139

HRDBQ38	351	533939	AC021305	2697	1-1626
HRDBQ38	351	533939	AC023188	2698	1-148 201-668 732-1141 1534-2038 3506-5131 5587-5713 6756-6945 7208-7408 7818-7942 8257-8658 9327-9745 10707-10838
HRDBQ38	351	533939	AF267168	2699	1-1626
HRDBQ38	351	533939	AC021305	2700	1-499
HRDBQ38	351	533939	AC023188	2701	1-427
HRDBQ38	351	533939	AF267168	2702	1-168
HRDBQ38	351	533939	AF267168	2703	1-190
HRDBQ82	353	533947	AC008596	2704	1-574
HRDBQ82	353	533947	AC008431	2705	1-574
HRDBQ82	353	533947	AC018752	2706	1-574
HRDBQ82	353	533947	AC008596	2707	1-459
HRDBQ82	353	533947	AC008431	2708	1-459
HRDBQ82	353	533947	AC018752	2709	1-459
HRDBR35	355	867167	AL137072	2710	1-445
HRDBR35	355	867167	AL137072	2711	1-378 417-818 867-1335
HRDCA61	358	921128	AL161775	2712	1-675
HRDCA61	358	921128	AL157877	2713	1-718 1161-1617 1682-2115 2257-2695 3740-4120 4204-4329 5302-5537 6599-7016 7601-7779 7869-9425 9638-10313 10567-11108 11241-11965 12442-12570 13069-13267 13683-13945 15087-15281 15761-16052

					17071-17217 17533-17737 19140-19633 19690-19820
HRDCA61	358	921128	AL157877	2714	1-103
HRDCB18	359	968554	AC009152	2715	1-330
HRDCD12	360	921796	AC068195	2716	1-497
HRDDN54	364	932764	AC004853	2717	1-318
HRDDY26	366	526783	AL035669	2718	1-516 736-1331 1746-2303 3453-4698 4716-5032 6454-6957 7257-7792 8310-8674 8721-8935 9029-9968
HRDDY26	366	526783	AL035669	2719	1-157
HRDDZ76	368	574324	AC002210	2720	1-117
HRDDZ76	368	574324	AC004227	2721	1-117
HRDDZ76	368	574324	AC004227	2722	1-986
HRDEB78	369	526861	AC053519	2723	1-322
HRDEB78	369	526861	AC053519	2724	1-193
HRDED92	371	936045	AL136418	2725	1-108 203-380 2017-2151 2671-2870 4311-5010 5613-6100 6341-6502 6658-6926 7119-7469 7746-8431 8470-8794 9256-9503 9582-10158 10571-10704 10849-11637 12112-12236 13750-13906 16846-16981 17153-17729 18146-18931 19273-19326 19553-19737 20127-20336

					20424-20467
HRDED92	371	936045	AL139054	2726	1-108 203-380 2017-2151 2671-2870 4311-5010 5613-6100 6341-6502 6658-6926 7119-7469 7746-8431 8470-8794 9256-9503 9582-10158 10571-10704 10849-11637 12112-12236 13750-13906 16846-16981 17153-17729 18146-18931 19273-19326 19553-19737 20127-20336 20424-20467
HRDED92	371	936045	AL136418	2727	1-121 402-727 1924-1974
HRDED92	371	936045	AL139054	2728	1-121 402-727 1924-1974
HRDEJ76	373	574335	AL160282	2729	1-483
HRDEJ76	373	574335	AL160282	2730	1-36 98-230 529-1060
HRDEJ76	373	574335	AL160282	2731	1-323
HRDEL91	375	790374	AL034553	2732	1-289
HRDEL91	375	790374	AL034553	2733	1-312
HRDEL91	375	790374	AL034553	2734	1-265
HRDEO12	376	867140	AC018519	2735	1-349
HRDEO12	376	867140	AC018519	2736	1-425
HRDEO76	377	952894	AC011787	2737	1-610
HRDEO76	377	952894	AC022467	2738	1-617
HRDEP31	378	766222	AC016493	2739	1-434
HRDEP31	378	766222	AC023577	2740	1-216
HRDEQ30	380	506774	AC026051	2741	1-571
HRDEQ30	380	506774	AC026051	2742	1-335

HRDEQ30	380	506774	AC026051	2743	1-383
HRDEQ96	381	507543	AL391069	2744	1-794
HRDEQ96	381	507543	AL158846	2745	1-794
HRDEQ96	381	507543	AL391069	2746	1-465
HRDEQ96	381	507543	AL158846	2747	1-465
HRDES52	382	867115	AL356785	2748	1-228 283-429 1240-1597 1870-2461
HRDES65	383	526823	AC008610	2749	1-417
HRDES65	383	526823	AC008610	2750	1-293
HRDET91	385	827084	AL354659	2751	1-429
HRDET91	385	827084	AC009420	2752	1-430
HRDEU33	386	572905	AC015467	2753	1-305
HRDEU33	386	572905	AC011927	2754	1-305
HRDEU33	386	572905	AC027542	2755	1-304
HRDEU33	386	572905	AC011927	2756	1-213
HRDEU33	386	572905	AC015467	2757	1-213
HRDEU33	386	572905	AC027542	2758	1-213
HRDEU42	387	881296	AL133411	2759	1-349
HRDEU42	387	881296	AL133411	2760	1-522
HRDEU43	388	765813	AC023817	2761	1-969 1121-5132 5167-12104
HRDEU43	388	765813	AL161433	2762	1-155
HRDEU43	388	765813	AC011244	2763	1-1453
HRDEU43	388	765813	AC044800	2764	1-1833 1988-7642
HRDEU43	388	765813	AC011244	2765	1-299 1027-1436 1568-2015 2133-2823 2887-3398 3894-3979 4893-5014 5145-5614 5696-7528 7544-7570 7688-15819
HRDEU43	388	765813	AC010237	2766	1-216 1036-2484 2512-3057
HRDEU43	388	765813	AL161433	2767	1-216 1038-3049
HRDEU43	388	765813	AC068735	2768	1-456
HRDEU43	388	765813	AC021725	2769	1-458

HRDEU43	388	765813	AL009030	2770	1-744
HRDEU43	388	765813	AL161433	2771	1-216 1038-3049
HRDEU43	388	765813	AL135916	2772	1-462
HRDEU43	388	765813	AL133255	2773	1-462
HRDEU43	388	765813	AL157879	2774	1-1453
HRDEU43	388	765813	AL021368	2775	1-462
HRDEU43	388	765813	AC011244	2776	1-130
HRDEU43	388	765813	AC044800	2777	1-468
HRDEU43	388	765813	AC023817	2778	1-1118
HRDEU43	388	765813	AL161433	2779	1-213
HRDEU43	388	765813	AC011244	2780	1-1398
HRDEU43	388	765813	AC010237	2781	1-596
HRDEU43	388	765813	AL161433	2782	1-596
HRDEU43	388	765813	AC068735	2783	1-659
HRDEU43	388	765813	AC044800	2784	1-101
HRDEU43	388	765813	AC021725	2785	1-679
HRDEU43	388	765813	AL009030	2786	1-116
HRDEU43	388	765813	AL161433	2787	1-596
HRDEU43	388	765813	AL161433	2788	1-213
HRDEU43	388	765813	AL135916	2789	1-664
HRDEU43	388	765813	AL161433	2790	1-213
HRDEU43	388	765813	AL133255	2791	1-2680 2909-4366 4651-5785 5798-8014 8020-11469
HRDEU43	388	765813	AL133255	2792	1-672
HRDEU43	388	765813	AL157879	2793	1-11071
HRDEU43	388	765813	AL021368	2794	1-104
HRDEU43	388	765813	AL021368	2795	1-664
HRDEU61	389	575566	AC040909	2796	1-403
HRDEU61	389	575566	AC020596	2797	1-426
HRDEU78	390	573031	AC004031	2798	1-1144
HRDEU78	390	573031	AC004031	2799	1-93 2963-3611 4073-4400 5450-5677 6354-6505 7666-7726 8063-8297 8342-9068 10411-10884 11187-11272 11986-12402 13606-13851

					15238-15358 16262-16453 16496-16995 17115-18395 18440-19183
HRDEU78	390	573031	AC004031	2800	1-322
HRDEW90	395	574288	AC003077	2801	1-487
HRDEW90	395	574288	AC003077	2802	1-104 456-579 905-971 1038-1354 2379-2754 2874-2985 5130-5202 6952-7023
HRDEW90	395	574288	AC003077	2803	1-317
HRDEZ60	399	919386	AL358781	2804	1-179 427-883 2033-2343 2644-3466 3901-6513 6897-7077 7651-7777 8930-9046 9640-9732
HRDEZ60	399	919386	AL160276	2805	1-146 567-729 776-1286 1630-2424 2523-2979 4129-4439 4740-5562 5997-8610 8991-9174 9748-9874 11027-11143 11737-11830 12258-12386 12685-12776 14133-14662 15697-15794 17888-17983 19086-19125
HRDEZ60	399	919386	AL160276	2806	1-106
HRDEZ64	400	536668	AC023671	2807	1-372
HRDFB47	402	508001	AC020913	2808	1-688
HRDFB47	402	508001	AC020913	2809	1-696

HRDFB47	402	508001	AC020913	2810	1-325
HRDFB78	403	589478	AC015962	2811	1-233 310-395 960-1280 1557-2072 2206-2494 2569-2818 2979-3097 3255-3441 3612-4965 5079-5476
HRDFB78	403	589478	AP002393	2812	1-234 311-396 961-1281 1558-2073 2207-2495 2570-2819 2980-3098 3256-3442 3613-4965 5079-5476
HRDFB78	403	589478	AP002393	2813	1-128
HRDFC68	404	574205	AC031980	2814	1-1179
HRDFC68	404	574205	AL109851	2815	1-1179
HRDFC68	404	574205	AL109851	2816	1-357
HRDFE73	405	574142	AL121586	2817	1-454
HRDFE73	405	574142	AL139226	2818	1-452
HRDFE74	406	765750	AL117382	2819	1-2573
HRDFE74	406	765750	AL117382	2820	1-473 547-956
HRDFG25	409	574433	AL157392	2821	1-132 790-1110 1296-1868
HRDFG25	409	574433	AL157392	2822	1-265
HRDFG37	410	792517	AC011922	2823	1-342
HRDFG37	410	792517	AC011922	2824	1-125 2864-3688 3709-4369
HRDFG46	411	574439	AL162711	2825	1-474
HRDFG46	411	574439	AL356752	2826	1-474
HRDFG46	411	574439	AC011695	2827	1-474
HRDFG46	411	574439	AL162711	2828	1-342
HRDFG46	411	574439	AL162711	2829	1-87
HRDFG46	411	574439	AL356752	2830	1-364
HRDFG46	411	574439	AC011695	2831	1-87
HRDFG46	411	574439	AL356752	2832	1-87

HRDFG46	411	574439	AC011695	2833	1-364
HRDFH14	412	575578	AC018665	2834	1-158
HRDFH14	412	575578	AC015801	2835	1-63 453-778 4523-4680 5968-6112 6637-6754 7236-7304 8220-8263 8968-9017 10646-10836 10839-11211 11761-11922 12118-12230 12547-13142 13423-13926 14192-14430 14653-15104 15264-15377 15434-15969 16518-16631 16642-16758 17442-17552 18028-18204 18449-18511 19115-20053 21297-21423
HRDFH14	412	575578	AC018665	2836	1-130
HRDFH14	412	575578	AC015801	2837	1-417
HRDFH24	413	575245	AL139013	2838	1-781
HRDFH24	413	575245	AL354953	2839	1-781 852-1127 1213-1311 1403-1624 1958-2075 2167-2363 2673-2786 4006-4467 4806-4837
HRDFH24	413	575245	AL139013	2840	1-276
HRDFH25	414	953882	AL136304	2841	1-292 646-1026 1500-1664
HRDFH25	414	953882	AL136304	2842	1-499
HRDFH25	414	953882	AL136304	2843	1-125
HRDFH39	415	574558	AC005079	2844	1-58 168-398

					2136-2596 4009-4424 6946-7338 7495-7617 9290-9470 12597-12947 14399-14487 17529-17581 18389-18476 19225-19699 20108-20419 21692-22122 23411-23477 25014-25104 26516-26877 27011-27457 28855-28909 29092-29282 31251-31492 31992-32485
HRDFH39	415	574558	AC005079	2845	1-2954
HRDFH39	415	574558	AC005079	2846	1-444
HRDFI13	417	574561	AC023876	2847	1-412
HRDFJ71	418	574553	AP001091	2848	1-446
HRDFJ71	418	574553	AP001091	2849	1-154 245-346 386-510 519-903 1419-1506
HRDFM18	421	574435	AL356321	2850	1-470
HRDFM18	421	574435	AC011692	2851	1-470
HRDFM18	421	574435	AL356321	2852	1-716
HRDFM18	421	574435	AC011692	2853	1-716
HRDFQ64	423	733847	AC025796	2854	1-273
HRDFQ64	423	733847	AC018638	2855	1-1347 1588-1655 1847-2885 2995-3729 3747-4192 5291-5467 5607-6427 6453-6942 7170-8109 8162-8361 8634-9418 9463-11111 11143-12777

					12930-15535
HRDFQ64	423	733847	AC005627	2856	1-1382 1388-1474 1510-1578 1768-2801 2912-3644 3666-4106 5212-5388 5528-6348 6373-6862 7090-8029 8082-8281 8506-9338 9383-11944 11951-12483 12512-12708 13012-15362
HRDFQ64	423	733847	AC004987	2857	1-1363 1369-1455 1491-1558 1757-2707 2907-3642 3660-4103 5231-5407 5547-6368 6393-6885 7114-7573 7669-7881 8109-8308 8581-9173 9404-11821
HRDFQ64	423	733847	AC018638	2858	1-946
HRDFQ64	423	733847	AC005627	2859	1-312
HRDFQ64	423	733847	AC005627	2860	1-210 234-933 942-1762 2071-2302 4137-5246 5292-5549
HRDFQ64	423	733847	AC004987	2861	1-2357
HRDFQ64	423	733847	AC004987	2862	1-1370
HRDFQ75	424	525524	AL136332	2863	1-303 455-868 1310-1564 2130-2482 3623-3828
HRDFQ75	424	525524	AL132987	2864	1-302

					454-867 1309-1563 2129-2481 3054-3086 3756-3807
HRDFQ75	424	525524	AL136332	2865	1-163
HRDFQ75	424	525524	AL136332	2866	1-458
HRDFQ75	424	525524	AL132987	2867	1-163
HRDFQ75	424	525524	AL132987	2868	1-458
HRDFU48	429	573030	AC010193	2869	1-335
HRDFU48	429	573030	AC013252	2870	1-335
HRDFU48	429	573030	AC010193	2871	1-366
HRDFU48	429	573030	AC013252	2872	1-366
HSHAX53	430	518795	AC068497	2873	1-297 898-1324
HSHAX53	430	518795	AC073936	2874	1-298
HSHAX53	430	518795	AC074283	2875	1-298
HSHAX53	430	518795	AC074283	2876	1-352
HSHAX53	430	518795	AC074283	2877	1-213
HSHBV66	431	523348	AC020921	2878	1-345
HSHBV66	431	523348	AC008908	2879	1-335
HSHBV66	431	523348	AC007554	2880	1-345
HSHBV67	432	529483	AL353777	2881	1-315
HSHBV67	432	529483	AL353777	2882	1-515
HSHCF34	433	529313	AL162404	2883	1-237
HSHCF34	433	529313	AC025990	2884	1-237
HSHCF34	433	529313	AL035415	2885	1-237
HSHCF34	433	529313	AL162404	2886	1-106
HSHCF34	433	529313	AC025990	2887	1-106
HSHCF34	433	529313	AL035415	2888	1-104
HSHCF34	433	529313	AL162404	2889	1-119
HSHCF34	433	529313	AC025990	2890	1-104
HSKCS36	434	529163	AC020884	2891	1-239
HSKCT33	435	866514	AC024714	2892	1-375
HSKCT33	435	866514	AC024714	2893	1-250
HSKEK63	439	744336	AL356734	2894	1-376
HSKEK63	439	744336	AL355388	2895	1-376
HSKEK63	439	744336	AL355388	2896	1-138
HSKEM02	440	969071	AL360170	2897	1-51 4919-5083 6145-6269 6769-6852 7424-7601
HSKEM02	440	969071	AL133355	2898	1-51 4919-5083 6145-6269

					6769-6852 7424-7601
HSKET11	441	967000	AC022123	2899	1-433
HSKET11	441	967000	AC073689	2900	1-823
HSKIT38	444	855173	AL159994	2901	1-613
HSKIT38	444	855173	AL159994	2902	1-389
HSKJS05	445	930979	AC036191	2903	1-109 274-433 756-1187 1853-2201 2902-4963
HSKKD70	446	916984	AC020886	2904	1-592
HSKKD70	446	916984	AC008792	2905	1-569
HSKKL06	447	934040	AC006184	2906	1-659
HSKKL06	447	934040	AC006184	2907	1-562
HSKWA56	449	916496	AL357565	2908	1-437
HSKWA56	449	916496	AL357565	2909	1-529
HSKWA56	449	916496	AL357565	2910	1-101
HSKXG06	452	935455	AF189005	2911	1-385
HSKXG06	452	935455	AC027698	2912	1-385
HSKXG06	452	935455	AF189005	2913	1-442
HSKXG06	452	935455	AC027698	2914	1-442
HSKXJ15	453	866373	AL354751	2915	1-1031
HSKXJ15	453	866373	AC018554	2916	1-1046
HSKXJ15	453	866373	AL158080	2917	1-1051
HSKXJ15	453	866373	AL355148	2918	1-1051
HSKXJ15	453	866373	AL117340	2919	1-1051
HSKXJ15	453	866373	AC018554	2920	1-825
HSKXJ15	453	866373	AL354751	2921	1-455
HSKXJ15	453	866373	AL158080	2922	1-442
HSKXJ15	453	866373	AL158080	2923	1-722
HSKXJ15	453	866373	AL355148	2924	1-442
HSKXJ15	453	866373	AL355148	2925	1-722
HSKXJ15	453	866373	AL117340	2926	1-442
HSKXJ15	453	866373	AL117340	2927	1-722
HSKXP58	455	955073	AC007336	2928	1-424 790-845 2072-2312 3699-3937 4799-4957 6084-6219 6394-6569 9325-9508 10439-10620 12486-12768 13934-14087

					17716-17856 19078-19243 23566-23682 24537-24930 25444-25739 26129-27483
HSKXP58	455	955073	AC007336	2929	1-265
HSKYG66	457	698007	AC062036	2930	1-507
HSKYG66	457	698007	AC062036	2931	1-286
HSKYG66	457	698007	AC062036	2932	1-360
HSKYH52	458	466574	AC021437	2933	1-31 476-587 1937-2394 2732-3167 3483-3664
HSKYH52	458	466574	AC021437	2934	1-282
HSKYH52	458	466574	AC021437	2935	1-333
HSKYJ96	459	921032	AC024502	2936	1-356
HSKYJ96	459	921032	AC024502	2937	1-885 1599-2695 2850-3162
HSKZE12	460	970639	AC023121	2938	1-129
HSKZE12	460	970639	AC023121	2939	1-211
HSKZE12	460	970639	AC023121	2940	1-144
HSKZE32	461	959400	AC012522	2941	1-905 1075-1401 1439-1665 1702-2222 2472-3734
HSKZE32	461	959400	AC006254	2942	1-216 836-937 1568-1787 2544-2645 2727-2779 2799-3098 5623-5715 5962-6414 7005-9162 9332-9658 9696-9922 9959-10479 10729-11991
HSKZE32	461	959400	AC012522	2943	1-322
HSKZE32	461	959400	AC012522	2944	1-1087
HSKZE32	461	959400	AC006254	2945	1-322
HSLAB77	462	772652	AC007392	2946	1-308
HSLAB77	462	772652	AC007392	2947	1-241

HSLAB77	462	772652	AC007392	2948	1-486
HSLBW19	464	671738	AC008443	2949	1-58 372-819 1181-1503 1878-2106 2630-5031
HSLBW19	464	671738	AL161615	2950	1-323
HSLBW19	464	671738	AC008620	2951	1-558 2623-2750 3090-3275 3856-3989 6489-6581 6895-7342 7704-8026 8401-8629 9153-11553
HSLBW19	464	671738	AL161615	2952	1-448
HSLBW19	464	671738	AC008443	2953	1-446
HSLBW19	464	671738	AC008620	2954	1-446
HSLBX08	465	959911	Z95152	2955	1-208 419-902 2123-2193 5253-5361 5517-5547 5983-6029 6154-6270 6376-6450 6770-7028 7865-7945 7967-8279 8378-8555 8794-9615
HSLBX08	465	959911	Z95152	2956	1-903
HSLBX20	466	574004	AC005922	2957	1-113 538-968 2413-2534
HSLBX20	466	574004	AC005922	2958	1-26 2837-2907 3657-3743 4961-5086 5993-6112
HSLBX20	466	574004	AC005922	2959	1-476
HSLBZ91	467	573987	AC016527	2960	1-304
HSLCB15	468	693455	AL022169	2961	1-1057 1142-1998
HSLCB15	468	693455	AL022169	2962	1-273
HSLCJ46	469	529622	AL096677	2963	1-35

					175-254 1355-1678 3882-3987 4912-4963 5142-5217
HSLCJ46	469	529622	AL390037	2964	1-35 175-254 1355-1678 3885-3982 4912-4963 5142-5217
HSLCJ46	469	529622	AL096677	2965	1-80 2735-3511 3742-4196 5721-6250
HSLCJ46	469	529622	AL096677	2966	1-714
HSLCJ46	469	529622	AL390037	2967	1-714
HSLCJ46	469	529622	AL390037	2968	1-80 3123-3512 3603-4197 5722-6251
HSLCJ47	470	908627	AL159994	2969	1-696
HSLCJ47	470	908627	AL159994	2970	1-241
HSLCL38	471	951028	AC024580	2971	1-246
HSLCP75	472	529631	AC074334	2972	1-139 258-583
HSLDA25	474	679301	AC022123	2973	1-548
HSLDB29	475	866340	AC005517	2974	1-428
HSLDB29	475	866340	AC005517	2975	1-422
HSLDB29	475	866340	AC005517	2976	1-384
HSLDC06	476	936010	AC015589	2977	1-1110
HSLDC06	476	936010	AC010328	2978	1-1110
HSLDC06	476	936010	AC015589	2979	1-320
HSLDC06	476	936010	AC010328	2980	1-320
HSLDG13	477	913664	AC074219	2981	1-333 477-952
HSLDI16	478	574014	AC009690	2982	1-1003
HSLDI16	478	574014	AC009690	2983	1-262
HSLDI16	478	574014	AC009690	2984	1-87
HSLDJ94	480	753657	AC068584	2985	1-554
HSLDJ94	480	753657	AC021215	2986	1-554
HSLDJ94	480	753657	AC068584	2987	1-883 906-1442 2137-2360 2379-3586
HSLDJ94	480	753657	AC021215	2988	1-883

					906-1442 1625-2050 2136-2359 2378-3585 3764-4356 4418-5605 5759-6797 7466-7550
HSLDJ94	480	753657	AC068584	2989	1-464
HSLDJ94	480	753657	AC021215	2990	1-464
HSLDM32	482	699486	AC074220	2991	1-366
HSLDM79	483	526740	AC018550	2992	1-342
HSLDM79	483	526740	AC034250	2993	1-433
HSLDM79	483	526740	AC020764	2994	1-433
HSLDM79	483	526740	AC020764	2995	1-257
HSLEC36	488	936003	AP000822	2996	1-407
HSLEC36	488	936003	AC008102	2997	1-413
HSLEC36	488	936003	AP000822	2998	1-390
HSLEC36	488	936003	AC008102	2999	1-390
HSLEC36	488	936003	AC008102	3000	1-254
HSLED42	490	572860	AC074219	3001	1-439
HSLED42	490	572860	AC074334	3002	1-366
HSLEJ22	495	572863	AC023237	3003	1-408
HSLEJ22	495	572863	AC023499	3004	1-408
HSLEJ22	495	572863	AC023237	3005	1-214
HSLEJ22	495	572863	AC023499	3006	1-214
HSLEJ22	495	572863	AC023237	3007	1-231
HSLEJ22	495	572863	AC023499	3008	1-231
HSLEL46	496	573212	AC073743	3009	1-176
HSLEL46	496	573212	AC020850	3010	1-281
HSLEL46	496	573212	AC073683	3011	1-276 426-672
HSLEL46	496	573212	AC078911	3012	1-276
HSLEL46	496	573212	AC024582	3013	1-161 173-284 432-678
HSLEL46	496	573212	AC073683	3014	1-198
HSLEL46	496	573212	AC078911	3015	1-196
HSLEL46	496	573212	AC073743	3016	1-196
HSLEL46	496	573212	AC020850	3017	1-198
HSLEL46	496	573212	AC024582	3018	1-199
HSLFM86	500	785489	AC016160	3019	1-448
HSLFM86	500	785489	AC074220	3020	1-445
HSLFM86	500	785489	AC009031	3021	1-429
HSLFM86	500	785489	AC074220	3022	1-151
HSLFS42	501	948740	AC009844	3023	1-377

HSLFS42	501	948740	AC020850	3024	1-378
HSLFS42	501	948740	AC020873	3025	1-587
HSLFS45	502	717782	AC068768	3026	1-375
HSLFS45	502	717782	AC068768	3027	1-37 165-259 346-389
HSLFS45	502	717782	AC068768	3028	1-202
HSLFT76	503	725788	AC008693	3029	1-615
HSLFT76	503	725788	AC022123	3030	1-886
HSLFU01	505	916448	AC078912	3031	1-412
HSLFU01	505	916448	AC010357	3032	1-415
HSLFU01	505	916448	AC010357	3033	1-276
HSLGD23	506	675872	AC026761	3034	1-452
HSLGD23	506	675872	AC068494	3035	1-451
HSLGD23	506	675872	AC022123	3036	1-429
HSLGK79	508	774049	AC019047	3037	1-391
HSLGK79	508	774049	AC019047	3038	1-386
HSLGX20	510	669648	AP001524	3039	1-147 1158-1621
HSLGX20	510	669648	AP001524	3040	1-147
HSLHP20	513	669210	AC020791	3041	1-427
HSLHP20	513	669210	AC020791	3042	1-89
HSLIG54	515	713982	AC025152	3043	1-439 454-684
HSLII61	516	918071	AC017074	3044	1-1642 1831-2269 2356-3482
HSLII61	516	918071	AC017074	3045	1-378
HSLII61	516	918071	AC017074	3046	1-221
HSLIJ57	517	659533	AC068497	3047	1-506
HSLIJ57	517	659533	AC015817	3048	1-512
HSLJB11	518	966227	Z83844	3049	1-372 1469-1781 2529-2839 3496-3656 3731-3846 4787-4930 5149-5433 6116-6202 7067-9372
HSLJB11	518	966227	Z83844	3050	1-351
HSLJB11	518	966227	Z83844	3051	1-274
HSLJQ31	526	961447	AC008821	3052	1-557
HSLJQ31	526	961447	AC008511	3053	1-164 351-836 1683-2140

					2279-2469 3331-3887 4692-5352 6418-7193 8506-8604 8913-9207 9220-9522 9781-10147 10996-16123
HSLJQ31	526	961447	AC008821	3054	1-661
HSLJW53	527	866261	AP001495	3055	1-712
HSLJW53	527	866261	AC021527	3056	1-290 1054-1348 1697-2100 2242-2953 3485-3866 4447-4756 5347-5572
HSLJW53	527	866261	AP001031	3057	1-392
HSLJW53	527	866261	AC021527	3058	1-284 862-894
HSLJW53	527	866261	AP001495	3059	1-404
HSLJW53	527	866261	AP001031	3060	1-403
HSLJW53	527	866261	AP001031	3061	1-121
HSRAX95	529	747078	AL132868	3062	1-125 590-843 1027-1154 1675-2044 2100-2449 3073-3176 4083-4263 4616-4769 4903-5110 5987-7410 8391-8663 8964-9308 9955-10064 10564-10943 11465-11991 12772-13089 13198-13772 14016-14322 14947-15596 15607-16408 17561-17863 22453-23182 23786-23925

					24209-24324 25277-25604 26333-26753 27095-31132
HSRAX95	529	747078	AL132868	3063	1-791 881-981 1133-1401 2093-2207 3061-3150 3393-3470 3557-3687 4140-4397 5208-5297 6997-7258 8272-8678 8835-8894
HSRAX95	529	747078	AL132868	3064	1-513
HSRDK92	534	838033	AC074012	3065	1-148 1201-1273
HSRDK92	534	838033	AC024085	3066	1-148 1201-1273
HSRDM42	536	523843	AC024704	3067	1-632
HSRDM42	536	523843	AC016683	3068	1-632
HSRDM42	536	523843	AC024704	3069	1-331
HSRDM42	536	523843	AC016683	3070	1-331
HSRDN23	537	530334	AC021300	3071	1-607
HSRDN23	537	530334	AC005703	3072	1-607
HSRDN23	537	530334	AC021300	3073	1-208
HSRDN23	537	530334	AC021300	3074	1-390
HSRDN23	537	530334	AC005703	3075	1-734
HSRDN23	537	530334	AC005703	3076	1-208
HSRDQ89	538	780221	AP001319	3077	1-471 761-1159 2076-2471 3129-4172 5710-6153
HSRDQ89	538	780221	AP000485	3078	1-471
HSRDQ89	538	780221	AP000485	3079	1-399
HSRDQ89	538	780221	AP001319	3080	1-790
HSRDQ89	538	780221	AP000485	3081	1-789
HSRDS77	539	530289	AC002059	3082	1-244
HSRDS77	539	530289	AC000026	3083	1-244
HSRDS77	539	530289	AC002059	3084	1-934
HSRDS77	539	530289	AC000026	3085	1-934
HSRDS77	539	530289	AC002059	3086	1-359 574-891

					1253-1789 1912-2029 2681-2847
HSRDS77	539	530289	AC000026	3087	1-359 574-678 798-891 1253-1789 1912-2029 2681-2847
HSREB43	540	524678	AC060805	3088	1-276
HSREB43	540	524678	AL356440	3089	1-276
HSREB43	540	524678	AC069107	3090	1-276
HSREB43	540	524678	AL356440	3091	1-476
HSREB43	540	524678	AC069107	3092	1-463
HSREB43	540	524678	AC060805	3093	1-248
HSREB43	540	524678	AL356440	3094	1-248
HSREB43	540	524678	AC069107	3095	1-248
HSRED45	542	530233	AP000442	3096	1-110 1671-1833 2258-2541 2656-3699 3792-3942 4306-6277
HSREG49	545	723267	AC018729	3097	1-217
HSREG49	545	723267	AC019250	3098	1-217
HSREG49	545	723267	AC007734	3099	1-219
HSREG49	545	723267	AC024119	3100	1-217
HSREG49	545	723267	AL049715	3101	1-217
HSREG49	545	723267	AC019250	3102	1-390
HSREG49	545	723267	AC007734	3103	1-468
HSREG49	545	723267	AC019250	3104	1-468
HSREG49	545	723267	AC024119	3105	1-468
HSREG49	545	723267	AC024119	3106	1-390
HSREG49	545	723267	AL049715	3107	1-468
HSREG49	545	723267	AL049715	3108	1-390
HSRFD34	547	575288	AP001780	3109	1-145
HSRFD34	547	575288	AL391069	3110	1-170
HSRFD34	547	575288	AC073120	3111	1-301
HSRFD34	547	575288	AL359892	3112	1-583 1605-1880 2039-2153 2927-3485 3613-3918 4038-4641 4679-5013 5296-5749

HSRFD34	547	575288	AL353759	3113	1-442 642-976 1259-1712
HSRFD34	547	575288	AL359892	3114	1-100
HSRFD34	547	575288	AL353759	3115	1-306
HSRFD34	547	575288	AL359892	3116	1-384
HSRFD34	547	575288	AL353759	3117	1-1110
HSRFD47	548	973782	AL138891	3118	1-514
HSRFD47	548	973782	AC002418	3119	1-513
HSRFD47	548	973782	AC004386	3120	1-513
HSRFD47	548	973782	AL138891	3121	1-324
HSRFD47	548	973782	AL138891	3122	1-259
HSRFD47	548	973782	AC002418	3123	1-247
HSRFD47	548	973782	AC002418	3124	1-324
HSRFD47	548	973782	AC004386	3125	1-326
HSRFE58	549	556519	AL359317	3126	1-361
HSRFE58	549	556519	AL359317	3127	1-469
HSRFG30	551	920265	AC074389	3128	1-301
HSRFG30	551	920265	AC074389	3129	1-134
HSRFR21	552	529767	AC068147	3130	1-530 887-1024 1825-1890 1972-2110 2349-3981
HSRFR21	552	529767	AL355075	3131	1-530 887-1024 1825-1890 1972-2110 2349-3981
HSRFR21	552	529767	AC068147	3132	1-312
HSRFR21	552	529767	AL355075	3133	1-37 3559-3797 4958-5393 5832-6145
HSRFZ71	553	557976	AC012321	3134	1-371
HSRFZ71	553	557976	AC009032	3135	1-424
HSRFZ71	553	557976	AC012321	3136	1-183
HSRFZ71	553	557976	AC009032	3137	1-117
HSRGA32	554	529726	AC023038	3138	1-651 2271-3138
HSRGE47	556	974539	AC073835	3139	1-618
HSRGE47	556	974539	AC067884	3140	1-618
HSRGE47	556	974539	AL035404	3141	1-618
HSRGE47	556	974539	AL033526	3142	1-618
HSRGE47	556	974539	AC073835	3143	1-498
HSRGE47	556	974539	AC067884	3144	1-498

HSRGE47	556	974539	AC073835	3145	1-115
HSRGE47	556	974539	AC067884	3146	1-105
HSRGE47	556	974539	AL035404	3147	1-112
HSRGE47	556	974539	AL035404	3148	1-498
HSRGE47	556	974539	AL033526	3149	1-542
HSRGE47	556	974539	AL033526	3150	1-498
HSRGG66	557	556518	AL359317	3151	1-361
HSRGG66	557	556518	AL359317	3152	1-469
HSRGK48	558	535012	AC021704	3153	1-333 585-958 1261-2724 3008-5183
HSRGK48	558	535012	AP000926	3154	1-1742
HSRGK48	558	535012	AC021704	3155	1-216
HSRGK48	558	535012	AP000926	3156	1-133
HSRGK48	558	535012	AC021704	3157	1-302
HSRGQ30	559	534479	AC019290	3158	1-958 1145-1459 2194-2545 5158-5806 5881-6559 6817-7280 9590-11032 15003-15425 15440-16134 16243-17784
HSRGQ30	559	534479	AC019290	3159	1-861
HSRGQ30	559	534479	AC019290	3160	1-106
HSRGS08	560	960211	AC025237	3161	1-313
HSRGS08	560	960211	AC068820	3162	1-294
HSRGS08	560	960211	AC007512	3163	1-313
HSRGS08	560	960211	AC025237	3164	1-170
HSRGV79	561	921005	AL358572	3165	1-347
HSRGV79	561	921005	AL358572	3166	1-272
HSRGW30	562	529624	AC048334	3167	1-443
HSRGW30	562	529624	AC048334	3168	1-590
HSRGZ32	563	699561	AC025360	3169	1-357
HSRGZ32	563	699561	AC025360	3170	1-357
HSRGZ32	563	699561	AL357392	3171	1-297 1639-2093 2352-2848 4569-4713 4984-5109 11452-11932 13121-13288 13549-13645

					13652-13839 15524-15838 16857-18913 20337-21103 21352-21708 22110-22238 22247-22869 22965-23776 23788-23974 24046-24148 26447-27494 30722-30802 31268-31671 32004-32170 32357-32872 33172-33626 34576-34976 34979-35314 35835-35960 37121-37649 38879-38931 39519-39903 41171-41423 42238-42335 42757-42896 43312-43990 44539-44733 45461-46240
HSRGZ32	563	699561	AL136373	3172	1-357 759-1545
HSRGZ32	563	699561	AL357392	3173	1-1942
HSRGZ32	563	699561	AL136373	3174	1-767
HSRGZ32	563	699561	AL136373	3175	1-812
HSRHA45	564	974551	AP002474	3176	1-293 1734-2394
HSRHA45	564	974551	AC017100	3177	1-293 1736-2380
HSRHA45	564	974551	AC017100	3178	1-295
HSSAE47	565	720685	AL354800	3179	1-399
HSSAE47	565	720685	AL354800	3180	1-2674
HSSAF46	566	508117	AL389915	3181	1-340
HSSAV18	569	508832	AC022827	3182	1-255
HSSAV18	569	508832	AC021755	3183	1-241
HSSAV18	569	508832	AC025429	3184	1-254
HSSAV18	569	508832	AC022827	3185	1-223
HSSAV18	569	508832	AC025429	3186	1-223
HSSBO48	571	871217	AC021150	3187	1-361

					534-773
HSSBO48	571	871217	AC010868	3188	1-652
HSSBO59	572	707683	AC010494	3189	1-6900 7239-7739
HSSBO59	572	707683	AC010494	3190	1-88
HSSDJ02	574	871226	AL035681	3191	1-339 570-635
HSSDJ02	574	871226	AL035681	3192	1-274
HSSDR63	577	537329	AC027775	3193	1-344
HSSDR63	577	537329	AC006071	3194	1-1724 27970-28313
HSSDR63	577	537329	AC002092	3195	1-344
HSSDR63	577	537329	AC027775	3196	1-131 463-743 2009-2872
HSSDR63	577	537329	AC006071	3197	1-366 595-1143 1448-1878
HSSDR63	577	537329	AC006071	3198	1-181 496-644 3728-3863 26357-26487 26819-27099 28365-29228
HSSDR63	577	537329	AC002092	3199	1-108 437-717 1984-2853
HSSSED56	579	625572	AC016217	3200	1-472
HSSSED56	579	625572	AC074059	3201	1-466
HSSSED56	579	625572	AC074059	3202	1-357
HSSEF29	580	689837	AC008871	3203	1-570
HSSEF29	580	689837	AC034207	3204	1-570
HSSEF29	580	689837	AC008871	3205	1-279
HSSEF29	580	689837	AC008871	3206	1-760
HSSEF29	580	689837	AC034207	3207	1-760
HSSEF29	580	689837	AC034207	3208	1-276
HSSEK75	581	766507	AC024895	3209	1-422
HSSEK75	581	766507	AC024895	3210	1-116
HSSFF80	585	753589	AC008969	3211	1-514 1300-1805 2627-2795 3012-3127 3212-3649 3737-4319
HSSFF80	585	753589	AC008969	3212	1-372
HSSFQ43	586	715318	AC007367	3213	1-405

HSSFQ43	586	715318	AC007367	3214	1-179
HSSFR41	587	707006	AC022554	3215	1-352
HSSFR41	587	707006	AC022554	3216	1-201 593-712 1881-2119
HSSGC66	590	319740	AL138932	3217	1-741
HSSGC66	590	319740	AL138932	3218	1-90 595-734 881-1278 1536-1738
HSSGC72	591	760648	AC024698	3219	1-336
HSSGD37	592	739505	AL049569	3220	1-82 275-341 1841-1977 2063-2139 2194-2691 5080-5358 5882-5991 6077-6125 6212-6453 7213-7705 8540-8750 9481-9914 9974-10134 10248-10369 10517-10947 11237-11378 12087-12252 12375-12492 12604-12686 13449-13596 13860-14052 14140-14239 15107-15333 15420-15572 15744-15914 16014-16419 16727-16993 19574-19616
HSSGD37	592	739505	AL049569	3221	1-66 84-587 615-747 1028-1293
HSSGD37	592	739505	AL049569	3222	1-44 726-974 3244-3325 4341-4452

					4637-4911 5009-5327 5626-6112 6215-6292 6536-7067
HSSGH47	593	720367	AC022702	3223	1-363
HSSGH47	593	720367	AC022702	3224	1-519
HSSGH47	593	720367	AC022702	3225	1-317 1555-1819
HSSGI20	594	668919	AC021706	3226	1-347
HSSGI20	594	668919	AL136450	3227	1-347
HSSGI20	594	668919	AC021706	3228	1-464
HSSGI20	594	668919	AL136450	3229	1-464
HSSGI75	595	767325	AL139383	3230	1-360
HSSGI75	595	767325	AL138999	3231	1-360
HSSGK96	597	960636	AC020917	3232	1-388
HSSGK96	597	960636	AC020917	3233	1-149
HSSGL78	599	788924	AC005841	3234	1-3246 4046-4159 5174-5965 7066-7244 7431-7504 8084-8427 8694-8902 9077-9497 9523-9904 10260-10424 11181-11505 11877-12297 12756-12874 14112-14459 14847-14996 15082-15195 16726-17286
HSSGL78	599	788924	AC005841	3235	1-693
HSSGM62	600	707685	AC064828	3236	1-65 2182-2642 3222-3329 3645-3854 4263-4601 5303-7155 8825-9100 9711-9935 10619-10701 11474-11616 11874-12030 13114-13218

					13874-14248 14325-14414 14931-15123 15201-15745
HSSGM62	600	707685	AC064828	3237	1-224
HSSGN47	601	707003	AC022315	3238	1-62 305-1003
HSSGN47	601	707003	AC022315	3239	1-426
HSSHA92	602	792714	AC023063	3240	1-724 973-1276 1397-2502 2614-3602 3807-4452 5922-6379 6627-7572 7734-8858 9293-9552 9731-9814 9877-10090 10212-11155 11222-12167
HSSHA92	602	792714	AC023063	3241	1-141
HSSJV60	606	970749	AL390920	3242	1-431
HSSJV60	606	970749	AL390920	3243	1-583
HSSKB40	607	711130	Z83844	3244	1-372 1469-1781 2529-2839 3496-3656 3731-3846 4787-4930 5149-5433 6116-6202 7067-9372
HSSKB40	607	711130	Z83844	3245	1-351
HSSKB40	607	711130	Z83844	3246	1-274
HSSMT78	608	712468	AP001473	3247	1-138 675-1422 1573-1870
HSSMT78	608	712468	AP001101	3248	1-748 899-1196 1239-1713
HSSMT78	608	712468	AP001473	3249	1-259
HYBAE74	609	925074	AC006121	3250	1-76 283-455 1081-2096 2241-2468 3824-3881

					4776-4998 5882-6048 7438-7572 8605-8867 8905-9483 9616-9748 10809-11421 12429-12580 12991-13310 14224-14404 15332-16217 18288-18453 18666-19007 19613-20374 20936-21073 21639-22085 22088-22332 22816-22950 24715-24977 25733-26161 26930-27124 27348-27453 28458-28682 28764-28863 31423-31717 32555-32715 32956-33127 33269-33545 33919-34319 36103-38140
HYBAE74	609	925074	AL109797	3251	1-76 283-455 1081-2096 2241-2468 2777-2914 3824-3881 4776-4998 5882-6048 7438-7572 8605-8867 8905-9483 9614-9744 10810-11422 12430-12580 12992-13311 14225-14405 15333-16218

					18289-18454 18667-19008 19614-20375 20937-21074 21640-22086 22089-22333 22817-22951 25734-26162 26931-27125 27349-27454 28228-28352 28459-28683 28765-28864 31425-31718 32476-32792 32957-33128 33270-33546 33920-34321 35214-35796 36099-38136
HYBAE74	609	925074	AL109797	3252	1-108
HYBAE74	609	925074	AL109797	3253	1-112
HYBAG11	610	967880	AC018381	3254	1-203
HYBAG11	610	967880	AC007734	3255	1-203
HYBAG11	610	967880	AL049715	3256	1-490
HYBAG11	610	967880	AC024119	3257	1-204
HYBAG11	610	967880	AC007734	3258	1-446
HYBAG11	610	967880	AL049715	3259	1-444
HYBAG11	610	967880	AL049715	3260	1-2160
HYBAG11	610	967880	AC024119	3261	1-444
HYBAU83	611	732419	AL353793	3262	1-133
HYBAY40	613	531202	AC022364	3263	1-385
HYBBB24	614	584989	AC024906	3264	1-488
HYBBI18	615	584991	AC073460	3265	1-339
HYBBI18	615	584991	AL354945	3266	1-339
HYBBI18	615	584991	AL355292	3267	1-339
HYBBI18	615	584991	AL355292	3268	1-784
HYBBI18	615	584991	AL354945	3269	1-192 214-889
HYBBI18	615	584991	AL355292	3270	1-192 214-889
HYBBJ30	616	693345	AC011973	3271	1-2411
HYBBJ30	616	693345	AC016999	3272	1-2448
HYBBJ30	616	693345	AC011973	3273	1-1242
HYBBJ30	616	693345	AC016999	3274	1-777
HYBBL17	617	691328	AC027074	3275	1-1214

					1541-2851
HYBBL17	617	691328	AC027074	3276	1-503
HYBAY92	620	792923	AC006095	3277	1-443 460-925
HYBAY92	620	792923	AC012470	3278	1-443 460-925
HYBAW03	621	925068	AP001628	3279	1-339
HYBAW03	621	925068	AP001628	3280	1-78 88-287
HYBAW03	621	925068	AP001628	3281	1-1050
HYBAF63	624	745585	AC022188	3282	1-616
HYBAF63	624	745585	AC022188	3283	1-523
HSSMZ93	625	530752	AL365272	3284	1-593
HSSMZ93	625	530752	AL035696	3285	1-593
HSSMW90	627	975081	AL360017	3286	1-734 1885-2084 2683-2777 2921-2978
HSSMW90	627	975081	AC026576	3287	1-734 1885-2084 2683-2777 2921-2978
HSSMW90	627	975081	AL035413	3288	1-734 1876-2075 2674-2768 2912-2969
HSSMT76	628	928421	AC023864	3289	1-142
HSSMT76	628	928421	AC010550	3290	1-127
HSSMT76	628	928421	AL117190	3291	1-102 2590-2699 2915-9959 10043-10287 13264-13656 15305-15737 17026-17496 18233-18688 19340-19416 19587-21391 21539-24538 25521-25888 26530-28357 28626-29805 29835-30529 30546-31506 33033-34910
HSSMT76	628	928421	AC023864	3292	1-3115 3220-4704

HSSMT76	628	928421	AL117190	3293	1-441
HSSMT70	629	530758	AC018546	3294	1-735
HSSMT70	629	530758	AC018546	3295	1-189
HSSMP20	630	854092	AC022784	3296	1-377
HSSJP81	633	911334	AC023133	3297	1-126 276-308 1686-1833 4690-4918 5836-6297 6805-7376 8288-8522 8528-9952 10213-10496 10505-11457 11505-13731 14167-14297 14407-14572 15189-15243 16434-16536 17286-17446 18631-18739 19790-19945 20293-20475 20724-20848 21136-21270 22395-22470 24078-24251 24582-24791 24797-25044 26412-26845 26967-27066 27787-28134 28454-28520 29195-30013
HSSJK65	635	747891	AC024293	3298	1-911
HSSJK65	635	747891	AC024293	3299	1-83
HSSJK65	635	747891	AC024293	3300	1-369
HSSJH78	636	773558	AC025637	3301	1-136 557-2246 2282-2427 2717-2843 2949-3739 3823-4409 4880-6134
HSSJH78	636	773558	AC024225	3302	1-1255
HSSJH78	636	773558	AC055707	3303	1-489
HSSJH78	636	773558	AC024225	3304	1-177

HSSJH78	636	773558	AC055707	3305	1-177
HSSJH78	636	773558	AC025637	3306	1-177
HSSJH78	636	773558	AC024225	3307	1-145 433-559 665-1455 1539-2125
HSSJA08	637	959336	AC026543	3308	1-1000 1171-1630 2138-2439 2590-3651
HSSJA08	637	959336	AC058799	3309	1-673
HSSJA08	637	959336	AC026543	3310	1-451
HSSGJ84	639	781975	AC023014	3311	1-65 1437-1596 1951-2373 2381-2579 2587-2748 3063-3531 3761-5598 5758-6269 6338-7043 8097-8460 9089-9348 9365-10612
HSSGJ84	639	781975	AL161635	3312	1-469
HSSGJ84	639	781975	AL139400	3313	1-65 1437-1596 1960-2372 2380-2578 2586-2747 3062-3530 3760-5597 5757-6268 6337-7352 8100-8463 9091-9350 9367-10614
HSSGJ84	639	781975	AC023014	3314	1-195
HSSGJ84	639	781975	AC023014	3315	1-1632
HSSGJ84	639	781975	AL161635	3316	1-162
HSSGJ84	639	781975	AL139400	3317	1-195
HSSGJ84	639	781975	AL139400	3318	1-1632
HSSFW84	643	781973	AC004590	3319	1-126 4595-5120 5544-5846
HSSFW84	643	781973	AC021491	3320	1-126 4596-5122

					5546-5848
HSSFW84	643	781973	AC004590	3321	1-363 528-624 1405-1605 1762-2101 3675-4861 4937-5153 5209-5321 5476-6047 6368-6572 6665-6815 6882-7049 7237-7358 7400-7575 7693-7815 8090-8192 8405-8680
HSSFW84	643	781973	AC021491	3322	1-363 528-624 1403-1603 1760-2099 3673-4859 4935-5151 5207-5319 5474-6045 6366-6570 6663-6813 6880-7047 7235-7356 7398-7573 7691-7813 8088-8190 8403-8677
HSSFU84	644	888462	Z82214	3323	1-554
HSSFU84	644	888462	Z82214	3324	1-468
HSSFU84	644	888462	Z82214	3325	1-37 826-1969 3475-3813
HSSFN08	645	959735	AF031078	3326	1-1820
HSSFN08	645	959735	AF030876	3327	1-1820
HSSFN08	645	959735	AF031075	3328	1-1820
HSSFN08	645	959735	AF031078	3329	1-171
HSSFN08	645	959735	AF031078	3330	1-403
HSSFN08	645	959735	AF030876	3331	1-171
HSSFN08	645	959735	AF031075	3332	1-171
HSSFN08	645	959735	AF030876	3333	1-403
HSSFN08	645	959735	AF031075	3334	1-403

HSSFK90	646	788687	Z93014	3335	1-587
HSSFK90	646	788687	AL121601	3336	1-368 1848-2434
HSSFK90	646	788687	AL121601	3337	1-617
HSSFB73	647	955200	AC022222	3338	1-504
HSSFB73	647	955200	AC007537	3339	1-374
HSSFB73	647	955200	AC007537	3340	1-288
HSSEU40	648	891055	AL137253	3341	1-1147
HSSEU40	648	891055	AL356299	3342	1-994
HSSEU40	648	891055	AL137253	3343	1-276
HSSEU40	648	891055	AL356299	3344	1-276
HSSEU40	648	891055	AL356299	3345	1-125
HSSEP69	649	871211	AC069454	3346	1-380
HSSEP69	649	871211	AC069454	3347	1-498
HSSEG25	651	679351	Z83845	3348	1-504 658-707 1786-3045 3351-4099
HSSEG25	651	679351	Z83845	3349	1-134 492-798 1739-1873 2345-2537 2704-2846 3729-3841 4515-4623 6820-6962 8496-8600 9505-10043 10660-10776 11694-11920 13014-13175 14177-14195 14510-16877
HSSEG25	651	679351	Z83845	3350	1-684
HSSDH37	656	575460	AC012645	3351	1-198 3475-3669 3852-3972 4235-4359 4732-4864 5008-5124 5225-5405 5625-5969 6143-6258 6374-6421 6906-7032 7306-8679 8955-8999

					9225-9361 9451-9491 9590-9712 9797-9886 10489-10631 10718-11123 11611-11742 12900-13178 13587-13646 13755-13808
HSSDH37	656	575460	AC012645	3352	1-102
HSSDH37	656	575460	AC012645	3353	1-377
HSSCC14	658	600216	AC010203	3354	1-1677 2250-3207 3870-4245 4249-5488 6198-6240 6837-6924 7178-7390 7472-7755 7836-8511 10534-10971 11857-12094 13226-13689 13754-15275 16452-16747
HSSCC14	658	600216	AC010203	3355	1-48 239-1330
HSSCC14	658	600216	AC010203	3356	1-101
HSSAZ04	659	933015	AC027783	3357	1-1623
HSSAZ04	659	933015	AC027576	3358	1-3083 3314-3536 3565-4033
HSSAZ04	659	933015	AC005768	3359	1-1734
HSSAZ04	659	933015	AC027783	3360	1-1467
HSSAZ04	659	933015	AC027576	3361	1-759
HSSAZ04	659	933015	AC027576	3362	1-300
HSSAZ04	659	933015	AC005768	3363	1-460 824-1439 3142-3504 3774-6883
HSSAZ04	659	933015	AC005768	3364	1-1314 1545-1767 1796-2264
HSSAY34	660	703345	AL138932	3365	1-2635
HSSAY34	660	703345	AL138932	3366	1-308
HSSAJ89	662	875882	AP002776	3367	1-1505

					1576-1638 1725-2468 2580-2670 2740-2899 3033-3576 3635-4235
HSSAJ89	662	875882	AP001885	3368	1-160 294-837 896-1496
HSSAJ89	662	875882	AP001885	3369	1-91
HSRAY10	665	961237	AC021441	3370	1-696
HSRAY10	665	961237	AC009908	3371	1-696
HSRAS82	666	780222	U73168	3372	1-66 273-3210 3587-3673 3859-5330 5564-5736 6777-6884 7014-7581 8079-8158 8239-8314 9254-9356 9595-10142 10389-10474 10689-11491 11670-12184 12238-13548 13949-14101 14179-14873 15079-15168 15181-15801 15905-16167 16535-16718 16934-18966
HSRAS82	666	780222	U73168	3373	1-1130
HSRAF70	667	524680	AC053513	3374	1-28 1617-1660 3033-3127 4677-4779 5039-6378 8362-8557 10265-11200 14774-14940 18361-18501 20445-20509 20542-20996 21185-21285

					21764-21855 22332-22430 23457-23543 23635-24413 24752-25169 27477-27906 28690-29213 29550-30031 32052-32497 32648-33369 34122-34768 35360-36282 39205-39354 43359-44706
HSRAD72	669	539530	AC048337	3375	1-110 147-669
HSRAD72	669	539530	AC048337	3376	1-176
HSRAD65	670	871268	AF128834	3377	1-979 1451-1781 1817-2962
HSRAD65	670	871268	AF128834	3378	1-195 1123-1226 1250-1367 2556-2701
HSRAD65	670	871268	AF128834	3379	1-784
HSRAD53	671	525490	AL353672	3380	1-316
HSRAD53	671	525490	AC026573	3381	1-316
HSRAD53	671	525490	AL353588	3382	1-316
HSRAD53	671	525490	AL353672	3383	1-523
HSRAD53	671	525490	AC026573	3384	1-526
HSRAD53	671	525490	AL353588	3385	1-526
HSRAD31	673	524845	AC073662	3386	1-247
HSRAD31	673	524845	AP001965	3387	1-247
HSRAD31	673	524845	AC073662	3388	1-1268
HSRAD31	673	524845	AP001965	3389	1-1268
HSRAD10	674	968614	AC018804	3390	1-814 1343-1452 1467-1598 2200-2386 2433-2474 4962-5052 6603-6691 7946-8094 8249-8326 8703-8816 8926-8978 9101-9255

					9847-10219 10951-11510 11979-12884 14012-14140 14282-14371 17152-17200
HSRAD10	674	968614	AC018804	3391	1-899 1121-1456
HSRAB87	676	823174	AP000729	3392	1-324
HSRAB82	677	522945	AL031733	3393	1-390
HSRAB82	677	522945	AL031733	3394	1-342
HSRAB76	678	508105	AL359476	3395	1-1292
HSRAB76	678	508105	AL356216	3396	1-286 1366-2105 2178-2289 2920-4211 4585-4674
HSRAB76	678	508105	AL356216	3397	1-121
HSRAB76	678	508105	AL359476	3398	1-286 1364-2103 2176-2286
HSRAB36	679	522946	AC011332	3399	1-379
HSRAB36	679	522946	AC005352	3400	1-379
HSRAB36	679	522946	AC011332	3401	1-329
HSRAB36	679	522946	AC005352	3402	1-329
HSRAB36	679	522946	AC005352	3403	1-189
HSRAB34	680	706996	AC068641	3404	1-298 389-1077 1855-2384 3111-3469 3930-4264 4638-4788 6878-6963 7577-7613 8676-8837 10894-11198 12629-13341 13502-13744 15053-15295
HSRAB34	680	706996	AC068641	3405	1-558
HSRAB08	681	960411	AC011406	3406	1-210
HSRAB08	681	960411	AC011406	3407	1-534
HSRAA64	684	955314	AL132838	3408	1-756
HSRAA64	684	955314	AC005924	3409	1-756
HSRAA51	685	522834	AC024243	3410	1-345
HSRAA51	685	522834	AC024243	3411	1-356

HSRAA24	688	795855	AP000437	3412	1-2275
HSRAA24	688	795855	AC006410	3413	1-174 873-953 1050-1077 1669-3953
HSRAA24	688	795855	AP000437	3414	1-575
HSRAA24	688	795855	AC006410	3415	1-448 911-1015
HSRAA23	689	524795	AC021586	3416	1-410
HSLKB37	691	929743	AL161799	3417	1-718
HSLKB37	691	929743	AL161799	3418	1-431
HSLKB37	691	929743	AL161799	3419	1-456
HSLKA06	692	934638	AP000594	3420	1-330 693-1279 1618-3031
HSLKA06	692	934638	AP001879	3421	1-330 693-1279 1618-3065
HSLKA06	692	934638	AP002500	3422	1-330 693-1279 1618-3063
HSLKA06	692	934638	AP000594	3423	1-129
HSLKA06	692	934638	AP001879	3424	1-436
HSLKA06	692	934638	AP001879	3425	1-129
HSLKA06	692	934638	AP002500	3426	1-129
HSLKA06	692	934638	AP002500	3427	1-436
HSLJF33	694	938811	AC022123	3428	1-577 587-898
HSLJF33	694	938811	AC008602	3429	1-577
HSLJD02	695	965826	AC025288	3430	1-904
HSLIJ48	696	721248	AL138792	3431	1-2086
HSLIJ48	696	721248	AL138792	3432	1-280
HSLIG07	697	952493	AL355520	3433	1-39 3561-3618 7841-7949 10375-11270 11589-11678 15048-15690 16028-16134 18215-18476 20699-20733 23616-23861 30319-35764
HSLIG07	697	952493	AL355520	3434	1-386
HSLIG07	697	952493	AL355520	3435	1-437
HSLHZ82	700	779067	AC026149	3436	1-537

HSLHZ82	700	779067	AC026149	3437	1-625
HSLHG49	703	722570	AC019335	3438	1-442
HSLHG49	703	722570	AC008716	3439	1-442
HSLHG49	703	722570	AC019335	3440	1-309 863-1408
HSLHG49	703	722570	AC019335	3441	1-302 1212-1582
HSLHG49	703	722570	AC008716	3442	1-309 863-1408
HSLHG49	703	722570	AC008716	3443	1-302 1212-1582
HSLHC40	704	710681	AF233070	3444	1-434
HSLHC40	704	710681	AF233070	3445	1-373
HSLGN78	709	773565	AC019171	3446	1-127 342-897 1993-2259 3055-3372 3423-4048 4089-4277 4324-6037 6069-8876 9013-9740 9791-9906 10195-10899 11064-13605
HSLGN78	709	773565	AC019171	3447	1-2093
HSLGN78	709	773565	AC019171	3448	1-739 2715-2831 3005-3561
HSLGN52	710	466026	AC023339	3449	1-63 297-528 1493-1596 1818-2263 3318-3424 3727-3831 3969-5442 6232-6460 6510-6993 7378-7695 7872-7910 8145-8265 8574-8985 9173-9375
HSLGK46	711	719031	AC009185	3450	1-155 997-1253 2053-2148 3496-4043

					7024-7126 9004-9098 10407-10717 10930-11047
HSLGK46	711	719031	AC009185	3451	1-534
HSLGK23	713	675266	AC013713	3452	1-764
HSLGK23	713	675266	AL157820	3453	1-443
HSLGK23	713	675266	AC013713	3454	1-1289 2601-3182 3702-4241 6170-8487
HSLGK23	713	675266	AL157820	3455	1-514
HSLGI76	715	770035	AC068404	3456	1-659 762-1460
HSLGI76	715	770035	AC068404	3457	1-405
HSLGH70	717	871888	AL133330	3458	1-5227
HSLGH70	717	871888	AL133330	3459	1-619
HSLGG79	719	775146	AC003086	3460	1-403 677-1512
HSLGG79	719	775146	AC003086	3461	1-399
HSLGA79	720	774051	AC016961	3462	1-505
HSLGA79	720	774051	AC016961	3463	1-291
HSLGA79	720	774051	AC016961	3464	1-148
HSLGA24	722	955333	AC074219	3465	1-807
HSLFU18	723	666405	AC008154	3466	1-3538
HSLFU18	723	666405	AC018646	3467	1-2673
HSLFU18	723	666405	AC008154	3468	1-116 3689-3797 4628-4674 7369-7452 7659-7721 9183-9329 9883-10172 11683-12183 13014-13093 14304-14396 14402-15694 15738-16337
HSLFT29	724	680451	AC022123	3469	1-584
HSLFI01	726	876881	AL049611	3470	1-1354 1780-1884 2174-2318 3163-3327 4645-10514
HSLFI01	726	876881	AL049611	3471	1-617
HSLFI01	726	876881	AL049611	3472	1-89

					350-654
HSLDW24	729	779689	AC073992	3473	1-860
HSLDW24	729	779689	AC005082	3474	1-846
					1190-1616
					1818-2495
					2513-2795
					3162-3896
					4168-6088
					7406-7663
					7675-7765
					8981-9162
					10202-11061
					11082-11558
					11572-12787
					12822-12981
					13008-13158
					13466-13960
					15708-15956
					17748-17924
					18094-18231
					18295-18381
					18409-18765
					18804-19172
HSLDW24	729	779689	AC073992	3475	1-1701
HSLDW24	729	779689	AC073992	3476	1-182
HSLDW24	729	779689	AC005082	3477	1-232
HSLDR18	731	578926	AC022123	3478	1-417
HSLDR05	732	932128	AC020850	3479	1-900
HSLDR05	732	932128	AC009091	3480	1-390
HSLDP66	733	866331	AC004796	3481	1-580
HSLDP66	733	866331	AC004796	3482	1-345
HSLDP66	733	866331	AC004796	3483	1-309
HSLDO01	734	916969	AC023093	3484	1-413
HSLDO01	734	916969	AC023093	3485	1-502
HSLCX61	738	742031	AC016582	3486	1-38
					1536-1812
					3968-4394
					5807-5918
					6477-6925
					7509-8029
					8979-9149
					9479-9566
HSLCX61	738	742031	AC007676	3487	1-38
					1534-1744
					3974-4400
					5302-5403
					5813-5924

					6483-6932 7515-8035 8957-9127 9457-9544 10602-10844 12165-12320 14170-14513 14771-14943 15727-15963 19812-20009 21301-21954 24254-24543 25372-25657 30663-30778 31145-31617 31632-31805 34572-34953 38596-38886 39180-39558 39601-41424 43326-43518
HSLCX61	738	742031	AC016582	3488	1-271
HSLCX61	738	742031	AC007676	3489	1-685
HSLCX61	738	742031	AC007676	3490	1-271
HSKZE91	741	790166	AC055855	3491	1-2128
HSKYG48	742	721631	AC027228	3492	1-260 548-710 759-1145 2793-2897 2990-3131 3303-3809 5167-5262 6266-6427 6512-6629 9491-9709 10402-13824
HSKYG48	742	721631	AC027228	3493	1-125
HSKJR15	745	866396	AC015844	3494	1-134 226-628 700-974 1061-1542
HSKJC88	746	866402	AL161627	3495	1-557
HSKJC88	746	866402	AL161627	3496	1-1635 2670-5996
HSKJC88	746	866402	AL161627	3497	1-352
HSKII90	747	788894	AC013764	3498	1-643
HSKII90	747	788894	AC013764	3499	1-550

HSKHZA7	748	720286	AC007228	3500	1-1190 1382-2390
HSKHZA7	748	720286	AC007228	3501	1-589
HSKHZA7	748	720286	AC007228	3502	1-481
HSKHP10	750	964568	AL109928	3503	1-187 303-387 1815-3282 3290-6558
HSKHP10	750	964568	AL109928	3504	1-363
HSKDC06	753	935452	AL138767	3505	1-884 905-1284 1325-4776 4912-5745 5809-6106 6202-6417
HSKDC06	753	935452	AL157893	3506	1-4395
HSKDC06	753	935452	AL132656	3507	1-885 906-1285 1326-4773 4909-5744
HSKDC06	753	935452	AL138767	3508	1-1087
HSKDC06	753	935452	AL157893	3509	1-307
HSKDC06	753	935452	AL157893	3510	1-380
HSKDC06	753	935452	AL132656	3511	1-1077
HSKDC06	753	935452	AL132656	3512	1-327
HSKCR54	754	922730	AC027641	3513	1-237 357-615 944-1561 1577-2998 3073-3185 3211-3347 4175-4715
HSKCR54	754	922730	AC027641	3514	1-216
HSKCR54	754	922730	AC027641	3515	1-216 224-383
HSKCD43	755	714389	AC009282	3516	1-857 1029-2227
HSKCD43	755	714389	AL390208	3517	1-115 1487-1848 1851-2468 2968-3545 4003-4349 4917-5481 5616-5922 5999-6459 7710-7823 7875-8320

					9771-9966 11924-12801 12973-14171
HSKCD43	755	714389	AL133266	3518	1-66 856-1060 1675-1854 3226-3587 3590-4207 5831-6177 6745-7309 7444-7750 7827-8287 9537-9650 9702-10147 11599-11794 13752-14628 14800-15998
HSKCD43	755	714389	AL158137	3519	1-857 1029-2227
HSKBW62	757	521937	AC023959	3520	1-329
HSKBW62	757	521937	AC011885	3521	1-329
HSKBW62	757	521937	AC013434	3522	1-329
HSKAE10	760	968508	AC015962	3523	1-697
HSKAE10	760	968508	AP002393	3524	1-697
HSJAY64	763	866540	AC011462	3525	1-1998 2010-2673 3157-3587 3611-3907 4926-5714 5719-6572 8490-8910 11142-11596 12706-13113 13191-13317 13415-13541 15366-15613
HSJAY64	763	866540	AC011462	3526	1-467
HSJAY64	763	866540	AC011462	3527	1-384 472-794
HSCAF60	770	537444	AL080250	3528	1-2220
HSCAF60	770	537444	AL080250	3529	1-487
HRDFU03	771	924698	AC026290	3530	1-365
HRDFU03	771	924698	AC048338	3531	1-365
HRDFU03	771	924698	AC026290	3532	1-521
HRDFU03	771	924698	AC048338	3533	1-521
HRDFH46	772	590391	AL355773	3534	1-854 2013-2134

					2650-3156 3284-3379 3563-3826 4498-4620 5597-5673 7008-7286 7721-8002 8099-8648 9030-9519
HRDFH46	772	590391	AL138499	3535	1-74 1171-1414 2003-2145 5281-5390 6571-6708 7273-8042 8498-8581 9242-9411 9823-9893 11229-11269 11959-12050 12418-12490 12981-13017 13172-13255 13739-13807 16333-16490 16856-16966 17025-17457 19018-19053 19571-19708 19739-20018 20071-20166 20847-20919 21057-21542 21820-21861 22375-22563 22606-22687 23332-23536 23934-23974 24441-25133 25607-26151 27567-27728 28089-28180 30591-30662 31711-31750 32025-32303 32728-33189 33569-33660

					34582-35243 36002-36089 37700-38027 38479-39379 39447-39994 39996-40412 40939-41175 42777-42859 43613-43709 43834-43926 44676-44750 44978-45061 45219-45304 45604-46116 46592-46981 47116-47969 49128-49249 49765-50272 50400-50495 50679-50942 51613-51736 52713-52789 54124-54402 54837-55118 55215-55764 56143-56632
HRDFH46	772	590391	AL138499	3536	1-386 635-1149
HRDFG13	773	925350	Z99716	3537	1-55 126-186 610-963 1193-1368 2995-3327
HRDFG13	773	925350	Z99716	3538	1-135
HRDFD56	775	733556	AC026198	3539	1-768
HRDFD56	775	733556	AC007174	3540	1-768
HRDFD56	775	733556	AC018812	3541	1-768
HRDFD56	775	733556	AC020752	3542	1-768
HRDFD56	775	733556	AC022012	3543	1-768
HRDFD56	775	733556	AC020750	3544	1-768
HRDFD56	775	733556	AC022002	3545	1-768
HRDFD56	775	733556	AC026198	3546	1-384
HRDFD56	775	733556	AC007174	3547	1-384
HRDFD56	775	733556	AC018812	3548	1-384
HRDFD56	775	733556	AC020752	3549	1-384
HRDFD56	775	733556	AC022012	3550	1-384
HRDFD56	775	733556	AC020750	3551	1-384

HRDFD56	775	733556	AC022002	3552	1-384
HRDFA03	776	867122	AC010240	3553	1-980
HRDFA03	776	867122	AC010240	3554	1-451
HRDFA03	776	867122	AC010240	3555	1-239
HRDEZ73	777	774414	AL049868	3556	1-937 1243-1407 1844-2172 2181-2679 2706-3392 3539-4236
HRDEZ73	777	774414	AL359704	3557	1-938 1244-1408 1845-2173 2182-2680 2707-3393 3540-4237
HRDEZ73	777	774414	AL391095	3558	1-938 1244-1408 1845-2173 2182-2680 2707-3393 3540-4237
HRDEZ73	777	774414	AL049868	3559	1-397
HRDEZ73	777	774414	AL359704	3560	1-397
HRDEZ73	777	774414	AL391095	3561	1-397
HRDEP20	781	690456	AC008663	3562	1-461 3399-3527 4652-5129 5447-6031 6123-6401 6651-7418 8095-9142
HRDEP20	781	690456	AC008663	3563	1-101
HRDEP20	781	690456	AC008663	3564	1-130
HRDEK53	782	867137	AC004832	3565	1-195 1361-1748 1778-1875 1957-2456 3189-3274 6415-7628 8053-8458 8539-8677 8730-9585 10648-10979 12618-12793 13105-14385 14859-16433

					16517-17216
HRDEK53	782	867137	AC005585	3566	1-195 1361-1748 1778-1875 1957-2456 3189-3274 6415-7628 8053-8458 8539-8677 8730-9585 10648-10979 13105-14385 14859-16434 16518-17217
HRDEK53	782	867137	AC004832	3567	1-694
HRDEK53	782	867137	AC004832	3568	1-546
HRDEK53	782	867137	AC005585	3569	1-694
HRDEK53	782	867137	AC005585	3570	1-546
HRDDU41	786	712572	AC016197	3571	1-351
HRDDU41	786	712572	AC022022	3572	1-351
HRDDU41	786	712572	AC016197	3573	1-247
HRDDU41	786	712572	AC016197	3574	1-171
HRDDU41	786	712572	AC022022	3575	1-247
HRDDU41	786	712572	AC022022	3576	1-171
HRDDR39	787	867151	AP001150	3577	1-601
HRDDR39	787	867151	AP001150	3578	1-217 379-588 1680-1812 2108-2969
HRDBH52	790	728715	AP001544	3579	1-573
HRDBH52	790	728715	AP001548	3580	1-573
HRDBH52	790	728715	AC073440	3581	1-573
HRDBH52	790	728715	AP001399	3582	1-573
HRDBH52	790	728715	AP001548	3583	1-490
HRDBH52	790	728715	AP001544	3584	1-490
HRDBH52	790	728715	AC073440	3585	1-490
HRDBH52	790	728715	AP001399	3586	1-490
HRDAB42	791	800333	AC023502	3587	1-435
HRDAB42	791	800333	AC022383	3588	1-864
HRDAB42	791	800333	AC022384	3589	1-861
HRDAB42	791	800333	AC008032	3590	1-864
HRDAB42	791	800333	AC008032	3591	1-101
HRDAB42	791	800333	AC008032	3592	1-282
HOSOW01	792	914804	AC015585	3593	1-927 954-1515
HOSOW01	792	914804	AC017101	3594	1-927

					954-1515
HOSOW01	792	914804	AC017026	3595	1-927 954-1515
HOSOW01	792	914804	AC015585	3596	1-1422
HOSOW01	792	914804	AC017026	3597	1-1657
HOSMP95	794	948496	AC004500	3598	1-886 1535-1939 2922-3397 3427-3540 4001-4264 4464-5586 7800-7945 7959-8108
HOSMP95	794	948496	AC004500	3599	1-226
HOSMP95	794	948496	AC004500	3600	1-56 310-377 1495-1589
HOSFV77	796	856933	AC025008	3601	1-3255
HOSFV77	796	856933	AL035411	3602	1-4240
HOSFV77	796	856933	AL035411	3603	1-227
HOSFL07	799	953183	AC016695	3604	1-2306
HOSFL07	799	953183	AC018640	3605	1-2311
HOSFL07	799	953183	AC009244	3606	1-2312
HOSFL07	799	953183	AC016695	3607	1-496
HOSFL07	799	953183	AC018640	3608	1-105
HOSFL07	799	953183	AC018640	3609	1-496
HOSFL07	799	953183	AC009244	3610	1-496
HOSFI46	801	719021	AC069073	3611	1-808
HOSFI46	801	719021	AC069073	3612	1-192
HOSDR12	804	971169	AL161740	3613	1-130 1984-2058
HOSDR12	804	971169	AL161740	3614	1-220
HOSDQ78	805	858983	AC006474	3615	1-418 552-1799
HOSDQ78	805	858983	AC006474	3616	1-384
HOSDA04	808	951842	AC012408	3617	1-2186
HOSBY89	813	787182	AC025800	3618	1-37 980-2429
HOSBY89	813	787182	AC011773	3619	1-66 1045-1184 1559-3179 3239-3435 3586-3922 3925-4354 4655-6627 7796-7829

					8768-9128 9311-9788 10585-10851 11117-11429 12515-12583 15318-15475 15541-15633 16787-16951 17797-17908
HOSBY89	813	787182	AC025800	3620	1-42 604-718 2247-2564 3873-4140
HOSBY89	813	787182	AC011773	3621	1-42 2263-2579 3892-4159
HOSBX46	814	719414	AL049781	3622	1-842 1381-2554 5735-5992 6879-7259 7587-9210
HOSBX46	814	719414	AL049781	3623	1-649
HOSBX46	814	719414	AL049781	3624	1-201
HOSBX34	815	706769	AC008009	3625	1-4301 4410-5419
HOSBX34	815	706769	AC008009	3626	1-74 485-636 859-951 1364-1487 3436-3606 4183-4714 5900-5979 9956-10067 11481-11963 13607-13693 15019-15227 20188-21030 21682-22252 22277-22497 22593-24241 24399-24692 25134-26128 27449-27554 27875-29607
HOSBX34	815	706769	AC008009	3627	1-1004 1875-2197 2217-2290

					3235-3317 3705-4524 4663-5005 5891-6065
HOSBO34	817	706770	AC018606	3628	1-680 1108-2215
HOSBO34	817	706770	AC018606	3629	1-111
HOSBM55	818	732550	AB014087	3630	1-1183
HOSBM55	818	732550	AC004188	3631	1-1183
HOSBM55	818	732550	AB014087	3632	1-427
HOSBM55	818	732550	AC004188	3633	1-521
HOSBM55	818	732550	AC004188	3634	1-427
HOSAY52	819	728759	AL049781	3635	1-842 1381-2554 5735-5992 6879-7259 7587-9210
HOSAY52	819	728759	AL049781	3636	1-649
HOSAY52	819	728759	AL049781	3637	1-201
HOSAL10	821	968710	AC015655	3638	1-709
HOSAL10	821	968710	AC025545	3639	1-465 616-1158
HOSAL10	821	968710	AC069523	3640	1-791 942-1485
HOSAL10	821	968710	AC025545	3641	1-259
HOSAL10	821	968710	AC069523	3642	1-258
HOSAL10	821	968710	AC069523	3643	1-50 978-1336 4572-4971 5922-6284
HOSAH30	823	693406	AL139162	3644	1-1851
HOSAH30	823	693406	AC073638	3645	1-1371 1464-3286 3846-4478 5145-5389 6355-6441 6990-7453 7636-8097 8679-9009 9507-9558
HOSAH30	823	693406	AL139162	3646	1-503
HOSAH30	823	693406	AC073638	3647	1-1605
HOSAF19	824	672078	AC069222	3648	1-576 755-1350
HOSAF19	824	672078	AC022883	3649	1-576 755-1350

HOSAF19	824	672078	AC024938	3650	1-576 755-1350
HOSAF19	824	672078	AC022883	3651	1-450
HOSAF19	824	672078	AC069222	3652	1-450
HOSAF19	824	672078	AC024938	3653	1-450
HOHEN28	825	686034	AC021923	3654	1-194 1261-1657 1673-1825 5781-6120 7234-7599 8092-8247 8353-8637 8801-10463 10487-11027
HOHEN28	825	686034	AC018790	3655	1-194 1261-1657 1673-1825 5781-6120 7234-7599 8092-8247 8353-8637 8801-10463 10487-11027
HOHEN28	825	686034	AC018790	3656	1-99
HOHEG71	826	760051	AC023120	3657	1-2351 2406-3121 3186-3327 5228-5903 6301-6724 6756-7347 8157-8780 8929-9270 9943-10371 10549-11021 11844-12347 17147-17451 17563-17662 18026-18260 18456-18609 19490-19959 25372-25481 26563-26665 27439-27568 27673-27966 29690-29884 33065-33887 33968-34187

					35050-35109 35958-36256 37813-37925
HOHEG71	826	760051	AC023120	3658	1-1768
HOHEG71	826	760051	AC023120	3659	1-518
HOHDF94	827	793970	AF260011	3660	1-392 1316-1511 3951-4175 4406-4711 5372-5546 5952-6147 6232-6688 7555-8129 9753-10326 12106-12182 12272-12752 13231-13444
HOHDF94	827	793970	AF260011	3661	1-25 165-266 531-2938
HOHCG79	831	859029	AC044820	3662	1-604 2939-3404 4741-5741
HOHCG79	831	859029	AC018590	3663	1-465
HOHCG79	831	859029	AC044820	3664	1-377
HOHCG79	831	859029	AC018590	3665	1-1001
HOHBZ27	833	588364	AL109966	3666	1-2391
HOHBZ27	833	588364	AL109966	3667	1-763
HOHBS10	836	964324	AC009088	3668	1-409
HOHBS10	836	964324	AC009088	3669	1-266
HOHBS10	836	964324	AC009088	3670	1-377 765-1140 1231-1302 1394-1850 1926-2050 2098-2221 2408-3127 3583-4516
HOHBP36	837	708158	AC013451	3671	1-602
HOHBP36	837	708158	AC013451	3672	1-281
HOHBL35	839	973238	AC055749	3673	1-521
HOHBL35	839	973238	AC023296	3674	1-521
HOHBI84	840	782908	AL359678	3675	1-306
HOHBI84	840	782908	AL359678	3676	1-84
HOHBB90	841	588308	AL035455	3677	1-74 680-1053 3541-3691

					3707-4349 5188-5434 6048-7834
HOHBB90	841	588308	AL354834	3678	1-74 680-1053 3541-3691 3707-4349 5188-5434 6050-7836
HOHBB90	841	588308	AL035455	3679	1-402
HOHBB90	841	588308	AL035455	3680	1-919
HOHBB90	841	588308	AL354834	3681	1-402
HOHAV60	842	489007	AC007279	3682	1-75 501-565 911-1115 1230-1298 1921-2242 2324-2419 2650-2943 3316-3483 4338-4457
HOHAV60	842	489007	AC007279	3683	1-278
HOHAV60	842	489007	AC007279	3684	1-508
HOHAT59	843	867949	AC018545	3685	1-442
HOHAT59	843	867949	AC018545	3686	1-113
HOHAQ65	845	859057	AC005042	3687	1-517
HOHAQ65	845	859057	AC005042	3688	1-373
HOEOA28	849	859156	AC002519	3689	1-77 1106-2134 2298-2635 2641-3321 4046-4668 5189-6072
HOEOA28	849	859156	AC002519	3690	1-1570
HOENH06	850	934095	AL050306	3691	1-1099 1852-2331
HOENH06	850	934095	AL050306	3692	1-530
HOENH06	850	934095	AL050306	3693	1-657
HOELI08	851	958181	AC011973	3694	1-34 56-1333
HOELI08	851	958181	AC016999	3695	1-34 52-1332
HOELI08	851	958181	AC011973	3696	1-277
HOELI08	851	958181	AC016999	3697	1-280
HOEXX37	852	708728	AC007285	3698	1-804 2127-2267

					3871-4235 4812-5113 7562-7921 10731-11065 11792-14461 14687-16100
HOEEX37	852	708728	AC007285	3699	1-415
HOECF70	856	573426	AL357134	3700	1-461 2473-2733 3125-3433 4108-4457 5818-5948 6438-6525 6727-7121 7632-7791
HOECF70	856	573426	AL357134	3701	1-550
HOECF70	856	573426	AL357134	3702	1-290
HOACG06	858	954572	AC008414	3703	1-51 569-1079 1980-2133 3558-3656 4387-4484 4587-4769 4787-5117 5819-6270 6420-6609 6704-6770 7446-7635 8689-10494
HOACG06	858	954572	AC016564	3704	1-511
HOACG06	858	954572	AC008485	3705	1-51 569-1079 1981-2134 3558-3666 4399-4504 4601-4784 5010-5135 5837-5946
HOABW12	862	968797	AC011489	3706	1-381
HOABW12	862	968797	AC011489	3707	1-489 1702-1734 2236-2554 2757-3239 4609-4999 5125-5159
HOABW12	862	968797	AC011489	3708	1-309
HOABG91	863	811156	AC021573	3709	1-460

					719-769
HOABG91	863	811156	AC021573	3710	1-104
HOABF65	864	888203	AL356274	3711	1-402
HOABF65	864	888203	AC055748	3712	1-402
HOAAX37	867	708718	AC027082	3713	1-1259 1518-1999 3241-3674 4056-4328 4693-5098 5853-6779
HOAAX37	867	708718	AL121985	3714	1-1259 1518-1999 3241-3674 4056-4328 4693-5098 5853-6779
HOAAX37	867	708718	AC027082	3715	1-408
HOAAX37	867	708718	AL121985	3716	1-408
HOAAW02	869	920869	AC021215	3717	1-435 440-949
HOAAV77	870	772512	AL121997	3718	1-409
HOAAV77	870	772512	AL121997	3719	1-91 2824-3176 3245-3444 3852-3982 4333-4864
HOAAV77	870	772512	AL121997	3720	1-147 621-1118
HOAAM67	872	751947	AC012580	3721	1-378
HOAAM67	872	751947	AL133502	3722	1-378
HOAAM67	872	751947	AC012580	3723	1-495
HOAAM67	872	751947	AL133502	3724	1-575
HOAAM67	872	751947	AC012580	3725	1-575
HOAAM67	872	751947	AL133502	3726	1-495
HOAAK71	873	761445	AL020991	3727	1-33 4960-5158 6138-6263 7108-7229 9543-9988 10472-10659 13310-13494 15235-15405 15620-16560 16591-16788 16873-17205 17324-17495 21634-22394

					22406-22487 22651-22786
HOAAK71	873	761445	AL020991	3728	1-1630 2519-3035 3135-3457 4050-4123 4811-4958 5219-5669 6291-6373 7336-7544
HOAAH77	876	772514	AC064860	3729	1-3600
HOAAH77	876	772514	AC010134	3730	1-3600
HOAAH77	876	772514	AC064860	3731	1-544
HOAAH77	876	772514	AC010134	3732	1-544
HOAAH41	877	712601	AC013285	3733	1-489
HOAAH41	877	712601	AC024603	3734	1-489
HMUBZ11	878	966856	AL356420	3735	1-476
HMUBZ11	878	966856	AL157386	3736	1-476
HMUBZ11	878	966856	AL121928	3737	1-476
HMUBZ11	878	966856	AL356420	3738	1-417
HMUBZ11	878	966856	AL356420	3739	1-292
HMUBZ11	878	966856	AL157386	3740	1-417
HMUBZ11	878	966856	AL157386	3741	1-287
HMUBZ11	878	966856	AL121928	3742	1-144
HMUBZ11	878	966856	AL121928	3743	1-417
HMUBY20	880	669581	AC026495	3744	1-433
HMUBY20	880	669581	AC026495	3745	1-425
HMUBY20	880	669581	AC026495	3746	1-1055
HMUBV40	881	837969	AL136087	3747	1-105 465-969 4861-4970
HMUBV40	881	837969	AL136087	3748	1-462
HMUBV40	881	837969	AL136087	3749	1-165
HMUBR94	882	793261	AL359264	3750	1-340 1138-2277 2905-3562
HMUBQ01	884	918052	AC023648	3751	1-381
HMUBQ01	884	918052	AC008121	3752	1-381
HMUBQ01	884	918052	AC023648	3753	1-2005
HMUBQ01	884	918052	AC008121	3754	1-2005
HMUBQ01	884	918052	AC023648	3755	1-5671
HMUBQ01	884	918052	AC008121	3756	1-5676
HMUBP74	885	765502	AC011553	3757	1-610 699-939 1219-1553
HMUBN05	888	932057	AC023534	3758	1-1710

HMUBN05	888	932057	AC023534	3759	1-774
HMUBN05	888	932057	AC023534	3760	1-1423
HMUBM89	889	786082	AL138898	3761	1-976
HMUBM85	890	784295	AL139253	3762	1-495
HMUBM85	890	784295	AL358492	3763	1-495
HMUBM85	890	784295	AL139253	3764	1-292
HMUBM85	890	784295	AL358492	3765	1-299
HMUBM23	891	675296	AC069198	3766	1-334
HMUBM23	891	675296	AC069198	3767	1-253 1480-1581 1922-2067
HMUBM21	892	861218	AP001447	3768	1-682
HMUBM21	892	861218	AC023532	3769	1-682
HMUBM21	892	861218	AP000571	3770	1-101 236-917 1917-1982 3068-3361 5001-5308 5847-5967 6768-6892
HMUBM21	892	861218	AP001447	3771	1-478
HMUBM21	892	861218	AC023532	3772	1-478
HMUBM01	893	916291	AC023855	3773	1-1257 3192-3270 3630-3976 4242-4343 4840-5519 6021-6104 6317-6420 6782-6893 6977-7017
HMUBM01	893	916291	AC004596	3774	1-192 639-819 2985-3379 5817-7073 9010-9088 9448-9794 10658-11337 12600-12711 12795-12835 13418-13458 15232-15558 15880-15985 16696-16987 18333-18617 18987-19269 19915-20522

HMUBM01	893	916291	AC004596	3775	1-87
HMUBL79	894	774904	AC005586	3776	1-554
HMUBL79	894	774904	AC005586	3777	1-816
HMUBL79	894	774904	AC005586	3778	1-1171
HMUBL25	895	678011	AC004051	3779	1-665
HMUBL25	895	678011	AC004051	3780	1-439
HMUBI26	896	424764	AC016922	3781	1-545
HMUBI26	896	424764	AC016922	3782	1-490
HMUBI26	896	424764	AC016922	3783	1-1159
HMUBH84	897	782971	AL353147	3784	1-108 1271-1606 6082-6170 6275-6854
HMUBH84	897	782971	AL353147	3785	1-337
HMUBC76	898	769968	AC040984	3786	1-479
HMUBC76	898	769968	AL133327	3787	1-480
HMUBC76	898	769968	AL133327	3788	1-613
HMUBC76	898	769968	AL133327	3789	1-545
HMUBA75	899	767192	AC073215	3790	1-43 178-631 4480-5300 5346-9872 10120-10587 10955-11119
HMUBA75	899	767192	AC007250	3791	1-43 178-631 4479-5299 5345-9871 10119-10586 10957-11121
HMUBA75	899	767192	AC073215	3792	1-274
HMUBA75	899	767192	AC007250	3793	1-274
HMUBA61	900	741710	AC067992	3794	1-96 245-337 889-1827 1921-2211 2213-2561 2581-3014 4496-7045
HMUBA61	900	741710	AC067992	3795	1-258
HMUBA61	900	741710	AC067992	3796	1-4074
HMUAT71	901	772958	AC006165	3797	1-153 256-1782 1869-2685 2766-3299 3543-3990

					4755-4931 5175-5337 5807-6087 6226-6455 7594-8044 8215-8373 9157-9392 9509-9883 11475-11999 12043-13604 13610-13734 13800-14134 14501-15266
HMUAT71	901	772958	AB023051	3798	1-153 256-1782 1869-2685 2766-3299 3543-3990 4755-4931 5175-5337 5811-6091 6230-6459 7598-8048 8219-8377 9162-9397 9514-9888 11480-12004 12048-13609 13615-13739 13805-14139 14506-15271
HMUAT71	901	772958	AC006165	3799	1-1342 1447-1578
HMUAT71	901	772958	AC006165	3800	1-2094 2393-2516 2641-2911 3529-3786 4862-5131
HMUAT71	901	772958	AB023051	3801	1-1342 1447-1578
HMUAT71	901	772958	AB023051	3802	1-2094 2393-2516 2641-2911 3529-3786 4862-5139
HFOZA47	904	909372	AL133243	3803	1-502 891-997

					3296-3521 5357-6137 7436-7920 8616-8765 9182-9311 10530-11068 11184-11626 12025-14398 14692-15155 15250-15383 15828-15994 17708-19731 19976-20476 21720-21860
HFOZA47	904	909372	AL133243	3804	1-428
HFOZA47	904	909372	AL133243	3805	1-1592
HFOYW76	905	769894	AL121926	3806	1-37 2244-2601 3232-3454 3491-3871 4270-4412 6007-7043 11144-11328 11354-11854 13821-14176 16051-16149 17699-18165 18180-18878
HFOYW76	905	769894	AL121926	3807	1-176
HFOYW76	905	769894	AL121926	3808	1-156 159-551
HFOYV08	906	959038	Z98048	3809	1-924
HFOYV08	906	959038	Z98048	3810	1-2141 2561-2701 2941-3483 3789-4096 4140-5159 5304-6198 6305-6424 8034-8140 8775-9044 11025-11657 14599-15000 16088-16163 18758-18801 18856-19427 20301-20375

					23760-23837 24870-24955 25120-25391 26285-26348 27214-28161 28757-29091 31718-32125
HFOYV08	906	959038	Z98048	3811	1-507
HFOYN65	908	747740	AL358152	3812	1-1355 1765-2516
HFOYN65	908	747740	AL358152	3813	1-984
HFOYN65	908	747740	AL358152	3814	1-293
HFOYN01	909	854780	AC027228	3815	1-454 469-1300 1311-1530 3141-3500 3595-4461 5573-5640 6780-6854 6924-7105
HFOYN01	909	854780	AC027228	3816	1-538
HFOYM48	910	721455	AC000076	3817	1-615
HFOYM48	910	721455	AC000076	3818	1-1684
HFOYM48	910	721455	AC000076	3819	1-38 63-269 319-413 415-847 2369-3063 3084-5496
HFOYK21	912	670653	AC010895	3820	1-1048
HFOYK21	912	670653	AC010895	3821	1-381
HFOYH01	915	916055	AC008397	3822	1-1320
HFOYH01	915	916055	AC008397	3823	1-658 739-3456
HFOYA17	919	662642	AC008602	3824	1-348
HFOYA17	919	662642	AC008602	3825	1-113
HFOXW67	920	494854	AC024606	3826	1-1234
HFOXW67	920	494854	AC024606	3827	1-508
HFOXV94	921	794175	AC005328	3828	1-191 282-1004
HFOXV94	921	794175	AC005328	3829	1-347
HFOXV94	921	794175	AC005328	3830	1-913
HFOXT35	923	707088	AL354890	3831	1-527
HFOXT35	923	707088	AL354890	3832	1-270
HFOXSA42	924	713514	AC015559	3833	1-739
HFOXSA42	924	713514	AC015559	3834	1-831

HFOXO57	925	928171	AL022165	3835	1-4237
HFOXO57	925	928171	AL022165	3836	1-601
HFOXO57	925	928171	AL022165	3837	1-229
HFOXM53	927	587972	AC011314	3838	1-563
HFOXM53	927	587972	AC010742	3839	1-563 692-1031
HFOXM53	927	587972	AC011314	3840	1-247
HFOXM53	927	587972	AC010742	3841	1-247
HFOXM53	927	587972	AC010742	3842	1-307
HFOXK96	929	732057	AC004918	3843	1-70 582-1137 2262-2357 2561-7148 7282-10885
HFOXK96	929	732057	AC004918	3844	1-269
HFOXK96	929	732057	AC004918	3845	1-2013
HFOXK42	930	587960	AC006487	3846	1-385 925-963 1241-1694 1773-1934 2006-2474
HFOXK42	930	587960	AC006487	3847	1-1810
HFOXK42	930	587960	AC006487	3848	1-406
HFOXF91	931	790103	AC027731	3849	1-1854 2517-2610 2974-3261 3694-5322
HFOXF91	931	790103	AL355880	3850	1-1856 2517-2610 2974-3261 3694-5322 9187-9303 9508-9667 10248-10546 11270-11400 14251-14404 14486-14589 16590-16688 17066-17146
HFOXF91	931	790103	AL034379	3851	1-146 669-818 2394-2571 2805-3392 3477-3584 3993-4434 4623-4804 5144-5315

					7457-7544 7619-7747 8093-10079 10742-10835 11199-11486 11919-13547 17412-17528 17733-17892 18473-18771 19495-19625 22477-22630 24816-24914 25282-25405 25841-26405 26938-27002 29800-30272 30380-30568
HFOXF91	931	790103	AC027731	3852	1-129
HFOXF91	931	790103	AL355880	3853	1-110
HFOXF91	931	790103	AL034379	3854	1-392
HFOXD78	933	856499	AC010794	3855	1-3291
HFOXD78	933	856499	AC009985	3856	1-3291
HFOXD78	933	856499	AC010794	3857	1-92
HFOXD78	933	856499	AC010794	3858	1-4024 4342-4788 6234-6476 6856-7117 7574-7852
HFOXD78	933	856499	AC009985	3859	1-4023 4341-4787 6219-6532 6855-7116 7573-7851
HFOXB33	934	701719	AL049775	3860	1-633
HFOXB33	934	701719	AL049775	3861	1-734
HFIZP86	937	785341	AC013644	3862	1-1064
HFIZP86	937	785341	AC055747	3863	1-1617
HFIZP86	937	785341	AC013644	3864	1-611
HFIZP86	937	785341	AC055747	3865	1-147
HFIZP86	937	785341	AC055747	3866	1-611
HFIYX08	939	958977	AL158813	3867	1-446
HFIYX08	939	958977	AL096678	3868	1-446
HFIYX08	939	958977	AL158813	3869	1-233
HFIYX08	939	958977	AL158813	3870	1-528
HFIYX08	939	958977	AL096678	3871	1-233
HFIYX08	939	958977	AL096678	3872	1-528

HFIYW79	940	858618	AC025840	3873	1-240 265-775 2493-2540
HFIYW79	940	858618	AC008723	3874	1-798 1753-1907 2217-2531 3008-3156
HFIYW79	940	858618	AC008723	3875	1-951 1396-1557 5031-5131 7701-7878 8580-8685 8771-8930 8966-9330 9366-9665 13147-13262 16273-16490 17741-17892 18390-18570 18692-18768 20484-20585 20675-20764 20927-21397 22110-22308 22665-22845 24200-24245 25983-26076 26511-26819 27138-27218 27987-28086 30157-30255 30579-31026 31198-31314
HFIYS11	941	966702	AC058804	3876	1-491
HFIYS11	941	966702	AC058804	3877	1-508
HFIYN50	942	724175	AC026028	3878	1-577
HFIYN50	942	724175	AL353708	3879	1-456 936-1243 1296-2012
HFIYN50	942	724175	AL359853	3880	1-456 936-1243 1296-2012
HFIYN50	942	724175	AC026028	3881	1-423
HFIYN50	942	724175	AL359853	3882	1-2482 2605-3854
HFIYN50	942	724175	AL359853	3883	1-423
HFIYJ92	943	791305	AC000016	3884	1-65

					793-4089
HFIYJ92	943	791305	AC000016	3885	1-140
HFIXR93	947	894013	AL157824	3886	1-33 5109-7241 7282-11311
HFIXR93	947	894013	AC012151	3887	1-68 2079-2213 2879-2965 3114-3257 4198-4337 6080-6204 8566-8644 13691-19866
HFIXR68	948	752858	AC019198	3888	1-1725 2960-3425
HFIXR68	948	752858	AC015982	3889	1-1725 2960-3438 5180-5529 5615-5769 6070-6262 6580-7062
HFIXR68	948	752858	AC019198	3890	1-593
HFIXR68	948	752858	AC015982	3891	1-593
HFIXP31	949	697759	AC009761	3892	1-420 661-1011 1193-2688
HFIXP31	949	697759	AC009761	3893	1-369 518-912
HFIXP04	950	839910	AC009311	3894	1-564
HFIXP04	950	839910	AC009311	3895	1-319
HFIXP04	950	839910	AC009311	3896	1-183
HFIVS08	955	959272	AC007032	3897	1-163 511-831 1581-1856 1918-2584 2587-2776 3944-4761 4855-7799 7849-8034 8580-8847 9303-10448 11604-12183 12772-13476 13563-13793 14201-14557 14872-17303 17312-17604

					17739-18258 18373-19256 20321-20694 20846-22055 22122-22853 22866-23293 23557-24012 24021-24459 25225-28897
HFIVS08	955	959272	AC007032	3898	1-445
HFIVS08	955	959272	AC007032	3899	1-449
HFIUZ63	956	745033	AC016065	3900	1-1167 1243-2315 2390-2968
HFIUZ63	956	745033	AC018398	3901	1-1167 1243-2314 2389-2967
HFIUV58	958	735350	AC063952	3902	1-1120
HFIUV58	958	735350	AC063952	3903	1-1755
HFIUV18	959	787095	AC024064	3904	1-1333
HFIUV18	959	787095	AC024064	3905	1-161
HFIUM33	960	702319	AC073108	3906	1-595
HFIUM33	960	702319	AL161642	3907	1-562
HFIUM33	960	702319	AC004980	3908	1-457
HFIUM33	960	702319	AC073108	3909	1-113
HFIUM33	960	702319	AL161642	3910	1-101
HFIUM33	960	702319	AC073108	3911	1-101
HFIUM33	960	702319	AL161642	3912	1-1274 1766-2280 2300-2807 2837-3110
HFIUM33	960	702319	AC004980	3913	1-101
HFIUM33	960	702319	AC004980	3914	1-1274 1766-2280 2300-2807 2837-3110
HFIUH65	961	747836	AC022400	3915	1-1987
HFIUH65	961	747836	AC037447	3916	1-1922
HFIUH65	961	747836	AC022400	3917	1-621 646-1082 1155-1312
HFIUH65	961	747836	AC037447	3918	1-621 646-1082 1155-1312
HFIUD47	962	720254	AC018927	3919	1-1277
HFIUD47	962	720254	AC027797	3920	1-1277

HFIUD47	962	720254	AC018927	3921	1-518
HFIUD47	962	720254	AC027797	3922	1-517
HFITH46	963	718078	AC009220	3923	1-460 670-783 1321-1430 4578-4950 5053-5122 8113-8243 11039-11159 11712-11992 12016-12129 12648-12771
HFITH46	963	718078	AC009220	3924	1-122
HFIJF58	966	735927	AL049780	3925	1-860
HFIJF58	966	735927	AC006530	3926	1-860
HFIJF58	966	735927	AL049780	3927	1-1091
HFIJF58	966	735927	AL049780	3928	1-589
HFIJF58	966	735927	AC006530	3929	1-802
HFIJF58	966	735927	AC006530	3930	1-1090
HFIIR63	969	744994	AL354797	3931	1-693 700-1411
HFIIR63	969	744994	AC068485	3932	1-693 700-1411
HFIIR63	969	744994	AC013740	3933	1-4690 6959-7154 7209-7389 7431-7731 11120-11377 12689-12782 13980-14669 27508-27734 30606-31559 31691-32383 32390-33101 33665-33950 35646-35944 36682-36970 37681-38105 38961-39244 42417-42581 43432-43781 45418-45605 46318-46443 46498-46727
HFIIR63	969	744994	AL354797	3934	1-954
HFIIR63	969	744994	AL354797	3935	1-286
HFIIR63	969	744994	AC068485	3936	1-286

HFIIR63	969	744994	AC068485	3937	1-954
HFIIR63	969	744994	AC013740	3938	1-345 615-1006
HFIIR63	969	744994	AC013740	3939	1-231
HFIIR75	971	767222	AC016722	3940	1-701 1766-2718
HFIIR75	971	767222	AC016722	3941	1-717
HFIIR07	973	953034	AC016394	3942	1-588 595-1084 1098-1581
HFIIR07	973	953034	AC068557	3943	1-588 595-1083 1097-1580
HFIIR07	973	953034	AC016394	3944	1-558 652-915 1677-5669 5844-5990 6502-6754 7996-8461 8748-8832 9129-9877
HFIIR07	973	953034	AC068557	3945	1-558 652-915 1677-5156
HFIIR14	974	839523	AP001973	3946	1-102
HFIIR14	974	839523	AL355880	3947	1-34
HFIHW16	976	858594	AC025891	3948	1-2095
HFIHW16	976	858594	AC016173	3949	1-2712
HFIHW16	976	858594	AP001600	3950	1-2711
HFIHW16	976	858594	AC016173	3951	1-509
HFIHW16	976	858594	AC016173	3952	1-463
HFIHW16	976	858594	AP001600	3953	1-509
HFIHW16	976	858594	AP001600	3954	1-187 869-1287 2982-3157 3423-3674 8406-8868
HFIHW11	977	947856	AF254981	3955	1-57 1142-1260
HFIHW11	977	947856	AC023188	3956	1-85 326-439 1924-2100 3184-3563
HFIHW11	977	947856	AC023188	3957	1-204 939-1163
HFIHW11	977	947856	AC023188	3958	1-475

HFIHV56	978	470954	AC022930	3959	1-121 959-1377 2087-2219 3018-3826 3852-4165 4657-4767 5284-5392 5999-6311 6327-6368 6940-7299 7610-8439
HFIHV56	978	470954	AF238376	3960	1-623 721-864 1041-1249 1439-1558 2395-2813 3523-3655 4454-5262 5288-5601 6093-6203 6720-6828 7435-7747 7763-7804 8376-8481 9046-9875
HFIHV56	978	470954	AF238376	3961	1-147 342-408
HFIHU76	979	769948	AC006995	3962	1-509
HFIHU76	979	769948	AC005098	3963	1-509
HFIHU76	979	769948	AC004166	3964	1-509
HFIHU76	979	769948	AC004883	3965	1-509
HFIHU76	979	769948	AC006995	3966	1-89
HFIHU76	979	769948	AC006995	3967	1-159
HFIHU76	979	769948	AC005098	3968	1-114 553-988 1601-1926 2188-2470 3568-3753 4168-4600 5038-5080 5881-5976 6271-6358 7128-8058 8786-10907
HFIHU76	979	769948	AC005098	3969	1-160
HFIHU76	979	769948	AC004166	3970	1-77 541-951

					1564-1889 2151-2235 3531-3716 4131-4563 4702-4802 5001-5043 5844-5939 6234-6321 7115-7476 7548-8020 8745-10867
HFIHU76	979	769948	AC004166	3971	1-163
HFIHU76	979	769948	AC004883	3972	1-114 459-988 1151-1251 1601-1926 2188-2470 3568-3753 4168-4600 5038-5080 5881-5976 6271-6358 7585-7796 7819-9872 10597-12718
HFIHU76	979	769948	AC004883	3973	1-163
HFIHS86	980	785419	AL158814	3974	1-1188
HFIHS86	980	785419	AL035694	3975	1-3503
HFIHS86	980	785419	AL035694	3976	1-131 3726-4036 9191-9552 10640-12003
HFIHK29	983	855174	AC012040	3977	1-1468
HFIHK29	983	855174	AC026464	3978	1-146 2144-2248 3425-4485 4538-6005 8727-8898 9137-9222 12214-12317 12384-12622 12696-12797 13071-13110 13572-15071
HFIHK29	983	855174	AC026474	3979	1-146 2144-2248 3425-4485

					4538-6005 9143-9228 12383-12621 12695-12796 13070-13109 13571-15070
HFIHK29	983	855174	AC026464	3980	1-568
HFIHK29	983	855174	AC012040	3981	1-146 2144-2248 3425-4485
HFIHK29	983	855174	AC026474	3982	1-568
HFIAL66	991	587837	AC012306	3983	1-565
HCDEL02	993	920831	AC061980	3984	1-628
HCDEL02	993	920831	AL159167	3985	1-1093 1477-1978
HCDEL02	993	920831	AC061980	3986	1-410
HCDEL02	993	920831	AL159167	3987	1-410
HCDEL02	993	920831	AL159167	3988	1-389
HCDDZ69	994	522220	AC002310	3989	1-256 411-537 2216-2825 2858-3950 4039-4108 4429-4979 5008-5410 5591-5625 5641-7301 7793-8106 8114-8234 11769-12452
HCDDZ69	994	522220	AC002310	3990	1-329
HCDDZ69	994	522220	AC002310	3991	1-1402 1469-3065
HCDDY54	995	529265	AC012488	3992	1-341
HCDDY54	995	529265	AC012488	3993	1-361
HCDDO80	996	778563	AC025165	3994	1-746
HCDDO80	996	778563	AC025165	3995	1-302
HCDCD64	997	863415	AC022197	3996	1-190
HCDCD64	997	863415	AC022197	3997	1-619
HCDBW41	998	712648	AP001325	3998	1-390
HCDBO86	999	784617	AC073487	3999	1-375 893-4326 4474-5168 5186-6317 6538-6708 6755-7192 7587-9453

HCDBO86	999	784617	AC023055	4000	1-246 485-1179 1198-2329 2550-2720 2767-3204 3603-5469
HCDBO86	999	784617	AC073487	4001	1-646
HCDBO86	999	784617	AC023055	4002	1-428
HCDBO86	999	784617	AC023055	4003	1-245
HCDAA68	1001	753814	AL353776	4004	1-560
HCDAA68	1001	753814	AL353776	4005	1-455
HCDAA68	1001	753814	AL353776	4006	1-130
HBACKF23	1003	675613	AC055747	4007	1-533 1236-1544 1697-1786
HBCGD25	1004	677689	AC023947	4008	1-691
HBCGD25	1004	677689	AC016946	4009	1-691
HBCGD25	1004	677689	AC022664	4010	1-691
HBCGD25	1004	677689	AC023947	4011	1-423
HBCGD25	1004	677689	AC016946	4012	1-423
HBCGD25	1004	677689	AC022664	4013	1-423
HBCGD25	1004	677689	AC016946	4014	1-100
HAOAE95	1005	795674	AC025225	4015	1-469 511-892 1010-2004
HAOAE95	1005	795674	AL034417	4016	1-469 511-892 1010-2004
HAOAE95	1005	795674	AC025225	4017	1-696
HAOAE95	1005	795674	AC025225	4018	1-430
HAOAE95	1005	795674	AL034417	4019	1-696
HAOAE95	1005	795674	AL034417	4020	1-430
HAOAD27	1006	848729	AL096776	4021	1-114 1783-2276 4713-5206 7371-10780
HAOAD27	1006	848729	AL096776	4022	1-418
HANKG10	1007	963926	AL353705	4023	1-565
HANKG10	1007	963926	AL353594	4024	1-565
HANKG10	1007	963926	AL353705	4025	1-405
HANKG10	1007	963926	AL353594	4026	1-405
HANKB13	1008	827062	AC023963	4027	1-139 1779-1929 2453-2599
HANKB13	1008	827062	AC023963	4028	1-610
HANKB13	1008	827062	AC023963	4029	1-349

HAMAC79	1009	872774	AC019066	4030	1-1701
HAMAC79	1009	872774	AC019066	4031	1-203

[066] Table 1B summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, "SEQ ID NO:X", for each contig sequence. The third column provides a unique contig identifier, "Contig ID:" for each contig sequence. The fourth column, provides a BAC identifier "BAC ID NO:A" for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, "Exon From-To", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

## **TABLE 2**

Clone ID NO:Z	Contig ID:	SEQ ID NO:X	Analysis Method	PFam/NR Description	PFam/NR Accession Number	Score/ Percent Identity	NT From	NT To
HANGC59	653577	20	HMMER 1.8	PFAM: Core histones H2A, H2B, H3 and H4	PF00125	11.44	96	164
HAOAE53	964029	41	HMMER 1.8	PFAM: Zinc finger, CCHC class	PF00098	6.5	136	168
HAOAE56	767915	42	blastx.2	(AF098066) squamous cell carcinoma antigen recognized by T cell [Homo sapiens]	gb AAF00087.1 AF 098066_1	88%	1	228
HBCKE78	746109	55	blastx.2	(AF038606) contains similarity to cytoskeletal keratin [Caenorhabditis elegans]	gb AAB92026.1	43%	55	225
HBFCMC73	764150	56	blastx.2	(AK000496) unnamed protein product [Homo sapiens]	dbj BAA91205.1	66% 100%	210 23	22 3
HBSAL69	573004	58	blastx.2	23 kD protein [Escherichia coli]	gb AAA61994.1	71% 100% 60%	423 103 422	130 2 366
HBSAL80	506580	59	blastx.2	No definition line found [Escherichia coli]	gb AAB18589.1	86%	378	82
HBSAM48	727635	61	blastx.2	Pyruvate formate-lyase 1 activating enzyme (EC 1.97.1.4). [Escherichia coli]	dbj BAA35637.1	87%	56	322
HBSAP73	764589	63	blastx.2	homoserine kinase [Escherichia coli]	gb AAA20618.1	99%	467	3

HBSDDB50	571365	65	HMMER 2.1.1 blastx.2	PFAM: TCP-1/cpn60 chaperonin family groEL protein (AA 1- 548) [Escherichia coli]	PF00118 emb CAA30698.1	89.7	2	226
HBSDDB63	745211	66	blastx.2	(AF090895) PRO0117 [Homo sapiens]	gb AAF24019.1 AF 090895 1	68% 71%	224 91	93 71
HCDAE77	533925	70	blastx.2	(AC006539) BC39498_2 [Homo sapiens]	gb AAD14470.1	48% 46% 45% 48% 47% 40% 45% 42% 39% 35% 37% 35% 40% 63% 37%	59 59 59 62 62 59 59 62 59 11 7 4 4 4 241	238 232 238 223 238 238 238 238 217 238 69 69 69 36 309
HFICA06	934675	125	blastx.14	NADH:ubiquinone oxidoreductase MLRQ subunit [Homo sapiens]	gi 1946692 gb AAB 52726.1	82% 33% 66%	122 2 302	172 127 355
HFIHE47	857988	140	blastx.2	weak similarity to ATP synthase B chain [Caenorhabditis elegans]	gb AAA50619.1	27% 37%	733 403	1644 687
HFIHF63	944246	141	HMMER 2.1.1	PFAM: Immunoglobulin domain	PF00047	22.4	92	364

HFITZ24	677144	152	HMMER 1.8	PFAM: Zinc finger, C2H2 type	PF00096	4.13	55	99
HFITYL01	919416	180	blastx.14	NADH:ubiquinone oxidoreductase MLRQ subunit [Homo sapiens]	gi 1946692 gb AAB 52726.1	71% 38%	173 53	277 178
HMUBM26	908912	210	HMMER 2.1.1	PFAM: Zinc finger, C2H2 type	PF00096	119.7	269	337
			blastx.2	zinc finger protein C2H2-25 [Homo sapiens]	gb AAA93261.1	61% 62% 60% 60% 59% 59% 61% 50% 51% 40% 28% 83% 72% 72% 66% 64% 61% 68% 68% 63% 63% 50%	2 2 8 8 8 8 8 29 167 251 254 511 511 511 511 511 511 511 511 456 456 456 511	508 460 460 460 460 460 436 460 460 460 478 564 564 564 564 561 564 558 512 512 512 564

HOEAK21	954961	239	blastx.14	similar to Azorhizobium caulinodans hypoth. protein, 1	gi 396396 gb AAC4 3155.1	61%	511	564
HOEJG04	859251	261	HMMER 2.1.1	PFAM: Pyruvate flavodoxin/ferredoxin oxidoreductase (N terminus)	PF01855	227.6	456	512
HOEMK02	918364	267	blastx.14	Periplasmic chaperone focC protein [Escherichia coli]	gi 4062507 dbj BA A35694.1	100%	79	2
HOEOE25	907806	269	HMMER 1.8	PFAM: Zinc finger, C3HC4 type (RING finger)	PF00097	41.99	59	208
			blastx.2	(A 224819) tumor suppressor [Homo sapiens]	emb CAA12136.1	41%	32	625
HRDAF69	956269	331	blastx.14	(AB012223) ORF2 [Canis familiaris]	gi 2981631 dbj BA A25253.1	42%	4	171
HRDBM42	530849	349	HMMER 1.8	PFAM: Helix-loop-helix DNA-binding domain	PF00010	8.1	139	246
HRDBT72	507847	356	HMMER 1.8	PFAM: Zinc-binding	PF00099	7.31	295	324

HSKET11	967000	441	blastx.14	metallopeptidase domain alternate name ygIP; ORF_310 [Escherichia coli]	gi 1203799 gb AAA89140.1	96% 100%	2 331	343 363
HSKHS71	911592	443	HMMER 2.1.1 blastx.14	PFAM: Ank repeat  contains 10 ankyrin-like repeats; similar to human 1 [Paramecium bursaria Chlorella virus 1]	PF00023  gi 2447128 gb AAC96986.1	63.1  42% 36% 35% 35% 38% 31% 40% 35%	94  106 97 103 100 103 103 196 1	192  366 357 372 372 357 366 381 84
HSKKD70	916984	446	blastx.14	ORF_f268a [Escherichia coli]	gi 537144 gb AAA97199.1	93%	420	1
HSLBZ91	573987	467	HMMER 2.1.1	PFAM: Domain of unknown function	PF00990	78.1	6	254
HSLC147	908627	470	blastx.14	basonuclin [Homo sapiens]	gi 179337 gb AAA35584.1	54%	263	361
HSLCL38	951028	471	blastx.14	3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41) II [Escherichia coli]	gi 4062664 dbj BA A35903.1	88% 100%	41 3	202 41
HSLDG13	913664	477	blastx.14	melibiose carrier [Escherichia coli]	gi 146804 gb AAA24148.1	96% 66%	274 314	2 270
HSLDP16	573210	484	HMMER 2.1.1	PFAM: 6,7-dimethyl-8-ribityllumazine synthase	PF00885	184.6	8	271

HSLEC25	572859	487	HMMER 2.1.1	PFAM: Methylmalonyl-CoA mutase	PF01642	20	8	76
HSLED38	709381	489	HMMER 2.1.1	PFAM: Fructose-1-6-bisphosphatase	PF00316	47.3	369	473
HSLEG74	825500	493	HMMER 1.8	PFAM: Bacterial mutT protein	PF00293	2.42	30	98
HSLFS42	948740	501	blastx.14	RhsE protein (fragment). [Escherichia coli]	gi 1742368 dbj BA A15087.1	100% 100%	34 2	300 34
HSLFU01	916448	505	blastx.14	Rod protein FlgC [Escherichia coli]	gi 4062651 dbj BA A35882.1	89% 100% 100%	259 383 408	5 261 385
HSLIJ57	659533	517	HMMER 2.1.1	PFAM: Pyridoxal-dependent decarboxylase	PF00278	94	150	365
HSLJN49	920062	523	blastx.14	Spermidine/putrescine transport system permease protein PotB. [Escherichia coli]	gi 1651552 dbj BA A35945.1	98% 80%	246 427	1 245
HSSAN96	936108	567	blastx.14	(AF000531) Tat protein [Human immunodeficiency virus type 1]	gi 2245487 gb AAB 62530.1	63% 63% 30%	246 56 108	214 24 49
HSSBO48	871217	571	HMMER 1.8	PFAM: Sugar (and other) transporters	PF00083	9.8	26	232
HSSEU93	911261	583	blastx.14	(AJ007012) Fish protein [Mus musculus]	gi 3702174 emb CA A07416.1	65% 39% 53% 54%	66 69 191 208	212 212 229 240

HSSAA15	965347	664	blastx.14	SM-20 [Rattus norvegicus]	gi 469478 gb AAA19321.1	77%	111	434
HSRAA80	937640	683	HMMER 1.8	PFAM: Reverse transcriptase (RNA-dependent DNA polymerase)	PF00078	20.88	11	130
			blastx.14	(AF080232) polymerase [Human endogenous retrovirus K]	gi 3600069 gb AAC63292.1	65%	17	325
HSLKB62	905738	690	HMMER 2.1.1	PFAM: Transglycosylase	PF00912	310.2	344	850
			blastx.14	ORF_f242 [Escherichia coli]	gi 606147 gb AAA58010.1	93%	290	937
HSLJF33	938811	694	blastx.2	(AE000391) putative transport protein [Escherichia coli]	gb AAC76123.1	84%	3	527
HSLJD02	965826	695	HMMER 1.8	PFAM: Sugar (and other) transporters	PF00083	19.53	464	874
			blastx.2	UhpC protein [Escherichia coli]	gb AAA24722.1	100%	56	907
HSLHZ10	963808	701	blastx.14	Hypothetical 17.3 kd protein in alpA-gabD intergenic region (o152). [Escherichia coli]	gi 4902983 dbj BA A77917.1	97% 100%	308 178	180 128
			HMMER 2.1.1	PFAM: NADH-Ubiquinone/plastoquinone (complex I), various chains	PF00361	115.1	917	615

				blastx.2	NADH dehydrogenase I, subunit nuoL [Escherichia coli]	emb CAA48371.1	99%	91	954
HSLGO19	668634	708		HMMER 1.8	PFAM: Basic region plus leucine zipper transcription factors	PF00170	17.19	265	372
HSLGA24	955333	722		HMMER 2.1.1	PFAM: Mur ligase family	PF01225	119.9	772	386
				blastx.2	UDP-MurNac-tripeptide synthetase (MurE) [Escherichia coli]	dbj BAA01350.1	91% 99%	33 434	476 805
HSLFT29	680451	724		HMMER 1.8	PFAM: Sigma-70 factors	PF00140	224.55	1	399
HSLDT25	949079	730		HMMER 2.1.1	PFAM: FecCD transport family	PF01032	86.6	1331	921
				blastx.2	ferrichrome-iron transport protein FhuB [Escherichia coli]	gb AAB08583.1	92% 97% 35% 28% 69%	32 661 673 101 3	712 1026 1011 613 41
HSLDR05	932128	732		blastx.14	UhpC protein [Escherichia coli]	gi 148114 gb AAA2 4722.1	97% 100% 42%	98 3 127	220 95 168
HSLCX61	742031	738		HMMER 2.1.1	PFAM: KRAB box	PF01352	49.2	373	474
HSLCF96	637670	739		HMMER 1.8	PFAM: Sugar (and other) transporters	PF00083	10.78	415	576
				blastx.2	(AE000352) putative	gb AAC75728.1	94%	415	1179

HSKCF96	954777	1016	HMMER 1.8	transport protein [Escherichia coli]		100%	297	413
						70%	1101	1211
						20%	409	600
						26%	1021	1179
						30.03	1296	1015
HSKKE11	965857	744	blastx.14	PFAM: Sugar (and other) transporters (AE000352) putative transport protein [Escherichia coli] cDNA EST EMBL:D70203 comes from this gene; cDNA EST 1 1 yk403g7.5 comes from this gene; cDNA EST EMBL:C08962 comes from	PF000083 gb AAC75728.1  gi 3877299 emb CA A93496.1	96% 91%	303 1147	1127 1215
						88% 62% 100%	117 28 3	245 75 26
HSKHT93	957866	749	blastx.14	(AF117815) molybdopterin synthase small subunit [Homo sapiens]	gi 4235630 gb AAD 13296.1	80%	275	364
HSKEH21	941976	752	blastx.14	diacylglycerol kinase eta [Cricetinae gen. sp.]	gi 1401232 gb AAC 52714.1	87%	8	703
HSKCR54	922730	754	HMMER 2.1.1	PFAM: Ribosomal protein L17	PF01196	29.6	260	394
HSKBW86	785783	756	HMMER 2.1.1	PFAM: Bacterial surface antigen	PF01103	75.2	1	165
HSACL04	840406	765	blastx.2	(AF118082) PRO1902 [Homo sapiens]	gb AAF22026.1 AF 118094 21	70% 61%	651 326	559 273

HOSMP95	948496	794	blastx.14	unknown [Mus musculus]	gi 1490330 emb CA B01546.1	77%	3	146
HOSCV06	960555	809	blastx.2	(AL133104) hypothetical protein [Homo sapiens]	emb CAB61411.1	100%	45	191
HOHAV60	489007	842	HMMER 1.8	PFAM: PH (pleckstrin homology) domain	PF00169	15.98	111	212
HOHAJ11	965035	1026	blastx.14	10-formyltetrahydrofolate dehydrogenase [Rattus norvegicus]	gi 908915 gb AAA70429.1	69% 100%	102 431	422 448
HOEEU57	932562	853	HMMER 2.1.1	PFAM: MYND finger	PF01753	45.6	139	255
HOABG91	811156	863	blastx.14	skm-BOP2 [Mus musculus]	gi 5870834 gb AAC53022.2	39% 41% 22%	76 556 289	279 750 552
HFOZC29	923288	903	HMMER 1.8	PFAM: Low-density lipoprotein receptor domain class B	PF00058	23.5	46	174
HFOYG86	955554	1029	blastx.14	coatamer [Bos taurus]	gi 441486 emb CA A53539.1	87%	568	422
HFOXL88	909839	928	blastx.14	G protein-coupled receptor [Lymnaea stagnalis] (AC004084) similar to GTPase-activating proteins; 1	emb CAA80651.1	31%	8	727
					gi 2822157 gb AAB97935.1	97% 100% 72% 83%	305 425 180 411	171 303 148 394

HFIXP31	697759	949	HMMER 2.1.1	PFAM: BTB/POZ domain	PF00651	49.8	9	146
HFHW91	907618	975	HMMER 2.1.1	PFAM: ADP- ribosylation factor family	PF00025	82.4	222	500
HFHW11	947856	977	blastx.14	GTP-binding protein [Drosophila melanogaster]	gi 290213 gb AAA7 4629.1	31% 54%	288 222	488 287
			blastx.14	Similarity to Yeast TAT-binding homolog 7 1 1 1 EMB	gi 4008355 emb CA A92596.1	81%	3	146
HFIDL68	928475	986	HMMER 1.8	PFAM: 7 transmembrane receptor (rhodopsin family)	PF00001	50.42	8	319
HFIBK83	939556	988	blastx.2	G protein-coupled receptor [Lymnaea stagnalis]	emb CAA80651.1	41%	11	340
			blastx.14	contains similarity to ATP/GTP-binding site motif (PS:PS00017) [Caenorhabditis elegans]	gi 1519671 gb AAB 07572.1	38%	20	289
HCOKA10	907080	992	HMMER 2.1.1	PFAM: Ribosomal protein L34e	PF01199	229.8	509	213
			blastx.2	ribosomal protein L34 [Homo sapiens]	gb AAC41916.1	98%	521	216
HCOKA10	918918	1031	HMMER 2.1.1	PFAM: Small cytokines (intercrine/chemokine), interleukin-8 like	PF00048	124.2	1447	1238

			blastx.14	granulocyte chemotactic protein, GCP-2 - bovine	pir B54188 B54188	100%	1444	1223
HCOKA10	919869	1032	HMMER 2.1.1	PFAM: Small cytokines (intecrine/chemokine), interleukin-8 like	PF00048	124.2	169	378

[067] Table 2 further characterizes certain encoded polypeptides of the invention, by providing the results of comparisons to protein and protein family databases. The first column provides a unique clone identifier, "Clone ID NO:", corresponding to a cDNA clone disclosed in Table 1A. The second column provides the unique contig identifier, "Contig ID:" which allows correlation with the information in Table 1A. The third column provides the sequence identifier, "SEQ ID NO:X", for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the row was determined. The fifth column provides a description of PFam/NR hits having significant matches identified by each analysis. Column six provides the accession number of the PFam/NR hit disclosed in the fifth column. Column seven, "Score/Percent Identity", provides a quality score or the percent identity, of the hit disclosed in column five. Comparisons were made between polypeptides encoded by polynucleotides of the invention and a non-redundant protein database (herein referred to as "NR"), or a database of protein families (herein referred to as "PFam"), as described below.

[068] The NR database, which comprises the NBRF PIR database, the NCBI GenPept database, and the SIB SwissProt and TrEMBL databases, was made non-redundant using the computer program nrdb2 (Warren Gish, Washington University in Saint Louis). Each of the polynucleotides shown in Table 1A, column 3 (e.g., SEQ ID NO:X or the 'Query' sequence) was used to search against the NR database. The computer program BLASTX was used to compare a 6-frame translation of the Query sequence to the NR database (for information about the BLASTX algorithm please see Altshul et al., J. Mol. Biol. 215:403-410 (1990), and Gish et al., Nat. Genet. 3:266-272 (1993)). A description of the sequence that is most similar to the Query sequence (the highest scoring 'Subject') is shown in column five of Table 2 and the database accession number for that sequence is provided in column six. The highest scoring 'Subject' is reported in Table 2 if (a) the estimated probability that the match occurred by chance alone is less than  $1.0e-07$ , and (b) the match was not to a known repetitive element. BLASTX returns alignments of short polypeptide segments of the Query and Subject sequences which share a high degree of similarity; these segments are known as High-Scoring Segment Pairs or HSPs. Table 2 reports the degree of similarity between the Query and the Subject for each HSP as a percent identity in Column 7.

The percent identity is determined by dividing the number of exact matches between the two aligned sequences in the HSP, dividing by the number of Query amino acids in the HSP and multiplying by 100. The polynucleotides of SEQ ID NO:X which encode the polypeptide sequence that generates an HSP are delineated by columns 8 and 9 of Table 2.

[069] The PFam database, PFam version 5.2, (Sonnhammer et al., Nucl. Acids Res., 26:320-322, (1998)) consists of a series of multiple sequence alignments; one alignment for each protein family. Each multiple sequence alignment is converted into a probability model called a Hidden Markov Model, or HMM, that represents the position-specific variation among the sequences that make up the multiple sequence alignment (see, e.g., R. Durbin et al., *Biological sequence analysis: probabilistic models of proteins and nucleic acids*, Cambridge University Press, 1998 for the theory of HMMs). The program HMMER version 1.8 (Sean Eddy, Washington University in Saint Louis) was used to compare the predicted protein sequence for each Query sequence (SEQ ID NO:Y in Table 1A) to each of the HMMs derived from PFam version 5.2. A HMM derived from PFam version 5.2 was said to be a significant match to a polypeptide of the invention if the score returned by HMMER 1.8 was greater than 0.8 times the HMMER 1.8 score obtained with the most distantly related known member of that protein family. The description of the PFam family which shares a significant match with a polypeptide of the invention is listed in column 5 of Table 2, and the database accession number of the PFam hit is provided in column 6. Column 7 provides the score returned by HMMER version 1.8 for the alignment. Columns 8 and 9 delineate the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence which shows a significant match to a PFam protein family.

[070] As mentioned, columns 8 and 9 in Table 2, "NT From" and "NT To", delineate the polynucleotides of "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFam/NR database as disclosed in the fifth column of Table 2. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the polynucleotides of SEQ ID NO:X delineated in columns 8 and 9 of Table 2. Also provided are polynucleotides encoding such proteins, and the complementary strand thereto.

[071] The nucleotide sequence SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, the nucleotide sequences of SEQ ID NO:X are useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in Clone ID NO:Z. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to these polypeptides, or fragments thereof, and/or to the polypeptides encoded by the cDNA clones identified in, for example, Table 1A.

[072] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[073] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and a predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing cDNA Clone ID NO:Z deposited with the ATCC (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Table 1A, 6 and 7). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.

[074] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

***RACE Protocol For Recovery of Full-Length Genes***

[075] Partial cDNA clones can be made full-length by utilizing the rapid amplification of cDNA ends (RACE) procedure described in Frohman, M.A., et al., Proc. Nat'l. Acad. Sci. USA, 85:8998-9002 (1988). A cDNA clone missing either the 5' or 3' end can be reconstructed to include the absent base pairs extending to the translational start or stop codon, respectively. In some cases, cDNAs are missing the start codon of translation. The following briefly describes a modification of this original 5' RACE procedure. Poly A<sup>+</sup> or total RNA is reverse transcribed with Superscript II (Gibco/BRL) and an antisense or complementary primer specific to the cDNA sequence. The primer is removed from the reaction with a Microcon Concentrator (Amicon). The first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL). Thus, an anchor sequence is produced which is needed for PCR amplification. The second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT primer containing three adjacent restriction sites (XhoI, SalI and ClaI) at the 5' end and a primer containing just these restriction sites. This double-stranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNA-specific antisense primer. The PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of missing protein-coding DNA is removed. cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with XhoI or SalI, and ligated to a plasmid such as pBluescript SKII (Stratagene) at XhoI and EcoRV sites. This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5' ends are confirmed by comparing this sequence with the putatively identified homologue and overlap with the partial cDNA clone. Similar

methods known in the art and/or commercial kits are used to amplify and recover 3' ends.

[076] Several quality-controlled kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5' and 3' RACE for recovery of full length genes. A second kit is available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single-stranded cDNA), developed by Dumas et al., *Nucleic Acids Res.*, 19:5227-32 (1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.

[077] An alternative to generating 5' or 3' cDNA from RNA is to use cDNA library double-stranded DNA. An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer. These primers are removed and a symmetric PCR reaction is performed with a nested cDNA-specific antisense primer and the plasmid-anchored primer.

***RNA Ligase Protocol For Generating The 5' or 3' End Sequences To Obtain Full Length Genes***

[078] Once a gene of interest is identified, several methods are available for the identification of the 5' or 3' portions of the gene which may not be present in the original cDNA plasmid. These methods include, but are not limited to, filter probing, clone enrichment using specific probes and protocols similar and identical to 5' and 3' RACE. While the full length gene may be present in the library and can be identified by probing, a useful method for generating the 5' or 3' end is to use the existing sequence information from the original cDNA to generate the missing information. A method similar to 5' RACE is available for generating the missing 5' end of a desired full-length gene. (This method was published by Fromont-Racine et al., *Nucleic Acids Res.*, 21(7):1683-1684 (1993)). Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcript. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is

used to PCR amplify the 5' portion of the desired full length gene which may then be sequenced and used to generate the full length gene. This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure. The RNA preparation may then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA, which may interfere with the later RNA ligase step. The phosphatase, if used, is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction can then be used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the musculoskeletal system antigen of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant musculoskeletal system antigen.

[079] The present invention also relates to vectors or plasmids, which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January 5, 2001, having the depositor reference numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Table 1A, 6 and 7) is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as shown, for example, in Table 7. These deposits are referred to as "the deposits" herein. The tissues from which some of the clones were derived are listed in Table 7, and the vector in which the corresponding cDNA is contained is also indicated in Table 7. The deposited material includes cDNA clones corresponding to SEQ ID NO:X described, for example, in Table 1A (Clone ID NO:Z). A clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X, may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Furthermore,

although the sequence listing may in some instances list only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA included in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables 1A or 2 by procedures hereinafter further described, and others apparent to those skilled in the art.

[080] Also provided in Table 7 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

[081] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., *Nucleic Acids Res.* 16:7583-7600 (1988); Altling-Mees, M. A. and Short, J. M., *Nucleic Acids Res.* 17:9494 (1989)) and pBK (Altling-Mees, M. A. et al., *Strategies* 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into *E. coli* strain XL-1 Blue, also available from Stratagene.

[082] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59- (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).

[083] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the deposited clone (Clone ID NO:Z). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[084] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of musculoskeletal system associated genes corresponding to SEQ ID NO:X or the complement thereof, polypeptides encoded by SEQ ID NO:X or the complement thereof, and/or the cDNA contained in Clone ID NO:Z, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[085] The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

[086] The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[087] The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides

of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the musculoskeletal system polypeptides of the present invention in methods which are well known in the art.

[088] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in Clone ID NO:Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, a polypeptide encoded by the cDNA contained in Clone ID NO:Z and/or a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, a nucleic acid sequence encoding a polypeptide encoded by the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA contained in Clone ID NO:Z.

[089] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in Table 1B column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in Table 1B column 6, or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table

1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[090] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B,

column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[091] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1B which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (See Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[092] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of Table 1B column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1B column 6, or any combination thereof. In preferred embodiments, the polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1B column 6, wherein sequentially delineated sequences in the table (i.e. corresponding to those exons located closest to each other) are directly contiguous in a 5' to 3' orientation. In further embodiments, above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[093] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1B, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other

polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[094] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same Clone ID NO:Z. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[095] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same row of column 6 of Table 1B. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[096] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[097] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[098] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[099] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other

polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides, are also encompassed by the invention.

[0100] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0101] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID NO:Z (see Table 1B, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0102] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one sequence in column 6 corresponding to the same contig sequence identifier SEQ ID NO:X (see Table 1B, column 2) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent

hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0103] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same row are directly contiguous. In preferred embodiments, the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table 1B, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0104] Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. Accordingly, for each contig sequence (SEQ ID NO:X) listed in the third column of Table 1A, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, b is an integer of 15 to the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. More specifically, preferably excluded are one or more polynucleotides

comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3. In specific embodiments, the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone). In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

**TABLE 3**

Clone ID NO: Z	SEQ ID NO: X	Contig ID:	EST Disclaimer Range of a Range of b	Accession #'s
HANGA63	11	927404	1 - 248	AL133312.
HANGA69	12	718174	1 - 431	
HANGA85	13	746265	1 - 305	
HANGA92	14	791182	1 - 134	
HANGC05	15	674059	1 - 144	
HANGC07	16	952586	1 - 212	
HANGC14	17	952581	1 - 246	
HANGC30	18	966430	1 - 324	
HANGC33	19	702072	1 - 237	
HANGC59	20	653577	1 - 167	<p> AI128945, AA181985, AI051473, AI811806, AI742394, AI796471, AA047524,  AW168284, AA644217, AA461312, AA223990, AI702471, AA449477, AI344611,  AI084340, AA047404, AI982714, AI655453, AI609227, AI953345, AI918075,  AI074844, AI948767, AI823646, AI125444, Z40657, AI942374, AA773940,  AW303808, AA996094, AW235687, AI718217, AW081809, AW339488, R97621,  AA678046, AA569360, AI581387, AI245396, T80973, AL121270, AI671642,  AI499483, AL045163, AA809974, AW020592, AL039276, AA715307, AI863629,  AI624543, AW189802, AA425228, AA975588, AL045620, AW084056, AI923509,  AA748353, AI064830, AL121328, AA525540, AA768725, AI890507, AA761557,  N72726, AI343091, AI364788, AW117882, AL119748, AI805774, F37323,  AI289791, AL043152, AL045500, AI557808, AI432644, AI702065, AI273179,  AW087445, AI494201, AA641818, AI624279, AI927233, AI312325, AL110402,  AI269862, AW161202, AI307604, AW019988, AW020419, AI433157, AI648567,  AI690946, AI554821, AW151136, N99180, AW081349, AA848069, AI539771,  AI537677, AI636581, AW410430, AI500659, AI866465, AI815232, AI801325,  AW082113, AL045413, AI500523, AI538850, AI431307, AI887775, AI582932,  AI590043, AI872423, AI284517, AI923989, AI866786, AI500706, AI445237,  AI491776, AW151138, AI521560, AI889189, AI500662, AW172723, AI582912,  AI539800, AI284509, AI889168, AI440263, AI538885, AI866573, AI633493,  AI434256, AI866469, AI805769, AI434242, AI888661, AW196105, AI500714,  AI284513, AI888118, AI285439, AI859991, AI436429, AI355779, AI889147, </p>

	<p>AI623736, AI371228, AI581033, AI491710, AI440252, AI860003, AI610557, AW162194, AI242736, AW075382, AI828574, AI887499, AW151979, AI539781, AI539707, AW071377, AI866820, AI885949, AI285419, AW089557, AI559957, AI521571, AI469775, AI866581, AL048644, AI567953, AI815150, AI446495, AL042595, AL042745, AW023351, AA743430, AW162189, AL047422, H41759, AI348897, AI433037, AI633125, AL041150, AI475817, AI612750, AL037582, AL037602, AL043981, AI909696, AI345688, AA460184, R75918, AI867068, AL043168, AW197139, AI525669, AI431316, AI275175, AI890907, AA857847, AI307494, AW022494, AW269097, AW265004, AI499890, AL040243, AW268072, AW268261, AI345608, AI636372, AI620284, AA575874, AI567582, AW020288, AI879064, AI309443, AL038564, AI565172, AL039783, AW083804, AI345471, AW022299, AL042628, AI561170, AW191003, AI702527, AW020425, AL079799, N27632, AI336585, AW020710, AI921057, AI623941, AI309401, AL120254, AI923046, AL048375, F36003, AL042627, AI866510, AI557238, AI446373, AL039390, AL042365, AL038605, AW238730, AI866461, AF081195, AI117440, Z99297, AL122049, AF081197, AC004805, AP000030, E06743, AI137665, E01314, AL137574, AL117457, AF141289, AL117435, S68736, I48978, AF113019, S63521, S77771, AF111851, A03736, M92439, AC006203, AL133072, I89947, AC004213, AR038854, AF162270, Y10080, I46765, Z49258, U77594, AO8913, AI8777, Z72491, AL122106, AC005874, AF134471, AO8912, AO8910, AO8909, I89931, L30117, AL034376, AF026124, AF036268, AF158248, I49625, AL122110, AF113690, AO8908, AL133080, AL133081, S76508, AL133077, AL133049, AR011880, AF110520, AF067728, AF058921, AL137558, I89934, IO0734, Y10655, D83989, AR020905, AF100931, L19437, AL137478, AL137271, AF153205, AF094480, AL117649, A91160, E00617, E00717, E00778, AL050092, AL137548, X96540, X72889, AF113013, AO8916, A65340, AL049314, AF125948, AF022813, AR053103, AL031732, AC004544, AF113689, Y10823, S36676, AL080110, AF111849, AF090886, AL122121, AC004686, AL033521, AF078844, Z13966, AF114818, AC008067, AL110221, M27260, AC005048, AJ010277, AL133568, U80742, IO3321, AC004383, E07361, D55641, Y11587, AL050277, E02349, Y14314, AO8907, X67813, U42766, AF061943, AL031274, Z82206, AC004594, AB007812, AF061795, AF151685, E06788, E06790, E06789, AJ012755, AL050310, AF169154, AF002985, Z98036, AC004989, S75997, AF003737, I89944, AO5788, A65341, U67958, AL049382, AL133640, AL050172, Z82022, AF183393, AL137554, AF106697, IO5037, AF113676, X06146, AF151109, AI137488, X93495, AI133565</p>
--	---

						AF061573, AL049452, AL110280, A58524, AL133665, A58523, AF095901, S78214, AC005488, AF113691, AL049347, AF026816, X63410, AJ001838, AL133067, E03348, AF090934, AF017437, AF113677, A86558, A08911, AF215669, E02253, E03349, AF118090, AL080154, U53505, AF079763, AF120268, AR059958, E15324, AL117460, AL050108, AF039138, AF039137, and S79832.
HANGC84	21	715991	1 - 440	15 - 454		
HANGF36	22	952583	1 - 263	15 - 277		
HANGF49	23	722635	1 - 112	15 - 126		AC007320.
HANGG22	24	848727	1 - 347	15 - 361		
HANGH48	25	718759	1 - 410	15 - 424		
HANGH53	26	727914	1 - 460	15 - 474		
HANGH58	27	811987	1 - 393	15 - 407		
HANGH66	28	661513	1 - 442	15 - 456		
HANKD09	29	625167	1 - 334	15 - 348		
HANKD47	30	719963	1 - 425	15 - 439		
HANKD83	31	963964	1 - 300	15 - 314		
HANKG78	32	710760	1 - 180	15 - 194		
HANKG90	33	746282	1 - 410	15 - 424		
HANKH48	34	721340	1 - 343	15 - 357		
HANKH56	35	733063	1 - 360	15 - 374		
HAOAA57	36	953693	1 - 228	15 - 242		AW138563, W39428, AA441848, AI928563, AW138262, AI825038, AA985573, AW162121, AA063432, AA583586, AW341116, AA372242, N26196, H50245, AI565281, AA861973, AA338299, T85197, C00398, AI810565, and AF187318.
HAOAA78	37	756979	1 - 544	15 - 558		
HAOAA90	38	919249	1 - 321	15 - 335		
HAOAC05	39	932017	1 - 502	15 - 516		
HAOAD47	40	864899	1 - 473	15 - 487		AC005495.
HAOAE53	41	964029	1 - 368	15 - 382		
HAOAE56	42	767915	1 - 323	15 - 337		AI927761, AW378374, AI932972, AI690765, T58205, AF098066, and Z84488.
HAOAE60	43	657909	1 - 226	15 - 240		AA348977.
HAOAF68	44	752788	1 - 951	15 - 965		AA031836, AA031837, AA909082, and AL134312.
HAOAH38	45	705946	1 - 325	15 - 339		AC005036.
HAOMA1	46	915881	1 - 414	15 - 428		

HAOMB64	47	960293	1 - 599	15 - 613	
HAOMC21	48	670518	1 - 542	15 - 556	
HAOMD9	49	788658	1 - 395	15 - 409	AL050343.
0					
HAOME45	50	705947	1 - 506	15 - 520	
HBCGA72	51	756953	1 - 137	15 - 151	A1126076, A1539265, A1458605, AW379387, and AW368357.
HBCKB24	52	676825	1 - 482	15 - 496	
HBCKB82	53	779562	1 - 522	15 - 536	AA961486.
HBCKE22	54	674041	1 - 147	15 - 161	A1954693, A1656728, A1281560, and AA491824.
HBCKE78	55	746109	1 - 647	15 - 661	AA204666, AA171635, AA632321, AA814237, AA631958, AW389228, A1167680, A1274831, AW023312, AA860756, AA631959, AW450236, T49450, A1168544, A1332870, AB014543, AC004494, and AC004224.
HBFCMC73	56	764150	1 - 385	15 - 399	AL135357, AW196064, A1002744, AA536040, AA515905, AA502860, AA493708, A1524360, A1252274, A1591375, AW274349, AA527602, A1053911, A1872020, AA658362, AA595499, AW020992, AA580808, AA630672, F17555, AA847499, AW237875, A1249880, AL046409, AA531079, AW302711, AA715814, AW270784, A1267269, AA613232, A1791913, AA527727, A1674873, A1792133, A1053560, A1821714, A1564185, AA574442, A1476049, AA664909, AA493845, A1687343, AA642060, AA297666, AA521323, AW339622, AW303196, A1144081, AA362698, AL037771, AA521399, AA621381, AA679532, AA749235, A1499938, AA652677, AA806796, A1744306, A1682665, A1821785, AW378968, AC007540, AP000495, AC004686, AC006151, AC005324, AC002352, AC005183, AC005859, AC004150, AL031311, AL117693, AF129756, AC004815, AC003982, AF196779, AC004019, Z97053, AC004383, AC004895, AL109829, AC005736, AL096867, AC006130, AC004144, AP000696, AL132796, AP000504, AC002115, AL021940, AC004263, Z68321, AC007617, AC004912, AC002395, D83989, AC007919, AC003006, U85195, AL021397, AC005799, AC002091, AE000658, AP000356, AC005327, AC005911, AC000052, AC007073, AL031597, Z93241, AL021155, AL022302, AC005863, AL031255, AC003109, AC004253, AP000044, AP000112, AC005668, AC002563, AC003689, AP000088, AP000365, AL110502, AC007649, AL080285, AL023575, AC004167, X75335, AL080114, Z99756, AC006985, AC006449, AC004821, AP000548, AC007114, AC004008, AL109628, AP000359, AC000353, AL008730, AL031003, AC006511, AC005822, AL030997, AP000117, AL034451, U89337, AC001231, AL035072, AC006251, AC002350, Z82976, AL035405, AC004655, AP000354, AL009177, AP000143, AC007371, AC006057, AC005261,

HBSAK76	57	506666	1 - 265	15 - 279	AF111169, AC006539, AC005081, AF227510, U07563, AC005533, AL049636, AF006501, AC005058, AL034554, AC005209, AC006211, AC011311, AC007285, AL009179, AL022165, AC006241, AC006035, Z83844, AL020995, AL078583, AC007917, AL109847, AC008498, AL049775, AC007160, AL021391, AC006487, AC005901, AC006037, AC007656, D88268, AB023051, AL121603, AC005399, AC005409, AC004890, AP000959, AL133355, AC005377, AC005484, AL022323, AC005730, AL034395, AL031767, AC007435, AL021154, AC008040, AC007384, U66061, AL024509, AC004472, AC004885, AC006953, AL121658, AC003101, AC010205, AL096701, L29074, AC004913, AF130343, AC005019, AC005184, AL031276, AL022476, AC002316, AL050341, AC007676, AC007126, Z93930, AC005530, AC003664, AL022163, AC004531, AL109798, Z99716, AC006044, AL135744, AC004033, AL031668, AL031591, AC006076, AC009516, AB023048, AC005255, AL049760, AC006578, M26434, AC005412, AC009028, Z85987, AC000114, AC008115, AL049872, AC005015, AC010206, AC005520, AC005695, AC007686, AL021878, AP000512, AC004099, AL034420, and AP000501.
HBSAL69	58	573004	1 - 419	15 - 433	
HBSAL80	59	506580	1 - 366	15 - 380	
HBSAM46	60	526732	1 - 331	15 - 345	
HBSAM48	61	727635	1 - 393	15 - 407	
HBSAP02	62	920648	1 - 325	15 - 339	
HBSAP73	63	764589	1 - 454	15 - 468	
HBSAQ64	64	530344	1 - 296	15 - 310	
HBSDB50	65	571365	1 - 353	15 - 367	
HBSDB63	66	745211	1 - 331	15 - 345	AP000689, AC006344, and AL096701.
HBSD91	67	775313	1 - 136	15 - 150	AA069743, and AA069767.
HCDAA94	68	661278	1 - 265	15 - 279	AL020995.
HCDAB17	69	530726	1 - 327	15 - 341	AA679229.
HCDAE77	70	533925	1 - 344	15 - 358	AI908895, and AB027251.
HCDAF27	71	592244	1 - 488	15 - 502	
HCDAF29	72	533812	1 - 265	15 - 279	
HCDAF54	73	530529	1 - 421	15 - 435	
HCDAG92	74	724693	1 - 363	15 - 377	
HCDAG95	75	533871	1 - 412	15 - 426	

HCDAH34	76	533870	1 - 390	15 - 404	
HCDAJ67	77	925362	1 - 305	15 - 319	AL049875.
HCDAK93	78	523648	1 - 186	15 - 200	T05398, and AC003029.
HCDAK96	79	960047	1 - 360	15 - 374	
HCDAM34	80	523607	1 - 265	15 - 279	AC005969.
HCDAO32	81	530006	1 - 316	15 - 330	
HCDAT56	82	533881	1 - 651	15 - 665	AA252681, N51549, AI026801, AI202595, AI000893, AW450220, W44769, AA923523, AI346827, AW090676, AI640582, AI659843, F22685, AI092608, AW102828, AA075433, AI350733, AA789132, N32022, N98535, N69933, and AL109657.
HCDBO13	83	709590	1 - 242	15 - 256	
HCDBR37	84	968501	1 - 329	15 - 343	AB011101, and AF106069.
HCDBR39	85	921893	1 - 347	15 - 361	
HCDBU77	86	661272	1 - 185	15 - 199	
HCDBW51	87	556469	1 - 281	15 - 295	
HCDBW61	88	960044	1 - 203	15 - 217	N51115.
HCDXB78	89	847580	1 - 243	15 - 257	Y18642.
HCDXCB84	90	670159	1 - 248	15 - 262	AI244405, AW072090, AA565081, AI253256, H64704, AW026742, AA243715, AW025779, AA455006, AA455005, AW117348, AI767598, AI206307, N46194, AA644147, AI420462, AL035634, AF076957, AF121859, and AF131214.
HCDCE48	91	529893	1 - 334	15 - 348	
HCDCE62	92	523582	1 - 226	15 - 240	AL031177.
HCDCF11	93	967768	1 - 243	15 - 257	AA844561, AA975423, AW173039, AI400317, AA937116, AI863192, AC006942, AC005758, and AL022170.
HCDCK07	94	865908	1 - 149	15 - 163	H89524.
HCDCK91	95	592465	1 - 255	15 - 269	AI268324.
HCDCK26	96	960048	1 - 307	15 - 321	AP000087, and AP000226.
HCDCK68	97	529778	1 - 103	15 - 117	AC003692.
HCDCK13	98	921702	1 - 60	15 - 74	
HCDDB52	99	847581	1 - 332	15 - 346	AA53216, AA586656, AA565319, AI251584, AI431434, AW192065, AA654781, AI537458, AI537538, AA303040, F13749, AI884383, F23258, AI355986, R33941, AI682665, AA484208, AI708005, AA603530, AA338289, AA639946, AA608751, AI280771, AW079664, AA487690, AA659608, AW068316, AI814739, AI475954, AW162288, AA845209, AC005015, AC006487, AC002126, AC005071, AC005048,

HCDDDB62	100	529890	1 - 240	15 - 254	AL121653, AP000350, AL034351, AL049780, AC002470, AL049539, AF135025, AC008273, AC005740, AC007114, AC004967, AC007051, AC006120, AC004814, AC004216, AC006530, AL035683, AC005682, AC005682, AJ003147, AL022316, AL031659, AC002511, AC006597, AC005231, AL035684, AC003684, AC002375, AC006211, U95742, AC007308, Z83822, AC005324, AF111167, AL096701, AC005011, Z97630, AC005229, AC005952, AC004815, AC002310, AP000088, AL133245, AL034420, AL080317, AC002544, AC005399, Z84466, AC003682, AL050341, AL109627, AC006064, AL021368, U89335, AC004125, AC005264, AF195658, AC004685, AC004492, AF001549, Z83846, AC005214, AC005081, AC005007, AC005261, Z98051, AC005940, AC007676, AC005880, AL049692, Z82206, AC007055, AC004796, AF064861, AL021937, AL049794, AC002991, AF196972, AL035405, AC004966, AC005378, AC004894, AL109952, Z98200, AC007227, AL109865, AC002394, AL133246, U78027, AL049832, AC007151, AC002996, AC002112, AC005746, AC005387, AL049591, AC005527, AL034548, U85195, AL121769, AC004832, AC006001, AP000692, U47924, AF053356, AC007371, AP000354, AL031281, AC007421, AC002483, AL034451, AL078581, AC005919, AC002477, AC006071, AC007263, AC004552, AF001552, AC004890, AB023049, AL024498, AL109847, AC007283, Z81364, AL035422, AC002350, AE000658, AC004897, AC004999, AC004025, AC005839, AC005535, AC005089, AC004491, AC006312, AL049829, AC006441, AP000462, AF038458, AC005179, AC002045, AC006011, AC005215, AL034379, AB026898, AL031427, AC006277, AC009396, AC007981, AC005562, AC005234, AC000025, AC007129, AL008718, AC007637, AL132712, AC003962, AC005529, AP000512, AC002546, AP000300, AC004382, AL080243, AP000031, Z84480, Z83840, AC016025, AC004934, AC006014, AB017654, AC002456, AL049833, AF024533, AC004837, AL110502, AC005821, Z82176, AC005067, AB023048, AC005730, AL035400, AJ246003, AL031984, AF165926, AC009516, AL035587, AF196969, AC005722, U91323, AC007225, Z99716, AC006544, AL031286, AC008372, and U80017.
HCDDI61	101	529937	1 - 103	15 - 117	AL248455, and AC005876.
HCDDU07	102	954177	1 - 200	15 - 214	AC005498.
HCDDV90	103	847575	1 - 241	15 - 255	
HCDDY57	104	556465	1 - 349	15 - 363	
HCDDZ09	105	523605	1 - 396	15 - 410	Z83820, AL022574, AP000261, AP000035, AP000100, and Z69722.
HCDDZ44	106	863388	1 - 484	15 - 498	

HCDEB49	107	847572	1 - 238	15 - 252	
HCDEB78	108	921710	1 - 125	15 - 139	
HCDEG67	109	531239	1 - 454	15 - 468	
HCDEG95	110	533879	1 - 467	15 - 481	
HCDEI16	111	667338	1 - 310	15 - 324	AC008064.
HCDEI29	112	523506	1 - 198	15 - 212	
HCDEI89	113	524045	1 - 341	15 - 355	
HFIAB89	114	848927	1 - 57	15 - 71	
HFIAB93	115	713799	1 - 592	15 - 606	AW299250, AW438583, AI261419, AI271941, AA688176, W19548, AI867634, N62642, AI718356, T59367, and AC005179.
HFIAB82	116	779898	1 - 437	15 - 451	
HFIAB10	117	964652	1 - 222	15 - 236	
HFIAB107	118	952884	1 - 528	15 - 542	H75698, and AC005722.
HFIAB31	119	697775	1 - 340	15 - 354	AI394725, T49120, AC004916, AP001052, and AP001051.
HFIAB89	120	587844	1 - 335	15 - 349	
HFIAB91	121	925831	1 - 603	15 - 617	AI754091, AI991838, AW005052, AW054864, AA603953, AA604330, AI147846, AI570396, AI497756, AI421847, AA877182, AI494281, N35004, AA775287, W46449, AA581458, AI086636, AI148897, AI278835, AA057575, AW168484, AW272886, R61553, AW196844, AI888235, AI679184, AW192289, H99897, W52277, AI356673, AA428604, AA969120, AI086886, AW167037, W47555, N69430, AA972050, AA579776, N93836, AI744805, W88660, F30196, H67841, AA703585, R54415, H80849, AA496690, AA777896, AA234453, AA035655, AA350919, F37094, AA234061, AA284876, T93624, AI474971, AA886060, F31971, AA150893, AA300810, AA376247, AW014654, AA977993, AA496609, H67163, AI310732, AI755278, AA430492, AA993506, AA558203, F31374, AA430533, AA477605, AA436330, AA410238, AI086193, H54089, AA682577, AI342640, AI161001, AI089475, AA290638, AA502644, AA402631, AW151250, AL045805, AA676716, U46298, AA724973, F36499, W52276, AA329392, W88866, T74861, AI659749, AA432307, W47495, W40292, AA419293, H38512, AA057574, AA203205, AL110156, AC002094, AF077203, and AC002324.
HFIABV83	122	780358	1 - 190	15 - 204	
HFIABZ63	123	966761	1 - 543	15 - 557	AI676091, and AC012039.
HFIAB148	124	587871	1 - 414	15 - 428	
HFIAB06	125	934675	1 - 430	15 - 444	AA452688, H91923, R18017, R69518, R74244, C04901, W73580, AA315530,

						R83609, AA159260, W84825, H84664, N53738, H28250, R49760, T64564, AA486811, H24652, AA931976, T79349, C05147, H92397, R62673, H25249, and AA010050.
HFICE40	126	587918	1 - 441	15 - 455		
HFICF01	127	916103	1 - 199	15 - 213		
HFICIS2	128	522239	1 - 635	15 - 649		AW303375, AW173315, AA417652, A1751258, AA364833, C05155, AA600736, AI090486, AA258414, AA625303, C04206, AA455496, A1768270, AA599207, AA446297, C03119, AA421744, A1828437, A1862133, AA834031, AA024968, AA446024, AA419609, AA419525, A1272646, A1148235, AA634323, A1092202, AA455497, A1191710, AA593295, A1218226, AA319726, A1754332, A1039656, AA774270, AA336003, AA384793, A1350380, AA978105, A1084698, AA912802, N64555, A1751035, A1673545, N67061, A1432010, A1754989, AA971661, D31528, A1609700, AA478719, A1221431, A1075349, AA456579, AW338252, AA375571, AA936765, AA610296, AA258397, TS9227, A1564218, D31541, TS9268, I76208, and AR020615.
HFICM95	129	587875	1 - 431	15 - 445		
HFICZ77	130	934192	1 - 323	15 - 337		A1803895, A1391495, AA974333, AA480293, A1418615, AW303930, AA976516, A1376344, AA027959, A1188582, AA772607, AA150835, N49399, W43008, A1073381, A1679130, A1679704, AA558944, AA748509, AA854570, A1084408, AA863284, A1094952, A1351871, A1271532, AA994580, A1370805, A1401404, AW044595, A1214656, R33818, AA772710, W95681, AA993489, A1023527, AA025063, AA456325, A1563920, A1887313, AA976183, W07752, AA683499, AA873879, AA894918, AA737975, A1432209, N80691, A1299818, AA991522, AA975924, AA047682, AA906771, AA665526, A1151172, A1379259, R33819, A1707592, AA984396, AA047733, AA025062, W45208, A1095417, AA662634, A1147183, C02347, F34897, AA972351, A1041404, AW024289, AA683598, AW027714, AW366247, A1119399, AW008226, A1277938, A1261589, A1499570, AW079334, AA910330, A1638644, AW166412, A1561177, A1884318, A1364167, AL042544, A1266652, A1419826, AW192461, A1275609, AW081383, AW087934, A1630947, AL037602, A1538564, AL037582, A1445829, A1934011, A1963763, A1679771, N29277, A1744268, A1370623, AA806720, A1421149, A1473536, A1633125, A1568293, A1916419, AW152182, A1345415, AA580663, AW129264, A1620864, A1522052, A1698391, AW148882, A1538850, A1648509, A1363741, A1860348, AL042382, AW089844, A1539690, A1701097, AW190194, A1524626, AA019328, A1374987, A1352514, A1679891, AW198090, A1371243, A1125015,


HFIDM69	133	926894	1 - 473	15 - 487	R31339, and AA251156.
HFIDN81	134	959050	1 - 441	15 - 455	
HFIEC13	135	883185	1 - 511	15 - 525	Z59127.
HFIEF04	136	926824	1 - 98	15 - 112	Z99396, AL036418, AL038837, AL037051, AL036725, AA631969, AW392670, AL039074, AW372827, AL038509, AL036924, U46341, AL036858, AW384394, AL039564, AL119497, AL039085, AW363220, AL039156, AL039108, AL039109, AL039128, AL119341, AL037639, AL119443, AL037094, AL039659, AL119457, AL134524, AL119319, AL119355, AL036196, AL036190, AL119324, AL119496, AL119483, AL119484, AL119363, AL119391, AL042965, AL038531, AL119335, U46350, AL037526, AL036767, AL119522, AL037082, AL119396, U46351, U46349, AL039625, AL039648, AL045337, AL119418, AL036238, AL038447, U46346, AL042978, AL042909, AL119444, AL042433, AL039678, AL039629, AL134902, U46347, AL037085, AL039386, AL036268, AL038520, AL134528, AL134920, AL039423, AL042551, AL037615, AL039150, AL037077, AL037205, AL042614, AL040992, AL119439, AL042984, AL042975, U46345, AL119399, AL119401, AL134536, AL036998, AL036733, AL119453, AL134531, AL119464, AL042450, AL134525, AL134538, AL042544, AL119413, AL043019, AL042970, AL119488, AL037027, AL037178, AL043029, AL039410, AL042973, AL036679, AL036719, AL043003, AL042542, AL042850, AL119413, AL036191, AL036765, AL037021, AL036774, AL036886, AL036158, AL036999, AL036836, AR066494, AR060234, AR069079, A81671, AR023813, AR064707, AR054110, and AB026436.
HFIEH79	137	855196	1 - 628	15 - 642	Z99396, AL038837, AL037051, AL036725, AL039074, AA631969, AL039085, AL039564, AL039156, AL039108, AL039109, AL039128, AL039659, AL038531, AL039625, AL039648, AL045337, AL037526, AL039678, AL039629, AL039150, AL039423, AL036924, AL040992, AL042909, AL037639, AL037094, AL037726, AL038447, AL039410, AL036858, AL036238, AL036190, AL036196, AL119483, AL036767, AL045353, AL037615, AL036973, AL038851, AL037082, AL119484, AL039440, AL044407, AL036418, AL038509, AL036268, AL036117, AL037077, AL039386, AL134524, AL036733, AL036998, AL039924, AL037027, AL036679, AL119418, AW392670, AL036191, AL037178, AL036719, AL037085, AL037021, AL037054, AL039538, AW384394, AL119341, AL038520, AL036765, AL119497, AL044530, AL036999, AW372827, AW363220, AL119363, U46350, AL119319, AL119457, AL036158, AL119443, AL037016, AL119324, AL119444, AL119335, AL119391, AL119355, AL119522, U46349, U46341, AL038821, U46351, AL119496, AL119396, AL036836, U46347, AL036964, AL119439, AL037205,

						U46346, AL042614, AL134531, AL134528, U46345, AL042984, AL042965, AL042975, AL119399, AL134518, AL134538, AL042551, AL042544, AL043019, AL043029, AL134542, AL042450, AL042542, AL119304, AL043003, AL036886, AL119464, AL036774, AR060234, AR066494, AR023813, AR064706, AR064707, A81671, Y11449, Y11447, AR069079, AB026436, and AR054110.
HFHIB16	138	661971	1 - 458	15 - 472		
HFHID91	139	702324	1 - 721	15 - 735		N31707.
HFHIE47	140	857988	1 - 1959	15 - 1973		AA534198, AI978627, AW166513, AI459812, AW166498, AI819341, AW195142, AI139595, AA209319, AI365580, AI620649, AI022352, AA583627, AW005402, AA583619, AI475193, AW166054, AI569467, AI540081, AI191668, AA331346, AI272323, R51977, AA508608, AA678590, AA524450, AW451651, AI090886, AW082159, F09189, R51978, AA378790, AI382250, AI378098, AI917676, AI868388, T46979, AI355097, AI635445, AW131365, F11527, AI291485, N64277, and T46978.
HFHIF63	141	944246	1 - 750	15 - 764		AW182823, AI378016, AI669104, AI420515, AA010826, W95509, AW297177, W95412, AA011202, AA782437, AI869000, AI702739, AA450119, AA889785, AA255554, and AI291551.
HFHJ60	142	740280	1 - 456	15 - 470		
HFHJ85	143	707899	1 - 548	15 - 562		
HFHJL29	144	690546	1 - 367	15 - 381		
HFHJS76	145	769952	1 - 390	15 - 404		
HFHJZ33	146	588058	1 - 496	15 - 510		
HFHJZ51	147	725587	1 - 370	15 - 384		AA054673, H89424, AA180830, and AF025422.
HFHJ73	148	669594	1 - 438	15 - 452		AL031296.
HFHJS21	149	670765	1 - 529	15 - 543		AI570906, AL118651, AL118594, AA644545, AL050343, AL133445, AL096791, Z93023, AC004020, AC004851, AC007450, AC000353, AL132712, AP000704, AC002400, AC004491, U91323, AL021579, AL022334, AL020997, AC005899, AL034417, AC002565, AL009181, AC004106, AC007298, AL139054, AC006449, AC002425, AC002544, AL109865, AL022313, AJ246003, AC007227, AC005071, AC006014, AC006285, AC005529, AC005488, AF205588, Z95152, AP000689, AL034419, U73640, AC004966, AC004477, AL035450, AL031577, AL133448, AC008372, AC003036, AC004685, AL009183, AC006013, AC005326, AC005225, AL117352, AP000240, AL049829, AC007773, AC004526, AP000047, Z85986, AC008115, AC005520, AC016025, AL121658, AC004638, AD000092, AL049795,

						AC004448, AC005015, Z98304, AC007050, AC003029, AC003101, AC007226, AC006965, and AC012384.
HFJF34	150	703972	1 - 448	15 - 462		
HFJTX48	151	934328	1 - 453	15 - 467		
HFJTX24	152	677144	1 - 412	15 - 426		AJ011930, AJ011931, and AP000219.
HFJUE17	153	855119	1 - 452	15 - 466		AW295133.
HFJUH54	154	929787	1 - 429	15 - 443		AC004774.
HFJUI66	155	746397	1 - 304	15 - 318		
HFJUI95	156	735969	1 - 425	15 - 439		AC009044.
HFJUM59	157	724249	1 - 308	15 - 322		
HFJUI063	158	691921	1 - 476	15 - 490		R64316.
HFJUP04	159	582296	1 - 158	15 - 172		R64259, AA344341, AI080039, AL046624, AA629791, AI368952, AW168763, AI952419, N26238, AA834946, AI524512, AI264761, AA393317, AI092959, N34467, AI167603, AI817019, AI186197, AW024266, AA220934, AI686547, AA079792, AI423180, AW294323, AI022487, AA298287, AI125828, AA977969, AI041033, AW167771, AI982550, AA577038, AW129990, AI219200, AI745726, AI872119, AA568591, AI074179, N23849, AI076303, AI126251, AI873831, H89854, AW410097, N73002, AA034187, AI077832, AI144021, AA961792, AA431977, AI818881, AI620483, AI827251, AA738013, AW450235, AI277544, AI049595, AA738259, AI263352, AI193279, R85594, AW351844, N52553, T57796, AI000731, AW177690, AI018741, AI125766, AA744959, AI351749, AI753417, AI865588, N76513, H71780, F25828, AI971511, AW389860, AA805498, AI699779, AW054724, AA417958, AI754465, AI189605, AA846282, H71692, N58371, AW028940, AI168778, AA033792, R85377, AI134572, AA702274, AA001869, AA371623, AI270649, AA704581, AA342144, T79160, AA151314, F00140, T99810, H90753, H42220, AA903483, AA700585, AA932956, AI557195, AI143854, AA682817, T95829, AI110192, AI050150, AF077054, AB020692, AL096773, X60127, and X52311.
HFIVB03	160	924021	1 - 324	15 - 338		
HFIVB25	161	678022	1 - 269	15 - 283		AA004777, T66806, AA033897, R75757, and AB014550.
HFIVB62	162	741665	1 - 241	15 - 255		AC004002.
HFIVQ02	163	919802	1 - 441	15 - 455		
HFIXA30	164	692637	1 - 313	15 - 327		AJ038502, AA993051, AI926924, AA836474, and AW269412.
HFIXC30	165	692635	1 - 345	15 - 359		

HFIXC44	166	839536	1 - 541	15 - 555	R52856, R16202, H09464, R16204, D53134, Z42545, T66661, and T66663.
HFIXC49	167	722886	1 - 369	15 - 383	
HFIXK83	168	767156	1 - 351	15 - 365	
HFIXK94	169	943717	1 - 412	15 - 426	
HFIXM11	170	966714	1 - 218	15 - 232	AF045448, and AF064860.
HFIXO03	171	923735	1 - 361	15 - 375	AA824654, AA810370, AA644538, AA824655, AA521376, AA649705, AA834755, C14793, H02877, AA483223, AA574110, AA704643, AA678436, AA640034, AA568778, AA858197, AA503473, AA973803, AA515909, AA719080, AA446657, AA906889, AA679009, AA577906, AA602528, AA605032, AA582911, AA804379, AA601355, T49241, AA721981, AA235466, AA668578, AA348504, AA533036, AA483731, T53128, AA910125, AA425922, AA573020, AA522942, AA533725, AA490183, AA304977, AA341336, AA527958, AA143490, AA838096, AA525249, AA668902, AA558616, AA191198, AA156338, AA578017, AA663486, AA434388, AA670468, AA525876, AA601499, AA846929, AA102006, AA053551, AA633094, AA403110, T16056, W16581, AA600222, AA623002, AA861959, AA280632, AA437161, AA831904, AA845843, AA127636, AA825357, AA873560, AA665021, AA630925, W05364, AA682912, AA521355, AA678453, AA564859, AA487225, AA401022, AA461206, AA599920, AA708311, AA649722, AA127517, AA524838, AA210852, AA847984, AA972238, AA654761, AA487858, AA644207, AA970213, T10560, R32415, AA169756, AA191227, AA634145, AA635442, AA524809, AA551201, AA325699, AA714595, AA595825, F32800, AA486885, AA808941, N46153, AA357307, AA059472, AA523815, AA664015, F09736, N69316, AA167643, AA134347, AA780515, AA569743, AA650271, AA715355, AA720691, H48636, AA678772, AA515435, AA629827, AA987619, AA729740, AA309196, T94075, AA768905, F23250, AA480790, AA767376, M85966, AA828042, AA728889, AA346575, AA604497, AA633266, AA095511, AA630606, AW088058, M77899, AA492140, AI002834, AA778110, AA613851, R95704, AA631799, T15897, AA081909, AA825455, T24049, AA405453, H02135, AA326589, AA434484, H11124, AA744338, AA834756, AA632755, AA774184, AA113376, AA486414, AL046457, AA788726, X62695, AP000302, AP000114, AP000046, Z83313, Z68192, AP000431, L43392, AF029750, AB012251, Z92844, AC004047, AC004216, AL031012, U07000, AC005755, S61977, AC006515, U67274, U20770, Y12508, M87919, AC004837, AL109798, AP000548, AL022325, AL031588, AC006466, AF193806, AC003681, U02044, U55180, A26236, L04965, AP000501, AL132712, L44140, AC007878, U14694, U13056, D49685, AL096765, AF112866,

					AC000047, S70689, AC002482, AL021878, M87918, U02058, U02063, Z82900, AC005280, AL117258, AC012627, AP000011, AL023578, U91326, AP0000473, AC002544, AC006546, AP000098, AC005245, Z48051, AC006162, Z73420, AF003530, AL021392, X88791, M74900, AL031542, AC006322, Z97206, I51997, U02048, S70697, S70692, AD000092, M94631, AC005778, AL035209, AL008726, AF003528, AL031428, AC007899, AC003954, AF139813, AC009044, AC004745, AC005907, X54178, X54181, D83253, X54175, AP000097, AC005610, AL022160, AL121754, Z15025, AC004820, U02532, AP000151, Z99495, AC002430, AC005923, AC006978, AC007314, Z94721, AP000367, AF060568, AC002431, AC005060, AC003003, AL122126, U91322, AP000009, AC007384, X58156, AL109807, AL031256, AC005384, AC005785, AL117355, AC003088, AL021406, AP000966, AF015148, Z49816, AC005071, AC008101, AC004940, AC009069, X77859, U18400, AC004825, AC005808, AB019005, L07900, AC005822, AC005775, AL121652, AC006055, AL049845, AC007237, AL031848, AL049795, AP000152, X55932, U18390, AL109653, U14702, AC000025, AL049757, AF027390, Z81311, U11309, AC007386, AC005527, U63721, AC002553, X55928, AL096734, X54179, AC005940, AC008115, AC000097, Z99289, AC007254, Z72521, AC006022, AC002110, AC002105, AC006049, AC000075, Z97184, AC004191, AC004802, AC003030, AP000220, AC010186, Z81364, AC004854, AP000513, AP000142, AP000084, AL133289, AC006486, U85196, AL031589, AP000090, AC005016, AB023049, AL031295, AC004947, AC007243, AC007114, AC005664, AC002402, U85198, AL132641, AC004691, AL035671, AL022310, Z98946, AP000470, AC005799, AC002289, U96629, AC005900, AC005324, AC007537, AC007392, AC008372, U57005, AC007450, U18393, X55925, U18394, AC006547, Z83846, U57006, U18392, AL080250, U18391, X54180, S41998, U57007, AC016026, AC003119, Z86090, AL033525, AL031447, AL080248, U57009, AL031680, AL096770, AL133399, AL022302, AC005912, and AC004470.
HFIXV93	172	597031	1 - 361	15 - 375	AL080075.
HFIXY13	173	656812	1 - 347	15 - 361	R54797.
HFIXY57	174	734580	1 - 352	15 - 366	
HFIXY80	175	965077	1 - 395	15 - 409	AA833709, AI342422, AI207067, AW303434, AW005730, and AW002395.
HFIXY86	176	757155	1 - 343	15 - 357	AF015720, AF015722, and AI229041.
HFIXY24	177	952847	1 - 291	15 - 305	AL022724.
HFIXY40	178	964251	1 - 428	15 - 442	
HFIXYK01	179	916125	1 - 154	15 - 168	W22304, and AC007510.

HFYV01	180	919416	1 - 418	15 - 432	R69518, AA452688, AA315530, R74244, H91923, C04901, AA159260, R18017, W73580, H28250, W84825, R49760, R83609, AA486811, N53738, H84664, T64564, T79349, H24652, AA931976, C05147, H92397, R62673, and H25249.
HFYV02	181	657598	1 - 281	15 - 295	AA927326.
HFYV03	182	919501	1 - 363	15 - 377	
HFYV04	183	916064	1 - 413	15 - 427	AL799462.
HFYV05	184	923755	1 - 389	15 - 403	Z97206, and AL034375.
HFYV59	185	861487	1 - 317	15 - 331	AA502207, AW188742, AA668896, AL355246, AL037771, AA975997, AA668915, AW023111, F35684, R64617, AA535736, AA536040, AL653999, AL791131, AA494174, AL791130, AA857518, AL119563, T05118, AA487209, AA364860, AA906536, F34170, AA084609, H47295, AL040009, AL446336, AL434513, AA676971, AA578690, AA581525, AA486565, AA309341, T71936, AL189682, AA483606, AA225273, AA737235, AA846923, AA991914, AA485328, AA630555, R89560, AA904211, AA689351, H07953, AL041375, AA630122, AL206841, AA983673, AA502532, AL866911, AA312303, AA654801, AW316777, AW020736, AA709362, N24909, AW192402, N55296, AL031730, AF205588, AC007637, AL031005, AC004477, AL109963, AC004000, AC004491, AL021937, AC004841, AC005740, AL049758, AL049636, AL117337, AC005670, U91326, AC005899, AL096791, AC007227, U96629, AL139054, AC004859, Z98946, AC002070, U91323, AC005696, AC005412, AF047825, U73024, Z95331, U80017, AC002301, AL031666, AC005317, AC002425, AP000689, AC005911, AC005089, AC005971, AC003098, AL022163, U78027, AC004525, AC005225, AC004921, AC008044, AC004922, AF001552, Z84480, AL135744, AC002094, AC004967, AF111168, AC003962, AJ246003, AC006512, AC005480, AL136295, AL035422, AL049843, AC005839, AL096701, AC006211, AC005183, AC005316, L78810, AL035249, AP000344, AP000555, AC005914, AC007376, AC005532, AC005523, AL021578, AC002477, AC004912, AC007546, AC005988, AL035587, AL049539, AC005704, AL078581, AL035417, AB003151, AC006101, U07561, AC005730, AP000557, Z84487, AL109758, AC008372, AL008726, AC004876, AC004134, AC005722, AC007686, AC002126, Z98750, AJ010770, AC005531, AC006441, AC004985, AC004895, AC004263, AC004383, AL031295, AL121658, AC005632, AC006120, AC008040, AC005043, AL109984, AC002430, Z99716, AC004966, AL035090, AF196779, AC005921, AL080243, AP000208, AC006505, AF117829, Z84466, AC006011, AB023051, AL049757, AC005261, AL009181, AC005562, AL035086, AL132777, AC002133, AL022318, AC007193, AP000066, AC005902, AC007384,

					AC004929, U85195, AL022336, AL050318, AC005224, AC004584, AC005375, AC005520, AC003041, AF053356, AP000115, AL049569, AL031432, AC006305, AC005088, U95739, Z68870, AC006480, AC009405, AL049856, AL049759, AC005484, AC002544, AC002059, AC005701, AC003689, AC006251, AC004854, AC009363, AC006210, Z93023, AC008989, AC004953, M17262, AP000512, AL109952, AC006511, AP000099, AC005049, AC005233, AC005529, AE000658, AC004517, AC012384, AC004991, AC006077, AC005377, Z92844, AC008115, AP001052, AC007551, AL031577, AC002476, AL023553, AL121653, AL049712, AL035659, AL049872, AC007057, AF030453, AC005071, AC002997, AC007263, AL022313, AC006255, AP000511, AF067844, AL050321, AL132712, AC005231, AL031680, U52112, AC004815, Z85986, AC005057, AC005409, AF064861, AC004526, AL031311, AL022311, AL109628, AC002369, AL031670, AC004167, AC006121, AC002300, AC005697, AC004125, AC007421, AL049780, AC002316, AC009516, AC005666, AB000882, Z75887, U62293, AL049631, AC001226, AL022320, and AP000036.
HFYW08	186	958978	1 - 472	15 - 486	
HFYZ13	187	656795	1 - 364	15 - 378	
HFIZF95	188	795734	1 - 351	15 - 365	AL1470647, and R26573.
HFIZG93	189	928170	1 - 537	15 - 551	AW070612.
HFIZH29	190	953895	1 - 390	15 - 404	
HFIZM92	191	791267	1 - 559	15 - 573	H13123, R82393, AI634609, AI925440, AI333038, AW195580, AA504939, AB014580, and AL049844.
HFOXA79	192	774901	1 - 238	15 - 252	AC004150.
HFOXB85	193	752957	1 - 362	15 - 376	AL133500.
HFOXC25	194	677995	1 - 335	15 - 349	AC012039.
HFOXC35	195	638311	1 - 560	15 - 574	AI284640, AA847499, AI499588, AI754336, AI802835, AA601876, AL138396, FI2561, AA728812, AI862939, AA847952, AA368059, AA358515, AA765736, AA514854, AI002510, F25733, AI537077, AA126450, AA508359, AI282511, AA620467, F08248, AW327868, AA935988, AL121235, C06339, N35602, AW028392, AA045017, AI338350, AA629992, AI079389, AA780784, AA724333, AA169263, AI093030, AI933534, AA493708, AA659360, AI536900, AA579075, AA719292, AL045808, AL046156, AI358812, AA347027, AA847515, AI312309, H71429, AA683258, AA491862, AA491831, AI564185, AW168618, AI921061, AA491650, AW075948, AL042853, AI290405, AW023149, AA368943, AI061143, AI076766, AA071393, AA679936, AA634196, AI610435, AI866964, AA351056,

					AI683446, AL134972, U95743, AC002477, AF117829, AF064858, AC002369, AC002368, AC008080, AC007298, Z97054, Z94056, AC003957, AF003626, AC007546, AC005823, AL034420, AP000113, AP000045, D84394, AC006443, Z82203, AF111168, Z86090, Y10196, AC007878, AC004024, AC005049, U80017, AC005031, AC005355, Z99916, AC006578, AC008013, AF207550, AC002385, AC007221, AC005484, AJ229043, Z83840, AC005915, AC007450, AL034400, AL035450, AP000347, AP000351, AF015262, AL049538, AC006137, AC006040, AC004032, Z98941, AC004382, AC005004, AC000113, AC005154, AC006536, AL023805, AC007065, AP000014, AL031684, AC005736, AC004112, AL022238, AL022477, AC004887, AC007225, AC003071, AC004585, AC003029, AC004019, AP000104, AL050318, AF149773, AC002350, U91322, AC007245, U91321, Z95400, AC006111, AC002091, AL031591, AC004617, AC002089, Z98036, AL049874, AC005342, AL022316, AL117354, AP000350, AC004816, AC002364, AL035555, AL078624, AC002416, Z97181, AP000355, AL117355, AP000156, X96421, AL049835, AL050343, AP000115, AC004496, AC006012, AC004813, AC005740, AC004796, AC005284, AC004664, AC005383, AL022323, AL049766, AP000048, AC005330, AC004924, AC006530, AL121820, AL035088, AC004386, AL009181, AL049780, AC002366, AL049837, AC015853, AC005863, AC003099, AC000052, L78833, AL035411, AC004491, AC004841, AC005919, AC016831, AC004253, AC004966, AC002994, AC000353, AL049557, AC004144, AL121653, AL049829, AL023653, AL050321, AL049869, AC007567, AC006316, AC004531, AC005036, AL031230, AC006450, AC005826, AC002316, AC009510, AC007314, U95090, AJ251973, AC004849, Z95114, AC005911, AL121652, Z93930, AC002418, AC006376, AL035563, AL022318, AC006205, AC002992, AC007684, AC005971, AF064862, AC000105, AC009514, U52111, AC006116, AL022273, AF107885, AF045555, AP000330, Z98884, AC007685, Z95113, AF001550, AL117667, AC002563, AL121578, AL136504, AC005013, AC002420, Z82190, AP000272, and AC005244.
HFOXE83	196	587955	1 - 271	15 - 285	AA928539, AI590043, AI863382, AI345415, AA830709, AI690813, AI679388, AA641818, AI612913, AI819545, AI491842, AW162194, AI954200, AW169291, AL047100, AI345612, AI452560, AI479292, AI345416, AI613038, AW198090, AI571439, AI702063, AA937566, AI859991, AI370623, AI635851, AI554402, AI376425, AW129722, AI885664, AL048538, AW084896, AI538850, AI540831, AI698391, R40363, AA804541, AI635216, AL120706, AL043166, AI863002, AI633125, AW130362, AI696714, AI909697, AI539800, AI927233, AI539260,

<p>             AI270183, AI619820, AW194014, AW022754, AI950865, AA743430, AW149937, AI889189, AI818562, AL042745, AL042744, AI580027, AA814517, AL037602, AI766348, AL043293, AW090550, AW152182, AI824688, AL037582, AI696583, AI830016, AI688854, AI538564, AI701097, AI872423, AI870192, AI440260, AL080045, AI635016, AI690784, AW058202, AI804515, AI699175, AI915291, AI678496, AW151974, AW105431, AI583032, AI473536, AI860027, AW022957, AL079799, AI884318, AI918677, AW151893, AI494198, AI890907, AW196720, N66892, AI868740, AW188525, AI654286, AI470717, AI499570, AI434229, AI434969, AI583065, AI653402, AW022636, AA575922, AI827212, AL046200, AL040366, AI684244, AI500061, AW148363, AW103628, AI921633, AI547265, AI309769, AI147877, AI446511, AW148544, AW151132, AI445025, AI095003, AI469784, AL042944, AI609375, AI798359, AI434731, AI440238, AI560569, T69241, AI453767, AW022856, AA128660, AI950729, AI358271, AI624543, AL046466, AI912356, AI624938, AI637584, AA715307, AI524654, AA809974, AW103878, AI419826, AI889191, AW019985, AW128971, AI275956, AI475331, AI670895, AI798456, AL043152, AI677796, AI687362, AA748353, AI699823, AI973152, AI540354, AI571442, AI161279, AI061405, AI866469, AW131165, AA814343, AI673278, AI887163, AI620643, AW090736, T49776, AW148536, AW194509, AI801515, AI343325, AI635287, AI469532, AI250282, F34309, AI364167, AL045453, AI683606, AI610690, AW089726, AI620056, AC004383, AL133029, AL117587, D44497, AI7115, AI18079, A86558, AF141289, AJ003198, AF090900, AL031732, AF013249, AR022283, A93914, AL133623, AL137488, AC006203, I33391, AL137459, AF124728, S65585, L04849, L04852, AF080068, AL022147, AL137657, AL133637, AF126372, AL137539, X97332, A41579, A27171, Z97214, AL136884, I34395, I18358, AF124435, AL133084, I28326, AL080146, AL117416, AF126247, AR066485, M85165, A15345, AR038854, AI2558, AF100931, Y16645, AL133053, I89947, A26498, U38419, AL137530, Y13350, AF222801, AF111849, AL080140, AL080148, AL133049, AF102578, A60092, A60094, AF031572, AI2522, AR050959, AR068753, AR012379, AC005291, AL080139, AF004162, A21625, AJ012755, S36676, X63162, X59812, AL110158, AL049466, AF002672, U49908, AJ238093, X15132, AF013214, AF200464, AJ005690, AL035407, A21103, AL049283, AF054988, AF111851, US8996, U75304, X78627, AL133015, AR066486, Y17327, AL122049, AB031064, AL050172, AL137254, AL137548, AL050322, AC018767, AF026124, AF061795, AF151685, U37359, AL137533, X68560, I03321, AL117575, AL080118, AF076464,           </p>					
---	--	--	--	--	--

					AL122104, Z93784, E12580, E12888, A20553, AF131773, I33392, A08907, AF153205, E03168, AL137529, AL050149, AF060555, AF106657, AC002471, AC005374, AF169154, AR013797, X60769, AF145233, E03671, AL049423, AL122100, AF058921, U51123, I09499, AF061981, AL133608, AF112208, AF116573, X06146, X61049, A23327, AL137478, A76337, I18355, I34392, AB020777, X69026, and X99971.
HFOX103	197	923772	1 - 309	15 - 323	AI394067, and AI056068.
HFOXM54	198	587974	1 - 346	15 - 360	
HFOXN89	199	587984	1 - 97	15 - 111	
HFOXO24	200	733377	1 - 517	15 - 531	AI026814.
HFOXR28	201	587994	1 - 310	15 - 324	
HFOXR67	202	806488	1 - 447	15 - 461	D56451, AI797289, AW008969, AI394269, AI541453, D56220, Z36872, H17761, AW009897, AA248589, AI278793, H59335, C04806, R01796, AW062936, N30347, H93411, AW263105, R62171, AW178925, AA613553, AI148761, AA960959, R52799, AA996071, AW363731, AI026967, AW069303, AA148228, AW247577, H41429, N91665, AA837473, AW247732, R86909, T34155, C05230, AA316485, N94214, AI751446, AI750270, AI276480, AA865609, T36130, R81681, N93270, AI383153, AF153605, and AF151861.
HFOXs81	203	588052	1 - 502	15 - 516	AC009509.
HFOXU83	204	887781	1 - 334	15 - 348	
HFOXU92	205	588057	1 - 64	15 - 78	AA225747.
HFOXV15	206	964296	1 - 451	15 - 465	AR038762.
HFOXV80	207	771290	1 - 442	15 - 456	AA308546, AW157090, AI937913, AW156893, AW162217, AW157724, AW161439, AI879643, AW156973, AI879261, AW163058, AI929716, AW087100, AA305024, AW157680, AW068829, AI929159, AW160392, AI928949, AI929458, AI879102, AI815607, AW163676, AI816107, AI929203, AA533150, AA603376, AA315102, AA557858, AI042255, AA316902, AA305999, AI929416, AA467847, F20887, AI148106, AA635409, AI080578, C16701, AI735002, AI703215, AI218297, AA578143, AA306384, C15041, AI004923, F34246, AI813679, AW161950, AI741580, AA558231, F27426, AA315107, AA316386, F28430, AA747217, F19264, AA582173, AW162077, AI880659, AI284407, AA969828, AA316519, AI797882, AA182966, AA312837, AA593697, AA429825, AA314832, AA534268, AW051532, AA551986, AA514368, AI283754, AA314733, AA857416, AA504055, AA099703, AA703668, AA813296, AA305425, AA627106, AA658158, AA102518, AA912491,

					W70100, AA806144, F21803, AA729466, AW188624, AA362481, AA378344, T58704, AA552195, AA570027, C14962, F27125, AI547077, F24635, AA146770, AA569705, F22538, AI051783, AA582239, AA954461, AA523344, F25970, AI818276, AA628531, F28354, AI541451, AI286214, AI302226, AI749166, AA593326, AA923442, AA970629, AA836780, AA382399, AA358548, AI589583, AA53775, AA302481, AA302037, AI015174, AA309890, AA639958, AA994774, AI928906, AA868034, F35973, AA366144, AA541672, AW162742, AA385897, AA305293, AA358129, AI383381, F19236, F27230, AA372465, AA532593, F35969, AA659394, R50158, AI815885, AI816148, AA353710, AA082359, AA320396, AA345921, N85393, AA506932, W44688, AA146771, AA894893, AA363398, AI347797, C15196, AA084010, H25768, AA352140, AA143324, F27370, AA535125, AA482870, AA126459, AA070860, AA112167, AA320816, AA559162, AA375521, AA186947, AA741424, AI476367, AA533959, AA302382, AI339429, F16378, AA304454, W44689, AI749986, AA303205, AA876719, H67183, AA355917, AA371889, AA303560, AA121010, T68786, AA190982, AI609251, AA187063, T61564, T47265, AA484195, AA669582, AA746899, AA375705, AA318361, AA373707, AI991245, F16990, AA721793, Z22017, AA633759, AA480788, AA099379, AI688209, AA181199, F17072, AA627728, AA358130, F21668, AA327089, H25809, F22482, AA514522, AA328203, AA608523, AA143373, AA531014, AI581577, AA318610, AA301081, Z20171, AA181098, T25773, AI906511, F29640, AA344773, AA559980, R29520, T58654, AI828156, AA662018, AI612840, T50358, AA126533, F29292, AA191447, AI459942, AI818088, AA662715, AA372830, AI420455, AI050273, AF077043, AC004884, AC007160, AC003071, and A74819.
HFOYI36	208	935532	1 - 412	15 - 426	
HFOYL77	209	494844	1 - 303	15 - 317	
HMUBM2 6	210	908912	1 - 551	15 - 565	
HMUBX25	211	678004	1 - 248	15 - 262	
HMUBY88	212	740311	1 - 360	15 - 374	D31124.
HOAABI5	213	575254	1 - 283	15 - 297	
HOAAB42	214	530605	1 - 246	15 - 260	AL047846, AC008013, AC009533, and AR050956.
HOAAB36	215	507839	1 - 361	15 - 375	
HOAAC31	216	693597	1 - 368	15 - 382	AA648984, AA866183, and AA236595.
HOAAD05	217	932756	1 - 546	15 - 560	AL045968, AL046394, AW449989, AI351357, AA757688, AI937374, AI129540,

HOAAD52	218	859628	1 - 317	15 - 331	AI952327, W28986, AI362659, AA704558, AA973323, AP000219, and AI239328.
HOAAE10	219	968532	1 - 325	15 - 339	AC005164.
HOAAE45	220	530602	1 - 316	15 - 330	
HOAAE49	221	859630	1 - 290	15 - 304	AI696455, AA631512, AA280198, AA063419, AA730609, AA063493, N53783, AI230815, AA094679, AI919048, T03774, AI547110, AA676462, AA484321, T94858, AI800189, AI683125, N64807, N63562, AI832554, AA338436, AA325104, AA485778, AW169324, H63173, AA229489, AA297208, AW085626, AA284638, AA720594, AA640104, C15279, AW192471, AI754926, T58562, AA594164, AA524804, AA524604, AA115769, AA302962, AI267285, AA362670, AA228268, R43468, AW086015, AA730325, AI523991, AW085751, H65404, AI708663, AA452912, AA516061, AA910236, AI299889, AA494145, AW169183, AA632355, AA507657, AI818921, AI079682, AI041740, AA338330, AA174108, AW089646, AA300221, H60396, AA082007, AI242994, AI207692, W02485, W45215, AL109984, AL035423, AC005763, AC006343, AC007225, AC006930, AC005231, AL020995, AB001523, AL021393, AC011594, AC005179, Z69364, AL034379, AC002316, AL135745, AC005775, AC001231, AC005082, AC007066, AC004106, AC019014, AC005694, AC003969, X64467, AB026906, AC005593, AC006205, AC004844, AC007238, AD000092, Y18000, AC005225, AC007686, AC005971, AC005527, AC003658, AC005695, AC004525, AC002463, AC006064, AC005277, Z93241, AL133243, AC005529, AC004033, AC007298, AC004686, AC005215, AL021391, AP000228, AC005412, AL031844, AC002070, AF169035, AP000140, AL022316, AF135028, Z85988, AC004447, AC004650, AL035420, AC004022, AL034417, AC008044, Z82188, AL031432, AL078474, AF064861, AC002504, AC004843, AL096678, AC006011, AC004765, AC010722, AC003013, AL117340, AL109628, AC004388, AF036121, AF196972, Z68756, AC005738, AC006120, AC003685, AC005516, AP000310, AL096703, AL035249, AP000116, AP000152, AP000010, Z97632, AC008085, AP000088, AC003041, AL080276, AC002350, AC005369, AL049709, AL022311, AC007050, AF184614, AC005331, AC005102, AC005410, AC005832, AC007240, AC006148, AC004816, AC007546, AC002076, AC006441, AC005937, AC004073, AB023048, AC005962, Z83844, AF069491, L78833, AC007971, Z83843, Z98946, AL033392, AL078581, AF196969, AL049631, U85195, AC000134, AP000335, AC004019, AL021453, AC002351, AL035658, AC007868, AL031680, AL022165, AC005768, AC006130, AL080242, AF081795, AE000658, AL024498, AL021808, U80459, AC003004, AB022785, AC005933,

						U73648, AL031721, AC005785, Z94161, AC006273, AL121934, AC002037, AL022237, AP000251, AL031255, AF023268, AL096757, AL031118, AL035398, AL049743, AL109963, AC004897, AC004771, AC006071, Z93930, AC005773, AP000065, AP000030, AC004079, AC004920, AC004703, AL049757, AL078476, AL035400, AC005033, and AL049745.
HOAAE73	222	960631	1 - 303	15 - 317		
HOAAF18	223	530600	1 - 343	15 - 357		
HOAAH10	224	968368	1 - 608	15 - 622		AI038589, H38572, AA604708, and H59854.
HOAAI05	225	932537	1 - 296	15 - 310		
HOAAJ23	226	531389	1 - 257	15 - 271		
HOAAK90	227	527490	1 - 280	15 - 294		
HOAAM0 8	228	960060	1 - 189	15 - 203		
HOAAR14	229	526530	1 - 230	15 - 244		H60486, H60440, AW151194, AW378516, AW378511, AC005696, AL031230, AC004771, AC006011, AL049872, AL096701, AC005034, AC003103, AC004983, AC004000, AP000696, AL109952, AL110122, Z99716, AC005031, AC005839, AF196970, AL023575, AL035458, AC004999, L78833, AC006441, AC004859, AL034548, AL023553, AC007390, U80017, AC005399, AC008372, M17262, AL035398, Z85986, AF000512, AL031680, AC004832, AC004797, and AC007182.
HOAAV23	230	527489	1 - 294	15 - 308		
HOAAW2 1	231	527487	1 - 296	15 - 310		
HOAAZ61	232	531065	1 - 320	15 - 334		
HOABA20	233	932539	1 - 104	15 - 118		
HOABA93	234	792929	1 - 198	15 - 212		
HOABD58	235	738359	1 - 96	15 - 110		
HOABP66	236	507175	1 - 277	15 - 291		
HOABP69	237	531049	1 - 98	15 - 112		
HOABR40	238	531051	1 - 344	15 - 358		
HOEAK21	239	954961	1 - 326	15 - 340		
HOEAY14	240	659258	1 - 336	15 - 350		AA010406, and AA513951.
HOEBL44	241	715851	1 - 288	15 - 302		
HOEBO31	242	693689	1 - 335	15 - 349		
HOEBP01	243	916957	1 - 565	15 - 579		R51124, R50890, H09201, F08412, H10008, R23547, and AC007688.

HOECN79	244	723113	1 - 223	15 - 237	
HOECY54	245	506692	1 - 532	15 - 546	
HOEDD40	246	572900	1 - 332	15 - 346	
HOEDD83	247	578934	1 - 311	15 - 325	
HOEDK10	248	915054	1 - 314	15 - 328	
HOEDT31	249	826009	1 - 461	15 - 475	N40134, AA459424, H23811, AA477809, AW361971, R22603, R80171, AA255699, AW388174, R07949, H43071, AA019983, AA491397, AA853328, AW167516, AA325547, AA156738, AW388175, N42726, AA333808, AA953943, AA299231, N41696, AA715394, T73669, AW083486, T63684, AA838699, AI890778, AA046378, AW008861, AW162991, AW300924, AI205997, H38711, AI125503, AW166548, AA911687, AA504780, AA434314, AI567841, R78822, and R67144.
HOEDU54	250	506576	1 - 501	15 - 515	AI954403.
HOEDU68	251	713695	1 - 156	15 - 170	
HOEEB63	252	745039	1 - 299	15 - 313	R47912.
HOEEC02	253	919822	1 - 226	15 - 240	
HOEE045	254	717754	1 - 336	15 - 350	Z64883.
HOEEQ17	255	663719	1 - 357	15 - 371	
HOEEQ22	256	744340	1 - 272	15 - 286	
HOEFL91	257	790134	1 - 346	15 - 360	AI042148, T72500, D45636, and AL049830.
HOEFN92	258	698444	1 - 312	15 - 326	R45895, AA585325, T18597, R28965, R29218, R28892, D54897, D60765, D60844, AA170832, AA585098, R28735, R29445, R29657, R28967, Z32887, D57491, D59751, AA585101, Z32822, AA585439, AA283326, C15406, D53161, AI547250, D61185, C15069, Z33559, AI546831, AA585476, D61254, AI525316, AI557262, C16294, C16315, D55233, AI557864, R28895, Z28355, D59458, AI541356, AI525306, AI546875, AI557734, AI525500, D59436, AI546999, AI546921, D54850, AI526078, AI526016, AA585155, AI526140, AI541365, AI557740, C16296, C16292, D53447, AI546971, C15120, C15762, AI557763, D52835, C16305, C16293, AI547122, AI557799, AI541383, D53472, AI546901, AI526194, AI526184, AI526109, AI535639, AI557718, AI541517, AI547039, C15737, R29179, AI541374, C16300, AI525339, AI557731, AI526112, AI541205, AI526117, AI526191, AI525556, D57186, AI557787, AI535660, AI546945, AI557727, AI547202, AI541535, AI525431, AI557808, AA585430, AI557809, AI557852, AI547006, D60730, AI541346, AI541013, AA585356, AI540903, AI541307, AI557084, AI540967, AI541034, AI557264, AI557758, AI557807, AI525320, Z30131,

					AI557408, AI546996, AI557533, AI526024, AI546891, R29262, R29172, AI557602, AI557317, AI536138, AI526158, AI541527, C16290, AI526195, AI525114, AI557155, R29177, AI547196, C14208, AI525168, AA585453, D61060, AI557279, T19407, AI540974, AI547189, AI525856, C14210, AI526113, AI526073, AI541422, AI524904, AI541515, AI557810, AI557796, T41289, AA585434, AA585117, AA514191, AI541321, AI541492, AI541345, AI540944, AI546829, AI556967, AI557041, AI557786, AI525076, AI524890, AI046024, T41329, AI525656, AI557785, AI547137, AI526169, AI525286, AI541506, AI557039, AI541415, AI546841, AC005913, AR038762, AR038855, AR062871, A25909, Y09813, X76012, X82786, AJ243486, AR003381, AJ244006, AJ244005, Y16359, AF082186, AR031358, X81969, AR031365, D50010, D13509, AJ244004, A20702, AR062872, AR062873, A20700, D78345, A43189, A43188, Z32836, AR054723, and X55486.
HOEFS83	259	615154	1 - 240	15 - 254	AL133353.
HOEJE18	260	666349	1 - 300	15 - 314	
HOEJG04	261	859251	1 - 470	15 - 484	AA1997.
HOEJW84	262	859225	1 - 511	15 - 525	R06873, and T84693.
HOEKH88	263	924112	1 - 692	15 - 706	AI694533.
HOEKP01	264	918873	1 - 436	15 - 450	AA043660, AA336439, D79158, T32005, Z24843, and AA482531.
HOEKP79	265	963337	1 - 455	15 - 469	AA506744, AA564925, AW080772, AA972523, W24312, N69686, AA501450, AA831345, AA515733, AW029515, AI264579, AI446127, F25580, AA524846, AI300054, W61253, R51582, AI421723, T64444, AL119156, AL119182, AL133353, AC006480, AC006160, AF011889, AC010206, AC008928, AL133163, AC004849, AC004596, AL121653, AL118510, AC008119, AL024498, AL133500, AL109753, AL096701, Z84488, AC004605, AC007684, AB020867, AL021940, AL031295, AL031602, AC003037, AL021368, AC007221, AL031659, Z98048, AL021877, AC005393, U50871, U96409, AF111168, Z95152, and AC003689.
HOEME76	266	974069	1 - 530	15 - 544	AA280295, H19334, AI371007, AA127347, N24841, F09340, AA635400, NS2087, and U60062.
HOEMK02	267	918364	1 - 94	15 - 108	
HOEMQ65	268	922789	1 - 309	15 - 323	
HOEOE25	269	907806	1 - 611	15 - 625	AW182459, AI376825, AI654638, AA866171, AA984176, AA806823, AA743557, AW340266, AA470942, AA470974, AI868578, AA743581, and AA761032.
HOHAA14	270	468867	1 - 371	15 - 385	

HOHAB04	271	665381	1 - 271	15 - 285	AA465435.
HOHAB21	272	670814	1 - 229	15 - 243	
HOHAE68	273	781448	1 - 321	15 - 335	AI751085, AA033678, D30912, and W55850.
HOHAM3	274	782043	1 - 539	15 - 553	AA059163, AA864897, H99945, and N64132.
HOHBE48	275	588317	1 - 386	15 - 400	
HOHBF30	276	859046	1 - 504	15 - 518	Z84484, and AC006571.
HOHBL11	277	966720	1 - 464	15 - 478	
HOHBL32	278	588329	1 - 538	15 - 552	
HOHBO79	279	588271	1 - 428	15 - 442	AI638299, AA918485, and AF077660.
HOHBW8	280	784723	1 - 264	15 - 278	AC009247.
HOHBX75	281	669536	1 - 493	15 - 507	AI735183.
HOHBY75	282	840109	1 - 413	15 - 427	AI215403, AW297341, Z21179, and AL137348.
HOHCH04	283	859047	1 - 621	15 - 635	
HOHC105	284	935123	1 - 380	15 - 394	
HOHCM38	285	709295	1 - 416	15 - 430	AA058800, AI268296, N47161, AA303034, and H45390.
HOHCM90	286	703734	1 - 140	15 - 154	
HOHCO85	287	751299	1 - 565	15 - 579	Z21583, and AL096771.
HOHCP35	288	656516	1 - 281	15 - 295	
HOHCQ76	289	825236	1 - 549	15 - 563	
HOHCQ77	290	661480	1 - 103	15 - 117	AP000274, and AP000104.
HOHCV83	291	735685	1 - 289	15 - 303	AI636734, T60940, H01852, AI078143, AI683019, AA854460, R35259, AA541794, N74027, AW167909, AI439676, W63553, AI472070, AI538106, AI332676, AI446259, W67486, AW245354, AA856817, AW152661, AI459617, AA845825, W67485, T49133, AI961232, AL041342, AI149238, AA807579, AA362037, AA565232, AA502813, AI434365, M78026, AA988600, AI127133, AA502498, T07225, H79586, AA471086, R83068, AA59205, AI223968, N68851, R48980, AI679496, N92064, AA702717, AW439625, AI962973, AW439820, N34258, AI859849, AI762302, AA636102, AA551548, N22153, AA572982, AW073498, AI929410, AI753672, AI750950, AC007371, AF165138, Z94277, AC004084, AC004838, AC005520, AC004985, AL008735, AC005751, AC005971, AF029062, AB000876, AC004181, AP000506, AL022313, AB000882, AC004655, AL031178, AC005377, AL022345, AL031584, AF227509, AF108083, AC005660, AC004941,

					AL035415, AC005486, Z98304, AC000049, AL096774, AC004079, AL033504, AC004020, AC007156, AC008372, AF008915, AC004750, AC005568, AC003959, AL050350, AL035410, AC005913, AC004805, AC005412, AC004854, AC002407, AL050318, AL096716, AC007686, AL022311, AL035587, AL096791, AC006368, AL109865, AC003664, AC008040, AF132033, U73630, Z81314, AC006347, AC006130, AL049748, AL096861, AL022400, AC003973, AC005081, AC005837, AC003991, Z72006, AC004797, AL021707, AP000045, AP000113, AL035417, AL079342, AC005043, AC008115, AC004953, AL022302, AL035249, AC005186, AL133163, AC004531, AL109628, AC005262, AC004771, AL021920, AC004967, AC011604, Z99716, AL049779, AC005005, AF043251, Z49236, AC004235, AC004034, AC002450, AF050154, AC005789, AC005233, AC004131, AC004913, AC004070, Z95116, AL049631, AL096712, AL031657, AC007114, AL031281, AF121782, AL022336, AC009275, AC007011, AC004098, Z98949, AC005058, AC006040, AF064857, L47234, AF179633, AL035683, AC012099, AF003529, AC009263, AC004893, AC002544, AP000555, AC004585, AL133245, Z97053, AC002302, AC005274, Z82173, AC005265, AB015355, AL031602, AL049540, AC005067, AC005255, Z98048, AP000502, AL117354, AL008583, AC005754, AL031280, U82671, AC005914, AF047825, AC005534, and AL031053.
HOHCW0 2	292	919142	1 - 290	15 - 304	
HOHDB11	293	966413	1 - 650	15 - 664	N29990, N36333, AI085776, H25536, H26237, H81879, H96029, N26443, N31186, W03046, W44451, AA037341, AA079718, AA203198, AA424475, AA745282, D82780, C00261, AA249588, and T48492.
HOHDB32	294	698781	1 - 303	15 - 317	
HOHDD23	295	675616	1 - 400	15 - 414	
HOHDF40	296	710748	1 - 357	15 - 371	AA640725, AI333044, AL042761, and AB011158.
HOHDF53	297	727620	1 - 410	15 - 424	
HOHDI48	298	966379	1 - 241	15 - 255	
HOHDY85	299	764155	1 - 407	15 - 421	
HOHDZ61	300	741382	1 - 272	15 - 286	
HOHEA19	301	668208	1 - 385	15 - 399	
HOHEC41	302	712037	1 - 523	15 - 537	AI971892, AI683311, AB033063, and AR065869.
HOHEN50	303	662365	1 - 150	15 - 164	
HOSAB04	304	531565	1 - 310	15 - 324	W61042, AA304276, AA099793, AW369803, AA451642, AI908298, AW369815,

AW369818, AA451620, AW369839, AA192643, AW151982, AI982623, AI857726, AW369763, AI204558, AA320140, W27176, AA319885, AW023791, W27949, AI670119, AI54355, AW051557, AI804785, AW236073, AI799768, AA192644, AA908706, AA888425, AA876810, AA167392, AA577519, AA876691, AA525477, AA879274, AI345444, CI7613, AI075107, AI114490, F34539, AI492852, AA593784, AA738303, F37334, AA566072, N86742, AA886806, AA503355, AA523167, AA541429, AA876872, AI933389, AA877045, AI352526, AW050724, AI536939, AA886558, AA469371, AI694189, AA937272, AI420436, AA542813, W21397, AI418514, AA166702, AA102263, AA522721, AA166638, AA526669, AW273151, AW327392, AA999779, F17050, AI042584, AA136123, AA747343, AF117616, AL031003, L39354, L39338, L39332, U95676, U95677, U95681, L39330, L39334, U95680, U95688, AJ230596, AJ230597, AJ230599, AJ230603, AJ230605, AJ230609, AJ230595, AJ230602, AJ230607, AJ230610, AJ230611, AJ230613, AJ230600, M76331, M76289, M76288, M76293, M76360, M76286, M76297, M76320, M76329, M76314, M76363, M76367, M76364, M76366, M76287, M76307, M76342, M76368, M76302, M76339, M76306, U25391, U25395, U25359, U25363, U25371, M76315, M76290, M76323, U25357, U25368, U25400, M76316, U25379, M76341, M76340, U25409, M76301, M76337, M76356, U25358, U25373, U25396, U25407, AF176190, M76296, M76304, M76347, M76348, U25372, U25412, AF176182, M76361, U25390, AF176138, AF176179, AF176180, M76335, M76351, M76354, U25397, M76362, U25369, AF176174, M76305, AF176202, M76328, M76350, U25403, U25408, AF176183, AF176205, M76352, U25364, U25366, AF176161, M76330, U25410, AF176171, AF176172, AF176200, AF176201, M76333, U25388, U25399, U25405, U25406, AF176166, M76292, M76295, M76326, M76359, U25356, U25361, U25384, U25402, U25365, U25370, U25374, U25413, AF176132, AF176181, AF176194, AF176203, M76353, U25362, U25367, U25392, U25393, U25394, U25401, AF176125, AF176140, AF176141, AF176164, AF176178, AF176189, AF176199, U25377, U25378, U25398, AF176130, AF176137, AF176142, AF176158, U25404, AF176139, AF176162, AF176167, AF176175, AF176204, U25354, U25355, AF176131, AF176134, AF176144, AF176159, AF176187, M76309, U25383, AF176126, AF176128, AF176160, AF176163, AF176170, AF176185, AF176198, M76319, AF176129, AF176186, AF176193, M76324, U25381, U25382, AF176143, AF176173, AF176184, AF176133, M76355, M76346, M76299, M76291, M76294, M76312, M76283, X93341, M76325, M76334, V00661, M76303, U25411, AF176156, U25360,				
--	--	--	--	--

					AF176195, X93334, U25375, U25376, L39322, L39320, L39352, L39350, L39326, L39328, L39348, U95685, L39344, U95684, AJ230601, AJ230606, M76327, U95687, AJ230614, K02485, M12531, AR058756, M76268, M76258, M76313, M76317, M76310, M76358, M76298, M76345, M76275, M76336, M76260, M76265, M76266, M76344, M76300, U25387, U25389, M76264, M76343, M76349, M76357, U25386, AF176169, U25385, M76276, AF176127, AF176168, AF176157, and AF176192.
HOSAR25	305	509226	1 - 319	15 - 333	
HOSBR08	306	925430	1 - 94	15 - 108	
HOSBU17	307	667195	1 - 569	15 - 583	AA181322.
HOSBU81	308	508735	1 - 156	15 - 170	
HOSBV22	309	780092	1 - 252	15 - 266	AI368409, AI767148, AI347671, AI400068, AA954702, AI583977, AA009615, AI418746, and AI457713.
HOSBW16	310	933016	1 - 238	15 - 252	AA421843.
HOSCG51	311	967584	1 - 421	15 - 435	AA381761.
HOSCM15	312	921336	1 - 384	15 - 398	AC005661.
HOSCC235	313	707379	1 - 356	15 - 370	AA330344, and AJ005821.
HOSDE63	314	580959	1 - 188	15 - 202	H15344, AI752743, R23438, AA401585, AW339993, Z44943, H06750, H50269, and H40825.
HOSDG51	315	523872	1 - 359	15 - 373	
HOSDN27	316	530459	1 - 256	15 - 270	
HOSEB61	317	741812	1 - 883	15 - 897	N98675, and AL049781.
HOSEM84	318	831049	1 - 354	15 - 368	AI073997, H87655, AA326173, AI157664, W45610, AA182685, AA352875, AA358040, and AA320365.
HOSFO57	319	736034	1 - 309	15 - 323	AW363743.
HOSFV63	320	873010	1 - 159	15 - 173	R32290, H56316, H56315, AI701812, AI818182, H02802, AW189354, AA179098, AI149010, AA903771, AA846152, AW236253, AI688210, AA219082, AI188637, AI457307, AW148946, AI912534, AW008419, AW149032, W56627, AA470757, AA464507, AI888588, AI056698, AW168755, AI924212, AA522891, AW089716, AW193562, AA987677, AA343171, AA769724, F35157, and AA361146.
HOSFY79	321	774052	1 - 417	15 - 431	
HOSFZ39	322	705351	1 - 355	15 - 369	
HOSGH28	323	686649	1 - 395	15 - 409	AA364637, AA149539, AA405966, AA828153, AI032490, AA320105, AA237098, AA662590, H85808, R64617, R70883, AA838091, AA714999, AI434513, N63149, AA632765, C14480, AI471467, AW007424, AA468196, AA558404, N95156,

<p>AA729512, AA551268, AA603400, AA838161, AL041375, T05118, AA526107, AA535579, R81911, AA528566, A728861, AW117860, AA715955, AI049630, AA548968, AI671077, AI452836, AA532732, AL118925, AI302156, AI045476, AW440451, N28624, AA612578, AA302978, F16848, N54538, AI870453, AA601237, AI249365, AA708132, AA586433, AI912401, AC005520, AC005736, AC007371, AC003973, AC007066, AL022165, AC003684, AF109907, AL008582, AC005233, AC004859, AF064861, AC005837, AC003108, AP000692, AL034379, AC008009, AL096704, Z83826, AC005839, AL022158, AL080243, U91326, AL049538, AF111168, AF051976, AC005531, AC007684, AC002558, AC008085, AC006023, AC005971, AC003669, L78810, L78760, U51561, U50871, AC003098, AC004991, AC004900, AC007845, AL035088, AL033381, AL133353, AC007637, AC016026, AL049780, AC007055, AC005486, AC005519, AC002550, AC007666, U91318, AC000052, AC004019, AC006211, AC004821, AC003951, AL021155, AB033026, AC005058, AC004782, AC006449, AC006947, AC002314, AC008015, AL049843, AP000133, AP000211, AL049735, AC005696, AC004000, AB022430, Z77852, U53583, AC005214, U89335, AL049653, AC004834, AL096757, AC004254, AB020877, AF155238, AC007129, AP000512, AC005164, AC005664, AC000025, AC005527, AC006547, AL021938, AC002044, AC005529, AL135744, AC005031, AC004712, AL133245, AL024498, AC007676, AP000358, Z93783, AL035587, AC002996, Z99716, Z93241, U80017, AL034429, AC004707, AP000353, AP000354, AL022330, AL022238, AC006487, AC005722, AC005730, AC005921, AL035405, AC002369, AC005412, AP000359, Y14768, AC004638, AC000081, AP000043, AP000111, AC005598, AC009247, AL031431, AP000212, AP000134, AP000030, AL022313, AC004909, AL049650, AC008122, AC005102, AC000159, AP000300, U43572, M84472, AP000299, AC000075, AC000084, AF039907, AC002491, AC005786, U34879, Z83847, AC004131, U82668, AF003626, AL035408, AC004897, AC005255, AC004913, AC005057, AP000504, AP000113, AP000045, AC005231, AC005004, AL031622, AL049748, Z83823, AC004259, AC006251, AL031735, AC004600, AC003043, Z84469, AC006996, AL023803, AC004534, AC005666, AC009542, AL133241, AP001053, AC009721, U91323, AC005695, AC010170, AC009330, AC005920, AL022069, AC005939, AC004216, AC007738, AF129756, AL079305, AC010582, AL132985, AL049569, AC005332, AC004615, AC005618, AC005663, AL035079, AC006505, AC007206, AP000251, AL035249, AL031291, AL035460, Z83844, AL133448, AC000353, AC005399, U95742, AL035685, AC008115, AC006441, AC005669, AL080317, AC007450,</p>					
---	--	--	--	--	--

						AC006125, AC005288, AF196969, AL023584, AL078638, Z98946, AC007057, AC007216, Z82194, Z81365, U91321, and U47924.
HOSGJ17	324	508870	1 - 319	15 - 333		AA430297, AI633618, and AW293117.
HOSMD84	325	959483	1 - 1036	15 - 1050		N75110, and H71506.
HOSNO86	326	858938	1 - 464	15 - 478		W19582.
HOSOE05	327	930946	1 - 494	15 - 508		AW341882, AW089950, AW392414, AA768179, AI223968, AA573000, AA429481, AI142551, AI135761, AA515172, AA568127, H86579, AW236277, AI185394, AI471455, AA626840, AA666295, AW151247, AA527109, AI687343, AA368155, AI370470, AA720582, AA507526, AA662629, AA664248, F23327, AA657910, AA225100, H01852, AA702717, AA706495, R34070, AI857366, AA480486, AA469230, AA338266, AA550959, AA829565, AI521042, AI701250, AA502110, AI709174, F23338, AA503142, AA250955, AI358501, AI590404, AI624379, T48723, AI521393, C75533, AA655037, AA469441, AW083934, AI523205, T94072, AI281943, AA484892, AL048825, AA716460, AI355103, AI431513, AI635440, AW080724, AA456937, AA377318, AA773881, AW409763, AA224525, AW404666, F34506, AI923331, AI187760, AA736447, AA714110, F27015, H85059, AI123488, AI762302, AA643434, AI114657, AA362349, AW068580, AA946848, AI821382, AI678812, AA535494, AW272389, AA548710, AI668605, AI499954, AI820534, F00688, AA610374, AI679394, AI925423, AA643424, AI369076, AI679902, AA228442, AI288033, R80563, AA483483, AA856817, W28961, T53133, AA741301, AA808725, AW150167, AA559241, T70539, AA678622, AW368401, AA601212, T07903, AA298365, AA487829, AA654464, T92803, AW162555, AI811647, AA368012, AI250019, AA598740, AW019964, AA709110, AI144055, H81700, AA481779, AI733856, T59930, AI366981, AA714073, AA074351, AA572921, AA810158, AA657835, AA468923, AA206163, T03928, AA715876, F32248, F35946, H77505, AL048060, AA664169, AA581525, R87135, AA373861, AA630845, AA487209, AA992126, AA578973, F26953, AA374525, AA568856, AI289505, AI359200, T03576, AF150410, AW157005, AI356440, AA507343, AW404647, AA458573, AI114680, AL021578, AC004673, AL034421, AC011456, U96629, AC018633, AP000503, AF134726, AL034345, AL033521, AC006101, AC002994, AL049869, AL022398, AC003966, AL109952, AC004623, AL031431, AC002400, AC004773, AF196779, AL050341, AC007068, AC002404, Z83847, AL009183, Z97876, AC005102, AL109827, AP000504, AC004849, AL080243, Z94801, AC019014, AF129756, AC004901, AC005189, AC006111, AC004895, AC004999, AC006511, Z68323, AF061032, AF003626,

					AL117328, AC000003, AF015164, AL022147, AC004587, AC004741, X64467, AF002993, AC004531, AL133245, AP000690, AL109963, AP000689, AC004448, AP001053, AC006057, AC005562, Z83846, AL078593, AC007276, AC004645, AC005484, U91318, AC005348, U80017, AL021707, AP000355, U73479, U89337, AL049570, AL034561, AC022517, AL022345, AC004882, AL049569, AL109628, AC004084, AC006344, AC005088, AC004782, AC004209, Z99291, AP000096, AL121603, AC004020, AP000240, AP000249, AC005785, AC007312, AC006600, AC005386, AC005531, AC005516, AP000555, AC009516, AC007308, AC005257, AP001068, AC002563, AP001067, AL031121, AJ011930, U52111, AC007671, AC005971, L77035, AC004125, AC006011, AC005031, AC004041, AL008710, AC006597, AL031275, AC004796, AC006160, AC006312, AF029308, AF053356, AL079305, AC006359, AP000514, AL035682, AC004893, AC004955, AL031283, AC006552, AF077186, AB014077, AF187320, AP000347, AL121757, AC005696, AC005726, AL008635, AC007228, AC009464, AL122020, AL031230, AC005225, AC005399, AL022476, AC000159, AC005944, AP000093, Z98051, AC005207, AC004584, L78833, AC002040, U95742, AC004984, AC007381, AC004112, AL022238, AC005690, AP000468, AC005907, AJ011932, M26434, AL023578, AF030453, AC003663, AP000556, AP000557, AC004383, AF111169, AJ246003, AL020997, AP000113, AP000045, AF190465, AL049745, AC006427, AL031657, AC008372, AC004706, Z95152, AC009731, AP000237, Z83845, AF107258, AC000075, AF051976, AP000210, AP000132, AP000558, AP000553, AL049636, Z97056, AL117436, AL031668, AL121658, AP000115, AC006962, AC004506, AL024474, AC005477, AC004590, Z77249, AL035089, AL049776, AL035681, AL022240, AP001054, Z69720, AC004539, AP000510, AC006449, AC005037, AC004883, AC005305, X65032, AC003086, AP000226, AF196969, AL109758, AL022332, AC005921, AC007537, AL022163, AC003109, AP000087, AC005378, AL020995, AL022311, AC005666, AB000462, Z68279, AC006540, AC005670, AP000348, AL049590, AC005619, Z73967, AC005800, AC007279, AC008273, AC002312, AC007207, AC006251, AL021808, AC005829, AF008915, AP000312, Z74617, and U73644.
HRDAB18	328	509019	1 - 263	15 - 277	AA372168.
HRDAB60	329	509428	1 - 323	15 - 337	AA372225, AA514809, AA501943, and AC008082.
HRDAF07	330	954331	1 - 317	15 - 331	
HRDAF69	331	956269	1 - 212	15 - 226	AL022320.
HRDAF90	332	531026	1 - 311	15 - 325	AB020878.

HRDAH91	333	525525	1 - 305	15 - 319	
HRDBA76	334	534304	1 - 337	15 - 351	Z98304.
HRDBC02	335	921144	1 - 599	15 - 613	AA372229.
HRDBC30	336	530858	1 - 235	15 - 249	
HRDBC52	337	867169	1 - 299	15 - 313	
HRDBD35	338	525526	1 - 367	15 - 381	
HRDBE07	339	954289	1 - 356	15 - 370	
HRDBE18	340	956267	1 - 466	15 - 480	AA253263, AA973971, and T88817.
HRDBE19	341	534495	1 - 381	15 - 395	
HRDBE41	342	530856	1 - 370	15 - 384	AB023049, AC006138, and AP000513.
HRDBG59	343	507381	1 - 300	15 - 314	
HRDBI81	344	932761	1 - 303	15 - 317	
HRDBI28	345	925457	1 - 336	15 - 350	
HRDBK03	346	925460	1 - 356	15 - 370	AI694154, N58235, T40838, T40853, AA485402, AI521019, AI761393, AW068580, AI620266, C15362, AI018726, AA584493, AA324088, AA326330, T47138, AA487415, AI872229, AA614647, AA487296, AA584183, AA487209, AA558404, AI955360, R94909, R84335, H94979, AA626840, AA514450, AI243793, AI538491, AI270647, AI744933, R76565, AL039761, AA167179, AL034417, AB017602, AC005697, Z93023, AL121694, AC005874, AF134471, AC007151, AC004750, AC005568, AL034555, AP000144, AC004983, AL031668, Z30952, U07561, AC004798, Z82214, AC004988, AC005206, AC008015, AL031662, AC005667, AC005288, AC005803, AC004067, AF112441, U63721, U52112, AL109628, AC001531, AC007566, AL008718, AP000555, Z98052, AL121603, AL109967, U70984, AL109623, AC003051, AC008273, AL031053, Y11493, AC007225, AC006277, AL031388, AP000689, AL033521, AC006120, X15943, AC005514, Z97876, AF141309, Z83840, AC005231, AL022330, AC007227, AC005600, AL031667, AC004478, AC005822, AC005768, AC003690, AC005316, AC005343, AL049697, AC005317, AC005406, AC005940, AC007993, AF031076, AC005775, U89337, AF031078, AF030876, AC002477, AC003665, U52111, AL096791, AC005736, AL021394, AC004149, AC005480, AF196970, AL133448, AL022401, AC004477, AC005755, AL050348, AL021578, AC005799, Z83844, AC002991, Z97635, AC004973, AL009051, AF196972, L78810, AC005146, AC005036, Z97054, AC005529, AL034420, AC002091, AL031597, AC006388, AC004953, AL031432, AC006948, AC006449, AI003147, AC005412, AP000493, AC003036, Z93016,

HRDBL61	347	575229	1 - 336	15 - 350	AC003002, AC005694, AL021707, AC007541, Z68192, AL022311, AC006130, AF015416, AC003661, AC005193, AC005184, AC007738, AC005919, AL080243, AC002364, AC006132, AC004414, AC004167, AF107885, AP000277, AC004034, AC004651, AC006293, AF184110, and AC004922.
HRDBL75	348	524423	1 - 254	15 - 268	AW139046.
HRDBM42	349	530849	1 - 361	15 - 375	
HRDBQ18	350	954274	1 - 380	15 - 394	U53331.
HRDBQ38	351	533939	1 - 310	15 - 324	AA513046.
HRDBQ64	352	879705	1 - 478	15 - 492	AL079303, AL133355, M15366, U91323, AL049569, AF217403, AF165124, AC006111, Z84488, and AC006241.
HRDBQ82	353	533947	1 - 401	15 - 415	
HRDBR04	354	927900	1 - 340	15 - 354	
HRDBR35	355	867167	1 - 303	15 - 317	
HRDBI72	356	507847	1 - 340	15 - 354	
HRDBU70	357	971700	1 - 75	15 - 89	AL049745.
HRDCA61	358	921128	1 - 442	15 - 456	
HRDCB18	359	968554	1 - 336	15 - 350	
HRDCD12	360	921796	1 - 419	15 - 433	
HRDDF49	361	867159	1 - 121	15 - 135	
HRDDF95	362	967837	1 - 434	15 - 448	
HRDDH84	363	867156	1 - 470	15 - 484	AA287503.
HRDDN54	364	932764	1 - 301	15 - 315	AC004853.
HRDDN90	365	531117	1 - 310	15 - 324	AF015262, and AJ229043.
HRDDY26	366	526783	1 - 153	15 - 167	
HRDDY73	367	574336	1 - 439	15 - 453	
HRDDZ76	368	574324	1 - 113	15 - 127	AC002210, and AC004227.
HRDEB78	369	526861	1 - 284	15 - 298	
HRDEC91	370	747169	1 - 627	15 - 641	
HRDED92	371	936045	1 - 296	15 - 310	AL139054.
HRDEG76	372	574326	1 - 310	15 - 324	
HRDEJ76	373	574335	1 - 152	15 - 166	
HRDEK44	374	574380	1 - 210	15 - 224	
HRDEL91	375	790374	1 - 204	15 - 218	T84539, AI858864, AL034553, Z85986, AC005288, L78833, AL049576, AL021707.

					AC007919, AL133163, AP000694, AL109799, AC005049, Y10196, AC003007, AL049839, AC005057, Z81308, AL023553, AL122020, AL049757, AC005632, U62293, AL031281, AL022163, AP000509, AC006530, AC006468, AC005253, AC006449, AL035088, AP000692, AC003663, AC004126, AC004526, AP000044, AP000112, AC005581, AP000023, AJ246003, AC005231, AC002301, AC006112, Z82178, AL031681, AC005746, AC005722, AC002431, AL121603, AC012627, AC006285, AC003101, AC007052, and AC005081.
HRDEO12	376	867140	1 - 279	15 - 293	AA745407, T52786, AA757869, AA320095, AA779599, AA508103, AA302763, F07564, AA745388, AW440424, AA366676, AI002863, AA424249, AA112791, AA084148, AA713720, AA083850, AA993165, AA339592, AA351808, AA362440, AA508882, AA496309, AA856815, AA230075, AA347203, AA496941, AA336058, AA744063, M86139, AI940546, AA015948, AI929418, AI929460, AA454504, H27788, AA748840, AI032411, AA768079, AI701898, AA010265, AA372231, AW028376, AI345256, T31290, AI571094, AA629939, X84712, AA372389, AA383937, AA297496, AA085372, AI337065, AA349923, AA736488, AA368329, AI445338, AW407007, AA744018, AA579044, AA557727, AA364006, AW377912, AA084950, AA338216, AW157128, AA812542, H87818, AL109801, AL133243, Z98036, AC007283, AL031767, AC004895, AL035658, AL034429, AF001548, AL132777, AC004893, AC004491, AL031283, AC006509, AC007688, AL021546, AF047825, AC007157, AL035454, AC005670, AC006088, AL049830, AC002425, U07561, AC005971, M63796, AC003043, AL049538, Z83844, AC012085, AC006312, AP000501, AC004158, AC004019, AC005330, AC004985, AL022336, AC007240, AC009247, AC004967, AL021453, Z82176, AL135960, AJ131016, AC007052, AP000349, AB008681, AC006946, AC004000, AC006148, AP000032, AC006101, AC005231, AC006006, AC004223, AL022316, U62293, Z82206, AL031295, AL031589, AC008928, AF064857, AF165926, AL117258, AC005057, AF134726, AL023775, Z82244, AL035455, AC006130, AL121934, AL117391, Z84480, AL034582, AC005516, AC009501, AC002126, AC005740, AL031657, AC005015, L05367, AD001527, AC005500, AC004815, AC005081, AC000159, AL031650, AC005940, Z95152, AC007367, AL049539, AF207550, AC004520, Z95889, AC007541, AC005786, AP000047, AL109628, U02057, AC007686, AL049764, AC003690, AL022721, AC004098, AC005871, AL049760, AC006084, AC005482, AC005581, AF001549, AC006441, AL031121, AF111168, Z70281, AC005599, AP000133, AP000211, AC006141, AL021808, AP000117, AC002350, AC004820, AL121658, Z99128, AC005778, AC004526, AP000500, AC004253,

HRDE076	377	952894	1 - 606	15 - 620	AC005060, AF111170, AB020868, AC004132, AC006511, AC006965, AL133448, AC003086, AL021394, AL031311, AC002369, AC004650, AL031291, U63721, AC004922, AL049569, AL031775, AC005565, AC011594, AP000050, AL049843, AL020997, AF042089, AL050348, AC004883, AL021392, AL008719, AL035696, AL024507, AL023880, AC006071, AP000269, AC006013, AL109952, AL031005, AC007243, AL033397, AP000555, AC005512, AC004914, AP000115, AC000070, AC004707, U89336, AC002395, AL121754, AL109963, AJ011930, AL035588, AC006162, AL117329, AC006063, U47924, AB014087, AC007917, AC008101, AC004084, AL008631, AF222684, Z97630, AL035249, AL080243, U81031, AC000028, Z93244, AP000116, AF129756, AL031433, AC005049, AC006505, AL049776, AC002314, AJ246003, AL080250, AC004856, AC002094, AC008009, AL096701, AL035457, AC016027, AP000103, AL096712, AL117330, AC005793, AC004188, AC006930, AL022163, AC016830, AC005484, AC004190, AC005531, AL022398, AC005914, AC007327, AF195658, AC004832, AL050341, AL035659, AL109956, AL031577, AC002470, AF124730, AC006360, AC005695, AL135744, and AC005235.
HRDE076	377	952894	1 - 606	15 - 620	
HRDEP31	378	766222	1 - 205	15 - 219	
HRDEP75	379	574431	1 - 366	15 - 380	
HRDEQ30	380	506774	1 - 314	15 - 328	AI051942.
HRDEQ96	381	507543	1 - 446	15 - 460	AA634654.
HRDES32	382	867115	1 - 340	15 - 354	
HRDES65	383	526823	1 - 395	15 - 409	
HRDET67	384	825182	1 - 333	15 - 347	
HRDET91	385	827084	1 - 426	15 - 440	
HRDEU33	386	572905	1 - 306	15 - 320	
HRDEU42	387	881296	1 - 323	15 - 337	
HRDEU43	388	765813	1 - 146	15 - 160	N95696, AA683130, N95587, N95562, and AL021368.
HRDEU61	389	575566	1 - 405	15 - 419	
HRDEU78	390	573031	1 - 321	15 - 335	AC004031.
HRDEU93	391	844316	1 - 449	15 - 463	R97129, and Z92544.
HRDEV13	392	574442	1 - 107	15 - 121	
HRDEW02	393	848793	1 - 319	15 - 333	R69655, AA504728, AW197426, AW239197, R61016, L44427, H09430, N98902, Z42694, AA432395, and AA337216.

HRDEW30	394	526812	1 - 482	15 - 496	Z68226:
HRDEW90	395	574288	1 - 415	15 - 429	AC003077.
HRDEY14	396	574438	1 - 485	15 - 499	AC009263.
HRDEZ06	397	936072	1 - 402	15 - 416	
HRDEZ54	398	867127	1 - 461	15 - 475	
HRDEZ60	399	919386	1 - 208	15 - 222	AI949774, AA493365, AI039944, AI332543, AW082899, AW157648, AA300420, AA706469, R88367, AI969957, and AI167160.
HRDEZ64	400	536668	1 - 66	15 - 80	
HRDEZ84	401	575553	1 - 474	15 - 488	
HRDFB47	402	508001	1 - 316	15 - 330	AI932599, AA486559, AW002350, AA719531, AI345418, Z18873, AI144101, AC005332, AC007546, AC004686, AL096791, AC007773, AC005736, AL022165, U50871, AL121655, AC002350, Z69838, AC002492, AC006064, AC004526, AL049759, AC005488, AL049636, AC005531, AC006449, AC008372, AC002992, AL031680, AC007308, AC005207, AC004033, AC003689, AC004797, AC005225, AC005081, AL035420, Z98743, AL020993, AC009247, AL049569, AC006285, AP000510, AL133246, AC002400, AL031291, AL109758, AC005412, AC004382, AC005829, AL022476, AJ229042, AC005632, AC006006, AC005703, AC016027, AC006581, AC016830, AL035413, AF129756, U91323, AC005324, AC005071, AC002395, AC004832, AL022326, AL049776, AC005015, D84394, AC004477, U80017, AP000086, AC002565, AL034548, AF015723, AL096701, AL049709, AC004821, AC004983, AC005037, AC005667, AP000117, AC009509, AL035683, AC007182, AC000353, U95742, AL049694, AL009183, AC007686, Z98884, Z84484, AC007216, U95090, AL049869, AC008018, AC005206, AC005104, Z97196, AL050307, AL133448, AC006121, AC006538, AC006160, AC005520, AC005924, AC004887, AC004087, AC008045, AC008119, AC004638, AC007435, AC002404, AL049539, AL133163, Z83822, AC000003, AL035086, AL117258, U07000, U93237, and AC002091.
HRDFB78	403	589478	1 - 402	15 - 416	Z78337, AW375353, U55777, T60176, AA364491, AI140371, AW393482, AW387144, AW402704, AA338532, and T30802.
HRDFC68	404	574205	1 - 384	15 - 398	Z94044.
HRDFE73	405	574142	1 - 322	15 - 336	
HRDFE74	406	765750	1 - 301	15 - 315	AI452477, AA526633, AC006211, AL031276, AC004893, AL096712, AC000025, AC003687, AL109760, and AC003101.
HRDFE42	407	953913	1 - 78	15 - 92	

HRDF62	408	574436	1 - 508	15 - 522	T77462.
HRDFG25	409	574433	1 - 332	15 - 346	
HRDFG37	410	792517	1 - 280	15 - 294	
HRDFG46	411	574439	1 - 365	15 - 379	
HRDFH14	412	575578	1 - 149	15 - 163	
HRDFH24	413	575245	1 - 423	15 - 437	<p>           AI284640, W00807, AI291124, R97934, AI471481, AI282832, AA862173,            AI245679, AA947811, AA362349, AA507547, AW265009, AI801600, AI889781,            AI357551, AA515224, AI439210, AA806796, AA828704, AA810370, AA348929,            AA775940, AW339568, F34498, AA557686, M86143, T07451, T05101, AA654771,            AI457397, AA593247, AI866908, AA584201, AA513293, AI358571, AI291268,            AI281697, AA678436, AA578861, AA213741, AA493708, AI298710, AA661948,            H86305, AA669840, AW089322, AA513141, AI049634, AA831375, AI564185,            AA554319, AI364809, AA525824, AI500454, HS1714, AA259245, AA713891,            AA491284, AI561255, AI046409, AA610611, AW327868, AW338086, AA603156,            AW103758, AI358343, AI499938, AA579075, AA348017, AA649722, AA346458,            AA492166, AA847985, AA908468, N25296, AI042853, T41242, AI904894,            AW265385, AA244357, AA502103, AA649542, AA649484, AA503283, AW168342,            AW193609, AI859251, F33121, AI888008, AA665330, AA426277, AW265699,            AI358501, AA630925, F04987, AA503284, AA25246, AI475569, AA916371,            D83989, M87919, X75335, S70707, U67827, U67829, M37547, AF077058, M37551,            X55923, AB023052, AC006203, AP000513, M87925, U14706, AC002536, Z94721,            AC002301, U73024, AC004821, AI031736, AF015151, AC006138, AI031685,            Y10196, AC005324, U14716, AF015156, U14713, AI133245, AL022238,            AL096707, AC005622, AC006292, AL035681, AC016830, AF018071, D87675,            D13624, AC007731, AI109984, AI078613, M19045, J03801, E01888, E02193,            AL022727, AC006449, AC006004, AI122003, AC002380, AP000141, AC004388,            AC007546, AB020863, S43650, AC007050, AC004263, AC005261, U07562,            AL132987, AC006274, AL021368, AC010175, L49046, Z68223, AR047856,            AC004687, AP001172, AF042090, AC004076, AC007064, AC007363, AF129756,            AC005900, AC005280, AC006057, AC008039, AC005682, AC008124, AP000326,            AP000353, AL021937, AC004853, AC002059, AI121934, AL022067, AC004151,            AP000054, AP000169, AP000359, AC000067, AC005940, Z68192, AL021154,            AC002480, Z69917, AI110172, AC002073, AI031729, AL022237, S75337, U14695,            AC006959, AC004858, AC000120, U14710, AL023656, AI117352, AC004408,            AL031281, AC005771, AC003688, AC002070, AI133371, AC006352, AL008709,         </p>

					AL035587, U91326, AL109612, AC006123, AL117258, AC005484, AL008629, AC005158, AC006079, AL035695, AL031123, AL080276, AC007450, AF109907, AP000122, AC007043, AC005563, X14008, AC004209, AC006001, AC010077, AC005703, AC004030, AC004901, AC004895, AC006998, D25272, U69569, AC006960, AL031224, AL117354, AP000517, Z92540, AL035496, AC005837, AC006285, AL049643, AC007536, AC009516, AC008115, AC007262, U14712, AC004638, AF132033, U95740, AC000086, AC006064, AP000349, AC004653, and AL035249.
HRDFH25	414	953882	1 - 370	15 - 384	
HRDFH39	415	574558	1 - 364	15 - 378	
HRDFH77	416	953673	1 - 422	15 - 436	
HRDFI13	417	574561	1 - 363	15 - 377	
HRDFJ71	418	574553	1 - 406	15 - 420	
HRDFK03	419	924925	1 - 464	15 - 478	AW410890, AL079806, and AB007931.
HRDFK41	420	867106	1 - 315	15 - 329	AI002928, AA804808, N55076, AA018258, AA804694, AC004983, AC004775, AC005225, AC005519, AL096791, AL031680, AC005291, AL022311, AC003072, AC004383, Z98949, AC006285, AL031602, AL021579, AL031985, AC005399, AP000113, AP000045, AL109623, Z84469, AC005755, AC007421, AC002395, AL022316, AP000555, AC002477, AF045555, Z94801, U66532, Z97056, AC007021, AL096701, AC005914, U95741, AL022238, AL049759, AC005696, AC005666, AC007225, AC004884, AF109907, AC016025, Y11107, AL008710, M26434, U47924, AC006388, Y14768, AP001054, AC005081, AF064861, AC005218, AF001548, AC009225, AC005730, AC006367, AC006101, AC005940, AC009509, AC005632, AL008718, AC004975, AC007283, and AC006362.
HRDFM18	421	574435	1 - 108	15 - 122	
HRDFN95	422	574565	1 - 116	15 - 130	
HRDFO64	423	733847	1 - 256	15 - 270	AA832055, AA077542, AA770651, AC004987, and AL133216.
HRDFQ75	424	525524	1 - 240	15 - 254	AL132987.
HRDFT06	425	867109	1 - 389	15 - 403	
HRDFT15	426	574549	1 - 415	15 - 429	
HRDFT45	427	506584	1 - 530	15 - 544	AC004142.
HRDFT84	428	584823	1 - 445	15 - 459	AA309894, AB009022, AB012143, AB012142, AF025654, AF034568, AF025653, AB009023, and AB009024.
HRDFU48	429	573030	1 - 301	15 - 315	

HSAX53	430	518795	1 - 302	15 - 316	
HSBHV66	431	523348	1 - 323	15 - 337	
HSBHV67	432	529483	1 - 308	15 - 322	AC007536, and Z97832.
HSBCE34	433	529313	1 - 214	15 - 228	AL035415.
HSKCS36	434	529163	1 - 233	15 - 247	
HSKCT33	435	866514	1 - 297	15 - 311	
HSKDA70	436	757183	1 - 599	15 - 613	W49690, AA284238, W49689, AI950805, AI085909, AI457351, AI866940, AW013806, AI246901, AW051765, AI739482, AA394133, AI380566, AI921768, AI827273, AI860590, AW009629, AI768051, AI392972, W45591, W45590, AI022944, and AB017614.
HSKDI16	437	661928	1 - 330	15 - 344	AL049464.
HSKEF43	438	866410	1 - 301	15 - 315	
HSKEK63	439	744336	1 - 376	15 - 390	AA372904, C16438, AW380254, AW168420, AA534258, AI674174, AA372949, T39494, AC005331, AC006013, AL022311, AC004827, Z99570, AL020997, AJ010770, Z93023, AC005746, AP000505, AC006007, AC007546, Z75741, AC002563, AL024498, AL021546, AC007845, AC002398, Z94722, AC004815, AC004703, AL133404, AC004526, Y14768, AC005482, AC005200, AC005039, AC002319, AL021451, AC004099, AC004884, AC008119, AC005324, Z95152, M29929, AC007877, AC006112, AF129756, AC003101, AF107885, AL031320, U82828, AF007136, AC004976, Z69666, AL031668, AC004953, AC006965, AF196779, AF064751, AC005355, AC004702, Z81314, AC002541, Z69388, U91318, L47234, AC008273, AP000690, AC004152, AF002997, AL031117, AC009784, AF111169, AC004106, AL109628, AC004148, AC004253, U07562, and AP000318.
HSKEM02	440	969071	1 - 426	15 - 440	AA143157, AA063324, N57369, W81341, and AL133355.
HSKET11	441	967000	1 - 414	15 - 428	
HSKH11	442	965002	1 - 433	15 - 447	Z98046.
HSKHS71	443	911592	1 - 367	15 - 381	
HSKIT38	444	855173	1 - 369	15 - 383	
HSKJS05	445	930979	1 - 64	15 - 78	AA731590.
HSKKD70	446	916984	1 - 563	15 - 577	
HSKKL06	447	934040	1 - 646	15 - 660	
HSKNO53	448	728210	1 - 521	15 - 535	AW275953.
HSKWA56	449	916496	1 - 423	15 - 437	
HSKWA78	450	731756	1 - 516	15 - 530	

HSKWA79	451	73394	1 - 488	15 - 502	W90331, AA398850, and AA435854.
HSKXG06	452	935455	1 - 312	15 - 326	
HSKXJ15	453	866373	1 - 437	15 - 451	AL117340.
HSKXN20	454	668928	1 - 290	15 - 304	AI610572, AA494027, AW089962, AW020620, AW021195, AP000703, Y10196, AC004079, AL080243, AP000702, AC005067, AC005874, AF134471, AC006453, AL031255, AL031733, AL049767, AC007450, AC005089, Z83836, U95090, AP000347, AC005803, AP000352, AC002381, Z98048, AL033397, AC005777, AC005265, AC005696, Z98200, AL024507, and AC002117.
HSKXP58	455	955073	1 - 352	15 - 366	AA372956, AL031737, AP000553, AC004491, Z83826, AL050318, L78810, AC005484, AC007685, AL078602, AC005667, AC007298, AF049895, AC004699, and AC005206.
HSKXQ58	456	736045	1 - 376	15 - 390	AI810143, AI799021, AI347650, AW020141, AA143516, AA551503, H56729, N29948, N54304, AA601919, AA079101, AW089810, H79394, AW402170, AI580898, AL031257, AL022719, AL021808, AC008123, AC003007, AC005632, D86864, AC005776, AC005539, AC005262, AL022315, AP000126, AP000204, AC005252, AP000556, AP000244, AP000557, AC007050, AC007308, X89398, AL031280, AC007637, AF087913, AC005251, AP000150, AP000009, AC006016, D28877, AC005071, AC004019, AC006137, AL031386, and AC003684.
HSKYG66	457	698007	1 - 333	15 - 347	AI209100.
HSKYH52	458	466574	1 - 419	15 - 433	
HSKYJ96	459	921032	1 - 346	15 - 360	
HSKZE12	460	970639	1 - 104	15 - 118	
HSKZE32	461	959400	1 - 273	15 - 287	AA464651, H60107, AA419210, R11432, AW151815, and AC006254.
HSLAB77	462	772652	1 - 301	15 - 315	AC007392.
HSLBO30	463	574086	1 - 198	15 - 212	
HSLBW19	464	671738	1 - 212	15 - 226	
HSLBX08	465	959911	1 - 257	15 - 271	Z95152.
HSLBX20	466	574004	1 - 422	15 - 436	AC005922.
HSLBZ91	467	573987	1 - 281	15 - 295	
HSLCB15	468	693455	1 - 619	15 - 633	H24866, AA031368, W47079, W46779, H84840, N30984, W32033, AA018530, H26464, N40269, AA459816, AA296636, AI751106, W19406, R24391, R21973, AA370945, AW366386, AA374691, N40640, H39859, AA296525, AA446165, AW377667, AA322178, AI366199, N28622, AW367978, AA382270, T85743, AA337106, AI684270, AW367975, R57416, Z92846, and AF125535.

HSLC146	469	529622	1 - 265	15 - 279	AL096677.
HSLC147	470	908627	1 - 352	15 - 366	
HSLC138	471	951028	1 - 232	15 - 246	
HSLCP75	472	529631	1 - 340	15 - 354	E08867.
HSLCV95	473	793080	1 - 315	15 - 329	
HSLDA25	474	679301	1 - 370	15 - 384	
HSLDB29	475	866340	1 - 424	15 - 438	
HSLDC06	476	936010	1 - 259	15 - 273	AI672480..
HSLDG13	477	913664	1 - 325	15 - 339	
HSLDI16	478	574014	1 - 202	15 - 216	
HSLDI24	479	574050	1 - 349	15 - 363	I09483, I09484, and I09485.
HSLDI94	480	753657	1 - 447	15 - 461	
HSLDK43	481	675440	1 - 521	15 - 535	
HSLDM32	482	699486	1 - 299	15 - 313	
HSLDM79	483	526740	1 - 335	15 - 349	
HSLDP16	484	573210	1 - 433	15 - 447	
HSLDW65	485	689722	1 - 416	15 - 430	
HSLB25	486	669654	1 - 389	15 - 403	
HSLC25	487	572859	1 - 400	15 - 414	
HSLC36	488	936003	1 - 365	15 - 379	
HSLD38	489	709381	1 - 506	15 - 520	
HSLD42	490	572860	1 - 375	15 - 389	
HSLD46	491	572878	1 - 322	15 - 336	
HSLF89	492	572883	1 - 346	15 - 360	
HSLG74	493	825500	1 - 385	15 - 399	AI526055.
HSLH57	494	584090	1 - 130	15 - 144	F07221, AA307815, N99978, AI660617, AI906507, AW166174, W30916, AA877685, AI692837, and AA434201.
HSLEI22	495	572863	1 - 304	15 - 318	
HSLEI46	496	573212	1 - 275	15 - 289	
HSLEO70	497	841952	1 - 354	15 - 368	AL048938, AW385766, AA417805, AA134623, AW239566, AA075905, AA167826, AA134649, AA375645, AW005427, and AI424382.
HSLEF34	498	706986	1 - 396	15 - 410	
HSLEF91	499	572885	1 - 413	15 - 427	AI095822, AI827514, AA909148, AI635994, AI339613, AI242071, and AI343397.
HSLFM86	500	785489	1 - 427	15 - 441	

HSLFS42	501	948740	1 - 287	15 - 301	
HSLFS45	502	717782	1 - 360	15 - 374	
HSLFT76	503	725788	1 - 382	15 - 396	
HSLFT89	504	786061	1 - 378	15 - 392	
HSLFU01	505	916448	1 - 404	15 - 418	
HSLGD23	506	675872	1 - 436	15 - 450	
HSLGH26	507	681705	1 - 426	15 - 440	
HSLGK79	508	774049	1 - 377	15 - 391	
HSLGV91	509	780005	1 - 428	15 - 442	
HSLGX20	510	669648	1 - 424	15 - 438	
HSLHA55	511	866273	1 - 392	15 - 406	AI699746, AI869424, AA484365, AA015948, AA788575, AI003051, AA598608, AA814719, AA463832, AA243128, AI798714, AA015753, AW148821, AI002786, AI383589, W21030, AA665411, AI000381, AI445699, AA846014, AA493245, AI791664, AA455804, AI702049, AL138262, AW192930, AI734158, AA455202, AL121039, AI734193, AW410844, AI064968, AA653228, D25266, AL038971, AA584738, AI167784, AA226133, AI800445, AA300049, AI016729, AW265468, AW085626, Z97206, AL022147, Z97181, AC007842, Z84480, AF053356, AF006501, AL031622, Z97056, AL031587, AL031117, AC007371, AL109628, AL024507, AC005399, AC005409, U82672, AC005565, AC007151, AC007676, AC004914, Z86090, X69907, D87008, AC000040, AJ250235, AC004663, D88268, AL096757, Z83851, AC005914, AC007690, AC007541, AL117329, AC005375, AC004067, AC005531, AC006198, AC005772, AC008040, AF053139, M94634, AC005368, AF111169, AC005345, AC000387, AC006006, L47222, AC006261, AC005808, AL035079, AC004020, AC002456, AL121595, AC005391, AC005379, AL035400, AL021937, AC004785, AJ010598, AC006285, AC009336, AL050333, AC004815, AF064865, AC004832, AC005060, D83402, Z69650, AP000227, AC002120, Z49918, Z68277, AC005256, AC006138, Z15025, AC002106, AC007565, AC005214, AC007536, AL022144, AF038458, AF190465, AP000087, AP000513, AL008731, AL020993, AC005033, AC007899, AC005277, AF064866, AB023049, Z98950, AC006509, AP000689, AC005844, AL021578, AL031311, and AL079342.
HSLHC22	512	673918	1 - 440	15 - 454	R64409.
HSLHP20	513	669210	1 - 418	15 - 432	
HSLIA21	514	668116	1 - 388	15 - 402	

HSLIG54	515	713982	1 - 382	15 - 396		
HSLIJ61	516	918071	1 - 458	15 - 472		W19840, R50853, AA482385, T72743, H21057, T72748, R10320, and W01711.
HSLIJ57	517	659533	1 - 377	15 - 391		
HSLJB11	518	966227	1 - 131	15 - 145		Z83844.
HSLJJ21	519	670330	1 - 329	15 - 343		A40155, and A40156.
HSLJJ83	520	727874	1 - 295	15 - 309		AC007193.
HSLJK88	521	923108	1 - 203	15 - 217		A1914865, AW377768, AA767396, AA975495, AA972715, A1991550, AL132776, and AB018319.
HSLJN31	522	750394	1 - 337	15 - 351		
HSLJN49	523	920062	1 - 448	15 - 462		
HSLJN61	524	966267	1 - 485	15 - 499		A1014258, and D89677.
HSLJN71	525	759941	1 - 335	15 - 349		
HSLJQ31	526	961447	1 - 427	15 - 441		H02450, R32623, AA349144, R11455, R27382, AA599094, N31153, N25174, N35733, H12488, AA082514, W60949, R06834, N26982, H04870, AW361043, and AB020685.
HSLJW53	527	866261	1 - 240	15 - 254		AA872180, AW304637, A1927741, R14941, T80162, AA702988, AA226346, AA134007, A1216978, A1358513, AA634227, A1151261, A1826253, AA662431, AA766883, AW028950, AA838162, AA297145, AA706845, T87973, AC006211, AL078639, AP001137, AP000325, AP000168, AP000054, AP000122, AC006344, AF196969, AL080239, AF110527, L78833, AC004876, AD000092, AL117330, AC004859, AL022476, AC004833, AC005476, Z83840, AC006441, AC006581, Z58851, AC005233, AC004057, AL035398, AC002365, AC003046, AC007371, AC007537, AL049776, AL022318, AC007868, AC005089, AC002400, AC007551, AC002470, AC007308, AF141325, AL121593, AC007377, M55523, AC004522, AC004817, AC007263, AC008498, AC005914, AL034420, AC004858, AC002476, AF109907, and D87675.
HSLKC70	528	866256	1 - 410	15 - 424		
HSRAX95	529	747078	1 - 311	15 - 325		Z68164.
HSRBE02	530	921205	1 - 341	15 - 355		W79904, R73478, H42289, and AL137459.
HSRDE58	531	519542	1 - 208	15 - 222		AC000378.
HSRD139	532	921749	1 - 381	15 - 395		AL117454.
HSRD168	533	530333	1 - 244	15 - 258		AL080190.
HSRDK92	534	838033	1 - 209	15 - 223		AF095719.
HSRDL32	535	530294	1 - 261	15 - 275		AL045354.

HSRDM42	536	523843	1 - 136	15 - 150	
HSRDN23	537	530334	1 - 200	15 - 214	AC005703.
HSRDQ89	538	780221	1 - 178	15 - 192	
HSRDS77	539	530289	1 - 230	15 - 244	AC000026, and AC002059.
HSREB43	540	524678	1 - 272	15 - 286	
HSREC27	541	753810	1 - 296	15 - 310	
HSRED45	542	530233	1 - 327	15 - 341	
HSREG25	543	523815	1 - 347	15 - 361	
HSREG40	544	712779	1 - 534	15 - 548	AI032560, AI040579, AI040370, AA702902, and AI685149.
HSREG49	545	723267	1 - 206	15 - 220	
HSRFC96	546	558385	1 - 279	15 - 293	AL109852, Z93403, AL035468, Z95124, AC008041, AL035552, AL135783, AC007736, and AL008709.
HSRFD34	547	575288	1 - 139	15 - 153	AA088873, AI079088, AI160732, AI381253, AW162324, AI992192, AI358948, AI933299, Z92910, AR036572, U91328, AC005393, AL035462, AC004890, AC005366, AC002509, AC007227, and AC010200.
HSRFD47	548	973782	1 - 428	15 - 442	AC004386, AC002418, and Z83843.
HSRFE58	549	556519	1 - 334	15 - 348	AC007198, and AC005280.
HSRFF03	550	925369	1 - 130	15 - 144	
HSRFG30	551	920265	1 - 286	15 - 300	
HSRFR21	552	529767	1 - 229	15 - 243	
HSRFZ71	553	557976	1 - 304	15 - 318	
HSRGA32	554	529726	1 - 306	15 - 320	AW192199, AL133312, AC005683, and AF172277.
HSRGB23	555	974538	1 - 413	15 - 427	AI207415.
HSRGE47	556	974539	1 - 327	15 - 341	
HSRGG66	557	556518	1 - 169	15 - 183	AC007198, and AC005280.
HSRGGK48	558	535012	1 - 110	15 - 124	AA373481, and AL134562.
HSRGQ30	559	534479	1 - 407	15 - 421	AI493261.
HSRGS08	560	960211	1 - 299	15 - 313	
HSRGV79	561	921005	1 - 356	15 - 370	
HSRGW30	562	529624	1 - 296	15 - 310	
HSRGZ32	563	699561	1 - 348	15 - 362	AI963683, and AI742748.
HSRHA45	564	974551	1 - 391	15 - 405	AL049871.
HSSAE47	565	720685	1 - 337	15 - 351	AA377682.
HSSAF46	566	508117	1 - 341	15 - 355	

HSSAN96	567	936108	1 - 239	15 - 253	AA378117, AL048143, and AA378114.
HSSAP44	568	508831	1 - 374	15 - 388	AA378135, and AA378220.
HSSAV18	569	508832	1 - 186	15 - 200	AA378151.
HSSAV88	570	508829	1 - 375	15 - 389	
HSSBO48	571	871217	1 - 357	15 - 371	
HSSBO59	572	707683	1 - 396	15 - 410	AA632960, H82330, R13151, AA528455, AL045709, AA657416, AA658320, AI150670, AA721615, AA077776, AI564508, AA652057, AA640979, F17700, AW407919, AA437402, AA487542, AA302732, AA516207, D58782, AA298387, AA125788, AA482896, F37052, AA775049, AA581914, AI446474, AI284595, AI014378, AI888405, T47460, AA362395, AA298386, AA743137, AA491484, AA809189, AI862716, AA483655, AW271904, AI679713, AA878140, AA569187, AI292236, AA663306, AW265654, AA720732, AA642053, N69462, AI165462, AL119025, AA448838, AI628224, AI493264, N45421, H55894, AA572960, H65439, AA371409, T48872, AA365744, AI524540, AW075979, AW103383, AA599495, AI473701, AI279759, AI471572, AA425922, AI627581, AA558344, AW440633, AI540107, AI803827, T03203, AA443426, AI609223, AA577732, AI460390, AW339622, AI754291, H65440, AW268277, AA493885, F26719, AI251111, AI184226, AW407340, AI114752, N38789, AA747472, AA848143, AL120976, AW117976, AA100884, AA654627, AA704643, AL037910, AW021917, AA127916, AW189353, AA507991, AI597832, AA283083, AI634323, H94289, AL041083, F33511, AI863399, AA167741, AA468051, AA228283, AA745560, AI832000, AI689019, F37223, AA632845, AA501418, AW192330, AI978792, R23352, AA831388, AA968509, AA192695, AI623563, AI270476, AI872503, AA311071, AW167154, AI253797, T94094, AW079809, AI859834, AA516225, R26134, AA515937, D56402, AW419081, AI473684, AA655005, AI754037, AI114477, AA569202, AA626829, AA467988, AI366982, AA58003, R32200, AI042342, H53562, AA579278, C06137, AI859280, AI889921, Z96050, AC004201, AC009510, Z82176, U97046, Z96568, AL109798, AL020990, Z95331, AC004902, AL033527, AC003991, AC006239, AC003042, AL023806, AC006450, AC006363, AC002065, AL121603, AL008710, AL079339, AL035454, AC005378, AL080286, AC005180, AC006372, AC005037, AF043105, AL022397, AC006006, AC005546, AC007358, AC002381, AC004643, AL024509, Z98743, M63543, M63544, AC006578, AC003098, AC006251, AC000083, U89337, AF059675, AP000500, U73167, U90094, Z73420, AL009031, Z84484, AC002326, AL009029, AC005011, AJ003147, AL031003, Z84469, AC005562, AF020503, M87918, AL021397, AC003101,

					AP000518, M87914, Z70289, AL110114, AL078639, U62317, AC002996, AC004531, AR036572, Z99572, AF019413, AL049766, AL117344, AC004816, AP000306, AB023054, Z69648, AC002550, AC004972, U63313, AC005095, AC003954, AF039401, AC002316, AC004703, AL023574, U95742, AC007216, AF001549, AL008725, AC005954, AC003051, AC008163, AC005701, D32202, AL035685, Z68224, Z82172, AL121915, AP000289, Z85994, AP000042, AP000110, AL031005, AL031447, AC009069, AC005618, AC005823, AC009498, AC005859, AF097026, AL096678, AC005664, Z69647, AC004851, AC005755, AL020993, AF196969, AC005914, U95740, U91326, AC007385, AC002504, AC004231, AC002365, AL049759, AC004024, AC002045, AC002039, AL022394, AL049553, AC005881, AC006443, AC009330, AC004762, AL096803, Z83838, AL109654, AC008498, Z92546, AC004887, AC005578, AF053356, AP000122, AF016052, Z69652, AL033543, AL035400, AL031055, AC002347, AL020997, AC005081, AL049761, AF067574, D87005, D88269, AL121587, AL049697, AL031655, AC005874, AF134471, AC000097, AC005372, AC004859, AC006547, AP000353, Y11312, L29766, AF190631, Z82097, AC004776, AL008635, AL022160, AC005921, AC005740, AC004253, AC007263, AC004834, AC004448, AC008124, AC005261, AC007327, AP000047, AC004051, AF039954, AB018249, AC005354, AC005339, AC004140, AP000093, AC004996, AL031775, AC004675, AL022576, AF047825, AP000237, AF107258, AP000473, AL133448, AL022328, AF088219, AC008125, AL133445, AC005291, AF052684, AC005971, AC006953, AC004409, AP000251, AC006985, AC004656, Z99755, AP000134, AP000212, AP000030, AB020871, AL033524, Z99128, AL050307, AC007628, AB020868, AC005411, AC006960, AC006111, AC008040, AL049776, AC004596, AL022400, Z93020, AC004152, AC004186, U07562, AC004694, AC007382, and AP000207.
HSSCC04	573	928001	1 - 119	15 - 133	
HSSDJ02	574	871226	1 - 348	15 - 362	
HSSDL20	575	667599	1 - 159	15 - 173	
HSSDL94	576	526758	1 - 285	15 - 299	
HSSDR63	577	537329	1 - 213	15 - 227	
HSSDX20	578	783128	1 - 113	15 - 127	
HSSD56	579	625572	1 - 358	15 - 372	
HSSDF29	580	689837	1 - 389	15 - 403	
HSSDK75	581	766507	1 - 166	15 - 180	
HSSDU91	582	766573	1 - 163	15 - 177	

HSSEU93	583	911261	1 - 358	15 - 372		A1961823, AW166279, Y17108, and Z92544.
HSSEV89	584	572851	1 - 296	15 - 310		
HSSFF80	585	753589	1 - 285	15 - 299		
HSSFQ43	586	715318	1 - 405	15 - 419		AC007367.
HSSFR41	587	707006	1 - 346	15 - 360		
HSSFX54	588	708845	1 - 429	15 - 443		T71424, R18371, and Z43782.
HSSGC65	589	955064	1 - 391	15 - 405		A1982519, AL042376, AL042377, A1361890, A1200168, A1656939, AC000385, AF061779, AC004923, and U73627.
HSSGC66	590	319740	1 - 231	15 - 245		
HSSGC72	591	760648	1 - 141	15 - 155		
HSSGD37	592	739505	1 - 308	15 - 322		AL049569.
HSSGH47	593	720367	1 - 355	15 - 369		
HSSGI20	594	668919	1 - 328	15 - 342		Z81364.
HSSGI75	595	767325	1 - 333	15 - 347		
HSSGI91	596	789411	1 - 338	15 - 352		AP000348, and AP000347.
HSSGK96	597	960636	1 - 378	15 - 392		AA378503.
HSSGL55	598	766115	1 - 599	15 - 613		W74502, AA602391, A1420864, AW249723, A166500, AA076659, AA947286, AW148931, AA523509, N59225, C14268, A1367349, A1421445, A1936982, A1769470, A1368200, A1419527, N98776, A1684498, A1572122, AW206959, A1634762, W49625, N34422, A1217398, W31030, AA725340, A1081813, AW373882, A1672387, AA641497, A1337000, AA478173, A1766926, A1365401, A1813446, A1608807, A1382536, A1950175, A1382559, AA827390, AW183593, A1420810, AA309806, A1565511, A1362447, AA478017, AA773507, T11147, C14269, A1738446, A1800023, A1242987, AA639592, A1399691, AA659150, AA371822, A1243140, AA631086, A1659508, A1927588, A1651868, A1699620, AA335673, A1805041, AA336127, W48799, AA335414, N76692, A1916893, A1468167, AA335239, AW206563, A1873196, AW137813, AW451053, AW137008, A1823968, H16597, AW006577, AW006554, N71461, A1401174, W79098, D19946, and A1541353.
HSSGL78	599	788924	1 - 376	15 - 390		R83708, AA515728, D44639, AL041894, AL038842, AA515138, A1762528, AA158759, AA452887, A1421257, AA581247, AA516320, A1792529, AA502991, AA630535, C14858, A1801701, H70108, AA182731, A1054193, AA773098, AC005841, AC005071, AF001550, AC007536, A1133448, AC007041, AL020997, U95739, AL034429, AL096701, AC005005, AC006597, AC002126, A1008635,

				AL109628, AC006121, AC004953, AC002301, AP000208, AP000130, AP000247, AC005324, AC005874, AF134471, AC004797, AC002404, AC007225, AF001549, AC005921, AC005919, Z85987, AC005261, AL049776, AC005740, AC007637, AC007298, AC003692, AC006130, AP000557, AF111167, AL133246, AC005102, AC004659, AC004882, AL109801, AC007537, AC005527, AC007114, AC004975, AC005529, AL049795, AF111163, AL096712, AC006312, AC006449, AL031680, AC002314, AC006942, AC000353, AC007664, AC005231, AL034420, AC002302, AL031295, AC005899, AL035209, AC000025, AC005488, Z95331, AC002472, AC002477, AP000704, AC006285, AC005351, AC002350, AC005828, AC008018, AF001548, AL096761, AL109623, L44140, AC005520, AC005920, AC002470, AF017104, AC005821, AC016025, AC007283, AC016831, AJ003147, Z98200, AC005086, AC004386, AC005220, AL022327, AL109984, AC006530, AC007546, AC004477, AC006511, AC004000, AL121754, AC004985, AC007040, AL035587, AC004534, AC007263, AL049843, AD000671, Z83844, AL117329, AC004019, Z95114, AF196779, AF134726, AC003043, Z93023, AC002288, AL021578, AC000134, AL132712, AC004999, AP000211, AP000133, AC005881, AL033521, AC005049, AL109758, AC005722, AC010209, AC005632, AC005531, AP000193, AF104455, AC004259, AL031228, AC004032, AP000050, AC005695, AL035422, AC005726, AC004600, AP000555, AP000117, D87675, AC004813, AL031737, AC007050, AC004851, AC005082, Z99943, AL024498, AC005332, AL049759, U29953, U96629, AL031577, AC009516, AL034548, AL021707, AL023284, AL023575, AC003037, AL022302, AC005697, Z99716, AC002425, AL050321, AL118497, AL133353, AF196970, AP000346, AC005300, Z95113, AL031005, Z83840, AC005624, AC004791, AC004149, AC006487, Z98044, AC006050, AL122021, AP001052, AC002310, AC002390, AL031681, AC004990, AC005088, AC006455, AC005081, AL022326, AC006203, AC002045, AL034351, AC005338, Z81314, Z84469, AP000248, AL021391, U91323, AL034553, AC002544, AL050312, AP000212, AP000134, AL031282, AC008015, AC004020, AL049569, AC007421, AL122126, AC007388, AC006080, Z93930, AC005067, AC007226, AC004099, AL139054, and AC005179.	
HSSGM62	600	707685	1 - 397	15 - 411	
HSSGN47	601	707003	1 - 324	15 - 338	AI076644, AI951987, AA969026, AD000671, AF186605, and AJ007041.
HSSHA92	602	792714	1 - 396	15 - 410	
HSSJN44	603	716573	1 - 428	15 - 442	AL139054.
HSSJN49	604	708841	1 - 331	15 - 345	

HSSJU66	605	653212	1 - 248	15 - 262	AW241370.
HSSJU60	606	970749	1 - 417	15 - 431	AA972086, and AW241953.
HSSKB40	607	711130	1 - 558	15 - 572	R78078, AI672012, AI291253, AW438453, Z83844, AI139054, AL008715, Z85996, AL035072, AL035695, AF218772, AC006056, AC006508, AF037046, AF146793, AF034692, AL118503, U31796, AF019657, AC006584, AF092084, and U31316.
HSSMT78	608	712468	1 - 481	15 - 495	AA378685, AA378686, AP001101, and AC004837.
HYBAE74	609	925074	1 - 314	15 - 328	AC006121.
HYBAG11	610	967880	1 - 194	15 - 208	
HYBAU83	611	732419	1 - 226	15 - 240	AA371642, AA345063, N87410, AI886060, AI886365, AA528441, AA652329, AI743721, AA987962, AA364488, AI954525, F13749, AA626829, AL135643, AW075915, AI982634, AI751162, AW162288, AI696793, N54179, AI610603, AA360260, AA258848, AI240339, F32893, AW341903, AI216998, AI370270, AI348302, AI024782, AW402145, AW157005, AI028510, AA968509, AI270524, AW157492, AI797901, AI653905, AI634691, AI797892, AA372881, AI678785, AI471418, AI345657, AI349966, AI879394, AI796594, AI345717, AA772016, AA507837, AL039187, AI467877, AA992126, AW088843, AA215335, AI332666, AI799303, AL038909, AA364315, H78031, AA367555, AI753365, AA617954, AW300776, AA843450, AA226584, AA319813, AI244758, AA657835, AA318652, N54764, AA192330, AA206807, AA364330, AI053981, AI051037, H79308, F33121, AW271904, AA347040, AI240891, AI719644, AI921541, AA984191, AI079423, AI144094, U73167, U90094, Z84469, AL034420, AL031296, AL050307, AC007688, Z82097, AC006211, AC004263, AC006441, AC004660, AC004921, AC006241, AC005971, AL008635, U80017, AL035089, AC007199, AP000697, AC009501, U78027, AC005209, AC007055, AC000353, AP000503, AL035422, AB008681, AC006084, AC007486, AC003684, AF134726, U80459, AC004235, AC004382, AL022336, U62293, AC005664, AC005071, AC005214, AL117694, AL121655, U85195, AC005529, AC000097, AC005856, Z86090, AP000500, AC003101, AC002470, AC006547, AC005940, AC006480, AE000658, AC005772, AC005057, AL022163, AC007283, AL121769, L78833, AC007842, AC006509, AL021808, AP000248, AC004678, AC005988, AL031774, X74984, AC005922, Z98744, AL079333, AF129756, AC007038, AC006449, AL022328, AC005086, AF045555, AL049795, AL117258, AL008582, AL031447, AL022578, AL078477, Z85986, AC008040, AC005844, AC006387, AC004236, AC004129, Z94057, AP000505, Z94056, AP000556, AP000557, AC004685, AC001231, AC007041, AC005696, AC005913, Z97056, Z93241, AC000070, Z83822, AC002073, AL133245,

					AC006155, AJ006996, AC005527, Y18000, AC005730, AC002350, AL035658, AL133448, AP000509, AJ003147, AC004477, AL109628, AP000552, AP000959, AC006213, AP000692, AC007276, AC009516, AC005180, Z82244, AJ239027, AL136504, AC006530, Z98036, AC004013, Z84474, AC006001, AC004668, AC002991, AC002040, AC006277, AC007387, AC006116, AL031053, AC003046, AC002310, AC005067, AL049779, D84149, AL049832, AL049540, AC004913, AL049834, AC007263, AC005755, AC005808, AF172277, AL024509, Z85996, AP000354, AL031675, AL009183, AL031662, AL139054, AC006020, Z84487, AC005041, AC007537, AC007073, AL021546, AP00010, AP000152, AC002385, AL035659, AC004814, AC002349, AC004882, AC007687, Z84480, AJ010770, AC006064, AC000085, AC005089, AL096791, AL049543, AL023804, AC004975, AC000134, Z93023, AP000477, Z94160, AL022397, AC005694, AL049761, AL034349, AC002425, AD000092, AL049539, AL031680, AP000553, AF222686, AC005996, AC005839, AC006013, and AC003688.
HYBAX25	612	456251	1 - 341	15 - 355	T55280, Y17457, AL031133, AC005089, AC005412, AC005886, AC004472, and AC006509.
HYBAY40	613	531202	1 - 284	15 - 298	
HYBBB24	614	584989	1 - 307	15 - 321	AA806538, AI005244, and AA535437.
HYBBB118	615	584991	1 - 340	15 - 354	Z98880.
HYBBB30	616	693345	1 - 228	15 - 242	AB032972.
HYBBB17	617	691328	1 - 232	15 - 246	AA04858, AI078144, AA022643, AI809791, N57180, AW170191, AA328923, AA401814, H27580, AI869993, AA249586, AA576955, and W67605.
HYBBK83	618	505138	1 - 595	15 - 609	AI923052, AW265688, AI862716, AA557911, AI358712, AI932871, AI380617, AW408767, AA533054, AA488687, AL039187, R92658, AW085758, AA528516, T05118, AI246796, AW268329, AI696955, AA599080, AA828834, AW023975, AA604751, AI357823, AI689198, AI821382, AA115865, AA469327, AL049576, AC002477, AC006157, AC007283, AC005089, Z98044, AL133448, AF064861, AC006071, Z82244, AC006511, AC004913, L44140, AL031589, AB003151, AC005399, Z93241, AC007707, AC007227, AC012627, AC005696, AC004254, AF134726, AC006312, U95740, Z98752, AC004967, AC004673, AC005409, AL030996, V00596, Z98200, AL049709, AC005028, AC002470, AC006057, AP000295, AC002352, AC005972, M17262, AC005288, AC005821, AC004878, AP000689, AC005519, AF111167, AC004990, AC006241, AC004242, AC002288, AC005907, AC004975, AC004933, AC005902, AC002558, AC005488, Z98036, AC005274, AC005067, AC004477, AC005379, AC007993, AC002997, AC007226,

					AC007421, AL022320, AL096701, AC003982, AP000270, AL049776, AC005829, AC004882, Z93242, AC005726, AC008115, AP000512, AC004752, AC004129, AC003108, AC006026, AC007225, AC005871, AC006530, AP000502, X55448, AC006050, AC005071, AL050318, AC003109, AL136295, AL008583, AF023268, AC005320, AC002492, AC006166, AC002126, AB023051, Z93020, Z99943, AL031584, AP000032, AP000553, D84394, AL035420, AC002984, AC000085, AL049829, AC004228, AC007040, AL049780, AC006013, AF165142, AL020995, AF196969, AC005180, AL031587, AC006080, AL021939, AF196779, AL034549, AL034429, AC004185, AC002563, AL035422, AC004985, Z98304, AL031281, AC007151, AC002301, AL023553, AC005755, Z94160, AP000346, AC010582, AF029308, AC003104, AL133399, AL031667, AP000557, AC009516, U78027, AC006064, AC000159, Z85987, AC007686, AL008719, AL109628, AC005520, AP000466, AC007276, AC006237, AC005784, AL121748, AC005837, AL096774, AC004851, AC004491, AC002040, Z83844, AL031681, AC005670, AF045555, AL133244, AC006011, AL109657, AC005736, AF111163, AC007540, AP000704, AL034379, AC004007, X96421, AC003093, AC004139, AL021878, AC003983, AP001052, AP000248, AC008040, AL031311, AC006040, AC006120, AL133485, AF051976, AP000356, AL022323, AC006121, AC004663, AL022316, AL121756, AC004020, AL121655, AC004686, AF165926, AC002395, AF207550, AC002314, AC005529, AC005527, AL022312, AL021977, U95742, AC004656, AL122020, AC004492, AC006285, AP000558, AC006277, Z97181, AC006571, AF139813, AC016025, AP000509, AC002038, AC004148, Z98257, AC005037, AP000065, AC004019, AL022302, AC000134, AL031432, AC005066, AL080243, AC006132, AC005952, Z97196, AC005663, AL021707, AC005697, AC011456, AC016027, AC004832, AL121658, AC005081, and AC005786.
HYBBG93	619	531201	1 - 60	15 - 74	AF024533, and AC005088.
HYBAY92	620	792923	1 - 426	15 - 440	W01795, and N99837.
HYBAW0 3	621	925068	1 - 323	15 - 337	AA435790.
HYBAH65	622	518736	1 - 592	15 - 606	H48087, T70307, W72466, H80227, H81398, T78885, AA704555, H73669, T78410, and AW236543.
HYBAG53	623	669602	1 - 463	15 - 477	H71386, AW408254, H81132, H44291, N21071, AL801120, N36421, AW341639, AA878376, C02991, A1758487, and AA280550.
HYBAF63	624	745585	1 - 649	15 - 663	N48536.
HSSMZ93	625	530752	1 - 346	15 - 360	AA378965, AA378966, and AL035696.

HSSMZ01	626	921800	1 - 401	15 - 415	AA378938, H90844, T57767, AA824453, AA92105, AI752358, AA458452, AI783911, AA723299, AA812684, AA728973, N67313, AA167489, AA483771, AA664604, AI241831, U63721, AC005071, AL049692, AC006312, AC004878, AC005229, AC002996, AC005520, AC002544, AL031670, AC005874, AF134471, AC004099, AL109984, Z95115, AF134726, AC004263, AC004983, AC004686, AF111167, AF095703, AP000692, U80017, U91326, AC007686, AL135783, AL031666, AC004475, AC005207, AC004217, AC004996, AC007563, AC006441, AL096791, AL022322, AL021154, AL035414, AC005821, AC006026, AC006960, U62293, Z83844, AC007450, AL024498, AC004520, AC004659, AL080243, AC006512, AP000356, AL049552, AP000505, AC006211, Z98051, AC004019, AC000003, AC006101, AL049745, Y14768, AC004132, AC016027, AC005031, AC004814, AC002045, AF129756, AC004938, AC005740, AC006111, AL033521, AL009181, AL008726, AC006237, AP000280, AC006450, AC005971, AC007344, AC007227, AC000025, Z83826, AC004491, AP000248, AC004883, AC002316, AC008064, AL035422, AP000503, AF109907, AP000107, AC005972, AC000026, AL049636, AC006487, AL109798, AL022316, AC005829, AC004386, AC005668, AC007376, AL049869, Z68756, AC005696, AP000552, AC016830, AC005057, AL023553, AL023913, AF190465, AP001054, AP000030, AP000133, AP000211, AF200465, AC005922, AC008498, AL031311, AL133243, AL117355, AC005369, AL022336, AC006511, AC002400, AC005914, AC008372, AF003626, Z95114, AL031390, AF196779, AL079304, AC004383, AL021579, AC007308, AC005702, AC009891, AP000228, AL133246, AC004125, AC004966, AC003110, AC002565, U78027, AC004453, AC006057, AL022323, AL021939, AP000035, AP000104, AC002472, AC007277, AL023653, AC003664, AC006040, AF111168, AC007546, AL132987, AP000557, AL020989, AL049776, Z93930, AP000497, AP000140, AC003667, AC006530, AL049653, AC007073, Z99716, AC005803, AC004032, AC004458, AP000696, AC008018, AF152364, AL133163, AC008062, AC005837, AC002288, AC007151, AC006254, AC006362, AC004967, Z93241, AC006480, AC004815, AC005412, AC005011, Z93017, AL023807, AL109628, AF024533, AL021393, AC004808, AC004583, AC007226, AC007540, AC005538, AC004655, AC000393, AL049569, AC005553, AC004663, AL049712, AL031729, and AL031005.
HSSMW90	627	975081	1 - 306	15 - 320	AA378852, AI149537, AW130188, AW173759, AA715418, AI280504, AW149288, AA489978, AL035413, AL050332, AB014078, AP000514, Z98749, AC006139, AC002468, AC008064, AC005589, Z80901, AL109753, AP000215, AP000128,

HSSMT76	628	928421	1 - 299	15 - 313	<p>AP000206, AP000245, AP001056, and AC008163.</p> <p>AA378683, N72524, AA378682, N57752, N53565, AA831903, AI017251, AW103030, N91572, AI689198, AA655005, AA716348, AI580898, AA077667, AW341903, AI336480, AA340747, AW002831, AA347114, C05986, AI457397, AA533033, AI866908, AI027056, N75391, AA071334, AW151247, AA599352, AI244356, AA086318, AA657416, AA664604, W47183, AI753365, AI824541, AI499376, AI500552, AA630535, AA347034, W79504, AI471481, AI537955, AA773463, T57267, AA603911, N32878, AI291268, AA086344, AA167659, AA644551, AI291124, AI745325, AA488620, AA300391, AA303054, AA613138, AA491814, R64617, AA832145, AI801563, AA665021, AA284184, AW277174, AI291037, AA568778, AA828637, AI267269, AW270768, AI446205, AA502991, AW157005, AA573213, AW438616, AI080618, AW276827, AW193432, AI339845, AA916600, AA483771, AI270476, AA362349, AA551503, AA577906, AA446616, AA350859, AI688846, AA599920, AA553363, H90844, AA579184, N25296, AI687206, AA381138, C15092, AA367986, AA437161, AI041706, AA579736, N22797, F01666, AI350211, AA992126, AI580652, AI344844, AI061334, AI679294, Z82205, AL049829, AC005666, Z93017, Z83840, AF111168, AC005696, AC006511, AC005971, AL049636, AC005488, AL031055, AL022721, AL035413, AC007774, AC005924, AC004797, AC005839, AL109628, AC002470, AL133246, AC005726, AC005841, AC007136, AP000354, AL109758, AP001053, AF064860, AL008635, AL035420, AC005037, AC005619, U80017, AL133448, AC004253, Z84487, AC005015, AL024509, AL096791, AC007878, AC004882, AL049832, Z83822, AP000555, Z97054, AC002094, AC002302, AL049766, Z82206, AC004862, AC002426, AL139054, AF207550, AL121769, Z85987, AC003982, AL079340, AC004678, AC005529, AC005829, Z93244, AP000116, AC004686, AL008725, AC003041, AC002476, I44140, AC005158, AL008718, AC006372, AL080243, Z84480, AC004590, AF134726, AC006285, AC002301, AC004019, AL078581, U47924, AR036572, U91328, AC004854, AC016025, AP000692, AC007388, AL049557, AC004878, AC002347, AC008372, AC004876, AC006327, AC005578, AP000501, AL033527, AC002073, AC006006, AP000547, AC000353, AC005089, AC006441, AC004765, AC004242, AC004150, AC005786, Z98884, AL121603, AC004983, AL024507, U85195, Z98950, AC002543, AF111167, AC005484, AC006274, AC007199, AL049872, AC004601, AC007688, AC003006, AC005070, AC002039, AF107885, AC004815, AL132987, AE000658, AB023049, AC003029, AL023804, AL022476, AC006088, AC005520, AC002115, Z83826, AL109801,</p>
---------	-----	--------	---------	----------	---

					AC006312, AC002544, AL133163, AL022237, AF045555, AC010205, AC005914, AC004895, U95742, AC005856, AC004477, AL049776, AC007263, AC005874, AF134471, AC005399, AC005799, AC005317, AC009509, AL031432, AC005207, AC004526, AC007376, AL031311, AC007687, Z97876, AC005899, AC007421, AL109952, AL049569, AL035400, AC007938, M63480, AC005086, AC004967, U95743, U78027, AF196972, AF196779, AC004448, AC003046, AC007666, AL031589, AJ011930, AC006273, AC005694, AC007386, AC005206, AC006241, AL049869, AC007308, AC007052, AL031427, AC000026, AC007371, AL049646, AC004531, AL049761, AC009516, AC000003, AC005972, AL021391, M63544, AC005722, AC005682, AC006480, AL031005, AC004099, AP000131, AP000209, AP000065, AC005667, AC002997, AC002119, AC005551, AP000505, AC002044, AC005684, AC006120, AL031685, AL008730, AF190465, Z83846, AC002059, AC006023, AP000248, AC006039, AC007216, AC005837, AF117829, AC005291, AC005527, AL031447, Z98946, U91326, Z85986, Z95115, AC003670, AC005756, AJ003147, AL035681, AC010206, AL021877, AL078638, AC005736, AC007363, AL135744, AL021397, AC004752, AF011889, AL031588, AF118808, AC010200, AC005844, AC005796, and AC005939.
HSSMT70	629	530758	1 - 284	15 - 298	AA378674, and AA378675.
HSSMP20	630	854092	1 - 360	15 - 374	R70723, and AA378431.
HSSKD17	631	726525	1 - 552	15 - 566	W68188, AW248260, AW379441, H14177, R51748, N45444, AA009502, AA121499, AI750975, AA521345, AW204392, and AC005306.
HSSJQ60	632	975185	1 - 192	15 - 206	
HSSJP81	633	911334	1 - 541	15 - 555	Z43294, AA252498, AW371259, R07447, AA403066, F07754, and AL133017.
HSSJL22	634	871170	1 - 1260	15 - 1274	D31661, L41939, AF025304, L25890, L36643, and D37827.
HSSJK65	635	747891	1 - 742	15 - 756	AA010525, R94490, N59062, AI032097, R94491, and AI241480.
HSSJH78	636	773558	1 - 371	15 - 385	W58293, H17374, and AC004552.
HSSJA08	637	959336	1 - 559	15 - 573	AA516469, AI796388, and AA579963.
HSSGK12	638	970714	1 - 407	15 - 421	Z73988, and AL050347.
HSSGI84	639	781975	1 - 492	15 - 506	H53756.
HSSGD96	640	796410	1 - 98	15 - 112	
HSSGD82	641	779899	1 - 558	15 - 572	R87893, and AL110228.
HSSGD56	642	608144	1 - 501	15 - 515	AA502843, AA470969, AI345157, AW150524, AL022323, AC002381, AL035555, AC005071, AL049776, AL022302, U91321, Z95152, AF165926, AC003029, AC006571, AC005154, AC005871, AC002402, AL096701, AC005899, U91323,

						AC005696, AC005089, AC005280, AC006581, Z86090, Z99716, AC007546, AP000553, Z83845, Z95116, AC006160, AC002425, Z84480, AP000346, AC007406, AC005412, AL121603, AC006441, AC007685, AC005081, AL133353, AC008101, AC002990, AF038458, AC002996, AC004859, AC004662, AP000023, AC005520, AP000210, AP000132, AL132712, AC007637, U80017, AL031662, AC000066, AC007537, Z93783, AC016830, AL021707, AC008045, AC005288, AC005841, AL033547, and AC005225.
HSSFW84	643	781973	1 - 623	15 - 637		H13333, Z46049, and AC004590.
HSSFU84	644	888462	1 - 388	15 - 402		Z82214.
HSSFN08	645	959735	1 - 529	15 - 543		AA584893, M62144, AJ132917, AF158180, AF031075, AF031078, and AF030876.
HSSFK90	646	788687	1 - 534	15 - 548		AI633959.
HSSFB73	647	955200	1 - 322	15 - 336		R16937, and AC007537.
HSSEU40	648	891055	1 - 352	15 - 366		AA004732, and R45758.
HSSEP69	649	871211	1 - 356	15 - 370		AC005484.
HSSEI90	650	789157	1 - 373	15 - 387		H91190, AI903727, AW367564, AW376992, AW367618, AW367543, AW367594, and AL080172.
HSSEG25	651	679351	1 - 490	15 - 504		AA481165, AA034225, AW131736, AW137070, AA063633, AA844084, AA482038, and Z83845.
HSSEF33	652	702701	1 - 530	15 - 544		H67629.
HSSEC79	653	775312	1 - 254	15 - 268		AA984057, AA084951, AB023138, M96377, and M96376.
HSSDQ07	654	880720	1 - 492	15 - 506		AI967980, AL035703, and U72207.
HSSDI03	655	924975	1 - 389	15 - 403		AA808840, W74796, W74722, AA723330, and AP000501.
HSSDH37	656	575460	1 - 256	15 - 270		AI869797, AA326034, AI689198, F01222, AA526683, AA032001, T30864, AA378474, AI590906, AA565319, AA856815, AA513851, AA364137, H93152, AA372106, N70449, AA343810, AI193417, AA225486, AA745302, AA714524, AA297698, AA384200, AA555232, AA086257, AI354333, AA831408, AA551067, AA745351, W44359, AI114557, R52008, AC005899, AC003029, AC007993, AC003025, AC004084, AF139813, AC000025, AC005527, AC006511, Z98750, AL035681, AC005529, Z94802, AC005399, AL135744, AL049776, AC007193, AC006277, AB001523, AC006388, AC000353, AL035659, AC006001, Z98946, AP000359, AC002351, AC004651, AL034417, AL109628, AL034420, AC002310, AC006023, AL035400, AC007731, AF038458, AC005365, AL049780, AC004491, AC005632, AC004973, AC005015, AL031056, AC005102, Z82206, AL133245, AC005841, AC005932, AP000689, AL121653, AP000279, AL031662, AC004019,

					AL121603, AL031602, AF031078, AC005081, AJ251973, AC005500, AC006449, AP000115, AL008730, AL024498, AL049636, AC004820, AF030876, AL080317, AP000305, AB003151, AL133163, AC002126, Z82203, Z99716, AC006121, AC004030, AC004967, U62293, AP000106, AP000038, AC005914, AL049694, AC002120, AC007226, AL022311, AC004821, AF088219, AC004596, Z85996, AL031588, AC005332, AP000045, AP000113, AL050348, AB023049, AC005484, AC002470, AP000355, AC002395, AP000209, AL109984, AC000026, AL033392, AL139054, AC008372, AC006257, AJ246003, Z93017, AL121658, AC004106, AC003982, AC004963, AL022326, AC005288, AP000692, AL049834, AP000116, AC006084, AC003041, AL022476, AL022721, AL031666, AC007773, AC002350, AP000694, AL049874, AF039906, AC005086, AL031848, AP000047, AL022238, AC002059, AL133246, AC004851, L48038, AP000248, AL008582, AC005696, AF134726, AC005067, AF196969, AL031427, AC004125, Z98051, AL034421, AC002369, AC005839, AL035455, AP000212, AP000134, U91318, AC007934, AC005940, Z93241, AL022336, AC004675, AC004655, AC007308, Z83846, AL109801, AJ003147, AC003109, AC004890, AC007227, AC002400, AC005378, AC002544, AC004975, AC005695, AL079342, U52112, AL117694, U63721, AC005972, AP000555, AP000504, AC005089, AC003010, AC004685, AP000553, AC005880, AC007066, AP000308, AC004033, Z93020, AL049869, AC005730, AC004000, AC007546, AL031295, AC004883, AL117344, AP000514, AL035413, and AC002306.
HSSDC50	657	724696	1 - 244	15 - 258	H16286, and R53150.
HSSCC14	658	600216	1 - 898	15 - 912	AI284640, AI281881, AI679782, AW276827, AA680243, AI334443, C75026, AI801591, AA720702, AA491814, AI368745, AW419262, AW162049, AI929531, AI683577, AI610159, AI732120, AI005388, AI471534, AW406447, AW088058, AW243960, AI469624, AI053672, AI471481, AA503015, AI962050, AI076616, AW303196, AW104748, AA649642, F36273, AA581903, AI339850, AW274349, AW022379, AW148792, AW166815, AW301350, AI358343, AI298710, AI434706, AL037683, AI567674, AL039958, AL048925, AI206785, AI138455, AI143242, AI564185, AI286356, AI625244, AL044858, AL119691, AI379719, AA613345, AA488746, AI355224, AI446638, AA394271, AA713815, AI927741, AI640702, AA178953, AA192740, AL042420, AW021583, AI246409, AW072587, AI133164, H71429, AI732186, AI696955, AI192631, AI355206, AI697208, AL044940, AW272758, AA521323, AL046898, AI674873, AW270270, AI110770, AI246796, AI376100, AI251002, AA665021, AI921649, AA620525, AW302013, AW270716,

	AI809923, W79504, AA521399, AI061227, AI367975, AI364020, AA598586, AA493708, AI049722, AI471543, AA587256, AA074130, AI471487, AA758934, AI133636, N27584, AW089322, AI434311, AA084070, AI148277, M77974, AI859251, AW073470, AW089789, AL134972, AI251436, AI568678, AW162489, AA302963, AW406162, AI921188, AW440836, AC004743, AI031005, AP001172, AC005037, AC006449, AC005324, AC004862, AC006241, AL031729, Z97053, U62293, AC007450, AF042090, AB023052, AC005785, AL117352, AC004263, AC005234, AC006468, AC002044, AC006115, AC006044, AP000513, AP000557, AC003026, AL022322, AB023049, AC010206, U63721, AP000020, AP001054, U91321, AC009516, AC005081, AC002542, AC005755, AC006487, AC009223, AC005280, AP000553, AC005261, AL050341, AL078477, AC007676, Z83846, AF134726, AD000684, AL031276, AL031965, AL021391, AC005218, AL096701, AF088219, AC005520, Z99758, AP000556, AC006079, AP000302, AC008039, AC005358, AC005341, AP000115, AC005412, AL096774, AL117258, AL034371, AC002429, U78027, AF015147, AL031123, U67221, AC005011, Z86061, AC006430, AL121603, AC004067, U07000, AC007308, AL031286, AP000503, AL096768, AC006985, AC007263, U07562, AL035659, AC005844, AF077058, AP000114, AP000046, AL035422, AC008079, AL008735, AC006213, Z94056, AP000359, AC000026, AP000304, U66059, AP000047, Z98200, AL022476, AC007842, AC005488, AC005288, AP000558, AL132987, AF123462, AC005778, AF109907, AC002525, AC004491, Z99129, AL035420, AC005004, AP000351, AL021707, Z98257, AC004492, AC005837, AL008629, AC002059, AL034561, AL021368, AC004531, AL022311, AL049569, AC002365, AC005747, AC005231, AL023575, AC006277, AL035417, AC007687, AL049759, AC004913, AL021393, AC005900, AL031651, AC002452, AC004158, AL078472, U95743, X75335, AC002549, AC005104, AL109753, AC004941, L48038, AC007731, AC004605, AC006071, AC004675, AC005500, AP000555, AC006459, AL139054, U62317, AC005043, AL035587, AC002460, AC003101, AC005664, AC002985, AP000348, AL021940, AC007043, AF015167, AP000356, AC005971, AC005257, AC005531, AC005175, AC004152, AP000950, AL109852, AC003074, AL031295, AP000689, AC005699, AC005682, AF045555, AL035683, AL031848, U47924, AL049562, AL021808, U80017, AC006211, AC004028, AC004253, Z95124, AC004987, AP001053, AL021977, AC000075, AL049835, AC012599, Z82244, AL096791, AC005072, AC022517, Z82210, AC004773, AF017104, AC007565, U18399, AF037338, AL022147, AC006998, AC003041, AC005057, AC007151, AL031542,
--	---

HSSAZ04	659	933015	1 - 447	15 - 461	and AF001550.
HSSAY34	660	703345	1 - 399	15 - 413	AW104609, AA731470, AA378296, AA093496, AA648807, and AC005768.
HSSAP68	661	564334	1 - 1137	15 - 1151	R33953, AA378260, AL137558, and AB033041. AL041924, AA569648, AA595661, AW020150, AL801505, AA974503, AA577706, AI521525, AI310670, AL041375, AI479148, AL282253, AW162314, AL036896, AA669238, AW151541, AI251034, AA526542, AA287363, AI890297, AW338376, AA171400, AI250552, AA218684, AA515728, AA533025, N68677, AW302048, AL079734, AW020094, AW069227, AI224583, AW408413, AW021399, AW275432, AI251284, AI754653, AI926102, AA313025, AA084320, AI284543, AI537020, AI809776, AA583245, N26159, AA719564, AW410844, AI355246, AI879968, AW086291, AW162332, AA180056, AI625604, AA610826, AA218851, AA935827, AI904840, H77492, AI732151, AI223626, AI197089, AI049845, AA829036, AI791659, AA601674, AI345394, AI095197, AI003626, AI049643, AW439224, AA584765, AW419389, N95424, AI753131, AI310787, AI719298, AI254770, AI733523, AA659324, AA225406, AW274182, AL121039, AI349130, AI702049, AI453155, AA598443, AW022796, AI570236, AI915081, AI697235, AI654738, AI570067, AI216990, AC006312, AC007151, AC002477, AC005696, AF001549, AP000046, AP000114, AC006064, AL024498, AC005480, AC004263, AL022323, AC005911, AC005207, AL008718, AL020997, AC002425, AL031602, AL031053, AL136295, AL031311, AC006480, AL049869, AC006071, AC007057, AL049570, AC004526, AC007055, AF196779, AL031680, AC004659, AF001548, AC003101, AF207550, AC005231, AC002312, AC005736, AC006121, AL021918, AL034451, AC005049, AF109907, AL034379, AL021393, AL049780, AL050312, AC002310, AC005531, AC004000, AL133353, AL022336, AC005913, AC007688, AC003982, AL031229, AC002316, AL049694, AC005102, AL049757, AC005486, AC003043, AC003665, AC006487, AC005914, AL031685, AC016831, AL031662, AP000692, AC005702, AF053356, AC007371, Z94056, AC016025, AL133245, U95742, AP000359, AC002044, AL031295, AC007021, AC002400, AC007207, AC005081, AL080243, AC005015, AC008040, AC007376, AL078463, AC004671, AC005324, Z93023, AL022327, AC007685, AC005288, AC002369, AC007395, AL023803, AC006115, AC002470, AB023049, AP000503, AC010205, AL049759, AC004382, AC006449, AC005527, AL022476, AC005088, AC007637, Z86090, AL022396, AC007227, AL034420, AL035072, AL122021, AC004131, AC007686, AL031291, AL031284, L44140, AC006088, AC000025, U85195, AC006581, AC002375, AP000555, AC005755, AC004796, AC005225, AP000065, AL139054,

					AC007308, AP000556, AL050341, AL109952, AL035587, AC007687, AE000658, AC006046, AL021155, AC004812, AC004890, Z95115, AL008583, AF111169, AC005821, AL109758, AC002303, AC004185, AC004699, AC005921, AP000688, AC004797, AL049793, AL021546, D87675, AC006023, AL049776, AC004491, AC004752, AP000501, AL022316, AC006965, AC002314, AJ003147, AP000514, AC005086, Z95113, AC006252, AL109627, AB000565, AC007225, AC004223, AC007845, AL034417, Z94801, AL034429, AL096791, AC004686, AC003109, AC004905, AC007664, AC005412, AC002544, AL022238, AC006077, AC009516, AC007011, AL021707, AC006241, AL023575, AL022313, AC005670, AC005619, Z93241, AF024533, AC005255, AL049569, AL035249, AC004814, AC009509, AC005529, AP000142, AP000509, AC004816, D84394, AC004253, AC004099, AC005726, AC009247, AC004876, AF134726, U62293, AC007193, AC004832, AC007684, AC005484, AC003108, AC007216, AC004112, AC005972, U91321, AF111168, AL117258, Z94161, AC005280, AL031123, AL121603, AC003663, AC005901, AC005971, AL022326, AC004552, AL133216, U91323, Z97056, U82828, AC003042, AL031282, AC002565, AL049539, AC005291, U89335, AC005800, AC005399, AL035681, Z84466, AC004765, AL031846, AC004963, and AL035443.
HSSAJ89	662	875882	1 - 302	15 - 316	W92215, AA377828, AI740584, N76763, T84274, R82785, T78575, R17095, T87269, R11236, and T79354.
HSSAE52	663	871244	1 - 167	15 - 181	AI472653, and AA377685.
HSSAA15	664	965347	1 - 796	15 - 810	AI110596, AA278446, R76143, AA312497, AA284193, AA355145, AA490794, AA377558, N79277, AA464226, AA363394, R24680, AA490748, AI902621, H56984, AA340607, R69950, AI830706, N78524, AW364076, H13787, AA366038, N80360, AA442589, AA046344, AA813247, AA215532, H45795, AW250076, AA147663, AI393282, AA282719, AI089657, AW043798, AI652874, AA557376, AW167542, AI982882, AA490235, AI143182, AI439663, AI017552, T89683, AW408401, AW402303, AA534702, AA284082, N51261, AI357897, AI089649, C14798, D60855, AA490509, AA864859, AA262577, AA812466, and AL133009.
HSRAY10	665	961237	1 - 731	15 - 745	AI565051.
HSRAS82	666	780222	1 - 259	15 - 273	AW385413, N78312, and U73168.
HSRAF70	667	524680	1 - 393	15 - 407	AB011100.
HSRAFI1	668	967886	1 - 296	15 - 310	AC002133, and AC004587.
HSRAD72	669	539530	1 - 434	15 - 448	R06151, AA385070, AA398993, AA491011, H28273, R00914, H69631, H87597, R17024, AW362296, AA064980, AI065074, H28240, AA043619, AA032023,

						AA069630, W81414, N76651, AA037103, H61103, AA243289, R02831, H28759, AL120864, T70140, A1735280, AA337374, AF191339, and AB019409.
HSRAD65	670	871268	1 - 239	15 - 253		AL119835, AW163089, AW162617, A1928782, and AW162588.
HSRAD53	671	525490	1 - 321	15 - 335		
HSRAD49	672	722134	1 - 377	15 - 391		AI394551, AA812658, and AA776285.
HSRAD31	673	524845	1 - 235	15 - 249		
HSRAD10	674	968614	1 - 464	15 - 478		AA312660, and AI474863.
HSRAD03	675	925505	1 - 303	15 - 317		AC002536.
HSRAB87	676	823174	1 - 325	15 - 339		AA661583, AI536625, AA078084, AI803827, AI472453, AI932902, T60674, AA377621, AA302970, AA372389, F23307, AA496309, AA346485, AW192199, AA366936, AA459962, AA371410, AW194802, AC005944, AP000553, AC005895, AF165926, Z84718, AC005277, AC005358, AC005971, AL136295, AC005619, AP000351, AC005696, Z97054, AC004019, AC002470, AC005225, AC005280, AC006515, AC006511, AC007421, AC005940, U78027, AF129756, AC007731, AL049653, AL031255, AL035422, AP000505, AL133353, AC005071, AP000512, AP000114, AP000046, AC007546, AC020663, AC006946, AL133448, AL031280, AL049694, AP000555, AC005746, AC005821, AC005231, AC005500, AC005067, AL031722, AC006538, AC005911, AL022331, AL021154, AB023051, AC006509, AL035458, AL121934, AP000300, AP000045, AP001056, AL035405, U63721, AP000302, Z97056, AL049829, Z86090, AL121653, AF207550, AC004859, AL031733, AL008719, AC004814, AC002996, AL049757, AF029308, Z99716, AC005041, L78833, Z69917, AL080243, Z85986, AP000113, AL022324, AF196779, AC004841, AC007319, AC000025, AL008582, AC006057, AL031311, AC004983, AP000557, U91326, AL049872, AL132987, AC006449, AC004963, AC004883, AC005288, AC007066, AC005664, AL034548, AC002072, AL050318, AC005529, AC002504, AP000031, Z98946, AC003041, AP000345, AC004552, AC007298, AL031291, AL049759, AC005694, AL109627, Z92540, AC009516, U52112, AC004386, AC005095, AC006479, AC004448, AC005082, Z81369, AC005599, AC006992, AF205588, AC000041, AP000563, AC005755, AC005412, AC006539, AC006077, AL121603, AL049636, AL031432, AC003030, AC004134, AC004771, AL033527, AC002073, AL121915, AL139054, AC002401, AC007283, AC011311, AJ003147, AL132712, AL049539, AL133243, AL021977, AC007277, AC004099, AC002369, AC005519, AC000353, AC005606, AC003051, AL132992, AC005355, AC005695, AL035089, AL079295, U85195, AC005773, AC007308, AC004884, AC008041, AC002492, AC005527, AC008115, AC004217, AC007216, AC000379,

						AC002301, Y14768, AL050332, AL034429, AL008718, AL049795, AC004643, Z98051, AC005924, AL031662, AL024498, AP000133, Z83843, AF109907, AF064861, AC008055, AC004655, AC006125, U62292, L44140, AL096701, AC002316, AC004821, Z83846, AC016026, AC002120, AR060470, AC016830, AC004559, AC005261, Z93017, and AC004216.
HSRAB82	677	522945	1 - 388	15 - 402		AL031733.
HSRAB76	678	508105	1 - 393	15 - 407		AW003750, and AA608656.
HSRAB36	679	522946	1 - 376	15 - 390		AC005352.
HSRAB34	680	706996	1 - 399	15 - 413		L14561.
HSRAB08	681	960411	1 - 134	15 - 148		
HSRAA86	682	527194	1 - 415	15 - 429		Z66025.
HSRAA80	683	937640	1 - 446	15 - 460		AC006504, AC007788, AL020995, AL031393, and AC006118.
HSRAA64	684	953114	1 - 315	15 - 329		AC005924.
HSRAA51	685	522834	1 - 314	15 - 328		AA287418.
HSRAA39	686	719712	1 - 406	15 - 420		W57866, AA405363, AW068952, AI347952, AW338731, AW262930, AI650770, AI827045, AA406218, AI224572, AI983500, AI659859, AW139817, AI367100, AW029065, AA860374, N29563, AI683067, AI148585, AI963162, AA457121, AI830485, AW129125, AI983651, AI800368, AA115644, AI817037, H26177, AI590898, AI811420, AI963645, AA857298, H99276, AW088836, AI421113, H22014, AI753020, Z40200, F04312, AI751902, AA131162, AI698346, AI955784, AI290179, R22616, AI955793, AA834648, AA826157, AW057686, R62159, T33749, AW392341, H26176, AW274070, AI750657, R22615, AL096713, AB033033, AF182317, and AF182316.
HSRAA37	687	522837	1 - 444	15 - 458		AC007684.
HSRAA24	688	795855	1 - 465	15 - 479		T80334.
HSRAA23	689	524795	1 - 406	15 - 420		AI783911, AA502532, AA552724, AA481887, AA376358, AA604147, AA452887, F30310, H90878, R95840, AA584756, AA613754, N72170, AA559241, AL048275, AA192252, AA975894, AA181363, AI879951, AW265688, AI620585, AA194285, AI742168, AI358776, AA564925, AA936718, H62343, AA581247, AA339923, AA021429, AA018588, AA021428, AA722336, F00564, R73744, AI431513, AA019872, AA470567, AA708753, H78898, AA862253, AA747757, AA078830, AA605243, AI302156, AA481970, Z83844, AC006271, AC007226, AC006538, AC004841, AC005620, AC005531, AP000030, AC004131, AF196969, AC005696, AC006581, Z93930, AC005274, AL080243, U91323, AC000026, AP000694,

					AC006011, AC005011, AC005800, Z98051, AC002059, U91326, AC004815, AC005480, AC005736, AL021579, AC006071, AC004887, AC008044, AC005527, AL034379, AC005225, AC004526, AL117337, AC005399, Z93023, AC005844, Z95116, AC004033, AL050332, AL049766, AC005876, AC007546, AC020663, AC006312, AC006966, AC007686, AP000553, AL121658, AC005516, AL133353, AC004491, AC004477, AC004929, AC002312, AL008710, AC005193, AC004019, AC007688, AC004996, AC003108, AC005667, AL096701, AF196970, AL022320, AC005015, Z98946, AL133448, AL008582, AC006468, AC002316, AC004263, Z97054, AC008072, AF111168, AC006515, AC002072, AC004551, AC005874, AF134471, AC002492, AC012627, AL035587, AL035088, AC005081, AC005358, AF053356, Z93017, AL022318, AC004914, U80017, AL050318, AC006449, AC006441, AL022323, AC004531, Z84466, AC005046, AC006064, AC004921, AL022328, AC000353, AL024506, AL035461, AL034549, AC005529, AL117258, AF205588, AL021707, AC005200, AC005839, AL109984, AC004659, AF111169, AC009516, AL022336, AP000501, AF109907, AL135744, AF111167, AC004832, AC006948, AL034420, AC016027, Z95114, Z98200, AC007308, Z81365, AC006111, AC003665, AC005730, U95090, AC000052, U91318, AC016830, AC002302, AL023807, D87675, AC006511, AF001549, AL031685, AL031680, AC005971, AP000704, AC004858, U07563, AC004087, Z95115, AC004408, AC007285, AC005914, AC007225, AC002369, AL034553, AC002476, AC005585, AC005088, AJ246003, AL049576, Z83826, AL139054, AC003684, AL035455, AL031597, AC002314, Z82203, L78833, AC004622, AC002094, AC006120, I34294, AL079342, AC005697, AC005086, AL031432, AL009172, AC005694, AC005231, AC002563, AC004812, AP000131, AP000209, AL031587, AL031283, AC004967, AC004851, AC005913, AC005067, AL049694, AC005755, AC004134, AL031657, AL031846, AC006509, AC004638, AF165926, AC007151, AL031848, AP000251, Z98884, AC006130, AL078638, AC005488, AP000355, AC003101, AC005037, AC004801, AC004859, AL035462, AP000090, AC005049, AJ251973, AL049631, AC007298, AC006088, AC006480, AC010205, AL049569, AL033527, AL034418, AC003661, AC005411, AC002425, AL050341, AC004821, AL096791, and U47924.
HSLKB62	690	905738	1 - 1727	15 - 1741	
HSLKB37	691	929743	1 - 687	15 - 701	N68327, AW139202, AI350326, AI279786, AW339260, AA513265, H66480, H38171, AI187961, and H69151.
HSLKA06	692	934638	1 - 838	15 - 852	AI623826, AI202494, and AI137429.
HSLJJ62	693	742895	1 - 423	15 - 437	R10605, T97572, and R91642.

HSLJF33	694	938811	1 - 542	15 - 556	T12297, and T12296.
HSLJD02	695	965826	1 - 942	15 - 956	AW360811, AW366296, AW375405, AW177440, AI905856, AW178893, AW377671, T03269, AW177501, AW177511, AW360844, AW360817, AW352117, C14389, AW179328, AW375406, AW378534, AW179332, D58283, AW377672, AW179023, AW178905, D59859, AW352170, D80022, C14331, D80166, D80195, D80193, D59927, D59467, D51423, D59619, D80210, D51799, D80391, D80164, D59275, D80240, D80253, D80043, D59787, D80227, D59502, AW378532, AW367967, D81030, D81026, AW178980, C14014, D80212, D80196, D80188, D80219, AW178775, AA305578, D80038, C15076, D80269, D59610, AW377676, AA305409, AW352171, D57483, C14429, D51022, D50979, D50995, AW177731, D80366, D59889, AW178907, AW178906, AW178762, D80248, D80045, D80132, AW179019, AW179024, D80522, D80024, D80134, AA514186, AA514188, D80378, D51060, D80133, D51097, AW177505, AW179020, AW178909, AW177456, D80251, AW179329, AW177733, AW378528, AW178908, AW178754, AW179018, AW352158, D58253, AW352174, D80268, AW179004, D80302, AW178914, AI535850, C75259, D80439, D80247, AW178774, T48593, D51103, D88547, X82626, A84916, A67220, D89785, A62300, A62298, Y17188, AB028859, A78862, D34614, D26022, AJ132110, AR018138, AR008278, X67155, Y12724, AF058696, A25909, A94995, AB012117, AR025207, I18367, AR008443, I19525, AR066490, A85396, D88507, AR066482, A44171, A85477, A86792, AR066488, X93549, A82595, AR016514, D50010, D13509, AR060138, A45456, A26615, AR052274, Y09669, AR060385, AB002449, AR066487, A43192, A43190, AR038669, AR008408, and AR060133.
HSLIJ48	696	721248	1 - 916	15 - 930	AL119990, AA524531, AI459232, AW295852, AW274849, AI990971, AI086621, AI703399, AI582316, AI887899, AW444954, AI198620, AI201159, AA769116, AA908833, AI769819, AI761662, AI678189, AI638810, AW001104, AW339272, AI025272, AW151222, AW015232, N30310, AI797112, AA781447, AW083242, AA291544, AW003604, AA831760, AI027612, AI624665, AW276610, AW168171, AW170708, T62956, AA42455, AI807572, AW080508, AI052790, AW378235, AA827853, AA737447, AI969056, AA465529, H03505, R78862, AW205495, AA515398, T88738, AI972735, AA436647, AA805386, H03615, N56642, AI825714, AA293351, AW292091, AI473377, AA404571, AI349471, T63206, R79349, AA399447, Z38283, AI582475, AA252529, AA252574, AA708728, AI670981, AA429843, C06324, AA748807, AI650622, AW392315, and D20600.
HSLIG07	697	952493	1 - 766	15 - 780	N31935, AI433732, N20982, AA736780, AA721230, AA460997, and AA018340.

HSLIE03	698	923393	1 - 636	15 - 650	AA164206, and Z98049.
HSLIC21	699	670359	1 - 499	15 - 513	H22544, A1204929, and H46842.
HSLHZ82	700	779067	1 - 512	15 - 526	H72516.
HSLHZ10	701	963808	1 - 294	15 - 308	T57527.
HSLHV27	702	964075	1 - 999	15 - 1013	T03269, D80212, D58283, D80166, D80195, D80193, D59927, D51423, D59619, D80210, D51799, D80391, D80240, D80253, D80043, D80227, D59859, D80196, D80188, D80219, D80269, D80038, C14429, D59889, D81030, D80366, D59502, D57483, D80022, D59275, D80045, D59610, D80024, AW178893, D80378, D50979, D50995, AW177440, C14389, AW179328, D59787, D80241, C14014, C75259, D80164, D51060, A1905856, C14331, D80134, D59467, AW378532, C15076, D51097, AW178775, AW177501, AW177511, AA305409, AW352138, D81026, AA285331, F13647, AW178762, AW352117, D80949, D80168, AW360811, AW176467, D51022, D58253, D80522, AW377671, AW377672, AA305578, AW375405, AW360834, AW360844, AW366296, AW360817, AW179023, AW375406, AW178905, AW378534, D80248, AW179332, AW352172, AW177731, D59695, D80251, AW352171, AW377676, AW179019, AW352170, AW179024, AA514188, AW178907, AW179220, AW177733, AW177505, AW179020, AW178909, AW177456, AW378528, AW179018, D80268, AW179329, AW178908, AW178754, AA514186, D80133, AW178906, AW178980, AW367967, AW179004, AW178911, AW178914, C05695, AW352174, AW178774, D80132, D80302, AW178983, T48593, D80439, D80247, AW177723, AW378533, D80157, D51103, AW367950, AA033512, AW178986, D45260, C06015, A1535850, C14975, AW378542, D80314, C03092, AW360855, A1525923, A1525913, A1525917, AA514184, A1535959, A84916, A67220, D89785, A62300, A62298, A78862, A1132110, X67155, A25909, Y17188, D26022, D34614, AR025207, D88547, X82626, AR018138, AB012117, Y12724, A85396, AR066482, X68127, A44171, AF058696, A85477, I19525, A86792, AR008278, X93549, AB028859, U87250, A94995, AF135125, AR008443, I50126, I50132, I50128, I50133, AR016514, A82595, AR066488, AR060138, A45456, A26615, AR052274, D88507, AR064240, A43192, A43190, AR038669, A30438, D50010, Y09669, AR060385, I18367, AR066490, AB002449, AR066487, AR008408, AB033111, Y17187, A63261, D13509, AR060133, AR062872, A70867, U87247, A64136, A68321, Z32749, AR016691, AR016690, U46128, U79457, AF123263, I14842, X93535, and AR008382.
HSLHG49	703	722570	1 - 455	15 - 469	T76925, and F13028.

HSLHC40	704	710681	1 - 386	15 - 400	H87626, and H87632.
HSLGY08	705	959371	1 - 459	15 - 473	H52847, and U73638.
HSLGQ48	706	720956	1 - 450	15 - 464	R14758.
HSLGP07	707	953305	1 - 430	15 - 444	H52460.
HSLGO19	708	668634	1 - 530	15 - 544	T69707, AI364440, N48142, and AI193460.
HSLGN78	709	773565	1 - 345	15 - 359	AA648821, AI937873, AW241962, AA085600, AA743475, and AA618255.
HSLGN52	710	466026	1 - 268	15 - 282	N44280, and AF030339.
HSLGK46	711	719031	1 - 479	15 - 493	AI029533, AA143673, AF160973, AB032994, AL136549, and AF162472.
HSLGK26	712	929286	1 - 594	15 - 608	R02405, AI902990, AL049742, and AB033071.
HSLGK23	713	675266	1 - 447	15 - 461	AA761431, W23694, and W35274.
HSLGI37	714	708824	1 - 438	15 - 452	R14817.
HSLGI76	715	770035	1 - 643	15 - 657	W03269.
HSLGI67	716	465989	1 - 681	15 - 695	R15431, R43754, R41977, AI684818, AW263190, R20728, and AA764976.
HSLGH70	717	871888	1 - 613	15 - 627	AA020737, AL120362, T04912, AI207884, and AL120567.
HSLGG86	718	784703	1 - 573	15 - 587	R13205, F06363, Z42917, Z42916, and AC005550.
HSLGG79	719	775146	1 - 469	15 - 483	N49335, N32155, AI378923, AA825350, AI168537, T75454, AA553340, and AC003086.
HSLGA79	720	774051	1 - 487	15 - 501	T89229.
HSLGA45	721	717776	1 - 198	15 - 212	AA456710.
HSLGA24	722	955333	1 - 793	15 - 807	
HSLFU18	723	666405	1 - 975	15 - 989	AI948585, AI091275, AI768335, AA002188, AA054389, AI422809, AA625455, AA152352, AA504767, AI091665, AI274082, AI151107, AI356672, AI276227, AW363928, AW293599, AI379300, AA028994, T06356, AI401834, D25946, Z41039, AA152353, H09081, AI695174, AL118909, AA429474, AI079113, and AC008154.
HSLFT29	724	680451	1 - 448	15 - 462	
HSLFN96	725	796375	1 - 267	15 - 281	
HSLFI01	726	876881	1 - 458	15 - 472	R74609, AW080754, AL049611, and D31762.
HSLD70	727	757319	1 - 501	15 - 515	AA463820, AW177073, AA235749, and AI940206.
HSLB84	728	783130	1 - 422	15 - 436	H02965.
HSLDW24	729	779689	1 - 442	15 - 456	AW237453, N56967, N47347, AA436760, R96401, H73070, and AC005082.
HSLDT25	730	949079	1 - 1531	15 - 1545	
HSLDR18	731	578926	1 - 371	15 - 385	
HSLDR05	732	932128	1 - 220	15 - 234	

HSLDP66	733	866331	1 - 389	15 - 403	AW151855, AC006597, AC004796, AC005844, AC005740, AC007563, AL049780, AC005015, AC006530, Z99716, AP000350, AC002365, AC004408, AC005747, AC004552, AC005663, AC007057, Z83820, AC005670, AC005242, AC009501, AL034343, and AC004125.
HSLDO01	734	916969	1 - 303	15 - 317	
HSLDM82	735	780055	1 - 533	15 - 547	T53015, T53016, and U88969.
HSLDF25	736	430328	1 - 541	15 - 555	
HSLCY75	737	766533	1 - 536	15 - 550	W88780, and AC000078.
HSLCX61	738	742031	1 - 538	15 - 552	H19015, R24546, and AC007676.
HSLCF96	739	637670	1 - 1575	15 - 1589	
HSLBW39	740	705630	1 - 419	15 - 433	AA190333, and AB029001.
HSKZE91	741	790166	1 - 531	15 - 545	AI904945, T48340, AI971328, AI147425, AW264955, AL079935, AF111163, AC004765, AL109827, AP000503, AF134726, AJ003147, AP000201, AF124731, AP000097, AL031295, AC000105, AC002565, AC006367, and AC004032.
HSKYG48	742	721631	1 - 294	15 - 308	AI204981, W23546, AA862243, AA579469, AA749235, AA572960, AA780929, AA808263, AA814778, AI446474, AA508873, AA857381, AL043289, H10143, AW022317, H29019, AW082744, AA634786, AA655005, T92957, AA577748, AW068394, AA384039, AI870204, AI623899, AA122028, AL120708, AA502175, AA426277, AL120897, AI216054, F17700, AI916335, F23327, AI754064, AI446464, AA558298, AI355119, AI908093, H45320, AA467988, AA492313, H10859, AA364814, AL133353, AL031289, AC007298, AC009479, Z98755, AC004815, AC005046, AP000348, AC008249, AL133244, AL133163, AL024498, AC008044, AL035455, U91323, AC002347, AC006965, Z97053, AL022318, AC005520, AC002477, AL031431, Z95889, AC007564, AC005089, AP000552, AF109907, AC002395, U95742, AC003029, AL035685, AL020993, AC005696, AB023049, AC005856, AC005837, AL031432, AF117829, AL109984, AC005071, AL117352, AL096864, U95740, AC004972, AC004675, AC009510, AC007536, AC005664, AL031012, AL050318, Z84466, AL050307, Z98051, AF190465, AL022312, AP000355, AC005632, AC005781, AC004149, AL132712, AF088219, Z85986, AF207550, AC000085, AC007216, AC005339, AP000117, AC005358, AL121653, AC007664, AC005291, AL035072, AC005412, AL021917, AC005776, AC000003, AC006450, AL031433, AF152365, AL031447, AF196969, AC004150, AC004797, AC002301, AL049694, AC005228, AC012384, AC006547, AC003071, AL031257, AP000553, AL049836, AC009516, Z98949, AC005057, AC003102, AC006285, AL031848, AC005907, AC004024, AC005538, AP000512, AC003992, AC010382,

					AC002524, AC006449, L78810, AC004765, AC005663, AC005747, AC005919, AF108083, Z82188, AL121603, AL031577, Z98752, AC007050, AC007283, AC007690, AF053356, AC005399, AC006257, AC002350, AC005500, AC002432, AF196779, AC008056, AL031685, AC003111, AL132777, AL023553, AC000075, AL008635, AL049776, AC006597, K00059, AL133448, AF196972, AL021453, AL096773, AC004883, AC004167, U47924, AL136295, AF129756, AC007376, AC004584, AC000084, AC005899, AC006211, AC007731, AC008018, AC006162, AC006271, AL033504, AC002351, AL080243, AL035587, AP000514, AC006077, AL022721, AC007136, AP000556, AL034402, AC002310, AC004814, AC005702, AL049797, AC004226, AL049869, AC007878, AC007191, AC004859, AC005839, AL022238, AL008726, AC006512, AC005037, AC006539, AC005790, U85195, AL133245, Z82190, Z83846, AC005189, AC004617, AL033521, AC005069, AL109985, Z84480, AC004477, AL031296, AC006120, AC004967, AP000313, AC005768, AC005988, AP000194, AL049757, AC004016, AC006530, AE000658, AC002980, AC005043, AC005701, AC004491, AC004000, Z99716, AL109627, AF001549, AP000050, AC005484, AC004983, U91629, AC005914, AC005070, AC006071, AC006365, Z85987, AC004810, Z84469, AL022163, AP000472, AC005971, AL031276, AC006130, AL121694, AL031277, AC008372, AC007917, U91326, AC004526, AC005932, AL031846, AL035089, AC006121, AP001054, and AC004849.
HSKXA69	743	754258	1 - 470	15 - 484	T71620, AA534420, AA831032, AA594106, AL263883, AL761286, AA983957, AL001173, T92198, AW004790, and T89254.
HSKKE11	744	965857	1 - 231	15 - 245	W16981, AF195534, and AF005355.
HSKJR15	745	866396	1 - 394	15 - 408	AL287342, N49215, and AB020629.
HSKJC88	746	866402	1 - 543	15 - 557	AL420428.
HSKII90	747	788894	1 - 628	15 - 642	AA216387, AA228676, T63548, and T63473.
HSKHZ47	748	720286	1 - 623	15 - 637	AA001179, AA001429, AA018483, AL119995, and AC007228.
HSKHT93	749	957866	1 - 437	15 - 451	AA252410, AA095264, AA310368, AA282860, R88254, AA131559, AA043465, AA319576, AA315504, AF091871, and AF117815.
HSKHP10	750	964568	1 - 316	15 - 330	AL1810136, AA974689, AA889167, and AL137442.
HSKGS69	751	755046	1 - 321	15 - 335	AI094227, R02713, T86217, W92159, W86709, AA885954, and W86575.
HSKEH21	752	941976	1 - 952	15 - 966	AI675047, and U59429.
HSKDC06	753	935452	1 - 318	15 - 332	R82607, R64237, and T92293.
HSKCR54	754	922730	1 - 743	15 - 757	AA203533, AW129778, W67725, AL760143, AL760154, AL760161, AL141700,

					AW291405, AW084971, AI249711, AI860954, T56255, AA521444, AA933784, AI357440, AI126235, AW024151, AW054658, AI073421, AI332800, AI088159, AA740986, AI436661, AA636135, AA780513, AA844488, W68184, AI359009, AA505079, AA863180, AA011196, AA878994, AI360359, AA435579, N92742, AA083868, AI151305, AA098801, AA312160, AI291546, AI370946, AA074916, AI298772, AI219280, AI498113, AW451298, AI095138, AA011293, AA947145, AA948297, AI962142, AA563646, AA010799, N30192, AA398878, AI076091, AA307568, AA316691, AA039627, AA843701, AI266592, F16320, R56976, AI918303, AA928915, N40842, AA706164, N57341, AA074919, R76961, AA721373, AA098800, AW451443, N29414, AI475037, AA872862, AA083975, AA320742, AA010857, AI265777, and T56399.
HSKCD43	755	714389	1 - 492	15 - 506	AA424097, AA452654, R02449, AF033120, AF033121, and AF033122.
HSKBW86	756	785783	1 - 351	15 - 365	
HSKBW62	757	521937	1 - 316	15 - 330	AA653323, AA598964, AA653202, AI732164, AI821721, AA745570, AA610482, AA569206, AA364953, AI624800, AI092525, AA564510, N25034, AC004253, Z83843, AC004386, Z95125, AI137312, AC005899, AI049709, AC007690, AC005746, AC003102, AC005616, AI133353, AC002456, AP000507, AI021154, Z97206, AC004699, AC004905, AC005844, AC004970, AC002326, AC004887, AC003047, AC005031, AC004999, U80017, S83170, AI031662, AC007314, AI035420, AI034561, AI135744, AC005011, AI022165, AI035090, AC006312, AB000880, AC006441, AC005903, AI031905, AI079342, AI139054, AC007151, AI078581, AC004491, AC004601, AI035587, AI050348, AI080243, AC005684, AC004832, AC004851, AC004938, AC009516, AC005200, AC006111, AC002978, AC002123, AC007425, AI078460, U82828, AC018633, AC004217, AC002465, AC002300, X76498, Z97055, AC007999, AC002302, AI035691, AI031003, AC007207, AB001523, AC002418, AC003010, AC008372, AI035361, AI111169, AC005553, and AI021578.
HSKBW21	758	671383	1 - 128	15 - 142	AI218427.
HSKBV67	759	561585	1 - 245	15 - 259	
HSKAE10	760	968508	1 - 680	15 - 694	AI478821, AI034114, AW057617, and AI034113.
HSKAC29	761	535402	1 - 362	15 - 376	AA381761.
HSJCA03	762	925252	1 - 450	15 - 464	AA813174.
HSJAY64	763	866540	1 - 301	15 - 315	T59788, and T59655.
HSJAB49	764	723261	1 - 325	15 - 339	H60179.

HSHCL04	765	840406	1 - 1575	15 - 1589	AI282710, AA469327, AW272815, AC007637, AL021154, AC007055, AL049780, AC007216, AL109827, AL035072, AC002369, AL096791, AL021453, AC002425, AP000501, AF196779, Z82206, AL031311, AC005837, AC006241, AC005409, L44140, AC004531, Z84469, AL133448, AC005520, AL022316, AP000689, AC005740, Z98941, AC005562, AC005914, AC004686, AC007263, AC004905, U91318, AC011311, AC005736, AC004525, AL110502, AC004217, AC004895, AC005899, AC005288, AC007298, AC005553, AL121658, AC005920, Z99716, AF109907, AC006064, AC005972, AL031447, AC005696, Z98742, AL133485, AC007225, AC004782, AC002492, AC004125, AL035420, AL022329, AC004985, AL008582, AC005280, AC004841, AC005911, AC018633, AC006006, AP000046, AP000140, and AL022320.
HSHCK86	766	785392	1 - 564	15 - 578	
HSHCI63	767	468536	1 - 489	15 - 503	
HSHBU07	768	866636	1 - 443	15 - 457	
HSHAH05	769	932689	1 - 379	15 - 393	H02663.
HSCAF60	770	537444	1 - 372	15 - 386	AI684502, and AL080250.
HRDFU03	771	924698	1 - 352	15 - 366	R07659.
HRDFH46	772	590391	1 - 523	15 - 537	AA102589, AA804174, and AA026519.
HRDFG13	773	925350	1 - 237	15 - 251	AA443411, Z99716, and AI236681.
HRDFF47	774	740594	1 - 101	15 - 115	H81628, N66263, and AL049835.
HRDFD56	775	733556	1 - 447	15 - 461	AW051571, AA662497, AI022097, AA779814, AA649495, AA621426, D62952, AA621628, AI470588, D79237, N50823, R51630, AA019034, R42166, and AA887956.
HRDFA03	776	867122	1 - 974	15 - 988	AI054414, AI608771, AI204309, AI037632, AA290878, AI791227, AA577824, AA714224, AI871954, AA547979, AI445582, AW405593, AA287259, AL048969, AI133516, AA206629, AI922805, AA601425, AI907046, AA838140, AW238345, U51704, AI061646, AL042310, AA443390, AA708108, AA429020, AI581006, AI281401, AI925321, AA737309, AW247819, AA829044, AA311156, AA524604, W96277, AA610433, AL135377, N49425, AA595093, AI110760, AA581471, AI679782, AA603315, AL079869, AA224525, AL138265, AA209415, AI354847, AI889426, AA287618, AA429197, AI745133, AC004797, AC005015, AP000134, AP000212, AL031281, AC009516, AC006211, U95742, AC007227, AC006285, AF047825, AP000692, AP000030, AL049569, AF109907, AC004019, AL049776, AL024507, AC007193, AL022238, Y10196, AC007216, AC007637, AC005519,

HRDEZ73	777	774414	1 - 371	15 - 385	<p>AP000558, AC006312, AC004659, AC002477, AL022320, AP000152, AC005696, AC005529, AC006480, AC004832, AL049636, AL049869, AC004865, AC007011, AC000025, AC005527, AC004217, AC006449, U85195, AL008716, AC009247, AL034420, AL021707, AC007546, AC005480, AC005037, AC006064, Z97630, AL034423, AC003043, AC002288, AL031311, AB023049, AC007688, AF207550, AE000658, AC004685, AL022476, AC016025, AL031284, AC006530, AC002316, AL035422, AL078581, AC007014, AC005785, AC005280, AC000353, U96629, U95740, AC004876, D88270, AL022316, AC002350, AC007308, U80017, AF045555, AL031848, Z98044, AC007684, AL133448, AC002314, AC002039, AC005081, AL096701, Z99716, AC002565, D86992, AC004253, AC005412, AC007387, AC004815, AC003108, AC005231, Z95152, AF031078, AC005736, Z85996, AC005488, AC005180, Z83844, Z93241, AC002310, AC004858, AC004675, AP000501, AL031447, AF030876, AL023807, AC005207, AC004686, AC000335, AL049780, AC002126, AC003101, Z95114, AC004878, AL049709, AC010205, AL049759, AP000553, AC005295, AC000134, AL049766, AC005274, AC002470, AC005821, AL031659, AC005071, AC004000, AL035086, AL035405, Z97054, AL049643, AP000113, AC004812, AP001052, AL022328, AC006571, AF001549, AL121652, Z98742, AP000689, AL021546, AL020997, AC004967, AC006966, Z98036, AC006441, AL049757, AL021154, AC005082, AC005920, AC005088, AC003695, AF038458, AF088219, Z68870, AC006130, AC006115, AC007919, AC006487, AC002303, AC005859, AC004765, AP000502, AL121825, AC004383, AL022237, AL096791, AC007934, AP000045, AL031680, AC005666, AC005225, U95743, AP000552, Z82190, AC005839, AL031597, AL022326, AC004883, AC005793, AC005921, AC005089, AC005031, AC002352, Z93930, AC005516, AC004851, AF129756, AC012384, AC007664, AC005520, AL050321, AC007225, AC007371, AL109798, AC007066, AC003690, AC005632, AL121655, AC004882, AL050348, Y14768, AC005914, AC005972, AC007358, AL050341, AL050318, AC004477, AC004491, AC002425, AC005971, AL009181, AL109827, AC007192, AF001548, AC004638, Z93023, AC005324, AP000505, AL080242, AL133243, AC005544, AC007676, AC006120, AC004933, AF111168, AL079342, U82828, AC002472, AC005387, Z83822, U91321, AL022165, AC002558, AL050332, AP000688, L78810, AC002544, AC005011, AL049872, AC005041, AJ003147, and AC005399.</p> <p>H26725, H22204, R48422, H40444, AW299397, AI125783, AI003778, AA470331, AA470347, AA468450, AA468277, AA468204, and AI924555.</p>
---------	-----	--------	---------	----------	---

HRDEX24	778	867123	1 - 750	15 - 764	AI347412, AA098880, AA099225, AI473261, AI308141, and AI468639.
HRDER90	779	789140	1 - 414	15 - 428	AA084891, H82037, T85036, R94550, and R01653.
HRDER35	780	707569	1 - 447	15 - 461	W02017, AB011399, AL049698, and AB016897.
HRDEP20	781	690456	1 - 878	15 - 892	N41324, AA196645, W80987, N56686, AA317626, H71355, AA305440, AA150080, AI885648, W92648, AA070703, AA824341, AW410573, AW157530, AL040266, AA045127, AA043642, AA368590, AA325559, AA587915, AW250790, AA778651, AA317723, AW410572, AI139138, AW007464, AI819989, AW188549, AI951992, AI951978, AA036715, AI677931, H92998, AI364379, AI758826, AA303613, AA749431, AW162769, AA584288, AI376410, AI373112, AA383234, AA977318, AI187131, AI768324, AI076148, AI934676, AA150015, AA057355, W70033, AA682387, AA196549, AI000432, AI040155, AA513466, AA946608, AI038499, AI279549, AA778720, AI887548, R60037, N86794, W94564, AA487107, AI758476, AW273537, AI077415, AA836837, AW103741, AI199096, AI439996, AI278114, AI038357, H94227, AA186980, AI253749, AI700221, AW004637, AA045098, AI200368, and T35014.
HRDEK53	782	867137	1 - 275	15 - 289	AA703174, AC005585, and AC004832.
HRDEI33	783	487523	1 - 110	15 - 124	AL034344.
HRDDX67	784	460145	1 - 438	15 - 452	AC007541.
HRDDX01	785	921501	1 - 376	15 - 390	AI871189, AA512915, AI636339, and AI017463.
HRDDU41	786	712572	1 - 297	15 - 311	AI280574, AA329535, AI559583, AW089016, AI983047, AA743968, AI453160, AI554725, AI564294, AI436330, AA715891, AA657910, AA613775, AA837715, AA287502, AA632765, AI471467, AA573693, AA326904, AI306717, AA643451, AA636102, AI628859, AI049701, AA577824, AI762528, AI253376, AW007424, AA809153, AA017240, D51809, F00688, AA552989, AW073498, AI929410, AI753672, AI049512, AI925978, AI750950, AL043212, AA993165, AI280535, AA857812, AA233951, AI590598, AA598734, AA099840, AL041019, AW265279, AW084100, AI244356, AW188791, AA608520, AA704393, AL041018, AI569363, AI002762, N22153, AI524471, AA558404, AA643441, M86139, AI417586, AI225179, AL138199, AI564301, T74524, F31654, AA679353, T40629, AA846923, AA084506, AI609972, AA302978, AI255004, AI049630, AI255015, AI569546, T74259, H74326, T92803, H38769, AI537800, AW263867, AA223910, AA230146, T90477, AL120543, AI061313, AW084173, AC004605, AC007283, AP000501, AL031659, AC005227, AC005180, AC006515, AP000365, AL049779, AC010206, AF003626, AC004707, Z95152, AC007193, AC004662, AL035555, AL031275, AL031407, AC004694, AI003081, U80017, AC004531, Z99943, AL022238,

					AC004955, AC006101, AC002375, AC004019, AL024498, AL031283, Z97876, AC008124, AC008119, AL034420, AC007376, AC003101, AF111168, AC008040, AC005317, AC004744, AC007050, AL022476, AC005562, AL021578, AC006208, AC007386, AC005529, AP000550, AL022324, AC007773, AC008018, Z97353, AC004242, AL023575, AC006449, AF064860, AC000025, AC004099, AC006011, AL031985, AC005527, AL133238, Z83847, AC004031, AC008009, AC003029, AL109963, AC005988, AC004738, AL109839, AC007057, AC002551, AL049758, AC005747, AL035682, AL031289, AC003964, AC008039, AL022336, AC004895, AP000692, AC016027, AC002312, Z98941, AC007630, Z75887, Z97054, AC007207, AL035462, AC004653, AC016830, Z85986, Z93016, AC005884, AB020864, AC002563, AC002470, AL049712, AC007938, AL023803, AL031295, AC006511, AL049694, AC005071, AL031228, AC005041, AC019014, AC005899, AC005300, AC004928, AC005288, AC000353, AF165138, AC004638, AL122020, AL133500, AC002395, AL035086, AP000088, AC005089, AL031729, AC006946, AC006254, Z73417, AF011889, AC004383, AL049757, AC005074, AF165926, AP000117, AL049691, AL021394, Z93023, AC005316, Z95118, AC006160, AL031277, AF038458, AB000882, AC005207, AC007240, AF196971, AC004859, AL117694, Y11107, AC005231, Z86090, AC005666, AC005280, AC005004, AL034423, AC002072, AC007421, AC004150, AC005632, AP000011, Z84480, AC004131, AP000032, AL022316, AC007363, Z93096, AC005971, AC012384, AL022165, AL049643, AC004088, K03021, AL050307, AL022313, AC002496, AC007664, AL031428, AC008115, L48038, AC007011, AC005102, X54150, AC007868, AC005412, AC002057, AC004552, AF047825, AF091544, AC005215, Z83840, Z93020, AP000313, AF207550, AP001053, AP000194, AL021546, AC005844, AL121923, AL031055, AL049642, AF152364, AC006312, AC006581, AC004491, AC004222, AC004033, AP000050, AC004381, Z93244, AC005399, AC005393, AC004985, U95740, AC006050, AC004921, AC007372, AC004967, AP000270, AC009721, AL096816, AC004782, AC005921, AC005837, AP000547, AL121825, and AL031735.
HRDDR39	787	867151	1 - 210	15 - 224	AA422067, AI822098, AI341461, and AI338541.
HRDDQ55	788	490884	1 - 598	15 - 612	AW410844, AW148821, AL121039, A1702049, AI890283, AW265468, AW162314, AA640305, AI567676, AA765899, AA507623, AW162332, AI064968, AI884404, AW275432, AI174703, AA601336, AW021674, AA280886, AA515727, AW151541, AI252005, AI254463, AW439224, AA831426, AA728954, AA313025, AI570067, AI250333, AI538404, AA524604, AW192930, AI090377, AA935827, AA558488,

AL138262, AW328185, AI445699, AA568303, AW238137, AA804177, AI819419, AI791659, AI609992, AA551062, AA101744, AI174827, AI039257, AI572680, AA496369, AA593168, AW338633, M77964, AI754653, AW057760, AI890857, AW020612, H86399, AI857834, AW239465, AW152451, AI890297, AW338376, AA171400, AI560241, AI798521, AA218684, AI921744, AA568433, AI281622, AI224583, AA661583, AA493245, AA584360, AI500645, R23873, AA568311, H05066, AI754421, AI815770, AL044966, AA676592, AI683079, AI926728, AC007934, Z85986, AC004150, AC006359, AL122023, AC005900, AL121655, AC005696, AC006057, Z98200, AL121595, AD000092, AC005089, AL031311, AL021808, AP000556, AC007637, AF109907, Z73979, AL049869, Z83840, Z84474, AL031983, AL132712, AL080317, AC002404, AF196779, AP000555, AC004491, AC005409, AL031281, AP000280, AL031289, AJ011930, AL121653, AP000107, AC016025, AC004796, AC016026, AC004814, AC004099, AC008044, AF129756, AC007240, Z98749, AC004000, AC005618, AC002347, U80017, AC007845, AC006487, AC005899, AC005175, AC008009, AC005839, Z98044, AC005822, AC007055, AC002565, AC005971, AJ003147, AC004891, AL022323, AC004584, AC005488, AL024474, AC007565, AP001068, AP000250, AC005500, AL022318, AC002310, AL035089, AC010205, AL049694, AP000211, AP000133, AL049538, Z92542, AL096712, AC005071, AL080243, AC004019, AP000030, AP000512, AC006013, AC005924, AL031670, AF196971, AC005755, AP000691, AC004263, AC005519, AC005295, AL133163, AL096791, AL022165, AL020993, AC007227, AC005037, AC005666, AP000692, AC008125, AD000864, AB033024, AP000553, AC005726, AC004066, AF118808, AC005399, AL049839, AC005730, AC004084, AC006121, AP000309, AC004799, AL132992, AC002996, AL049646, AF111168, AL022336, AC006050, AF088219, AP000275, AL031257, AC007510, AL109628, AC002126, AC005291, AC005280, AP000037, AP000105, AC002036, AC004895, AC005003, AL031680, AL024498, AL050308, AC002477, AL034420, AC007688, AC005251, AC004685, AP000116, AP000326, AF165926, AL031587, AL022240, AC005031, AC000075, AC005722, Z98950, AC006454, AF002993, AC004673, AP000054, AP000169, AC006547, AC004821, AC003109, AC004890, AC004913, AL031255, AF191071, AC008115, AC002492, AL022326, AC007687, AP000048, AC004097, AC005412, Z98048, AC007536, AC005253, AL023879, AL049653, AL033539, Z98742, AL049776, AC005921, AL109952, AL035460, AF038458, AC004999, AC005881, AL049709, AL021154, AC005261, Z15025, AL078593, AP000248, AC005808, AC004593, AL022313, AL022315, AC005531, AL035450,					
---	--	--	--	--	--

						AC004907, AC007298, AP000505, AC004033, AC006241, AC002306, AC005701, AC009178, U91326, AL049636, AC008134, AC005216, AC003982, AL035086, AC005365, AC005844, AC005535, AC004476, AF205588, AC005763, AL020997, AC008372, AC003043, AC007676, AC005244, AC005281, AP000036, AL021579, AC006160, AC005102, AC004771, AL022320, AL031427, AC006530, U52112, AP000039, Z97183, AC006978, AL121825, AL008582, AL050307, AL109753, AL034343, AC006369, AC002544, AC005664, AB023051, AF134726, and AC006277.
HRDCD44	789	715769	1 - 558	15 - 572		W03563.
HRDBH52	790	728715	1 - 559	15 - 573		W69216, R85388, AA677237, and AW295702.
HRDAB42	791	800333	1 - 415	15 - 429		AA372217, and N74721.
HOSOW01	792	914804	1 - 472	15 - 486		R12246, T97409, H20317, F10552, AA642698, AA463715, T03808, AA135561, AI912860, T16035, H17063, AL109623, AC010206, AC004787, AL031186, and AC007358.
HOSNO25	793	974291	1 - 601	15 - 615		AC005243.
HOSMP95	794	948496	1 - 591	15 - 605		R09369, N78208, N59653, AW295483, T85232, R09252, T89192, A1638845, AI824892, AF161355, AC004500, and AF197927.
HOSGN29	795	830653	1 - 420	15 - 434		AA463363, AA490561, AA452944, T66840, AI907242, AA774254, AA972623, AA459531, AA355833, N77376, Z20330, AA088535, AI561196, H90342, AA610050, AA883211, H90382, and AF155107.
HOSFV77	796	856933	1 - 645	15 - 659		AI302244, AI376858, AA744868, AI655166, AA206365, AI016092, AW117621, AL135188, AI473834, AA442880, AI218992, AW440891, AI619652, AI218976, N58875, AA005386, AA515059, R83118, T66299, R37419, AA227169, R66694, N54853, R67572, AW168764, AI862971, R83130, AA782861, R27978, T95799, AA731049, Z38308, AA813893, AA256649, R28234, R66224, and AL035411.
HOSFU59	797	739262	1 - 424	15 - 438		AA026237.
HOSFL57	798	734709	1 - 351	15 - 365		R21661.
HOSFL07	799	953183	1 - 677	15 - 691		H80558, AA011699, AA249550, N50173, AA720594, AA812006, N53417, AI985322, and AB032996.
HOSFK40	800	711140	1 - 566	15 - 580		AA056618, AW015136, AI640750, AI814601, AI215460, AI478294, and T98138.
HOSFI46	801	719021	1 - 297	15 - 311		N55220, AA488250, W92994, AA897297, D81949, AP000495, and AC002076.
HOSFC66	802	750560	1 - 671	15 - 685		W52745, AB023145, and AB028449.
HOSFB04	803	615200	1 - 412	15 - 426		R15372, HI6359, and RI9326.
HOSDR12	804	971169	1 - 447	15 - 461		Z99943, AC004000, L78810, AL117352, AC006387, AF155238, AP000556,

						AP000557, AC003006, AL031685, AL049759, AC004590, AC007371, AC004069, and AR038753.
HOSDQ78	805	858983	1 - 488	15 - 502		AC006474.
HOSDP27	806	682113	1 - 500	15 - 514		N26610.
HOSDG79	807	781787	1 - 913	15 - 927		W95020, R91323, H70373, and AL655142.
HOSDA04	808	951842	1 - 525	15 - 539		AA846729, AI028108, AA846827, AI609525, AA724378, AA843409, AW195335, AI949374, AI129292, AA706724, AI806599, AA700507, AI031774, AI478383, AW003724, AA056023, AA029907, AI206246, AW197629, AI082553, AI026964, AI023934, AI026963, AW235807, AI079146, AI056148, AA424153, AA854249, AA843263, AI022608, AA479110, AI802270, N90579, AA846140, AI168397, AI031992, W39235, AA846163, AI022871, AI335584, NS2355, AA723602, N35347, W04599, W15275, AI026070, AA044387, AA452000, AA772698, AA724104, W45008, NS2362, N94993, AI478133, R54828, AA772128, W32433, AA479261, AA411010, D79933, D79420, AI382712, AA056071, C00297, N75133, D62903, and AL110152.
HOSCV06	809	960555	1 - 346	15 - 360		AI610013, AI090186, AW173233, AI127920, AA058965, AA099683, AW082370, AA146976, AI873263, T94367, AA099684, AA136188, AA137215, AA279168, and AL133104.
HOSCT25	810	783692	1 - 449	15 - 463		T83223, AI074110, W47135, N27470, W24127, AA284235, Z19637, AA936569, and A74325.
HOSCP67	811	753874	1 - 505	15 - 519		AA181657, and AA190577.
HOSCO73	812	764756	1 - 305	15 - 319		T90400, and AC008063.
HOSBY89	813	787182	1 - 429	15 - 443		W03298, AW453073, R91771, AA248939, and AA281702.
HOSBX46	814	719414	1 - 352	15 - 366		AI435472, NS2787, N48806, AL049781, AB002309, and U17195.
HOSBX34	815	706769	1 - 533	15 - 547		HI0526, R20107, F05110, and AC008009.
HOSBR53	816	728525	1 - 613	15 - 627		H29345.
HOSBO34	817	706770	1 - 474	15 - 488		AA167280, AI269650, and AW404853.
HOSBM55	818	732550	1 - 528	15 - 542		N70015, N70098, W00901, R17917, W00930, R18009, AB014087, AC004188, and AP000516.
HOSAY52	819	728759	1 - 352	15 - 366		AA249054, AL118892, N45598, AA628647, AI016287, N57609, AL049781, AB002309, and U17195.
HOSAX03	820	960942	1 - 931	15 - 945		AA400703, AI684638, AW070184, AI090864, AW183803, AA400657, and AW293645.
HOSAL10	821	968710	1 - 299	15 - 313		AA075375.

HOSAI41	822	712708	1 - 1063	15 - 1077	AA203712, AI807483, AA203713, AI088364, AI131250, AA489726, AA489625, AA004409, AA705699, AA723797, AW293365, H95647, T98715, H82415, and AI022074.
HOSAH30	823	693406	1 - 479	15 - 493	H19428.
HOSAF19	824	672078	1 - 516	15 - 530	AA147082, and AA312956.
HOHEN28	825	686034	1 - 444	15 - 458	N33237, AI631133, AI917082, AI657012, AI624839, AA902453, AI655635, AI273682, AA729233, H27969, AA761232, N21684, AA417084, T06849, AW004990, AI280456, AI865276, AI638369, and D31765.
HOHEG71	826	760051	1 - 529	15 - 543	AA233884, and AA232830.
HOHDF94	827	793970	1 - 702	15 - 716	AA081832, and AB018257.
HOHCV57	828	734413	1 - 488	15 - 502	N76235, AB007936, and AL109755.
HOHCL29	829	634778	1 - 381	15 - 395	AI525843, AI541231, AI541114, AI541109, AI547179, H41687, AA984744, AI547043, AL044967, AI547164, AA094680, AA525444, AW014590, H18262, H50911, H45071, H41335, H42388, F33456, AI979115, AI547122, AA484568, AA28311, AA090063, AI498779, AA096319, AA426205, M27358, K01364, X00686, X56974, X82564, M10098, K03432, U13369, X03205, AF000381, K01593, M29839, X01117, V01270, M11188, X06778, J01876, X00640, X59733, X59734, K01373, X04025, AF115860, M97576, J00999, X02995, AJ279506, M91183, M15821, L11288, M91181, AJ270030, X98837, AB029314, X98838, X98841, X98839, X98843, X98846, M91180, X98840, X98844, M91182, AF169014, AB016657, X98836, AF030250, M97575, M97573, M59398, U76257, U11437, M59400, M91179, Z61867, M59402, M59401, AF021880, M59384, M59387, M59392, M59390, M59383, M59403, M59393, M59397, X98845, M36006, M59389, M59385, AB016658, M59386, M16759, S60585, AB016659, M59395, M59391, D38360, D38357, D38341, D38358, D38354, D38363, D38362, M59396, M59388, D38359, M59399, and M59394.
HOHCH52	830	588375	1 - 555	15 - 569	R63803.
HOHCG79	831	859029	1 - 453	15 - 467	AI025117.
HOHCD58	832	973105	1 - 442	15 - 456	
HOHBZ27	833	588364	1 - 453	15 - 467	T26461, R12434, and AI909064.
HOHBY26	834	588358	1 - 464	15 - 478	AA190664.
HOHBV67	835	718562	1 - 527	15 - 541	AA464946, AA045533, AA058869, Z43315, F07427, R34556, D20922, and R17869.
HOHBS10	836	964324	1 - 396	15 - 410	AW072006, AA992322, AW183466, AI590479, AI610065, AA524829, H53828, AA828610, AA476397, AA572713, AA431949, AW440299, R49657, AI436608,

					AI114557, AA480574, AA847702, AA482953, Z84469, AC005899, AC005822, AC006079, AC008125, Z93016, AC002544, AC004408, AC005411, AJ011930, AC005996, AC007773, Z98257, AC002553, AC006211, AL035086, AC006088, AC005332, AC004263, AC009225, AC004841, D87675, AL133243, AC004884, AC004460, AC020663, K03176, K03178, Z99716, AP000961, AC005747, AC006080, AC004659, AC006978, Z84480, AC002316, U96629, AC006959, AC005186, AC006318, AC007050, AF165176, AL022326, Z68164, AF008191, AF017104, AC004230, AJ003147, AC002091, AC011504, and AL022329.
HOHBP36	837	708158	1 - 468	15 - 482	N53160, H56717, N58596, H56640, W27084, AA516214, F19606, AA515728, AA558487, AA278482, A1823533, A1823535, AW057873, AW151288, A1356264, Z54073, AF001548, AF205588, AC004263, AC004982, AC006948, AC005081, AC005476, AC002390, AL049843, AL009181, Z82215, AC007312, AL049757, AF129756, AC003010, AC009225, AC006312, AP000555, AC004601, AL021878, AC005684, AL035411, Z98949, Z93020, AL049709, AF134726, AC004985, Z84476, AC003101, AC004820, AL109627, Z85987, Z93241, AC009405, AL049613, AC005036, AL109753, AP000091, Z95115, AF196779, and AL008721.
HOHBN56	838	859041	1 - 897	15 - 911	AA489227, AA490533, AA504306, and AA490534.
HOHBL35	839	973238	1 - 462	15 - 476	
HOHB184	840	782908	1 - 363	15 - 377	H46912, AA287471, AA399188, AW007707, AL036600, AA025639, and AA405089.
HOHBB90	841	588308	1 - 448	15 - 462	R76965, AI077565, AA452929, AI393755, and AL035455.
HOHAV60	842	489007	1 - 827	15 - 841	N20939, AI337242, H68935, AI224489, F27732, F37358, and AC007279.
HOHAT59	843	867949	1 - 454	15 - 468	AI124699.
HOHAT11	844	966727	1 - 622	15 - 636	U83208.
HOHAQ65	845	859057	1 - 501	15 - 515	R06584, R06638, AA086435, AW408596, AA111870, CI4480, AA279649, AI680547, AA608570, AL135363, AA595661, AA158018, AA554257, AA205436, AW162227, AA470512, AA599423, AA315361, AA722336, AW082098, AA470559, AA569053, H64278, F33037, AA348399, AI298079, AA378489, AI271762, R81167, R89129, AW069537, AI440037, AA368659, AC005042, AC005207, AC002425, Y08864, AC005531, Z49236, AP000099, AC005598, AL109865, S42653, AC007182, AL034420, AC007637, AL022720, AP000036, AC007738, AP000553, AC004820, AC004531, AC008273, AF069074, U91326, U68041, AC003684, AL049712, AL021453, AC007563, AC005746, AC008015, AL031228, Z49862, AL031681, AF181897, Y10196, AC007050, AL023494, AL031311, AL049776, AC004900, AL031291, AC002492, AL096791, AP000133, AP000133, AP000211, AC006211, AC002477,

					L78833, AL022329, AF030453, AC007011, AC003108, AC002094, AC002301, AL034429, AL035422, AL049636, AC005082, AC005324, AF099810, AC005412, AL121578, AB026898, AF001550, AC002132, AC004472, AC002996, AL049538, AC004223, AL035413, AL033521, AC005180, AL121658, AL050318, AP000354, AC006312, AP000086, AC005484, AL080243, AL132712, AC004526, AL049569, Z49235, AL021155, AP000117, AC002456, X84664, AF196779, AC002375, AL096818, AC003966, AC005305, AP000349, AL021546, AC004927, AC005911, AC005102, Z93023, AL034423, AC006062, AP000353, AC005048, AC004655, AC002347, AC002563, AC006011, AC005486, AC004551, AC003685, AP000555, AP000689, AC004750, AC006023, AC004890, AC002429, U95740, AC006057, AC004883, AP000047, AC002385, AC005300, AC007388, AC003109, AL035071, AC006377, AC008372, AP000049, AC004893, AC006017, AC009516, AL096815, AC006538, AP000497, AP000311, Z98036, AL022316, AC010206, AC006071, AL030996, AP000223, AC005399, AC004787, AF109907, AC006328, AC004805, AC006430, AL096712, AC004881, AF053356, U95742, AL031666, AC005821, AC005736, AC007250, AC009399, AF172277, AC005220, AC005914, and U91323, H02088, R30796, AI904000, and AW175694.
HOHAM6 6	846	859058	1 - 545	15 - 559	
HOHAII1	847	947140	1 - 4073	15 - 4087	AA424371, AA417690, N72255, AA417582, W02998, AI378916, AA424511, and AF086109.
HOHAE76	848	494001	1 - 453	15 - 467	T59559, and T59513.
HOEOA28	849	859156	1 - 786	15 - 800	AI276895, AW026397, AA053296, AA054752, AA789119, AI745474, AA744964, AW087227, AW379213, and AC002519.
HOENH06	850	934095	1 - 844	15 - 858	AW007160, AA393649, AI022457, AI139147, AW386744, R40518, HI4594, Z40081, F01575, R48161, F10287, N93352, AA468505, AA614254, AA228368, AA468371, AA230025, AA467760, AA224889, AA228269, AA298789, AA838161, AA599710, T47138, AI355385, AA381754, AI418967, AA224815, AI270370, AA197218, H63066, AW057873, AA259267, AA558404, AA130647, F00533, AI192440, AA836552, AA302971, T49633, AI290405, AA668915, N63149, AA668896, AL050306, AC003030, AC006965, AC004491, Z85986, AC007283, AL096703, AC004765, AL078581, AL050318, AC005280, AL022311, AC002477, AL109628, Z84480, U91318, AC007055, AC004815, AC002472, AC006124, AC006071, AC005829, AC005682, AC006079, AC002997, AC004216, AC005932, AC007546, AC007664, AC007536, U63721, Z73963, AF047825, AF196969, AC005764, AC007566, AC004560, AC005632, AC004222, AC004638, AP000696,

					AL049780, AL049538, AC007226, AC002369, AL032821, AP000112, AP000044, AL050348, AL049569, AP000695, AC006006, AC006449, AC006208, AL035398, AL035405, AC007917, AL022324, AC006255, AP000501, AC004590, AP000245, AP000497, U89337, AC007052, AC005225, AC000052, AC004019, AL035410, Z99716, AC004030, AC007541, AC000353, AP000557, AL035422, Z68226, L44140, AC005952, AC007066, U82668, AC005899, AL035587, AC005324, AC007537, AC005015, U91326, AC007371, AC004655, AC002310, AC003983, AL020997, AL035659, AC006480, AC005081, Z93023, AC005529, AC005182, AC006277, AL049869, AC006211, AC005291, AP000512, AC007860, Z97054, AL049694, AP000115, AB023050, AP000034, AC016025, AC004477, U96629, AC005102, AL031577, AL034429, AC004129, AL034548, AP000502, AC005881, AC005231, AC012331, Z98745, AC005387, Z98946, AL021878, AC005338, AL022320, AL049830, U78027, AC006344, AL035086, AB026898, AC006285, AC005519, AL031282, AC005369, Z99128, AC003041, AC005071, AC003010, U95740, AC002425, AC006115, AC002303, AC003982, AL022163, U91319, AL008582, AB003151, AC005678, AC005058, U82828, AC007216, M13792, AL049576, AB022785, AC005694, AC007687, AL022326, AL033397, AC004217, AL031680, AP000244, AC006530, AL008719, AF001550, AP000065, Z93017, AL133245, U91321, AC005183, AL035555, AC003029, AL031985, AL035249, AP000326, AC004686, AC002544, AP000212, AC007738, AC002107, AC005209, AC004526, AP000122, AP000054, AP000169, AL049776, AL031311, AC006450, AC005365, AC005014, AC005488, and AC004024.
HOELI08	851	958181	1 - 669	15 - 683	AI862922, AI983798, AI817696, AA465702, AI768039, AI831870, and AA459562.
HOEX37	852	708728	1 - 703	15 - 717	H44964, AI570044, AI078541, AI570062, AA733022, H45674, AI084055, W94003, N28018, and AC007285.
HOEEU57	853	932562	1 - 818	15 - 832	AW387014, AI831578, AW387023, AW386986, AA862453, AI276148, AI923983, AI925229, AI344497, AI299183, AI343937, AI086925, AW374923, R21305, R18269, AA333257, AI991662, AI093616, W02289, R87814, H08423, AA528079, Z45607, AA455633, W49743, R58057, AI124525, AA767913, Z42086, and R56671.
HOEER75	854	767265	1 - 800	15 - 814	AI989799, AW299570, AI978646, AI638110, AW290948, N67990, AI962847, AW167412, AA706538, N80412, AA961236, AI557808, AI525653, AI557238, AI525669, AI541321, AI541048, AI557258, AI557602, AI541205, AI541353, AI557809, AI535813, AI546829, AI557222, AI535994, AI557543, AI525840, AI541346, AI525656, and AI133617.
HOECI59	855	739426	1 - 640	15 - 654	AI016603, AA884245, AI806142, AI199574, W07522, AI492605, AI767868,

						AW014287, AI143416, AA126482, AW072550, AI377899, AW002034, AI223352, AW418843, AI033261, AI018587, AI760070, AA908231, N80857, AI660406, AW449281, AI479045, AW303620, AW184004, AW195771, AA250993, AI332874, AC003959, and AF086145.
HOECF70	856	573426	1 - 193	15 - 207		AA602457.
HOEBT89	857	921065	1 - 352	15 - 366		R66475, AI692694, AI677948, N32840, AI187227, T19392, AI499800, H51056, AA169602, AI208443, AW134907, R67315, and AI209123.
HOACG06	858	954572	1 - 485	15 - 499		AW152166, AA011199, H18839, AI718722, and AA010802.
HOABY40	859	711510	1 - 540	15 - 554		N62212.
HOABX26	860	753954	1 - 562	15 - 576		AA065209, AA077377, T32948, AI571240, T08560, R90825, AI033147, AI277382, AI453118, R88021, AA663789, H14060, R87895, AA077707, and AC005071.
HOABX21	861	531390	1 - 75	15 - 89		
HOABW1	862	968797	1 - 387	15 - 401		AI075814.
	2					
HOABG91	863	811156	1 - 221	15 - 235		AB011540, and AB011533.
HOABF65	864	888203	1 - 284	15 - 298		
HOABD07	865	954060	1 - 358	15 - 372		AI269153.
HOABA95	866	796063	1 - 405	15 - 419		R31045.
HOAAAX37	867	708718	1 - 330	15 - 344		T97580, and AF143887.
HOAAW1	868	967660	1 - 489	15 - 503		AA525910, and AC004049.
	1					
HOAAW0	869	920869	1 - 393	15 - 407		AA284348.
	2					
HOAAV77	870	772512	1 - 398	15 - 412		H84034, and N44965.
HOAAO86	871	859626	1 - 431	15 - 445		AA662926, AW204080, AA700032, AA514295, N52358, AA621278, AI126468, AA653154, AI986182, AI174766, AA933084, AA829039, AA547947, AI135357, TS2475, AW303008, AA601356, AA565484, AI366993, AI002744, AA630672, AI635819, AA570230, AI630176, AL042756, AW068596, AI920802, N41888, F08230, AW263724, AA507612, AI611960, H93097, T90263, AW002350, AI583255, AI890324, H73230, AA629872, AI628929, AA443390, AC005914, AC002301, AC002395, AC005488, AL109865, AC004801, AC007051, AL034420, AL031846, AC002554, AC007298, AC006057, AC007201, AC008055, AC005668, AL035089, AC005043, AL049569, AC009247, AC004491, AL133246, AL022319, AL009181, AC004216, AF205588, AC003104, AC005482, AP000694, AC007225,

AL023284, U91323, AC005280, AL031905, AC004859, AC007919, AC005839, AC005678, AC004821, AC006313, AC005632, AC000353, AL080243, AC002303, AC006211, AF111169, AC002449, AC005225, AC005261, AL049869, AC005694, AF181897, AC004659, AC007242, AC005046, AL035685, AC007510, AC005484, AL049764, AL139054, U91326, AC006039, AC006026, AL035448, AC006040, AF107885, AL121653, AC005874, AF134471, AC007666, AJ246003, AC007358, AC004685, Z86061, AC002365, AC004525, AL021707, AC004913, AP000088, AC004813, AC007204, AC004955, AL033397, AC006088, AC006312, AL020993, AC004887, AC005829, AC007676, AC007559, Z84487, AC006538, AC005378, AL133243, AC005015, AP000134, AP000212, AL121658, AC004814, AC005531, AC002115, AC005332, AC003962, U91321, AL031055, AL031985, AL096701, AC004851, AF196779, AC007546, Z97054, AC006064, AC004953, AL133448, AC006501, AC003957, AC020663, AC006115, AP000031, AC004797, AL035361, AL008718, AC004595, AL078477, Z98946, AP000152, AC004638, AL035405, AC006013, AC004968, AL031255, Z85986, AC005102, AC005152, AC000052, AC005386, AL008629, AL023807, AP001052, AC004019, AC010206, AP000039, AP000280, AC007011, AL080241, AC005081, Z99916, AC007845, D87675, Z85987, AC005088, AC005988, AC002091, Z97055, AC005291, AC005529, AC002544, AL031279, AC006480, AL021391, AL021154, U95742, AC004070, AF130343, AC007055, AP000107, AC002563, AC006277, AC007245, AL022574, AL133355, Z97987, AC009223, AL022238, AC004655, U89337, AL117351, AC005690, AL109798, AC006120, AC022517, AC002994, AP000348, AC005740, AL135745, AC007216, AL133396, AL031311, AC006449, AL049843, AC006042, AL136295, AC004230, Y14768, AC004383, AC007688, AC016025, AL031295, AC005913, AL096791, AP000555, AC004967, AC007690, AC016831, AC005701, AL096775, AC007057, AC000025, AC004773, Y10196, AC006946, AL031668, AL023553, AC006001, AC004593, AC005399, AC005777, AC006285, AC003029, AC007684, AC007227, AL117344, AC003688, AC005585, AC018633, AL049766, AC005250, AC007193, and AC005175.					
HOAAM6 7	872	751947	1 - 292	15 - 306	H50680, and AA779243.
HOAAK71	873	761445	1 - 407	15 - 421	T95206, Z83821, AL020991, and AF088624.
HOAAK11	874	859624	1 - 430	15 - 444	
HOAAI58	875	859643	1 - 679	15 - 693	AW303494, A1039909, AA448710, D31172, D31271, AW195840, D31138, D31112, AA133322, H89975, and AB032978.

909448, W76097, AA999702, AI051236, and AI419691.  
 703576, and AA203612.  
 1H69385.  
 L037582, AL037602, AA782332, AI125109, AI039104, AW263805,  
 A830709, AI590043, AI370623, AI500061, AL046466, AI569440,  
 I613038, AI612913, AW103928, AI698391, AI887163, AI610714,  
 I581088, AW130362, AI537187, AI345010, AW118448, AW166870,  
 AI636588, AW411225, AW128834, AA720924, AI241741, AI580027,  
 I332957, AI524654, AA831128, AI950887, AI912434, AI678681,  
 AA102339, AA748729, AW073858, AW167926, AI963846, AI758445,  
 AI184903, AI950892, AI245008, T49776, AI499057, AI923989,  
 A824435, AI832038, AI635851, AI538867, AA130341, AI359744,  
 I537273, N25033, AW129456, AW103628, AL041587, AI540831,  
 I270183, AI697045, AL040161, AI141400, AW027898, AI581362,  
 I798456, AI288285, AI282669, AI472650, AI141406, AI828239,  
 AI638644, AW262552, AI521594, AI554402, AW263709, AL045610,  
 AI283385, AL119399, AI635016, AI419826, AI638798, AI434109,  
 AW087199, AI699823, AI473536, N66391, AI682968, AL042193,  
 AI586931, AI934011, AI250282, AI925164, AW081902, AI241923,  
 I590755, AI567513, AI863002, H89138, AW020358, AI884318,  
 W188525, F37323, AL040844, AI457589, AI498582, AI634223,  
 AI452560, AA665612, AW051088, AI956080, AI963191, AI445620,  
 W129659, AW169626, AW162194, AI364167, AI623835, AI619820,  
 AI434731, AI583578, AI421252, AW055252, AI567769, AA761557,  
 I446511, AA555145, AW264009, AI075885, AI889189, AI538885,  
 AA810677, AI114703, AA641577, AI824576, AI688854, AA641818,  
 L080011, AI889916, AI784214, AI538564, AI251221, AI915291,  
 AI819545, AW270013, AI683606, AW104141, AI828806, AA744531,  
 I648494, AI701097, AI225000, AI687568, AI282688, AW059818,  
 I630932, AI491842, AI627339, AI610446, AI909641, AI624279,  
 I445611, AI673363, AW087538, AI818980, AI582529, AI249389,  
 AI690813, AI962900, AI697359, AI927233, AI539690, AW190297,  
 21341, AI147877, AI254731, AW087217, AI580436, AI138221,  
 AI888480, AA52445, AI696714, AI824746, AI739583, AW131024,  
 AW129106, AI866090, AI371872, AI345415, AI435253, AI499890,

HMUBY20	880	669581	1 - 425	15 - 439	AI440284, AI374987, AI608882, AI635634, AI522256, AI093315, AI049733, AW080746, AI473652, AI874261, AW089233, AI633434, AW117675, AL117587, AC004594, AL110218, A03736, AL136884, A86558, AF102578, I89947, AF076633, AL133665, S36676, I09499, AL137550, U00686, AF040751, AL137554, AF008439, Z97214, AL035458, I48978, X99971, AL133608, Z94277, Z93784, AF026816, AF013214, AP000130, AP000208, AF185614, AF124728, AL137284, AP000247, AL133062, AL133619, U83980, AF150103, AF161418, X66871, S59519, AC005091, AJ010277, AL049426, AL137292, X96540, AL137529, AF090900, AL133560, AR050959, AF100931, AF061795, AF151685, AF044323, AJ005690, AL137479, AL110280, AL133637, AF111851, AF106697, U37359, AC006288, A26498, AR013797, X82434, AL080146, X61399, AF069506, AF047716, U72621, X66366, J05277, AL137270, E12747, X97332, X66862, I80062, AL133088, E07108, AL137533, AR034821, A60092, A60094, AF031572, AR038854, AR022283, AL137657, AL049324, AL137711, AC009233, AL022147, AL050393, U02475, AL049423, AF007142, AF200464, I17544, AL122100, U62807, AF004162, U78525, AF106657, U42766, AL137521, AC006112, Y16645, AL137298, AF184965, AL133565, AF116573, AF061573, A08912, I34395, I18358, AF000458, A08911, I48979, M19658, AB016226, X79812, A77033, A77035, I33392, AL133640, Z72491, U53505, AL110228, A08913, AL080118, X61970, AL049447, X98066, AF067790, L19437, A65341, Z13966, M85164, AL122098, S76508, S83440, S68736, AL137476, AL137254, AL122104, AL117416, AF079763, AF126488, X69026, A21625, I32738, U35846, AC009501, AL133558, AF106827, U49434, AF061981, AF019298, AJ012755, U75604, AC018767, Z98036, A92311, AF082526, AL035587, AL137557, S77771, AB031064, AF090886, A08910, Y09972, U62966, U80742, AL117394, AL133113, A12297, AL080129, AL137548, AF032666, AF055917, M80340, U49908, A08907, AC004200, AF130342, A08909, A70386, AF215669, AL080159, X83544, AL110296, AF031147, AF111849, AL137658, AF002672, AL050092, AL133049, X72889, AC004383, A08908, X06146, AC010202, E12579, E12580, and AL133084.
HMUBY20	880	669581	1 - 425	15 - 439	
HMUBV40	881	837969	1 - 420	15 - 434	
HMUBR94	882	793261	1 - 438	15 - 452	AL135377, AA828637, AA084766, AI446336, AA773463, AA984114, AL036037, R20544, AC000025, AC005527, AC005529, AC007227, AL035086, AL035400, AC004859, AC002347, AL008719, AC004531, AL078581, AC006312, AC002563, AC000353, AC004953, AC006111, AP000512, Z95115, AL024498, AC005821,

					AL023575, AL022238, AC004821, AC006011, AJ246003, AL049589, AC006261, AC004644, AC003030, AC006430, AC005520, AC004858, AL109802, AP001054, AL033527, Z98200, AC005102, AL109758, AL034420, AL020997, AC002375, AC007191, U47924, AC016027, AC005089, Z93930, Z98742, AC003007, AC006050, AF196779, AC004815, AC006509, AL049830, AC016830, AL133246, AC005209, AC002287, AC006480, AC006117, AC005837, AF129756, AL022316, AL049869, AL049776, AL035587, AC007052, AC007773, Z83840, AC002119, AP000113, AP000045, AL022322, AC007842, AC004491, AC004983, Z84466, AL024508, AL009181, AL031295, AC004967, Z84480, AC006014, AC005180, AC007298, AC006004, AC005632, AC004996, AL049697, AL049713, and AC005881.
HMUBR78	883	955060	1 - 526	15 - 540	AA019047, AI343422, and Z92845.
HMUBQ01	884	918052	1 - 377	15 - 391	
HMUBP74	885	765502	1 - 539	15 - 553	AJ432103, N66775, AA555232, AA410788, AA491361, AA228778, AI798449, AA084504, W45274, AI753904, AA324059, AA326603, T93109, AF196779, Z93017, AP000350, Z95116, AF196972, AC004832, AL023575, AL049776, AF024533, AL031311, AL139054, AC003043, AC005089, AC005015, AC005399, AC003029, AL121603, AL034417, AC007934, AC005971, AC005736, AL132777, AF111167, AC007308, AC006057, AP000008, AC000134, AC000052, AL109801, AC002316, AC000159, Z85986, AC007227, AC005088, AC005722, AC004019, AC004890, AC002369, AC008394, AP000704, AC007151, AL049780, U91321, AC005696, AC006064, Z93930, Z82180, Z85987, AC007666, AC006285, AC007878, AP000512, U85195, AC006205, AC003010, AE000658, AC005193, AL031295, AC008072, AC004967, AL022316, AC004030, AF196969, AC006088, AC003684, AC007055, AL031848, Z95331, AC004999, AC006011, AC007051, AC004821, AL035079, and AC005086.
HMUBP38	886	716800	1 - 274	15 - 288	D62503, W31481, W31478, AI031797, AW194041, AW050479, AA737576, AA693819, AA825328, AA860686, AA843163, AA782544, AI026970, AA450017, AA772466, AW152339, AI263677, AI804555, AA347503, AI824356, AI191171, AA993329, AI470261, AI886205, AA632359, AA863458, AI289935, AW132079, AI678407, AI800349, AI623948, AA450366, AA044819, AW188740, AA878533, AI364418, AI874104, AI933937, AA358323, AW131974, AA894788, AW103212, N76132, AA897025, AI915173, AI933628, AI913873, AA860713, N30064, AI579994, AI299561, AA025007, AA781624, R36254, AA934658, AW088795, AW080423, T97261, AI690491, AA614454, AI095864, AW024736, AI016555,

HMUBN15	887	659543	1 - 452	15 - 466	AI569566, AI298435, R92692, AI266450, AI689224, AI015682, AI889552, AW014696, AW189459, AA005320, AI424177, AI041476, AI801066, AW168035, W32273, AW152395, AI276661, AI028138, AA954648, AW166786, AA099737, AI344521, AI874055, AW193867, AI355584, AI734946, AA860530, AI874021, N70641, AI185811, N30060, R00232, AI138761, AI276660, AI362305, AI332470, AA024894, N22767, AW139075, AW129011, T57193, N30057, N91781, N71091, AI092410, AI288216, AI244973, T57088, AW139081, AI160023, AA490670, AI560718, AI887980, AW080420, AW419084, AI126270, AI859726, AI457657, AI274779, AI962882, AI564514, AI589042, AI689396, AA993572, N94949, AI979109, AA411838, AA602523, AA827550, AW150847, AA772171, AA917826, AI859443, AI524525, AW169111, W72460, AA056733, AI126748, AI133968, N90530, AI475928, AI344395, R82315, AW303738, AA983225, AA628813, AI564394, H13839, AA771989, AI951442, AA024806, AW021070, H22324, AI680522, R34368, AA418061, AW129473, AW151046, T48350, AA846743, N71006, AA001714, AA027095, T65946, AI921252, AI933525, AI691098, AI364257, AA011167, AI357333, T85101, AA772584, AW194109, AW022540, AW090282, and AI318244.
HMUBN05	888	932057	1 - 455	15 - 469	AA772883.
HMUBM8	889	786082	1 - 444	15 - 458	AF090896.
9					AW302705, AW302659, AI792521, AI792499, AL079734, AI801141, AA468505, AI635440, AL042667, AL042670, T74524, AW192179, AI962030, AL135357, AI053793, AI267269, AI267356, AA603567, AI049709, AA601336, AI267450, AI053688, AA772906, H07953, H82636, AA809546, T41134, AA669238, AA491767, AI733856, AW023111, AI016560, AA659832, AI982884, AI923050, H38769, AI590442, AI754291, Z98044, Z97630, Z84469, AC004764, AL049776, AL035422, AC002470, AC004813, AC009247, AL139054, AC007308, AP000694, AL079304, AF129756, AC005218, AC005874, AF134471, AL133245, AC004382, AL031228, Y10196, AC006511, AF196779, AL049872, AB004907, Z82176, AC008055, AF053356, AC006530, Z86090, AC005081, AL121655, AC002425, AC003962, AC004655, AC005776, AC006509, AP000354, AC005678, U61375, AC006130, AC005520, U07562, AC006050, AP000501, AL031311, U85195, AL023803, AF165926, U91323, AL049697, AE000658, AL009181, AC005323, AC009516, Z98745, AC005071, AC010200, AC002310, AL096761, AF039907, AL135959, AL031276, AL133485, AL021707, AL109798, AC004887, AC007227, AC005015, AL133244, AC006312, AC005924, AC005180, AC006544, AF031078,

					<p>AC002430, AL022320, AL050306, AF030876, AC002432, AL109758, AC005701, AL132987, AJ003147, AC007384, AC002351, AP000128, AP000206, AP000150, AC005531, AL031575, AC000134, AL050332, AL034553, AC003983, AC007688, AC004765, AL049538, AC004985, L48038, AC007030, AL021808, AC005913, U78027, AC007686, AC007738, AP000009, AC005412, AL021978, AC004967, AL049692, AC007899, AL035071, AC006474, AC005829, AL008718, AC004150, AP000245, Z84466, AC002350, AC005821, D87675, AL031589, AC002395, AC005600, AL022316, AL035089, AC005781, AL020997, AC006071, AC007676, AC005803, AC004526, AC002455, AC004638, AC002352, AC005233, AC004895, AL022326, AC004231, AP000094, AL136295, AC005914, AF111168, AL031595, AC004552, AL049834, AL049653, AL031729, U80017, AL021579, AF123462, AC005037, Z83840, AC005632, AL080317, AC003101, AC004386, AC004000, AP000555, AC005730, AL050321, AL121825, AC006023, AC003108, AC006441, AL020995, AL008715, Z85987, AC007216, AC005625, D49558, AL035455, AC004694, AC007536, AC004131, AC007041, AC006450, Z83838, AC000026, AC004671, AC006057, AC006581, AC003687, AC016025, AF024534, AC005899, AC004945, AC003112, AL008630, AC004999, AC005500, AC004520, AF045555, AC006160, AB023050, AC004099, AC004659, AC004855, AC005138, AP000143, AC005837, AC007225, AC005004, AL022336, Z98949, AC006313, AL078462, AC000159, AL021939, AL022322, AC006241, AL080243, L47234, AC004922, AC005288, AP000090, AC004492, AC002059, AC006120, AL121754, AL031650, AC005994, AL133371, AL021940, AC004884, AC005846, AC005084, AC002476, Z98048, L78810, AC006449, AC003036, AC005684, AC001228, and U47924.</p>
HMUBM8 5	890	784295	1 - 492	15 - 506	<p>AW162314, AW021674, AW265468, N95424, AW438757, AW162332, AI431442, AI755227, AW410844, AW022796, AW327673, AI609992, AI475297, AA112864, AW148821, AL039471, N99245, AW403177, AA568311, AI114494, AA568303, AA631915, AI797998, AA659923, AA618531, AI065031, AA554289, AI076729, AW157128, AW410561, AA507623, AI270280, H96966, AA280886, AI038029, AI144125, AA064983, AA557945, AI567676, AW162762, N72509, AI538404, AA669238, AA568433, AI609107, AI419390, AI568260, AL044701, AI421783, AA847341, AA550837, AW020682, AW277240, AA182577, AW409621, AI819419, AA640305, AI064968, AA074086, AW301712, AW272513, AI859368, AI828721, AA489390, AI224583, AA657392, AI572680, AW246579, AL121039, AW439224, AI702049, AW273201, AW273146, AA101265, AI813920, R99253, AI061313, AI613459, AI281622, AA658890, AL079734, AA225754, AA632355, AI745666,</p>

AI62213, N58334, AI744963, AW238699, AW069769, AA225392, AW274180, AA935827, AA535558, AA533660, AA158023, AI027602, AI590404, AA829693, AA569220, T03928, AI049845, AI569401, AI185856, AI307563, AI174703, AI573009, AI300356, AA157876, AL044966, AW239465, AA772818, AA593168, AI275631, AA610644, AI884404, AI703335, AI423034, AI419419, AI120616, AI049999, AI608751, AA525156, AW008217, AI251024, AA572982, AI283329, AI708175, D88268, AF205588, AC005921, AI135744, AI121658, AC007066, D87008, Z99943, AC005519, Z86061, AC005057, AL049833, AC005839, AL117337, AC007371, AL109809, AL096701, Z84466, AC005913, U62293, AP000152, AC007216, Z93023, D87012, Z83844, AL031311, Z97053, AC005081, AL050321, AC007934, AC004913, Z84480, AC002350, AP000011, AC003688, AC007151, AP000211, AP000133, AC007308, AL034429, AL109623, AC007546, AE000659, AL008582, AL022238, AC004231, U91326, AC007676, AF109907, Z84469, AC005288, AL022162, AP000703, AE000661, AL035422, U85195, AB023050, AF196779, AE000658, AC005084, AC005696, AC007052, AC005920, AL022165, Z98946, AC005500, AC004673, AC007298, U89335, AC002115, AC004383, AC004841, AL049843, AL049759, AF124731, AC005969, AF118808, AC002563, AC005291, AL031733, AL080243, Z84487, AC007899, AC000025, AP000044, AP000112, AC005529, AC004890, AL133163, AC005527, Z93241, AJ006345, AL132777, AC007686, AC005484, AC002055, AC007240, U95742, AC016026, AC003110, AC002369, AL133245, AC004967, AL031985, AF047825, AC007845, AC007055, AL049830, AL133312, AC003051, AC007637, AC004929, AC004645, AL049872, AC006449, AC003043, AC015853, AC004106, Z98200, AC006121, AC002544, AL118497, AC008134, AC006004, AC005594, AL022315, Z98742, AC000111, AC005011, AL078621, Z82190, AC002425, AL139054, AF023268, AF134726, AC006441, AC009501, AL031589, AL049569, AF207550, AL031670, AL035398, AC005261, AC009247, AC004797, AC005808, AF055066, AC006317, AL022333, AC005488, AC006166, AC006006, AC005102, AP000555, AC012627, AL109963, AL020997, AC005822, AC007666, AC008928, AC004139, AL121652, U78027, AC004974, AC004765, AC004686, AC005666, AC005736, AC004820, AC004491, AL109758, AF124523, Z84474, Z97056, AC005778, AC005277, AC000003, AC004506, AC002470, AP001052, AC005399, AC004019, AC006600, AL078639, AC003982, AF001550, AC005971, AC006111, AC007226, AL078584, U85199, AL049576, AL034561, AC006211, AC006511, AC004668, AC002133, Z84476, AC005914, AI023803, AC016025, AP000511, AC004887	
---	--

					AL031282, AL049697, AC004966, AC005516, AC008072, AC005730, AC001226, AL031055, AC005911, AC004531, AC006101, AC006026, AP000556, D84394, AL031281, Z99570, AL023876, AC005899, Z98950, AC003695, AC005037, AL034421, AC004870, AL121754, AP000065, AC006509, AL021940, AL096791, AC005632, AC005537, AC007376, AC002301, AC004859, AL034451, Z93017, AP001053, AL080317, AC002553, AC005274, M63796, AL049539, AC000353, AP000344, and AC004659.
HMUBM2 3	891	675296	1 - 361	15 - 375	R51236, R45099, Z40109, and AF107403.
HMUBM2 1	892	861218	1 - 513	15 - 527	
HMUBM0 1	893	916291	1 - 541	15 - 555	AF039239, AA156352, AI928298, and AC004596.
HMUBL79	894	774904	1 - 279	15 - 293	
HMUBL25	895	678011	1 - 735	15 - 749	T83448, and AC004051.
HMUBJ26	896	424764	1 - 534	15 - 548	R11938, and R17505.
HMUBH84	897	782971	1 - 467	15 - 481	AI300542, W91888, N63093, AL117338, AL049569, AL031687, AL035209, AP000697, AC004099, AL035415, AL008718, AC005089, and AC002563.
HMUBC76	898	769968	1 - 466	15 - 480	H53236.
HMUBA75	899	767192	1 - 363	15 - 377	AC007250.
HMUBA61	900	741710	1 - 429	15 - 443	AP000365, and AP000547.
HMUA71	901	772958	1 - 350	15 - 364	AA160854, R71813, R71760, R48639, N42220, AW247533, R50575, AW170393, AA083908, AA313213, AA455790, AI372424, AI700503, H30234, AI807620, AI149104, R85186, H74174, AA371702, H67210, R90881, AI148673, R70330, AA380748, W86716, AI421626, R80075, R35880, H30476, W31820, AA099322, AI014871, AA323925, H04088, AI951537, AI498026, AW027328, R70448, AC006165, AB023051, AP000512, AF085357, AF089750, AF145044, U90435, U60976, and U60977.
HMUA85	902	783543	1 - 313	15 - 327	AA027138, AI752271, AI880296, AI752272, and D80011.
HFOZC29	903	923288	1 - 555	15 - 569	AI095431, AI571923, AW261883, AI200605, AA482065, AI200699, AI017296, AI923202, AW015684, AA767648, AA883935, AA677666, AI573221, AI033576, AI126442, AI369853, AI249160, AI142443, AW264134, AA806683, AI092218, AA858007, W94283, AI339695, AI262289, AI076383, AI311852, AI910100, H46722, W85678, W74408, AA631052, AA918365, AI301845, AA604026, W72883,

					<p> H47019, AA635622, AA045304, AA746223, AW408264, AI038223, AA482654, AA137252, AI985703, AW023603, T32125, W07308, AI658934, T30570, AA502009, Z25192, H46795, AA326741, H46480, AA658982, H81844, AA736875, AI678243, AW401539, AW352130, AA481943, AA359248, AI832746, AI383918, H97071, AI784354, AA344343, AI137251, AW339756, AW188941, D56149, N57967, AI382332, N48245, H61635, AA086068, AA603737, AI362081, AA434581, AA490441, AI828818, AI220855, AA295325, AI814087, AA830821, AI925463, AL039086, AL119791, AW079159, AW074993, AW072484, AI349614, AI349937, AI349256, AI312152, AI783504, AW075084, AI872910, AI312399, AI334884, AI307543, AI345251, AW071412, AI307708, AI312325, AI340659, AW071377, AI340644, AI867042, AI334930, AI309443, AI632997, AI307520, AI874166, AI499886, AI340664, AI310592, AW193236, AI345739, AI312143, AI349637, AI310927, AI307578, AI349955, AW075093, AI312357, AW268072, AI801325, AI923989, AL036631, AL040241, AI919345, AW243886, AW071395, AI830029, AI273142, AI636719, AW029271, AW089689, AW268964, AW302965, AI349269, N71180, AA572758, AI312432, AI811785, AI440263, AI312237, AW196141, AI886415, AW071380, AI358701, AL048656, AI343112, AW301300, AI349598, AW075207, AI343037, AW269097, N75771, AI345735, AL079963, AI310925, AI635067, AW162189, AI863411, AL047422, AL036265, AI307210, AI345224, AI625595, AI345156, AI307569, AI311159, AI313320, AI336495, AI336654, AW148320, AI313352, AI311892, AI307736, AI345562, AI284517, AI345026, AI307454, AI349266, AI334452, AI349787, AI343471, AI345817, AI344808, AI312146, AI538342, AI312339, AI309431, AI345674, AI345258, AI344260, AI866573, AI312168, AI348879, AW071276, AI344779, AI344785, AI311604, AL119863, AI824576, AW168121, AI310945, AL036664, AI312988, AW059828, AW151136, AI475377, AI312428, AI696819, AL037454, AI345111, AI863321, AW072588, AW160916, AL110306, AI689420, AL045500, AI912866, AI929108, AI683684, AI174394, AI349645, AI431408, AW089572, AI345370, AI471361, AI282355, AL036274, AI352326, AI284509, AI358455, AI287704, AI345347, AW161579, AI538829, H89138, AI432040, AW161156, AL036396, AI620284, AL038605, AL036403, AF161529, AF151878, X75935, AB037370, I89947, A08916, A08913, AL050108, A08912, AF097996, I48978, A08910, A08909, U00763, AL133104, AL049300, I89931, AL110218, I49625, U80742, A07647, AL050393, Y10655, E03348, AL122121, I96214, AR034830, AL049283, AL122050, AF106827, A93350, AL133077, AF113013, AR038854, A08908, AF054599, U67958, AI8777, </p>
--	--	--	--	--	--

					AR059958, AL050149, A65341, AL049430, AF113699, AL049452, E02349, E07108, AL117457, AF113676, AF177401, AL110225, AL117394, AJ012755, AL049314, AF090903, AL133606, AL133067, AF111849, AF113691, X65873, AL133560, AF113694, AL122049, AF113677, Y16645, AL137557, AF067728, AL133080, AL080159, I48979, AL137648, AF183393, AL117585, AL133075, AL133016, AL050146, AL122093, U91329, AB019565, AL049466, AL050024, AL110196, AL080127, AF090896, AL133072, AF079765, A03736, AL110280, AF119337, AF113019, I26207, AL049382, Y11254, AL137560, X70685, AL133081, AJ242859, AL137550, AL117460, AL133113, AL137521, AF061573, AF057300, AF057299, AL122123, X72889, AL080060, AR020905, AF113690, X82434, AF090934, A77033, A77035, AF087943, AL137271, U58996, AL117583, Z82022, AL137459, AF079763, AF153205, AL137538, AF090900, Y09972, AF158248, AL133568, AF185576, AF146568, AF090901, AL050092, AL133565, AL137479, AL050277, AF113689, AF118094, I09360, AJ000937, M30514, A90832, AL133098, X92070, AF125948, S78214, U42766, X98834, AL080124, AL049464, AL122110, AF091084, AL137283, I89934, AR038969, AL049938, Y11587, I03321, AL133640, AL049465, AF125949, X93495, X63574, AF106862, AF104032, AR011880, AF111112, AF003737, AF118064, AL137478, U68233, I92592, AF000301, AL110221, AL096744, AF039138, AF039137, A12297, E02221, X96540, I00734, U72620, AF026816, A58524, A58523, AF078844, AF126247, AF090943, AL133558, I33392, AF051325, L31396, E00617, E00717, E00778, U68387, E15569, AL137488, L31397, AF100931, E02253, AF118070, X62580, AL137523, AF118090, I42402, AL050116, AF026124, Z37987, Y10080, AF106657, AL117435, U35846, AJ006417, AL137463, A93016, AR013797, I89944, X84990, AL133557, Y07905, AL050138, X83508, AF061943, AL137556, AF162270, AL133093, AF111851, AL110197, AL122098, AF017152, E08631, S68736, AL080137, AL137527, AL137292, I41145, AL080074, AF017437, Z72491, AJ238278, AL080158, AL137529, AL133014, AL137476, AC004883, E04233, AR000496, AF132676, U39656, AF061836, AL050172, U35146, and X52128.
HFOZA47	904	909372	1 - 303	15 - 317	T99977, AA386007, AW419200, AI301419, T99978, AA813111, and AL133243.
HFOYW76	905	769894	1 - 387	15 - 401	Z43100, R23391, R18897, and AA775801.
HFOYV08	906	959038	1 - 503	15 - 517	AI885037, AW005574, AI127653, AI471784, AW002166, AI652199, AA775784, AA398384, AA525786, C21259, and Z98048.
HFOYS58	907	735816	1 - 267	15 - 281	AA464919, AI360067, and AI563967.
HFOYN65	908	747740	1 - 403	15 - 417	R42824, AI418414, AI094617, AI159874, AA614150, AI420613, AI082558,

						AI478270, AA928271, AA477739, H29542, AW297075, F35711, AW292053, Z39149, AW362068, F25020, and AI597841.
HFOYN01	909	854780	1 - 446	15 - 460		AA188606, and AL109710.
HFOYN48	910	721455	1 - 461	15 - 475		N69806, AI692502, AI077479, AA811249, N69787, and AC0000076.
HFOYL33	911	702209	1 - 593	15 - 607		W03664, and AW070784.
HFOYK21	912	670653	1 - 852	15 - 866		AA428559, AA429496, and AA909127.
HFOYK02	913	919458	1 - 475	15 - 489		W38502, and W21229.
HFOYJ30	914	932485	1 - 669	15 - 683		W67514, AI655409, AW051595, AI799668, AI400464, AA563735, AI183528, AI354914, AA652158, AI337235, AA652105, AA961057, AA772564, AI093875, AA889803, AA442063, AI652462, H17951, AA442166, W68127, H12516, AI365333, N95071, AA861656, AA939316, R71444, AA917342, AA487907, R81789, D62541, R71096, AI355106, F13621, AI277031, Z38139, AA773369, AI419837, H12464, C18326, AA767156, and AF116827.
HFOYH01	915	916055	1 - 555	15 - 569		AI733400, AI392911, AA669057, AI522044, AW293639, AI261721, AI791812, AI792235, AA948371, R82728, and AI017805.
HFOYG88	916	494875	1 - 794	15 - 808		W81024, AA040397, AI806528, AI626098, AI474320, W81060, AW181963, and N92485.
HFOYG86	917	949496	1 - 549	15 - 563		AI089319, AA495807, AA122079, AI682875, and AA626188.
HFOYC08	918	958975	1 - 627	15 - 641		AI939308, AI089885, AI674951, and AW452881.
HFOYA17	919	662642	1 - 334	15 - 348		H85252, and Z59473.
HFOXW67	920	494854	1 - 497	15 - 511		R59304, Z41276, and F01353.
HFOXV94	921	794175	1 - 494	15 - 508		AA224103, and AC005328.
HFOX74	922	875383	1 - 522	15 - 536		AA203672, AA521316, AW025339, AI971502, AA833669, N71094, AA832189, and AC003029.
HFOX735	923	707088	1 - 506	15 - 520		
HFOX842	924	713514	1 - 462	15 - 476		
HFOX057	925	928171	1 - 493	15 - 507		N62077, AW408398, R14585, W44378, R52298, H29068, AA258983, R14764, R60391, and AL022165.
HFOX033	926	702212	1 - 555	15 - 569		R00471, F22586, AI473631, AA773289, AI758435, AI471914, F34093, AA397821, H48670, AA251356, AA298788, F27108, AI798493, T06210, AW439008, AA130501, AW245331, AA737039, AA523695, AI366902, AA804866, AA523812, AI865375, AW021619, AI054339, AC006509, AC011456, AC002504, Z98750, AC006960, AC004526, AP000466, Z83844, AF048729, AC005261, AC007695, AC006285, AC003043, AC003010, AC004844, AC004067, AC005102, AC004841,

					AC007276, AC005844, AP000354, AC008372, AC016025, AC007546, AL031681, AC000029, AC007845, AL035398, AP000045, AP000113, U91326, AC005911, AL035086, AL023513, AC005081, AL049569, AL009183, AC005231, AL078581, AC004828, L78810, AL031005, AC005326, AC007993, AC005015, AL022316, AC006262, Z98749, AL133246, AL008733, AC006480, AL132712, AC005821, AC007225, U95739, D86566, AC005328, AC002352, AC003108, AC005520, AL121653, AC005969, AC002425, AC007363, AC005562, AC005071, AJ010770, AC005632, AL020997, AC006241, AL080243, AL022313, L44140, AC006026, AC004985, AF001548, AC005037, AC004216, AL078638, AC005279, AF053356, AC003013, AC004815, AL133243, AC005225, U91323, AC005274, AC007686, AC006487, U91322, U89335, Z98941, AP000030, AF196969, AC006312, AP000208, AP000130, X99832, AC002544, Z99943, AC005578, AC005088, Z83840, AC006530, AL031296, AC006947, AC002430, AC006011, L04193, AL133245, AL049776, AC003982, AC007878, AC006387, Z98036, AC007384, AL034549, AC004589, AC007283, AB003151, AL109627, AP000211, AP000133, AC004590, AC005914, AC009946, AL049835, AC004967, AC007938, AC002527, AL023281, AC005244, Z95114, AC004491, AC008498, AC004583, AC002126, AC004158, Z98742, AL079342, AF139813, AF030453, AC005324, AF111168, AC003684, AJ003147, AC000085, AF015262, AC004259, AC002476, AC004600, AJ229043, AC006449, AL031670, AF064861, AC005921, AF020503, AL139054, AL132641, AC003015, AL049830, U62317, Z94056, AC004686, AC003025, AL031230, AC002395, AC005940, AC007773, AL031680, AL136504, AC004605, AL024507, AC006511, AC011311, AL031432, AC004953, AC005531, and AP000555.
HFOXMS3	927	587972	1 - 546	15 - 560	T95196.
HFOXL88	928	909839	1 - 412	15 - 426	AA077980, AA010232, AA077893, AA149376, AA029227, AA077669, AA077229, AW386712, AW386708, AA076983, AA076893, R53155, AB011110, and AC004084.
HFOXK96	929	732057	1 - 549	15 - 563	N95619, AI522016, AW418929, AI739123, AI589262, W81467, AA679593, AI358082, AI968962, H29504, W81348, AI802044, AA860722, AI299531, AA861993, AI240698, AW293669, AA946852, AI538012, AI872899, R40786, AA703596, AA426331, N45617, AC004918, and AL049792.
HFOXK42	930	587960	1 - 400	15 - 414	AI369443, H40699, H38679, T10030, AI359972, AB032985, and AC006487.
HFOXFP91	931	790103	1 - 640	15 - 654	AW299538, AI700655, AA542898, AI201894, AW002387, AW299893, AW135284, N48798, AI953361, AI088991, AI381950, AI239629, AI206950, AI217419, AI361123, AI687555, N62233, AI669545, AI700194, W40211, AI537667,

						AW118331, AI569799, AI300682, H22991, AI86217, R45601, W45433, AI867656, AA402541, AA766044, AW156969, AW162279, AW157242, AW301566, and AL034379.
HFOXF42	932	854797	1 - 410	15 - 424		F00438, AB029032, and AL137384.
HFOXDF78	933	856499	1 - 320	15 - 334		W00471, AW363484, H05198, F11931, T66107, and AL049471.
HFOXFB33	934	701719	1 - 617	15 - 631		AA070455, and AL049775.
HFOXBB26	935	681593	1 - 455	15 - 469		AA159285.
HFOXA62	936	743466	1 - 435	15 - 449		T86297.
HFIZP86	937	785341	1 - 409	15 - 423		AA418200, AI280402, and AI350784.
HFIZB62	938	743122	1 - 693	15 - 707		AA131059.
HFIYX08	939	958977	1 - 443	15 - 457		AA605145, AA702116, AA708181, and AL096678.
HFIYW79	940	858618	1 - 652	15 - 666		R56716, AW075513, AW002149, H39705, H28690, F11371, AA768949, AA384664, AI337892, AI057281, AI458151, AI570407, AW134516, AI350058, AI470179, AI215812, AA854471, R26470, AA251002, AA573328, AI216845, AI200607, AI984370, AA411536, AI298938, AI818816, AW083096, AI300345, W92747, AI147626, AI948774, AI262533, AA725905, AA442075, AI565962, AI301560, N52183, AA935514, AW149691, AI194002, AI291200, AI304886, AI953743, AW270856, R63834, W35349, AW340470, AI765586, AI298116, and AA292171.
HFIYS11	941	966702	1 - 467	15 - 481		N58560.
HFIYN50	942	724175	1 - 538	15 - 552		AI458879, AA463632, AA496023, AI168467, AA778374, AI580056, AI056137, AI269041, and AI360731.
HFIYJ92	943	791305	1 - 462	15 - 476		H96503, AI629004, AI436691, AW264067, AI796727, AW341625, N20097, H15455, N24619, AI949464, D62682, D63004, T65294, N23339, N94925, AA099864, AI095277, F09804, R40594, R60524, and N59847.
HFIYA08	944	962212	1 - 536	15 - 550		AA438753, AI870866, W72843, AA772868, AI130854, AI083630, AA130359, AA056018, AA332556, AI199995, AA469081, AA661635, AI183475, AA457490, AA931966, W67545, W67527, W81565, AA826675, T12258, W76412, AA989066, W81612, AA630878, AI243042, AA027306, and AA056067.
HFIIXZ95	945	915703	1 - 466	15 - 480		AA126477, AW299841, AI742474, AI672617, AW001691, AW008181, R76817, R43164, AI990788, R22570, R28278, H95582, H95556, R75986, R92020, AI983816, and AC006055.
HFIIXZ19	946	683033	1 - 600	15 - 614		AA053791, AI755151, AI633860, AL046181, AA205728, AA211578, AA204943, AI635990, AI830932, AI949778, AI949366, AI634857, AI823973, AI423292, AI627291, AI418579, AI890410, AA836883, AI480105, AI669422, AI095121,

					AI057276, AI890178, AA205729, AI200542, AW078637, AI166692, AI669371, AI332344, AI217515, AI359771, AI378663, AA224514, AI554321, AI990118, AA630767, AA410286, AW264316, AW206186, AI669078, AI923406, AA468567, AA52010, AA121794, AI754877, NS1861, AI823545, AI650324, AA099437, AI356067, AI038127, AW129642, AI273625, AI619475, AI767029, AI827395, AI022904, AI174419, AI765993, AI091669, AA165151, AA961611, AA780769, AW020059, AA169647, N90277, AA035739, AA788579, AA169822, AI830936, AA452593, AI002825, AA706408, AI583400, AI559181, AW023827, AA205712, DI2323, AI367552, DI11546, AI571708, AA807016, AW382024, AW382030, AW382019, DI11548, AI349108, AA027830, AL045597, AI564852, AI914393, W35293, AW381974, AA746978, AW393593, AI685993, AA678665, AI392778, D54048, F37948, R44031, AI695043, AW382056, AI619567, AA431088, AA664873, AW381977, AA860448, F25971, AA760888, AI630054, AA214120, F37021, HI1493, C15312, AI571876, AA216657, AA779052, AI521854, Z28566, AA436971, AA502233, AI300701, AI872541, AA256938, W38598, HI3644, AA224488, AI567021, Z38535, F01833, AI245064, AA431553, AW382004, H43488, AA884498, R57005, H39529, AA912371, AF131807, Z99716, and AL008721.
HFIXR93	947	894013	1 - 572	15 - 586	N25971, N29465, AW410261, and AI435020.
HFIXR68	948	752858	1 - 805	15 - 819	R11083, and AA393561.
HFIXP31	949	697759	1 - 453	15 - 467	AA227552, AI080405, AA227929, AI972469, and U69274.
HFIXP04	950	839910	1 - 549	15 - 563	AA883171.
HFIXJ53	951	489122	1 - 409	15 - 423	T72754, and AL049713.
HFIXB77	952	772116	1 - 501	15 - 515	R82686, and HI9381.
HFIVS81	953	387591	1 - 230	15 - 244	AI420574, AW237773, AI375677, AI244780, AA528140, AI624970, AI624952, HI5695, and Z39216.
HFIVS21	954	855131	1 - 267	15 - 281	AA578341.
HFIVS08	955	959272	1 - 390	15 - 404	C01483, and AC007032.
HFIVZ63	956	745033	1 - 554	15 - 568	AI672293, N59774, AW014476, AI091467, AI740712, AI306424, AI215771, AI652127, AA683496, AA868095, AA436090, AI379664, AI419802, and AA435990.
HFIVY49	957	855133	1 - 394	15 - 408	AA501785, T74524, AW274349, AW303196, AW301350, AL049539, AP000555, AP000223, and AP000086.
HFIVU58	958	735350	1 - 752	15 - 766	N22766, AI094120, W94915, AI140008, AI339057, W91968, AI378174, AA628702, AA628693, AI080429, AI168313, H97684, AI868702, AI886569, and AA236390.

HFUUV18	959	787095	1 - 499	15 - 513	H29983, A W298799, T86660, T79509, AA400497, AA400589, T96108, H54131, R98500, R98518, T80762, and AA359852.
HFUUM33	960	702319	1 - 359	15 - 373	AA634147, AC006014, AC005488, AP000696, AC007226, AL109952, U80017, AL031985, Z95114, AC005578, Z85987, AL008715, AL031297, AL049576, AP000088, AC004765, AC002470, AC007899, Z97054, AL049843, AL022721, AC005081, AP000689, AC005924, AC003010, AC004002, AC004662, AC007934, AC005399, D87675, AC004966, Z95116, AL133245, Z49236, AC004033, AC005520, AC005368, AC007537, AP000047, AC004941, AC007285, AC005280, AL109628, AC004890, AL022313, AC002310, AL078475, AP000031, AC004019, AL031295, AC007731, AC005874, AF134471, AL022163, AC005500, AL121603, Z86090, AC005004, AC007842, AC004668, AL132712, AC005324, AL021918, AP000553, AC002425, AL031311, AC004985, AL049869, AC016026, AB023050, AC005082, AC005666, AC005527, AF109907, AF030876, AC007227, AC007536, Y07848, AC004526, AL024498, AC000025, AP000512, AC004858, AJ251973, AC004263, AC004531, AC005971, AC005409, AL049643, AP000115, AP000116, AP000049, AL109798, AC005881, AC003041, AC007358, AL021391, AL031670, AL021707, AC006026, AB003151, AC004686, AL096791, AC004228, Z81364, AL078581, AC002395, AC005736, AL049872, AC007845, AP000311, U95740, AC004491, AP000251, AC005598, AC004132, AC002546, AC009247, AL050332, Z99127, AC003665, AC004895, Z98742, AC003109, AC005730, AC002544, Y10196, AC002477, AF031078, AL133445, U95742, AL049697, AC005899, AC005841, AL034379, AC005529, AC016025, AF181896, AL132987, AC002059, AF129756, AL024474, AC005911, AC002996, AC005046, AC004067, AP000211, AP000133, AP000030, AC000120, AC006511, AC002350, U91323, AC003688, AF088219, AC004988, AL049776, AL117337, AL049759, AC005668, AC005839, AL009179, AC000134, AC006111, AC006211, AL049795, AC006597, AF196779, AD000864, AC007546, AC005233, AC005746, AL080243, AC004841, and AL034418.
HFUHH65	961	747836	1 - 517	15 - 531	AL608715, AL422803, AL432163, W63666, H81684, C05948, W37721, AL493291, AL356167, H84536, AA988027, AA401876, AA872375, AA932978, H84219, AA868682, and H81685.
HFUUD47	962	720254	1 - 570	15 - 584	W07634, AA194651, W94182, AA133411, and W07638.
HFUHH46	963	718078	1 - 659	15 - 673	H83995, R84314, AA813574, T05535, and AL915423.
HFUJG36	964	707883	1 - 733	15 - 747	AA001287.
HFUJG20	965	669580	1 - 421	15 - 435	R05639.

HFJUF58	966	735927	1 - 659	15 - 673	AA242859, AA252126, AI693348, H99361, AL049780, and AC006530.
HFJUZ92	967	494044	1 - 461	15 - 475	AA493255, and AL049781.
HFJUU85	968	793332	1 - 789	15 - 803	AA486519, N75864, AA282436, AI311373, AA987662, AW378576, AA258100, D20734, AA398828, AI340090, AI806551, AI827300, AA322510, AW167535, AA486153, AI580840, AA307592, AI300646, AI365620, R63162, AW190730, N80417, AA074806, AI380183, AI807739, AI683461, AI817082, AI798145, AI423017, AI056695, AI590919, AI127969, AW055144, AA648622, AI860727, AI571273, AW173640, AW305299, AI445732, AI283109, AA173927, HI3876, AA486091, AI692781, AI692782, AI475726, AI567671, AW368584, AW339198, AA598864, D57989, AA773684, AI347553, AW304900, AI310482, AW103494, AA135489, AA300795, AW377765, AA424654, W53016, AI950989, AA150819, AI024706, AA360720, AI751636, AI753529, AI950558, AA604851, AA579895, AA931400, AW129397, N39046, N35027, AI355248, AI805101, AA424557, H07110, AI860066, AW192391, AI469260, N67995, AA223733, AI863857, AI302384, AI355266, AI299079, AI148180, AI003944, AI934032, AI830970, N70657, AI340222, AW402035, AA554911, AA565608, AL080212, and U07795.
HFJIR63	969	744994	1 - 732	15 - 746	R60665, H06153, and R14432.
HFJIL37	970	561375	1 - 337	15 - 351	AI1185219, Z99396, AL038837, AL037051, AL036725, AL036418, AA631969, AL039074, AW392670, AL036858, AL036924, AW372827, AL039564, AL039085, AL038509, AL039156, AL039108, AL039109, AL039128, AW384394, AL119497, AW363220, AL037094, AL039659, AL038531, AL036196, AL036190, AL119335, AL119443, AL037639, AL039625, AL039648, AL119319, AL045337, U46351, AL119457, AL036767, AL037082, U46350, AL037526, U46341, AL119496, AL119324, AL119484, AL119363, AL119391, AL119483, AL119522, AL039678, AL039629, AL119341, AL119355, AL039423, U46349, AL036238, AL119396, AL038447, AL039150, AL040992, AL134528, AL042909, AL042450, AL039386, U46346, AL134524, AL037077, AL036268, U46347, AL119418, AL042614, AL119444, AL037085, AL038520, AL037726, AL119439, AL036998, AL036733, AL042975, AL039410, AL037615, AL038851, AL134533, AL037205, U46345, AL134518, AL042965, AL134531, AL119399, AL037027, AL036719, AL037178, AL042984, AL042970, AL043029, AL042551, AL134538, AL119488, AL036679, AL134542, AL036191, AL042544, AL043019, AL042542, AL036765, AL043003, AL037054, AL119464, AL036774, AL037021, AL036836, AL036999, AL036886, AL036158, AC006001, AR060234, AR066494, A81671, AR023813, AR069079, AR064707, AR054110, and AB026436.

HFUK75	971	767222	1 - 845	15 - 859	AI458975, AW296300, R44335, AW452866, AI276446, AI700567, R40979, AI264364, AA884637, AA257160, Z17361, and AA257067.
HFUK32	972	424259	1 - 396	15 - 410	R81615.
HFUK07	973	953034	1 - 481	15 - 495	AI630872.
HFUJ14	974	839523	1 - 694	15 - 708	AI888852, AL046620, AL044458, AW085811, AI732327, AA780914, AA618132, AI679294, AI679871, AA525818, AA524604, AA640305, AA523718, AI828721, AI282322, AL121039, AI702049, AI732720, AI344906, AA313025, AI567676, AI285651, AA493245, AA054283, AA631915, AA577706, N27362, AA515727, AI984168, AA664963, AA935827, AW072963, AW265006, AA482682, AI049845, AI926102, AA493546, AI734075, AI246541, AI734076, AA831913, AI114494, AW238242, AI275631, AI570067, AW157128, AI813920, AI572680, AA554289, AI242236, N49298, AI733523, AI889177, AA507623, AI538404, AA618531, AI038029, AW085626, AA593168, AI174827, AW327673, AA601336, AI860423, AI609992, AA601376, AL044701, AA834891, AW419201, AI734119, AA523719, AI003068, AA404619, AI521525, W44797, AW268793, AW265468, AI434103, AA602939, AA493464, AA425283, AW301483, AA595508, AW021674, AA728954, AA723282, AA584360, AI753092, AA557945, AI889236, AI281622, AA676462, AI002950, AA629668, AA834799, AI312614, AI826857, AI350189, AA167656, AA493808, AI064968, AW057760, AI039257, H29593, AA847341, AA728952, R92703, AA299490, AA526542, AA491941, AI744890, AI884404, AA515728, AA811451, AW410844, AL118843, AA558488, AI342863, AI061158, AW339619, R61887, AA729004, AI745666, AA421536, AI148840, AW103990, AA197089, AA636077, AI003391, AA489390, AI889995, AI791720, AI791408, AP000512, AL009181, AC005081, AC005911, AC004491, AC004765, U62317, AC005231, AC004801, AB017602, AD000092, AL031666, AL117258, AC004967, AC006271, AF003626, AL049694, AL136504, AL020997, AC004000, AL031133, AC002310, AC005015, AC007637, U47924, AC004671, AL022323, AC004834, AL136295, AC005800, AC006449, AC005412, AC009247, AL049569, AC004752, AL133245, AL031311, AF111169, AC005046, AC005887, Z95116, AL080243, Z93241, AL031668, AP000692, AC005004, AC004805, AC005755, AL008582, AF053356, AF109907, AC002565, AL023575, AL031602, AC005088, AL109628, AP000356, AC007151, AP000211, AP000133, AL008719, AC004253, AF038458, AC004854, AC007934, AF003529, AC007030, AC005041, AL035423, AC007226, AC002477, AL096701, AC007666, AF111168, AC006211, AC004659, AF047825, AF067844, AL022316, AL031680, AL022326, AF064861, AC007707, AC005562, AB023051,

					AC016025, AP000131, Z99716, AC006450, AC005619, AC006080, AC004799, AL031733, AC005722, AL021395, AC006064, AC005089, AL031431, AC003007, AC004031, AC005881, AC002314, AP000503, AC005913, AC000353, AL031730, AC007055, AC004678, AC005519, AL035413, AC003006, AL133448, AC002425, AC005971, AC002404, AL035460, AC005406, AC003956, AL109758, AP000555, Z92542, AP000501, AC005067, AL031589, AL133163, AL049757, AL031846, AC008044, AF111167, AC005839, AC005102, AF165926, AC006285, AC005180, AC004382, AP000350, AC006261, AP000688, AJ003147, AC005696, AF134726, AL139054, L78833, AL050348, AC005808, AC002126, Z85986, AL049776, AL049780, AC007227, Z86090, AL031657, AL049759, AC006013, AC004703, Z98044, AC002381, AC006160, AC005225, AC002470, AC006011, AL031291, AC006006, AC005914, AC005280, AL034423, AL034429, AC004686, AC002400, AC004216, AC005258, AC003029, AC004983, AP000346, AC005537, AP000152, AL050321, AC005736, AC000003, AP000510, AC005527, AL034555, AJ246003, Z95114, AC007774, AL008726, AC006101, AL022311, AP000247, AC004560, AL121657, AL035587, AC005484, AC005480, AC007688, AC004887, AC004605, AL034451, AC000039, AC005632, AC007536, AL049745, U91328, AC002554, AC002073, AL050307, AC005921, AC005566, AC007011, AC003950, AC010077, AC002558, AC007216, AC004257, AC008009, AP000553, AL034417, AP000511, Z98051, AC006057, AC007371, AC006312, AC007450, AC004662, Z98742, AP000008, AC004263, AC007050, AL049576, AC004876, AC003982, AP000466, AC006205, AC003108, AL050341, AB000882, AC005245, AL121825, U52112, AC004033, AJ011930, AC004477, AC004849, AB023048, AP000500, AC004526, AC004643, AC006115, AL022302, and AC008372.
HFHW91	975	907618	1 - 515	15 - 529	AI743173, AA909302, AA447375, AI470475, and AI066540.
HFHW16	976	858594	1 - 659	15 - 673	H42111, and AF142099.
HFHW11	977	947856	1 - 269	15 - 283	AA828809, and AA828563.
HFHW56	978	470954	1 - 687	15 - 701	AA160654.
HFHW76	979	769948	1 - 347	15 - 361	AW055256, T59260, H67680, AI002890, H68002, AC004883, and AC005412.
HFHS86	980	785419	1 - 344	15 - 358	H89010, AW021356, AW023646, and AL035694.
HFHW78	981	773512	1 - 457	15 - 471	H84598, AA777769, AA682587, AI090880, and AI862169.
HFHN35	982	707075	1 - 895	15 - 909	N54488, H47963, AA708179, H56418, R92521, H83039, and H60100.
HFHK29	983	855174	1 - 834	15 - 848	AW082328, AA056697, AA058386, AI582825, AW376061, AW204615, AA847499, AI923052, AI754105, AI755214, AI754567, AI278972, AA630854, AI962030, AW328202, AA584484, AA904211, AA503019, AA410788, T74524, AA704393,

<p>             AI69421, AA084609, AI963720, AA713705, AI653776, AI249688, AW023111, AI904586, AI904594, AW272294, AW188427, H07953, AA126450, AW082104, AW328331, AI279417, AI635028, AA535216, AW193265, W96522, AA720582, AI609972, AI307201, AA613227, AA536040, AI038304, AA225406, AI431303, AI918419, AI674840, AI912401, W96277, AI471572, AW020088, AI056177, AA228778, AA572974, AI569100, AA634991, AI077941, AI350211, AA525293, AW020992, AW192599, AI587349, AA456924, AA838091, AI859438, AI049955, AA668455, AW265688, AL037683, AA559241, AW438643, AC005666, AC005288, AF053356, AC002563, AC005480, AC006317, Z83843, AC004552, AL022323, AC004386, AC002476, AC005914, AC004542, AC002504, AC005367, AL035685, AL096701, AL034549, AC005907, AC006211, AC003089, AL035555, AL133355, Z95115, AC007655, AC007681, AC006275, AC005726, AC009516, Z97987, AC005701, AL035045, AC005899, AC000025, AC004659, AP000208, AP000130, AL035405, AC005527, AP000247, U91325, AC002366, AC022517, AC004593, AL031283, AC004099, AL117354, AC004805, AL031657, AL035691, AL121825, AC003683, AC005808, AC004865, X87344, AL031293, AC007637, AC002407, AC004525, AL049869, AC005668, AL022313, AC005529, AL034429, AL050321, AC003666, AF001550, AP000045, AC007308, Y10196, AC005255, AC004834, AL049780, Z98047, AC004782, AC006441, AL031311, AC005189, AC002978, AL133244, AC004585, AC004828, AC004814, AC004815, U95743, AC002418, AC005562, AC007899, AL035634, AC007488, AC007686, AC005206, X99832, U91318, AF001548, AL008718, Z98884, Z93020, AC005243, AP000356, AC005531, AC006960, AL024509, AC005667, Z85986, AC006312, Z82203, AC005859, AC006080, AC005049, AL031230, AL031736, AC007055, AC007666, AC005261, AF001551, AC000353, AC004019, Z86064, AP000692, AC010202, AC008101, AC006974, U95737, AL031650, AL049776, AL035071, AC003043, AL022067, AL109758, AC007774, AC007536, AC006515, AC002477, AC002449, AL034379, U08988, AC005482, AL022311, AC016830, AL035587, AF001549, AC000118, AC005225, AL031575, AC003072, AC007528, AC007390, AC005920, Z95331, AC004559, AP000044, AP000112, U89335, AC006958, AL121603, AL031984, AC006581, AL024498, AJ246003, X55923, AC000378, Z84469, AC008033, AL031178, AL109963, X54181, AC004909, AC004526, Z98751, X54178, X55931, AC006111, AC004017, X55925, AL078463, AL031662, AF107885, AL031295, AC002990, AC002470, AC006050, AJ229043, U57007, AC005694, D88270, AL031276, AC005387, AC005730, AL031666, AF064858, AP000113, AL034417,           </p>					
---	--	--	--	--	--

					AC006344, AL050332, AC005071, AC004106, AC004475, AC005002, AC009044, AF196779, AC005829, AC005952, AL020993, AL035423, AC002352, AL031589, AF031078, AL021939, AC002126, AL109952, AC000134, AC007225, AL031767, AC005410, AC007652, AC004253, AL031667, AC005409, AC004913, AC004020, Z81314, AC007993, AF134726, AP000563, AF111167, AL078581, AF030876, Y18000, AC002996, AL121658, AF067844, AC002551, AC004242, AC006120, AL035403, AC005375, Z93241, AC004150, AC000088, AL050341, and AC007688.
HFHF53	984	728259	1 - 560	15 - 574	R65697, R65696, AC007688, AF165926, AL022165, AC005702, and AC005519.
HFHD20	985	669731	1 - 496	15 - 510	T55518, AI762631, and AB002380.
HFIDL68	986	928475	1 - 516	15 - 530	AI375172.
HFIDL06	987	837524	1 - 599	15 - 613	AI141922, W51817, AA515912, AI925832, AA614027, and AL133051.
HFIBK83	988	939556	1 - 490	15 - 504	R15292, AW339546, Z42543, AA251688, Z44339, W60548, F06562, AW377760, and AA011443.
HFIA X78	989	773445	1 - 280	15 - 294	
HFIA S49	990	722728	1 - 599	15 - 613	N35671, AI301181, and AC007093.
HFIAL66	991	587837	1 - 503	15 - 517	AW172309, and N42465.
HCOKA10	992	907080	1 - 759	15 - 773	AW327294, F31091, AA528669, AA505384, AW328419, AW328418, AW419243, AA187998, AA640483, F31092, AA420717, AI348852, W81029, AA482925, AI879569, AA946918, AA314600, AA825612, AA808869, W45176, AA316648, AA651658, AI735276, W52650, AA534263, AA314556, AA417254, AI342431, AA622408, AA181138, AA506547, W68664, AA635583, AA991834, AA187537, AA128015, W96306, AA505394, AA186606, AA524595, AI336250, AA862109, N90275, AA187128, AA737195, AA659642, AI879186, AA307087, AA991775, AA579430, AA643777, F32467, AA654628, F33074, AW082068, AA484856, AA653801, AA469168, AA420763, AI090379, AA421550, AA469285, AA775298, N78682, AA225075, AA314013, AI735264, C15999, AI004885, AI185905, AA155975, AA541346, AW006688, AA838376, AA507479, AA315116, AA147815, AW440264, F25989, AA528681, AI718105, AI185191, AI830011, AI074436, AI193986, AA483568, AA844667, F30622, AI598223, AI431978, AA157591, AW340929, AI718714, AA147943, AA960763, AI140252, AI131544, AA659113, C14408, F28423, AI193088, AI749326, C14506, AA181285, C14409, AI302400, AI570974, AI936281, AA229654, AA229788, AA302294, AI982992, F31208, AA935155, AI193847, H46476, AA838474, F20187, AA492052, AI609502, AI709111, AA469365, F32353, AA608589, AA643956, AA961534, AA226596, AI973135, AA128058, AA829205, AA501744, AW276969, AI721218, AI924736,

AA147740, AA579354, AA995673, AI253661, AA022517, D52050, F27939, AA74974, D52103, C14325, F26226, C14332, AI440106, C14532, C14505, AA229085, AI205658, W38596, AA613651, H89629, AA029290, AA975314, C14296, F33568, W90547, F30424, AI748823, F25844, AA932252, AA229038, AA569478, AI300774, AA483111, AA631847, AI523368, AA363475, W81066, AI094402, AI440377, AA131139, F29490, AA554888, C14458, AW262694, N57388, AA658868, AA320538, F30326, F30077, AI718951, AA664723, W45081, C14216, AI151472, AA601532, C14355, AI032761, AI720880, F19339, AA594497, AA654880, AI510833, AA320738, AI718725, AA181139, T48033, AA082246, AA318164, AA023034, AI379782, AA501349, AI709200, AW020881, F26870, AI919316, AA985525, AA318175, AA375674, H47015, AI709292, AI580440, T78704, AA226675, AA595613, AA230292, AA528661, AA101676, AA188186, AA372741, AA320632, F34274, D51607, F32629, T54178, AI352694, AI720481, F31158, AA469169, AA642170, AA230044, AA661507, T40904, T57476, AI832316, AA373500, T57504, T54087, C14334, AA729378, F31962, AW272552, D51810, AI675421, N29450, AA679894, AA375716, AI021397, L38941, AI147334, AF084363, AC003061, AC005372, X14401, AC004796, AC006597, AI049714, AF109472, A75356, S76596, AB007181, Y11587, I48979, AF113690, AF118070, S78214, AF113691, AI133640, AF090934, AF090900, AF106862, AI050393, L31396, L31397, AF090943, AF078844, AI122093, AI117457, AF113694, AI117460, U42766, I89947, AI049938, AI050146, AF113013, AF118064, I89931, AI133016, AF125949, AI110196, AI110221, A93016, AI050108, AF090901, AI133606, AI122050, AF104032, AI050116, AF090896, AJ242859, AF090903, AF113676, S68736, AI049452, AB019565, AI137527, AI080060, AF113019, AF113677, A08913, AR059958, A08916, AF113689, X84990, AI050149, AF113699, AI049314, AI133075, AI049466, AI080124, AI133557, AI050277, AI080137, AF017152, AI096744, AF158248, I48978, E03348, AI133565, AI137557, E07361, AI133093, AI133080, AI137283, Y16645, AI122121, AF111851, AF017437, AI137459, Y11254, AJ000937, X63574, AI122123, X82434, AR011880, AF097996, U91329, AI050138, AF091084, AF125948, AF146568, AI137550, AI117394, AI110225, AF079765, A65341, AI117585, AI049430, AI117435, I49625, AF177401, AI133560, AI117583, A08912, AI049300, U00763, E02349, AI049464, A08910, E07108, AI238278, X72889, AI049382, I33392, AI122098, A03736, AF067728, X70685, AI050024, A08909, A77033, A77035, AF183393, Z82022, I03321, A58524, A58523, AI122110, AI137271, AF118094,					
--	--	--	--	--	--

					AC007390, A12297, S61953, U35846, AL137648, AL137463, AF095901, U72620, AL049283, X96540, AC004093, AF061943, AF026816, AL133113, AL035458, AL137538, AL080127, X93495, U80742, X65873, E05822, AF087943, X98834, AF109906, AC006336, I42402, AL137521, Z72491, AL110197, I09360, U67958, AL080159, Y09972, Y07905, E08263, E08264, AL122049, AL133072, AJ012755, AF026124, AL137560, I26207, E15569, AC006112, AL050172, I17767, AF003737, AC006840, AF210052, AL137294, AF119337, AL133568, AF091512, AF162270, A93350, AC004878, AL110280, AF111112, AF057300, AF008439, AF057299, M30514, AC004690, AC002467, AL137526, A08911, AC004200, AR013797, L13297, I00734, L30117, E00617, E00717, E00778, AL133077, AL137523, AC004987, AF185576, AL137556, AR000496, U39656, I66342, AL133014, AF000145, AF061795, A07647, AF151685, AL133104, E04233, AL133098, AC006371, AF177767, AR038969, T39948, T48092, T53717, T54310, T58614, T58631, T58665, T58680, T59454, T59609, T60693, T60724, T61517, T40270, H89483, N31100, W15188, W79553, W90546, AA101675, AA177148, AA230059, AA230201, AA482934, AA501580, AA514483, AA523478, AA527911, AA533427, AA541546, AA548914, F15751, AA579103, AA654916, AA659893, AA662847, AA729739, AA746663, AA746696, AA746820, AA917622, AA953954, AA962129, N83299, N84751, N85724, N85940, C14425, C14487, C14529, AA090952, AA089892, C15916, AA094133, AA095139, AA652445, D11811, D11899, Z19815, F22033, AA722737, AA775136, T25716, AI302923, AI370276, AI474980, AI567460, AI198759, and AI292268.
HCDEL02	993	920831	1 - 279	15 - 293	AI300611, and AI700656.
HCDDZ69	994	522220	1 - 329	15 - 343	AA631784, T53408, AA427747, AA904211, AI473671, AA721530, AA721523, AA604831, AA017583, AA731361, R94436, AW080215, AW054936, AC002310, AC006312, AC005924, AC005519, AC004883, AP000501, U80017, AC009399, AP000359, AC004796, AL021154, AC004448, AC012384, AC005088, AC002365, AC003110, AC005722, AC005844, AC007666, AC005280, AP000555, AF024533, AC004983, AC003029, AC005899, AC005740, AL049759, AL022316, Z93023, AP000692, AL133353, AC005209, AB023049, AP000008, AC007308, AL031666, AL022318, AL023575, AC009247, AC004895, AC003101, AC002477, AC005932, AC005482, AC006057, AC004019, AC007066, Z99943, AC002432, AC006071, AC007934, AC003042, AL049709, AL022163, AC003690, AC007298, AC006084, and AC002301.
HCDDY54	995	529265	1 - 344	15 - 358	

HCDDO80	996	778563	1 - 421	15 - 435	AI732570, AA134460, AI871333, AI744693, AI610347, and AI563999.
HCDCD64	997	863415	1 - 389	15 - 403	N31472, N29138, AI880074, and H85753.
HCDBW41	998	712648	1 - 463	15 - 477	R43504, R59580, Z39594, T15652, F01654, and Z95118.
HCDBO86	999	784617	1 - 672	15 - 686	W93682, AW242652, AW173253, AI139152, AI53736, AI290544, N49727, N52656, Z41613, AI184287, D61097, AI918560, AA258656, and AF028333.
HCDAO39	1000	704504	1 - 264	15 - 278	AA188026.
HCDA68	1001	753814	1 - 617	15 - 631	R95822, and AA019299.
HBSAP57	1002	531874	1 - 631	15 - 645	AI500721, AA534064, AA829251, AI380617, AW304580, AI826761, AW020150, AA714110, AI560085, F35374, AI278972, AA904211, AW303196, AL042735, AW301350, AA282951, AW410354, AL079734, AW151541, AA515728, T50676, N23913, AA706495, AA983673, AA086318, AA613627, AI440117, AA515048, AA503298, AI962030, AI436433, AI683131, AA833875, AA833896, AI133083, AI249365, AI049709, AI279417, AI354333, AI755214, AW188427, T74524, AW237905, AA704393, AA456924, AI744199, AI754567, AI792521, AA526542, AW069769, AI754105, AA535216, AI053398, W96522, AA284247, AI114557, AI469577, H63660, AI565084, AI950963, AI114733, AI133552, AI216990, AL046746, AL041894, AA809546, AA225406, AI587349, AI355007, AI681962, AI186438, AA659832, AI192440, AI923052, AA420801, AW020094, AA502532, AA719524, AW272294, AA975779, AW271904, AW019964, H82636, AI343169, H73561, AW081303, AL048135, AW157731, AI801505, AI491765, F35097, AA654013, AW419389, AW021399, AI609972, AI859438, AA470578, AA524616, AI362442, AI499954, AI521525, AI635028, AW243793, AC005746, AC005288, AP001060, AC005015, AJ009610, AC005940, AL021453, AC007421, AP000501, AC005409, AC005412, Z99714, AC002565, AC010205, Z95331, AC004805, AC007376, AL049776, AC007227, AC005378, AL008627, AC006160, AC004242, AC007546, AL049869, AL139054, Z84480, AC004895, AC002375, AC006040, AC005747, AL022163, AC002302, AC007263, AC005212, AP000696, AB026898, AC005089, AL022165, AC005837, AC003101, AC004886, Z97054, U47924, AC008154, AL031587, AL022336, AC004134, AL117355, AC002430, AC005261, AC007014, AP000704, AL031281, AC003692, AC007384, AF053356, AC006538, AP000086, AC005828, AC004019, AC007934, AC006449, AC005041, AC005399, AP000555, AL022721, AC005531, AC005037, AF111167, AL022302, AL049766, AP000131, AP000209, AC007919, AP000553, AL117354, U91326, AC005722, AC007676, AC002299, AC005304, AC006468, AL109984, AP000694, AC007225, AL133245, AC011311, AC005071, Z95114, AC002551, Z99716, AC007051,

					AL024498, AC002425, AL050318, AL096701, AL050321, AL049569, AC007055, AC005529, AL049712, AC006480, AP000225, AC005102, AC000134, AC002369, AC002091, AF001548, L78833, AC007868, AC003109, Z97056, AC016830, AL031311, AL022345, AC002544, AC005881, AC004382, AL034451, AF134726, AL031602, AL020997, AC004079, AF111168, AC004883, AC005225, AC005829, AC004858, AC006211, AP000512, AF196779, AC005209, AL008636, AC003663, AL121652, AC004814, AC002563, U91323, AL109628, AP000252, AC007993, AL109758, AC004263, AL133163, AL133371, Z86090, AL049871, AC007308, AL049872, AC006450, AC005632, AL035071, AC004076, AC005081, AC005046, AL021939, AC003982, AC005678, AC006312, AF047825, AL020995, AC003043, U62317, L44140, AC004167, AC002070, AC007011, AL050324, AC016027, AC005859, AL049780, U78027, AC005808, AP000115, Z83844, AC004821, AC010582, AC004882, AC007685, AC005566, AL035461, AC005823, AP000503, U91322, AC003108, AC006141, AC005562, AL031666, AC005480, AC005736, AL021707, AC007537, AC005291, AL121825, AP000008, D87675, U80017, AC005701, AC004057, AC004099, AC006162, AL021918, AC006130, U96629, AL078581, AL133246, AC004552, AC007666, AC005921, AL078638, Z98742, AC002351, AL035587, M89651, AL096761, AC005004, AC006344, AL135744, AC000025, AC000052, AC004990, AC007390, AC005914, AC006463, AC002352, AC006333, AC005514, AC005284, AC004232, AL034548, AL034351, AL049757, AL024497, AC002115, AC004812, AL035072, AC005565, AC002504, AC005484, AC005377, AJ246003, AC004590, AC004985, AL031228, Z93241, AL021393, AL122021, AC004797, and U85195.
HBCKE23	1003	675613	1 - 505	15 - 519	AA429449, AA428527, AA995146, and AI041267.
HBCGD25	1004	677689	1 - 462	15 - 476	H40377, H51703, T70759, T69773, and H40323.
HAOAE95	1005	795674	1 - 304	15 - 318	T39786, T39845, and AL034417.
HAOAD27	1006	848729	1 - 472	15 - 486	AI123100, AW195077, and AL096776.
HANKG10	1007	963926	1 - 456	15 - 470	AI373332, AW243457, AW235081, AA748692, and AW362939.
HANKB13	1008	827062	1 - 423	15 - 437	AA278465, AI979103, and AI908300.
HAMAC79	1009	872774	1 - 1081	15 - 1095	AI358042, AI874151, AL039730, AI400725, F37364, AI887268, AL080011, AW302924, AW193203, AW088899, AW409775, AI433206, AA807088, AA864562, AI355008, AI537677, AI434242, AI345347, AI918554, H89138, AI859464, AI800464, AW411235, AL038445, AI251221, AA911767, AW168503, AL046926, AI521386, AL119863, AI582483, AI886594, AW022682, AI829990, AI922577, AW089006, AA464646, AI954422, AL036638, AI612015, AW161579, AW168031,

<p> AI620093, AW058233, AI573026, AL120853, AI919593, AI590423, AA100772, AI539153, AI933992, AL042382, AI345224, AA127565, AL120526, AI917959, AI311892, AI697324, AA643261, AI280670, AA603709, AI344928, AI952064, AL038069, AA853213, AW021373, AI680498, AI698401, AI580674, AA853539, AI659795, AL048871, AI470293, AI570966, AW089932, AI344933, AI554343, AI916419, AI677797, AW238730, AI537617, AI494201, AW076127, AI920782, AL119791, AL041150, AI335449, AL038076, AW265004, AI927755, AI963040, AI582871, W81248, AA761557, AI573093, AW029401, AA420758, AI537837, AL046463, AI241819, AI874166, AI340533, AW083804, AL038715, AI955945, AI334445, AI336575, AI696969, AW059828, AI073952, AI633477, AW078680, AW004886, AW082623, AI312399, AI648502, AW238688, AI802240, AI866127, AI335426, AL110306, AI348777, AW410969, AA572758, AI889168, AI671661, AI690663, AI929108, AL036772, AI500039, AW162194, AW305233, AI678355, AW074869, AI612014, AL037041, AI471361, AI866100, AW160376, AI343059, AI284509, AW193134, AI669639, AI866082, AI280661, AA493647, AI042365, AI349933, AA420722, AW268261, AI345608, AI285586, AI446124, AI923989, AI348897, D50977, AI174591, AI345251, AW020710, AI419650, AW081255, AI689420, AW301300, AI348847, AI251830, AI917963, AW193872, R36271, AI344819, AI862220, AI648567, AA291456, AW029579, AI343483, AL040241, AW075207, AA848053, AI345253, AW020397, AI312152, AI950688, AI343037, AW269097, AI345677, AA938383, AI696611, AI446373, AW075084, AW087385, AI523806, AW301409, AL047387, AI932458, AI473451, AI340603, AI919345, AI290153, AW151714, AW088903, AI364788, AW130863, AW129230, AI830030, AW084097, AI307543, AI249877, AI345370, AI932949, AI799234, AI345527, AW021717, AI289542, AI348854, AI817430, AI242736, AI699056, AI446092, AI307369, AI345471, AI344935, AI805638, AI334820, AI365256, AI366549, AI366992, AI636719, AI313320, AW190286, AI336495, AI478123, AI453487, AW085786, AW081034, AI539771, AL039086, AI866608, AI472536, AI307520, AL043981, AI805688, AI611743, AI340664, AI590686, AL040207, AI368816, AA830821, AW191844, AI309431, AI888621, AI348917, L78810, AL035407, AC005091, AC006013, AC004686, AC002454, AC004383, AC004878, AL022147, U62317, AI137705, AC004837, AC004797, AC007114, AL049594, AC004159, AC005250, AC005057, AL035587, AL033521, AC004883, AL031295, AC006222, AC004987, AC005488, AC002416, AC007406, AP000030, AL035458, AC007172, AL031984, AL137294, Z82206, AP000514, AC005048, AC006039, AC009286 </p>	
---	--

AC006112, AF091512, and AP000344.									
-----------------------------------	--	--	--	--	--	--	--	--	--

**TABLE 4**

Code	Description	Tissue	Organ	Cell Line	Disease	Vector
AR022	a_Heart	a_Heart				
AR023	a_Liver	a_Liver				
AR024	a_mammary gland	a_mammary gland				
AR025	a_Prostate	a_Prostate				
AR026	a_small intestine	a_small intestine				
AR027	a_Stomach	a_Stomach				
AR028	Blood B cells	Blood B cells				
AR029	Blood B cells activated	Blood B cells activated				
AR030	Blood B cells resting	Blood B cells resting				
AR031	Blood T cells activated	Blood T cells activated				
AR032	Blood T cells resting	Blood T cells resting				
AR033	brain	brain				
AR034	breast	breast				
AR035	breast cancer	breast cancer				
AR036	Cell Line CAOV3	Cell Line CAOV3				
AR037	cell line PA-1	cell line PA-1				
AR038	cell line transformed	cell line transformed				
AR039	colon	colon				
AR040	colon (9808co65R)	colon (9808co65R)				
AR041	colon (9809co15)	colon (9809co15)				
AR042	colon cancer	colon cancer				
AR043	colon cancer (9808co64R)	colon cancer (9808co64R)				
AR044	colon cancer 9809co14	colon cancer 9809co14				
AR045	corn clone 5	corn clone 5				
AR046	corn clone 6	corn clone 6				
AR047	corn clone2	corn clone2				
AR048	corn clone3	corn clone3				
AR049	Corn Clone4	Corn Clone4				
AR050	Donor II B Cells 24hrs	Donor II B Cells 24hrs				
AR051	Donor II B Cells 72hrs	Donor II B Cells 72hrs				
AR052	Donor II B-Cells 24 hrs.	Donor II B-Cells 24 hrs.				
AR053	Donor II B-Cells 72hrs	Donor II B-Cells 72hrs				
AR054	Donor II Resting B Cells	Donor II Resting B Cells				
AR055	Heart	Heart				
AR056	Human Lung (clontech)	Human Lung (clontech)				
AR057	Human Mammary (clontech)	Human Mammary (clontech)				
AR058	Human Thymus (clontech)	Human Thymus (clontech)				
AR059	Jurkat (unstimulated)	Jurkat (unstimulated)				
AR060	Kidney	Kidney				
AR061	Liver	Liver				
AR062	Liver (Clontech)	Liver (Clontech)				
AR063	Lymphocytes chronic	Lymphocytes				

	lymphocytic leukaemia	chronic lymphocytic leukaemia				
AR064	Lymphocytes diffuse large B cell lymphoma	Lymphocytes diffuse large B cell lymphoma				
AR065	Lymphocytes follicular lymphoma	Lymphocytes follicular lymphoma				
AR066	normal breast	normal breast				
AR067	Normal Ovarian (4004901)	Normal Ovarian (4004901)				
AR068	Normal Ovary 9508G045	Normal Ovary 9508G045				
AR069	Normal Ovary 9701G208	Normal Ovary 9701G208				
AR070	Normal Ovary 9806G005	Normal Ovary 9806G005				
AR071	Ovarian Cancer	Ovarian Cancer				
AR072	Ovarian Cancer (9702G001)	Ovarian Cancer (9702G001)				
AR073	Ovarian Cancer (9707G029)	Ovarian Cancer (9707G029)				
AR074	Ovarian Cancer (9804G011)	Ovarian Cancer (9804G011)				
AR075	Ovarian Cancer (9806G019)	Ovarian Cancer (9806G019)				
AR076	Ovarian Cancer (9807G017)	Ovarian Cancer (9807G017)				
AR077	Ovarian Cancer (9809G001)	Ovarian Cancer (9809G001)				
AR078	ovarian cancer 15799	ovarian cancer 15799				
AR079	Ovarian Cancer 17717AID	Ovarian Cancer 17717AID				
AR080	Ovarian Cancer 4004664B1	Ovarian Cancer 4004664B1				
AR081	Ovarian Cancer 4005315A1	Ovarian Cancer 4005315A1				
AR082	ovarian cancer 94127303	ovarian cancer 94127303				
AR083	Ovarian Cancer 96069304	Ovarian Cancer 96069304				
AR084	Ovarian Cancer 9707G029	Ovarian Cancer 9707G029				
AR085	Ovarian Cancer 9807G045	Ovarian Cancer 9807G045				
AR086	ovarian cancer 9809G001	ovarian cancer 9809G001				
AR087	Ovarian Cancer 9905C032RC	Ovarian Cancer 9905C032RC				
AR088	Ovarian cancer 9907 C00 3rd	Ovarian cancer 9907 C00 3rd				
AR089	Prostate	Prostate				
AR090	Prostate (clonetechn)	Prostate (clonetechn)				
AR091	prostate cancer	prostate cancer				
AR092	prostate cancer #15176	prostate cancer #15176				
AR093	prostate cancer #15509	prostate cancer #15509				
AR094	prostate cancer #15673	prostate cancer #15673				
AR095	Small Intestine	Small Intestine				

	(Clontech)	(Clontech)				
AR096	Spleen	Spleen				
AR097	Thymus T cells activated	Thymus T cells activated				
AR098	Thymus T cells resting	Thymus T cells resting				
AR099	Tonsil	Tonsil				
AR100	Tonsil germinal center centroblast	Tonsil germinal center centroblast				
AR101	Tonsil germinal center B cell	Tonsil germinal center B cell				
AR102	Tonsil lymph node	Tonsil lymph node				
AR103	Tonsil memory B cell	Tonsil memory B cell				
AR104	Whole Brain	Whole Brain				
AR105	Xenograft ES-2	Xenograft ES-2				
AR106	Xenograft SW626	Xenograft SW626				
H0041	Human Fetal Bone	Human Fetal Bone	Bone			Uni-ZAP XR
H0122	Human Adult Skeletal Muscle	Human Skeletal Muscle	Sk Muscle			Uni-ZAP XR
H0124	Human Rhabdomyosarcoma	Human Rhabdomyosarcoma	Sk Muscle		disease	Uni-ZAP XR
H0135	Human Synovial Sarcoma	Human Synovial Sarcoma	Synovium			Uni-ZAP XR
H0251	Human Chondrosarcoma	Human Chondrosarcoma	Cartilage		disease	Uni-ZAP XR
H0252	Human Osteosarcoma	Human Osteosarcoma	Bone		disease	Uni-ZAP XR
H0381	Bone Cancer	Bone Cancer			disease	Uni-ZAP XR
H0419	Bone Cancer, re-excision	Bone Cancer				Uni-ZAP XR
H0529	Myoloid Progenitor Cell Line	TF-1 Cell Line; Myoloid progenitor cell line				pCMVSPORT 3.0
H0636	Chondrocytes	Chondrocytes				pSport1
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	9809C332- Poorly differentiate	Ovary & Fallopian Tubes		disease	pSport1
S0001	Brain frontal cortex	Brain frontal cortex	Brain			Lambda ZAP II
S0003	Human Osteoclastoma	Osteoclastoma	bone		disease	Uni-ZAP XR
S0011	STROMAL - OSTEOCLASTOMA	Osteoclastoma	bone		disease	Uni-ZAP XR
S0022	Human Osteoclastoma Stromal Cells - unamplified	Osteoclastoma Stromal Cells				Uni-ZAP XR
S0027	Smooth muscle, serum treated	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0028	Smooth muscle, control	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0032	Smooth muscle-ILb induced	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0037	Smooth muscle, IL1b induced	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0118	Smooth muscle control 2	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0122	Osteoclastoma-	Osteoclastoma	bone		disease	pBluescript

	normalized A					
S0126	Osteoblasts	Osteoblasts	Knee	Cell Line		Uni-ZAP XR
S0192	Synovial Fibroblasts (control)	Synovial Fibroblasts				pSport1
S0194	Synovial hypoxia	Synovial Fibroblasts				pSport1
S0196	Synovial IL-1/TNF stimulated	Synovial Fibroblasts				pSport1
S0206	Smooth Muscle-HASTE normalized	Smooth muscle	Pulmonary artery	Cell Line		pBluescript
S0214	Human Osteoclastoma, re-excision	Osteoclastoma	bone		disease	Uni-ZAP XR
S0242	Synovial Fibroblasts (II1/TNF), subt	Synovial Fibroblasts				pSport1
S0250	Human Osteoblasts II	Human Osteoblasts	Femur		disease	pCMVSPORT 2.0
S0276	Synovial hypoxia-RSF subtracted	Synovial fobroblasts (rheumatoid)	Synovial tissue			pSport1
S0312	Human osteoarthritic;fraction II	Human osteoarthritic cartilage			disease	pSport1
S0314	Human osteoarthritis;fraction I	Human osteoarthritic cartilage			disease	pSport1
S0316	Human Normal Cartilage,Fraction I	Human Normal Cartilage				pSport1
S0318	Human Normal Cartilage Fraction II	Human Normal Cartilage				pSport1
S0334	Human Normal Cartilage Fraction III	Human Normal Cartilage				pSport1
S0336	Human Normal Cartilage Fraction IV	Human Normal Cartilage				pSport1
S0338	Human Osteoarthritic Cartilage Fraction III	Human osteoarthritic cartilage			disease	pSport1
S0340	Human Osteoarthritic Cartilage Fraction IV	Human osteoarthritic cartilage			disease	pSport1
S0362	Human Gastrocnemius	Gastrocnemius muscle				pSport1
S0390	Smooth muscle, control; re-excision	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S3012	Smooth Muscle Serum Treated, Norm	Smooth muscle	Pulmonary artery	Cell Line		pBluescript
S3014	Smooth muscle, serum induced,re-exc	Smooth muscle	Pulmonary artery	Cell Line		pBluescript
L0021	Human adult (K.Okubo)					
L0022	Human adult lung 3" directed MboI cDNA					
L0040	Human colon mucosa					
L0055	Human promyelocyte					
L0180	Human GM-CSF-deprived TF-1 cell line (Liu,Hongtao)			GM-CSF-deprived TF-1 cell line		
L0361	Stratagene ovary (#937217)		ovary			Bluescript SK
L0362	Stratagene ovarian cancer (#937219)					Bluescript SK-
L0365	NCI_CGAP_Phe1	pheochromocytoma				Bluescript

						SK-
L0366	Stratagene schizo brain S11	schizophrenic brain S-11 frontal lobe				Bluescript SK-
L0369	NCI_CGAP_AA1	adrenal adenoma	adrenal gland			Bluescript SK-
L0370	Johnston frontal cortex	pooled frontal lobe	brain			Bluescript SK-
L0375	NCI_CGAP_Kid6	kidney tumor	kidney			Bluescript SK-
L0384	NCI_CGAP_Pr23	prostate tumor	prostate			Bluescript SK-
L0387	NCI_CGAP_GCB0	germinal center B-cells	tonsil			Bluescript SK-
L0415	b4HB3MA Cot8-HAP-Ft					Lafmid BA
L0435	Infant brain, LLNL array of Dr. M. Soares 1NIB					lafmid BA
L0438	normalized infant brain cDNA	total brain	brain			lafmid BA
L0439	Soares infant brain 1NIB		whole brain			Lafmid BA
L0455	Human retina cDNA randomly primed sublibrary	retina	eye			lambda gt10
L0465	TEST1, Human adult Testis tissue					lambda nm1149
L0471	Human fetal heart, Lambda ZAP Express					Lambda ZAP Express
L0485	STRATAGENE Human skeletal muscle cDNA library, cat. #936215.	skeletal muscle	leg muscle			Lambda ZAPII
L0498	NCI_CGAP_HSC3	CD34+, T negative, patient with chronic myelogenous	bone marrow			pAMP1
L0517	NCI_CGAP_Pr1					pAMP10
L0518	NCI_CGAP_Pr2					pAMP10
L0520	NCI_CGAP_Alv1	alveolar rhabdomyosarcoma				pAMP10
L0521	NCI_CGAP_Ew1	Ewing's sarcoma				pAMP10
L0523	NCI_CGAP_Lip2	liposarcoma				pAMP10
L0526	NCI_CGAP_Pr12	metastatic prostate bone lesion				pAMP10
L0527	NCI_CGAP_Ov2	ovary				pAMP10
L0529	NCI_CGAP_Pr6	prostate				pAMP10
L0530	NCI_CGAP_Pr8	prostate				pAMP10
L0538	NCI_CGAP_Ov5	normal surface epithelium	ovary			pAMP10
L0545	NCI_CGAP_Pr4.1	prostatic intraepithelial neoplasia - high grade	prostate			pAMP10
L0559	NCI_CGAP_Ov39	papillary serous ovarian metastasis	ovary			pAMP10
L0562	Chromosome 7 HeLa cDNA Library			HeLa cell line; ATCC		pAMP10
L0581	Stratagene liver (#937224)		liver			pBluescript SK

L0586	HTCDL1					pBluescript SK(-)
L0588	Stratagene endothelial cell 937223					pBluescript SK-
L0589	Stratagene fetal retina 937202					pBluescript SK-
L0590	Stratagene fibroblast (#937212)					pBluescript SK-
L0591	Stratagene HeLa cell s3 937216					pBluescript SK-
L0592	Stratagene hNT neuron (#937233)					pBluescript SK-
L0594	Stratagene neuroepithelium NT2RAMI 937234					pBluescript SK-
L0595	Stratagene NT2 neuronal precursor 937230	neuroepithelial cells	brain			pBluescript SK-
L0596	Stratagene colon (#937204)		colon			pBluescript SK-
L0597	Stratagene corneal stroma (#937222)		cornea			pBluescript SK-
L0598	Morton Fetal Cochlea	cochlea	ear			pBluescript SK-
L0599	Stratagene lung (#937210)		lung			pBluescript SK-
L0601	Stratagene pancreas (#937208)		pancreas			pBluescript SK-
L0602	Pancreatic Islet	pancreatic islet	pancreas			pBluescript SK-
L0604	Stratagene muscle 937209	muscle	skeletal muscle			pBluescript SK-
L0605	Stratagene fetal spleen (#937205)	fetal spleen	spleen			pBluescript SK-
L0606	NCI_CGAP_Lym5	follicular lymphoma	lymph node			pBluescript SK-
L0607	NCI_CGAP_Lym6	mantle cell lymphoma	lymph node			pBluescript SK-
L0608	Stratagene lung carcinoma 937218	lung carcinoma	lung	NCI-H69		pBluescript SK-
L0623	HM3	pectoral muscle (after mastectomy)				pcDNAII (Invitrogen)
L0636	NCI_CGAP_Pit1	four pooled pituitary adenomas	brain			pCMV-SPORT6
L0640	NCI_CGAP_Br18	four pooled high-grade tumors, including two prima	breast			pCMV-SPORT6
L0646	NCI_CGAP_Co14	moderately-differentiated adenocarcinoma	colon			pCMV-SPORT6
L0653	NCI_CGAP_Lu28	two pooled squamous cell carcinomas	lung			pCMV-SPORT6
L0655	NCI_CGAP_Lym12	lymphoma, follicular mixed small and large cell	lymph node			pCMV-SPORT6
L0659	NCI_CGAP_Pan1	adenocarcinoma	pancreas			pCMV-SPORT6
L0661	NCI_CGAP_Mel15	malignant melanoma, metastatic to lymph	skin			pCMV-SPORT6

		node				
L0662	NCI_CGAP_Gas4	poorly differentiated adenocarcinoma with signet r	stomach			pCMV-SPORT6
L0663	NCI_CGAP_Ut2	moderately-differentiated endometrial adenocarcino	uterus			pCMV-SPORT6
L0665	NCI_CGAP_Ut4	serous papillary carcinoma, high grade, 2 pooled t	uterus			pCMV-SPORT6
L0666	NCI_CGAP_Ut1	well-differentiated endometrial adenocarcinoma, 7	uterus			pCMV-SPORT6
L0731	Soares_pregnant_uterus_NbHPU		uterus			pT7T3-Pac
L0740	Soares melanocyte 2NbHM	melanocyte				pT7T3D (Pharmacia) with a modified polylinker
L0741	Soares adult brain N2b4HB55Y		brain			pT7T3D (Pharmacia) with a modified polylinker
L0742	Soares adult brain N2b5HB55Y		brain			pT7T3D (Pharmacia) with a modified polylinker
L0743	Soares breast 2NbHBst		breast			pT7T3D (Pharmacia) with a modified polylinker
L0744	Soares breast 3NbHBst		breast			pT7T3D (Pharmacia) with a modified polylinker
L0745	Soares retina N2b4HR	retina	eye			pT7T3D (Pharmacia) with a modified polylinker
L0746	Soares retina N2b5HR	retina	eye			pT7T3D (Pharmacia) with a modified polylinker
L0747	Soares_fetal_heart_NbH H19W		heart			pT7T3D (Pharmacia) with a modified polylinker
L0748	Soares fetal liver spleen 1NFLS		Liver and Spleen			pT7T3D (Pharmacia) with a modified polylinker
L0749	Soares_fetal_liver_splee		Liver and			pT7T3D

	n_1NFLS_S1		Spleen			(Pharmacia) with a modified polylinker
L0750	Soares_fetal_lung_NbH L19W		lung			pT7T3D (Pharmacia) with a modified polylinker
L0751	Soares ovary tumor NbHOT	ovarian tumor	ovary			pT7T3D (Pharmacia) with a modified polylinker
L0752	Soares_parathyroid_tum or_NbHPA	parathyroid tumor	parathyroi d gland			pT7T3D (Pharmacia) with a modified polylinker
L0753	Soares_pineal_gland_N 3HPG		pineal gland			pT7T3D (Pharmacia) with a modified polylinker
L0754	Soares placenta Nb2HP		placenta			pT7T3D (Pharmacia) with a modified polylinker
L0755	Soares_placenta_8to9we eks_2NbHP8to9W		placenta			pT7T3D (Pharmacia) with a modified polylinker
L0756	Soares_multiple_scleros is_2NbHMSP	multiple sclerosis lesions				pT7T3D (Pharmacia) with a modified polylinker V_TYPE
L0757	Soares_senescent_fibro lasts_NbHSF	senescent fibroblast				pT7T3D (Pharmacia) with a modified polylinker V_TYPE
L0758	Soares_testis_NHT					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0759	Soares_total_fetus_Nb2 HF8_9w					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0760	Barstead aorta HPLRB3	aorta				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0761	NCI_CGAP_CLL1	B-cell, chronic				pT7T3D-Pac

		lymphotic leukemia				(Pharmacia) with a modified polylinker
L0763	NCI_CGAP_Br2	breast				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0764	NCI_CGAP_Co3	colon				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0766	NCI_CGAP_GCB1	germinal center B cell				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0768	NCI_CGAP_GC4	pooled germ cell tumors				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0769	NCI_CGAP_Brn25	anaplastic oligodendroglioma	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0770	NCI_CGAP_Brn23	glioblastoma (pooled)	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0774	NCI_CGAP_Kid3		kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0775	NCI_CGAP_Kid5	2 pooled tumors (clear cell type)	kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0776	NCI_CGAP_Lu5	carcinoid	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0777	Soares_NhHMPu_S1	Pooled human melanocyte, fetal heart, and pregnant	mixed (see below)			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0779	Soares_NFL_T_GBC_S 1		pooled			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0780	Soares_NSF_F8_9W_O T_PA_P_S1		pooled			pT7T3D-Pac (Pharmacia) with a

						modified polylinker
L0783	NCI_CGAP_Pr22	normal prostate	prostate			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0787	NCI_CGAP_Sub1					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0788	NCI_CGAP_Sub2					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0789	NCI_CGAP_Sub3					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0790	NCI_CGAP_Sub4					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0792	NCI_CGAP_Sub6					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0794	NCI_CGAP_GC6	pooled germ cell tumors				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0796	NCI_CGAP_Brn50	medulloblastoma	brain			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0800	NCI_CGAP_Co16	colon tumor, RER+	colon			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0803	NCI_CGAP_Kid11		kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0804	NCI_CGAP_Kid12	2 pooled tumors (clear cell type)	kidney			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0805	NCI_CGAP_Lu24	carcinoid	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker

L0806	NCI_CGAP_Lu19	squamous cell carcinoma, poorly differentiated (4	lung			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0807	NCI_CGAP_Ov18	fibrotheoma	ovary			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0809	NCI_CGAP_Pr28		prostate			pT7T3D-Pac (Pharmacia) with a modified polylinker
L2245	NEM subtracted human fetal kidney cDNA					pUEX1
L2251	Human fetal lung	Fetal lung				

**TABLE 5**

OMIM Reference	Description
104770	Amyloidosis, secondary, susceptibility to
107670	Apolipoprotein A-II deficiency
109270	Renal tubular acidosis, distal, 179800
109270	Spherocytosis, hereditary
109270	[Acanthocytosis, one form]
109270	[Elliptocytosis, Malaysian-Melanesian type]
109270	Hemolytic anemia due to band 3 defect
110700	Vivax malaria, susceptibility to
114208	Malignant hyperthermia susceptibility 5, 601887
114208	Hypokalemic periodic paralysis, 170400
114290	Campomelic dysplasia with autosomal sex reversal
118210	Charcot-Marie-Tooth neuropathy-2A
119300	van der Woude syndrome
120110	Metaphyseal chondrodysplasia, Schmid type
120150	Osteogenesis imperfecta, 4 clinical forms, 166200, 166210, 259420, 166220
120150	Osteoporosis, idiopathic, 166710
120150	Ehlers-Danlos syndrome, type VIIA1, 130060
120160	Osteogenesis imperfecta, 4 clinical forms, 166200, 166210, 259420, 166220
120160	Osteoporosis, idiopathic, 166710
120160	Ehlers-Danlos syndrome, type VIIA2, 130060
120160	Marfan syndrome, atypical
120550	C1q deficiency, type A
120570	C1q deficiency, type B
120575	C1q deficiency, type C

120620	SLE susceptibility
120620	CR1 deficiency
120920	Measles, susceptibility to
121014	Heterotaxia, viscerotaxial, autosomal recessive
121800	Corneal dystrophy, crystalline, Schnyder
123829	Melanoma
126650	Chloride diarrhea, congenital, Finnish type, 214700
126650	Colon cancer
130500	Elliptocytosis-1
133200	Erythrokeratoderma variabilis
133701	Exostoses, multiple, type 2
134370	Factor H deficiency
134370	Hemolytic-uremic syndrome, 235400
134370	Membroproliferative glomerulonephritis
134580	Factor XIIB deficiency
136550	Macular dystrophy, North Carolina type
138033	Diabetes mellitus, type II
138140	Glucose transport defect, blood-brain barrier
138971	Kostmann neutropenia, 202700
139250	Isolated growth hormone deficiency, Illig type with absent GH and Kowarski type with bioinactive GH
144200	Epidermolytic palmoplantar keratoderma
145001	Hyperparathyroidism-jaw tumor syndrome
145260	Pseudohypoaldosteronism, type II
146760	[IgG receptor I, phagocytic, familial deficiency of]
146790	Lupus nephritis, susceptibility to
147570	Interferon, immune, deficiency
148065	White sponge nevus, 193900
148066	Epidermolysis bullosa simplex, Koebner, Dowling-Meara, and Weber-Cockayne types, 131900, 131760, 131800
148066	Epidermolysis bullosa simplex, recessive, 601001
148067	Nonepidermolytic palmoplantar keratoderma, 600962
148067	Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200
148069	Pachyonychia congenita, Jackson-Lawler type, 167210
148080	Epidermolytic hyperkeratosis, 113800
150200	[Placental lactogen deficiency]
150240	Cutis laxa, marfanoid neonatal type
150292	Epidermolysis bullosa, Herlitz junctional type, 226700
150310	Epidermolysis bullosa, Herlitz junctional type, 226700
150310	Epidermolysis bullosa, generalized atrophic benign, 226650
152760	Hypogonadotropic hypogonadism due to GNRH deficiency, 227200
153454	Ehlers-Danlos syndrome, type VI, 225400
154275	Malignant hyperthermia susceptibility 2
154276	Malignant hyperthermia susceptibility 3

156490	Neuroblastoma
159001	Muscular dystrophy, limb-girdle, type 1B
162100	Neuralgic amyotrophy with predilection for brachial plexus
164731	Ovarian carcinoma, 167000
168500	Parietal foramina
170500	Myotonia congenita, atypical acetazolamide-responsive
170500	Paramyotonia congenita, 168300
170500	Hyperkalemic periodic paralysis
170995	Zellweger syndrome-2
171190	Hypertension, essential, 145500
171650	Lysosomal acid phosphatase deficiency
171760	Hypophosphatasia, adult, 146300
171760	Hypophosphatasia, infantile, 241500
172400	Hemolytic anemia due to glucosephosphate isomerase deficiency
172400	Hydrops fetalis, one form
172411	Colorectal cancer, resistance to
173360	Thrombophilia due to excessive plasminogen activator inhibitor
173360	Hemorrhagic diathesis due to PAI1 deficiency
173370	Plasminogen activator deficiency
175100	Turcot syndrome, 276300
175100	Adenomatous polyposis coli
175100	Adenomatous polyposis coli, attenuated
175100	Colorectal cancer
175100	Desmoid disease, hereditary, 135290
175100	Gardner syndrome
176930	Dysprothrombinemia
176930	Hypoprothrombinemia
176960	Pituitary tumor, invasive
179820	[Hyperproreninemia]
180100	Retinitis pigmentosa-1
180105	Retinitis pigmentosa-10
180240	Leukemia, acute promyelocytic
180860	Russell-Silver syndrome
180901	Malignant hyperthermia susceptibility 1, 145600
180901	Central core disease, 117000
181430	Scapuloperoneal syndrome, myopathic type
182138	Anxiety-related personality traits
185430	Atherosclerosis, susceptibility to
185470	Myopathy due to succinate dehydrogenase deficiency
185800	Symphalangism, proximal
190900	Colorblindness, tritan
191045	Cardiomyopathy, familial hypertrophic, 2, 115195
191315	Insensitivity to pain, congenital, with anhidrosis, 256800
191540	[Urate oxidase deficiency]
203310	Ocular albinism, autosomal recessive

208250	Jacobs syndrome
217300	Cornea plana congenita, recessive
221770	Polycystic lipomembranous osteodysplasia with sclerosing leukencephalopathy
221820	Gliososis, familial progressive subcortical
222800	Hemolytic anemia due to bisphosphoglycerate mutase deficiency
226450	Epidermolysis bullosa inversa, junctional
230350	Galactose epimerase deficiency
236250	Homocystinuria due to MTHFR deficiency
246900	Lipoamide dehydrogenase deficiency
248600	Maple syrup urine disease, type Ia
249000	Meckel syndrome
252940	Sanfilippo syndrome, type D
253200	Maroteaux-Lamy syndrome, several forms
253250	Mulibrey nanism
255800	Schwartz-Jampel syndrome
256700	Neuroblastoma
264470	Adrenoleukodystrophy, pseudoneonatal
264700	Pseudo-vitamin D dependency rickets 1
270800	Spastic paraplegia-5A
274270	Thymine-uraciluria
274270	Fluorouracil toxicity, sensitivity to
277700	Werner syndrome
300031	Mental retardation, X-linked, FRAXF type
300044	Wernicke-Korsakoff syndrome, susceptibility to
300048	Intestinal pseudoobstruction, neuronal, X-linked
300049	Nodular heterotopia, bilateral periventricular
300049	BPNH/MR syndrome
300055	Mental retardation with psychosis, pyramidal signs, and macroorchidism
300100	Adrenoleukodystrophy
300100	Adrenomyeloneuropathy
300104	Mental retardation, X-linked nonspecific, 309541
300126	Dyskeratosis congenita-1, 305000
301201	Amelogenesis imperfecta-3, hypoplastic type
301590	Anophthalmos-1
302060	Noncompaction of left ventricular myocardium, isolated
302060	Barth syndrome
302060	Cardiomyopathy, X-linked dilated, 300069
302060	Endocardial fibroelastosis-2
302960	Chondrodysplasia punctata, X-linked dominant
303700	Colorblindness, blue monochromatic
303800	Colorblindness, deutan
303900	Colorblindness, protan
304800	Diabetes insipidus, nephrogenic

305900	Favism
305900	G6PD deficiency
305900	Hemolytic anemia due to G6PD deficiency
306700	Hemophilia A
306995	[Homosexuality, male]
308310	Incontinentia pigmenti, familial
308840	Spastic paraplegia, 312900
308840	Hydrocephalus due to aqueductal stenosis, 307000
308840	MASA syndrome, 303350
309200	Manic-depressive illness, X-linked
309548	Mental retardation, X-linked, FRAXE type
309620	Mental retardation-skeletal dysplasia
309900	Mucopolysaccharidosis II
310300	Emery-Dreifuss muscular dystrophy
310400	Myotubular myopathy, X-linked
310460	Myopia-1
310460	Bornholm eye disease
311300	Otopalatodigital syndrome, type I
311510	Waisman parkinsonism-mental retardation syndrome
314300	Goeminne TKCR syndrome
314400	Cardiac valvular dysplasia-1
600105	Retinitis pigmentosa-12, autosomal recessive
600119	Muscular dystrophy, Duchenne-like, type 2
600119	Adhalinopathy, primary
600309	Atrioventricular canal defect-1
600525	Trichodontoosseous syndrome, 190320
600623	Prostate cancer, 176807
600759	Alzheimer disease-4
600808	Enuresis, nocturnal, 2
600811	Xeroderma pigmentosum, group E, DDB-negative subtype, 278740
600852	Retinitis pigmentosa-17
600881	Cataract, congenital, zonular, with sutural opacities
600887	Endometrial carcinoma
600897	Cataract, zonular pulverulent-1, 116200
600918	Cystinuria, type III
600958	Cardiomyopathy, familial hypertrophic, 4, 115197
600995	Nephrotic syndrome, idiopathic, steroid-resistant
601284	Hereditary hemorrhagic telangiectasia-2, 600376
601363	Wilms tumor, type 4
601412	Deafness, autosomal dominant 7
601414	Retinitis pigmentosa-18
601494	Cardiomyopathy, familial, dilated-2
601652	Glaucoma 1A, primary open angle, juvenile-onset, 137750
601666	Insulin-dependent diabetes mellitus-15

601687	Meesmann corneal dystrophy, 122100
601769	Osteoporosis, involutional
601769	Rickets, vitamin D-resistant, 277440
601844	Pseudohypoaldosteronism type II
601863	Bare lymphocyte syndrome, complementation group C
601954	Muscular dystrophy, limb-girdle, type 2G
601975	Ectodermal dysplasia/skin fragility syndrome
602094	Lipodystrophy, familial partial
602116	Glioma
602136	Refsum disease, infantile, 266510
602136	Zellweger syndrome-1, 214100
602136	Adrenoleukodystrophy, neonatal, 202370
602447	Coronary artery disease, susceptibility to
602491	Hyperlipidemia, familial combined, 1
602629	Dystonia-6, torsion
602716	Nephrosis-1, congenital, Finnish type, 256300
602771	Muscular dystrophy, congenital, with early spine rigidity
602772	Retinitis pigmentosa-24

#### *Polynucleotide and Polypeptide Variants*

[0105] The present invention is also directed to variants of the musculoskeletal system associated polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, nucleotide sequences encoding the polypeptide of SEQ ID NO:Y, the nucleotide sequence of SEQ ID NO:X encoding the polypeptide sequence as defined in column 6 of Table 1A, nucleotide sequences encoding the polypeptide as defined in column 6 of Table 1A, the nucleotide sequence as defined in columns 8 and 9 of Table 2, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, the nucleotide sequence as defined in column 6 of Table 1B, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in column 6 of Table 1B, the cDNA sequence contained in Clone ID NO:Z, and/or nucleotide sequences encoding a polypeptide encoded by the cDNA sequence contained in Clone ID NO:Z.

[0106] The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y, a polypeptide sequence as defined in column 6 of Table 1A, a polypeptide sequence encoded by the polynucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the nucleotide sequence as defined in

columns 8 and 9 of Table 2, a polypeptide sequence encoded by the nucleotide sequence as defined in column 6 of Table 1B, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, and/or a polypeptide sequence encoded by the cDNA sequence contained in Clone ID NO:Z.

[0107] "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

[0108] Thus, one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence described in SEQ ID NO:X or contained in the cDNA sequence of Clone ID NO:Z; (b) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes a mature musculoskeletal system associated polypeptide; (c) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes a biologically active fragment of a musculoskeletal system associated polypeptide; (d) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes an antigenic fragment of a musculoskeletal system associated polypeptide; (e) a nucleotide sequence encoding a musculoskeletal system associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (f) a nucleotide sequence encoding a mature musculoskeletal system associated polypeptide of the amino acid sequence of SEQ ID NO:Y or the amino acid sequence encoded by the cDNA in Clone ID NO:Z; (g) a nucleotide sequence encoding a biologically active fragment of a musculoskeletal system associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (h) a nucleotide sequence encoding an antigenic fragment of a musculoskeletal system associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; and (i) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), or (h), above.

[0109] The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i) above, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the cDNA contained in Clone ID NO:Z or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in Clone ID NO:Z, the nucleotide coding sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, the nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto, the nucleotide sequence in SEQ ID NO:X encoding the polypeptide sequence as defined in column 6 of Table 1A or the complementary strand thereto, nucleotide sequences encoding a polypeptide as defined in column 6 of Table 1A or the complementary strand thereto, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides and nucleic acids.

[0110] In a preferred embodiment, the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under lower stringency conditions, to a polynucleotide in (a), (b), (c), (d), (e), (f), (g), (h), or (i) above, as are polypeptides encoded by these polynucleotides. In another preferred

embodiment, polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0111] In another embodiment, the invention provides a purified protein comprising, or alternatively consisting of, a polypeptide having an amino acid sequence selected from the group consisting of: (a) the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (b) the amino acid sequence of a mature musculoskeletal system associated polypeptide having the amino acid sequence of SEQ ID NO:Y or the amino acid sequence encoded by the cDNA in Clone ID NO:Z; (c) the amino acid sequence of a biologically active fragment of a musculoskeletal system associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; and (d) the amino acid sequence of an antigenic fragment of a musculoskeletal system associated polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z.

[0112] The present invention is also directed to proteins which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, any of the amino acid sequences in (a), (b), (c), or (d), above, the amino acid sequence shown in SEQ ID NO:Y, the amino acid sequence encoded by the cDNA contained in Clone ID NO:Z, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B, the amino acid sequence as defined in column 6 of Table 1A, an amino acid sequence encoded by the nucleotide sequence in SEQ ID NO:X, and an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X. Fragments of these polypeptides are also provided (e.g., those fragments described herein). Further proteins encoded by polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these amino acid sequences under stringent hybridization conditions or alternatively, under lower

stringency conditions, are also encompassed by the invention, as are the polynucleotides encoding these proteins.

[0113] By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence referred to in Table 1A or 2 as the ORF (open reading frame), or any fragment specified, as described herein.

[0114] As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

[0115] If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3'

truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

[0116] For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[0117] By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other

words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0118] As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of a polypeptide referred to in Table 1A (e.g., an amino acid sequence identified in columns 5 or 6) or Table 2 (e.g., the amino acid sequence of the polypeptide encoded by the polynucleotide sequence defined in columns 8 and 9 of Table 2) or a fragment thereof, the amino acid sequence of the polypeptide encoded by the polynucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1B or a fragment thereof, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X or a fragment thereof, or an amino acid sequence of the polypeptide encoded by cDNA contained in Clone ID NO:Z, or a fragment thereof, can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237-245 (1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

[0119] If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N-

and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.

[0120] For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[0121] The polynucleotide variants of the invention may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide

variants containing alterations, which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, polypeptide variants in which less than 50, less than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

[0122] Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

[0123] Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptides of the present invention without substantial loss of biological function. As an example, the authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

[0124] Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the

molecule could be altered with little effect on either [binding or biological activity]." In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

[0125] Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

[0126] Thus, the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) of the polypeptides of the invention. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.

[0127] The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, (e.g., encoding a polypeptide having the amino acid sequence of an N and/or C terminal deletion), irrespective of whether they encode a polypeptide having functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having functional activity include, *inter alia*, (1) isolating a gene or allelic or splice variants thereof in a cDNA library; (2) in situ hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern Blot analysis for detecting mRNA expression in specific tissues (e.g., normal musculoskeletal system tissue or diseased

musculoskeletal system tissues); and (4) *in situ* hybridization (e.g., histochemistry) for detecting mRNA expression in specific tissues (e.g., normal musculoskeletal system tissue or diseased musculoskeletal system tissues).

[0128] Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having functional activity. By a polypeptide having "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an anti-polypeptide of the invention antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

[0129] The functional activity of the polypeptides, and fragments, variants and derivatives of the invention, can be assayed by various methods.

[0130] For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the present invention for binding to an anti-polypeptide of the invention antibody, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

[0131] In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky et al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, the ability of physiological correlates of a polypeptide of the present invention to bind to a substrate(s) of the polypeptide of the invention can be routinely assayed using techniques known in the art.

[0132] In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants and derivatives thereof to elicit polypeptide related biological activity (either *in vitro* or *in vivo*). Other methods will be known to the skilled artisan and are within the scope of the invention.

[0133] Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to, for example, the nucleic acid sequence of the cDNA contained in Clone ID NO:Z, a nucleic acid sequence referred to in Table 1A (e.g., SEQ ID NO:X), a nucleic acid sequence disclosed in Table 2 (e.g., the nucleic acid sequence delineated in columns 8 and 9) or fragments thereof, will encode polypeptides "having functional activity." In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

[0134] For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310

(1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0135] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

[0136] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. See Cunningham et al., Science 244:1081-1085 (1989). The resulting mutant molecules can then be tested for biological activity.

[0137] As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Besides conservative amino acid substitutions, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitutions with one or more of the amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example,

polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, serum albumin (preferably human serum albumin) or a fragment or variant thereof, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

[0138] For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. See Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).

[0139] A further embodiment of the invention relates to polypeptides which comprise the amino acid sequence of a polypeptide having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions from a polypeptide sequence disclosed herein. Of course it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of a polypeptide of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, an amino acid sequence encoded by the complement of SEQ ID NO:X, and/or the amino acid sequence encoded by cDNA contained in Clone ID NO:Z which contains, in order of ever-increasing preference, at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions.

[0140] In specific embodiments, the polypeptides of the invention comprise, or alternatively, consist of, fragments or variants of a reference amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO:Y or fragments thereof (e.g., the mature form and/or other fragments described herein); (b) the amino acid sequence encoded by SEQ ID NO:X or fragments thereof; (c) the amino acid sequence encoded by the complement of SEQ ID NO:X or fragments thereof; (d) the amino acid

sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or fragments thereof; and (e) the amino acid sequence encoded by cDNA contained in Clone ID NO:Z or fragments thereof; wherein the fragments or variants have 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, amino acid residue additions, substitutions, and/or deletions when compared to the reference amino acid sequence. In preferred embodiments, the amino acid substitutions are conservative. Polynucleotides encoding these polypeptides are also encompassed by the invention.

#### *Polynucleotide and Polypeptide Fragments*

[0141] The present invention is also directed to polynucleotide fragments of the polynucleotides (nucleic acids) of the invention. In the present invention, a "polynucleotide fragment" refers to a polynucleotide having a nucleic acid sequence which, for example: is a portion of the cDNA contained in Clone ID NO:Z or the complementary strand thereto; is a portion of the polynucleotide sequence encoding the polypeptide encoded by the cDNA contained in Clone ID NO:Z or the complementary strand thereto; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence in SEQ ID NO:X or the complementary strand thereto; is a polynucleotide sequence encoding a portion of the polypeptide of SEQ ID NO:Y; is a polynucleotide sequence encoding a portion of a polypeptide encoded by SEQ ID NO:X; is a polynucleotide sequence encoding a portion of a polypeptide encoded by the complement of the polynucleotide sequence in SEQ ID NO:X; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto; or is a portion of the polynucleotide sequence of SEQ ID NO:B as defined in column 6 of Table 1B or the complementary strand thereto.

[0142] The polynucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75

nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in Clone ID NO:Z, or the nucleotide sequence shown in SEQ ID NO:X or the complementary strand thereto. In this context "about" includes the particularly recited value or a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 160, 170, 180, 190, 200, 250, 500, 600, 1000, or 2000 nucleotides in length) are also encompassed by the invention.

[0143] Moreover, representative examples of polynucleotide fragments of the invention, comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of SEQ ID NO:X, or the complementary strand

thereto. In this context "about" includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0144] Further representative examples of polynucleotide fragments of the invention, comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of the cDNA sequence contained in Clone ID NO:Z, or the complementary strand thereto. In this context "about" includes the

particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0145] Moreover, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence delineated in Table 1B column 6. Additional, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence that is the complementary strand of a sequence delineated in column 6 of Table 1B. In further embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1B, column 5). In additional embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1B, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated Table 1B, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1B, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also

encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0146] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1B, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0147] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1B which correspond to the same Clone ID NO:Z (see Table 1B, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0148] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in the same row of column 6 of Table 1B, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A or 1B) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0149] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that

encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0150] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X (e.g., as described herein) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0151] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1B are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0152] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. In preferred

embodiments, the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table 1B is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table 1B, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0153] In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y, a portion of an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a portion of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:X, a portion of an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, and/or a portion of an amino acid sequence encoded by the cDNA contained in Clone ID NO:Z. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region. In a preferred embodiment, polypeptide fragments of the invention include, for example, fragments comprising, or alternatively consisting

of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region of SEQ ID NO:Y. Moreover, polypeptide fragments of the invention may be at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, or ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

[0154] Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0155] Accordingly, polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or

the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions is preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

[0156] The present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X or the complement thereof, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a polypeptide encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1B, and/or a polypeptide encoded by the cDNA contained in Clone ID NO:Z). In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a polypeptide of the invention (e.g., the polypeptide disclosed in SEQ ID NO:Y, or the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0157] The present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or a polypeptide encoded by the cDNA contained in Clone ID NO:Z). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where n corresponds to the position of amino acid residue in a polypeptide of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0158] In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also

provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a polypeptide encoded by SEQ ID NO:X (e.g., including, but not limited to, the preferred polypeptide disclosed as SEQ ID NO:Y and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), the cDNA contained in Clone ID NO:Z, and/or the complement thereof, where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0159] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0160] The present application is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence set forth herein. In preferred embodiments, the application is directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to polypeptides having the amino acid sequence of the specific N- and C-terminal deletions. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0161] Any polypeptide sequence encoded by, for example, the polynucleotide sequences set forth as SEQ ID NO:X or the complement thereof, (presented, for example, in Tables 1A and 2), the cDNA contained in Clone ID NO:Z, or the polynucleotide sequence as defined in column 6 of Table 1B, may be analyzed to

determine certain preferred regions of the polypeptide. For example, the amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X (e.g., the polypeptide of SEQ ID NO:Y and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2) or the cDNA contained in Clone ID NO:Z may be analyzed using the default parameters of the DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, WI 53715 USA; <http://www.dnastar.com/>).

[0162] Polypeptide regions that may be routinely obtained using the DNASTAR computer algorithm include, but are not limited to, Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions; Chou-Fasman alpha-regions, beta-regions, and turn-regions; Kyte-Doolittle hydrophilic regions and hydrophobic regions; Eisenberg alpha- and beta-amphipathic regions; Karplus-Schulz flexible regions; Emini surface-forming regions; and Jameson-Wolf regions of high antigenic index. Among highly preferred polynucleotides of the invention in this regard are those that encode polypeptides comprising regions that combine several structural features, such as several (e.g., 1, 2, 3 or 4) of the features set out above.

[0163] Additionally, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Emini surface-forming regions, and Jameson-Wolf regions of high antigenic index (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) can routinely be used to determine polypeptide regions that exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from data by DNASTAR analysis by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

[0164] Preferred polypeptide fragments of the invention are fragments comprising, or alternatively, consisting of, an amino acid sequence that displays a functional activity (e.g. biological activity) of the polypeptide sequence of which the amino acid sequence is a fragment. By a polypeptide displaying a "functional activity" is meant a polypeptide capable of one or more known functional activities associated with a full-

length protein, such as, for example, biological activity, antigenicity, immunogenicity, and/or multimerization, as described herein.

[0165] Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[0166] In preferred embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the antigenic fragments of the polypeptide of SEQ ID NO:Y, or portions thereof. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0167] The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of: the polypeptide sequence shown in SEQ ID NO:Y; a polypeptide sequence encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2; the polypeptide sequence encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1B or the complement thereto; the polypeptide sequence encoded by the cDNA contained in Clone ID NO:Z; or the polypeptide sequence encoded by a polynucleotide that hybridizes to the sequence of SEQ ID NO:X, the complement of the sequence of SEQ ID NO:X, the complement of a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, or the cDNA sequence contained in Clone ID NO:Z under stringent hybridization conditions or alternatively, under lower stringency hybridization as defined *supra*. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X, or a fragment thereof), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or alternatively, under lower stringency hybridization conditions defined *supra*.

[0168] The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and

most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

[0169] Fragments, which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

[0170] In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

[0171] Non-limiting examples of epitopes of polypeptides that can be used to generate antibodies of the invention include a polypeptide comprising, or alternatively consisting of, at least one, two, three, four, five, six or more of the portion(s) of SEQ

ID NO:Y specified in column 6 of Table 1A. These polypeptide fragments have been determined to bear antigenic epitopes of the proteins of the invention by the analysis of the Jameson-Wolf antigenic index, which is included in the DNASTar suite of computer programs. By "comprise" it is intended that a polypeptide contains at least one, two, three, four, five, six or more of the portion(s) of SEQ ID NO:Y shown in column 6 of Table 1A, but it may contain additional flanking residues on either the amino or carboxyl termini of the recited portion. Such additional flanking sequences are preferably sequences naturally found adjacent to the portion; i.e., contiguous sequence shown in SEQ ID NO:Y. The flanking sequence may, however, be sequences from a heterologous polypeptide, such as from another protein described herein or from a heterologous polypeptide not described herein. In particular embodiments, epitope portions of a polypeptide of the invention comprise one, two, three, or more of the portions of SEQ ID NO:Y shown in column 6 of Table 1A. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0172] Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

[0173] Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, *in vivo* immunization, *in vitro* immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). If *in vivo* immunization is used, animals may be immunized

with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

[0174] As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention (e.g., those comprising an immunogenic or antigenic epitope) can be fused to heterologous polypeptide sequences. For example, polypeptides of the present invention (including fragments or variants thereof), may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof, resulting in chimeric polypeptides. By way of another non-limiting example, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1 – 585 of human serum albumin as shown in Figures 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred

embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Patent 5,766,883 herein incorporated by reference in its entirety. Polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

[0175] Such fusion proteins as those described above may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin (HA) tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

***Fusion Proteins***

[0176] Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, polypeptides of the present invention which are shown to be secreted can be used as targeting molecules once fused to other proteins.

[0177] Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

[0178] In certain preferred embodiments, proteins of the invention are fusion proteins comprising an amino acid sequence that is an N and/or C- terminal deletion of a polypeptide of the invention. In preferred embodiments, the invention is directed to a fusion protein comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence of the invention. Polynucleotides encoding these proteins are also encompassed by the invention.

[0179] Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

[0180] As one of skill in the art will appreciate that, as discussed above, polypeptides of the present invention, and epitope-bearing fragments thereof, can be combined with heterologous polypeptide sequences. For example, the polypeptides of the present invention may be fused with heterologous polypeptide sequences, for example, the polypeptides of the present invention may be fused with the constant

domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), or albumin (including, but not limited to, native or recombinant human albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties (EP-A 0232 262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).

[0181] Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a polypeptide, which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984).)

[0182] Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"), briefly described below, and further described herein. DNA shuffling may be employed to modulate the activities of

polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference in its entirety). In a preferred embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc., of one or more heterologous molecules encoding a heterologous polypeptide.

[0183] Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Recombinant and Synthetic Production of Polypeptides of the Invention**

[0184] The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by synthetic and recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

[0185] The polynucleotides of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

[0186] The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp*, *phoA* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination,

and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

[0187] As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance, glutamine synthase, for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, NSO and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

[0188] Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

[0189] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulfoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors is the availability of cell lines (e.g., the murine myeloma cell line, NS0) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g., Chinese Hamster Ovary (CHO) cells) by

providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657, which are hereby incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors can be obtained from Lonza Biologics, Inc. (Portsmouth, NH). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington *et al.*, *Bio/technology* 10:169(1992) and in Biblia and Robinson *Biotechnol. Prog.* 11:1 (1995) which are herein incorporated by reference.

[0190] The present invention also relates to host cells containing the above-described vector constructs described herein, and additionally encompasses host cells containing nucleotide sequences of the invention that are operably associated with one or more heterologous control regions (e.g., promoter and/or enhancer) using techniques known of in the art. The host cell can be a higher eukaryotic cell, such as a mammalian cell (e.g., a human derived cell), or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. A host strain may be chosen, which modulates the expression of the inserted gene sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus expression of the genetically engineered polypeptide may be controlled. Furthermore, different host cells have characteristics and specific mechanisms for the translational and post-translational processing and modification (e.g., phosphorylation, cleavage) of proteins. Appropriate cell lines can be chosen to ensure the desired modifications and processing of the foreign protein expressed.

[0191] Introduction of the nucleic acids and nucleic acid constructs of the invention into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

[0192] In addition to encompassing host cells containing the vector constructs

discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., musculoskeletal system antigen coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with musculoskeletal system associated polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous musculoskeletal system associated polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous musculoskeletal system associated polynucleotide sequences via homologous recombination (see, e.g., US Patent Number 5,641,670, issued June 24, 1997; International Publication Number WO 96/29411; International Publication Number WO 94/12650; Koller *et al.*, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra *et al.*, *Nature* 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0193] Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

[0194] In one embodiment, the yeast *Pichia pastoris* is used to express polypeptides of the invention in a eukaryotic system. *Pichia pastoris* is a

methylophilic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolism pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

[0195] In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

[0196] Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

[0197] In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be

achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

[0198] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra et al., *Nature* 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0199] In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid

analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0200] The invention encompasses polypeptides of the present invention which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

[0201] Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

[0202] Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include iodine ( $^{121}\text{I}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{111}\text{In}$ ,  $^{112}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{115\text{m}}\text{In}$ ), technetium ( $^{99}\text{Tc}$ ,  $^{99\text{m}}\text{Tc}$ ), thallium ( $^{201}\text{Tl}$ ), gallium ( $^{68}\text{Ga}$ ,  $^{67}\text{Ga}$ ), palladium ( $^{103}\text{Pd}$ ), molybdenum ( $^{99}\text{Mo}$ ), xenon ( $^{133}\text{Xe}$ ), fluorine ( $^{18}\text{F}$ ),  $^{153}\text{Sm}$ ,  $^{177}\text{Lu}$ ,  $^{159}\text{Gd}$ ,  $^{149}\text{Pm}$ ,  $^{140}\text{La}$ ,  $^{175}\text{Yb}$ ,  $^{166}\text{Ho}$ ,  $^{90}\text{Y}$ ,  $^{47}\text{Sc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{142}\text{Pr}$ ,  $^{105}\text{Rh}$ , and  $^{97}\text{Ru}$ .

[0203] In specific embodiments, a polypeptide of the present invention or fragment or variant thereof is attached to macrocyclic chelators that associate with

radiometal ions, including but not limited to,  $^{177}\text{Lu}$ ,  $^{90}\text{Y}$ ,  $^{166}\text{Ho}$ , and  $^{153}\text{Sm}$ , to polypeptides. In a preferred embodiment, the radiometal ion associated with the macrocyclic chelators is  $^{111}\text{In}$ . In another preferred embodiment, the radiometal ion associated with the macrocyclic chelator is  $^{90}\text{Y}$ . In specific embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). In other specific embodiments, DOTA is attached to an antibody of the invention or fragment thereof via a linker molecule. Examples of linker molecules useful for conjugating DOTA to a polypeptide are commonly known in the art - see, for example, DeNardo et al., *Clin Cancer Res.* 4(10):2483-90 (1998); Peterson et al., *Bioconjug. Chem.* 10(4):553-7 (1999); and Zimmerman et al, *Nucl. Med. Biol.* 26(8):943-50 (1999); which are hereby incorporated by reference in their entirety.

[0204] As mentioned, the musculoskeletal system associated proteins of the invention may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given musculoskeletal system associated polypeptide. Musculoskeletal system associated polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic musculoskeletal system associated polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, *PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993);

POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0205] Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0206] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

[0207] As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides Nucleotides 18:2745-2750 (1999); and Caliceti et al., Bioconjug. Chem. 10:638-646 (1999), the disclosures of each of which are incorporated herein by

reference.

[0208] The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, such as; for example, the method disclosed in EP 0 401 384 (coupling PEG to G-CSF), herein incorporated by reference; see also Malik et al., Exp. Hematol. 20:1028-1035 (1992), reporting pegylation of GM-CSF using tresyl chloride. For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

[0209] As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

[0210] One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the

N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

[0211] As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado et al., *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis et al., *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

[0212] One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ( $\text{ClSO}_2\text{CH}_2\text{CF}_3$ ). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

[0213] Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number of additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in

International Publication No. WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

[0214] The number of polyethylene glycol moieties attached to each protein of the invention (i.e., the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado et al., *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

[0215] The musculoskeletal system associated polypeptides of the invention can be recovered and purified from chemical synthesis and recombinant cell cultures by standard methods which include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

[0216] Musculoskeletal system associated polynucleotides and polypeptides may be used in accordance with the present invention for a variety of applications, particularly those that make use of the chemical and biological properties of musculoskeletal system associated antigens. Among these are applications in the detection, prevention, diagnosis and/or treatment of diseases associated with musculoskeletal system, such as e.g., bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and sciolosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders (e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis,

polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or those disorders described under "Musculoskeletal System Disorders". Additional applications relate to diagnosis and to treatment of disorders of cells, tissues and organisms. These aspects of the invention are discussed further below.

[0217] In a preferred embodiment, polynucleotides expressed in a particular tissue type are used to detect, diagnose, treat, prevent and/or prognose disorders associated with the tissue type.

[0218] The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

[0219] Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer refers to a multimer containing only polypeptides corresponding to a protein of the invention (e.g., the amino acid sequence of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X or the complement of SEQ ID NO:X, the amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or an amino acid sequence encoded by cDNA contained in Clone ID NO:Z (including fragments, variants, splice variants, and fusion proteins, corresponding to these as described herein)). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing two polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing three polypeptides having identical and/or different

amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

[0220] As used herein, the term heteromer refers to a multimer containing two or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

[0221] Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked by, for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:Y, encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or encoded by the cDNA contained in Clone ID NO:Z). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., U.S. Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the

invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

[0222] Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

[0223] Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

[0224] In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention

containing Flag® polypeptide sequence. In a further embodiment, proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

[0225] The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

[0226] Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by

reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

### **Antibodies**

[0227] Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of the invention (e.g., a polypeptide or fragment or variant of the amino acid sequence of SEQ ID NO:Y or a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or an epitope, of the present invention) as determined by immunoassays well known in the art for assaying specific antibody-antigen binding. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), intracellularly-made antibodies (i.e., intrabodies), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

[0228] Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable

region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described *infra* and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

[0229] The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutti, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

[0230] Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention, which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, or by size in contiguous amino acid residues, or listed in the Tables and Figures. Preferred epitopes of the invention include those shown in column 6 of Table 1A, as well as polynucleotides that encode these epitopes. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

[0231] Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that

bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies, which bind polypeptides encoded by polynucleotides, which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

[0232] The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

[0233] Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies, which disrupt the receptor/ligand interactions with the polypeptides of the

invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies, which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described *supra*). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

[0234] The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies, which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., *Blood* 92(6):1981-1988 (1998); Chen et al., *Cancer Res.* 58(16):3668-3678 (1998); Harrop et al., *J. Immunol.* 161(4):1786-1794 (1998); Zhu et al., *Cancer Res.* 58(15):3209-3214 (1998); Yoon et al., *J. Immunol.* 160(7):3170-3179 (1998); Prat et al., *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard et al., *J. Immunol. Methods* 205(2):177-190 (1997); Liautard et al., *Cytokine* 9(4):233-241 (1997); Carlson et al., *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman et al., *Neuron*

14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

[0235] Antibodies of the present invention may be used, for example, to purify, detect, and target the polypeptides of the present invention, including both *in vitro* and *in vivo* diagnostic and therapeutic methods. For example, the antibodies have utility in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); incorporated by reference herein in its entirety.

[0236] As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalent and non-covalent conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387; the disclosures of which are incorporated herein by reference in their entireties.

[0237] The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0238] The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

[0239] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

[0240] Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art

for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

[0241] Accordingly, the present invention provides methods of generating monoclonal antibodies, as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

[0242] Another well known method for producing both polyclonal and monoclonal human B cell lines is transformation using Epstein Barr Virus (EBV). Protocols for generating EBV-transformed B cell lines are commonly known in the art, such as, for example, the protocol outlined in Chapter 7.22 of *Current Protocols in Immunology*, Coligan et al., Eds., 1994, John Wiley & Sons, NY, which is hereby incorporated in its entirety by reference herein. The source of B cells for transformation is commonly human peripheral blood, but B cells for transformation may also be derived from other sources including, but not limited to, lymph nodes, tonsil, spleen, tumor tissue, and infected tissues. Tissues are generally made into single cell suspensions prior to EBV transformation. Additionally, steps may be taken to either physically remove or inactivate T cells (e.g., by treatment with cyclosporin A) in B cell-containing samples, because T cells from individuals seropositive for anti-EBV antibodies can suppress B cell immortalization by EBV.

[0243] In general, the sample containing human B cells is inoculated with EBV, and cultured for 3-4 weeks. A typical source of EBV is the culture supernatant of the B95-8 cell line (ATCC #VR-1492). Physical signs of EBV transformation can generally be seen towards the end of the 3-4 week culture period. By phase-contrast microscopy, transformed cells may appear large, clear, hairy and tend to aggregate in tight clusters of cells. Initially, EBV lines are generally polyclonal. However, over prolonged periods of cell cultures, EBV lines may become monoclonal or polyclonal as a result of the selective outgrowth of particular B cell clones. Alternatively, polyclonal EBV transformed lines may be subcloned (e.g., by limiting dilution culture)

or fused with a suitable fusion partner and plated at limiting dilution to obtain monoclonal B cell lines. Suitable fusion partners for EBV transformed cell lines include mouse myeloma cell lines (e.g., SP2/0, X63-Ag8.653), heteromyeloma cell lines (human x mouse; e.g., SPAM-8, SBC-H20, and CB-F7), and human cell lines (e.g., GM 1500, SKO-007, RPMI 8226, and KR-4). Thus, the present invention also provides a method of generating polyclonal or monoclonal human antibodies against polypeptides of the invention or fragments thereof, comprising EBV-transformation of human B cells.

[0244] Antibody fragments, which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain. For example, the antibodies of the present invention can also be generated using various phage display methods known in the art and as discussed in detail in the Examples (e.g., Example 10). In phage display methods, functional antibody domains are displayed on the surface of phage particles, which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S.

Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

[0245] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

[0246] Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known

in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., *Nature* 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology* 28(4/5):489-498 (1991); Studnicka et al., *Protein Engineering* 7(6):805-814 (1994); Roguska. et al., *PNAS* 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

[0247] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

[0248] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring, which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all

or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; 5,939,598; 6,075,181 and 6,114,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

[0249] Completely human antibodies, which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

[0250] Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, J. *Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand/receptor. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or

to bind its ligand(s)/receptor(s), and thereby block its biological activity. Alternatively, antibodies, which bind to and enhance polypeptide multimerization and/or binding, and/or receptor/ligand multimerization, binding and/or signaling can be used to generate anti-idiotypes that function as agonists of a polypeptide of the invention and/or its ligand/receptor. Such agonistic anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens as agonists of the polypeptides of the invention or its ligand(s)/receptor(s). For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligand(s)/receptor(s), and thereby promote or enhance its biological activity.

[0251] Intrabodies of the invention can be produced using methods known in the art, such as those disclosed and reviewed in Chen et al., Hum. Gene Ther. 5:595-601 (1994); Marasco, W.A., Gene Ther. 4:11-15 (1997); Rondon and Marasco, Annu. Rev. Microbiol. 51:257-283 (1997); Proba et al., J. Mol. Biol. 275:245-253 (1998); Cohen et al., Oncogene 17:2445-2456 (1998); Ohage and Steipe, J. Mol. Biol. 291:1119-1128 (1999); Ohage et al., J. Mol. Biol. 291:1129-1134 (1999); Wirtz and Steipe, Protein Sci. 8:2245-2250 (1999); Zhu et al., J. Immunol. Methods 231:207-222 (1999); and references cited therein.

#### *Polynucleotides Encoding Antibodies*

[0252] The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or alternatively, under lower stringency hybridization conditions, e.g., as defined *supra*, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y, to a polypeptide encoded by a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or to a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0253] The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in

Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

[0254] Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A<sup>+</sup> RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

[0255] Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

[0256] In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within

framework regions, e.g., into human framework regions to humanize a non-human antibody, as described *supra*. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed *supra*, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

[0257] In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described *supra*, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

[0258] Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038-1041 (1988)).

*Methods of Producing Antibodies*

[0259] The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques. Methods of producing antibodies include, but are not limited to, hybridoma technology, EBV transformation, and other methods discussed herein as well as through the use recombinant DNA technology, as discussed below.

[0260] Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

[0261] The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells

containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

[0262] A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

[0263] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0264] In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

[0265] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals

include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol.* 153:51-544 (1987)).

[0266] In addition, a host cell strain may be chosen, which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells, which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

[0267] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines, which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may

advantageously be used to engineer cell lines, which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

[0268] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., *Cell* 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA* 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., *Cell* 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., *Natl. Acad. Sci. USA* 77:357 (1980); O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (*Clinical Pharmacy* 12:488-505; Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); TIB TECH 11(5):155-215 (1993)); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

[0269] The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the

amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

[0270] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulfoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors are the availability of cell lines (e.g., the murine myeloma cell line, NS0) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g., Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657 which are incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors that may be used according to the present invention are commercially available from suppliers, including, for example Lonza Biologics, Inc. (Portsmouth, NH). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington et al., Bio/technology 10:169(1992) and in Biblia and Robinson Biotechnol. Prog. 11:1 (1995) which are incorporated in their entireties by reference herein.

[0271] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0272] Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example,

by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

[0273] The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either *in vitro* or *in vivo*, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in *in vitro* immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452 (1991), which are incorporated by reference in their entireties.

[0274] The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through

disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341 (1992) (said references incorporated by reference in their entireties).

[0275] As discussed, *supra*, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the *in vivo* half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. See, for example, Fountoulakis et al., J. Biochem. 270:3958-3964 (1995). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. See, for example, EP A 232,262. Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

[0276] Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

[0277] The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention.

[0278] Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, <sup>213</sup>Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine,

lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0279] The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti- angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

[0280] Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0281] Techniques for conjugating such therapeutic moiety to antibodies are well known. See, for example., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom

et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

[0282] Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

[0283] An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

#### *Immunophenotyping*

[0284] The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. Translation products of the genes of the present invention may be useful as cell specific markers, or more specifically as cellular markers that are differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison et al., *Cell*, 96:737-49 (1999)).

[0285] These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the

screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

*Assays For Antibody Binding*

[0286] The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays, which can be used, include but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

[0287] Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al., eds., (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 10.16.1.

[0288] Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al., eds., (1994), *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York, section 10.8.1.

[0289] ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al., eds., (1994), *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York, section 11.2.1.

[0290] The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

[0291] Antibodies of the invention may be characterized using immunocytochemistry methods on cells (e.g., mammalian cells, such as CHO cells) transfected with a vector enabling the expression of a musculoskeletal system antigen or with vector alone using techniques commonly known in the art. Antibodies that bind musculoskeletal system antigen transfected cells, but not vector-only transfected cells, are musculoskeletal system antigen specific.

#### *Therapeutic Uses*

[0292] The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited

to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0293] In a specific and preferred embodiment, the present invention is directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the diseases, disorders, or conditions of the musculoskeletal system, including, but not limited to, bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and sciolosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders (e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis, polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or those disorders described under "Musculoskeletal System Disorders". Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (e.g., antibodies directed to the full length protein expressed on the cell surface of a mammalian cell; antibodies directed to an epitope of a musculoskeletal system associated polypeptide of the invention (such as, a linear epitope (shown in Table 1A, column 6) or a conformational epitope), including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions of the musculoskeletal system described herein. The treatment and/or prevention of diseases, disorders, or conditions of the musculoskeletal system associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention

may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0294] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0295] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells, which interact with the antibodies.

[0296] The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

[0297] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,

$10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### *Gene Therapy*

[0298] In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

[0299] Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

[0300] For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

[0301] In a preferred embodiment, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, *Proc. Natl.*

Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

[0302] Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

[0303] In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

[0304] In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

[0305] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

[0306] Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

[0307] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

[0308] In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0309] The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

[0310] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

[0311] In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

[0312] In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

[0313] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by the presence or absence of an appropriate inducer of transcription.

#### *Demonstration of Therapeutic or Prophylactic Activity*

[0314] The compounds or pharmaceutical compositions of the invention are preferably tested *in vitro*, and then *in vivo* for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, *in vitro* assays which can be used to determine whether administration of a specific compound is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

#### *Therapeutic/Prophylactic Administration and Composition*

[0315] The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably a polypeptide or antibody of the invention. In a preferred embodiment, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

[0316] Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

[0317] Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0318] In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local

infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

[0319] In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

[0320] In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J.Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

[0321] Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

[0322] In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use

of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

[0323] The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide

the form for proper administration to the patient. The formulation should suit the mode of administration.

[0324] In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0325] The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0326] The amount of the compound of the invention, which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0327] For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a

patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

[0328] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

#### *Diagnosis and Imaging*

[0329] Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

[0330] The invention provides a diagnostic assay for diagnosing a musculoskeletal system disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a

particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0331] Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0332] One facet of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. A preferred embodiment of the invention is the detection and diagnosis of a disease or disorder of the musculoskeletal system associated with aberrant expression of a musculoskeletal system antigen in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide

of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

[0333] It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0334] Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

[0335] In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

[0336] Presence of the labeled molecule can be detected in the patient using methods known in the art for *in vivo* scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

[0337] In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al.,

U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

### *Kits*

[0338] The present invention provides kits that can be used in the above methods.

In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody, which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

[0339] In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum-containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope, which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine, which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

[0340] In a more specific embodiment, the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

[0341] In an additional embodiment, the invention includes a diagnostic kit for use in screening serum-containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

[0342] In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

[0343] The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

[0344] Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

#### **Uses of the Polynucleotides**

[0345] Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

[0346] The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome, thus each polynucleotide of the present invention can routinely be used as a chromosome marker using techniques known in the art. Table 1A, column 8 provides the chromosome location of some of the polynucleotides of the invention.

[0347] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably at least 15 bp (e.g., 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can optionally be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to SEQ ID NO:X will yield an amplified fragment.

[0348] Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries, and computer mapping techniques (See, e.g., Shuler, Trends

Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety).

[0349] Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

[0350] For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

[0351] Thus, the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table 1A and/or Table 2 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.

[0352] The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g. Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999), each of which is hereby incorporated by reference in its entirety.

[0353] Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Column 9 of Table 1A provides an OMIM reference identification number of diseases associated with the cytologic band disclosed in column 8 of Table 1A, as determined using techniques described herein and by reference to Table 5. Assuming 1 megabase mapping resolution and one gene per 20

kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

[0354] Thus, once coinheritance is established, differences in a polynucleotide of the invention and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicate that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

[0355] Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using the polynucleotides of the invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker. Diagnostic and prognostic methods, kits and reagents encompassed by the present invention are briefly described below and more thoroughly elsewhere herein (see e.g., the sections labeled "Antibodies", "Diagnostic Assays", and "Methods for Detecting Musculoskeletal System Disease, Including Cancer").

[0356] Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder. Additional non-limiting examples of diagnostic methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., Example 12).

[0357] In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject, as further described herein. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will

specifically hybridize with a polynucleotide of the invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the invention, where each probe has one strand containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

[0358] Where a diagnosis of a related disorder, including, for example, diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0359] By "measuring the expression level of polynucleotides of the invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the invention or the level of the mRNA encoding the polypeptide of the invention in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the related disorder or being determined by averaging levels from a population of individuals not having a related disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0360] By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains polypeptide of the present invention or the corresponding mRNA. As indicated, biological samples include body fluids (such as semen, lymph, vaginal pool, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0361] The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides of the invention are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in U.S. Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the invention attached may be used to identify polymorphisms between the isolated polynucleotide sequences of the invention, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e., their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, such as for example, in neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, digestive disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. Such a method is described in U.S. Patents 5,858,659 and 5,856,104. The U.S. Patents referenced *supra* are hereby incorporated by reference in their entirety herein.

[0362] The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides of the invention are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by Nielsen et al., Science 254:1497 (1991); and Egholm et al., Nature 365:666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with

PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point (T<sub>sub.m</sub>) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

[0363] The compounds of the present invention have uses, which include, but are not limited to, detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

[0364] The compounds of the present invention have preferred uses, which include, but are not limited to, detecting cancer of musculoskeletal system tissues in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: osteochondroma, benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor, multiple myeloma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's tumor, and malignant lymphoma of bone. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

[0365] Pathological cell proliferative disorders are often associated with inappropriate activation of proto-oncogenes. (Gelman, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelman et al., *supra*) It is likely that mutated or altered expression of specific genes is involved in the

pathogenesis of some leukemias, among other tissues and cell types. (Gelmann et al., *supra*) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelmann et al., *supra*)

[0366] For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580). However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness is not be limited to treatment, prevention, diagnosis and/or prognosis, of proliferative disorders of cells and tissues of hematopoietic origin, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes. In preferred embodiments, the compounds and/or methods of the invention are used to treat, prevent, diagnose, and/or prognose, proliferative disorders of musculoskeletal system cells and tissues.

[0367] In addition to the foregoing, a polynucleotide of the present invention can be used to control gene expression through triple helix formation or through antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself

(antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. The oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of polypeptide of the present invention antigens. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease, and in particular, for the treatment of proliferative diseases and/or conditions. Non-limiting antisense and triple helix methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the section labeled "Antisense and Ribozyme (Antagonists)").

[0368] Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell. Additional non-limiting examples of gene therapy methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the sections labeled "Gene Therapy Methods" and Examples 16, 17 and 18).

[0369] The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

[0370] The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

[0371] Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

[0372] There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention, specific to tissues, including but not limited to, those sequences referred to in Table 1A. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination. Additional non-limiting examples of such uses are further described herein.

[0373] Because musculoskeletal system antigens are found expressed in musculoskeletal system tissues, the polynucleotides of the present invention are also useful as hybridization probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed

to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In a specific embodiment, the polynucleotides of the present invention are also useful as hybridization probes for differential identification of musculoskeletal system tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of musculoskeletal system tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In addition, for a number of disorders of the above tissues or cells, significantly higher or lower levels of gene expression of the polynucleotides/polypeptides of the present invention may be detected in certain tissues (e.g., tissues expressing polypeptides and/or polynucleotides of the present invention, for example, normal musculoskeletal system tissues or diseased musculoskeletal system tissues, and/or those tissues/cells corresponding to the library source relating to a polynucleotide sequence of the invention as disclosed in column 7 of Table 1A, and/or cancerous and/or wounded tissues) or bodily fluids (e.g., semen, lymph, vaginal pool, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

[0374] Thus, the invention provides a diagnostic method of a disorder, which involves: (a) assaying gene expression level in cells or body fluid of an individual; (b) comparing the gene expression level with a standard gene expression level, whereby an increase or decrease in the assayed gene expression level compared to the standard expression level is indicative of a disorder.

[0375] In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

**Uses of the Polypeptides**

[0376] Each of the polypeptides identified herein can be used in numerous ways.

The following description should be considered exemplary and utilizes known techniques.

[0377] Polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays such as, for example, ABC immunoperoxidase (Hsu et al., J. Histochem. Cytochem. 29:577-580 (1981)) or cell type(s) (e.g., immunocytochemistry assays).

[0378] Antibodies can be used to assay levels of polypeptides encoded by polynucleotides of the invention in a biological sample using classical immunohistological methods known to those of skill in the art (see, e.g., Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{115\text{m}}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{112}\text{In}$ ,  $^{111}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ,  $^{99\text{m}}\text{Tc}$ ), thallium ( $^{201}\text{Tl}$ ), gallium ( $^{68}\text{Ga}$ ,  $^{67}\text{Ga}$ ), palladium ( $^{103}\text{Pd}$ ), molybdenum ( $^{99}\text{Mo}$ ), xenon ( $^{133}\text{Xe}$ ), fluorine ( $^{18}\text{F}$ ),  $^{153}\text{Sm}$ ,  $^{177}\text{Lu}$ ,  $^{159}\text{Gd}$ ,  $^{149}\text{Pm}$ ,  $^{140}\text{La}$ ,  $^{175}\text{Yb}$ ,  $^{166}\text{Ho}$ ,  $^{90}\text{Y}$ ,  $^{47}\text{Sc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{142}\text{Pr}$ ,  $^{105}\text{Rh}$ ,  $^{97}\text{Ru}$ ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0379] In addition to assaying levels of polypeptide of the present invention in a biological sample, proteins can also be detected *in vivo* by imaging. Antibody labels or markers for *in vivo* imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

[0380] A musculoskeletal system antigen-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ , ( $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{115\text{m}}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{112}\text{In}$ ,  $^{111}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ,  $^{99\text{m}}\text{Tc}$ ), thallium ( $^{201}\text{Tl}$ ), gallium ( $^{68}\text{Ga}$ ,  $^{67}\text{Ga}$ ), palladium ( $^{103}\text{Pd}$ ), molybdenum ( $^{99}\text{Mo}$ ), xenon ( $^{133}\text{Xe}$ ), fluorine ( $^{18}\text{F}$ ,  $^{153}\text{Sm}$ ,  $^{177}\text{Lu}$ ,  $^{159}\text{Gd}$ ,  $^{149}\text{Pm}$ ,  $^{140}\text{La}$ ,  $^{175}\text{Yb}$ ,  $^{166}\text{Ho}$ ,  $^{90}\text{Y}$ ,  $^{47}\text{Sc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{142}\text{Pr}$ ,  $^{105}\text{Rh}$ ,  $^{97}\text{Ru}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for musculoskeletal system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which express the polypeptide encoded by a polynucleotide of the invention. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0381] In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0382] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

[0383] In a preferred embodiment, the invention provides a method for the specific destruction of musculoskeletal system cells (e.g., aberrant musculoskeletal system cells, musculoskeletal system neoplasm) by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) in association with toxins or cytotoxic prodrugs. In another preferred embodiment the invention provides a method for the specific destruction of tissues/cells corresponding to the library source relating to a polynucleotide sequence of the invention as disclosed in column 7 of Table 1A by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

[0384] By "toxin" is meant one or more compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ , or other radioisotopes such as, for example,  $^{103}\text{Pd}$ ,  $^{133}\text{Xe}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{68}\text{Ge}$ ,  $^{57}\text{Co}$ ,  $^{65}\text{Zn}$ ,  $^{85}\text{Sr}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{153}\text{Sm}$ ,  $^{153}\text{Gd}$ ,  $^{169}\text{Yb}$ ,  $^{51}\text{Cr}$ ,  $^{54}\text{Mn}$ ,  $^{75}\text{Se}$ ,  $^{113}\text{Sn}$ ,  $^{90}\text{Yttrium}$ ,  $^{117}\text{Tin}$ ,  $^{186}\text{Rhenium}$ ,  $^{166}\text{Holmium}$ , and  $^{188}\text{Rhenium}$ ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0385] In a specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope  $^{90}\text{Y}$ . In another specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope  $^{111}\text{In}$ . In a further specific embodiment, the invention provides a method for the

specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope  $^{131}\text{I}$ .

[0386] Techniques known in the art may be applied to label polypeptides of the invention (including antibodies). Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety).

[0387] Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression level of a polypeptide of the present invention in cells or body fluid of an individual; and (b) comparing the assayed polypeptide expression level with a standard polypeptide expression level, whereby an increase or decrease in the assayed polypeptide expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0388] Moreover, polypeptides of the present invention can be used to treat or prevent diseases or conditions of the musculoskeletal system such as, for example, bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and scoliosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders (e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis, polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or those disorders described under "Musculoskeletal System Disorders". In preferred embodiments, polynucleotides expressed in a particular tissue type (see,

e.g., Table 1A, column 7) are used to diagnose, detect, prevent, treat and/or prognose disorders associated with the tissue type. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

[0389] Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease (as described *supra*, and elsewhere herein). For example, administration of an antibody directed to a polypeptide of the present invention can bind, and/or neutralize the polypeptide, and/or reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

[0390] At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the biological activities described herein.

### **Diagnostic Assays**

[0391] The compounds of the present invention are useful for diagnosis, treatment, prevention and/or prognosis of various musculoskeletal system related disorders in mammals, preferably humans. Such disorders include, but are not limited to bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and sciolosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders

(e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis, polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or those disorders described under "Musculoskeletal System Disorders". In preferred embodiments, polynucleotides expressed in a particular tissue type (see, e.g., Table 1A, column 7) are used to diagnose, detect, prevent, treat and/or prognose disorders associated with the tissue type.

[0392] Musculoskeletal system antigens are expressed in the musculoskeletal system, with an increased expression level in musculoskeletal system tissues. For a number of musculoskeletal system-related disorders, substantially altered (increased or decreased) levels of musculoskeletal system antigen gene expression can be detected in musculoskeletal system tissue or other cells or bodily fluids (e.g., sera, plasma, urine, semen, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" musculoskeletal system antigen gene expression level, that is, the musculoskeletal system antigen expression level in musculoskeletal system tissues or bodily fluids from an individual not having the musculoskeletal system disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a musculoskeletal system disorder, which involves measuring the expression level of the gene encoding the musculoskeletal system associated polypeptide in musculoskeletal system tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard musculoskeletal system antigens gene expression level, whereby an increase or decrease in the gene expression level(s) compared to the standard is indicative of a musculoskeletal system disorder.

[0393] In specific embodiments, the invention provides a diagnostic method useful during diagnosis of a disorder of a normal or diseased tissue/cell source corresponding to column 7 of Table 1A, which involves measuring the expression level of the coding sequence of a polynucleotide sequence associated with this tissue/cell source as disclosed in Table 1A in the tissue/cell source or other cells or body fluid from an individual and comparing the expression level of the coding sequence with a standard expression level of the coding sequence of a polynucleotide sequence, whereby an

increase or decrease in the gene expression level(s) compared to the standard is indicative of a disorder of a normal or diseased tissue/cell source corresponding to column 7 of Table 1A.

[0394] In particular, it is believed that certain tissues in mammals with cancer of cells or tissue of the musculoskeletal system express significantly enhanced or reduced levels of normal or altered musculoskeletal system antigen expression and mRNA encoding the musculoskeletal system associated polypeptide when compared to a corresponding "standard" level. Further, it is believed that enhanced or depressed levels of the musculoskeletal system associated polypeptide can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) or cells or tissue from mammals with such a cancer when compared to sera from mammals of the same species not having the cancer.

[0395] For example, as disclosed herein, musculoskeletal system associated polypeptides of the invention are expressed in musculoskeletal system tissues. Accordingly, polynucleotides of the invention (e.g., polynucleotide sequences complementary to all or a portion of a musculoskeletal system antigen mRNA nucleotide sequence of SEQ ID NO:X, nucleotide sequence encoding SEQ ID NO:Y, nucleotide sequence encoding a polypeptide encoded by SEQ ID NO:X and/or a nucleotide sequence delineated by columns 8 and 9 of Table 2) and antibodies (and antibody fragments) directed against the polypeptides of the invention may be used to quantitate or qualitate concentrations of cells of the musculoskeletal system expressing musculoskeletal system antigens, preferably on their cell surfaces. These polynucleotides and antibodies additionally have diagnostic applications in detecting abnormalities in the level of musculoskeletal system antigens gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of musculoskeletal system antigens. These diagnostic assays may be performed *in vivo* or *in vitro*, such as, for example, on blood samples, biopsy tissue or autopsy tissue. In specific embodiments, polynucleotides and antibodies of the invention are used to quantitate or qualitate tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding musculoskeletal system sequence disclosed in the same row of Table 1A, preferably on their cell surface.

[0396] Thus, the invention provides a diagnostic method useful during diagnosis of a musculoskeletal system disorder, including cancers, which involves measuring the expression level of the gene encoding the musculoskeletal system antigen polypeptide in musculoskeletal system tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard musculoskeletal system antigen gene expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a musculoskeletal system disorder. In specific embodiments, polynucleotides and antibodies of the invention are used to quantitate or qualitate tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding musculoskeletal system sequence disclosed in the same row of Table 1A, preferably on their cell surface.

[0397] Where a diagnosis of a disorder in the musculoskeletal system, including diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed musculoskeletal system antigen gene expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0398] By "assaying the expression level of the gene encoding the musculoskeletal system associated polypeptide" is intended qualitatively or quantitatively measuring or estimating the level of the musculoskeletal system antigen polypeptide or the level of the mRNA encoding the musculoskeletal system antigen polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the musculoskeletal system associated polypeptide level or mRNA level in a second biological sample). Preferably, the musculoskeletal system antigen polypeptide expression level or mRNA level in the first biological sample is measured or estimated and compared to a standard musculoskeletal system antigen polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder of the musculoskeletal system. As will be appreciated in the art, once a standard musculoskeletal system antigen polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0399] By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source containing musculoskeletal system antigen polypeptides (including portions thereof) or mRNA. As indicated, biological samples include body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain cells expressing musculoskeletal system antigen polypeptides, musculoskeletal system tissue, and other tissue sources found to express the full length or fragments thereof of a musculoskeletal system antigen. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0400] Total cellular RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). Levels of mRNA encoding the musculoskeletal system antigen polypeptides are then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

[0401] The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of musculoskeletal system antigen polypeptides, in a biological sample (e.g., cells and tissues), including determination of normal and abnormal levels of polypeptides. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of musculoskeletal system antigens compared to normal control tissue samples may be used to detect the presence of tumors. Assay techniques that can be used to determine levels of a polypeptide, such as a musculoskeletal system antigen polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Assaying musculoskeletal system antigen polypeptide levels in a biological sample can occur using any art-known method.

[0402] Assaying musculoskeletal system antigen polypeptide levels in a biological sample can occur using antibody-based techniques. For example, musculoskeletal system antigen polypeptide expression in tissues can be studied with classical

immunohistological methods (Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting musculoskeletal system antigen polypeptide gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0403] The tissue or cell type to be analyzed will generally include those, which are known, or suspected, to express the musculoskeletal system antigen gene (such as, for example, cells of the musculoskeletal system or cancer of musculoskeletal system tissues). The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the musculoskeletal system antigen gene.

[0404] For example, antibodies, or fragments of antibodies, such as those described herein, may be used to quantitatively or qualitatively detect the presence of musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0405] In a preferred embodiment, antibodies, or fragments of antibodies directed to any one or all of the predicted epitope domains of the musculoskeletal system antigen polypeptides (Shown in Table 1A, column 6) may be used to quantitatively or qualitatively detect the presence of musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled

antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0406] In an additional preferred embodiment, antibodies, or fragments of antibodies directed to a conformational epitope of a musculoskeletal system antigen may be used to quantitatively or qualitatively detect the presence of musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0407] The antibodies (or fragments thereof), and/or musculoskeletal system antigen polypeptides of the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immunological assays, for in situ detection of musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or musculoskeletal system antigen polypeptide of the present invention. The antibody (or fragment thereof) or musculoskeletal system antigen polypeptide is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the musculoskeletal system antigen gene product, or conserved variants or peptide fragments, or musculoskeletal system antigen polypeptide binding, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

[0408] Immunoassays and non-immunoassays for musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of binding musculoskeletal system antigen gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

[0409] The biological sample may be brought in contact with and immobilized

onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled anti-musculoskeletal system antigen antibody or detectable musculoskeletal system antigen polypeptide. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or polypeptide. Optionally the antibody is subsequently labeled. The amount of bound label on solid support may then be detected by conventional means.

[0410] By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

[0411] The binding activity of a given lot of anti-musculoskeletal system antigen antibody or musculoskeletal system antigen polypeptide may be determined according to well-known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

[0412] In addition to assaying musculoskeletal system antigen polypeptide levels or polynucleotide levels in a biological sample obtained from an individual, musculoskeletal system antigen polypeptide or polynucleotide can also be detected *in vivo* by imaging. For example, in one embodiment of the invention, musculoskeletal system antigen polypeptide and/or anti-musculoskeletal system antigen antibodies are used to image musculoskeletal system diseased cells, such as neoplasms. In another

embodiment, musculoskeletal system antigen polynucleotides of the invention (e.g., polynucleotides complementary to all or a portion of musculoskeletal system antigen mRNA) and/or anti-musculoskeletal system antigen antibodies (e.g., antibodies directed to any one or a combination of the epitopes of musculoskeletal system antigens, antibodies directed to a conformational epitope of musculoskeletal system antigens, antibodies directed to the full length polypeptide expressed on the cell surface of a mammalian cell) are used to image diseased or neoplastic cells of the musculoskeletal system.

[0413] Antibody labels or markers for *in vivo* imaging of musculoskeletal system antigen polypeptides include those detectable by X-radiography, NMR, MRI, CAT-scans or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma. Where *in vivo* imaging is used to detect enhanced levels of musculoskeletal system antigen polypeptides for diagnosis in humans, it may be preferable to use human antibodies or "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using techniques described herein or otherwise known in the art. For example methods for producing chimeric antibodies are known in the art. See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., *Nature* 312:643 (1984); Neuberger et al., *Nature* 314:268 (1985).

[0414] Additionally, any musculoskeletal system antigen polypeptides whose presence can be detected, can be administered. For example, musculoskeletal system antigen polypeptides labeled with a radio-opaque or other appropriate compound can be administered and visualized *in vivo*, as discussed, above for labeled antibodies. Further such musculoskeletal system antigen polypeptides can be utilized for *in vitro* diagnostic procedures.

[0415] A musculoskeletal system antigen polypeptide-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging

moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for a musculoskeletal system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain musculoskeletal system antigen protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0416] With respect to antibodies, one of the ways in which the anti-musculoskeletal system antigen antibody can be detectably labeled is by linking the same to an enzyme and using the linked product in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller et al., *J. Clin. Pathol.* 31:507-520 (1978); Butler, J.E., *Meth. Enzymol.* 73:482-523 (1981); Maggio, E. (ed.), 1980, *Enzyme Immunoassay*, CRC Press, Boca Raton, FL.; Ishikawa, E. et al., (eds.), 1981, *Enzyme Immunoassay*, Kaku Shoin, Tokyo). The enzyme, which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. Additionally, the detection can be accomplished by colorimetric methods, which employ a chromogenic substrate for the enzyme. Detection may also be accomplished

by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

[0417] Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect musculoskeletal system antigens through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by means including, but not limited to, a gamma counter, a scintillation counter, or autoradiography.

[0418] It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine.

[0419] The antibody can also be detectably labeled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0420] The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent-labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

[0421] Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

**Methods for Detecting Musculoskeletal System Disease, Including Cancer**

[0422] In general, a musculoskeletal system disease or cancer may be detected in a patient based on the presence of one or more musculoskeletal system antigen proteins of the invention and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, urine, and/or tumor biopsies) obtained from the patient. In other words, such proteins and/or polynucleotides may be used as markers to indicate the presence or absence of a musculoskeletal system disease or disorder, including cancer. Cancers that may be diagnosed, and/or prognosed using the compositions of the invention include but are not limited to, cancer of musculoskeletal system tissues. In addition, such proteins and/or polynucleotides may be useful for the detection of other diseases and cancers, including cancers of tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding musculoskeletal system sequence disclosed in the same row of Table 1A. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding musculoskeletal system antigen polypeptides, which is also indicative of the presence or absence of a musculoskeletal system disease or disorder, including cancer. In general, musculoskeletal system antigen polypeptides should be present at a level that is at least three fold higher in diseased tissue than in normal tissue.

[0423] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, *supra*. In general, the presence or absence of a musculoskeletal system disease in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[0424] In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the musculoskeletal system antigen polypeptide of the invention from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection

reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include musculoskeletal system antigen polypeptides and portions thereof, or antibodies, to which the binding agent binds, as described above.

[0425] The solid support may be any material known to those of skill in the art to which musculoskeletal system antigen polypeptides of the invention may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for the suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 ug, and preferably about 100 ng to about 1 ug, is sufficient to immobilize an adequate amount of binding agent.

[0426] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with

both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

#### **Gene Therapy Methods**

[0427] Also encompassed by the present invention are gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a musculoskeletal system antigen of the present invention. This method requires a polynucleotide, which codes for a polypeptide of the present invention operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

[0428] Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the present invention ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide of the present invention. Such methods are well-known in the art. For example, see Belldegrun, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106 (1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J.-F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells, which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

[0429] As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[0430] In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

[0431] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

[0432] Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

[0433] Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[0434] The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[0435] For the naked nucleic acid sequence injection, an effective dosage amount of DNA or-RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

[0436] The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or

bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[0437] The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

[0438] The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

[0439] In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

[0440] Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y., (see, also, Felgner et al., Proc. Natl Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

[0441] Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of

DOTMA liposomes is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

[0442] Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

[0443] For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

[0444] The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., Methods of Immunology (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a

homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell 17:77 (1979); ether injection (Deamer, D. and Bangham, A., Biochim. Biophys. Acta 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun. 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA 76:3348 (1979)); detergent dialysis (Enoch, H. and Strittmatter, P., Proc. Natl. Acad. Sci. USA 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem. 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA 75:145 (1978); Schaefer-Ridder et al., Science 215:166 (1982)), which are herein incorporated by reference.

[0445] Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

[0446] U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and International Publication No. WO 94/9469 provide methods for delivering DNA-cationic lipid complexes to mammals.

[0447] In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA, which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia

Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

[0448] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0449] The producer cell line generates infectious retroviral vector particles, which include polynucleotide encoding a polypeptide of the present invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express a polypeptide of the present invention.

[0450] In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz, et al., Am. Rev. Respir. Dis. 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1991)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al., Proc. Natl. Acad. Sci. USA 76:6606 (1979)).

[0451] Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, *Curr. Opin. Genet. Devel.* 3:499-503 (1993); Rosenfeld et al., *Cell* 68:143-155 (1992); Engelhardt et al., *Human Genet. Ther.* 4:759-769 (1993); Yang et al., *Nature Genet.* 7:362-369 (1994); Wilson et al., *Nature* 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

[0452] Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest, which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

[0453] In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., *Curr. Topics in Microbiol. Immunol.* 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

[0454] For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus,

using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles, which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

[0455] Another method of gene therapy involves operably associating heterologous control regions and endogenous musculoskeletal system antigen polynucleotide sequences (e.g., encoding a musculoskeletal system antigen polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra et al., *Nature* 342:435-438 (1989), which are herein incorporated by reference. This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

[0456] Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

[0457] The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the

amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

[0458] The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

[0459] The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

[0460] The polynucleotide encoding a polypeptide of the present invention may contain a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the musculoskeletal system antigen polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

[0461] Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda et al., Science 243:375 (1989)).

[0462] A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

[0463] Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

[0464] Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site. In specific embodiments, suitable delivery vehicles for use with systemic administration comprise liposomes comprising polypeptides of the invention for targeting the vehicle to a particular site.

[0465] Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

[0466] Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of

treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

[0467] Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

### **Biological Activities**

[0468] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or polypeptides, or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat, prevent diagnose and/or prognose the associated disease.

[0469] The musculoskeletal system antigen polynucleotides and polypeptides of the invention are predicted to have predominant expression in musculoskeletal system tissues.

[0470] Thus, the musculoskeletal system antigens of the invention may be useful as therapeutic molecules. Each would be useful for diagnosis, detection, treatment and/or prevention of diseases or disorders of the musculoskeletal system, including but not limited to bone disorders (e.g., osteoporosis, osteomyelitis, Paget's disease, and sciolosis); joint disorders (e.g., osteoarthritis, rheumatoid arthritis, infectious arthritis, systemic lupus erythematosus, gout, and Reiter's syndrome); ligament, tendon, and bursa disorders (e.g., bursitis, tendinitis, and tenosynovitis); muscle disorders (e.g., muscular dystrophy, Pompe's disease, periodic paralysis, polymyalgia rheumatica, polymyositis, and Steinert's disease), neoplasms and/or cancers of musculoskeletal tissues (e.g., osteochondroma, benign chondroma, chondroblastoma, osteoid osteoma, and giant cell tumor), and/or those disorders described under "Musculoskeletal System Disorders".

[0471] In a preferred embodiment, polynucleotides of the invention (e.g., a nucleic acid sequence of SEQ ID NO:X or the complement thereof; or the cDNA sequence contained in Clone ID NO:Z, or fragments or variants thereof) and/or polypeptides of the invention (e.g., an amino acid sequence contained in SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, or the complement thereof, an amino acid sequence encoded by the cDNA sequence contained in Clone ID NO:Z and fragments or variants thereof as described herein) are useful for the diagnosis, detection, treatment, and/or prevention of diseases or disorders of the tissues/cells corresponding to the library source disclosed in column 7 of Table 1A expressing the corresponding musculoskeletal system sequence disclosed in the same row of Table 1A.

[0472] Particularly, the musculoskeletal system antigens may be a useful therapeutic for cancer of musculoskeletal system tissues. Treatment, diagnosis, detection, and/or prevention of musculoskeletal system disorders could be carried out using a musculoskeletal system antigen or soluble form of a musculoskeletal system antigen, a musculoskeletal system antigen ligand, gene therapy, or ex vivo applications. Moreover, inhibitors of a musculoskeletal system antigen, either blocking antibodies or mutant forms, could modulate the expression of the musculoskeletal system antigen. These inhibitors may be useful to treat, diagnose, detect, and/or prevent diseases associated with the misregulation of a musculoskeletal system antigen.

[0473] In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells (e.g., normal or diseased musculoskeletal system cells) by administering polypeptides of the invention (e.g., musculoskeletal system antigen polypeptides or anti-musculoskeletal system antigen antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell (e.g., an aberrant musculoskeletal system cell or musculoskeletal system cancer cell). In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0474] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of aberrant musculoskeletal system cells, including, but not limited to, musculoskeletal system tumor cells) by administering polypeptides of the invention (e.g., musculoskeletal system antigen polypeptides or fragments thereof, or anti-musculoskeletal system antigen antibodies) in association with toxins or cytotoxic prodrugs.

[0475] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, cytotoxins (cytotoxic agents), or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ , or other radioisotopes such as, for example,  $^{103}\text{Pd}$ ,  $^{133}\text{Xe}$ ,  $^{131}\text{I}$ ,  $^{68}\text{Ge}$ ,  $^{57}\text{Co}$ ,  $^{65}\text{Zn}$ ,  $^{85}\text{Sr}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{153}\text{Sm}$ ,  $^{153}\text{Gd}$ ,  $^{169}\text{Yb}$ ,  $^{51}\text{Cr}$ ,  $^{54}\text{Mn}$ ,  $^{75}\text{Se}$ ,  $^{113}\text{Sn}$ ,  $^{90}\text{Yttrium}$ ,  $^{117}\text{Tin}$ ,  $^{186}\text{Rhenium}$ ,  $^{166}\text{Holmium}$ , and  $^{188}\text{Rhenium}$ ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0476] Techniques known in the art may be applied to label antibodies of the invention. Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety). A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine,

tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0477] By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

[0478] It will be appreciated that conditions caused by a decrease in the standard or normal level of a musculoskeletal system antigen activity in an individual, particularly disorders of the musculoskeletal system, can be treated by administration of a musculoskeletal system antigen polypeptide (e.g., such as, for example, the complete musculoskeletal system antigen polypeptide, the soluble form of the extracellular domain of a musculoskeletal system antigen polypeptide, or cells expressing the complete protein) or agonist. Thus, the invention also provides a method of treatment of an individual in need of an increased level of musculoskeletal system antigen activity comprising administering to such an individual a pharmaceutical composition comprising an amount of an isolated musculoskeletal system antigen polypeptide of the invention, or agonist thereof (e.g., an agonistic anti-musculoskeletal system antigen antibody), effective to increase the musculoskeletal system antigen activity level in such an individual.

[0479] It will also be appreciated that conditions caused by a increase in the standard or normal level of musculoskeletal system antigen activity in an individual, particularly disorders of the musculoskeletal system, can be treated by administration of musculoskeletal system antigen polypeptides (e.g., such as, for example, the

complete musculoskeletal system antigen polypeptide, the soluble form of the extracellular domain of a musculoskeletal system antigen polypeptide, or cells expressing the complete protein) or antagonist (e.g., an antagonistic musculoskeletal system antigen antibody). Thus, the invention also provides a method of treatment of an individual in need of an decreased level of musculoskeletal system antigen activity comprising administering to such an individual a pharmaceutical composition comprising an amount of an isolated musculoskeletal system antigen polypeptide of the invention, or antagonist thereof (e.g., an antagonistic anti-musculoskeletal system antigen antibody), effective to decrease the musculoskeletal system antigen activity level in such an individual.

[0480] In certain embodiments, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0481] More generally, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis, prognosis, prevention, and/or treatment of diseases and/or disorders associated with the following systems.

#### **Musculoskeletal System Disorders**

[0482] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the musculoskeletal system, including but not limited to, disorders of the bone, joints, ligaments, tendons, bursa, muscle, and/or neoplasms and cancers associated with musculoskeletal tissue.

[0483] Diseases or disorders of the bone include, but are not limited to, Albers-Schönberg disease, bowlegs, heel spurs, Köhler's bone disease, knock-knees, Legg-Calvé-Perthes disease, Marfan's syndrome, mucopolysaccharidoses, Osgood-Schlatter disease, osteochondroses, osteochondrodysplasia, osteomyelitis, osteopetroses,

osteoporosis (postmenopausal, senile, and juvenile), Paget's disease, Scheuermann's disease, scoliosis, Sever's disease, and patellofemoral stress syndrome.

[0484] Joint diseases or disorders include, but are not limited to, ankylosing spondylitis, Behçet's syndrome, CREST syndrome, Ehlers-Danlos syndrome, infectious arthritis, discoid lupus erythematosus, systemic lupus erythematosus, Lyme disease, osteoarthritis, psoriatic arthritis, relapsing polychondrites, Reiter's syndrome, rheumatoid arthritis (adult and juvenile), scleroderma, and Still's disease.

[0485] Diseases or disorders affecting ligaments, tendons, or bursa include, but are not limited to, ankle sprain, bursitis, posterior Achilles tendon bursitis (Haglund's deformity), anterior Achilles tendon bursitis (Albert's disease), tendinitis, tenosynovitis, popliteus tendinitis, Achilles tendinitis, medial or lateral epicondylitis, rotator cuff tendinitis, spasmodic torticollis, and fibromyalgia syndrome.

[0486] Muscle diseases or disorders include, but are not limited to, Becker's muscular dystrophy, Duchenne's muscular dystrophy, Landouzy-Dejerine muscular dystrophy, Leyden-Möbius muscular dystrophy, Erb's muscular dystrophy, Charcot's joints, dermatomyositis, gout, pseudogout, glycogen storage diseases, Pompe's disease, mitochondrial myopathy, periodic paralysis, polymyalgia rheumatica, polymyositis, Steinert's disease, Thomsen's disease, anterolateral and posteromedial shin splints, posterior femoral muscle strain, and fibromyositis.

[0487] Musculoskeletal tissue may also develop cancers and/or neoplasms that include, but are not limited to, osteochondroma, benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor, multiple myeloma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's tumor, and malignant lymphoma of bone.

#### **Immune Activity**

[0488] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and

macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies; and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

[0489] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to treat diseases and disorders of the immune system and/or to inhibit or enhance an immune response generated by cells associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0490] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing, and/or prognosing immunodeficiencies, including both congenital and acquired immunodeficiencies. Examples of B cell immunodeficiencies in which immunoglobulin levels B cell function and/or B cell numbers are decreased include: X-linked agammaglobulinemia (Bruton's disease), X-linked infantile agammaglobulinemia, X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, X-linked lymphoproliferative syndrome (XLP), agammaglobulinemia including congenital and acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, -unspecified hypogammaglobulinemia, recessive agammaglobulinemia (Swiss type), Selective IgM deficiency, selective IgA deficiency, selective IgG subclass deficiencies, IgG subclass deficiency (with or without IgA deficiency), Ig deficiency with increased IgM, IgG and IgA deficiency with increased IgM, antibody deficiency with normal or elevated Igs, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), common variable immunodeficiency (CVID), common variable immunodeficiency (CVI) (acquired), and transient hypogammaglobulinemia of infancy.

[0491] In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are treated, prevented, diagnosed, and/or prognosing using

the polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof.

[0492] Examples of congenital immunodeficiencies in which T cell and/or B cell function and/or number is decreased include, but are not limited to: DiGeorge anomaly, severe combined immunodeficiencies (SCID) (including, but not limited to, X-linked SCID, autosomal recessive SCID, adenosine deaminase deficiency, purine nucleoside phosphorylase (PNP) deficiency, Class II MHC deficiency (Bare lymphocyte syndrome), Wiskott-Aldrich syndrome, and ataxia telangiectasia), thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia, immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity.

[0493] In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

[0494] Other immunodeficiencies that may be treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention; and/or agonists or antagonists thereof, include, but are not limited to, chronic granulomatous disease, Chédiak-Higashi syndrome, myeloperoxidase deficiency, leukocyte glucose-6-phosphate dehydrogenase deficiency, X-linked lymphoproliferative syndrome (XLP), leukocyte adhesion deficiency, complement component deficiencies (including C1, C2, C3, C4, C5, C6, C7, C8 and/or C9 deficiencies), reticular dysgenesis, thymic aplasia, immunodeficiency with thymoma, severe congenital leukopenia, dysplasia with immunodeficiency, neonatal neutropenia, short limbed dwarfism, and Nezelof syndrome-combined immunodeficiency with Igs.

[0495] In a preferred embodiment, the immunodeficiencies and/or conditions associated with the immunodeficiencies recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0496] In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among immunodeficient individuals. In specific

embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

[0497] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

[0498] Autoimmune diseases or disorders that may be treated, prevented, diagnosed and/or prognosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following: systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, hemolytic anemia, thrombocytopenia, autoimmune thrombocytopenia purpura, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, purpura (e.g., Henloch-Scoenlein purpura), autoimmunocytopenia, Goodpasture's syndrome, Pemphigus vulgaris, myasthenia gravis, Grave's disease (hyperthyroidism), and insulin-resistant diabetes mellitus.

[0499] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, type II collagen-induced arthritis, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia, polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disorders.

[0500] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the

invention include, but are not limited to, scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

[0501] Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

[0502] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific

preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0503] In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0504] In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0505] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0506] In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

[0507] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or

conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

[0508] Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

[0509] Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

[0510] Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy); gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass

complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

[0511] Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides, polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chondritis, cochlitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

[0512] In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or

chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

[0513] In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

[0514] Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

[0515] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

[0516] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from

the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

[0517] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

[0518] In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

[0519] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

[0520] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

- [0521] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.
- [0522] In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.
- [0523] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell responsiveness to pathogens.
- [0524] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.
- [0525] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.
- [0526] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce higher affinity antibodies.
- [0527] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.
- [0528] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

[0529] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

[0530] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

[0531] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

[0532] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

[0533] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one

embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

[0534] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

[0535] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

[0536] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

[0537] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

[0538] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immunoincompetence/immunodeficiency such as observed among SCID patients.

[0539] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of

activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

[0540] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

[0541] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications described herein, as they may apply to veterinary medicine.

[0542] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and diseases/disorders associated with pathogens.

[0543] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis.

[0544] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

[0545] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.

[0546] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance

to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

[0547] The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration.

[0548] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

[0549] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

[0550] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.

[0551] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

[0552] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

[0553] In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or

prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

[0554] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

[0555] In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

[0556] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

[0557] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

[0558] In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

[0559] Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of the present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

[0560] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741). Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention.

#### **Blood-Related Disorders**

[0561] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping

of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

[0562] In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[0563] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

[0564] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets.. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

[0565] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

[0566] Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides,

polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias arising from drug treatments such as anemias associated with methyldopa, dapsone, and/or sulfadruugs. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

[0567] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

[0568] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A2 dysfunction, thromboasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophelias such as hemophilia A or Factor VII deficiency and Christmas disease or Factor IX deficiency, Hereditary Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

[0569] The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

[0570] Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

[0571] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer. Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

[0572] Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis, familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

[0573] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating lymphocytopenias (decreased numbers of B and/or T lymphocytes), including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

[0574] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

[0575] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to, idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

[0576] In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

[0577] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and Raynaud's phenomenon.

[0578] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis, acute myelofibrosis, agnogenic myeloid metaplasia, thrombocythemia, (including both primary and secondary thrombocythemia) and chronic myelocytic leukemia.

[0579] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

[0580] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.

[0581] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

[0582] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

[0583] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

#### **Hyperproliferative Disorders**

[0584] Musculoskeletal system associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, diagnose and/or prognose hyperproliferative diseases, disorders, and/or conditions, including neoplasms.

[0585] In a specific embodiment, musculoskeletal system associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions of the musculoskeletal system.

[0586] In a preferred embodiment, musculoskeletal system associated polynucleotides or polypeptides, or agonists or antagonists thereof, can be used to treat, prevent, and/or diagnose neoplasms of musculoskeletal system tissues.

[0587] Musculoskeletal system associated polynucleotides or polypeptides, or agonists or antagonists of the invention, may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, musculoskeletal system

associated polynucleotides or polypeptides, or agonists or antagonists thereof, may proliferate other cells, which can inhibit the hyperproliferative disorder.

[0588] For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

[0589] Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by musculoskeletal system associated polynucleotides or polypeptides, or agonists or antagonists thereof, include, but are not limited to neoplasms located in the: prostate, colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0590] Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer, Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia,

Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease, Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma, Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer, Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Paraproteinemias,

Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis Sarcomas, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0591] In another preferred embodiment, polynucleotides or polypeptides, or agonists or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

[0592] Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal

epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

[0593] Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

[0594] Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atriadigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, florid

osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertbral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

[0595] Additional pre-neoplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

[0596] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, 7 (Tissue Distribution Library Code).

[0597] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including, but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

[0598] Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated

by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0599] In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[0600] Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous

gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0601] Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[0602] Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0603] Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders,

paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0604] One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

[0605] Thus, the present invention provides a method for treating cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said cell proliferation, disease, disorder, and/or condition.

[0606] In a preferred embodiment, the present invention provides a method for treating cell proliferative diseases, disorders and/or conditions of the musculoskeletal system by inserting into a cell, a polynucleotide of the present invention, wherein said polynucleotide represses said cell proliferation, disease and/or disorder.

[0607] Another embodiment of the present invention provides a method of treating cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (see, e.g., G J. Nabel, et. al., PNAS 96: 324-326 (1999), which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e., magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e., to

increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

[0608] Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

[0609] For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

[0610] The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site.

The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

[0611] By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

[0612] Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

[0613] The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0614] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g., as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0615] In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

[0616] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

[0617] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

[0618] Moreover, musculoskeletal system antigen polypeptides of the present invention or fragments thereof, are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (see, e.g., Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (see, e.g., Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

[0619] Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the

induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (see, e.g., Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat. Res. 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem. Biol. Interact. Apr 24;111-112:23-34 (1998), J. Mo. Med. 76(6):402-12 (1998), Int. J. Tissue React. 20(1):3-15 (1998), which are all hereby incorporated by reference).

[0620] Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

[0621] In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or anti-musculoskeletal system antigen polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Musculoskeletal system antigen polypeptides or anti-musculoskeletal system antigen polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

[0622] Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

#### **Urinary System Disorders**

[0623] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the urinary system, including but not limited to disorders of the renal system, bladder, ureters, and urethra. Renal disorders include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

[0624] Kidney failure diseases include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, and end-stage renal disease. Inflammatory diseases of the kidney include acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis.

[0625] Blood vessel disorders of the kidneys include, but are not limited to, kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal ischemia-reperfusion, renal artery embolism, and renal artery stenosis. Kidney disorders resulting from urinary tract problems include, but are not limited to, pyelonephritis, hydronephrosis, urolithiasis

(renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.

[0626] Metabolic and congenital disorders of the kidneys include, but are not limited to, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, vitamin D-resistant rickets, Hartnup disease, Bartter's syndrome, Liddle's syndrome, polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy. Kidney disorders resulting from an autoimmune response include, but are not limited to, systemic lupus erythematosus (SLE), Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis.

[0627] Sclerotic or necrotic disorders of the kidney include, but are not limited to, glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis. Kidneys may also develop carcinomas, including, but not limited to, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, squamous cell cancer, and Wilm's tumor.

[0628] Kidney disorders may also result in electrolyte imbalances, including, but not limited to, nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia.

[0629] Bladder disorders include, but are not limited to, benign prostatic hyperplasia (BPH), interstitial cystitis (IC), prostatitis, proteinuria, urinary tract infections, urinary incontinence, urinary retention. Disorders of the ureters and urethra include, but are not limited to, acute or chronic unilateral obstructive uropathy. The bladder, ureters, and urethra may also develop carcinomas, including, but not limited to, superficial bladder cancer, invasive bladder cancer, carcinoma of the ureter, and urethra cancers.

[0630] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials,

osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

### **Cardiovascular Disorders**

[0631] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

[0632] Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, total anomalous pulmonary venous connection, hypoplastic left heart syndrome, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, atrioventricular canal defect, trilogly of Fallot, ventricular heart septal defects.

[0633] Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, sudden cardiac death, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy

complications, Scimitar Syndrome, diastolic dysfunction, enlarged heart, heart block, J-curve phenomenon, rheumatic heart disease, Marfan syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

[0634] Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

[0635] Heart valve disease include aortic valve insufficiency, aortic valve stenosis, heart murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, tricuspid valve stenosis, and bicuspid aortic valve.

[0636] Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, Barth syndrome, myocardial reperfusion injury, and myocarditis.

[0637] Myocardial ischemias include coronary disease, such as angina pectoris, Prinzmetal's angina, unstable angina, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

[0638] Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomas, bacillary angiomas, Hippiel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia,

hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension (shock), ischemia, peripheral vascular diseases, phlebitis, superficial phlebitis, pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, Buerger's disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, deep vein thrombosis, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

[0639] Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

[0640] Arterial occlusive diseases include arteriosclerosis, arteriolosclerosis, atherosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

[0641] Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

[0642] Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, deep vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

[0643] Ischemia includes cerebral ischemia, ischemic colitis, silent ischemia, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node

syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

[0644] Cardiovascular diseases can also occur due to electrolyte imbalances that include, but are not limited to hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia. Neoplasm and/or cancers of the cardiovascular system include, but are not limited to, myxomas, fibromas, and rhabdomyomas.

[0645] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

### **Respiratory Disorders**

[0646] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

[0647] Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary

aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and *Pseudomonas spp.*), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

[0648] Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal infections in people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia spp.*), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

**Anti-Angiogenesis Activity**

[0649] The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

[0650] The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administration to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the

invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

[0651] Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

[0652] Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation;

Crohn's disease; and atherosclerosis.

[0653] For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

[0654] Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

[0655] Moreover, ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

[0656] Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue, which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in

a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

[0657] Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer, which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

[0658] Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation, the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary

invasion of transplanted corneas. In a sustained-release form, injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

[0659] Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

[0660] Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

[0661] Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

[0662] Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

[0663] Moreover, disorders and/or states, which can be treated, prevented, diagnosed and/or prognosed with the polynucleotides, polypeptides, agonists and/or agonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

[0664] In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

[0665] Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

[0666] Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to

surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes, which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

[0667] Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

[0668] Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

[0669] The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator

Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0670] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0671] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0672] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0673] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26 (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-

3,4-dehydropoline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326 (1992)); Chymostatin (Tomkinson et al., Biochem J. 286:475-480 (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557 (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446 (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664 (1987)); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

#### **Neural Activity and Neurological Diseases**

[0674] The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a

portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

[0675] In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

[0676] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

[0677] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

[0678] The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

[0679] In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor Sensory Neuropathy (Charcot-Marie-Tooth Disease).

[0680] Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

[0681] Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus

thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

[0682] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

[0683] Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

[0684] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral

arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

[0685] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

[0686] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine

Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

[0687] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uve-meningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

[0688] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral scleritis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff

Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolysaccharidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydranencephaly, Arnold-Chiari Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

[0689] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord

paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

[0690] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as

polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

### **Endocrine Disorders**

[0691] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine system.

[0692] Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues to respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular disease or disorder related to the endocrine system and/or hormone imbalance.

[0693] Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual cycle (e.g., dysmenorrhea and endometriosis).

[0694] Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma--islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example, Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism,

pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism, hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

[0695] In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

[0696] Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

[0697] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 7 (Tissue Distribution Library Code).

#### **Gastrointestinal Disorders**

[0698] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g.,

intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic ulcers.

[0699] Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess).

[0700] Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum, Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascariasis lumbricoides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).

[0701] Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolentricular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis), parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral

human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma, cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).

[0702] Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

[0703] Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

[0704] Diseases and/or disorders of the large intestine include antibiotic-associated colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms), malabsorption syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphagiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

[0705] Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)).

#### **Reproductive System Disorders**

[0706] The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

[0707] Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including, but not limited to, testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example,

gonorrhea, mumps, tuberculosis, and syphilis), testicular torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

[0708] Reproductive system disorders also include, but are not limited to, disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

[0709] Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including, but not limited to, inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid papulosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

[0710] Moreover, diseases and/or disorders of the vas deferens include, but are not limited to, vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of

diseases and/or disorders of the seminal vesicles, including but not limited to, hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

[0711] Other disorders and/or diseases of the male reproductive system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

[0712] Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including, but not limited to, bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenosis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

[0713] Disorders and/or diseases of the uterus that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a communicating cavitary horn, arcuate uterus, uterine didelphys, and T-shaped uterus.

[0714] Ovarian diseases and/or disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

[0715] Cervical diseases and/or disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

[0716] Additionally, diseases and/or disorders of the reproductive system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis,

hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus eryematosiis, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

[0717] Complications associated with labor and parturition that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

[0718] Further, diseases and/or disorders of the postdelivery period, that may be diagnosed, treated, and/or prevented with the compositions of the invention, include, but are not limited to, endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis, pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

[0719] Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, but are not limited to, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

#### **Developmental and Inherited Disorders**

[0720] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases associated with mixed fetal tissues, including, but not limited to, developmental and inherited disorders or defects of the nervous system, musculoskeletal system, excretory system, cardiovascular system, hematopoietic system, gastrointestinal system, reproductive system, and respiratory system. Compositions of the present invention may also be used to treat, prevent, diagnose, and/or prognose developmental and inherited disorders or defects associated with, but not limited to, skin, hair, visual, and auditory

tissues, metabolism. Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases associated with, but not limited to, chromosomal or genetic abnormalities and hyperproliferation or neoplasia.

[0721] Disorders or defects of the nervous system associated with developmental or inherited abnormalities that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, adrenoleukodystrophy, agenesis of corpus callosum, Alexander disease, anencephaly, Angelman syndrome, Arnold-Chiari deformity, Batten disease, Canavan disease, cephalic disorders, Charcot-Marie-Tooth disease, encephalocele, Friedreich's ataxia, Gaucher's disease, Gorlin syndrome, Hallervorden-Spatz disease, hereditary spastic paraplegia, Huntington disease, hydranencephaly, hydrocephalus, Joubert syndrome, Lesch-Nyhan syndrome, leukodystrophy, Menkes disease, microcephaly, Niemann-Pick Type C1, neurofibromatosis, porencephaly, progeria, proteus syndrome, Refsum disease, spina bifida, Sturge-Weber syndrome, Tay-Sachs disease, tuberous sclerosis, and von Hippel-Lindau disease.

[0722] Developmental and inherited disorders resulting in disorders or defects of the musculoskeletal system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, achondroplasia, atlanto-occipital fusion, arthrogryposis multiplex congenita, autosomal recessive muscular dystrophy, Becker's muscular dystrophy, cerebral palsy, choanal atresia, cleft lip, cleft palate, clubfoot, congenital amputation, congenital dislocation of the hip, congenital torticollis, congenital scoliosis, dopa-responsive dystonia, Duchenne muscular dystrophy, early-onset generalized dystonia, femoral torsion, Gorlin syndrome, hypophosphatasia, Klippel-Feil syndrome, knee dislocation, myoclonic dystonia, myotonic dystrophy, nail-patella syndrome, osteogenesis imperfecta, paroxysmal dystonia, progeria, prune-belly syndrome, rapid-onset dystonia parkinsonism, scoliosis, syndactyly, Treacher Collins' syndrome, velocardiofacial syndrome, and X-linked dystonia-parkinsonism.

[0723] Developmental or hereditary disorders or defects of the excretory system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, Alport's syndrome, Bartter's syndrome,

bladder diverticula, bladder exstrophy, cystinuria, epispadias, Fanconi's syndrome, Hartnup disease, horseshoe kidney, hypospadias, kidney agenesis, kidney ectopia, kidney malrotation, Liddle's syndrome, medullary cystic disease, medullary sponge, multicystic kidney, kidney polycystic kidney disease, nail-patella syndrome, Potter's syndrome, urinary tract flow obstruction, vitamin D-resistant rickets, and Wilm's tumor.

[0724] Cardiovascular disorders or defects of developmental or hereditary origin that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, aortic valve stenosis, atrial septal defects, artioventricular (A-V) canal defect, bicuspid aortic valve, coarctation of the aorta, dextrocardia, Ebstein's anomaly, Eisenmenger's complex, hypoplastic left heart syndrome, Marfan syndrome, patent ductus arteriosus, progeria, pulmonary atresia, pulmonary valve stenosis, subaortic stenosis, tetralogy of fallot, total anomalous pulmonary venous (P-V) connection, transposition of the great arteries, tricuspid atresia, truncus arteriosus, ventricular septal defects. Developmental or inherited disorders resulting in disorders involving the hematopoietic system that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but not limited to, Bernard-Soulier syndrome, Chédiak-Higashi syndrome, hemophilia, Hermansky-Pudlak syndrome, sickle cell anemia, storage pool disease, thromboxane A2 dysfunction, thrombasthenia, and von Willebrand's disease.

[0725] The compositions of the invention may also be used to diagnose, treat, and/or prevent developmental and inherited disorders resulting in disorders or defects of the gastrointestinal system, including, but not limited to, anal atresia, biliary atresia, esophageal atresia, diaphragmatic hernia, Hirschsprung's disease, Meckel's diverticulum, oligohydramnios, omphalocele, polyhydramnios, porphyria, situs inversus viscerum. Developmental or inherited disorders resulting in metabolic disorders that may be diagnosed, treated, and/or prevented with the compositions of the invention include, but are not limited to, alpha-1 antitrypsin deficiency, cystic fibrosis, hemochromatosis, lysosomal storage disease, phenylketonuria, Wilson's disease, and Zellweger syndrome.

[0726] Disorders of the reproductive system that are developmentally or hereditary related that may also be diagnosed, treated, and/or prevented with the compositions of

the invention include, but are not limited to, androgen insensitivity syndrome, ambiguous genitalia, autosomal sex reversal, congenital adreneal hyperplasia, gonadoblastoma, ovarian germ cell cancer, pseudohermaphroditism, true hermaphroditism, undescended testis, XX male syndrome, and XY female type gonadal dysgenesis. The compositions of the invention may also be used to diagnose, treat, and/or prevent developmental or inherited respiratory defects including, but not limited to, askin tumor, azygos lobe, congenital diaphragmatic hernia, congenital lobar emphysema, cystic adenomatoid malformation, lobar emphysema, hyaline membrane disease, and pectus excavatum.

[0727] Developmental or inherited disorders may also result from chromosomal or genetic aberration that may be diagnosed, treated, and/or prevented with the compositions of the invention including, but not limited to, 4p- syndrome, cri du chat syndrome, Digeeorge syndrome, Down's syndrome, Edward's syndrome, fragile X syndrome, Klinefelter's syndrome, Patau's syndrome, Prader-Willi syndrome, progeria, Turner's syndrome, triple X syndrome, and XYY syndrome. Other developmental disorders that can be diagnosed, treated, and/or prevented with the compositions of the invention, include, but are not limited to, fetal alcohol syndrome, and can be caused by environmental factors surrounding the developing fetus.

[0728] The compositions of the invention may further be able to be used to diagnose, treat, and/or prevent errors in development or a genetic disposition that may result in hyperproliferative disorders or neoplasms, including, but not limited to, acute childhood lymphoblastic leukemia, askin tumor, Beckwith-Wiedemann syndrome, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood extracranial germ cell tumors childhood (primary), gonadoblastoma, hepatocellular cancer, childhood Hodgkin's disease, childhood Hodgkin's lymphoma, childhood hypothalamic and visual pathway glioma, childhood (primary) liver cancer, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkin's lymphoma, childhood pineal and supratentorial primitive neuroectodermal tumors, childhood primary liver cancer, childhood rhabdomyosarcoma, childhood soft tissue sarcoma, Gorlin syndrome, familial multiple endocrine neoplasia type I, neuroblastoma, ovarian germ cell cancer, pheochromocytoma, retinoblastoma, and Wilm's tumor.

[0729] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

#### **Diseases at the Cellular Level**

[0730] Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0731] In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those [listed above] involving tissues of the musculoskeletal system.

[0732] Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or

antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0733] Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis

related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

### **Wound Healing and Epithelial Cell Proliferation**

[0734] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss.

[0735] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or

antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

[0736] It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

[0737] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

[0738] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases, which result in destruction of the mucosal surface of the small or large

intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

[0739] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

[0740] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art). In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists

or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

### **Infectious Disease**

[0741] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

[0742] Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic

infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

[0743] Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*, Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), Erysipelothrix, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, Gonorrhea, Meningococcal), *Meisseria meningitidis*, Pasteurellaceae Infections (e.g., *Actinobacillus*, *Heamophilus* (e.g., *Heamophilus influenza type B*), *Pasteurella*), *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, *Treponema* spp., *Leptospira* spp., *Shigella* spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., *Streptococcus pneumoniae* and Group B *Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis),

gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diphtheria, botulism, and/or meningitis type B.

[0744] Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases.

[0745] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

**Regeneration**

[0746] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

[0747] Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

[0748] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

[0749] Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases

(e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

### **Chemotaxis**

[0750] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

[0751] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

[0752] It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

### **Binding Activity**

[0753] A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples

of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0754] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., *Current Protocols in Immunology* 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

[0755] Preferably, the screening for these molecules involves producing appropriate cells, which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

[0756] The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

[0757] Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[0758] Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[0759] Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., *Current Protocols in*

Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

[0760] Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding single clones that encode the putative receptor.

[0761] As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

[0762] Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the

assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

[0763] Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[0764] Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, the polypeptide of the present invention, the compound to be screened and <sup>3</sup>[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of <sup>3</sup>[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography, which measures the incorporation of <sup>3</sup>[H]

thymidine. Both agonist and antagonist compounds may be identified by this procedure.

[0765] In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

[0766] All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

[0767] Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

### **Targeted Delivery**

[0768] In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

[0769] As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0770] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

[0771] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

**Drug Screening**

[0772] Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules, which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

[0773] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

[0774] Thus, the present invention provides methods of screening for drugs or any other agents, which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

[0775] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The

peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[0776] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

#### **Antisense And Ribozyme (Antagonists)**

[0777] In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to cDNA sequences contained in cDNA Clone ID NO:Z identified for example, in Table 1A. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., *Neurochem.* 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., *Neurochem.* 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

[0778] For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed *in vitro* by incubating cells with the

oligoribonucleotide. A similar procedure for *in vivo* use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

[0779] For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into receptor polypeptide.

[0780] In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

[0781] The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[0782] Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

[0783] The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or

phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[0784] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[0785] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0786] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a

phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[0787] In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

[0788] Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[0789] While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

[0790] Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is

located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

[0791] As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells, which express *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[0792] Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

[0793] The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

[0794] The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

[0795] The antagonist/agonist may also be employed to treat the diseases described herein.

[0796] Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

**Binding Peptides and Other Molecules**

[0797] The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind musculoskeletal system antigen polypeptides, and the musculoskeletal system antigen binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the musculoskeletal system antigen polypeptides. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

[0798] This method comprises the steps of:  
contacting musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides with a plurality of molecules; and  
identifying a molecule that binds the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides.

[0799] The step of contacting the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides. The molecules having a selective affinity for the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides can then be purified by affinity selection. The nature of the solid support, process for attachment of the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

[0800] Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For

instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides and the individual clone. Prior to contacting the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

[0801] In certain situations, it may be desirable to wash away any unbound musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides, or alternatively, unbound polypeptides, from a mixture of the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the musculoskeletal system antigen polypeptides or

musculoskeletal system antigen-like polypeptides or the plurality of polypeptides is bound to a solid support.

[0802] The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries, which can be screened for molecules that specifically bind musculoskeletal system antigen polypeptides. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and *in vitro* translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[0803] Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R. B., et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

[0804] *In vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[0805] By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[0806] The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, *Bio/Technology* 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

[0807] Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

[0808] Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

[0809] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott and Smith, 1990, *Science* 249:386-390; Fowlkes et al., 1992; *BioTechniques* 13:422-427; Oldenburg et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu et al., 1994, *Cell* 76:933-945; Staudt et al., 1988, *Science* 241:577-580; Bock et al., 1992, *Nature* 355:564-566; Tuerk et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington et al., 1992, *Nature* 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, *Science* 263:671-673; and CT Publication No. WO 94/18318.

[0810] In a specific embodiment, screening to identify a molecule that binds musculoskeletal system antigen polypeptides can be carried out by contacting the

library members with a musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides immobilized on a solid phase and harvesting those library members that bind to the musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, *Gene* 73:305-318; Fowlkes et al., 1992, *BioTechniques* 13:422-427; International Publication No. WO 94/18318; and in references cited herein.

[0811] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, *Nature* 340:245-246; Chien et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:9578-9582) can be used to identify molecules that specifically bind to musculoskeletal system antigen polypeptides or musculoskeletal system antigen-like polypeptides.

[0812] Where the musculoskeletal system antigen binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

[0813] Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occurs every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

[0814] As mentioned above, in the case of a musculoskeletal system antigen binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a

musculoskeletal system antigen binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

[0815] The selected musculoskeletal system antigen binding polypeptide can be obtained by chemical synthesis or recombinant expression.

#### Other Activities

[0816] A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

[0817] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

[0818] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth; therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

[0819] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

[0820] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members

activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

[0821] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

[0822] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

[0823] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

[0824] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

[0825] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

[0826] The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-

human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

#### **Other Preferred Embodiments**

[0827] Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

[0828] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in column 4, "ORF (From-To)", in Table 1A.

[0829] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in columns 8 and 9, "NT From" and "NT To" respectively, in Table 2.

[0830] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

[0831] Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.

- [0832] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in column 4, "ORF (From-To)", in Table 1A.
- [0833] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in columns 8 and 9, "NT From" and "NT To", respectively, in Table 2.
- [0834] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z.
- [0835] Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in Clone ID NO:Z, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.
- [0836] Also preferred is a composition of matter comprising a DNA molecule which comprises the cDNA contained in Clone ID NO:Z.
- [0837] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides of the cDNA sequence contained in Clone ID NO:Z.
- [0838] Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by cDNA contained in Clone ID NO:Z.
- [0839] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.

[0840] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.

[0841] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by cDNA contained in Clone ID NO:Z.

[0842] A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence encoded by cDNA contained in Clone ID NO:Z; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

[0843] Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[0844] A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of

Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of the cDNA contained in Clone ID NO:Z.

[0845] The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[0846] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; or the cDNA contained in Clone ID NO:Z which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of cDNA contained in Clone ID NO:Z.

[0847] The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[0848] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 4 of Table 1A or columns 8 and 9 of Table 2 or the complementary strand

thereto; and a nucleotide sequence encoded by cDNA contained in Clone ID NO:Z. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[0849] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or "chip" of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000, or 4000 nucleotide sequences, wherein at least one sequence in said DNA microarray or "chip" is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA "Clone ID" in Table 1A.

[0850] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0851] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0852] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0853] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto;

the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0854] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by contained in Clone ID NO:Z

[0855] Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by cDNA contained in Clone ID NO:Z; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or the polypeptide sequence of SEQ ID NO:Y.

[0856] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0857] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA contained in Clone ID NO:Z.

[0858] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0859] Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0860] Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a

sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

[0861] Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0862] Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

[0863] Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0864] Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide

molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

[0865] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1A or Table 2 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0866] In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

[0867] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0868] Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

[0869] Also preferred is a polypeptide molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as

defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z.

[0870] Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

[0871] Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in Clone ID NO:Z. The isolated polypeptide produced by this method is also preferred.

[0872] Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

[0873] Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

[0874] Also preferred is a method of treatment of an individual in need of a specific delivery of toxic compositions to diseased cells (e.g., tumors, leukemias or lymphomas), which method comprises administering to such an individual a

Therapeutic comprising an amount of an isolated polypeptide of the invention, including, but not limited to a binding agent, or antibody of the claimed invention that are associated with toxin or cytotoxic prodrugs.

[0875] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

**TABLE 6**

ATCC Deposits	Deposit Date	ATCC Designation Number
LP01, LP02, LP03, LP04, LP05, LP06, LP07, LP08, LP09, LP10, LP11,	May-20-97	209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069
LP12	Jan-12-98	209579
LP13	Jan-12-98	209578
LP14	Jul-16-98	203067
LP15	Jul-16-98	203068
LP16	Feb-1-99	203609
LP17	Feb-1-99	203610
LP20	Nov-17-98	203485
LP21	Jun-18-99	PTA-252
LP22	Jun-18-99	PTA-253
LP23	Dec-22-99	PTA-1081

## *Examples*

### *Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample*

[0876] Each Clone ID NO:Z is contained in a plasmid. Table 7 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 7 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

[0877] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer

sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

[0878] Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lacmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the vector sequences identified for the particular clone in Table 7, as well as the corresponding plasmid vector sequences designated above.

[0879] The deposited material in the sample assigned the ATCC Deposit Number cited by reference to Tables 1A, 2, 6 and 7 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each Clone ID NO:Z.

**TABLE 7**

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKF HUKG	Human Uterine Cancer	Lambda ZAP II	LP01
HCNA HCNB	Human Colon	Lambda Zap II	LP01
HFFA	Human Fetal Brain, random primed	Lambda Zap II	LP01
HTWA	Resting T-Cell	Lambda ZAP II	LP01

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP01
HLMB HLMF HLMG HLMH HLMI HLMJ HLMM HLMN	breast lymph node CDNA library	Lambda ZAP II	LP01
HCQA HCQB	human colon cancer	Lambda ZAP II	LP01
HMEA HMEC HMED HMEE HMEF HMEG HMEI HMEJ HMEK HMEL	Human Microvascular Endothelial Cells, fract. A	Lambda ZAP II	LP01
HUSA HUSC	Human Umbilical Vein Endothelial Cells, fract. A	Lambda ZAP II	LP01
HLQA HLQB	Hepatocellular Tumor	Lambda ZAP II	LP01
HHGA HHGB HHGC HHGD	Hemangiopericytoma	Lambda ZAP II	LP01
HSDM	Human Striatum Depression, re-rescue	Lambda ZAP II	LP01
HUSH	H Umbilical Vein Endothelial Cells, fract A, re-excision	Lambda ZAP II	LP01
HSGS	Salivary gland, subtracted	Lambda ZAP II	LP01
HFXA HFXB HFXC HFXD HFXE HFXF HFXG HFXH	Brain frontal cortex	Lambda ZAP II	LP01
HPQA HPQB HPQC	PERM TF274	Lambda ZAP II	LP01
HFXJ HFXK	Brain Frontal Cortex, re-excision	Lambda ZAP II	LP01
HCWA HCWB HCWC HCWD HCWE HCWF HCWG HCWH HCWI HCWJ HCWK	CD34 positive cells (Cord Blood)	ZAP Express	LP02
HCUA HCUB HCUC	CD34 depleted Buffy Coat (Cord Blood)	ZAP Express	LP02
HRSM	A-14 cell line	ZAP Express	LP02
HRSA	A1-CELL LINE	ZAP Express	LP02
HCUD HCUE HCUF HCUG HCUH HCUI	CD34 depleted Buffy Coat (Cord Blood), re-excision	ZAP Express	LP02
HBXE HBXF HBXG	H. Whole Brain #2, re-excision	ZAP Express	LP02
HRLM	L8 cell line	ZAP Express	LP02
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP02
HUDA HUDB HUDC	Testes	ZAP Express	LP02
HHTM HHTN HHTO	H. hypothalamus, fract A; re-excision	ZAP Express	LP02
HHTL	H. hypothalamus, fract A	ZAP Express	LP02
HASA HASD	Human Adult Spleen	Uni-ZAP XR	LP03
HFKD HFKD HFKF HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HE8A HE8B HE8C HE8D HE8E HE8F HE8M HE8N	Human 8 Week Whole Embryo	Uni-ZAP XR	LP03
HGBA HGBD HGBE HGBF HGBG HGBH HGBI	Human Gall Bladder	Uni-ZAP XR	LP03
HLHA HLHB HLHC HLHD HLHE HLHF HLHG HLHH HLHQ	Human Fetal Lung III	Uni-ZAP XR	LP03
HPMA HPMB HPMC HPMD HPME HPMF HPMG HPMH	Human Placenta	Uni-ZAP XR	LP03
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP03
HSIA HSIC HSID HSIE	Human Adult Small Intestine	Uni-ZAP XR	LP03
HTEA HTEB HTEC HTED HTEE HTEF HTEG HTEH HTEI HTEJ HTEK	Human Testes	Uni-ZAP XR	LP03
HTPA HTPB HTPC HTPD HTPF	Human Pancreas Tumor	Uni-ZAP XR	LP03
HTTA HTTB HTTC HTTD HTTE HTTF	Human Testes Tumor	Uni-ZAP XR	LP03
HAPA HAPB HAPC HAPM	Human Adult Pulmonary	Uni-ZAP XR	LP03
HETA HETB HETC HETD HETE HETF HETG HETH HETI	Human Endometrial Tumor	Uni-ZAP XR	LP03
HHFB HHFC HHFD HHFE HHFF HHFG HHFH HHFI	Human Fetal Heart	Uni-ZAP XR	LP03
HHPB HHPC HHPD HHPE HHPF HHPG HHPH	Human Hippocampus	Uni-ZAP XR	LP03
HCE1 HCE2 HCE3 HCE4 HCE5 HCEB HCEC HCED HCEE HCEF HCEG	Human Cerebellum	Uni-ZAP XR	LP03
HUVB HUV C HUVD HUVE	Human Umbilical Vein, Endo. remake	Uni-ZAP XR	LP03
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP03
HTAA HTAB HTAC HTAD HTAE	Human Activated T-Cells	Uni-ZAP XR	LP03
HFEA HFEB HFEC	Human Fetal Epithelium (Skin)	Uni-ZAP XR	LP03
HJPA HJPB HJPC HJPD	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Uni-ZAP XR	LP03
HESA	Human epithelioid sarcoma	Uni-Zap XR	LP03
HLTA HLTB HLTC HLTD HLTE HLTF	Human T-Cell Lymphoma	Uni-ZAP XR	LP03
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP03
HRDA HRDB HRDC HRDD	Human Rhabdomyosarcoma	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HRDE HRDF			
HCAA HCAB HCAC	Cem cells cyclohexamide treated	Uni-ZAP XR	LP03
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HSUA HSUB HSUC HSUM	Supt Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HT4A HT4C HT4D	Activated T-Cells, 12 hrs.	Uni-ZAP XR	LP03
HE9A HE9B HE9C HE9D HE9E HE9F HE9G HE9H HE9M HE9N	Nine Week Old Early Stage Human	Uni-ZAP XR	LP03
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP03
HT5A	Activated T-Cells, 24 hrs.	Uni-ZAP XR	LP03
HFGA HFGM	Human Fetal Brain	Uni-ZAP XR	LP03
HNEA HNEB HNEC HNEE HNEE	Human Neutrophil	Uni-ZAP XR	LP03
HBGB HBGD	Human Primary Breast Cancer	Uni-ZAP XR	LP03
HBNA HBNB	Human Normal Breast	Uni-ZAP XR	LP03
HCAS	Cem Cells, cyclohexamide treated, subtra	Uni-ZAP XR	LP03
HHPS	Human Hippocampus, subtracted	pBS	LP03
HKCS HKCU	Human Colon Cancer, subtracted	pBS	LP03
HRGS	Raji cells, cyclohexamide treated, subtracted	pBS	LP03
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBS	LP03
HT4S	Activated T-Cells, 12 hrs, subtracted	Uni-ZAP XR	LP03
HCDA HCDB HCDC HCDD HCDE	Human Chondrosarcoma	Uni-ZAP XR	LP03
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP03
HTLA HTLB HTLC HTLD HTLE HTLF	Human adult testis, large inserts	Uni-ZAP XR	LP03
HLMA HLMC HLMD	Breast Lymph node cDNA library	Uni-ZAP XR	LP03
H6EA H6EB H6EC	HL-60, PMA 4H	Uni-ZAP XR	LP03
HTXA HTXB HTXC HTXD HTXE HTXF HTXG HTXH	Activated T-Cell (12hs)/Thiouridine labelledEco	Uni-ZAP XR	LP03
HNFA HNFH HNFC HNFD HNFE HNFF HNFG HNFH HNFJ	Human Neutrophil, Activated	Uni-ZAP XR	LP03
HTOB HTOC	HUMAN TONSILS, FRACTION 2	Uni-ZAP XR	LP03
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP03
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP03
HORB	Human OB HOS treated (10 nM E2)	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
	fraction I		
HSVA HSVB HSVC	Human Chronic Synovitis	Uni-ZAP XR	LP03
HROA	HUMAN STOMACH	Uni-ZAP XR	LP03
HBJA HBJB HBJC HBJD HBJE HBJF HBJG HBJH HBJI HBJJ HBJK	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP03
HCRA HCRB HCRC	human corpus colosum	Uni-ZAP XR	LP03
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP03
HDSA	Dermatofibrosarcoma Protuberance	Uni-ZAP XR	LP03
HMWA HMWB HMWC HMWD HMWE HMWF HMWG HMWH HMWI HMWJ	Bone Marrow Cell Line (RS4;11)	Uni-ZAP XR	LP03
HSOA	stomach cancer (human)	Uni-ZAP XR	LP03
HERA	SKIN	Uni-ZAP XR	LP03
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP03
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP03
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP03
HBCA HBCB	H. Lymph node breast Cancer	Uni-ZAP XR	LP03
HPWT	Human Prostate BPH, re-excision	Uni-ZAP XR	LP03
HFVG HFVH HFVI	Fetal Liver, subtraction II	pBS	LP03
HNFI	Human Neutrophils, Activated, re-excision	pBS	LP03
HBMB HBMC HBMD	Human Bone Marrow, re-excision	pBS	LP03
HKML HKMM HKMN	H. Kidney Medulla, re-excision	pBS	LP03
HKIX HKIY	H. Kidney Cortex, subtracted	pBS	LP03
HADT	H. Amygdala Depression, subtracted	pBS	LP03
H6AS	HL-60, untreated, subtracted	Uni-ZAP XR	LP03
H6ES	HL-60, PMA 4H, subtracted	Uni-ZAP XR	LP03
H6BS	HL-60, RA 4h, Subtracted	Uni-ZAP XR	LP03
H6CS	HL-60, PMA 1d, subtracted	Uni-ZAP XR	LP03
HTXJ HTXK	Activated T-cell(12h)/Thiouridine-re-excision	Uni-ZAP XR	LP03
HMSA HMSB HMSC HMSD HMSE HMSF HMSG HMSH HMSI HMSJ HMSK	Monocyte activated	Uni-ZAP XR	LP03
HAGA HAGB HAGC HAGD HAGE HAGF	Human Amygdala	Uni-ZAP XR	LP03
HSRA HSRB HSRE	STROMAL -OSTEOCLASTOMA	Uni-ZAP XR	LP03
HSRD HSRF HSRG HSRH	Human Osteoclastoma Stromal Cells -	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
	unamplified		
HSQA HSQB HSQC HSQD HSQE HSQF HSQG	Stromal cell TF274	Uni-ZAP XR	LP03
HSKA HSKB HSKC HSKD HSKE HSKF HSKZ	Smooth muscle, serum treated	Uni-ZAP XR	LP03
HSLA HSLB HSLC HSLD HSLE HSLF HSLG	Smooth muscle, control	Uni-ZAP XR	LP03
HSDA HSDD HSDE HSDF HSDG HSDH	Spinal cord	Uni-ZAP XR	LP03
HPWS	Prostate-BPH subtracted II	pBS	LP03
HSKW HSKX HSKY	Smooth Muscle- HASTE normalized	pBS	LP03
HFPB HFPC HFPD	H. Frontal cortex, epileptic, re-excision	Uni-ZAP XR	LP03
HSDI HSDJ HSDK	Spinal Cord, re-excision	Uni-ZAP XR	LP03
HSKN HSKO	Smooth Muscle Serum Treated, Norm	pBS	LP03
HSKG HSKH HSKI	Smooth muscle, serum induced, re-exc	pBS	LP03
HFCA HFCB HFCC HFCD HFCE HFCF	Human Fetal Brain	Uni-ZAP XR	LP04
HPTA HPTB HPTD	Human Pituitary	Uni-ZAP XR	LP04
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP04
HE6B HE6C HE6D HE6E HE6F HE6G HE6S	Human Whole Six Week Old Embryo	Uni-ZAP XR	LP04
HSSA HSSB HSSC HSSD HSSE HSSF HSSG HSSH HSSI HSSJ HSSK	Human Synovial Sarcoma	Uni-ZAP XR	LP04
HE7T	7 Week Old Early Stage Human, subtracted	Uni-ZAP XR	LP04
HEPA HEPB HEPC	Human Epididymus	Uni-ZAP XR	LP04
HSNA HSNB HSNB HSNM HSNN	Human Synovium	Uni-ZAP XR	LP04
HPFB HPFC HPFD HPFE	Human Prostate Cancer, Stage C fraction	Uni-ZAP XR	LP04
HE2A HE2D HE2E HE2H HE2I HE2M HE2N HE2O	12 Week Old Early Stage Human	Uni-ZAP XR	LP04
HE2B HE2C HE2F HE2G HE2P HE2Q	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP04
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP04
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP04
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP04
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HBSD	Bone Cancer, re-excision	Uni-ZAP XR	LP04
HSGB	Salivary gland, re-excision	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP04
HSXA HSXB HSXC HSXD	Human Substantia Nigra	Uni-ZAP XR	LP04
HSJA HSHB HSHC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP04
HOUA HOUB HOUC HOUD HOUE	Adipocytes	Uni-ZAP XR	LP04
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP04
HELA HELB HELC HELD HELE HELF HELG HELH	Endothelial cells-control	Uni-ZAP XR	LP04
HEMA HEMB HEMC HEMD HEME HEMF HEMG HEMH	Endothelial-induced	Uni-ZAP XR	LP04
HBIA HBIB HBIC	Human Brain, Striatum	Uni-ZAP XR	LP04
HHSA HHSB HHSC HHSD HHSE	Human Hypothalamus, Schizophrenia	Uni-ZAP XR	LP04
HNGA HNGB HNGC HNGD HNGE HNGF HNGG HNGH HNGI HNGJ	neutrophils control	Uni-ZAP XR	LP04
HNHA HNHB HNHC HNHD HNHE HNHF HNHG HNHH HNHI HNHI	Neutrophils IL-1 and LPS induced	Uni-ZAP XR	LP04
HSDB HSDC	STRIATUM DEPRESSION	Uni-ZAP XR	LP04
HHPT	Hypothalamus	Uni-ZAP XR	LP04
HSAT HSAU HSAV HSAW HSAX HSAY HSAZ	Anergic T-cell	Uni-ZAP XR	LP04
HBMS HBMT HBMU HBMV HBMW HBMX	Bone marrow	Uni-ZAP XR	LP04
HOEA HOEB HOEC HOED HOEE HOEF HOEJ	Osteoblasts	Uni-ZAP XR	LP04
HAIA HAIB HAIC HAID HAIE HAIF	Epithelial-TNF $\alpha$ and INF induced	Uni-ZAP XR	LP04
HTGA HTGB HTGC HTGD	Apoptotic T-cell	Uni-ZAP XR	LP04
HMCA HMCB HMCC HMCD HMCE	Macrophage-oxLDL	Uni-ZAP XR	LP04
HMAA HMAB HMAE HMAD HMAE HMAF HMAG	Macrophage (GM-CSF treated)	Uni-ZAP XR	LP04
HPHA	Normal Prostate	Uni-ZAP XR	LP04
HPIA HPIB HPIC	LNCAP prostate cell line	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP04
HOSE HOSF HOSG	Human Osteoclastoma, re-excision	Uni-ZAP XR	LP04
HTGE HTGF	Apoptotic T-cell, re-excision	Uni-ZAP XR	LP04
HMAJ HMAK	H Macrophage (GM-CSF treated), re-excision	Uni-ZAP XR	LP04
HACB HACC HACD	Human Adipose Tissue, re-excision	Uni-ZAP XR	LP04
HFPA	H. Frontal Cortex, Epileptic	Uni-ZAP XR	LP04
HFAA HFAB HFAC HFAD HFAE	Alzheimers, spongy change	Uni-ZAP XR	LP04
HFAM	Frontal Lobe, Dementia	Uni-ZAP XR	LP04
HMIA HMIB HMIC	Human Manic Depression Tissue	Uni-ZAP XR	LP04
HTSA HTSE HTSF HTSG HTSH	Human Thymus	pBS	LP05
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBS	LP05
HSAA HSAB HSAC	HSA 172 Cells	pBS	LP05
HSBA HSBB HSBC HSBM	HSC172 cells	pBS	LP05
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBS	LP05
HJBA HJBB HJBC HJBD	Jurkat T-Cell, S phase	pBS	LP05
HAFA HAFB	Aorta endothelial cells + TNF-a	pBS	LP05
HAWA HAWB HAWC	Human White Adipose	pBS	LP05
HTNA HTNB	Human Thyroid	pBS	LP05
HONA	Normal Ovary, Premenopausal	pBS	LP05
HARA HARB	Human Adult Retina	pBS	LP05
HLJA HLJB	Human Lung	pCMVSPORT 1	LP06
HOFM HOFN HOFO	H. Ovarian Tumor, II, OV5232	pCMVSPORT 2.0	LP07
HOGA HOGB HOGC	OV 10-3-95	pCMVSPORT 2.0	LP07
HCGL	CD34+cells, II	pCMVSPORT 2.0	LP07
HDLA	Hodgkin's Lymphoma I	pCMVSPORT 2.0	LP07
HDTA HDTB HDTC HDTD HDTE	Hodgkin's Lymphoma II	pCMVSPORT 2.0	LP07
HKAA HKAB HKAC HKAD HKA E HKAF HKAG HKAH	Keratinocyte	pCMVSPORT2.0	LP07
HCIM	CAPFINDER, Crohn's Disease, lib 2	pCMVSPORT 2.0	LP07
HKAL	Keratinocyte, lib 2	pCMVSPORT2.0	LP07
HKAT	Keratinocyte, lib 3	pCMVSPORT2.0	LP07
HNDA	Nasal polyps	pCMVSPORT2.0	LP07
HDRA	H. Primary Dendritic Cells, lib 3	pCMVSPORT2.0	LP07
HOHA HOHB HOHC	Human Osteoblasts II	pCMVSPORT2.0	LP07
HLDA HLDB HLDC	Liver, Hepatoma	pCMVSPORT3.0	LP08

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HLDN HLDO HLDP	Human Liver, normal	pCMVSPORT3.0	LP08
HMTA	pBMC stimulated w/ poly I/C	pCMVSPORT3.0	LP08
HNTA	NTERA2, control	pCMVSPORT3.0	LP08
HDP A HDPB HDP C HDPD HDPF HDPG HDPH HDPI HDPIJ HDPK	Primary Dendritic Cells, lib 1	pCMVSPORT3.0	LP08
HDP M HDP N HDPO HDPP	Primary Dendritic cells, frac 2	pCMVSPORT3.0	LP08
HMUA HMUB HMUC	Myeloid Progenitor Cell Line	pCMVSPORT3.0	LP08
HHEA HHEB HHEC HHED	T Cell helper I	pCMVSPORT3.0	LP08
HHEM HHEN HHEO HHEP	T cell helper II	pCMVSPORT3.0	LP08
HEQA HEQB HEQC	Human endometrial stromal cells	pCMVSPORT3.0	LP08
HJMA HJMB	Human endometrial stromal cells- treated with progesterone	pCMVSPORT3.0	LP08
HSWA HSWB HSWC	Human endometrial stromal cells- treated with estradiol	pCMVSPORT3.0	LP08
HSYA HSYB HSYC	Human Thymus Stromal Cells	pCMVSPORT3.0	LP08
HLWA HLWB HLWC	Human Placenta	pCMVSPORT3.0	LP08
HRAA HRAB HRAC	Rejected Kidney, lib 4	pCMVSPORT3.0	LP08
HMTM	PCR, pBMC I/C treated	PCR II	LP09
HMJA	H. Meningioma, M6	pSport 1	LP10
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSport 1	LP10
HUSG HUSI	Human umbilical vein endothelial cells, IL-4 induced	pSport 1	LP10
HUSX HUSY	Human Umbilical Vein Endothelial Cells, uninduced	pSport 1	LP10
HOFA	Ovarian Tumor I, OV5232	pSport 1	LP10
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport 1	LP10
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport 1	LP10
HADA HADC HADD HADE HADG HADG	Human Adipose	pSport 1	LP10
HOVA HOVB HOVC	Human Ovary	pSport 1	LP10
HTWB HTWC HTWD HTWE HTWF	Resting T-Cell Library, II	pSport 1	LP10
HMMA	Spleen metastatic melanoma	pSport 1	LP10
HLYA HLYB HLYC HLYD HLYE	Spleen, Chronic lymphocytic leukemia	pSport 1	LP10
HCGA	CD34+ cell, I	pSport 1	LP10
HEOM HEON	Human Eosinophils	pSport 1	LP10

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTDA	Human Tonsil, Lib 3	pSport 1	LP10
HSPA	Salivary Gland, Lib 2	pSport 1	LP10
HCHA HCHB HCHC	Breast Cancer cell line, MDA 36	pSport 1	LP10
HCHM HCHN	Breast Cancer Cell line, angiogenic	pSport 1	LP10
HCIA	Crohn's Disease	pSport 1	LP10
HDAA HDAB HDAC	HEL cell line	pSport 1	LP10
HABA	Human Astrocyte	pSport 1	LP10
HUFA HUFB HUFC	Ulcerative Colitis	pSport 1	LP10
HNTM	NTERA2 + retinoic acid, 14 days	pSport 1	LP10
HDQA	Primary Dendritic cells, CapFinder2, frac 1	pSport 1	LP10
HDQM	Primary Dendritic Cells, CapFinder, frac 2	pSport 1	LP10
HLDX	Human Liver, normal, CapFinder	pSport 1	LP10
HULA HULB HULC	Human Dermal Endothelial Cells, untreated	pSport1	LP10
HUMA	Human Dermal Endothelial cells, treated	pSport1	LP10
HCJA	Human Stromal Endometrial fibroblasts, untreated	pSport1	LP10
HCJM	Human Stromal endometrial fibroblasts, treated w/ estradiol	pSport1	LP10
HEDA	Human Stromal endometrial fibroblasts, treated with progesterone	pSport1	LP10
HFNA	Human ovary tumor cell OV350721	pSport1	LP10
HKGA HKGB HKGC HKGD	Merkel Cells	pSport1	LP10
HISA HISB HISC	Pancreas Islet Cell Tumor	pSport1	LP10
HLSA	Skin, burned	pSport1	LP10
HBZA	Prostate, BPH, Lib 2	pSport 1	LP10
HBZS	Prostate BPH, Lib 2, subtracted	pSport 1	LP10
HFIA HFIB HFIC	Synovial Fibroblasts (control)	pSport 1	LP10
HFIH HFII HFII	Synovial hypoxia	pSport 1	LP10
HFIT HFIU HFIV	Synovial IL-1/TNF stimulated	pSport 1	LP10
HGCA	Mesangial cell, frac 1	pSport1	LP10
HMVA HMVB HMVC	Bone Marrow Stromal Cell, untreated	pSport1	LP10
HFIX HFTY HFIZ	Synovial Fibroblasts (II1/TNF), subt	pSport1	LP10
HFOX HFOY HFOZ	Synovial hypoxia-RSF subtracted	pSport1	LP10
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP11
HLIA HLIB HLIC	Human Liver	pCMVSPORT 1	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HHBA HHBB HHBC HHBD HHBE	Human Heart	pCMVSPORT 1	LP012
HBBA HBBB	Human Brain	pCMVSPORT 1	LP012
HLJA HLJB HLJC HLJD HLJE	Human Lung	pCMVSPORT 1	LP012
HOGA HOGB HOGC	Ovarian Tumor	pCMVSPORT 2.0	LP012
HTJM	Human Tonsils, Lib 2	pCMVSPORT 2.0	LP012
HAMF HAMG	KMH2	pCMVSPORT 3.0	LP012
HAJA HAJB HAJC	L428	pCMVSPORT 3.0	LP012
HWBA HWBB HWBC HWBD HWBE	Dendritic cells, pooled	pCMVSPORT 3.0	LP012
HWAA HWAB HWAC HWAD HWAE	Human Bone Marrow, treated	pCMVSPORT 3.0	LP012
HYAA HYAB HYAC	B Cell lymphoma	pCMVSPORT 3.0	LP012
HWHG HWHH HWHI	Healing groin wound, 6.5 hours post incision	pCMVSPORT 3.0	LP012
HWHP HWHQ HWHR	Healing groin wound; 7.5 hours post incision	pCMVSPORT 3.0	LP012
HARM	Healing groin wound - zero hr post-incision (control)	pCMVSPORT 3.0	LP012
HBIM	Olfactory epithelium; nasalcavity	pCMVSPORT 3.0	LP012
HWDA	Healing Abdomen wound; 70&90 min post incision	pCMVSPORT 3.0	LP012
HWEA	Healing Abdomen Wound;15 days post incision	pCMVSPORT 3.0	LP012
HWJA	Healing Abdomen Wound;21&29 days	pCMVSPORT 3.0	LP012
HNAL	Human Tongue, frac 2	pSport1	LP012
HMJA	H. Meningioma, M6	pSport1	LP012
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSport1	LP012
HOFA	Ovarian Tumor I, OV5232	pSport1	LP012
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport1	LP012
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport1	LP012
HMMA HMMB HMMC	Spleen metastatic melanoma	pSport1	LP012
HTDA	Human Tonsil, Lib 3	pSport1	LP012
HDBA	Human Fetal Thymus	pSport1	LP012
HDLA	Pericardium	pSport1	LP012
HBZA	Prostate,BPH, Lib 2	pSport1	LP012
HWCA	Larynx tumor	pSport1	LP012
HWKA	Normal lung	pSport1	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HSMB	Bone marrow stroma, treated	pSport1	LP012
HBHM	Normal trachea	pSport1	LP012
HLFC	Human Larynx	pSport1	LP012
HLRB	Siebben Polyposis	pSport1	LP012
HNIA	Mammary Gland	pSport1	LP012
HNJB	Palate carcinoma	pSport1	LP012
HNKA	Palate normal	pSport1	LP012
HMZA	Pharynx carcinoma	pSport1	LP012
HABG	Cheek Carcinoma	pSport1	LP012
HMZM	Pharynx Carcinoma	pSport1	LP012
HDRM	Larynx Carcinoma	pSport1	LP012
HVAA	Pancreas normal PCA4 No	pSport1	LP012
HICA	Tongue carcinoma	pSport1	LP012
HUKA HUKB HUKC HUKD HUKE	Human Uterine Cancer	Lambda ZAP II	LP013
HFFA	Human Fetal Brain, random primed	Lambda ZAP II	LP013
HTUA	Activated T-cell labeled with 4-thioluri	Lambda ZAP II	LP013
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP013
HMEB	Human microvascular Endothelial cells, fract. B	Lambda ZAP II	LP013
HUSH	Human Umbilical Vein Endothelial cells, fract. A, re-excision	Lambda ZAP II	LP013
HLQC HLQD	Hepatocellular tumor, re-excision	Lambda ZAP II	LP013
HTWJ HTWK HTWL	Resting T-cell, re-excision	Lambda ZAP II	LP013
HF6S	Human Whole 6 week Old Embryo (II), subt	pBluescript	LP013
HHPS	Human Hippocampus, subtracted	pBluescript	LP013
HLIS	LNCAP, differential expression	pBluescript	LP013
HLHS HLHT	Early Stage Human Lung, Subtracted	pBluescript	LP013
HSUS	Supt cells, cyclohexamide treated, subtracted	pBluescript	LP013
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBluescript	LP013
HSDS	H. Striatum Depression, subtracted	pBluescript	LP013
HPTZ	Human Pituitary, Subtracted VII	pBluescript	LP013
HSDX	H. Striatum Depression, subt II	pBluescript	LP013
HSDZ	H. Striatum Depression, subt	pBluescript	LP013
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBluescript SK-	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HRTA	Colorectal Tumor	pBluescript SK-	LP013
HSBA HSBB HSBC HSBM	HSC172 cells	pBluescript SK-	LP013
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBluescript SK-	LP013
HJBA HJBB HJBC HJBD	Jurkat T-cell, S1 phase	pBluescript SK-	LP013
HTNA HTNB	Human Thyroid	pBluescript SK-	LP013
HAHA HAHB	Human Adult Heart	Uni-ZAP XR	LP013
HE6A	Whole 6 week Old Embryo	Uni-ZAP XR	LP013
HFCA HFCB HFCC HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP013
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP013
HGBA HGBD HGBE HGBF HGBG	Human Gall Bladder	Uni-ZAP XR	LP013
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP013
HTEA HTEB HTEC HTED HTEE	Human Testes	Uni-ZAP XR	LP013
HTTA HTTB HTTC HTTD HTTE	Human Testes Tumor	Uni-ZAP XR	LP013
HYBA HYBB	Human Fetal Bone	Uni-ZAP XR	LP013
HFLA	Human Fetal Liver	Uni-ZAP XR	LP013
HHFB HHFC HHFD HHFE HHFF	Human Fetal Heart	Uni-ZAP XR	LP013
HUVB HUV C HUVD HUVE	Human Umbilical Vein, End. remake	Uni-ZAP XR	LP013
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP013
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP013
HTAA HTAB HTAC HTAD HTAE	Human Activated T-cells	Uni-ZAP XR	LP013
HFEA HFEB HFEC	Human Fetal Epithelium (skin)	Uni-ZAP XR	LP013
HJPA HJPB HJPC HJPD	Human Jurkat Membrane Bound Polysomes	Uni-ZAP XR	LP013
HESA	Human Epithelioid Sarcoma	Uni-ZAP XR	LP013
HALS	Human Adult Liver, Subtracted	Uni-ZAP XR	LP013
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP013
HCAA HCAB HCAC	Cem cells, cyclohexamide treated	Uni-ZAP XR	LP013
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP013
HE9A HE9B HE9C HE9D HE9E	Nine Week Old Early Stage Human	Uni-ZAP XR	LP013
HSFA	Human Fibrosarcoma	Uni-ZAP XR	LP013
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP013
HTRA	Human Trachea Tumor	Uni-ZAP XR	LP013
HE2A HE2D HE2E HE2H HE2I	12 Week Old Early Stage Human	Uni-ZAP XR	LP013
HE2B HE2C HE2F HE2G HE2P	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP013
HBGA	Human Primary Breast Cancer	Uni-ZAP XR	LP013
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP013
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP013
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP013
HTOA HTOD HTOE HTOF HTOG	human tonsils	Uni-ZAP XR	LP013
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP013
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP013
HOQB	Human OB HOS treated (1 nM E2) fraction I	Uni-ZAP XR	LP013
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP013
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP013
HROA HROC	HUMAN STOMACH	Uni-ZAP XR	LP013
HBJA HBJB HBJC HBJD HBJE	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP013
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP013
HCPA	Corpus Callosum	Uni-ZAP XR	LP013
HSOA	stomach cancer (human)	Uni-ZAP XR	LP013
HERA	SKIN	Uni-ZAP XR	LP013
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP013
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP013
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP013
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP013
HAPN HAPO HAPP HAPQ HAPR	Human Adult Pulmonary;re-excision	Uni-ZAP XR	LP013
HLTG HLTH	Human T-cell lymphoma;re-excision	Uni-ZAP XR	LP013
HAHC HAHD HAHE	Human Adult Heart;re-excision	Uni-ZAP XR	LP013
HAGA HAGB HAGC HAGD HAGE	Human Amygdala	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP013
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP013
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP013
HBTA	Bone Marrow Stroma, TNF&LPS ind	Uni-ZAP XR	LP013
HMCF HMCG HMCH HMCI HMCJ	Macrophage-oxLDL; re-excision	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HAGG HAGH HAGI	Human Amygdala;re-excision	Uni-ZAP XR	LP013
HACA	H. Adipose Tissue	Uni-ZAP XR	LP013
HKFB	K562 + PMA (36 hrs),re-excision	ZAP Express	LP013
HCWT HCWU HCWV	CD34 positive cells (cord blood),re-ex	ZAP Express	LP013
HBWA	Whole brain	ZAP Express	LP013
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP013
HAVM	Temporal cortex-Alzheimer	pT-Adv	LP014
HAVT	Hippocampus, Alzheimer Subtracted	pT-Adv	LP014
HHAS	CHME Cell Line	Uni-ZAP XR	LP014
HAJR	Larynx normal	pSport 1	LP014
HWLE HWLF HWLG HWLH	Colon Normal	pSport 1	LP014
HCRM HCRN HCRO	Colon Carcinoma	pSport 1	LP014
HWLI HWLJ HWLK	Colon Normal	pSport 1	LP014
HWLQ HWLR HWLS HWLT	Colon Tumor	pSport 1	LP014
HBFM	Gastrocnemius Muscle	pSport 1	LP014
HBOD HBOE	Quadriceps Muscle	pSport 1	LP014
HBKD HBKE	Soleus Muscle	pSport 1	LP014
HCCM	Pancreatic Langerhans	pSport 1	LP014
HWGA	Larynx carcinoma	pSport 1	LP014
HWGM HWGN	Larynx carcinoma	pSport 1	LP014
HWLA HWLB HWLC	Normal colon	pSport 1	LP014
HWLM HWLN	Colon Tumor	pSport 1	LP014
HVAM HVAN HVAO	Pancreas Tumor	pSport 1	LP014
HWGQ	Larynx carcinoma	pSport 1	LP014
HAQM HAQN	Salivary Gland	pSport 1	LP014
HASM	Stomach; normal	pSport 1	LP014
HBCM	Uterus; normal	pSport 1	LP014
HCDM	Testis; normal	pSport 1	LP014
HDJM	Brain; normal	pSport 1	LP014
HEFM	Adrenal Gland,normal	pSport 1	LP014
HBAA	Rectum normal	pSport 1	LP014
HFDM	Rectum tumour	pSport 1	LP014
HGAM	Colon, normal	pSport 1	LP014
HHMM	Colon, tumour	pSport 1	LP014
HCLB HCLC	Human Lung Cancer	Lambda Zap II	LP015
HRLA	L1 Cell line	ZAP Express	LP015
HHAM	Hypothalamus, Alzheimer's	pCMVSport 3.0	LP015

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HKBA	Ku 812F Basophils Line	pSport 1	LP015
HS2S	Saos2, Dexamethosome Treated	pSport 1	LP016
HA5A	Lung Carcinoma A549 TNFalpha activated	pSport 1	LP016
HTFM	TF-1 Cell Line GM-CSF Treated	pSport 1	LP016
HYAS	Thyroid Tumour	pSport 1	LP016
HUTS	Larynx Normal	pSport 1	LP016
HXOA	Larynx Tumor	pSport 1	LP016
HEAH	Ea.hy.926 cell line	pSport 1	LP016
HINA	Adenocarcinoma Human	pSport 1	LP016
HRMA	Lung Mesothelium	pSport 1	LP016
HLCL	Human Pre-Differentiated Adipocytes	Uni-Zap XR	LP017
HS2A	Saos2 Cells	pSport 1	LP020
HS2I	Saos2 Cells; Vitamin D3 Treated	pSport 1	LP020
HUCM	CHME Cell Line, untreated	pSport 1	LP020
HEPN	Aryepiglottis Normal	pSport 1	LP020
HPSN	Sinus Piniformis Tumour	pSport 1	LP020
HNSA	Stomach Normal	pSport 1	LP020
HNSM	Stomach Tumour	pSport 1	LP020
HNLA	Liver Normal Met5No	pSport 1	LP020
HUTA	Liver Tumour Met 5 Tu	pSport 1	LP020
HOCN	Colon Normal	pSport 1	LP020
HOCT	Colon Tumor	pSport 1	LP020
HTNT	Tongue Tumour	pSport 1	LP020
HLXN	Larynx Normal	pSport 1	LP020
HLXT	Larynx Tumour	pSport 1	LP020
HTYN	Thymus	pSport 1	LP020
HPLN	Placenta	pSport 1	LP020
HTNG	Tongue Normal	pSport 1	LP020
HZAA	Thyroid Normal (SDCA2 No)	pSport 1	LP020
HWES	Thyroid Thyroiditis	pSport 1	LP020
HFHD	Ficoll Human Stromal Cells, 5Fu treated	pTrip1Ex2	LP021
HFHM,HFHN	Ficoll Human Stromal Cells, Untreated	pTrip1Ex2	LP021
HPCI	Hep G2 Cells, lambda library	lambda Zap-CMV XR	LP021
HBCA,HBCB,HBCC	H. Lymph node breast Cancer	Uni-ZAP XR	LP021

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HCOK	Chondrocytes	pSPORT1	LP022
HDCA, HDCB, HDCC	Dendritic Cells From CD34 Cells	pSPORT1	LP022
HDMA, HDMB	CD40 activated monocyte dendritic cells	pSPORT1	LP022
HDDM, HDDN, HDDO	LPS activated derived dendritic cells	pSPORT1	LP022
HPCR	Hep G2 Cells, PCR library	lambda Zap-CMV XR	LP022
HAAA, HAAB, HAAC	Lung, Cancer (4005313A3): Invasive Poorly Differentiated Lung Adenocarcinoma	pSPORT1	LP022
HIPA, HIPB, HIPC	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	pSPORT1	LP022
HOOH, HOOI	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	pSPORT1	LP022
HIDA	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HUJA, HUJB, HUJC, HUJD, HUJE	B-Cells	pCMVSPORT 3.0	LP022
HNOA, HNOB, HNOG, HNOD	Ovary, Normal: (9805C040R)	pSPORT1	LP022
HNLM	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HSCL	Stromal Cells	pSPORT1	LP022
HAAX	Lung, Cancer: (4005313 A3) Invasive Poorly-differentiated Metastatic lung adenocarcinoma	pSPORT1	LP022
HUUA, HUUB, HUUC, HUUD	B-cells (unstimulated)	pTrip1Ex2	LP022
HWWA, HWWB, HWWC, HWWD, HWWF, HWWG, HWWH	B-cells (stimulated)	pSPORT1	LP022
HCCC	Colon, Cancer: (9808C064R)	pCMVSPORT 3.0	LP023
HPDO HPDP HPDQ HPDR HPD	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	pSport 1	LP023
HPCO HPCP HPCQ HPCT	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	pSport 1	LP023
HOCM HOCO HOCQ HOCQ	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	pSport 1	LP023
HCBM HCBN HCBO	Breast, Cancer: (4004943 A5)	pSport 1	LP023
HNBT HNBU HNBV	Breast, Normal: (4005522B2)	pSport 1	LP023
HBCP HBCQ	Breast, Cancer: (4005522 A2)	pSport 1	LP023
HBCJ	Breast, Cancer: (9806C012R)	pSport 1	LP023
HSAM HSAN	Stromal cells 3.88	pSport 1	LP023

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HVCA HVCB HVCC HVCD	Ovary, Cancer: (4004332 A2)	pSport 1	LP023
HSCK HSEN HSEO	Stromal cells (HBM3.18)	pSport 1	LP023
HSCP HSCQ	stromal cell clone 2.5	pSport 1	LP023
HUXA	Breast Cancer: (4005385 A2)	pSport 1	LP023
HCOM HCON HCOO HCOP HCOQ	Ovary, Cancer (4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	pSport 1	LP023
HBNM	Breast, Cancer: (9802C020E)	pSport 1	LP023
HVVA HVVB HVVC HVVD HVVE	Human Bone Marrow, treated	pSport 1	LP023

[0880] Two nonlimiting examples are provided below for isolating a particular clone from the deposited sample of plasmid cDNAs cited for that clone in Table 7. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEQ ID NO:X.

[0881] Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

[0882] Alternatively, two primers of 17-20 nucleotides derived from both ends of the nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase

chain reaction is carried out under routine conditions, for instance, in 25  $\mu$ l of reaction mixture with 0.5  $\mu$ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM  $MgCl_2$ , 0.01% (w/v) gelatin, 20  $\mu$ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[0883] Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

[0884] Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

[0885] This above method starts with total RNA isolated from the desired source, although poly-A<sup>+</sup> RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

[0886] This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

***Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide***

[0887] A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X according to the method described in Example 1. (See also, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edn., (1989), Cold Spring Harbor Laboratory Press).

***Example 3: Tissue specific expression analysis***

[0888] The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue and/or disease specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs and assembled contigs which show tissue specific expression are selected.

[0889] The original clone from which the specific EST sequence was generated, or in the case of an assembled contig, the clone from which the 5' most EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured and then transferred in 96 or 384 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.

- [0890] Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed (e.g., bone, bone cancer, muscle, muscular cancer, joints, cancers of joints, tendons, cancers of tendons, prostate, prostate cancer, ovarian, ovarian cancer, etc.). The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65°C overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.
- [0891] Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified.

#### ***Example 4: Chromosomal Mapping of the Polynucleotides***

- [0892] An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions are analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

#### ***Example 5: Bacterial Expression of a Polypeptide***

- [0893] A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the

DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance ( $Amp^r$ ), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

[0894] The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance ( $Kan^r$ ). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

[0895] Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

[0896] Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

[0897] Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8. The column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

[0898] The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

[0899] In addition to the above expression vector, the present invention further includes an expression vector, called pHE4a (ATCC Accession Number 209645, deposited on February 25, 1998) which contains phage operator and promoter elements operatively linked to a polynucleotide of the present invention. This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter and operator sequences are made synthetically.

[0900] DNA can be inserted into the pHE4a by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

[0901] The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

***Example 6: Purification of a Polypeptide from an Inclusion Body***

[0902] The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

[0903] Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

[0904] The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

[0905] The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

[0906] Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

[0907] To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate

surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

[0908] Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

[0909] The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5  $\mu$ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

### ***Example 7: Cloning and Expression of a Polypeptide in a Baculovirus***

#### ***Expression System***

[0910] In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")

is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

[0911] Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

[0912] Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

[0913] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[0914] The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

[0915] The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation

mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion  
[0916] roduct by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five  $\mu$ g of a plasmid containing the polynucleotide is co-transfected with 1.0  $\mu$ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One  $\mu$ g of BaculoGold™ virus DNA and 5  $\mu$ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50  $\mu$ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10  $\mu$ l Lipofectin plus 90  $\mu$ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

[0917] After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200  $\mu$ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

[0918] To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection

("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  $\mu$ Ci of  $^{35}$ S-methionine and 5  $\mu$ Ci  $^{35}$ S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

[0919] Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

### ***Example 8: Expression of a Polypeptide in Mammalian Cells***

[0920] The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

[0921] Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[0922] Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, or hygromycin allows the identification and isolation of the transfected cells.

[0923] The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., *J. Biol. Chem.* 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., *Biochem. et Biophys. Acta*, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., *Biotechnology* 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.* 227:277-279 (1991); Bebbington et al., *Bio/Technology* 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

[0924] Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell* 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

[0925] Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

[0926] A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the

vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.)

[0927] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[0928] The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

[0929] Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

### ***Example 9: Protein Fusions***

[0930] The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example,

fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time *in vivo*. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

[0931] Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

[0932] For example, if pC4 (ATCC Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[0933] If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
```

CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTG  
 GTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA  
 CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTAC  
 AACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGG  
 CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAAC  
 CCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCAC  
 AGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTC  
 AGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAG  
 TGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGT  
 GCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAA  
 GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGG  
 CTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT  
 GAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO: 1)

***Example 10: Production of an Antibody from a Polypeptide***

**Hybridoma Technology**

[0934] The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

[0935] Monoclonal antibodies specific for polypeptide of the present invention are prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide of the present invention or, more preferably, with a secreted polypeptide of the present invention-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified

Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

[0936] The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

[0937] Alternatively, additional antibodies capable of binding to polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide of the present invention-specific antibody can be blocked by polypeptide of the present invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibodies.

[0938] For *in vivo* use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., International Publication No. WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Isolation Of Antibody Fragments Directed Against Polypeptide of the Present Invention  
From A Library Of scFvs

[0939] Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

[0940] *Rescue of the Library.* A library of scFvs is constructed from the RNA of human PBLs as described in International Publication No. WO 92/01047. To rescue phage displaying antibody fragments, approximately  $10^9$  *E. coli* harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU,  $2 \times 10^8$  TU of delta gene 3 helper (M13 delta gene III, see International Publication No. WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in International Application No. WO 92/01047.

[0941] M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately  $10^{13}$  transducing units/ml (ampicillin-resistant clones).

[0942] *Panning of the Library.* Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately  $10^{13}$  TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

[0943] *Characterization of Binders.* Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., International Application No. WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

***Example 11: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide***

[0944] RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X; and/or the nucleotide sequence of the cDNA contained in Clone ID NO:Z. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

[0945] PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase (Epicentre Technologies). The intron-exon boundaries of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing.

[0946] PCR products are cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

[0947] Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

[0948] Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology,

Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

***Example 12: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample***

[0949] A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

[0950] For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

[0951] The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

[0952] Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

- [0953] Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### *Example 13: Formulation*

- [0954] The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).
- [0955] The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.
- [0956] As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to

observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[0957] Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0958] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0959] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

[0960] Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

[0961] Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. (USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

[0962] In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

[0963] Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

[0964] For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

[0965] Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[0966] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[0967] The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[0968] Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0969] Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

[0970] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use

or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

[0971] The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[0972] The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This

includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[0973] In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

[0974] Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead);

DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'-azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of  $\beta$ -L-FD4C and  $\beta$ -L-FddC (WO 98/17281).

[0975] Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

[0976] Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™ (PNU-140690, a non-peptic dihydropyrrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Wellcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

[0977] Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

[0978] Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include

CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , etc., may also inhibit fusion.

[0979] Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

[0980] Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycophenolic acids such as CellCept (mycophenolate mofetil; Roche).

[0981] Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

[0982] Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 $\alpha$ , MIP-1 $\beta$ , SDF-1 $\alpha$ , IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN- $\alpha$ 2a; antagonists of TNFs, NF $\kappa$ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as Remune™ (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and

Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targetted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, *PNAS* 94:11567-72 (1997); Chen *et al.*, *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- $\alpha$  antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and  $\alpha$ -naphthoflavone (WO 98/30213); and antioxidants such as  $\gamma$ -L-glutamyl-L-cysteine ethyl ester ( $\gamma$ -GCE; WO 99/56764).

[0983] In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

[0984] In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™,

RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

[0985] In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

[0986] In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are

not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUNE™, NEORAL™, SANGDYA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate mofetil, of which the active metabolite is mycophenolic acid), IMURAN™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™ (methoxsalen) and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

[0987] In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, ATGAM™ (antithymocyte globulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

[0988] In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin,

phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

[0989] In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, MD), Troponin-1 (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0990] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0991] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0992] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl

complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0993] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., *Cancer Res.* 51:22-26, (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.* 262(4):1659-1664, (1987)); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

[0994] Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J Clin. Invest.* 103:47-54 (1999)); carboxynaminolimidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap

Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlitin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

[0995] Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS-275291 (Bristol Myers Squibb, Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are not limited to, EMD-121974 (Merck KGaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include, but are not

limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

[0996] In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

[0997] In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

[0998] In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

[0999] In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine, cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcosine), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazines (for example, Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouracil

(5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2'-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; MIH), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate), estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example, methyltestosterone, estramustine, estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

[01000] In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also known as Arava™ from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.).

[01001] In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another

embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

[01002] In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are <sup>90</sup>Y and <sup>111</sup>In.

[01003] In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

[01004] In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),

OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

[01005] In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

[01006] In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

[01007] In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKINE™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

[01008] In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

[01009] In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amidoarone, bretylium, digitalis, digoxin, digitoxin, diltiazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

[01010] In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit  $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$  symport (e.g., furosemide, bumetanide, azosemide, piretanide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone,

indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

[01011] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to,  $^{127}\text{I}$ , radioactive isotopes of iodine such as  $^{131}\text{I}$  and  $^{123}\text{I}$ ; recombinant growth hormone, such as HUMATROPE™ (recombinant somatropin); growth hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™ (octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T<sub>4</sub>™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T<sub>3</sub>™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-*n*-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLE™ (methimazole), NEO-MERCAZOLE™ (carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca<sup>2+</sup> channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate); estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and

ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA™ (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone), LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel); testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™ (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone enanthate), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotrophic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate),

CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate), CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEF™ (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate), HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™ (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetonide), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN™ (triamcinolone hexacetonide); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™ (ketoconazole), MODRASTANE™ (trilostane),

and METOPIRONE™ (metyrapone); bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOR™ (acetohexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), ciglitazone, pioglitazone, and alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide).

[01012] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN® (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example, conjugated estrogens/medroxyprogesterone (e.g., PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estradiol (e.g., FEMHRT™).

[01013] In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B<sub>12</sub>, cyancobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalamin, folic acid (e.g., FOLVITE™), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

[01014] In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not

limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

[01015] In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa, selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, benzotropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

[01016] In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to

amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and verapamil.

[01017] In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

***Example 14: Method of Treating Decreased Levels of the Polypeptide***

[01018] The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or antagonist to increase the activity level of the polypeptide in such an individual.

[01019] For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

***Example 15: Method of Treating Increased Levels of the Polypeptide***

[01020] The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

[01021] In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

[01022] For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 13.

### *Example 16: Method of Treatment Using Gene Therapy-Ex Vivo*

[01023] One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

[01024] At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[01025] pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[01026] The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an

EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

[01027] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[01028] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

[01029] The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

***Example 17: Gene Therapy Using Endogenous Genes Corresponding To  
Polynucleotides of the Invention***

[01030] Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

[01031] Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

[01032] The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel, then purified by phenol extraction and ethanol precipitation.

[01033] In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

[01034] Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

[01035] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

[01036] Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The

resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

[01037] Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

[01038] Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

[01039] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

### ***Example 18: Method of Treatment Using Gene Therapy - In Vivo***

[01040] Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to (i.e., associated with) a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S.

Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al., *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

[01041] The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[01042] The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

[01043] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[01044] The polynucleotide construct can be delivered to the interstitial space of tissues within an animal, including muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in

the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[01045] For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[01046] The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

[01047] Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template

DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

[01048] After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

### *Example 19: Transgenic Animals*

[01049] The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

[01050] Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem

cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993)); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

[01051] Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campbell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

[01052] The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-

type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

[01053] Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

[01054] Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

[01055] Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

### ***Example 20: Knock-Out Animals***

[01056] Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (See e.g., Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety.) For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

[01057] In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that

integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

[01058] Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

[01059] When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

[01060] Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

### ***Example 21: Assays Detecting Stimulation or Inhibition of B cell***

#### ***Proliferation and Differentiation***

[01061] Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed

development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

[01062] One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

[01063] *In vitro* Assay- Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

[01064] Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and

$10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

[01065] In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

[01066] Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

[01067] Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.

[01068] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

### ***Example 22: T Cell Proliferation Assay***

[01069] A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4$ /well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5  $\mu\text{Ci}$  of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative control for the effects of agonists or antagonists of the invention.

[01070] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

***Example 23: Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells***

[01071] Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the

characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

[01072] FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[01073] Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of agonists or antagonists of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

[01074] Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation.

Increased expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

[01075] FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[01076] Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

[01077] Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated processes (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

[01078] Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in the presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

[01079] Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.

[01080] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

***Example 24: Biological Effects of Agonists or Antagonists of the Invention*****Astrocyte and Neuronal Assays**

[01081] Agonists or antagonists of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an agonist or antagonist of the invention's activity on these cells.

[01082] Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

**Fibroblast and endothelial cell assays**

[01083] Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000

cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

[01084] Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

#### Parkinson Models.

[01085] The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

[01086] It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

[01087] Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

[01088] Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

[01089] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

***Example 25: The Effect of Agonists or Antagonists of the Invention on the Growth of Vascular Endothelial Cells***

[01090] On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

[01091] An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cells indicates that the compound of the invention inhibits vascular endothelial cells.

[01092] The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

***Example 26: Rat Corneal Wound Healing Model***

[01093] This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

Inserting a spatula below the lip of the incision facing the outer corner of the eye.

Making a pocket (its base is 1-1.5 mm from the edge of the eye).

Positioning a pellet, containing 50ng- 5ug of an agonist or antagonist of the invention, within the pocket.

Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily

treatment for five days).

[01094] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

### ***Example 27: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing***

#### ***Models***

##### ***Diabetic db+/db+ Mouse Model.***

[01095] To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

[01096] The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

- [01097] The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).
- [01098] Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.
- [01099] Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.
- [01100] Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.
- [01101] An agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.
- [01102] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for

histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[01103] Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

[01104] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

[01105] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

[01106] Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

[01107] Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based

on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

[01108] Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

#### *Steroid Impaired Rat Model.*

[01109] The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

[01110] To demonstrate that an agonist or antagonist of the invention can accelerate the healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

[01111] Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is

conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

[01112] The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

[01113] Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

[01114] The agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

[01115] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[01116] Three groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

[01117] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

[01118] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with an agonist or antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

[01119] Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

[01120] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

### ***Example 28: Lymphadema Animal Model***

[01121] The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of an agonist or antagonist of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

[01122] Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws

after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

[01123] Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

[01124] Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

[01125] Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

[01126] To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect of plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

[01127] Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people and those 2 readings are averaged. Readings are taken from both control and edematous limbs.

- [01128]      **Volumetric Measurements:** On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), and both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level, then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.
- [01129]      **Blood-plasma protein measurements:** Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and  $\text{Ca}^{2+}$  comparison.
- [01130]      **Limb Weight Comparison:** After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.
- [01131]      **Histological Preparations:** The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..
- [01132]      The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

***Example 29: Suppression of TNF alpha-induced adhesion molecule  
expression by a Agonist or Antagonist of the Invention***

- [01133]      The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells

(EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[01134] Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

[01135] The potential of an agonist or antagonist of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

[01136] To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

[01137] Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

[01138] Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin

and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

[01139] Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

[01140] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

### ***Example 30: Production Of Polypeptide of the Invention For High-Throughput Screening Assays***

[01141] The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 32-41.

[01142] First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well

plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

[01143] Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

[01144] The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

[01145] Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

[01146] While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of Kcl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50

mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of NaH<sub>2</sub>PO<sub>4</sub>-H<sub>2</sub>O; 71.02 mg/L of Na<sub>2</sub>HPO<sub>4</sub>; 4320 mg/L of ZnSO<sub>4</sub>-7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust osmolarity to 327 mOsm) with 2mM glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

[01147] The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

[01148] On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 32-39.

[01149] It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

### ***Example 31: Construction of GAS Reporter Construct***

[01150] One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

[01151] GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

[01152] The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

[01153] The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xaa-Trp-Ser (SEQ ID NO:2)).

[01154] Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

[01155] Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>		<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATs</u>	<u>GAS(elements) or ISRE</u>
<u>IFN family</u>							
IFN-a/B	+	+	-	-	1,2,3		ISRE
IFN-g			+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10		+	?	?	-	1,3	
<u>gp130 family</u>							
IL-6 (Pleiotropic) +		+	+	?	1,3		GAS (IRF1>Lys6>IFP)
IL-11(Pleiotropic) ?		+	?	?	1,3		
OnM(Pleiotropic) ?		+	+	?	1,3		
LIF(Pleiotropic) ?		+	+	?	1,3		
CNTF(Pleiotropic)		-/+	+	+	?	1,3	
G-CSF(Pleiotropic)		?	+	?	?	1,3	
IL-12(Pleiotropic)		+	-	+	+	1,3	
<u>g-C family</u>							
IL-2 (lymphocytes)		-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)		-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)		-	+	-	+	5	GAS
IL-9 (lymphocytes)		-	+	-	+	5	GAS
IL-13 (lymphocyte)		-	+	?	?	6	GAS
IL-15		?	+	?	+	5	GAS
<u>gp140 family</u>							
IL-3 (myeloid)		-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)		-	-	+	-	5	GAS
GM-CSF (myeloid)		-	-	+	-	5	GAS
<u>Growth hormone family</u>							
GH		?	-	+	-	5	
PRL		?	+/-	+	-	1,3,5	
EPO		?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>							
EGF		?	+	+	-	1,3	GAS (IRF1)
PDGF		?	+	+	-	1,3	
CSF-1		?	+	+	-	1,3	GAS (not IRF1)

[01156] To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 32-33, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO: 3)

[01157] The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO: 4)

[01158] PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO: 5)

[01159] With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be used instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

[01160] The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[01161] Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 32-33.

[01162] Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 34 and 35. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

### ***Example 32: High-Throughput Screening Assay for T-cell Activity.***

[01163] The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP

activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

[01164] Jurkat T-cells are lymphoblastic CD4<sup>+</sup> Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

[01165] Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

[01166] During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

[01167] The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 30.

[01168] On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

- [01169] Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).
- [01170] After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.
- [01171] The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 36. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.
- [01172] As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.
- [01173] The above protocol may be used in the generation of both transient, as well as stable, transfected cells, which would be apparent to those of skill in the art.

***Example 33: High-Throughput Screening Assay Identifying Myeloid Activity***

- [01174] The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

- [01175] To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 31, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.
- [01176] Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675 uM  $\text{CaCl}_2$ . Incubate at 37 degrees C for 45 min.
- [01177] Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.
- [01178] The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.
- [01179] These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).
- [01180] Add 50 ul of the supernatant prepared by the protocol described in Example 30. Incubate at 37 degree C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 36.

***Example 34: High-Throughput Screening Assay Identifying Neuronal Activity.***

- [01181] When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,

EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

[01182] Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

[01183] The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO: 6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO: 7)

[01184] Using the GAS:SEAP/Neo vector produced in Example 31, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

[01185] To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

[01186] PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is

done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

[01187] Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 30. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

[01188] To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

[01189] The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

[01190] Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 30, 37 degree C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 36.

### ***Example 35: High-Throughput Screening Assay for T-cell Activity***

[01191] NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

[01192] In non-stimulated conditions, NF- KB is retained in the cytoplasm with I- KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

[01193] Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 30. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

[01194] To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO: 8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO: 9)

[01195] The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO: 4)

[01196] PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2- (Stratagene). Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA

CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTAT  
TCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGC  
TT:3' (SEQ ID NO: 10)

[01197] Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[01198] In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

[01199] Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 32. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 32. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

### *Example 36: Assay for SEAP Activity*

[01200] As a reporter molecule for the assays described in Examples 32-35, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

[01201] Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

[01202] Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the

Table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on a luminometer, thus one should treat 5 plates at each time and start the second set 10 minutes later.

[01203] Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

[01204] Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25

36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

---

***Example 37: High-Throughput Screening Assay Identifying Changes in  
Small Molecule Concentration and Membrane Permeability***

[01205] Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

[01206] The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

[01207] For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20

hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

[01208] A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

[01209] For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

[01210] For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

[01211] To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

***Example 38: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity***

[01212] The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth

factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

[01213] Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

[01214] Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

[01215] Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

[01216] To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyn plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 30, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN)) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C at 16,000 x g.

[01217] Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

[01218] Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

[01219] The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate (1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

- [01220] The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.
- [01221] Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase (anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.
- [01222] Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

***Example 39: High-Throughput Screening Assay Identifying  
Phosphorylation Activity***

- [01223] As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 38, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.
- [01224] Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

[01225] A431 cells are seeded at 20,000/well in a 96-well Loprodyn filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 30 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

[01226] After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by polypeptide of the present invention or a molecule induced by polypeptide of the present invention.

***Example 40: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation***

[01227] This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

[01228] It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the

presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. —Therefore, if the tested polypeptide has a stimulatory effect on hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL-3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

[01229] Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l of the supernatants prepared in Example 30 (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

[01230] Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for

counting. The sealed plates are then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

[01231] The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

[01232] The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

***Example 41: Assay for Extracellular Matrix Enhanced Cell Response  
(EMECR)***

[01233] The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

[01234] Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is

dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and are responsible for stimulating stem cell self-renewal have not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

[01235] Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 30), are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernatants represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$ ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

[01236] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

[01237] If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease"

sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

[01238] Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

[01239] Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

***Example 42: Human Dermal Fibroblast and Aortic Smooth Muscle Cell  
Proliferation***

[01240] The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

[01241] Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation at 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 $\mu$ g/ml Amphotericin B, 0.4% FBS. Incubate at 37 °C until day 2.

[01242] On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides of the present invention and incubate at 37 degrees C/5% CO<sub>2</sub> until day 5.

[01243] Transfer 60 $\mu$ l from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4 degrees C until Day 6 (for IL6 ELISA). To the remaining 100  $\mu$ l in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10 $\mu$ l). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

[01244] On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100  $\mu$ l/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

[01245] On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200  $\mu$ l/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50  $\mu$ l/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make

dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

[01246] Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100  $\mu$ l/well. Cover the plate and incubate 1 h at RT. Plates are again washed with wash buffer and blotted on paper towels.

[01247] Add 100  $\mu$ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

[01248] A positive result in this assay suggests AoSMC cell proliferation and that the polypeptide of the present invention may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular agent (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular

adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

[01249] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

***Example 43: Cellular Adhesion Molecule (CAM) Expression  
on Endothelial Cells***

[01250] The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[01251] Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h

(selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$ ) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

#### ***Example 44: Alamar Blue Endothelial Cells Proliferation Assay***

[01252] This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay

is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

[01253] Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37degrees C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

[01254] Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form (i.e., stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity). The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

***Example 45: Detection of Inhibition of a Mixed Lymphocyte Reaction***

[01255] This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

[01256] Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

[01257] Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

[01258] Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

[01259] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

#### *Example 46: Assays for Protease Activity*

[01260] The following assay may be used to assess protease activity of the polypeptides of the invention.

[01261] Gelatin and casein zymography are performed essentially as described (Heusen et al., Anal. Biochem., 102:196-202 (1980); Wilson et al., Journal of Urology, 149:653-658 (1993)). Samples are run on 10% polyacryamide/0.1% SDS gels containing 1% gelatin or casein, soaked in 2.5% triton at room temperature for 1 hour, and in 0.1M glycine, pH 8.3 at 37°C 5 to 16 hours. After staining in amido black areas of proteolysis appear as clear areas against the blue-black background. Trypsin (Sigma T8642) is used as a positive control.

[01262] Protease activity is also determined by monitoring the cleavage of n-a-benzoyl-L-arginine ethyl ester (BAEE) (Sigma B-4500). Reactions are set up in (25mM NaPO<sub>4</sub>, 1mM EDTA, and 1mM BAEE), pH 7.5. Samples are added and the change in adsorbance at 260nm is monitored on the Beckman DU-6 spectrophotometer in the time-drive mode. Trypsin is used as a positive control.

[01263] Additional assays based upon the release of acid-soluble peptides from casein or hemoglobin measured as adsorbance at 280 nm or colorimetrically using the Folin method are performed as described in Bergmeyer, et al., Methods of Enzymatic Analysis, 5 (1984). Other assays involve the solubilization of chromogenic substrates (Ward, Applied Science, 251-317 (1983)).

***Example 47: Identifying Serine Protease Substrate Specificity***

[01264] Methods known in the art or described herein may be used to determine the substrate specificity of the polypeptides of the present invention having serine protease activity. A preferred method of determining substrate specificity is by the use of positional scanning synthetic combinatorial libraries as described in GB 2 324 529 (incorporated herein in its entirety).

***Example 48: Ligand Binding Assays***

[01265] The following assay may be used to assess ligand binding activity of the polypeptides of the invention.

[01266] Ligand binding assays provide a direct method for ascertaining receptor pharmacology and are adaptable to a high throughput format. The purified ligand for a polypeptide is radiolabeled to high specific activity (50-2000 Ci/mmol) for binding studies. A determination is then made that the process of radiolabeling does not diminish the activity of the ligand towards its polypeptide. Assay conditions for buffers, ions, pH and other modulators such as nucleotides are optimized to establish a workable signal to noise ratio for both membrane and whole cell polypeptide sources. For these assays, specific polypeptide binding is defined as total associated radioactivity minus the radioactivity measured in the presence of an excess of unlabeled competing ligand. Where possible, more than one competing ligand is used to define residual nonspecific binding.

***Example 49: Functional Assay in *Xenopus* Oocytes***

[01267] Capped RNA transcripts from linearized plasmid templates encoding the polypeptides of the invention are synthesized *in vitro* with RNA polymerases in accordance with standard procedures. *In vitro* transcripts are suspended in water at a final concentration of 0.2 mg/ml. Ovarian lobes are removed from adult female toads, Stage V defolliculated oocytes are obtained, and RNA transcripts (10 ng/oocyte) are

injected in a 50 nl bolus using a microinjection apparatus. Two electrode voltage clamps are used to measure the currents from individual *Xenopus oocytes* in response to polypeptides and polypeptide agonist exposure. Recordings are made in  $\text{Ca}^{2+}$  free Barth's medium at room temperature. The *Xenopus* system can be used to screen known ligands and tissue/cell extracts for activating ligands.

### ***Example 50: Microphysiometric Assays***

[01268] Activation of a wide variety of secondary messenger systems results in extrusion of small amounts of acid from a cell. The acid formed is largely as a result of the increased metabolic activity required to fuel the intracellular signaling process. The pH changes in the media surrounding the cell are very small but are detectable by the CYTOSENSOR microphysiometer (Molecular Devices Ltd., Menlo Park, Calif.). The CYTOSENSOR is thus capable of detecting the activation of polypeptide which is coupled to an energy utilizing intracellular signaling pathway.

### ***Example 51: Extract/Cell Supernatant Screening***

[01269] A large number of mammalian receptors exist for which there remains, as yet, no cognate activating ligand (agonist). Thus, active ligands for these receptors may not be included within the ligands banks as identified to date. Accordingly, the polypeptides of the invention can also be functionally screened (using calcium, cAMP, microphysiometer, oocyte electrophysiology, etc., functional screens) against tissue extracts to identify its natural ligands. Extracts that produce positive functional responses can be sequentially subfractionated until an activating ligand is isolated and identified.

### ***Example 52: Calcium and cAMP Functional Assays***

[01270] Seven transmembrane receptors which are expressed in HEK 293 cells have been shown to be coupled functionally to activation of PLC and calcium mobilization and/or cAMP stimulation or inhibition. Basal calcium levels in the HEK 293 cells in receptor-transfected or vector control cells were observed to be in the normal, 100 nM to 200 nM, range. HEK 293 cells expressing recombinant receptors are loaded with fura 2 and in a single day >150 selected ligands or tissue/cell extracts are evaluated for agonist induced calcium mobilization. Similarly, HEK 293 cells expressing recombinant receptors are evaluated for the stimulation or inhibition of cAMP production using standard cAMP quantitation assays. Agonists presenting a calcium transient or cAMP fluctuation are tested in vector control cells to determine if the response is unique to the transfected cells expressing receptor.

### *Example 53: ATP-binding assay*

[01271] The following assay may be used to assess ATP-binding activity of polypeptides of the invention.

[01272] ATP-binding activity of the polypeptides of the invention may be detected using the ATP-binding assay described in U.S. Patent 5,858,719, which is herein incorporated by reference in its entirety. Briefly, ATP-binding to polypeptides of the invention is measured via photoaffinity labeling with 8-azido-ATP in a competition assay. Reaction mixtures containing 1 mg/ml of the ABC transport protein of the present invention are incubated with varying concentrations of ATP, or the non-hydrolyzable ATP analog adenylyl-5'-imidodiphosphate for 10 minutes at 4°C. A mixture of 8-azido-ATP (Sigma Chem. Corp., St. Louis, MO.) plus 8-azido-ATP (<sup>32</sup>P-ATP) (5 mCi/μmol, ICN, Irvine CA.) is added to a final concentration of 100 μM and 0.5 ml aliquots are placed in the wells of a porcelain spot plate on ice. The plate is irradiated using a short wave 254 nm UV lamp at a distance of 2.5 cm from the plate for two one-minute intervals with a one-minute cooling interval in between. The reaction is stopped by addition of dithiothreitol to a final concentration of 2mM. The incubations are subjected to SDS-PAGE electrophoresis, dried, and autoradiographed. Protein bands corresponding to the particular polypeptides of the invention are

excised, and the radioactivity quantified. A decrease in radioactivity with increasing ATP or adenylyl-5'-imidodiphosphate provides a measure of ATP affinity to the polypeptides.

### ***Example 54: Small Molecule Screening***

[01273] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and polypeptide of the invention.

[01274] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the invention. These methods comprise contacting such an agent with a polypeptide of the invention or fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the invention.

[01275] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is herein incorporated by reference in its entirety. Briefly stated, large numbers of different small molecule test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are

reacted with polypeptides of the invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[01276] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

#### ***Example 55: Phosphorylation Assay***

[01277] In order to assay for phosphorylation activity of the polypeptides of the invention, a phosphorylation assay as described in U.S. Patent 5,958,405 (which is herein incorporated by reference) is utilized. Briefly, phosphorylation activity may be measured by phosphorylation of a protein substrate using gamma-labeled  $^{32}\text{P}$ -ATP and quantitation of the incorporated radioactivity using a gamma radioisotope counter. The polypeptides of the invention are incubated with the protein substrate,  $^{32}\text{P}$ -ATP, and a kinase buffer. The  $^{32}\text{P}$  incorporated into the substrate is then separated from free  $^{32}\text{P}$ -ATP by electrophoresis, and the incorporated  $^{32}\text{P}$  is counted and compared to a negative control. Radioactivity counts above the negative control are indicative of phosphorylation activity of the polypeptides of the invention.

#### ***Example 56: Detection of Phosphorylation Activity (Activation) of the Polypeptides of the Invention in the Presence of Polypeptide Ligands***

[01278] Methods known in the art or described herein may be used to determine the phosphorylation activity of the polypeptides of the invention. A preferred method of

determining phosphorylation activity is by the use of the tyrosine phosphorylation assay as described in US 5,817,471 (incorporated herein by reference).

***Example 57: Identification Of Signal Transduction Proteins That Interact With Polypeptides Of The Present Invention***

[01279] The purified polypeptides of the invention are research tools for the identification, characterization and purification of additional signal transduction pathway proteins or receptor proteins. Briefly, labeled receptor PTK polypeptide is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, receptor PTK polypeptide is covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as carcinoma tissues, is passed over the column, and molecules with appropriate affinity bind to the receptor PTK polypeptides, or specific phosphotyrosine-recognition domains thereof. The receptor PTK polypeptide interacting protein-complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

***Example 58: IL-6 Bioassay***

[01280] To test the proliferative effects of the polypeptides of the invention, the IL-6 Bioassay as described by Marz *et al.* is utilized (*Proc. Natl. Acad. Sci., U.S.A.*, 95:3251-56 (1998), which is herein incorporated by reference). Briefly, IL-6 dependent B9 murine cells are washed three times in IL-6 free medium and plated at a concentration of 5,000 cells per well in 50  $\mu$ l, and 50  $\mu$ l of the IL-6-like polypeptide is added. After 68 hrs. at 37°C, the number of viable cells is measured by adding the tetrazolium salt thiazolyl blue (MTT) and incubating for a further 4 hrs. at 37°C. B9 cells are lysed by SDS and optical density is measured at 570 nm. Controls containing

IL-6 (positive) and no cytokine (negative) are utilized. Enhanced proliferation in the test sample(s) relative to the negative control is indicative of proliferative effects mediated by polypeptides of the invention.

***Example 59: Support of Chicken Embryo Neuron Survival***

[01281] To test whether sympathetic neuronal cell viability is supported by polypeptides of the invention, the chicken embryo neuronal survival assay of Senaldi *et al* is utilized (*Proc. Natl. Acad. Sci., U.S.A.*, 96:11458-63 (1998), which is herein incorporated by reference). Briefly, motor and sympathetic neurons are isolated from chicken embryos, resuspended in L15 medium (with 10% FCS, glucose, sodium selenite, progesterone, conalbumin, putrescine, and insulin; Life Technologies, Rockville, MD.) and Dulbecco's modified Eagles medium [with 10% FCS, glutamine, penicillin, and 25 mM Hepes buffer (pH 7.2); Life Technologies, Rockville, MD.], respectively, and incubated at 37°C in 5% CO<sub>2</sub> in the presence of different concentrations of the purified IL-6-like polypeptide, as well as a negative control lacking any cytokine. After 3 days, neuron survival is determined by evaluation of cellular morphology, and through the use of the colorimetric assay of Mosmann (Mossmann, T., *J. Immunol. Methods*, 65:55-63 (1983)). Enhanced neuronal cell viability as compared to the controls lacking cytokine is indicative of the ability of the inventive purified IL-6-like polypeptide(s) to enhance the survival of neuronal cells.

***Example 60: Assay for Phosphatase Activity***

[01282] The following assay may be used to assess serine/threonine phosphatase (PTPase) activity of the polypeptides of the invention.

[01283] In order to assay for serine/threonine phosphatase (PTPase) activity, assays can be utilized which are widely known to those skilled in the art. For example, the serine/threonine phosphatase (PSPase) activity is measured using a PSPase assay kit from New England Biolabs, Inc. Myelin basic protein (MyBP), a substrate for PSPase, is phosphorylated on serine and threonine residues with cAMP-dependent Protein

Kinase in the presence of [ $^{32}\text{P}$ ]ATP. Protein serine/threonine phosphatase activity is then determined by measuring the release of inorganic phosphate from  $^{32}\text{P}$ -labeled MyBP.

***Example 61: Interaction of Serine/Threonine Phosphatases with other Proteins***

[01284] The polypeptides of the invention with serine/threonine phosphatase activity as determined in Example 60 are research tools for the identification, characterization and purification of additional interacting proteins or receptor proteins, or other signal transduction pathway proteins. Briefly, labeled polypeptide(s) of the invention is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, polypeptide of the invention is covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as neural or liver cells, is passed over the column, and molecules with appropriate affinity bind to the polypeptides of the invention. The polypeptides of the invention -complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

***Example 62: Assaying for Heparanase Activity***

[01285] In order to assay for heparanase activity of the polypeptides of the invention, the heparanase assay described by Vlodavsky et al is utilized (Vlodavsky, I., et al., Nat. Med., 5:793-802 (1999)). Briefly, cell lysates, conditioned media or intact cells ( $1 \times 10^6$  cells per 35-mm dish) are incubated for 18 hrs at  $37^\circ\text{C}$ , pH 6.2-6.6, with  $^{35}\text{S}$ -labeled ECM or soluble ECM derived peak I proteoglycans. The incubation medium is centrifuged and the supernatant is analyzed by gel filtration on a Sepharose CL-6B column (0.9 x 30 cm). Fractions are eluted with PBS and their radioactivity is

measured. Degradation fragments of heparan sulfate side chains are eluted from Sepharose 6B at  $0.5 < K_{av} < 0.8$  (peak II). Each experiment is done at least three times. Degradation fragments corresponding to "peak II," as described by Vlodavsky et al., is indicative of the activity of the polypeptides of the invention in cleaving heparan sulfate.

### ***Example 63: Immobilization of biomolecules***

[01286] This example provides a method for the stabilization of polypeptides of the invention in non-host cell lipid bilayer constructs (see, e.g., Bieri et al., Nature Biotech 17:1105-1108 (1999), hereby incorporated by reference in its entirety herein) which can be adapted for the study of polypeptides of the invention in the various functional assays described above. Briefly, carbohydrate-specific chemistry for biotinylation is used to confine a biotin tag to the extracellular domain of the polypeptides of the invention, thus allowing uniform orientation upon immobilization. A 50uM solution of polypeptides of the invention in washed membranes is incubated with 20 mM NaIO<sub>4</sub> and 1.5 mg/ml (4mM) BACH or 2 mg/ml (7.5mM) biotin-hydrazide for 1 hr at room temperature (reaction volume, 150ul). Then the sample is dialyzed (Pierce Slidealizer Cassett, 10 kDa cutoff; Pierce Chemical Co., Rockford IL) at 4C first for 5 h, exchanging the buffer after each hour, and finally for 12 h against 500 ml buffer R (0.15 M NaCl, 1 mM MgCl<sub>2</sub>, 10 mM sodium phosphate, pH7). Just before addition into a cuvette, the sample is diluted 1:5 in buffer ROG50 (Buffer R supplemented with 50 mM octylglucoside).

### ***Example 64: TAQMAN***

[01287] Quantitative PCR (QPCR). Total RNA from cells in culture are extracted by Trizol separation as recommended by the supplier (LifeTechnologies). (Total RNA is treated with DNase I (Life Technologies) to remove any contaminating genomic

DNA before reverse transcription.) Total RNA (50 ng) is used in a one-step, 50ul, RT-QPCR, consisting of Taqman Buffer A (Perkin-Elmer; 50 mM KCl/10 mM Tris, pH 8.3), 5.5 mM MgCl<sub>2</sub>, 240 μM each dNTP, 0.4 units RNase inhibitor(Promega), 8%glycerol, 0.012% Tween-20, 0.05% gelatin, 0.3uM primers, 0.1uM probe, 0.025units Amplitaq Gold (Perkin-Elmer) and 2.5 units Superscript II reverse transcriptase (Life Technologies). As a control for genomic contamination, parallel reactions are setup without reverse transcriptase. The relative abundance of (unknown) and 18S RNAs are assessed by using the Applied Biosystems Prism 7700 Sequence Detection System (Livak, K. J., Flood, S. J., Marmaro, J., Giusti, W. & Deetz, K. (1995) PCR Methods Appl. 4, 357-362). Reactions are carried out at 48°C for 30 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15s, 60°C for 1 min. Reactions are performed in triplicate.

[01288] Primers (f & r) and FRET probes sets are designed using Primer Express Software (Perkin-Elmer). Probes are labeled at the 5'-end with the reporter dye 6-FAM and on the 3'-end with the quencher dye TAMRA (Biosource International, Camarillo, CA or Perkin-Elmer).

### *Example 65: Assays for Metalloproteinase Activity*

[01289] Metalloproteinases (EC 3.4.24.-) are peptide hydrolases which use metal ions, such as Zn<sup>2+</sup>, as the catalytic mechanism. Metalloproteinase activity of polypeptides of the present invention can be assayed according to the following methods.

#### *Proteolysis of alpha-2-macroglobulin*

[01290] To confirm protease activity, purified polypeptides of the invention are mixed with the substrate alpha-2-macroglobulin (0.2 unit/ml; Boehringer Mannheim, Germany) in 1x assay buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM CaCl<sub>2</sub>, 25 μM ZnCl<sub>2</sub> and 0.05% Brij-35) and incubated at 37°C for 1-5 days. Trypsin is used as positive control. Negative controls contain only alpha-2-macroglobulin in assay buffer. The samples are collected and boiled in SDS-PAGE sample buffer containing 5% 2-

mercaptoethanol for 5-min, then loaded onto 8% SDS-polyacrylamide gel. After electrophoresis the proteins are visualized by silver staining. Proteolysis is evident by the appearance of lower molecular weight bands as compared to the negative control.

*Inhibition of alpha-2-macroglobulin proteolysis by inhibitors of metalloproteinases*

[01291] Known metalloproteinase inhibitors (metal chelators (EDTA, EGTA, AND  $\text{HgCl}_2$ ), peptide metalloproteinase inhibitors (TIMP-1 and TIMP-2), and commercial small molecule MMP inhibitors) are used to characterize the proteolytic activity of polypeptides of the invention. The three synthetic MMP inhibitors used are: MMP inhibitor I, [ $\text{IC}_{50}$  = 1.0  $\mu\text{M}$  against MMP-1 and MMP-8;  $\text{IC}_{50}$  = 30  $\mu\text{M}$  against MMP-9;  $\text{IC}_{50}$  = 150  $\mu\text{M}$  against MMP-3]; MMP-3 (stromelysin-1) inhibitor I [ $\text{IC}_{50}$  = 5  $\mu\text{M}$  against MMP-3], and MMP-3 inhibitor II [ $\text{K}_i$  = 130 nM against MMP-3]; inhibitors available through Calbiochem, catalog # 444250, 444218, and 444225, respectively). Briefly, different concentrations of the small molecule MMP inhibitors are mixed with purified polypeptides of the invention (50 $\mu\text{g}/\text{ml}$ ) in 22.9  $\mu\text{l}$  of 1x HEPES buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM  $\text{CaCl}_2$ , 25  $\mu\text{M}$   $\text{ZnCl}_2$  and 0.05%Brij-35) and incubated at room temperature (24 °C) for 2-hr, then 7.1  $\mu\text{l}$  of substrate alpha-2-macroglobulin (0.2 unit/ml) is added and incubated at 37°C for 20-hr. The reactions are stopped by adding 4x sample buffer and boiled immediately for 5 minutes. After SDS-PAGE, the protein bands are visualized by silver stain.

*Synthetic Fluorogenic Peptide Substrates Cleavage Assay*

[01292] The substrate specificity for polypeptides of the invention with demonstrated metalloproteinase activity can be determined using synthetic fluorogenic peptide substrates (purchased from BACHEM Bioscience Inc). Test substrates include, M-1985, M-2225, M-2105, M-2110, and M-2255. The first four are MMP substrates and the last one is a substrate of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) converting enzyme (TACE). All the substrates are prepared in 1:1 dimethyl sulfoxide (DMSO) and water. The stock solutions are 50-500  $\mu\text{M}$ . Fluorescent assays are performed by using a Perkin Elmer LS 50B luminescence spectrometer equipped with a constant temperature water bath. The excitation  $\lambda$  is 328 nm and the emission  $\lambda$  is 393 nm.

Briefly, the assay is carried out by incubating 176  $\mu$ l 1x HEPES buffer (0.2 M NaCl, 10 mM  $\text{CaCl}_2$ , 0.05% Brij-35 and 50 mM HEPES, pH 7.5) with 4  $\mu$ l of substrate solution (50  $\mu$ M) at 25 °C for 15 minutes, and then adding 20  $\mu$ l of a purified polypeptide of the invention into the assay cuvet. The final concentration of substrate is 1  $\mu$ M. Initial hydrolysis rates are monitored for 30-min.

***Example 66: Characterization of the cDNA contained in a deposited plasmid***

[01293] The size of the cDNA insert contained in a deposited plasmid may be routinely determined using techniques known in the art, such as PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the cDNA sequence. For example, two primers of 17-30 nucleotides derived from each end of the cDNA (i.e., hybridizable to the absolute 5' nucleotide or the 3' nucleotide end of the sequence of SEQ ID NO:X, respectively) are synthesized and used to amplify the cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu$ l of reaction mixture with 0.5  $\mu$ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu$ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[01294] Use of the above methodologies and/or other methodologies known in the art generates fragments from the clone corresponding to the approximate fragments described in Table 8, below. Accordingly, Table 8 provides a physical characterization of certain clones encompassed by the invention. The first column provides the unique clone identifier, "Clone ID NO:Z", for cDNA clones of the

invention, as described in Table 1A. The second column provides the approximate size of the cDNA insert contained in the corresponding cDNA clone.

**TABLE 8**

Clone ID NO:Z	cDNA Insert Size:
HFOXC35	600
HSSGD56	500
HSSCC14	900
HSSAP68	1200
HSLKB62	1800
HSLJD02	1000
HSLHV27	1000
HSLGA24	900
HSLDT25	1600
HSLCF96	1600
HSKEH21	900
HSHCL04	1500
HRDFA03	1000
HFIIJ14	700
HBSAP57	700

[01295] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

[01296] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is

hereby incorporated herein by reference. In addition, the CD-R copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. The specification and Sequence Listing of each of the following U.S. applications are herein incorporated by reference in their entirety: Application No. 60/179,065, filed on 31-Jan-2000; Application No. 60/180,628, filed on 04-Feb-2000; Application No. 60/214,886, filed on 28-Jun-2000; Application No. 60/217,487, filed on 11-Jul-2000; Application No. 60/225,758, filed on 14-Aug-2000; Application No. 60/220,963, filed on 26-Jul-2000; Application No. 60/217,496, filed on 11-Jul-2000; Application No. 60/225,447, filed on 14-Aug-2000; Application No. 60/218,290, filed on 14-Jul-2000; Application No. 60/225,757, filed on 14-Aug-2000; Application No. 60/226,868, filed on 22-Aug-2000; Application No. 60/216,647, filed on 07-Jul-2000; Application No. 60/225,267, filed on 14-Aug-2000; Application No. 60/216,880, filed on 07-Jul-2000; Application No. 60/225,270, filed on 14-Aug-2000; Application No. 60/251,869, filed on 08-Dec-2000; Application No. 60/235,834, filed on 27-Sep-2000; Application No. 60/234,274, filed on 21-Sep-2000; Application No. 60/234,223, filed on 21-Sep-2000; Application No. 60/228,924, filed on 30-Aug-2000; Application No. 60/224,518, filed on 14-Aug-2000; Application No. 60/236,369, filed on 29-Sep-2000; Application No. 60/224,519, filed on 14-Aug-2000; Application No. 60/220,964, filed on 26-Jul-2000; Application No. 60/241,809, filed on 20-Oct-2000; Application No. 60/249,299, filed on 17-Nov-2000; Application No. 60/236,327, filed on 29-Sep-2000; Application No. 60/241,785, filed on 20-Oct-2000; Application No. 60/244,617, filed on 01-Nov-2000; Application No. 60/225,268, filed on 14-Aug-2000; Application No. 60/236,368, filed on 29-Sep-2000; Application No. 60/251,856, filed on 08-Dec-2000; Application No. 60/251,868, filed on 08-Dec-2000; Application No. 60/229,344, filed on 01-Sep-2000; Application No. 60/234,997, filed on 25-Sep-2000; Application No. 60/229,343, filed on 01-Sep-2000; Application No. 60/229,345, filed on 01-Sep-2000; Application No. 60/229,287, filed on 01-Sep-2000; Application No. 60/229,513, filed on 05-Sep-2000; Application No. 60/231,413, filed on 08-Sep-2000; Application No. 60/229,509, filed on 05-Sep-2000; Application No. 60/236,367, filed on 29-Sep-2000; Application No. 60/237,039, filed on 02-Oct-2000; Application No. 60/237,038, filed on 02-Oct-2000; Application No. 60/236,370, filed


on 29-Sep-2000; Application No. 60/236,802, filed on 02-Oct-2000; Application No. 60/237,037, filed on 02-Oct-2000; Application No. 60/237,040, filed on 02-Oct-2000; Application No. 60/240,960, filed on 20-Oct-2000; Application No. 60/239,935, filed on 13-Oct-2000; Application No. 60/239,937, filed on 13-Oct-2000; Application No. 60/241,787, filed on 20-Oct-2000; Application No. 60/246,474, filed on 08-Nov-2000; Application No. 60/246,532, filed on 08-Nov-2000; Application No. 60/249,216, filed on 17-Nov-2000; Application No. 60/249,210, filed on 17-Nov-2000; Application No. 60/226,681, filed on 22-Aug-2000; Application No. 60/225,759, filed on 14-Aug-2000; Application No. 60/225,213, filed on 14-Aug-2000; Application No. 60/227,182, filed on 22-Aug-2000; Application No. 60/225,214, filed on 14-Aug-2000; Application No. 60/235,836, filed on 27-Sep-2000; Application No. 60/230,438, filed on 06-Sep-2000; Application No. 60/215,135, filed on 30-Jun-2000; Application No. 60/225,266, filed on 14-Aug-2000; Application No. 60/249,218, filed on 17-Nov-2000; Application No. 60/249,208, filed on 17-Nov-2000; Application No. 60/249,213, filed on 17-Nov-2000; Application No. 60/249,212, filed on 17-Nov-2000; Application No. 60/249,207, filed on 17-Nov-2000; Application No. 60/249,245, filed on 17-Nov-2000; Application No. 60/249,244, filed on 17-Nov-2000; Application No. 60/249,217, filed on 17-Nov-2000; Application No. 60/249,211, filed on 17-Nov-2000; Application No. 60/249,215, filed on 17-Nov-2000; Application No. 60/249,264, filed on 17-Nov-2000; Application No. 60/249,214, filed on 17-Nov-2000; Application No. 60/249,297, filed on 17-Nov-2000; Application No. 60/232,400, filed on 14-Sep-2000; Application No. 60/231,242, filed on 08-Sep-2000; Application No. 60/232,081, filed on 08-Sep-2000; Application No. 60/232,080, filed on 08-Sep-2000; Application No. 60/231,414, filed on 08-Sep-2000; Application No. 60/231,244, filed on 08-Sep-2000; Application No. 60/233,064, filed on 14-Sep-2000; Application No. 60/233,063, filed on 14-Sep-2000; Application No. 60/232,397, filed on 14-Sep-2000; Application No. 60/232,399, filed on 14-Sep-2000; Application No. 60/232,401, filed on 14-Sep-2000; Application No. 60/241,808, filed on 20-Oct-2000; Application No. 60/241,826, filed on 20-Oct-2000; Application No. 60/241,786, filed on 20-Oct-2000; Application No. 60/241,221, filed on 20-Oct-2000; Application No. 60/246,475, filed on 08-Nov-2000; Application No.

60/231,243, filed on 08-Sep-2000; Application No. 60/233,065, filed on 14-Sep-2000; Application No. 60/232,398, filed on 14-Sep-2000; Application No. 60/234,998, filed on 25-Sep-2000; Application No. 60/246,477, filed on 08-Nov-2000; Application No. 60/246,528, filed on 08-Nov-2000; Application No. 60/246,525, filed on 08-Nov-2000; Application No. 60/246,476, filed on 08-Nov-2000; Application No. 60/246,526, filed on 08-Nov-2000; Application No. PT172, filed on 17-Nov-2000; Application No. 60/246,527, filed on 08-Nov-2000; Application No. 60/246,523, filed on 08-Nov-2000; Application No. 60/246,524, filed on 08-Nov-2000; Application No. 60/246,478, filed on 08-Nov-2000; Application No. 60/246,609, filed on 08-Nov-2000; Application No. 60/246,613, filed on 08-Nov-2000; Application No. 60/249,300, filed on 17-Nov-2000; Application No. 60/249,265, filed on 17-Nov-2000; Application No. 60/246,610, filed on 08-Nov-2000; Application No. 60/246,611, filed on 08-Nov-2000; Application No. 60/230,437, filed on 06-Sep-2000; Application No. 60/251,990, filed on 08-Dec-2000; Application No. 60/251,988, filed on 05-Dec-2000; Application No. 60/251,030, filed on 05-Dec-2000; Application No. 60/251,479, filed on 06-Dec-2000; Application No. PJ005, filed on 05-Dec-2000; Application No. PJ006, filed on 01-Dec-2000; Application No. 60/251,989, filed on 08-Dec-2000; Application No. 60/250,391, filed on 01-Dec-2000; and Application No. 60/254,097, filed on 11-Dec-2000.

[01297] Moreover, the microfiche copy and the corresponding computer readable form of the Sequence Listing of U.S. Application Serial No. 60/179,065, and the hard copy of and the corresponding computer readable form of the Sequence Listing of U.S. Application Serial No. 60/180,628 are also incorporated herein by reference in their entireties.


<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209059	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MEVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5163</b> <div style="text-align: right;">MSB</div>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution ( <i>including postal code and country</i> ) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209060	
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> ) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> )			
The indications listed below will be submitted to the international Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MELVIN S. BROOKS SR.</b> <b>INTERNATIONAL DIVISION</b> <b>703-895-5163</b> MSB		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209061	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <div style="text-align: center;">  </div>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit      May 20, 1997		Accession Number      209062	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer: <b>MELVIN S. BROOKS SR.</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5163</b> <i>MSB</i>		Authorized officer:	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit      May 20, 1997		Accession Number      209063	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MEVIN S. BROOKS JR</b> <b>INTERNATIONAL DIVISION</b> <b>703-895-5163</b> MSJ		Authorized officer	


<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209064	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer 		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit      May 20, 1997		Accession Number      209065	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer: <b>MELVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5163</b> <i>MSB</i>		Authorized officer:	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209066	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MELVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5162</b> <div style="text-align: right;">MB</div>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit May 20, 1997		Accession Number 209067	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer <div style="text-align: center;"> <b>MELVIN S. BROOKS SR</b>  <b>INTERNATIONAL DIVISION</b>  <b>703-805-5163</b>  <i>MS</i> </div>	Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)					
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit    May 20, 1997			Accession Number    209068		
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>					
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
<div style="border: 1px solid black; height: 40px; width: 100%;"></div>		<div style="border: 1px solid black; height: 40px; width: 100%;"></div>		<div style="border: 1px solid black; height: 40px; width: 100%;"></div>	
For receiving Office use only		For International Bureau use only			
<input checked="" type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer <div style="text-align: center;"> <b>MELVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DIVISION</b>  <b>703-305-9103</b>  <i>MSD</i> </div>			Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    May 20, 1997		Accession Number    209069	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <div style="text-align: center;">               ROBERT S. DEJURE SR.              INTERNATIONAL DIVISION              703-305-9165              MSA           </div>	Authorized officer		


<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution ( <i>including postal code and country</i> ) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit January 12, 1998		Accession Number 209579	
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> ) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> )			
The indications listed below will be submitted to the international Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MELVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-805-5163</b> <i>msg</i>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    January 12, 1998		Accession Number    209578	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer MELVIN S. BROOKS SR INTERNATIONAL DEPOSITION 703-505-5163	Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit     July 16, 1998		Accession Number     203067	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MELVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DIVISION</b>  <b>750-365-7143</b> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    July 16, 1998		Accession Number    203068	
<b>C. ADDITIONAL INDICATIONS</b> <i>(leave blank if not applicable)</i> <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> <i>(if the indications are not for all designated States)</i>			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> <i>(leave blank if not applicable)</i>			
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MEVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DIVISION</b>  <b>703-805-5165</b>  <i>M.S.</i> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit February 1, 1999		Accession Number 203609	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MELVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DEPOSITION</b>  <b>703-501-9163</b>  <i>MSB</i> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    February 1, 1999		Accession Number    203610	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <div style="text-align: center;">               MELVIN S. BROOKS SR.              INTERNATIONAL UNIVERSITY              703-393-5103           </div> <div style="text-align: right;">H 53</div>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)					
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.					
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>					
Name of depositary institution: American Type Culture Collection					
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit    November 17, 1998			Accession Number    203485		
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>					
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)					
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")					
For receiving Office use only		For International Bureau use only			
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center; font-weight: bold;">MILVIN S. BROOKS SR. INTERNATIONAL DIVISION 703-305-5163</div> Authorized officer			<input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <div style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></div>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit     June 18, 1999		Accession Number     PTA-252	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <div style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></div>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MELVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DIVISION</b>  <b>700-303-1169</b> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit      June 18, 1999		Accession Number      PTA-253	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>ALVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-7169</b> <i>MSB</i>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at Table 6.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit      December 22, 1999		Accession Number      PTA-1081	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer MELVIN S. BROOKS SR INTERNATIONAL DIVISION 703-505-5169 MFS	Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047].			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    October 5, 2000		Accession Number    PTA-2574	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MELVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5163</b> <i>MSB</i>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047].			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    October 5, 2000		Accession Number    PTA-2575	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<div style="text-align: center;"> <b>MELVIN S. BROOKS SR</b>  <b>INTERNATIONAL DIVISION</b>  <b>712 383 9169</b>  <i>MSA</i> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer		

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047]..			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit     January 5, 2001		Accession Number     (HGS reference code TS-1)	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<div style="text-align: center;"> <b>MELVIN S. BROOKS SR</b>  <b>INTERNATIONAL DIVISION</b>  <b>703 305 5163</b> </div>		<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	<div style="text-align: center;"> <b>750</b> </div>		Authorized officer

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047].			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit January 5, 2001		Accession Number (HGS reference code TS-2)	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MELVIN S. BROOKS SR</b>  <b>INTERNATIONAL DEPOSITION</b>  <b>702-503-5169</b>  <i>MSA</i> </div> Authorized officer		<input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047].			
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>			
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    January 5, 2001		Accession Number (HGS reference code AC-1)	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>			
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <span style="float: right;">Continued on additional sheets</span>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer <b>MEVIN S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-305-5163</b>		Authorized officer	

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description at page 17, paragraph [047].			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit    January 5, 2001		Accession Number    (HGS reference code AC-2)	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center;"> <b>MELVIN S. BROOKS SR.</b>  <b>INTERNATIONAL DEPOSITION</b>  <b>703-505-5163</b> </div> Authorized officer		<input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer	

**ATCC Deposit No.:** 209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069, 209579, 209578, 203067, 203068, 203609, 203610, 203485, PTA-252, PTA-253, PTA-1081, PTA-2574, PTA-2575, TS-1, TS-2, AC-1, AC-2

#### **CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

#### **NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

#### **AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

#### **FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.:** 209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069, 209579, 209578, 203067, 203068, 203609, 203610, 203485, PTA-252, PTA-253, PTA-1081, PTA-2574, PTA-2575, TS-1, TS-2, AC-1, AC-2

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

#### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

#### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

#### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence contained in Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;
  - (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (g) a polynucleotide which is a variant of SEQ ID NO:X;
  - (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
  - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
  - (e) a full length protein of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;
  - (f) a variant of SEQ ID NO:Y;
  - (g) an allelic variant of SEQ ID NO:Y; or
  - (h) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
  - (b) recovering said polypeptide.
16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

24. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01338

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>												
IPC(7) : C12N 15/11, 15/12												
US CL : 536/23.1, 23.5; 435/6, 320.1, 325												
According to International Patent Classification (IPC) or to both national classification and IPC												
<b>B. FIELDS SEARCHED</b>												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 23.5; 435/6, 320.1, 325												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)												
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	Database CNS01DUP, Accession Number AL135752, GENOSCOPE. Direct Submission. 17 December 1999.	1-10 and 21										
X	Genbank CNS01DUP, Accession No. AL133312, GENOSCOPE. Direct Submission. 01 December 1999.	1-10 and 21										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 05 May 2001 (05.05.2001)		Date of mailing of the international search report 14 MAY 2001										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Marianne P. Allen</i> Marianne P. Allen Telephone No. 703-308-0196										

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01338

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10 and 21 with respect to SEQ ID NO: 11

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01338

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING:** This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-10 and 21, drawn to polynucleotides.

Group II, claim(s) 11-12 and 14-16, drawn to polypeptides and methods of making them.

Group III, claim(s) 13, drawn to antibodies. Group IV, claim(s) 17, drawn to methods of treatment using polynucleotides.

Group V, claim(s) 18, drawn to methods of diagnosis using polynucleotides..

Group VI, claim(s) 19, drawn to methods of diagnosis using polypeptides.

Group VII, claim(s) 20, drawn to methods of identifying binding partners.

Group VIII, claim(s) 22, drawn to methods of identifying activity in cells.

Group IX, claim(s) 23, drawn to binding partners.

Group X, claim(s) 24, drawn to methods of treatment using polypeptides.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The inventions of Groups I-X do not share the same or corresponding special technical feature as a special technical feature must distinguish over the prior art. (See attached Search Report.). In addition, the sequence identifiers recited in the claims are not considered to share the same or corresponding special technical feature as each is structurally distinct. As such, each particular SEQ ID NO. is considered to be a separate invention.

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
WO 01/55367 A1

(51) International Patent Classification <sup>7</sup> :	C12N 15/11,	60/224,519	14 August 2000 (14.08.2000)	US	
	15/12	60/225,759	14 August 2000 (14.08.2000)	US	
		60/225,213	14 August 2000 (14.08.2000)	US	
(21) International Application Number:	PCT/US01/01338	60/225,266	14 August 2000 (14.08.2000)	US	
		60/225,214	14 August 2000 (14.08.2000)	US	
(22) International Filing Date:	17 January 2001 (17.01.2001)	60/226,279	18 August 2000 (18.08.2000)	US	
		60/226,868	22 August 2000 (22.08.2000)	US	
(25) Filing Language:	English	60/227,182	22 August 2000 (22.08.2000)	US	
		60/226,681	22 August 2000 (22.08.2000)	US	
(26) Publication Language:	English	60/227,009	23 August 2000 (23.08.2000)	US	
		60/228,924	30 August 2000 (30.08.2000)	US	
		60/229,344	1 September 2000 (01.09.2000)	US	
(30) Priority Data:		60/229,343	1 September 2000 (01.09.2000)	US	
60/179,065	31 January 2000 (31.01.2000)	US	60/229,287	1 September 2000 (01.09.2000)	US
60/180,628	4 February 2000 (04.02.2000)	US	60/229,345	1 September 2000 (01.09.2000)	US
60/184,664	24 February 2000 (24.02.2000)	US	60/229,513	5 September 2000 (05.09.2000)	US
60/186,350	2 March 2000 (02.03.2000)	US	60/229,509	5 September 2000 (05.09.2000)	US
60/189,874	16 March 2000 (16.03.2000)	US	60/230,438	6 September 2000 (06.09.2000)	US
60/190,076	17 March 2000 (17.03.2000)	US	60/230,437	6 September 2000 (06.09.2000)	US
60/198,123	18 April 2000 (18.04.2000)	US	60/231,413	8 September 2000 (08.09.2000)	US
60/205,515	19 May 2000 (19.05.2000)	US	60/232,080	8 September 2000 (08.09.2000)	US
60/209,467	7 June 2000 (07.06.2000)	US	60/231,414	8 September 2000 (08.09.2000)	US
60/214,886	28 June 2000 (28.06.2000)	US	60/231,244	8 September 2000 (08.09.2000)	US
60/215,135	30 June 2000 (30.06.2000)	US	60/232,081	8 September 2000 (08.09.2000)	US
60/216,647	7 July 2000 (07.07.2000)	US	60/231,242	8 September 2000 (08.09.2000)	US
60/216,880	7 July 2000 (07.07.2000)	US	60/231,243	8 September 2000 (08.09.2000)	US
60/217,487	11 July 2000 (11.07.2000)	US	60/231,968	12 September 2000 (12.09.2000)	US
60/217,496	11 July 2000 (11.07.2000)	US	60/232,401	14 September 2000 (14.09.2000)	US
60/218,290	14 July 2000 (14.07.2000)	US	60/232,399	14 September 2000 (14.09.2000)	US
60/220,963	26 July 2000 (26.07.2000)	US	60/232,400	14 September 2000 (14.09.2000)	US
60/220,964	26 July 2000 (26.07.2000)	US	60/232,397	14 September 2000 (14.09.2000)	US
60/225,757	14 August 2000 (14.08.2000)	US	60/233,063	14 September 2000 (14.09.2000)	US
60/225,270	14 August 2000 (14.08.2000)	US	60/233,064	14 September 2000 (14.09.2000)	US
60/225,447	14 August 2000 (14.08.2000)	US	60/233,065	14 September 2000 (14.09.2000)	US
60/225,267	14 August 2000 (14.08.2000)	US	60/232,398	14 September 2000 (14.09.2000)	US
60/225,758	14 August 2000 (14.08.2000)	US	60/234,223	21 September 2000 (21.09.2000)	US
60/225,268	14 August 2000 (14.08.2000)	US	60/234,274	21 September 2000 (21.09.2000)	US
60/224,518	14 August 2000 (14.08.2000)	US	60/234,997	25 September 2000 (25.09.2000)	US

[Continued on next page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens", and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

WO 01/55367 A1



60/234,998	25 September 2000 (25.09.2000)	US	60/256,719	5 December 2000 (05.12.2000)	US
60/235,484	26 September 2000 (26.09.2000)	US	60/251,030	5 December 2000 (05.12.2000)	US
60/235,834	27 September 2000 (27.09.2000)	US	60/251,988	5 December 2000 (05.12.2000)	US
60/235,836	27 September 2000 (27.09.2000)	US	60/251,479	6 December 2000 (06.12.2000)	US
60/236,369	29 September 2000 (29.09.2000)	US	60/251,869	8 December 2000 (08.12.2000)	US
60/236,327	29 September 2000 (29.09.2000)	US	60/251,856	8 December 2000 (08.12.2000)	US
60/236,370	29 September 2000 (29.09.2000)	US	60/251,868	8 December 2000 (08.12.2000)	US
60/236,368	29 September 2000 (29.09.2000)	US	60/251,990	8 December 2000 (08.12.2000)	US
60/236,367	29 September 2000 (29.09.2000)	US	60/251,989	8 December 2000 (08.12.2000)	US
60/237,039	2 October 2000 (02.10.2000)	US	60/254,097	11 December 2000 (11.12.2000)	US
60/237,038	2 October 2000 (02.10.2000)	US	60/259,678	5 January 2001 (05.01.2001)	US
60/237,040	2 October 2000 (02.10.2000)	US			
60/237,037	2 October 2000 (02.10.2000)	US	(71) Applicant (for all designated States except US): HUMAN		
60/236,802	2 October 2000 (02.10.2000)	US	GENOME SCIENCES, INC. [US/US]; 9410 Key West		
60/239,937	13 October 2000 (13.10.2000)	US	Avenue, Rockville, MD 20850 (US).		
60/239,935	13 October 2000 (13.10.2000)	US			
60/241,785	20 October 2000 (20.10.2000)	US	(72) Inventors; and		
60/241,809	20 October 2000 (20.10.2000)	US	(75) Inventors/Applicants (for US only): ROSEN, Craig,		
60/240,960	20 October 2000 (20.10.2000)	US	A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD		
60/241,787	20 October 2000 (20.10.2000)	US	20882 (US). BARASH, Steven, C. [US/US]; 111 Watkins		
60/241,808	20 October 2000 (20.10.2000)	US	Pond Blvd. #301, Rockville, MD 20850 (US). RUBEN,		
60/241,221	20 October 2000 (20.10.2000)	US	Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney,		
60/241,786	20 October 2000 (20.10.2000)	US	MD 20832 (US).		
60/241,826	20 October 2000 (20.10.2000)	US			
60/244,617	1 November 2000 (01.11.2000)	US	(74) Agents: HOOVER, Kenley, K. et al.; Human Genome		
60/246,474	8 November 2000 (08.11.2000)	US	Sciences, Inc., 9410 Key West Avenue, Rockville, MD		
60/246,532	8 November 2000 (08.11.2000)	US	20850 (US).		
60/246,476	8 November 2000 (08.11.2000)	US			
60/246,526	8 November 2000 (08.11.2000)	US	(81) Designated States (national): AE, AG, AL, AM, AT, AU,		
60/246,475	8 November 2000 (08.11.2000)	US	AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,		
60/246,525	8 November 2000 (08.11.2000)	US	DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,		
60/246,528	8 November 2000 (08.11.2000)	US	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,		
60/246,527	8 November 2000 (08.11.2000)	US	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,		
60/246,477	8 November 2000 (08.11.2000)	US	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,		
60/246,611	8 November 2000 (08.11.2000)	US	TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.		
60/246,610	8 November 2000 (08.11.2000)	US			
60/246,613	8 November 2000 (08.11.2000)	US	(84) Designated States (regional): ARIPO patent (GH, GM,		
60/246,609	8 November 2000 (08.11.2000)	US	KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian		
60/246,478	8 November 2000 (08.11.2000)	US	patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European		
60/246,524	8 November 2000 (08.11.2000)	US	patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,		
60/246,523	8 November 2000 (08.11.2000)	US	IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,		
60/249,299	17 November 2000 (17.11.2000)	US	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
60/249,210	17 November 2000 (17.11.2000)	US			
60/249,216	17 November 2000 (17.11.2000)	US	Published:		
60/249,217	17 November 2000 (17.11.2000)	US	— with international search report		
60/249,211	17 November 2000 (17.11.2000)	US	— with sequence listing part of description published sepa-		
60/249,215	17 November 2000 (17.11.2000)	US	rately in electronic form and available upon request from		
60/249,218	17 November 2000 (17.11.2000)	US	the International Bureau		
60/249,208	17 November 2000 (17.11.2000)	US			
60/249,213	17 November 2000 (17.11.2000)	US	(48) Date of publication of this corrected version:		
60/249,212	17 November 2000 (17.11.2000)	US	20 December 2001		
60/249,207	17 November 2000 (17.11.2000)	US			
60/249,245	17 November 2000 (17.11.2000)	US	(15) Information about Correction:		
60/249,244	17 November 2000 (17.11.2000)	US	see PCT Gazette No. 51/2001 of 20 December 2001, Sec-		
60/249,297	17 November 2000 (17.11.2000)	US	tion II		
60/249,214	17 November 2000 (17.11.2000)	US			
60/249,264	17 November 2000 (17.11.2000)	US	For two-letter codes and other abbreviations, refer to the "Guid-		
60/249,209	17 November 2000 (17.11.2000)	US	ance Notes on Codes and Abbreviations" appearing at the begin-		
60/249,300	17 November 2000 (17.11.2000)	US	ning of each regular issue of the PCT Gazette.		
60/249,265	17 November 2000 (17.11.2000)	US			
60/250,391	1 December 2000 (01.12.2000)	US			
60/250,160	1 December 2000 (01.12.2000)	US			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**